Our O
data O
suggest O
that O
lipoxygenase O
metabolites O
activate O
ROI O
formation O
which O
then O
induce O
IL B
- I
2 I
expression O
via O
NF B
- I
kappa I
B I
activation O
. O

This O
is O
the O
first O
description O
of O
an O
HIV B
- I
2 I
enhancer I
element I
which O
displays O
such O
monocyte O
specificity O
, O
and O
no O
comparable O
enhancer B
element I
has O
been O
clearly O
defined O
for O
HIV O
- O
1 O
. O

While O
a O
nuclear B
factor I
( O
s O
) O
from O
both O
peripheral O
blood O
monocytes O
and O
T O
cells O
binds O
the O
peri B
- I
kappa I
B I
site I
, O
electrophoretic O
mobility O
shift O
assays O
suggest O
that O
either O
a O
different O
protein O
binds O
to O
this O
site O
in O
monocytes O
versus O
T O
cells O
or O
that O
the O
protein O
recognizing O
this O
enhancer B
element I
undergoes O
differential O
modification O
in O
monocytes O
and O
T O
cells O
, O
thus O
supporting O
the O
transfection O
data O
. O

Distinct O
signaling O
properties O
identify O
functionally O
different O
CD4 B
epitopes I
. O

Whereas O
different O
anti B
- I
CD4 I
mAb I
or O
HIV O
- O
1 O
gp120 O
could O
all O
trigger O
activation O
of O
the O
protein B
tyrosine I
kinases I
p56lck B
and O
p59fyn B
and O
phosphorylation O
of O
the O
Shc O
adaptor O
protein O
, O
which O
mediates O
signals O
to O
Ras B
, O
they O
differed O
significantly O
in O
their O
ability O
to O
activate O
NF B
- I
AT I
. O

To O
address O
potential O
mechanisms O
by O
which O
estrogens O
suppress O
erythropoiesis O
, O
we O
have O
examined O
their O
effects O
on O
GATA B
- I
1 I
, O
an O
erythroid B
transcription I
factor I
that O
participates O
in O
the O
regulation O
of O
the O
majority O
of O
erythroid B
cell I
- I
specific I
genes I
and O
is O
necessary O
for O
full O
maturation O
of O
erythrocytes O
. O

ER B
- O
mediated O
repression O
of O
GATA B
- I
1 I
activity O
occurs O
on O
an O
artificial B
promoter I
containing O
a O
single O
GATA B
- I
binding I
site I
, O
as O
well O
as O
in O
the O
context O
of O
an O
intact O
promoter O
which O
is O
normally O
regulated O
by O
GATA B
- I
1 I
. O

In O
coimmunoprecipitatio O
experiments O
using O
transfected O
COS O
cells O
, O
GATA B
- I
1 I
and O
ER B
associate O
in O
a O
ligand O
- O
dependent O
manner O
. O

The O
transcriptional O
response O
of O
the O
IL B
- I
2R I
alpha I
gene I
to O
stimulation O
by O
IL B
- I
1 I
+ O
IL B
- I
2 I
is O
biphasic O
. O

It O
also O
primes O
cells O
to O
become O
IL B
- I
2 I
responsive O
and O
thereby O
prepares O
the O
second O
phase O
, O
in O
which O
IL B
- I
2 I
induces O
a O
100 O
- O
fold O
further O
increase O
in O
IL O
- O
2R O
alpha O
transcripts O
. O

Transient O
transfection O
experiments O
show O
that O
several O
elements O
in O
the O
promoter B
- I
proximal I
region I
of O
the O
IL B
- I
2R I
alpha I
gene I
contribute O
to O
IL B
- I
1 I
responsiveness O
, O
most O
importantly O
an O
NF B
- I
kappa I
B I
site I
conserved O
in O
the O
human O
and O
mouse O
gene O
. O

IL B
- I
2 I
responsiveness O
, O
on O
the O
other O
hand O
, O
depends O
on O
a O
78 O
- O
nucleotide O
segment O
1 O
. O
3 O
kilobases O
upstream O
of O
the O
major B
transcription I
start I
site I
. O

The O
appearance O
of O
the O
BamHI O
ZLF O
- O
1 O
gene O
product O
, O
ZEBRA B
, O
by O
RT O
- O
PCR O
, O
was O
observed O
within O
8 O
hr O
of O
infection O
. O

Several O
recent O
studies O
have O
implicated O
Jak O
kinases O
in O
the O
signaling O
pathway O
induced O
by O
IL B
- I
2 I
. O

We O
demonstrate O
, O
through O
the O
deletion O
of O
the O
human O
UDG O
promoter O
sequences O
, O
that O
expression O
of O
E2F B
- I
1 I
activates O
the O
UDG O
promoter O
through O
several O
E2F B
sites I
. O

Overexpression O
of O
UDG B
in O
Saos O
2 O
cells O
was O
observed O
to O
delay O
growth O
late O
in O
G1 O
phase O
and O
transiently O
arrest O
these O
cells O
from O
progressing O
into O
the O
S O
phase O
. O

Cellular O
and O
molecular O
mechanisms O
of O
IFN B
- I
gamma I
production O
induced O
by O
IL B
- I
2 I
and O
IL B
- I
12 I
in O
a O
human O
NK O
cell O
line O
. O

In O
addition O
, O
when O
used O
together O
IL B
- I
2 I
and O
IL B
- I
12 I
synergized O
in O
the O
induction O
of O
IFN B
- I
gamma I
and O
GM B
- I
CSF I
and O
this O
synergy O
was O
attributed O
to O
an O
increased O
accumulation O
and O
stability O
of O
the O
IFN O
- O
gamma O
and O
GM O
- O
CSF O
mRNAs O
. O

To O
investigate O
the O
signaling O
pathways O
involved O
in O
the O
gene O
induction O
, O
five O
inhibitors O
, O
cyclosporin O
A O
( O
CsA O
) O
, O
transforming B
growth I
factor I
- I
beta I
, O
cycloheximide O
, O
genistein O
, O
and O
staurosporine O
A O
, O
were O
used O
in O
analyzing O
the O
effects O
of O
IL B
- I
2 I
and O
IL B
- I
12 I
on O
NK3 O
. O
3 O
cells O
. O

In O
addition O
, O
IL B
- I
2 I
but O
not O
IL B
- I
12 I
induced O
nuclear B
factors I
NF B
- I
kappa I
B I
and O
AP1 B
, O
and O
regulation O
of O
the O
nuclear O
levels O
of O
these O
two O
DNA O
binding O
protein O
complexes O
is O
correlated O
with O
IFN O
- O
gamma O
and O
GM O
- O
CSF O
gene O
expression O
. O

One O
substrate O
is O
p95vav B
, O
which O
is O
expressed O
exclusively O
in O
hematopoietic O
and O
trophoblast O
cells O
. O

Furthermore O
, O
p95vav B
synergizes O
with O
TCR B
stimulation O
in O
inducing O
NFAT O
- O
and O
interleukin O
- O
2 O
- O
dependent O
transcription O
. O

Furthermore O
, O
the O
activating O
function O
of O
p95vav B
is O
blocked O
by O
FK506 O
, O
suggesting O
that O
its O
activity O
also O
depends O
on O
calcineurin B
. O

alpha B
B I
is O
the O
mouse O
homologue O
of O
human O
AML1 O
gene O
detected O
at O
the O
breakpoints O
of O
t O
( O
8 O
; O
21 O
) O
and O
t O
( O
3 O
; O
21 O
) O
myeloid O
leukemias O
. O

We O
examined O
alpha O
A1 O
( O
an O
alpha O
A O
- O
gene O
product O
) O
and O
alpha B
B1 I
and O
alpha B
B2 I
( O
two O
alpha O
B O
- O
encoded O
isomers O
) O
for O
their O
effects O
on O
the O
GM B
- I
CSF I
promoter I
. O

Although O
further O
studies O
are O
required O
to O
determine O
the O
precise O
role O
of O
PEBP2 B
in O
the O
GM B
- I
CSF I
promoter O
activity O
, O
the O
present O
findings O
suggested O
the O
importance O
of O
the O
relative O
ratio O
of O
different O
PEBP2 O
isoforms O
in O
regulating O
the O
levels O
of O
the O
promoter O
activity O
. O

IFN B
- I
gamma I
priming O
of O
monocytes O
enhances O
LPS O
- O
induced O
TNF B
production O
by O
augmenting O
both O
transcription O
and O
MRNA O
stability O
. O

The O
induction O
of O
cytokine B
expression O
in O
monocytes O
/ O
macrophages O
by O
bacterial B
endotoxin I
or O
lipopolysaccharide O
is O
a O
critical O
, O
highly O
regulated O
host O
defence O
response O
. O

The O
increased O
transcriptional O
rate O
correlated O
with O
a O
marked O
increase O
in O
nuclear B
factor I
- I
kappa I
B I
activity O
in O
these O
cells O
as O
determined O
by O
electrophoretic O
mobility O
shift O
assay O
using O
a O
consensus O
NF O
- O
kappa O
B O
oligonucleotide O
. O

Consistent O
with O
the O
increased O
mRNA B
stability O
, O
the O
duration O
of O
mRNA B
accumulation O
was O
longer O
following O
LPS O
stimulation O
in O
primed O
monocytes O
, O
in O
addition O
to O
being O
of O
greater O
magnitude O
. O

H O
- O
89 O
substantially O
suppressed O
LPS O
- O
induced O
TNF B
mRNA I
accumulation O
in O
unprimed O
cells O
, O
but O
had O
no O
effect O
on O
primed O
monocytes O
following O
LPS O
stimulation O
. O

A O
Myc O
- O
associated O
zinc O
finger O
protein O
binding O
site O
is O
one O
of O
four O
important O
functional B
regions I
in O
the O
CD4 B
promoter I
. O

Since O
the O
terminal O
events O
of O
erythropoiesis O
are O
controlled O
by O
the O
glycoprotein O
hormone O
erythropoietin O
( O
Epo B
) O
, O
we O
investigated O
whether O
the O
expression O
or O
activity O
of O
the O
TAL1 B
gene I
and O
its O
protein B
products I
were O
affected O
by O
Epo B
in O
splenic O
erythroblasts O
from O
mice O
infected O
with O
an O
anemia O
- O
inducing O
strain O
of O
Friend O
virus O
( O
FVA O
cells O
) O
. O

The O
role O
of O
shared O
receptor O
motifs O
and O
common O
Stat O
proteins O
in O
the O
generation O
of O
cytokine B
pleiotropy O
and O
redundancy O
by O
IL B
- I
2 I
, O
IL B
- I
4 I
, O
IL B
- I
7 I
, O
IL B
- I
13 I
, O
and O
IL B
- I
15 I
. O

IL B
- I
13 I
Induced O
the O
same O
complexes O
as O
IL B
- I
4 I
, O
a O
finding O
explained O
by O
our O
studies O
implicating O
IL B
- I
4R I
as O
a O
shared O
component O
of O
the O
receptors B
. O

Control O
of O
I B
kappa I
B I
- I
alpha I
proteolysis O
by O
site O
- O
specific O
, O
signal O
- O
induced O
phosphorylation O
. O

When O
either O
serine O
- O
32 O
or O
serine O
- O
36 O
of O
I B
kappa I
B I
- I
alpha I
was O
mutated O
, O
the O
protein O
did O
not O
undergo O
signal O
- O
induced O
phosphorylation O
or O
degradation O
, O
and O
NF B
- I
kappa I
B I
could O
not O
be O
activated O
. O

Erythropoietin B
( O
Epo B
) O
, O
the O
primary O
regulator O
of O
the O
production O
of O
erythroid O
cells O
, O
acts O
by O
binding O
to O
a O
cell B
surface I
receptor I
( O
EpoR B
) O
on O
erythroid O
progenitors O
. O

Interestingly O
, O
when O
we O
mutated O
the O
Sp1 B
site I
, O
resulting O
in O
a O
marked O
decrease O
in O
hEpoR B
promoter I
activity O
, O
we O
could O
restore O
transactivation O
by O
increasing O
GATA B
- I
1 I
levels O
in O
OCIM1 O
cells O
. O

These O
data O
suggest O
that O
while O
GATA B
- I
1 I
can O
transactivate O
the O
EpoR O
promoter O
, O
the O
level O
of O
hEpoR O
gene O
expression O
does O
not O
depend O
on O
GATA B
- I
1 I
alone O
. O

The O
deduced O
amino O
acid O
sequence O
similarity O
to O
the O
proteins O
encoded O
by O
these O
two O
latter O
genes O
is O
approximately O
65 O
% O
and O
includes O
domains O
and O
amino O
acid O
residues O
( O
the O
leucine O
zipper O
- O
like O
and O
the O
RGD O
domain O
, O
a O
serine O
and O
a O
histidine O
residue O
in O
the O
NH2 B
- I
and O
in O
the O
COOH O
- O
terminal O
portion O
of O
the O
protein O
, O
respectively O
) O
postulated O
to O
be O
important O
for O
nm23 B
function O
. O

Treatment O
of O
U937 O
with O
IFN B
- I
gamma I
for O
9 O
hr O
in O
the O
presence O
of O
cycloheximide O
led O
to O
super O
- O
induction O
of O
Fc B
gamma I
RI I
expression O
. O

Genomic O
sequence O
upstream O
of O
the O
Fc B
gamma I
RIC I
gene I
was O
cloned O
and O
subjected O
to O
primer O
extension O
analysis O
, O
which O
demonstrated O
a O
single O
transcription B
initiation I
site I
without O
a O
TATA B
box I
. O

Double O
- O
stranded O
GIRE O
sequence O
, O
but O
not O
a O
scrambled O
sequence O
, O
was O
specifically O
bound O
by O
nuclear B
proteins I
from O
IFN O
- O
gamma O
treated O
U937 O
cells O
. O

The O
Fc B
gamma I
RIC I
GIRE I
is O
homologous O
to O
the O
IFN O
- O
gamma O
activation O
sequence O
( O
GAS B
) O
of O
the O
guanylate O
binding O
protein O
and O
to O
X O
box O
elements O
of O
class O
II O
MHC O
genes O
. O

In O
HTLV O
- O
I O
- O
infected O
cord O
blood O
lymphocytes O
, O
the O
transition O
from O
IL B
- I
2 I
- O
dependent O
to O
IL B
- I
2 I
- O
independent O
growth O
correlated O
with O
the O
acquisition O
of O
a O
constitutively O
activated O
Jak B
- B
STAT I
pathway O
, O
which O
suggests O
that O
this O
pathway O
participates O
in O
HTLV O
- O
I O
- O
mediated O
T O
cell O
transformation O
. O

Nitric O
oxide O
selectively O
reduces O
endothelial O
expression O
of O
adhesion B
molecules I
and O
proinflammatory B
cytokines I
. O

In O
a O
concentration O
- O
dependent O
manner O
, O
NO O
inhibited O
interleukin B
( I
IL I
) I
- I
1 I
alpha O
- O
stimulated O
VCAM B
- I
1 I
expression O
by O
35 O
- O
55 O
% O
as O
determined O
by O
cell O
surface O
enzyme O
immunoassays O
and O
flow O
cytometry O
. O

Inhibition O
of O
endogenous O
NO O
production O
by O
L O
- O
N O
- O
monomethyl O
- O
arginine O
also O
induced O
the O
expression O
of O
VCAM B
- I
1 I
, O
but O
did O
not O
augment O
cytokine O
- O
induced O
VCAM B
- I
1 I
expression O
. O

Murine O
macrophage O
inflammatory O
protein O
1 O
alpha O
( O
MIP B
- I
1 I
alpha I
) O
and O
its O
human O
equivalent O
( O
GOS19 B
, O
LD78 O
, O
or O
AT464 O
) O
are O
members O
of O
the O
- O
C O
- O
C O
family O
of O
low O
- O
molecular O
- O
weight O
chemokines O
. O

We O
provide O
evidence O
for O
an O
additional O
binding B
site I
, O
the O
MIP O
- O
1 O
alpha O
nuclear O
protein O
( O
MNP O
) O
site O
, O
which O
overlaps O
the O
ICK O
- O
1 O
site O
. O

The O
signal O
is O
subsequently O
propagated O
through O
the O
activation O
of O
Raf B
- I
1 I
, O
MEK B
, O
and O
MAP B
kinases I
as O
shown O
by O
their O
increased O
autophosphorylation O
in O
vitro O
and O
phosphorylation O
in O
situ O
. O

We O
conclude O
that O
IL B
- I
5 I
induced O
signals O
are O
propagated O
through O
two O
distinct O
pathways O
: O
( O
1 O
) O
Lyn B
- O
- O
> O
Ras B
- O
- O
> O
Raf B
- I
1 I
- O
- O
> O
MEK B
- O
- O
> O
MAP B
kinase I
and O
( O
2 O
) O
Jak2 B
- O
- O
> O
STAT1 B
. O

The O
retinoblastoma B
gene I
product I
negatively O
regulates O
transcriptional O
activation O
mediated O
by O
the O
human O
cytomegalovirus O
IE2 O
protein O
. O

We O
found O
that O
the O
retinoblastoma O
susceptibility O
gene O
product O
( O
Rb B
) O
dramatically O
suppressed O
this O
IE2 B
transactivation O
of O
various O
promoters O
. O

And O
there O
was O
no O
statistically O
significant O
difference O
in O
NDP B
kinase I
expression O
between O
SCC O
with O
metastasis O
and O
SCC O
without O
metastasis O
. O

Retinoblastoma B
protein I
( O
RB B
) O
is O
a O
tumor O
suppressor O
and O
functions O
as O
a O
transcriptional B
repressor I
by O
binding O
and O
inactivating O
the O
transactivator O
E2F O
- O
I O
. O

RB O
- O
defective O
tumor O
lines O
are O
non O
- O
inducible O
for O
MHC B
class I
II I
by O
IFN B
- I
gamma I
, O
or O
very O
weakly O
inducible O
, O
but O
transfection O
of O
2 O
different O
lines O
with O
RB O
expression O
vectors O
re O
- O
establishes O
or O
substantially O
enhances O
class O
II O
inducibility O
. O

We O
also O
examined O
the O
IFN B
- I
gamma I
induction O
of O
CIITA B
in O
RB B
- O
defective O
lines O
. O

We O
have O
recently O
demonstrated O
that O
stimulation O
of O
human O
T O
and O
natural O
killer O
cells O
with O
IL B
- I
12 I
induces O
tyrosine O
phosphorylation O
of O
the O
Janus B
family I
tyrosine I
kinase I
JAK2 B
and O
Tyk2 B
, O
implicating O
these O
kinases B
in O
the O
immediate O
biochemical O
response O
to O
IL B
- I
12 I
. O

Furthermore O
, O
we O
show O
that O
IL B
- I
12 I
stimulates O
formation O
of O
a O
DNA B
- I
binding I
complex I
that O
recognizes O
a O
DNA O
sequence O
previously O
shown O
to O
bind O
STAT B
proteins I
and O
that O
this O
complex O
contains O
STAT4 B
. O

DESIGN O
: O
The O
effects O
of O
hypercortisolaemia O
, O
hyperthermia O
and O
cellular O
composition O
on O
number O
of O
glucocorticoid B
receptors I
per O
cell O
and O
their O
affinity O
were O
evaluated O
, O
both O
in O
vitro O
and O
in O
vivo O
, O
in O
peripheral O
blood O
mononuclear O
leucocytes O
of O
control O
subjects O
and O
in O
patients O
with O
sepsis O
or O
septic O
shock O
. O

RESULTS O
: O
Hypercortisolaemia O
, O
in O
vitro O
, O
resulted O
in O
a O
decreased O
affinity O
and O
a O
decreased O
binding O
capacity O
of O
the O
glucocorticoid B
receptor I
. O

Integrin O
- O
mediated O
tyrosine O
phosphorylation O
and O
cytokine B
message O
induction O
in O
monocytic O
cells O
. O

The O
tyrosine O
kinase O
inhibitors O
genistein O
and O
herbimycin O
A O
block O
both O
integrin B
- O
mediated O
tyrosine O
phosphorylation O
and O
increases O
in O
IL B
- I
1 I
beta I
message O
levels O
, O
indicating O
a O
causal O
relationship O
between O
the O
two O
events O
. O

These O
observations O
indicate O
that O
the O
Syk B
tyrosine O
kinase O
may O
be O
an O
important O
component O
of O
an O
integrin B
signaling O
pathway O
in O
monocytic O
cells O
, O
leading O
to O
activation O
of O
NF B
- I
kappa I
B I
and O
to O
increased O
levels O
of O
cytokine B
messages O
. O

To O
determine O
if O
New O
World O
primates O
express O
an O
inhibitor O
that O
influences O
glucocorticoid B
receptor I
( O
GR B
) O
binding O
characteristics O
, O
we O
examined O
[ O
3H O
] O
dexamethasone O
binding O
in O
cytosol O
prepared O
from O
B95 O
- O
8 O
lymphoid O
cells O
, O
derived O
from O
the O
cotton O
top O
tamarin O
( O
Saguinus O
oedipus O
) O
, O
in O
combination O
with O
cytosol O
prepared O
from O
human O
or O
rat O
tissues O
. O

The O
results O
further O
demonstrated O
the O
activation O
of O
S6 O
kinase O
( O
pp90rsk B
) O
, O
evidenced O
by O
phosphorylation O
of O
S6 B
and O
serum O
response O
factor O
( O
SRF O
) O
peptides O
, O
in O
PWM O
treated O
B O
cells O
. O

We O
have O
recently O
found O
a O
novel O
conserved B
motif I
in O
the O
promoters B
of O
several O
T O
- O
cell O
- O
expressed O
cytokines O
[ O
human O
interleukin O
- O
2 O
, O
- O
4 O
, O
- O
5 O
and O
- O
13 O
and O
human O
and O
mouse O
granulocyte O
/ O
macrophage O
- O
colony O
stimulating O
factor O
( O
GM B
- I
CSF I
) O
] O
. O

In O
transfection O
assays O
, O
the O
human O
GM O
- O
CSF O
element O
has O
a O
strong O
positive O
effect O
on O
the O
expression O
of O
a O
reporter B
gene I
by O
the O
human O
T O
cell O
line O
Jurkat O
J6 O
upon O
stimulation O
. O

In O
different O
genes B
, O
the O
core O
sequences O
are O
separated O
by O
integer O
numbers O
of O
helical O
turns O
. O

Aspirin O
inhibits O
nuclear B
factor I
- I
kappa I
B I
mobilization O
and O
monocyte O
adhesion O
in O
stimulated O
human O
endothelial O
cells O
. O

These O
effects O
of O
aspirin O
were O
not O
related O
to O
the O
inhibition O
of O
cyclooxygenase B
activity O
, O
since O
indomethacin O
was O
ineffective O
. O

Activation O
of O
NF B
- I
kappa I
B I
by O
various O
cellular O
stimuli O
involves O
the O
phosphorylation O
and O
subsequent O
degradation O
of O
its O
inhibitor O
, O
I B
kappa I
B I
alpha I
, O
although O
the O
underlying O
mechanism O
remains O
unclear O
. O

Together O
, O
these O
results O
suggest O
that O
phosphorylation O
of O
I B
kappa I
B I
alpha I
, O
mediated O
through O
both O
the O
TNF B
- I
alpha I
- O
inducible O
and O
the O
PP O
- O
2A O
- O
opposing O
kinases O
, O
may O
serve O
to O
target O
I B
kappa I
B I
alpha I
for O
proteasome B
- O
mediated O
degradation O
. O

The O
5 B
' I
flanking I
region I
of O
the O
human O
alpha O
- O
globin O
gene O
is O
highly O
G O
+ O
C O
rich O
and O
contains O
multiple O
copies O
of O
the O
consensus B
sequence I
for O
the O
Sp1 B
binding I
site I
. O

Finally O
, O
we O
show O
by O
both O
footprint O
analysis O
and O
functional O
assays O
that O
the O
ability O
of O
the O
G B
+ I
C I
- I
rich I
region I
to O
increase O
alpha B
- I
globin I
promoter I
activity O
from O
a O
stably O
integrated O
alpha B
- I
globin I
gene I
is O
mediated O
by O
its O
multiple B
binding I
sites I
for O
the O
transcription B
factor I
Sp1 B
. O

LFA B
- I
3 I
induced O
moderate O
levels O
of O
AP B
- I
1 I
, O
but O
did O
not O
influence O
the O
levels O
of O
NF B
- I
kappa I
B I
, O
while O
B7 B
costimulation O
strongly O
induced O
both O
AP B
- I
1 I
and O
substantially O
enhanced O
NF B
- I
kappa I
B I
binding I
proteins I
. O

The O
Ah B
receptor I
recognizes O
DNA B
binding I
sites I
for O
the O
B B
cell I
transcription I
factor I
, O
BSAP B
: O
a O
possible O
mechanism O
for O
dioxin O
- O
mediated O
alteration O
of O
CD19 B
gene I
expression O
in O
human O
B O
lymphocytes O
. O

In O
addition O
, O
the O
Ah O
receptor O
complex O
recognized O
a O
DNA B
binding I
site I
for O
B O
cell O
lineage O
- O
specific O
activator O
protein O
( O
BSAP B
) O
in O
the O
promoter B
region I
of O
the O
human O
CD19 B
gene I
which O
is O
similar O
to O
the O
consensus O
Ah O
receptor O
DNA O
binding O
site O
. O

We O
recently O
identified O
a O
differentiation O
inhibitory O
factor O
( O
I O
- O
factor O
) O
in O
mouse O
myeloid O
leukemia O
M1 O
cells O
as O
a O
murine B
homolog I
of O
the O
human O
nm23 O
- O
H2 O
gene O
product O
. O

In O
the O
present O
experiment O
, O
we O
examined O
the O
effect O
of O
nm23 B
proteins I
on O
various O
differentiation O
induction O
systems O
of O
human O
leukemic O
cells O
including O
HL O
- O
60 O
, O
U937 O
, O
HEL O
/ O
S O
, O
KU812F O
, O
K562 O
, O
and O
HEL O
cells O
. O

Delayed O
administration O
of O
rBPI21 B
also O
affected O
LPS O
- O
mediated O
activation O
of O
the O
nuclear B
factor I
, O
NF B
- I
kappa I
B I
. O

Two O
to O
4 O
h O
following O
LPS O
addition O
to O
endothelial O
cells O
, O
when O
NF B
- I
kappa I
B I
was O
already O
activated O
, O
addition O
of O
rBPI21 B
resulted O
in O
marked O
reduction O
of O
NF B
- I
kappa I
B I
detectable O
at O
4 O
or O
6 O
h O
. O

GM B
- I
CSF I
and O
IL B
- I
2 I
share O
common O
control O
mechanisms O
in O
response O
to O
costimulatory O
signals O
in O
T O
cells O
. O

Antigen O
complexed O
with O
major O
histocompatibility O
complex O
class O
I O
or O
II O
molecules O
on O
the O
surface O
of O
antigen O
presenting O
cells O
interacts O
with O
the O
T B
cell I
receptor I
( O
TCR B
) O
on O
the O
surface O
of O
T O
cells O
and O
initiates O
an O
activation O
cascade O
. O

Human O
T O
leukemia O
virus O
type O
1 O
( O
HTLV O
- O
1 O
) O
infects O
T O
cells O
and O
can O
lead O
to O
increase O
GM B
- I
CSF I
expression O
. O

This O
observation O
, O
together O
with O
the O
fact O
that O
both O
GM B
- I
CSF I
and O
IL B
- I
2 I
respond O
to O
TCR B
signals O
via O
NFAT B
, O
implies O
a O
high O
degree O
of O
conservation O
in O
the O
regulation O
of O
cytokine B
gene O
expression O
in O
T O
cells O
. O

3 O
. O
Danazol O
decreased O
the O
transcription O
rate O
of O
ER B
gene I
to O
approximately O
50 O
% O
in O
monocytes O
in O
a O
run O
- O
on O
assay O
. O

Formation O
of O
the O
NFAT B
- I
1 I
transcriptional I
complex I
on O
the O
IL B
- I
2 I
promoter I
is O
essential O
for O
IL B
- I
2 I
transcription O
. O

WIN O
53071 O
inhibited O
IL B
- I
2 I
production O
induced O
in O
the O
calcium O
- O
dependent O
PMA O
and O
ionomycin O
pathway O
. O

We O
examined O
mRNA B
levels O
of O
various O
V B
- I
ATPase I
subunits O
during O
differentiation O
of O
both O
native O
monocytes O
and O
the O
cell O
line O
THP O
- O
1 O
, O
and O
found O
that O
transcriptional O
and O
post O
- O
transcriptional O
mechanisms O
could O
account O
for O
increases O
in O
cell O
V B
- I
ATPase I
content O
. O

Primer O
extension O
and O
ribonuclease B
protection O
analyses O
indicate O
a O
single O
major B
transcriptional I
start I
site I
. O

Okadaic O
acid O
augments O
PMA O
- O
as O
well O
as O
calcium O
- O
mediated O
activation O
of O
c B
- I
fos I
, O
and O
has O
little O
or O
no O
effect O
when O
combined O
with O
cAMP O
. O

The O
main O
difference O
between O
Ramos O
( O
B O
cells O
) O
and O
Jurkat O
( O
T O
cells O
) O
in O
the O
regulation O
of O
c B
- I
fos I
is O
that O
cAMP O
plus O
calcium O
is O
strongly O
synergistic O
in O
Jurkat O
and O
is O
without O
effect O
in O
Ramos O
. O

These O
results O
suggest O
that O
cell O
- O
specific O
patterns O
of O
synergy O
are O
an O
essential O
feature O
for O
c B
- I
fos I
induction O
and O
may O
be O
relevant O
for O
c B
- I
fos I
control O
through O
B O
and O
T O
cell O
antigen O
receptors O
. O

These O
results O
imply O
that O
at O
least O
three O
signals O
are O
required O
to O
activate O
the O
GM B
- I
CSF I
proximal I
promoter I
, O
and O
that O
the O
signals O
impinge O
on O
distinct O
transcription B
factors I
that O
bind O
to O
the O
hCLEO O
and O
NF O
- O
kappa O
B O
regions O
of O
the O
promoter B
. O

In O
this O
report O
, O
we O
show O
that O
in O
monocytes O
and O
T O
cells O
IL B
- I
10 I
stimulates O
tyrosine O
phosphorylation O
of O
the O
signal O
transducers O
and O
activators B
of I
transcription I
, O
STAT1 B
alpha I
and O
STAT3 B
, O
in O
a O
differential O
manner O
such O
that O
the O
relative O
formation O
of O
homo O
- O
and O
heterodimers O
varies O
between O
the O
two O
cell O
types O
. O

IL B
- I
10 I
treatment O
of O
both O
T O
cells O
and O
monocytes O
results O
in O
the O
ligand O
- O
induced O
tyrosine O
phosphorylation O
of O
tyk2 B
and O
Jak1 B
, O
but O
not O
Jak2 B
or O
Jak3 B
. O

Selective O
modulation O
of O
immune O
responsiveness O
by O
IL B
- I
10 I
in O
cells O
such O
as O
monocytes O
and O
T O
cells O
may O
result O
in O
part O
from O
the O
differential O
activation O
of O
STAT O
protein O
pairs O
. O

They O
also O
display O
constitutively O
high O
levels O
of O
p59fyn B
and O
CD3 O
zeta O
tyrosine O
phosphorylation O
. O

The O
generation O
of O
second O
messengers O
in O
T O
cells O
normally O
leads O
to O
downstream O
signaling O
that O
results O
in O
transcriptional O
activation O
of O
the O
IL B
- I
2 I
gene I
. O

Levels O
of O
the O
octamer O
, O
NF B
- I
kappa I
B I
( O
p50 B
- I
p65 I
heterodimer I
) O
, O
and O
AP O
- O
1 O
transcriptional O
factors O
are O
constitutively O
elevated O
in O
freshly O
isolated O
Ipr O
CD4 O
- O
8 O
- O
T O
cells O
, O
consistent O
with O
the O
activated O
phenotype O
of O
these O
cells O
. O

We O
demonstrate O
that O
cross O
- O
linking O
CD30 B
with O
an O
anti O
- O
CD30 B
- O
specific O
monoclonal O
antibody O
, O
which O
mimics O
the O
described O
biological O
activities O
of O
the O
CD30 O
ligand O
( O
CD30L B
) O
, O
results O
in O
HIV O
expression O
. O

Type O
II O
major O
histocompatibility O
complex O
combined O
immune O
deficiency O
( O
type O
II O
MHC B
CID O
or O
bare O
lymphocyte O
syndrome O
) O
is O
a O
congenital O
immunodeficiency O
disease O
characterized O
by O
absent O
MHC B
class I
II I
expression O
. O

Here O
, O
we O
demonstrate O
that O
CIITA B
is O
an O
MHC O
class O
II O
gene O
- O
specific O
transcription O
activator O
. O

These O
results O
demonstrate O
that O
P B
- I
selectin I
, O
through O
its O
ligands O
on O
monocytes O
, O
may O
locally O
regulate O
cytokine B
secretion O
in O
inflamed O
tissues O
. O

Here O
, O
we O
report O
that O
nitric O
oxide O
( O
NO O
) O
activates O
p21ras B
in O
human O
T O
cells O
as O
evidenced O
by O
an O
increase O
in O
GTP O
- O
bound O
p21ras O
. O

Circular O
dichroism O
analysis O
reveals O
that O
NO O
induces O
a O
profound O
conformational O
change O
in O
p21ras B
in O
association O
with O
GDP O
/ O
GTP O
exchange O
. O

Furthermore O
, O
we O
demonstrate O
that O
p21ras B
is O
essential O
for O
NO O
- O
induced O
downstream O
signaling O
, O
such O
as O
NF B
- I
kappa I
B I
activation O
, O
and O
that O
endogenous O
NO O
can O
activate O
p21ras B
in O
the O
same O
cell O
. O

These O
studies O
identify O
p21ras B
as O
a O
target O
of O
the O
same O
cell O
. O

These O
studies O
identify O
p21ras B
as O
a O
target O
of O
NO O
in O
T O
cells O
and O
suggest O
that O
NO O
activates O
p21ras B
by O
an O
action O
which O
mimics O
that O
of O
guanine O
nucleotide O
exchange O
factors O
. O

In O
the O
present O
study O
we O
analyzed O
the O
control O
of O
IL B
- I
2 I
promoter I
activity O
in O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
- O
transformed O
B O
cell O
clones O
which O
are O
capable O
of O
secreting O
IL B
- I
2 I
at O
a O
low O
level O
after O
stimulation O
with O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
and O
the O
Ca2 O
+ O
ionophore O
ionomycin O
. O

Transient O
transfections O
using O
reporter B
constructs I
with O
multiples O
of O
transcription B
factor I
binding I
sites I
from O
the O
IL B
- I
2 I
promoter I
[ O
distal O
nuclear O
factor O
( O
NF O
) O
- O
AT O
, O
proximal O
NF O
- O
AT O
, O
AP O
- O
1 O
/ O
Octamer O
( O
UPS O
) O
or O
NF B
- I
chi I
B I
( O
TCEd B
) O
sites O
] O
were O
performed O
. O

In O
EBV O
- O
transformed O
B O
clones O
, O
the O
chi O
B O
site O
exerted O
the O
strongest O
inducible O
activity O
; O
the O
NF B
- I
AT I
binding I
sites I
showed O
either O
no O
or O
only O
weak O
activity O
compared O
to O
Jurkat O
T O
cells O
. O

In O
seven O
EBV O
- O
B O
cell O
clones O
or O
lines O
differing O
in O
their O
capacity O
to O
secrete O
IL B
- I
2 I
, O
the O
activity O
of O
the O
IL B
- I
2 I
promoter I
correlated O
well O
with O
the O
status O
of O
IL B
- I
2 I
secretion O
. O

Latent B
membrane I
protein I
- I
1 I
induces O
cyclin B
D2 I
expression O
, O
pRb B
hyperphosphorylation O
, O
and O
loss O
of O
TGF B
- I
beta I
1 I
- O
mediated O
growth O
inhibition O
in O
EBV O
- O
positive O
B O
cells O
. O

Here O
, O
we O
show O
that O
the O
presence O
of O
either O
wild O
- O
type O
EBV O
or O
its O
transforming O
latent O
membrane O
protein O
- O
1 O
( O
LMP B
- I
1 I
) O
results O
in O
the O
loss O
of O
TGF B
- I
beta I
1 I
- O
mediated O
growth O
inhibition O
in O
human O
B O
cells O
. O

A O
further O
decrease O
in O
the O
T O
cell O
reactivity O
to O
TSHR B
peptides O
was O
observed O
3 O
- O
6 O
months O
after O
surgery O
. O

We O
have O
identified O
an O
in O
vivo O
footprint O
over O
the O
PuF B
site I
on O
the O
translocated O
c B
- I
myc I
allele I
in O
Burkitt O
' O
s O
lymphoma O
cells O
. O

Transfection O
experiments O
with O
c O
- O
myc O
promoter O
constructs O
in O
both O
DHL O
- O
9 O
and O
Raji O
cells O
revealed O
that O
the O
PuF B
site I
functioned O
as O
a O
positive B
regulatory I
element I
in O
B O
cells O
with O
a O
drop O
in O
activity O
with O
mutation O
of O
this O
site O
. O

These O
results O
indicate O
that O
the O
5 B
' I
- I
UTR I
of O
the O
gamma B
- I
gene I
contains O
sequences O
that O
may O
be O
important O
for O
its O
transcriptional O
and O
developmental O
regulation O
. O

However O
, O
this O
deletion O
mutation O
prevented O
the O
induced O
phosphorylation O
, O
degradative O
loss O
, O
and O
functional O
release O
of O
I B
kappa I
B I
alpha I
from O
NF B
- I
kappa I
B I
in O
Tax O
- O
expressing O
cells O
. O

Alanine O
substitutions O
introduced O
at O
two O
serine O
residues O
positioned O
within O
this O
N O
- O
terminal O
regulatory O
region O
of O
I B
kappa I
B I
alpha I
also O
yielded O
constitutive O
repressors O
that O
escaped O
from O
Tax B
- O
induced O
turnover O
and O
that O
potently O
inhibited O
immune O
activation O
pathways O
for O
NF B
- I
kappa I
B I
induction O
, O
including O
those O
initiated O
from O
antigen O
and O
cytokine O
receptors O
. O

In O
contrast O
, O
introduction O
of O
a O
phosphoserine O
mimetic O
at O
these O
sites O
rectified O
this O
functional O
defect O
, O
a O
finding O
consistent O
with O
a O
causal O
linkage O
between O
the O
phosphorylation O
status O
and O
proteolytic O
stability O
of O
this O
cytoplasmic B
inhibitor I
. O

Together O
, O
these O
in O
vivo O
studies O
define O
a O
critical O
signal O
response O
domain O
in O
I B
kappa I
B I
alpha I
that O
coordinately O
controls O
the O
biologic O
activities O
of O
I B
kappa I
B I
alpha I
and O
NF B
- I
kappa I
B I
in O
response O
to O
viral O
and O
immune O
stimuli O
. O

These O
included O
vimentin B
, O
correlating O
to O
cell O
shape O
changes O
, O
cytokeratins O
8 O
and O
18 O
, O
associated O
with O
differentiated O
cell O
types O
of O
prostate O
epithelia O
, O
and O
neuron O
- O
specific O
enolase O
and O
serotonin O
, O
associated O
with O
neuroendocrine O
cells O
. O

Human O
peripheral O
blood O
monocytes O
responded O
to O
stimulation O
of O
platelet B
- I
activating I
factor I
( O
PAF B
) O
with O
up O
- O
regulation O
of O
the O
transcript O
for O
heparin B
- I
binding I
epidermal I
growth I
factor I
- I
like I
growth I
factor I
( O
HB B
- I
EGF I
) O
, O
a O
potent O
mitogen O
for O
vascular O
smooth O
muscle O
cells O
. O

This O
function O
of O
PAF B
was O
observed O
at O
nanomolar O
concentrations O
of O
the O
ligand O
, O
starting O
at O
30 O
min O
after O
stimulation O
. O

These O
functions O
of O
PAF B
appeared O
to O
be O
mediated O
through O
the O
cell O
surface O
PAF O
receptors O
, O
as O
two O
PAF B
receptor O
antagonists O
, O
WEB O
2086 O
and O
L O
- O
659 O
, O
989 O
, O
blocked O
both O
the O
up O
- O
regulation O
of O
HB B
- I
EGF I
mRNA I
and O
kappa O
B O
binding O
activity O
induced O
by O
PAF B
. O

The O
antagonists O
, O
however O
, O
had O
no O
effect O
on O
phorbol O
ester O
- O
induced O
up O
- O
regulation O
of O
HB B
- I
EGF I
mRNA I
and O
kappa O
B O
binding O
activity O
. O

Moreover O
, O
replacement O
of O
the O
DQB O
X2 O
- O
box O
with O
the O
DRA B
X2 I
- I
box I
markedly O
diminished O
the O
activity O
of O
the O
DQB O
promoter O
in O
the O
mutant O
cell O
. O

ZEBRA B
is O
a O
bZIP O
transcriptional O
activator O
which O
binds O
as O
a O
dimer O
to O
7 O
- O
bp O
response O
elements O
within O
EBV B
promoters I
and O
is O
directly O
involved O
in O
the O
stimulation O
of O
virus O
replication O
at O
the O
EBV B
lytic I
origin I
. O

Both O
chimeras O
were O
found O
to O
transactivate O
model O
and O
native O
promoters O
at O
equivalent O
or O
better O
levels O
than O
ZEBRA B
itself O
. O

These O
activation O
domains O
restored O
ZEBRA B
' O
s O
ability O
to O
induce O
early B
antigen I
and O
to O
stimulate O
origin O
replication O
to O
levels O
that O
were O
equal O
to O
or O
greater O
than O
those O
of O
wild O
type O
. O

Because O
these O
are O
the O
characteristics O
of O
a O
signal B
transducer I
and I
activator I
of I
transcription I
( I
Stat I
) I
protein I
, O
we O
determined O
whether O
antibodies O
to O
Stat O
proteins O
will O
interfere O
with O
gel O
mobility O
shift O
and O
found O
that O
antibodies O
to O
IL O
- O
4 O
Stat O
, O
also O
known O
as O
Stat6 B
, O
but O
not O
antibodies B
to O
other O
Stat B
proteins I
, O
interfere O
with O
the O
formation O
of O
the O
IL O
- O
4 O
NAF O
complex O
. O

Monoallelic O
expression O
of O
TAL1 B
was O
observed O
in O
the O
leukemic O
cells O
of O
all O
patients O
( O
8 O
of O
8 O
) O
bearing O
a O
TAL1 B
gene I
rearrangement O
. O

In O
the O
leukemic O
cells O
of O
patients O
without O
detectable O
TAL1 B
rearrangements O
, O
TAL1 B
transcription O
occurred O
in O
either O
a O
monoallelic O
( O
3 O
of O
7 O
patients O
) O
or O
a O
biallelic O
( O
4 O
of O
7 O
patients O
) O
fashion O
. O

Expression O
of O
erythroid B
- I
specific I
genes I
in O
acute O
megakaryoblastic O
leukaemia O
and O
transient O
myeloproliferative O
disorder O
in O
Down O
' O
s O
syndrome O
. O

Acute O
megakaryoblastic O
leukaemia O
( O
M7 O
) O
and O
transient O
myeloproliferative O
disorder O
in O
Down O
' O
s O
syndrome O
( O
TMD O
) O
are O
characterized O
by O
rapid O
growth O
of O
abnormal O
blast O
cells O
which O
express O
megakaryocytic B
markers I
. O

Erythroid B
- I
specific I
mRNAs I
encoding O
gamma B
- I
globin I
and O
erythroid B
delta I
- I
aminolevulinate I
synthase I
were O
found O
to O
be O
expressed O
in O
blasts O
from O
most O
of O
these O
cases O
, O
indicating O
that O
majorities O
of O
the O
blasts O
in O
M7 O
and O
TMD O
cases O
have O
erythroid O
and O
megakaryocytic O
phenotypes O
. O

The O
incubation O
with O
transforming B
growth I
factor I
beta I
1 I
and O
1 O
alpha O
, O
25 O
- O
dihydroxyvitamin O
D3 O
resulted O
in O
a O
5 O
- O
to O
7 O
- O
fold O
increase O
of O
AhR B
mRNA I
. O

In O
vitro O
translated O
Spi O
- O
B O
protein O
can O
bind O
to O
PU O
. O
1 O
binding O
sites O
in O
myeloid B
promoters I
and O
transactivate O
these O
promoters B
in O
nonmyeloid O
cells O
. O

In O
contrast O
, O
PU B
. I
1 I
is O
expressed O
at O
high O
levels O
not O
only O
in O
monocytes O
and O
macrophages O
but O
also O
in O
neutrophils O
, O
indicating O
that O
PU B
. I
1 I
can O
activate O
gene O
expression O
in O
both O
major O
myeloid O
lineages O
. O

The O
promoters B
were O
used O
without O
enhancers B
, O
or O
with O
enhancers B
derived O
from O
the O
beta B
- I
globin I
locus I
control I
region I
and O
the O
alpha O
- O
globin O
HS O
- O
40 O
enhancer O
. O

When O
transfected O
into O
K562 O
cells O
, O
which O
express O
zeta B
- I
globin I
, O
comparable O
amounts O
of O
activity O
were O
obtained O
from O
the O
- O
557 O
and O
- O
417 O
zeta O
- O
luciferase O
constructs O
and O
the O
alpha O
- O
luciferase O
constructs O
when O
no O
enhancers B
or O
the O
alpha O
- O
globin O
locus O
enhancers O
were O
used O
. O

This O
element O
requires O
GATA B
- I
1 I
and O
additional O
unknown O
factors O
for O
maximal O
activity O
. O

Accordingly O
, O
the O
effects O
of O
the O
constitutively O
active O
PKCs O
were O
compared O
to O
the O
effects O
of O
mutationally O
activated O
p21ras B
. O

The O
ability O
of O
PKC B
- I
epsilon I
to O
induce O
transactivation O
of O
NF B
- I
AT I
- I
1 I
and O
AP B
- I
1 I
was O
similar O
to O
the O
stimulatory O
effect O
of O
a O
constitutively O
activated O
p21ras O
. O

These O
results O
indicate O
selective O
functions O
for O
different O
PKC B
isotypes I
in O
T O
cells O
. O

Moreover O
, O
the O
data O
comparing O
the O
effects O
of O
activated B
Ras I
and O
PKC O
mutants O
suggest O
that O
PKC B
- I
alpha I
, O
p21ras B
, O
and O
PKC B
- I
epsilon I
are O
not O
positioned O
linearly O
on O
a O
single O
signal O
transduction O
pathway O
. O

Differences O
in O
binding O
of O
glucocorticoid B
receptor I
to O
DNA O
in O
steroid O
- O
resistant O
asthma O
. O

We O
examined O
the O
ability O
of O
nuclear O
translocated O
glucocorticoid B
receptors I
to O
bind O
to O
their O
DNA B
binding I
sites I
( O
GRE B
) O
using O
electrophoretic O
mobility O
shift O
assays O
in O
PBMC O
from O
patients O
with O
steroid O
- O
sensitive O
and O
steroid O
- O
resistant O
asthma O
. O

Scatchard O
analysis O
of O
glucocorticoid B
receptor I
- O
GRE B
binding O
showed O
no O
change O
in O
binding O
affinity O
but O
did O
show O
a O
reduced O
number O
of O
receptors B
available O
for O
DNA O
binding O
in O
the O
steroid O
- O
resistant O
patients O
. O

Interleukin B
- I
5 I
signaling O
in O
human O
eosinophils O
involves O
JAK2 B
tyrosine I
kinase I
and O
Stat1 B
alpha I
. O

Signaling O
by O
a O
wide O
variety O
of O
cytokines B
, O
including O
interferons B
, O
interleukins B
, O
and O
growth B
factors I
, O
involves O
activation O
of O
JAK B
kinases I
and O
Stat O
( O
Signal O
transducers O
and O
activators O
of O
transcription O
) O
proteins O
. O

From O
supershift O
experiments O
it O
was O
concluded O
that O
one O
DNA B
- I
binding I
complex I
contained O
Stat1 B
alpha I
, O
probably O
as O
a O
homodimer O
. O

It O
was O
found O
that O
the O
propagation O
of O
the O
Tat B
mutants I
containing O
wild B
- I
type I
LTRs I
was O
less O
efficient O
than O
that O
of O
the O
LTR B
- I
modified I
Tat I
mutants I
. O

Here O
we O
show O
that O
the O
lymphoid O
- O
specific O
transcription O
factor O
Oct O
- O
2A O
plays O
a O
critical O
role O
in O
HLA B
- I
DRA I
gene I
expression O
in O
class O
II O
- O
positive O
B O
cell O
lines O
, O
and O
that O
the O
high B
mobility I
group I
protein I
( O
HMG B
) O
I B
/ I
Y I
binds O
to O
multiple O
sites O
within O
the O
DRA B
promoter I
, O
including O
the O
Oct O
- O
2A O
binding O
site O
. O

We O
conclude O
that O
distinct O
sets O
of O
transcription B
factors I
are O
involved O
in O
the O
two O
modes O
of O
HLA B
- I
DRA I
expression O
, O
and O
that O
HMG B
I I
/ I
Y I
may O
be O
important O
for O
B O
cell O
- O
specific O
expression O
, O
and O
is O
essential O
for O
IFN B
- I
gamma I
induction O
. O

In O
lymphoblastoid O
cell O
lines O
, O
six O
EBV O
- O
encoded O
nuclear O
antigens O
( O
EBNA1 O
, O
2 O
, O
3A O
, O
3B O
, O
3C O
, O
- O
LP O
) O
, O
three O
latent B
membrane I
proteins I
( O
LMP1 B
, O
2A B
, O
2B O
) O
, O
and O
two O
nuclear O
RNAs O
( O
EBERs O
) O
are O
expressed O
. O

Expression O
of O
LMP1 B
was O
seen O
in O
variable O
proportions O
of O
tumor O
cells O
in O
two O
cases O
and O
EBNA2 B
was O
detected O
in O
some O
tumor O
cells O
in O
three O
other O
cases O
. O

Eosinophils O
were O
purified O
from O
peripheral O
blood O
by O
discontinuous O
Percoll O
gradients O
and O
stimulated O
with O
IL B
- I
5 I
. O

Whereas O
PHA B
- O
induced O
proliferation O
of O
PBMCs O
derived O
from O
patients O
with O
breast O
cancer O
preoperatively O
was O
significantly O
decreased O
when O
compared O
with O
data O
obtained O
in O
healthy O
control O
individuals O
( O
P O
< O
0 O
. O
001 O
) O
, O
the O
degree O
of O
the O
defect O
in O
PHA B
- O
induced O
proliferation O
of O
PBMCs O
depended O
upon O
the O
tumour O
burden O
as O
manifested O
by O
tumour O
size O
and O
axillary O
lymph O
node O
involvement O
( O
P O
< O
0 O
. O
003 O
in O
each O
case O
) O
. O

PHA B
- O
induced O
proliferation O
of O
PBMCs O
dropped O
significantly O
in O
patients O
who O
received O
adjuvant O
chemotherapy O
consisting O
of O
cyclophosphamide O
, O
methotrexate O
and O
fluorouracil O
( O
CMF O
) O
after O
an O
observation O
period O
of O
6 O
months O
( O
P O
< O
0 O
. O
01 O
) O
, O
but O
not O
in O
patients O
under O
adjuvant O
treatment O
with O
tamoxifen O
only O
. O

We O
thus O
conclude O
that O
PHA B
- O
induced O
proliferation O
of O
PBMCs O
derived O
from O
patients O
with O
breast O
cancer O
depends O
upon O
the O
tumour O
load O
and O
is O
a O
good O
clinical O
predictor O
for O
the O
further O
course O
of O
the O
disease O
. O

A O
previously O
unrecognized O
element O
, O
located O
downstream O
of O
the O
start O
site O
of O
transcription O
in O
the O
first O
exon B
of O
the O
DR O
alpha O
gene O
, O
has O
been O
defined O
that O
enhances O
promoter O
activity O
up O
to O
eightfold O
in O
a O
position O
- O
dependent O
manner O
. O

One O
of O
the O
genes O
that O
encodes O
a O
CBF B
alpha I
subunit I
is O
AML1 B
, O
also O
called O
Cbf O
alpha O
2 O
. O

Three O
different O
isoforms O
of O
CBF B
beta I
were O
also O
tested O
for O
transcriptional O
activity O
on O
the O
SL3 B
enhancer I
. O

These O
results O
indicated O
that O
at O
least O
in O
certain O
cell O
types O
, O
the O
maximum O
activity O
of O
CBF B
required O
both O
subunits O
. O

We O
also O
examined O
whether O
CBF B
could O
distinguish O
a O
1 O
- O
bp O
difference O
between O
the O
enhancer O
core O
of O
SL3 O
and O
the O
core O
of O
the O
nonleukemogenic O
virus O
, O
Akv O
. O

However O
, O
no O
combination O
of O
CBF B
alpha I
and O
CBF B
beta I
subunits O
that O
we O
tested O
was O
able O
to O
distinguish O
the O
1 O
- O
bp O
difference O
in O
transcription O
assays O
. O

Using O
electrophoretic O
mobility O
shift O
assays O
( O
EMSA O
) O
, O
we O
now O
show O
that O
, O
in O
monocytes O
stimulated O
with O
LPS O
or O
TNF B
alpha I
, O
IL B
- I
10 I
inhibits O
nuclear O
stimulation O
of O
nuclear B
factor I
kappa I
B I
( O
NF B
kappa I
B I
) O
, O
a O
transcription B
factor I
involved O
in O
the O
expression O
of O
inflammatory B
cytokine I
genes I
. O
Several O
other O
transcription B
factors I
including O
NF O
- O
IL B
- I
6 I
, O
AP B
- I
1 I
, O
AP B
- I
2 I
, O
GR B
, O
CREB B
, O
Oct B
- I
1 I
, O
and O
Sp B
- I
1 I
are O
not O
affected O
by O
IL B
- I
10 I
. O

Furthermore O
, O
compounds O
such O
as O
tosylphenylalanyl O
chloromethyl O
ketone O
and O
pyrrolidinedithiocar O
that O
are O
known O
to O
selectively O
inhibit O
NF B
kappa I
B I
activation O
block O
cytokine O
gene O
transcription O
in O
LPS O
- O
stimulated O
monocytes O
. O

Taken O
together O
, O
these O
results O
suggest O
that O
inhibition O
of O
NF B
kappa I
B I
activation O
may O
be O
an O
important O
mechanism O
for O
IL B
- I
10 I
suppression O
of O
cytokine O
gene O
transcription O
in O
human O
monocytes O
. O

In O
addition O
, O
this O
TR2RE B
- I
SV40 I
can O
function O
as O
a O
repressor O
to O
suppress O
the O
transcriptional O
activities O
of O
both O
SV40 O
early O
and O
late O
promoters O
. O

We O
have O
analyzed O
CBF B
beta I
- I
MYH11 I
fusion I
transcripts I
by O
RT O
- O
PCR O
in O
myelomonocytic O
leukemias O
, O
with O
or O
without O
eosinophilia O
, O
to O
determine O
whether O
their O
presence O
correlates O
with O
morphology O
. O

Both O
cases O
tested O
also O
showed O
MYH11 B
genomic O
rearrangement O
. O

HIV B
- I
1 I
Tat I
potentiates O
TNF B
- O
induced O
NF B
- I
kappa I
B I
activation O
and O
cytotoxicity O
by O
altering O
the O
cellular O
redox O
state O
. O

In O
HeLa O
cells O
stably O
transfected O
with O
the O
HIV O
- O
1 O
tat O
gene O
( O
HeLa O
- O
tat O
cells O
) O
, O
expression O
of O
the O
Tat B
protein I
enhanced O
both O
TNF B
- O
induced O
activation O
of O
NF B
- I
kappa I
B I
and O
TNF B
- O
mediated O
cytotoxicity O
. O

Thus O
, O
Mn B
- I
SOD I
RNA O
protein O
levels O
and O
activity O
were O
markedly O
reduced O
in O
the O
presence O
of O
Tat B
. O

EBNA B
- I
2 I
is O
known O
to O
interact O
with O
the O
cellular O
DNA O
- O
binding O
protein O
J B
kappa I
and O
is O
recruited O
to O
promoters B
containing O
the O
GTGGGAA O
J O
kappa O
recognition O
sequence O
. O

The O
minimal O
EBNA O
- O
2 O
- O
responsive O
LMP O
- O
1 O
promoter O
includes O
one O
J O
kappa O
- O
binding O
site O
, O
and O
we O
now O
show O
that O
mutation O
of O
that O
site O
, O
such O
that O
J B
kappa I
can O
not O
bind O
, O
reduces O
EBNA B
- I
2 I
responsiveness O
by O
60 O
% O
. O

LBF4 B
is O
B O
- O
and O
T O
- O
cell O
specific O
and O
recognizes O
the O
PU O
. O
1 O
GGAA O
core O
sequence O
as O
shown O
by O
methylation O
interference O
. O

Abnormal O
fast O
feedback O
and O
negative O
feedback O
of O
the O
hypothalamic O
- O
pituitary O
- O
adrenal O
axis O
implicates O
a O
dampened O
limbic O
- O
hippocampal O
glucocorticoid O
type O
II O
receptor O
( O
GCII B
) O
. O

The O
role O
of O
NFATp B
in O
cyclosporin O
A O
- O
sensitive O
tumor O
necrosis O
factor O
- O
alpha O
gene O
transcription O
. O

Thus O
, O
although O
the O
kappa B
3 I
element I
has O
little O
sequence O
similarity O
to O
other O
NFATp B
- I
binding I
sites I
, O
it O
appears O
to O
function O
as O
a O
cyclosporin O
- O
sensitive O
promoter O
element O
in O
T O
cells O
by O
virtue O
of O
its O
ability O
to O
bind O
NFATp B
. O

By O
contrast O
, O
three O
lymphoblastoid O
cell O
lines O
( O
immortalized O
in O
vitro O
with O
Epstein O
- O
Barr O
virus O
) O
were O
weakly O
positive O
and O
MNDA B
was O
up O
- O
regulated O
by O
interferon B
- I
alpha I
( O
IFN B
- I
alpha I
) O
treatment O
. O

Changes O
in O
MNDA B
expression O
occurred O
slowly O
( O
hours O
to O
days O
) O
, O
suggesting O
that O
MNDA B
could O
mediate O
changes O
realized O
over O
a O
long O
period O
. O

EBNA B
- I
2 I
is O
able O
to O
trans O
- O
activate O
the O
expression O
of O
the O
LMP O
gene O
in O
several O
cell O
lines O
. O

Various O
reports O
have O
delineated O
the O
cis B
- I
acting I
elements I
of O
the O
LMP B
promoter I
through O
which O
EBNA B
- I
2 I
mediates O
trans O
- O
activation O
. O

Enhanced O
Ig B
synthesis O
is O
a O
result O
of O
coordinated O
transcriptional O
activation O
of O
Ig B
genes I
without O
promoter O
or O
isotype O
specificity O
, O
and O
differential O
accumulation O
of O
the O
mRNA B
encoding O
the O
secreted O
form O
of O
Ig B
heavy I
chain I
. O

It O
is O
saturable O
and O
subject O
to O
negative O
control O
when O
IL B
- I
6 I
stimulation O
is O
prolonged O
. O

Thus O
, O
differentiation O
of O
B O
cells O
with O
IL B
- I
6 I
in O
vitro O
recapitulates O
the O
hallmarks O
of O
terminal O
B O
differentiation O
in O
vivo O
; O
Oct B
- I
2 I
may O
have O
a O
role O
in O
this O
process O
. O

We O
have O
previously O
shown O
that O
treatment O
of O
Jurkat O
T O
cells O
with O
phytohemaglutinin O
( O
PHA B
) O
and O
the O
phorbol O
ester O
, O
PMA O
, O
activated O
transcription O
initiation O
from O
the O
IL B
- I
3 I
gene I
. O

We O
also O
examined O
the O
function O
of O
the O
IL O
- O
3 O
CK O
- O
1 O
/ O
CK O
- O
2 O
elements O
that O
are O
present O
in O
many O
cytokine B
genes I
and O
found O
that O
they O
acted O
as O
a O
repressor O
of O
basal O
level O
expression O
when O
cloned O
upstream O
of O
a O
heterologous B
promoter I
but O
were O
also O
inducible O
by O
PMA O
/ B
PHA I
. O

Glucocorticoids O
have O
an O
inhibitory O
effect O
on O
inflammatory O
and O
immune O
responses O
, O
and O
this O
may O
be O
through O
the O
modulation O
of O
transcription B
factor I
binding O
to O
DNA O
. O

TNF O
- O
alpha O
, O
IL O
- O
1 O
beta O
and O
phorbol O
myristate O
acetate O
( O
PMA O
) O
treatment O
increased O
AP B
- I
1 I
and O
NF O
kappa O
B O
DNA O
binding O
by O
up O
to O
200 O
% O
but O
decreased O
CREB B
binding O
( O
38 O
% O
) O
over O
a O
60 O
- O
min O
time O
course O
. O

When O
restimulated O
, O
however O
, O
anergic O
T O
cells O
fail O
to O
up O
- O
regulate O
transcription O
of O
the O
IL B
- I
2 I
gene I
and O
in O
consequence O
do O
not O
produce O
IL B
- I
2 I
. O

Using O
a O
highly O
sensitive O
mutation O
screening O
assay O
of O
the O
DNA O
- O
and O
the O
steroid O
- O
binding O
region O
, O
none O
of O
the O
treated O
patients O
revealed O
any O
mutation O
, O
suggesting O
that O
the O
glucocorticoid B
receptor I
in O
the O
CLL O
patients O
tested O
is O
not O
altered O
in O
these O
domains O
. O

Expression O
of O
the O
kappa O
immunoglobulin O
light O
chain O
gene O
requires O
developmental O
- O
and O
tissue O
- O
specific O
regulation O
by O
trans B
- I
acting I
factors I
which O
interact O
with O
two O
distinct O
enhancer B
elements I
. O

Methylation O
studies O
indicated O
that O
the O
tal O
- O
15 O
' O
GC O
- O
rich O
region O
behaves O
like O
a O
CpG B
island I
, O
hypomethylated O
in O
normal O
cells O
, O
and O
methylated O
de O
novo O
on O
transcriptionally O
inactive O
alleles O
in O
established O
cell O
lines O
. O

In O
contrast O
, O
the O
addition O
of O
GM B
- I
CSF I
to O
the O
M O
- O
TAT O
/ O
EPO O
cell O
culture O
decreased O
the O
amount O
of O
hemoglobin O
, O
even O
in O
the O
presence O
of O
EPO B
, O
indicating O
that O
the O
EPO B
signal O
for O
erythroid O
differentiation O
is O
suppressed O
by O
GM B
- I
CSF I
. O

Transient O
chloramphenicol B
acetyltransferase I
assay O
revealed O
that O
the O
region O
containing O
E2F O
binding O
site O
had O
a O
strong O
promoter O
activity O
, O
and O
introduction O
of O
the O
mutation O
at O
the O
E2F O
binding O
site O
resulted O
in O
a O
significant O
loss O
of O
the O
activity O
. O

The O
NFATd O
element O
, O
which O
binds O
the O
transcription B
factor I
NFAT B
- I
1 I
and O
is O
very O
active O
in O
T O
cells O
, O
is O
only O
weakly O
active O
in O
one O
B O
clone O
and O
not O
at O
all O
in O
another O
. O

This O
parallels O
the O
increased O
I B
kappa I
B I
alpha I
synthesis O
secondary O
to O
increased O
I B
kappa I
B I
alpha I
gene O
transcription O
, O
i O
. O
e O
. O
, O
increased O
RNA O
and O
transcriptional O
activity O
of O
its O
promoter O
- O
enhancer O
. O

Transcriptional O
activity O
of O
p105 B
is O
also O
increased O
in O
infected O
cells O
and O
is O
also O
mediated O
by O
NF B
- I
kappa I
B I
through O
a O
specific O
kappa O
B O
motif O
. O

In O
this O
study O
, O
we O
show O
that O
an O
activation O
- O
deficient O
glucocorticoid O
receptor O
mutant O
is O
as O
effective O
as O
the O
wild O
- O
type O
receptor O
in O
repression O
of O
AP B
- I
1 I
activity O
, O
inhibition O
of O
interleukin B
- I
2 I
production O
, O
inhibition O
of O
c B
- I
myc I
expression O
and O
induction O
of O
apoptosis O
. O

HIV O
type O
1 O
protease B
activation O
of O
NF B
- I
kappa I
B I
within O
T O
lymphoid O
cells O
. O

It O
has O
been O
reported O
that O
HIV B
- I
1 I
protease I
may O
cleave O
the O
NF B
- I
kappa I
B I
precursor O
to O
its O
active O
form O
in O
vitro O
. O

Insertion O
of O
this O
chimeric O
promoter O
( O
ISG15 O
LTR O
) O
upstream O
of O
the O
human O
IFNA2 O
gene O
directed O
high O
levels O
of O
IFN B
synthesis O
in O
Tat O
- O
expressing O
cells O
, O
while O
this O
promoter O
was O
not O
responsive O
to O
tumor B
necrosis I
factor I
alpha I
- O
mediated O
activation O
. O

Selected O
transfected O
clones O
produced O
low O
levels O
of O
IFN O
A O
( O
IFNA B
) O
constitutively O
, O
and O
their O
abilities O
to O
express O
interleukin B
- I
2 I
and O
interleukin B
- I
2 I
receptor I
upon O
stimulation O
with O
phytohemagglutinin B
and O
phorbol O
myristate O
acetate O
were O
retained O
. O

Flow O
cytometric O
analysis O
also O
showed O
that O
at O
72 O
h O
of O
virus O
exposure O
fewer O
T O
cells O
from O
the O
elderly O
produced O
interferon B
- I
gamma I
( O
IFN B
- I
gamma I
) O
, O
suggesting O
a O
link O
between O
the O
magnitude O
of O
the O
Fos B
and O
Jun B
and O
IFN B
- I
gamma I
responses O
. O

The O
regulation O
of O
HIV O
by O
retinoic O
acid O
correlates O
with O
cellular O
expression O
of O
the O
retinoic B
acid I
receptors I
. O

The O
second O
abnormality O
in O
kappa O
B O
- O
binding O
activity O
in O
T O
cells O
from O
these O
patients O
is O
that O
RelA B
, O
a O
member O
of O
the O
Rel O
homology O
family O
which O
is O
part O
of O
the O
normal O
NF B
- I
kappa I
B I
complex I
, O
was O
not O
induced O
in O
the O
nucleus O
following O
activation O
. O

In O
extracts O
from O
nonstimulated O
cells O
the O
receptor O
is O
recovered O
in O
an O
inducible O
cytoplasmic O
form O
associated O
with O
the O
90 O
- O
kDa O
heat O
shock O
protein O
( O
hsp90 B
) O
, O
a O
molecular O
chaperone O
. O

It O
was O
not O
possible O
to O
reconstitute O
dioxin B
receptor I
function O
with O
proteins O
expressed O
in O
wheat O
germ O
lysate O
. O

In O
line O
with O
these O
observations O
, O
reticulocyte O
lysate O
but O
not O
wheat O
germ O
lysate O
promoted O
the O
association O
of O
de O
novo O
synthesized O
dioxin B
receptor I
with O
hsp90 B
. O

Induction O
of O
transcription B
factors I
in O
human O
T O
lymphocytes O
by O
aspirin O
- O
like O
drugs O
. O

Protein B
kinase I
C I
is O
not O
a O
downstream O
effector O
of O
p21ras B
in O
activated O
T O
cells O
. O

Data O
is O
presented O
, O
using O
the O
potent O
and O
selective O
PKC B
inhibitor O
Ro O
31 O
- O
8425 O
and O
transient O
expression O
of O
a O
constitutively O
active O
ras O
mutant O
, O
which O
clearly O
shows O
that O
PKC B
is O
not O
downstream O
of O
p21ras B
in O
the O
induction O
of O
NF B
- I
AT I
and O
AP B
- I
1 I
transcriptional O
activity O
and O
in O
the O
expression O
of O
IL B
- I
2 I
in O
human O
Jurkat O
T O
cells O
. O

The O
signaling O
pathways O
involving O
PKC B
activation O
, O
calcium O
mobilization O
and O
ras B
activation O
combine O
to O
provide O
the O
necessary O
components O
for O
production O
of O
IL B
- I
2 I
during O
T O
cell O
activation O
. O

Here O
, O
we O
report O
that O
stimulation O
through O
the O
IL B
- I
2R I
induced O
tyrosine O
phosphorylation O
and O
subsequent O
nuclear O
translocation O
of O
stat3 B
, O
a O
newly O
identified O
member O
of O
the O
signal O
transducers O
and O
activators O
of O
transcription O
( O
STAT O
) O
family O
of O
proteins O
. O

Apart O
from O
stat3 B
, O
another O
cytoplasmic B
protein I
was O
tyrosine O
phosphorylated O
and O
subsequently O
translocated O
to O
the O
nucleus O
in O
response O
to O
IL B
- I
2 I
. O

This O
protein O
had O
an O
apparent O
molecular O
mass O
of O
84 O
kDa O
and O
was O
not O
recognized O
by O
stat3 B
or O
stat1 O
mAb O
or O
antisera O
. O

Taken O
together O
, O
we O
report O
that O
IL B
- I
2 I
induces O
tyrosine O
phosphorylation O
and O
subsequent O
nuclear O
translocation O
of O
stat3 B
and O
an O
as O
yet O
undefined O
84 B
- I
kDa I
protein I
in O
antigen O
- O
specific O
human O
T O
cell O
lines O
. O

Human O
T O
- O
cell O
leukemia O
virus O
type O
I O
Tax B
activation O
of O
NF B
- I
kappa I
B I
/ I
Rel I
involves O
phosphorylation O
and O
degradation O
of O
I B
kappa I
B I
alpha I
and O
RelA B
( O
p65 B
) O
- O
mediated O
induction O
of O
the O
c B
- I
rel I
gene I
. O

The O
tax O
gene O
product O
of O
human O
T O
- O
cell O
leukemia O
virus O
type O
I O
( O
HTLV O
- O
I O
) O
is O
a O
potent O
transcriptional B
activator I
that O
both O
stimulates O
viral O
gene O
expression O
and O
activates O
an O
array O
of O
cellular B
genes I
involved O
in O
T O
- O
cell O
growth O
. O

In O
contrast O
to O
prior O
in O
vitro O
studies O
, O
at O
least O
a O
fraction O
of O
the O
phosphorylated O
form O
of O
I B
kappa I
B I
alpha I
remains O
physically O
associated O
with O
the O
NF B
- I
kappa I
B I
complex I
in O
vivo O
but O
is O
subject O
to O
rapid O
degradation O
, O
thereby O
promoting O
the O
nuclear O
translocation O
of O
the O
active O
NF B
- I
kappa I
B I
complex I
. O

Therefore O
we O
investigated O
the O
modifications O
imposed O
on O
NF O
- O
kappa O
B O
/ O
I O
kappa O
B O
components O
following O
stimulation O
and O
show O
that O
the O
final O
step O
of O
NF B
- I
kappa I
B I
induction O
in O
vivo O
involves O
phosphorylation O
of O
several O
members O
of O
the O
NF O
- O
kappa O
B O
/ O
I O
kappa O
B O
protein O
families O
. O

Isolation O
of O
differentially O
expressed O
sequence O
tags O
from O
steroid O
- O
responsive O
cells O
using O
mRNA B
differential O
display O
. O

In O
this O
paper O
we O
describe O
results O
using O
mRNA B
differential O
display O
reverse B
transcriptase I
PCR O
( O
DDPCR O
) O
to O
identify O
and O
isolate O
short O
cDNA O
sequence O
tags O
from O
thymocyte O
and O
prostate O
cells O
under O
various O
hormone O
conditions O
. O

GIG10 B
is O
a O
novel O
sequence O
and O
GIG18 B
is O
the O
mouse O
homologue O
of O
a O
human O
expressed O
sequence O
tag O
isolated O
from O
activated O
B O
lymphocytes O
. O

We O
have O
shown O
that O
, O
within O
the O
thymus O
, O
a O
population O
of O
large O
, O
immature O
cells O
expresses O
CD21 B
. O

This O
function O
was O
a O
result O
of O
the O
interaction O
of O
EBV O
with O
its O
receptor O
, O
CD21 B
, O
but O
was O
caused O
by O
infection O
rather O
than O
surface O
signaling O
, O
because O
neither O
specific O
mAb O
nor O
the O
P3HR O
- O
1 O
strain O
of O
virus O
mimicked O
the O
effect O
of O
B95 O
- O
8 O
. O

A O
second O
transcript O
was O
identified O
as O
encoding O
the O
recently O
characterized O
RAZ B
, O
which O
also O
is O
associated O
with O
replicative O
infection O
. O

The O
regulation O
of O
nuclear B
factor I
( I
NF I
) I
- I
kappa I
B I
activation O
by O
the O
T B
cell I
receptor I
( I
TcR I
) I
/ I
CD3 I
complex I
in O
primary O
human O
T O
cells O
has O
been O
studied O
at O
various O
times O
after O
activation O
. O

These O
results O
indicate O
that O
the O
regulation O
of O
NF B
- I
kappa I
B I
activation O
during O
T O
cell O
activation O
by O
TcR B
/ I
CD3 I
signals O
is O
biphasic O
: O
TcR B
/ I
CD3 I
triggers O
its O
immediate O
translocation O
, O
which O
is O
transient O
if O
no O
TNF B
- I
alpha I
is O
present O
. O

The O
cis B
- I
acting I
region I
, O
GM B
- I
kappa I
B I
/ I
GC I
- I
box I
( O
positions O
- O
95 O
and O
- O
73 O
) O
, O
within O
the O
murine O
GM O
- O
CSF O
gene O
promoter O
is O
required O
for O
maximal O
induction O
by O
stimulation O
with O
phorbol O
- O
12 O
- O
myristate O
acetate O
( O
PMA O
) O
and O
calcium O
ionophore O
( O
A23187 O
) O
in O
T O
cells O
. O

We O
report O
here O
that O
three O
copies O
of O
the O
GC B
- I
box I
can O
functionally O
compensate O
for O
the O
GM O
- O
kappa O
B O
/ O
GC O
- O
box O
region O
, O
suggesting O
that O
the O
GC O
- O
motif O
can O
function O
independently O
of O
the O
GM O
- O
kappa O
B O
motif O
. O

A O
factor O
that O
regulates O
the O
class B
II I
major I
histocompatibility I
complex I
gene I
DPA O
is O
a O
member O
of O
a O
subfamily O
of O
zinc B
finger I
proteins I
that O
includes O
a O
Drosophila O
developmental O
control O
protein O
. O

It O
encodes O
a O
protein O
predicted O
to O
contain O
688 O
amino O
acid O
residues O
, O
including O
11 O
zinc B
finger I
motifs I
of O
the O
C2H2 O
type O
in O
the O
C B
- I
terminal I
region I
, O
that O
are O
Kruppel O
- O
like O
in O
the O
conservation O
of O
the O
H O
/ O
C O
link O
sequence O
connecting O
them O
. O

One O
of O
the O
Drosophila O
sequences O
, O
ttk O
, O
is O
a O
developmental O
control O
gene O
, O
while O
a O
second O
does O
not O
contain O
a O
zinc B
finger I
region I
but O
encodes O
a O
structure O
important O
in O
oocyte O
development O
. O

These O
initial O
pathways O
culminate O
in O
a O
common O
pathway O
through O
which O
all O
of O
the O
stimulating O
agents O
ultimately O
signal O
NF B
- I
kappa I
B I
activation O
. O

This O
Oct B
- I
2 I
- O
dependent O
transactivation O
is O
inhibited O
by O
RA O
. O

We O
also O
show O
that O
both O
Fos B
and O
Jun B
components O
of O
the O
AP B
- I
1 I
factors O
participate O
in O
the O
OAP40 O
complex O
. O

OAP B
confers O
to O
Oct B
- I
2 I
responsivity O
to O
both O
TPA O
/ O
Ca2 O
+ O
and O
RA O
, O
since O
specific O
mutations O
of O
the O
AP O
- O
1 O
/ O
OAP O
- O
binding O
site O
significantly O
reduce O
the O
transactivation O
by O
Oct B
- I
2 I
in O
response O
to O
TPA O
and O
Ca2 O
+ O
and O
abolish O
the O
inhibition O
by O
RA O
. O

Therefore O
, O
we O
propose O
that O
the O
TPA O
/ O
calcium O
- O
activated O
AP B
- I
1 I
/ B
OAP I
element O
is O
the O
main O
target O
of O
positive O
or O
negative O
regulatory O
signals O
influencing O
the O
IL B
- I
2 I
octamer I
motif I
, O
through O
synergism O
with O
Oct B
- I
2 I
and O
antagonism O
by O
RAR B
. O

An O
NF B
- I
kappa I
B I
binding O
site O
is O
an O
essential O
component O
of O
the O
element O
but O
alone O
is O
not O
sufficient O
to O
account O
for O
the O
activity O
or O
the O
specificity O
of O
the O
element O
. O

Thapsigargin O
( O
TG O
) O
, O
an O
inhibitor O
of O
Ca B
( I
2 I
+ I
) I
- I
ATPase I
, O
depletes O
intracellular O
Ca2 O
+ O
stores O
and O
induces O
a O
sustained O
Ca2 O
+ O
influx O
without O
altering O
phosphatidyl O
inositol O
levels O
. O

A O
similar O
increase O
in O
IL B
- I
2R I
alpha I
by O
TG O
was O
also O
observed O
in O
human O
peripheral O
T O
cells O
. O

However O
, O
TG O
and O
PMA O
exhibited O
a O
synergistic O
action O
on O
IL B
- I
2R I
alpha I
expression O
, O
suggesting O
that O
TG O
and O
PMA O
induce O
IL B
- I
2R I
alpha I
through O
distinct O
pathways O
. O

PMA O
- O
but O
not O
TG O
- O
induced O
IL O
- O
2R O
alpha O
is O
inhibited O
by O
the O
PKC B
inhibitor O
H7 O
, O
whereas O
TG O
- O
but O
not O
PMA O
- O
induced O
IL O
- O
2R O
alpha O
was O
inhibited O
by O
cholera O
toxin O
, O
forskolin O
and O
1 O
, O
9 O
- O
dideoxy O
forskolin O
. O

Two O
gel O
shift O
complexes O
( O
Mono B
A I
and O
Mono B
B I
) O
were O
formed O
with O
separate O
sequence O
elements O
within O
this O
region O
. O

Pyrrolidine O
dithiocarbamate O
, O
a O
potent O
inhibitor O
of O
nuclear B
factor I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
activation O
, O
prevents O
apoptosis O
in O
human O
promyelocytic O
leukemia O
HL O
- O
60 O
cells O
and O
thymocytes O
. O

However O
, O
PDTC O
failed O
to O
inhibit O
the O
endonuclease B
activity O
contained O
in O
the O
whole O
cell O
lysates O
. O

PKC O
- O
zeta O
cells O
expressed O
a O
more O
differentiated O
phenotype O
as O
assessed O
by O
changes O
in O
morphology O
, O
surface O
antigen O
expression O
, O
and O
lysosomal B
enzyme I
activities O
and O
were O
distinct O
from O
parental O
U937 O
cells O
stimulated O
to O
differentiate O
by O
exposure O
to O
phorbol O
esters O
. O

Increased O
expression O
of O
the O
c B
- I
jun I
protooncogene O
and O
an O
increase O
in O
AP B
- I
1 I
binding O
activity O
in O
PKC O
- O
zeta O
cells O
provides O
a O
potential O
mechanism O
for O
explaining O
the O
altered O
differentiation O
status O
of O
this O
cell O
. O

It O
is O
surprising O
that O
the O
faster B
- I
migrating I
complex I
was O
composed O
also O
of O
p50 B
and O
p65 B
. O

OBF B
- I
1 I
, O
a O
novel O
B O
cell O
- O
specific O
coactivator O
that O
stimulates O
immunoglobulin B
promoter I
activity O
through O
association O
with O
octamer B
- I
binding I
proteins I
. O

The O
first O
early O
- O
induced O
peak O
was O
transient O
and O
likely O
corresponds O
to O
the O
well O
documented O
typical O
junB B
mRNA I
, O
stimulated O
in O
response O
to O
numerous O
growth B
factors I
, O
including O
IL B
- I
6 I
. O

Second O
, O
tyrphostin O
, O
a O
tyrosine O
kinase O
inhibitor O
, O
impaired O
the O
expression O
of O
the O
first O
but O
not O
the O
second O
junB B
mRNA I
peak O
. O

Erythropoietin B
( O
Epo B
) O
, O
granulocyte B
/ I
macrophage I
colony I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
, O
and O
interleukin B
3 I
( O
IL B
- I
3 I
) O
promoted O
the O
growth O
of O
NS O
- O
Meg O
cells O
. O

Ten O
- O
day O
exposure O
to O
Epo B
induced O
mature O
erythroblasts O
and O
red O
cells O
. O

These O
benzidine O
- O
positive O
cells O
were O
positive O
for O
hemoglobin B
F O
staining O
. O

The O
T B
cell I
surface I
molecule I
CD28 B
binds O
to O
ligands O
on O
accessory O
cells O
and O
APCs O
, O
playing O
an O
important O
costimulatory O
role O
in O
the O
response O
of O
T O
cells O
to O
Ags B
. O

Enhanced O
responsiveness O
to O
nuclear B
factor I
kappa I
B I
contributes O
to O
the O
unique O
phenotype O
of O
simian O
immunodeficiency O
virus O
variant O
SIVsmmPBj14 O
. O

In O
a O
wide O
range O
of O
cell O
types O
, O
the O
basal O
transcriptional O
activity O
of O
the O
LTR B
from O
SIVsmmPBj14 O
was O
found O
to O
be O
2 O
- O
to O
4 O
. O
5 O
- O
fold O
higher O
than O
that O
of O
an O
LTR B
from O
a O
non O
- O
acutely O
pathogenic O
strain O
. O

Mutagenesis O
studies O
, O
and O
the O
use O
of O
a O
reporter O
construct O
containing O
an O
enhancerless O
promoter O
, O
indicate O
that O
these O
transcriptional O
effects O
are O
due O
principally O
to O
the O
22 O
- O
bp O
sequence O
duplication O
and O
the O
NF B
kappa I
B I
site I
contained O
within O
it O
. O

In O
such O
cells O
, O
DNA O
binding O
activity O
of O
NF B
- I
kappa I
B I
can O
be O
detected O
without O
intentional O
stimulation O
. O

This O
nuclear B
NF I
- I
kappa I
B I
was O
still O
present O
when O
contaminant O
LPS O
was O
removed O
by O
ultrafiltration O
and O
when O
serum O
was O
omitted O
. O

Using O
LPS O
- O
free O
and O
serum O
- O
free O
conditions O
, O
constitutive O
NF B
- I
kappa I
B I
can O
be O
detected O
in O
different O
cell O
lines O
of O
the O
monocytic O
lineage O
( O
HL60 O
, O
U937 O
, O
THP O
- O
1 O
, O
Mono O
Mac O
1 O
and O
Mono O
Mac O
6 O
) O
, O
but O
not O
in O
Molt O
4 O
T O
cells O
or O
K562 O
stem O
cells O
. O

The O
constitutive O
NF B
- I
kappa I
B I
appears O
to O
be O
functionally O
active O
, O
since O
a O
low O
level O
of O
tumour O
necrosis O
factor O
( O
TNF O
) O
transcript O
is O
detectable O
in O
monocytes O
, O
and O
this O
level O
can O
be O
increased O
by O
blocking O
transcript O
degradation O
using O
cycloheximide O
. O

In O
contrast O
, O
SCL B
mRNA I
levels O
did O
not O
decrease O
significantly O
between O
day O
7 O
and O
day O
14 O
cells O
, O
suggesting O
that O
posttranscriptional O
mechanisms O
are O
largely O
responsible O
for O
the O
decrease O
in O
SCL B
protein I
observed O
. O

In O
BFU O
- O
E O
- O
derived O
colonies O
cultured O
with O
Steel B
factor I
, O
colony O
size O
was O
significantly O
increased O
compared O
to O
control O
. O

Activated O
macrophages O
contribute O
to O
chronic O
inflammation O
by O
the O
secretion O
of O
cytokines B
and O
proteinases O
. O

Tumor B
necrosis I
factor I
alpha I
( O
TNF B
alpha I
) O
is O
particularly O
important O
in O
this O
process O
because O
of O
its O
ability O
to O
regulate O
other O
inflammatory O
mediators O
in O
an O
autocrine O
and O
paracrine O
fashion O
. O

We O
present O
data O
to O
show O
that O
the O
expression O
of O
TNF B
alpha I
is O
regulated O
by O
the O
transcription B
factor I
C B
/ I
EBP I
beta I
( O
NF B
- I
IL6 I
) O
. O

Calcium O
/ O
calmodulin O
- O
dependent O
protein O
kinase O
II O
downregulates O
both O
calcineurin O
and O
protein O
kinase O
C O
- O
mediated O
pathways O
for O
cytokine B
gene I
transcription O
in O
human O
T O
cells O
. O

However O
, O
the O
role O
of O
CaM B
- I
K I
II I
remains O
unknown O
. O

We O
have O
used O
mutants O
of O
these O
kinases B
and O
phosphatases B
( O
gamma B
B I
* I
CaM I
- I
K I
and O
delta B
CaM I
- I
AI I
, O
respectively O
) O
to O
explore O
their O
relative O
role O
in O
cytokine B
gene I
transcription O
and O
their O
interactions O
with O
PKC B
- O
dependent O
signaling O
systems O
. O

When O
both O
mutants O
were O
used O
in O
combination O
, O
gamma B
B I
* I
CaM I
- I
K I
inhibited O
the O
induction O
of O
the O
IL B
- I
2 I
promoter I
by O
delta B
CaM I
- I
AI I
. O

Similar O
results O
were O
obtained O
when O
a O
construct O
containing O
the O
IL B
- I
4 I
promoter I
also O
was O
used O
. O

Induction O
of O
TaxI B
in O
a O
human O
T O
- O
cell O
line O
Jurkat O
carrying O
the O
TaxI O
gene O
under O
the O
metallothionein B
promoter I
led O
to O
increases O
in O
mRNA B
and O
surface O
expression O
of O
ICAM B
- I
I I
. O

Three O
other O
ATL O
cell O
lines O
( O
TL O
- O
OmI O
, O
H582 O
, O
HuT102 O
) O
were O
found O
to O
have O
little O
mRNA B
for O
the O
LFA O
- O
I O
beta O
chain O
( O
CD18 B
) O
. O

Infection O
with O
Theileria O
annulata O
induces O
expression O
of O
matrix B
metalloproteinase I
9 I
and O
transcription B
factor I
AP B
- I
1 I
in O
bovine O
leucocytes O
. O

T O
. O
annulata O
- O
infected O
leucocytes O
produce O
a O
number O
of O
novel O
metalloproteinase B
activities O
. O

One O
of O
these O
, O
previously O
called O
B1 B
, O
is O
a O
97 B
- I
kDa I
protein I
which O
is O
secreted O
in O
large O
amounts O
and O
has O
been O
purified O
from O
protein O
- O
free O
, O
conditioned O
medium O
. O

In O
addition O
we O
assayed O
the O
level O
of O
mRNA B
encoding O
c B
- I
Fos I
, O
a O
common O
component O
of O
AP B
- I
1 I
and O
observed O
that O
it O
was O
indeed O
up O
- O
regulated O
in O
infected O
cells O
. O

We O
generated O
conditional O
EBV O
mutants O
by O
expressing O
EBNA2 B
as O
chimeric O
fusion O
protein O
with O
the O
hormone O
binding O
domain O
of O
the O
estrogen B
receptor I
on O
the O
genetic O
background O
of O
the O
virus O
. O

These O
data O
suggest O
that O
EBV O
is O
using O
a O
common O
pathway O
for O
B O
- O
cell O
activation O
bypassing O
the O
requirement O
for O
antigen O
, O
T O
- O
cell O
signals O
and O
growth B
factors I
. O

The O
synergistic O
antigen B
receptor I
initiated O
signals O
are O
mediated O
through O
protein B
kinase I
C I
because O
they O
can O
be O
mimicked O
by O
the O
phorbol O
ester O
, O
12 O
- O
O O
- O
tetradecanoylphorbol O
- O
13 O
- O
acetate O
, O
but O
not O
with O
calcium O
ionophores O
; O
and O
are O
staurosporine O
sensitive O
but O
cyclosporine O
resistant O
. O

The O
IL B
- I
1 I
- O
induced O
NF B
- I
kappa I
B I
DNA O
nuclear O
localization O
is O
transient O
and O
can O
be O
prolonged O
either O
by O
an O
antigen O
receptor O
- O
initiated O
signal O
or O
by O
inhibiting O
protein O
synthesis O
. O

A O
synthetic O
oligodeoxyribonucleo O
containing O
an O
SP1 O
- O
box O
( O
5 O
' O
- O
GGGCGG O
) O
could O
compete O
with O
factors O
binding O
to O
the O
12 B
- I
bp I
insert I
. O

Computer O
analysis O
of O
the O
SM B
protein I
sequence O
showed O
a O
C O
terminal O
section O
of O
SM B
to O
be O
related O
to O
genome O
positional O
homologues O
of O
four O
other O
herpesviruses O
and O
revealed O
consensus O
CKII O
sites O
near O
the O
N O
termini O
of O
the O
EBV O
SM O
protein O
, O
the O
herpes O
simplex O
virus O
( O
HSV O
) O
ICP27 O
protein O
and O
the O
herpesvirus O
saimiri O
( O
HVS O
) O
open O
reading O
frame O
57 O
protein O
. O

Mutagenesis O
of O
the O
CKII B
site O
in O
SM B
made O
no O
difference O
to O
the O
transactivation O
in O
this O
transient O
transfection O
assay O
. O

The O
proto B
- I
oncogene I
c I
- I
fos I
is O
an O
immediate B
- I
early I
gene I
, O
and O
one O
of O
the O
first O
genes O
transcribed O
after O
stimulation O
of O
most O
cells O
with O
a O
variety O
of O
ligands O
. O

The O
serum B
response I
element I
( O
SRE B
) O
in O
the O
c O
- O
fos O
regulatory O
region O
participates O
in O
induction O
of O
transcription O
by O
various O
growth B
factors I
and O
by O
phorbol O
esters O
and O
subsequent O
squelching O
of O
transcription O
. O

Band B
A I
contains O
the O
serum B
response I
factor I
plus O
additional O
factor O
( O
s O
) O
. O

Thus O
, O
the O
use O
of O
DNase B
I I
allowed O
us O
, O
for O
the O
first O
time O
, O
to O
correlate O
the O
AIR B
- I
1 I
locus I
defect I
with O
class O
II O
promoter O
occupancy O
alterations O
and O
distinguish O
these O
alterations O
from O
the O
ones O
observed O
in O
phenotypically O
similar O
but O
genetically O
distinct O
MHC O
class O
II O
- O
negative O
cells O
. O

The O
interleukin B
2 I
receptor I
alpha I
- I
chain I
( I
IL I
- I
2R I
alpha I
) I
gene I
is O
rapidly O
and O
potently O
induced O
in O
T O
cells O
in O
response O
to O
mitogenic O
stimuli O
. O

This O
element O
had O
maximal O
activity O
in O
lymphoid O
cells O
, O
paralleling O
the O
cell O
type O
specificity O
of O
Elf B
- I
1 I
expression O
. O

Elf B
- I
1 I
physically O
associated O
with O
HMG B
- I
I I
and O
with O
NF B
- I
kappa I
B I
p50 B
and O
c B
- I
Rel I
in O
vitro O
, O
suggesting O
that O
protein O
- O
protein O
interactions O
might O
functionally O
coordinate O
the O
actions O
of O
the O
upstream O
and O
downstream O
positive O
regulatory O
elements O
. O

Aspirin O
- O
like O
drugs O
can O
protect O
human O
T O
lymphocytes O
against O
benzoquinone O
cytotoxicity O
: O
evidence O
for O
a O
NAD B
( I
P I
) I
H I
: I
quinone I
reductase I
- O
dependent O
mechanism O
. O

The O
expression O
of O
the O
QR O
gene O
is O
regulated O
by O
the O
transcription B
factor I
AP B
- I
1 I
. O

ALDs O
induced O
QR B
activity O
in O
the O
M4 O
cells O
in O
the O
same O
range O
of O
concentrations O
that O
protected O
the O
cells O
against O
BQ O
toxicity O
. O

These O
findings O
suggest O
a O
molecular O
mechanism O
of O
positive O
regulation O
of O
PAFR O
gene O
expression O
by O
PAF B
through O
NF B
- I
kappa I
B I
, O
possibly O
by O
a O
phosphorylation O
reaction O
involving O
protein B
kinase I
C I
by O
PAF B
. O

One O
gene O
, O
two O
transcripts B
: O
isolation O
of O
an O
alternative O
transcript O
encoding O
for O
the O
autoantigen O
La O
/ O
SS O
- O
B O
from O
a O
cDNA B
library I
of O
a O
patient O
with O
primary O
Sjogrens O
' O
syndrome O
. O

These O
inhibitors O
specifically O
prevented O
degradation O
of O
I B
kappa I
B I
alpha I
and O
nuclear O
translocation O
of O
c B
- I
Rel I
/ I
p65 I
heterodimers I
. O

In O
contrast O
, O
TPCK O
and O
TLCK O
did O
not O
block O
induction O
of O
an O
immediate B
- I
early I
gene I
encoding O
the O
transcription B
factor I
, O
Egr B
- I
1 I
. O

Studies O
of O
these O
females O
show O
that O
the O
XIST O
locus O
on O
their O
tiny B
ring I
X I
chromosomes I
is O
either O
not O
present O
or O
not O
expressed O
. O

As O
XIST O
transcription O
is O
well O
correlated O
with O
inactivation O
of O
the O
X B
chromosome I
in O
female O
somatic O
cells O
and O
spermatogonia O
, O
nonexpression O
of O
the O
locus O
even O
when O
it O
is O
present O
suggests O
that O
these O
chromosomes B
are O
transcriptionally O
active O
. O

We O
examined O
the O
transcriptional O
activity O
of O
ring O
X B
chromosomes I
lacking O
XIST O
expression O
( O
XISTE O
- O
) O
, O
from O
three O
females O
with O
severe O
phenotypes O
. O

The O
increase O
in O
IL B
- I
2 I
gene O
expression O
triggered O
by O
CD28 B
involves O
a O
kappa O
B O
- O
like O
sequence O
in O
the O
5 B
' I
- I
regulatory I
region I
of O
the O
IL B
- I
2 I
promoter I
, O
called O
CD28 B
- I
responsive I
element I
. O

Here O
we O
report O
that O
CD28 B
engagement O
, O
however O
, O
exerts O
opposite O
effects O
on O
the O
transcription B
factor I
AP I
- I
1 I
. O

The O
activity O
of O
constructs O
containing O
5 O
' O
deletion O
mutants O
of O
the O
alpha B
4 I
gene I
promoter I
was O
compared O
in O
transfection O
assays O
into O
cell O
lines O
that O
express O
alpha B
4 I
and O
cell O
lines O
that O
do O
not O
. O

The O
sequence O
between O
position O
- O
42 O
and O
- O
76 O
base O
pairs O
( O
bp O
) O
was O
required O
for O
efficient O
transcription O
in O
cells O
that O
express O
alpha B
4 I
, O
but O
it O
showed O
no O
activity O
in O
HeLa O
cells O
, O
which O
do O
not O
express O
alpha B
4 I
. O

When O
all O
three O
sites O
were O
present O
, O
a O
second O
complex O
` O
` O
a O
' O
' O
was O
detected O
, O
which O
contains O
an O
unknown O
member O
of O
the O
Ets B
family I
. O

This O
arrangement O
of O
Ets B
sites I
, O
coupled O
with O
the O
tissue O
- O
and O
developmental O
- O
specific O
expression O
of O
Ets O
members O
, O
likely O
play O
a O
key O
role O
in O
defining O
the O
pattern O
of O
alpha O
4 O
integrin O
. O

Antiandrogens O
result O
in O
protection O
of O
both O
the O
hinge B
region I
and O
C B
- I
terminus I
of O
the O
androgen B
receptor I
agonist O
proteolytic O
attack O
, O
whereas O
other O
studies O
showed O
that O
antiestrogens O
and O
antiprogestagens O
expose O
the O
C O
- O
terminal O
end O
of O
the O
ligand B
binding I
domain I
of O
their O
respective O
receptors O
to O
protease B
. O

However O
, O
reagents O
such O
as O
nerve O
growth O
factor O
( O
NGF B
) O
and O
the O
phorbol O
ester O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
PMA O
) O
, O
which O
induce O
phenotypical O
differentiation O
of O
the O
SH O
- O
SY5Y O
neuroblastoma O
cell O
line O
, O
activated O
NF B
- I
kappa I
B I
, O
but O
only O
in O
that O
particular O
cell O
line O
. O

To O
identify O
ets O
- O
related O
transcriptional O
regulators O
expressed O
in O
pre O
- O
B O
lymphocytes O
that O
may O
interact O
with O
either O
the O
pi B
or O
the O
microB O
site O
, O
we O
have O
used O
a O
PCR O
approach O
with O
degenerate O
oligonucleotides O
encoding O
conserved O
sequences O
in O
all O
members O
of O
the O
ets B
family I
. O

We O
have O
cloned O
the O
gene O
for O
a O
new O
ets B
- I
related I
transcription I
factor I
, O
ERP B
( O
ets B
- I
related I
protein I
) O
, O
from O
the O
murine O
pre O
- O
B O
cell O
line O
BASC O
6C2 O
and O
from O
mouse O
lung O
tissue O
. O

Full O
- O
length O
ERP B
expresses O
only O
negligible O
DNA O
- O
binding O
activity O
by O
itself O
. O

Two O
cis B
- I
acting I
elements I
GM B
- I
kappa I
B I
/ I
GC I
- I
box I
and O
CLE0 B
, O
of O
the O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( I
GM I
- I
CSF I
) I
gene I
are O
required O
for O
maximal O
induction O
in O
Jurkat O
T O
cells O
by O
costimulation O
with O
phorbol O
- O
12 O
- O
myristate O
acetate O
( O
PMA O
) O
and O
Ca2 O
+ O
ionophore O
( O
A23187 O
) O
. O

Nonpituitary O
human O
prolactin O
gene O
transcription O
is O
independent O
of O
Pit B
- I
1 I
and O
differentially O
controlled O
in O
lymphocytes O
and O
in O
endometrial O
stroma O
. O

Our O
experiments O
also O
show O
that O
activated O
PR B
does O
not O
confer O
direct O
transcriptional O
control O
on O
the O
dPRL B
promoter I
. O

One O
of O
the O
nuclear B
factors I
( O
NFs O
) O
that O
regulates O
the O
response O
of O
the O
IL B
- I
5 I
promoter I
to O
cAMP O
and O
PMA O
has O
properties O
similar O
to O
NF O
for O
activated O
t O
cell O
. O

JNK B
is O
involved O
in O
signal O
integration O
during O
costimulation O
of O
T O
lymphocytes O
. O

T O
lymphocyte O
activation O
and O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
production O
require O
at O
least O
two O
signals O
, O
generated O
by O
phorbol O
ester O
( O
TPA O
) O
and O
Ca2 O
+ O
ionophore O
or O
costimulation O
of O
the O
T B
cell I
receptor I
( O
TCR B
) O
and O
the O
CD28 O
auxiliary O
receptor O
. O

Full O
activation O
of O
the O
MAP B
kinases I
that O
phosphorylate O
the O
Jun O
activation O
domain O
, O
JNK1 B
and O
JNK2 O
, O
required O
costimulation O
of O
T O
cells O
with O
either O
TPA O
and O
Ca2 O
+ O
ionophore O
or O
antibodies O
to O
TCR B
and O
CD28 B
. O

In O
vivo O
protein O
- O
DNA O
contacts O
are O
detectable O
at O
Ii B
kappa I
B I
- I
1 I
in O
cell O
lines O
in O
which O
this O
site O
is O
functional O
as O
either O
a O
positive O
or O
negative O
regulator O
. O

Ii B
kappa I
B I
- I
2 I
is O
a O
site O
of O
positive O
regulation O
in O
B O
- O
cell O
lines O
and O
a O
site O
of O
negative O
regulation O
in O
H9 O
T O
cells O
, O
myelomonocytic O
, O
and O
glial O
cell O
lines O
. O

Again O
, O
in O
vitro O
supershift O
studies O
indicate O
that O
the O
presence O
of O
p50 B
, O
p52 B
, O
p65 B
, O
and O
cRel B
correlates O
with O
positive O
function O
whereas O
the O
presence O
of O
only O
p50 B
and O
p52 B
correlates O
with O
negative O
function O
. O

OBJECTIVE O
: O
To O
determine O
whether O
activation O
of O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
replication O
in O
tumour O
cells O
of O
AIDS O
- O
related O
non O
- O
Hodgkin O
' O
s O
lymphoma O
( O
ARNHL O
) O
is O
correlated O
with O
CD4 B
+ I
cell O
counts O
and O
influences O
antibody O
response O
to O
EBV O
[ O
anti O
- O
Z O
Epstein O
- O
Barr O
replicative O
activator O
( O
ZEBRA B
) O
, O
anti O
- O
early O
antigen O
( O
EA O
) O
, O
anti O
- O
viral O
capsid O
antigen O
( O
VCA B
) O
] O
. O

DESIGN O
: O
Retrospective O
study O
based O
on O
immunohistochemistry O
and O
in O
situ O
hybridization O
to O
detect O
EBV O
replicative O
gene O
products O
in O
tissue O
samples O
from O
patients O
affected O
by O
ARNHL O
and O
correlation O
with O
CD4 B
+ I
cell O
counts O
and O
results O
of O
EBV O
serology O
( O
including O
anti O
- O
ZEBRA B
activity O
) O
in O
sera O
from O
the O
same O
patients O
. O

In O
cells O
stimulated O
with O
anti B
- I
CD3 I
mAb I
, O
PGE2 B
inhibited O
cell O
proliferation O
and O
the O
production O
of O
all O
the O
cytokines B
examined O
. O

Addition O
of O
rIL O
- O
2 O
fully O
restored O
the O
proliferative O
response O
and O
partially O
restored O
the O
production O
of O
IL B
- I
4 I
and O
IL B
- I
5 I
, O
but O
not O
that O
of O
other O
cytokines B
. O

It O
seems O
therefore O
that O
PGE2 B
, O
by O
elevating O
cAMP O
levels O
, O
interferes O
with O
the O
activation O
pathway O
for O
NF B
- I
kappa I
B I
but O
not O
for O
NF B
- I
AT I
, O
AP B
- I
1 I
or O
CLE0 O
binding O
protein O
. O

Moreover O
, O
rapamycin O
, O
an O
inhibitor O
of O
pp70S6K B
activation O
, O
had O
no O
effect O
on O
induction O
of O
EGR B
- I
1 I
expression O
. O

In O
contrast O
, O
analysis O
of O
pp90rsk B
activity O
by O
phosphorylation O
of O
a O
peptide O
derived O
from O
S6 O
protein O
demonstrated O
stimulation O
of O
this O
kinase B
in O
TPA O
- O
treated O
U O
- O
937 O
, O
and O
not O
TUR O
, O
cells O
. O

We O
have O
identified O
a O
` O
` O
two O
- O
handed O
' O
' O
zinc O
finger O
protein O
, O
denoted O
ZEB B
, O
the O
DNA O
- O
binding O
specificity O
of O
which O
mimics O
that O
of O
the O
cellular O
repressor O
. O

By O
employing O
a O
derivative O
E B
box I
that O
binds O
ZEB B
but O
not O
E2A B
, O
we O
have O
shown O
that O
the O
repressor B
is O
active O
in O
B O
cells O
and O
the O
IgH B
enhancer I
is O
silenced O
in O
the O
absence O
of O
binding O
competition O
by O
bHLH B
proteins I
. O

In O
order O
to O
elucidate O
the O
role O
of O
c O
- O
myb O
gene O
in O
erythroid O
differentiation O
of O
K562 O
cell O
induced O
by O
hemin B
( O
Hm B
) O
and O
erythropoietin B
( O
Epo B
) O
, O
we O
constructed O
recombinant B
plasmid I
that O
could O
produce O
antisense B
myb I
RNA I
after O
induction O
with O
dexamethasone O
. O

During O
treatment O
with O
Hm B
, O
K562 O
cells O
constitutively O
expressed O
c B
- I
myb I
mRNA I
, O
and O
50 O
% O
of O
them O
began O
to O
synthesize O
hemoglobin B
( O
Hb B
) O
. O

Both O
groups O
showed O
substantial O
decreases O
in O
mineralocorticoid O
( O
MR O
) O
and O
glucocorticoid O
receptor O
( O
GR O
) O
levels O
in O
the O
hippocampus O
, O
a O
limbic O
brain O
structure O
critical O
for O
HPA O
axis O
regulation O
, O
whereas O
GR B
concentrations O
in O
the O
hypothalamus O
were O
unchanged O
and O
in O
anterior O
pituitary O
were O
slightly O
increased O
. O

NM23 B
was O
identified O
in O
a O
system O
of O
murine O
melanoma O
cell O
lines O
, O
in O
which O
an O
inverse O
relationship O
was O
found O
between O
NM23 B
expression O
and O
metastatic O
ability O
. O

Fos B
kinase I
may O
play O
a O
role O
in O
transcriptional O
regulation O
through O
its O
capacity O
to O
phosphorylate O
c B
- I
Fos I
at O
a O
site O
required O
for O
expression O
of O
the O
transcriptional O
transrepressive O
activity O
of O
this O
molecule O
. O

Human O
T O
- O
cell O
clones O
reactive O
with O
gC B
and O
VP16 B
are O
reported O
here O
for O
the O
first O
time O
. O

We O
studied O
genomic B
DNA I
and O
RNA O
extracted O
from O
the O
patient O
' O
s O
peripheral O
leucocytes O
in O
order O
to O
determine O
the O
origin O
of O
the O
basophils O
. O

The O
RAR B
alpha I
rearranged O
band O
in O
the O
Southern O
blot O
analysis O
and O
a O
chimaeric O
product O
of O
PML B
- I
RAR I
alpha I
by O
polymerase O
chain O
reaction O
were O
strongly O
visible O
before O
ATRA O
treatment O
, O
but O
at O
the O
time O
of O
maximal O
basophilia O
both O
of O
them O
were O
markedly O
diminished O
. O

Activation O
of O
the O
interleukin B
6 I
gene I
by O
Mycobacterium O
tuberculosis O
or O
lipopolysaccharide O
is O
mediated O
by O
nuclear O
factors O
NF O
- O
IL6 O
and O
NF B
- I
kappa I
B I
[ O
published O
erratum O
appears O
in O
Proc O
Natl O
Acad O
Sci O
U O
S O
A O
1995 O
Apr O
11 O
; O
92 O
( O
8 O
) O
: O
3632 O
] O

In O
this O
regard O
, O
the O
cytokine B
interleukin B
6 I
( O
IL B
- I
6 I
) O
may O
play O
a O
role O
in O
the O
clinical O
manifestations O
and O
pathological O
events O
of O
tuberculosis O
infection O
. O

LAM B
and O
LPS O
were O
potent O
inducers O
of O
IL B
- I
6 I
gene I
expression O
in O
peripheral O
blood O
monocytes O
. O

We O
conclude O
that O
the O
NF O
- O
IL6 O
and O
NF O
- O
kappa O
B O
sites O
mediate O
IL B
- I
6 I
induction O
in O
response O
to O
both O
LPS O
and O
LAM B
, O
acting O
as O
bacterial O
or O
mycobacterial O
response O
elements O
. O

Using O
FACS O
, O
Northern O
blotting O
, O
and O
nuclear O
run O
- O
on O
analyses O
, O
we O
demonstrate O
that O
the O
up O
- O
regulation O
of O
CD14 B
expression O
during O
monocytic O
cell O
maturation O
is O
regulated O
mainly O
at O
the O
level O
of O
gene O
transcription O
, O
and O
that O
new O
protein O
synthesis O
is O
required O
for O
CD14 B
induction O
. O

This O
region O
contains O
two O
binding B
sites I
for O
the O
Sp1 B
transcription I
factor I
. O

This O
nuclear B
complex I
was O
activated O
by O
LPS O
with O
kinetics O
that O
preceded O
induction O
of O
the O
TF B
gene I
. O

Human O
immunodeficiency O
virus O
type O
1 O
Nef O
protein O
down O
- O
regulates O
transcription B
factors I
NF B
- I
kappa I
B I
and O
AP B
- I
1 I
in O
human O
T O
cells O
in O
vitro O
after O
T O
- O
cell O
receptor O
stimulation O
. O

To O
define O
the O
mechanism O
of O
action O
of O
the O
Nef B
protein O
, O
the O
signal O
transduction O
pathways O
which O
may O
be O
affected O
in O
T O
cells O
by O
constitutive O
expression O
of O
the O
nef O
gene O
were O
examined O
. O

When O
cells O
were O
preincubated O
with O
dihydrolipoic O
acid O
( O
0 O
. O
2 O
mM O
) O
the O
expression O
of O
c B
- I
fos I
mRNA I
was O
suppressed O
at O
30 O
min O
after O
stimulation O
of O
TPA O
( O
0 O
. O
5 O
microM O
) O
whereas O
in O
the O
case O
of O
preincubation O
of O
alpha O
- O
lipoic O
acid O
( O
0 O
. O
2 O
microM O
) O
, O
the O
expression O
was O
enhanced O
at O
30 O
min O
. O

This O
resulted O
in O
only O
a O
partial O
inhibition O
of O
TNF B
- O
or O
PMA O
- O
induced O
HIV O
replication O
in O
U1 O
cells O
, O
and O
no O
detectable O
effect O
on O
HIV O
replication O
in O
chronically O
infected O
U937 O
cells O
. O

Another O
limitation O
is O
that O
antioxidant O
concentrations O
high O
enough O
to O
block O
NK B
- I
kappa I
B I
activation O
were O
shown O
to O
have O
a O
suppressive O
effect O
on O
immune O
functions O
in O
vitro O
, O
because O
NAC O
and O
BHA O
blocked O
IL O
- O
2 O
- O
induced O
PBMC O
proliferation O
. O

This O
allows O
us O
to O
characterize O
these O
two O
granule O
populations O
with O
regard O
to O
their O
content O
of O
membrane B
proteins I
, O
which O
become O
incorporated O
into O
the O
plasma O
membrane O
during O
exocytosis O
. O

Furthermore O
, O
we O
found O
that O
20 O
% O
to O
25 O
% O
of O
both O
the O
adhesion O
protein O
Mac O
- O
1 O
and O
the O
NADPH O
- O
oxidase O
component O
cytochrome O
b558 O
is O
localized O
in O
gelatinase B
granules O
. O

This O
shows O
that O
gelatinase B
granules O
are O
functionally O
important O
relative O
to O
specific O
granules O
in O
mediating O
early O
inflammatory O
responses O
. O

Treatment O
of O
human O
resting O
T O
cells O
with O
phorbol O
esters O
strongly O
induced O
the O
expression O
of O
IL B
- I
2R I
alpha I
and O
the O
activation O
of O
NF B
. I
kappa I
B I
. O

Rather O
, O
the O
data O
indicate O
that O
mitogen O
increases O
the O
levels O
of O
a O
nuclear O
factor O
( O
s O
) O
that O
dimerizes O
with O
CREB B
. O

Central O
nervous O
system O
- O
derived O
cells O
express O
a O
kappa O
B O
- O
binding O
activity O
that O
enhances O
human O
immunodeficiency O
virus O
type O
1 O
transcription O
in O
vitro O
and O
facilitates O
TAR B
- O
independent O
transactivation O
by O
Tat B
. O

Tat B
transactivation O
mediated O
by O
the O
kappa B
B I
domain I
is O
sufficient O
to O
allow O
replication O
of O
TAR B
- O
deleted O
mutant O
HIV O
- O
1 O
in O
astrocytes O
. O

For O
one O
of O
these O
proteins O
, O
p57 B
, O
binding O
to O
the O
IRES B
correlates O
with O
translation O
. O

Retinoid O
- O
like O
receptors O
play O
a O
central O
role O
in O
hormonal O
responses O
by O
forming O
heterodimers B
with O
other O
nuclear O
hormone O
receptors O
. O

Hence O
, O
PPAR B
can O
positively O
or O
negatively O
influence O
TH O
action O
depending O
on O
TRE B
structure O
and O
THR O
isotype O
. O

Several O
human O
myeloid O
leukemia O
cell O
lines O
growing O
in O
vitro O
can O
be O
induced O
to O
differentiate O
to O
more O
mature O
monocyte O
/ O
macrophage O
- O
like O
cells O
by O
treatment O
with O
protein B
kinase I
C I
- O
activating O
phorbol O
esters O
, O
such O
as O
PMA O
. O

Lymphoid O
cells O
transformed O
by O
Abelson O
murine O
leukemia O
virus O
have O
provided O
one O
of O
the O
classic O
models O
for O
study O
of O
early O
B O
- O
cell O
development O
and O
immunoglobulin B
rearrangement O
. O

Our O
studies O
reveal O
that O
inactivation O
of O
the O
v B
- I
abl I
protein I
tyrosine I
kinase I
triggers O
high O
- O
frequency O
rearrangement O
of O
kappa O
and O
lambda O
light O
- O
chain O
genes O
. O

Expression O
and O
genomic O
configuration O
of O
GM B
- I
CSF I
, O
IL B
- I
3 I
, O
M B
- I
CSF I
receptor I
( O
C O
- O
FMS O
) O
, O
early B
growth I
response I
gene I
- I
1 I
( O
EGR B
- I
1 I
) O
and O
M O
- O
CSF O
genes O
in O
primary O
myelodysplastic O
syndromes O
. O

The O
expression O
of O
the O
M B
- I
CSF I
gene I
, O
that O
has O
been O
recently O
reassigned O
to O
the O
short O
arm O
of O
chromosome O
1 O
( O
lp O
) O
, O
was O
also O
investigated O
. O

Similar O
analysis O
of O
poly B
( I
A I
) I
RNA I
from O
a O
variety O
of O
adult O
tissues O
demonstrated O
HB9 B
transcripts O
in O
pancreas O
, O
small O
intestine O
, O
and O
colon O
. O

The O
observed O
increase O
in O
IL B
- I
2 I
levels O
might O
facilitate O
virus O
spread O
from O
or O
to O
T O
cells O
. O

Recent O
reports O
demonstrated O
that O
ionizing O
radiation O
in O
the O
dose O
range O
of O
2 O
- O
50 O
Gy O
results O
in O
expression O
of O
NF B
- I
kappa I
B I
in O
human O
KG O
- O
1 O
myeloid O
leukemia O
cells O
and O
human O
B O
- O
lymphocyte O
precursor O
cells O
; O
the O
precise O
mechanism O
involved O
and O
the O
significance O
are O
not O
yet O
known O
. O

The O
present O
report O
demonstrates O
that O
even O
lower O
doses O
of O
ionizing O
radiation O
, O
0 O
. O
25 O
- O
2 O
. O
0 O
Gy O
, O
are O
capable O
of O
inducing O
expression O
of O
NF B
- I
kappa I
B I
in O
EBV O
- O
transformed O
244B O
human O
lymphoblastoid O
cells O
. O

The O
two O
human O
GATA3 O
zinc O
fingers O
are O
encoded O
by O
two O
separate O
exons B
highly O
conserved O
with O
those O
of O
GATA1 B
, O
but O
no O
other O
structural O
homologies O
between O
these O
two O
genes O
can O
be O
found O
. O

Retinoic O
acid O
- O
induced O
expression O
of O
CD38 B
antigen I
in O
myeloid O
cells O
is O
mediated O
through O
retinoic B
acid I
receptor I
- I
alpha I
. O

CD38 B
is O
a O
leukocyte O
differentiation O
antigen O
that O
has O
been O
thought O
to O
be O
a O
phenotypic O
marker O
of O
different O
subpopulations O
of O
T O
- O
and O
B O
- O
lymphocytes O
. O

In O
myeloid O
cells O
, O
CD38 B
is O
expressed O
during O
early O
stages O
of O
differentiation O
. O

Some O
antioxidants O
inhibit O
, O
in O
a O
co O
- O
ordinate O
fashion O
, O
the O
production O
of O
tumor B
necrosis I
factor I
- I
alpha I
, O
IL O
- O
beta O
, O
and O
IL B
- I
6 I
by O
human O
peripheral O
blood O
mononuclear O
cells O
. O

Inhibition O
of O
cytokine B
production O
was O
gene O
selective O
and O
not O
due O
to O
general O
effects O
on O
protein O
synthesis O
. O

Much O
higher O
concentrations O
of O
other O
antioxidants O
- O
- O
including O
ascorbic O
acid O
, O
trolox O
, O
alpha O
- O
tocopherol O
, O
butylated O
hydroxytoluene O
, O
and O
the O
5 O
- O
lipoxygenase O
inhibitor O
zileuton O
- O
- O
did O
not O
affect O
the O
production O
of O
these O
cytokines B
. O

Thus O
antioxidants O
vary O
widely O
in O
potency O
as O
inhibitors O
of O
the O
activation O
of O
transcription B
factors I
and O
of O
the O
transcription O
of O
genes B
for O
pro B
- I
inflammatory I
cytokines I
. O

Examination O
of O
the O
primary O
amino O
acid O
sequence O
of O
this O
protein O
indicates O
that O
it O
is O
a O
member O
of O
the O
signal O
transducers O
and O
activators O
of O
transcription O
( O
Stat O
) O
family O
of O
DNA B
binding I
proteins I
, O
hereby O
designated O
IL B
- I
4 I
Stat I
. O

Such O
observations O
indicate O
that O
IL B
- I
4 I
Stat I
has O
the O
same O
functional O
domain O
for O
both O
receptor O
coupling O
and O
dimerization O
. O

Tumor O
cells O
showed O
an O
overexpression O
of O
p53 B
protein I
and O
were O
estrogen B
receptor I
- O
positive O
. O

The O
magnitude O
and O
time O
kinetics O
of O
the O
LIF B
effects O
were O
similar O
to O
interleukin B
1 I
( O
IL B
- I
1 I
) O
, O
IL B
- I
6 I
, O
and O
tumor B
necrosis I
factor I
( O
TNF B
) O
, O
other O
cytokines O
known O
to O
induce O
HIV O
replication O
in O
this O
cell O
line O
. O

To O
characterize O
mechanisms O
responsible O
for O
these O
LIF B
effects O
, O
levels O
of O
HIV B
mRNA I
, O
activation O
of O
the O
DNA O
binding O
protein O
nuclear O
factor O
( B
NF I
) I
- I
kB I
, O
signal O
transduction O
pathways O
, O
and O
potential O
interactions O
with O
other O
cytokines B
were O
analyzed O
. O

In O
both O
cell O
lines O
LIF B
increased O
NF B
- I
kB I
activity O
. O

Induction O
of O
NF B
- I
kB I
and O
HIV O
replication O
by O
cytokines B
are O
at O
least O
in O
part O
dependent O
on O
reactive O
oxygen O
intermediates O
. O

The O
mechanisms O
involved O
in O
the O
inhibition O
of O
growth O
of O
a O
human O
B O
lymphoma O
cell O
line O
, O
B104 O
, O
by O
anti B
- I
MHC I
class I
II I
antibodies I
( O
Ab O
) O
were O
compared O
with O
those O
in O
anti B
- I
IgM I
Ab I
- O
induced O
B104 O
growth O
inhibition O
. O

Four O
regions O
in O
this O
DNA B
fragment I
interact O
with O
nuclear B
proteins I
isolated O
from O
monocytic O
cells O
. O

The O
Sp1 B
transcription B
factor I
bound O
to O
three O
different O
regions O
in O
the O
CD14 O
promoter O
. O

In O
fertile O
women O
remarkable O
changes O
in O
androgen B
binding I
sites I
were O
seen O
in O
the O
course O
of O
the O
menstrual O
cycle O
, O
with O
a O
significant O
increase O
in O
the O
immediate O
preovulatory O
period O
. O

Stimulation O
of O
the O
CD28 O
cell O
surface O
molecule O
delivers O
costimulatory O
signals O
essential O
for O
lymphokine B
production O
in O
activated O
T O
cells O
via O
a O
conserved B
sequence I
element I
found O
in O
the O
promoter B
of O
several O
lymphokine B
genes I
. O

Diminished O
glucocorticoid B
receptors I
do O
not O
result O
in O
glucocorticoid O
resistance O
. O

Corticosteroid B
Type I
I I
and I
Type I
II I
receptors I
are O
inversely O
correlated O
with O
age O
. O

That O
RA O
promotes O
both O
neutrophil O
and O
monocyte O
differentiation O
has O
implications O
for O
the O
use O
of O
RA O
and O
D3 O
in O
treatment O
of O
leukemias O
and O
provides O
insight O
into O
mechanisms O
whereby O
RAR O
, O
VDR B
and O
RXR B
facilitate O
monocyte O
differentiation O
. O

Thrombin B
and O
thrombin B
receptor I
agonist O
peptide O
induce O
early O
events O
of O
T O
cell O
activation O
and O
synergize O
with O
TCR B
cross O
- O
linking O
for O
CD69 B
expression O
and O
interleukin O
2 O
production O
. O

There O
was O
a O
good O
correlation O
between O
thrombin B
- O
induced O
tyrosine O
phosphorylation O
of O
the O
latter O
three O
proteins O
and O
Ca2 O
+ O
mobilization O
. O

Stress O
response O
of O
senescent O
T O
lymphocytes O
: O
reduced O
hsp70 B
is O
independent O
of O
the O
proliferative O
block O
. O

Wortmannin O
, O
an O
inhibitor O
of O
receptor O
- O
coupled O
PLD B
activation O
, O
blocked O
the O
anti B
- I
CD3 I
- O
induced O
increases O
in O
both O
PLD B
activity O
and O
AP B
- I
1 I
enhancer I
activity O
. O

We O
found O
a O
good O
correlation O
in O
the O
transfected O
cells O
between O
PLD B
activation O
and O
induction O
of O
AP B
- I
1 I
enhancer I
activity O
under O
different O
experimental O
conditions O
. O

We O
therefore O
reexamined O
this O
issue O
by O
using O
two O
different O
experimental O
approaches O
that O
allowed O
LMP1 B
- O
induced O
effects O
to O
be O
monitored O
immediately O
following O
expression O
of O
the O
viral O
protein O
and O
in O
the O
absence O
of O
selective O
pressures O
; O
activation O
of O
the O
NF B
- I
kappa I
B I
transcription B
factor I
and O
upregulation O
of O
the O
cell O
adhesion O
molecule O
ICAM B
- I
1 I
were O
used O
as O
early O
indices O
of O
LMP1 B
function O
. O

In O
the O
second O
approach O
, O
we O
tested O
the O
generality O
of O
this O
phenomenon O
by O
transiently O
expressing O
LMP1 B
from O
a O
strong O
constitutively O
active O
promoter O
in O
a O
range O
of O
different O
cell O
types O
. O

In O
the O
same O
experiments O
, O
all O
three O
non O
- O
B O
- O
cell O
lines O
showed O
NF B
- I
kappa I
B I
activation O
and O
ICAM B
- I
1 I
upregulation O
but O
never O
any O
effect O
upon O
Bcl B
- I
2 I
. O

We O
found O
that O
tyrosine B
kinase I
activity O
was O
similar O
for O
both O
mAbs B
over O
a O
period O
of O
hours O
. O

However O
, O
the O
inositol O
phosphate O
response O
was O
stronger O
for O
64 B
. I
1 I
than O
for O
OKT3 B
. O

To O
tie O
these O
events O
to O
gene O
activation O
, O
we O
measured O
NF B
- I
kappa I
B I
and O
NF B
- I
AT I
activity O
in O
the O
nucleus O
after O
anti B
- I
CD3 I
stimulation O
. O

Both O
stimuli O
induced O
the O
appearance O
of O
the O
NF B
- I
kappa I
B I
components I
( O
c B
- I
Rel I
, O
p65 B
( O
RelA B
) O
, O
and O
p50 B
( O
NF B
- I
kappa I
B1 I
) O
) O
and O
NF B
- I
kappa I
B I
DNA O
binding O
activity O
in O
the O
nucleus O
. O

From O
a O
consecutive O
series O
of O
350 O
cases O
of O
adult O
de O
novo O
acute O
myeloid O
leukemia O
( O
AML O
) O
, O
we O
identified O
20 O
cases O
( O
6 O
% O
) O
with O
a O
unique O
immunophenotype O
: O
CD33 O
+ O
, O
CD56 O
+ O
, O
CD11a O
+ O
, O
CD13lo O
, O
CD15lo O
, O
CD34 O
+ O
/ O
- O
, O
HLA B
- I
DR I
- O
, O
CD16 B
- O
. O

This O
was O
supported O
by O
the O
observation O
that O
the O
down O
- O
regulatory O
capacity O
of O
IL B
- I
4 I
appeared O
to O
be O
dependent O
on O
de O
novo O
protein O
synthesis O
. O

Although O
these O
data O
suggest O
AP B
- I
1 I
regulated O
cytokine B
mRNA O
expression O
, O
results O
from O
PBMo O
are O
not O
in O
accordance O
with O
this O
notion O
. O

It O
, O
thus O
, O
appears O
as O
an O
integral B
membrane I
protein I
. O

Analysis O
of O
the O
chromatin O
organization O
of O
the O
integrated O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
genome I
has O
previously O
revealed O
a O
major O
constitutive O
DNase O
I O
- O
hypersensitive O
site O
associated O
with O
the O
pol B
gene I
( O
E O
. O
Verdin O
, O
J O
. O
Virol O
. O
65 O
: O
6790 O
- O
6799 O
, O
1991 O
) O
. O

NF B
- I
kappa I
B I
is O
a O
rapidly O
inducible O
transcriptional B
activator I
that O
responds O
to O
a O
variety O
of O
signals O
and O
influences O
the O
expression O
of O
many O
genes O
involved O
in O
the O
immune O
response O
. O

Sequence O
analyses O
of O
pCD41 B
indicate O
that O
there O
are O
two O
potential O
open B
reading I
frames I
( O
ORFs B
) O
, O
A B
and O
B B
, O
which O
are O
homologous O
to O
the O
ORFs B
found O
in O
the O
genomic O
clone O
pGD41 B
. O

CD14 B
- O
mediated O
translocation O
of O
nuclear B
factor I
- I
kappa I
B I
induced O
by O
lipopolysaccharide O
does O
not O
require O
tyrosine B
kinase I
activity O
. O

LPS O
- O
stimulated O
translocation O
of O
NF B
- I
kappa I
B I
in O
CHO O
/ O
CD14 O
cells O
resembled O
the O
same O
response O
in O
the O
murine O
macrophage O
- O
like O
cell O
line O
RAW O
264 O
. O
7 O
. O

The O
stimulatory O
effects O
of O
gp160 O
are O
mediated O
through O
the O
CD4 B
molecule I
, O
since O
pretreatment O
with O
soluble O
CD4 B
abrogates O
its O
activity O
. O

The O
stimulatory O
effect O
of O
gp160 O
on O
NF B
- I
kappa I
B I
activation O
is O
protein O
synthesis O
independent O
, O
is O
dependent O
upon O
protein O
tyrosine O
phosphorylation O
, O
and O
abrogated O
by O
inhibitors O
of O
protein B
kinase I
C I
. O

No O
evidence O
for O
the O
expression O
of O
the O
progesterone B
receptor I
on O
peripheral O
blood O
lymphocytes O
during O
pregnancy O
[ O
see O
comments O
] O

A O
role O
for O
the O
progesterone B
receptor I
in O
the O
mechanism O
of O
the O
known O
effect O
of O
progesterone O
on O
peripheral O
blood O
lymphocytes O
is O
also O
excluded O
. O

The O
CD14 B
LPS O
receptor O
is O
, O
however O
, O
up O
- O
regulated O
( O
not O
down O
- O
regulated O
) O
in O
tolerant O
cells O
, O
and O
LPS O
can O
, O
in O
fact O
, O
still O
lead O
to O
activation O
of O
tolerant O
cells O
as O
evidenced O
by O
mobilization O
of O
the O
transcription B
factor I
nuclear B
factor I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
. O

Resolution O
of O
the O
NF B
- I
kappa I
B I
complex I
in O
gel O
shift O
analysis O
shows O
that O
the O
binding B
protein I
, O
mobilized O
in O
naive O
Mono O
Mac O
6 O
cells O
, O
consists O
mainly O
of O
p50 B
- I
p65 I
heterodimers I
, O
while O
in O
tolerant O
cells O
, O
the O
p50 B
homodimer I
is O
predominant O
. O

This O
increase O
in O
p50 B
homodimers I
coincides O
with O
an O
increase O
in O
p105 B
mRNA I
, O
suggestive O
of O
a O
transcriptional O
up O
- O
regulation O
of O
p50 B
. O

A O
new O
exon B
containing O
a O
highly O
basic O
region O
( O
4c O
) O
was O
characterized O
, O
between O
exons O
4 O
and O
5 O
. O

In O
addition O
, O
a O
new O
combination O
isoform O
containing O
Oct2a O
' O
s O
amino O
terminal O
insert O
( O
exon O
7a O
) O
and O
Oct2b O
' O
s O
carboxy O
terminal O
insert O
( O
exon O
13 O
) O
was O
found O
that O
created O
a O
novel O
large O
isoform O
, O
Oct2ab B
. O

Positive O
regulators O
of O
the O
lineage O
- O
specific O
transcription B
factor I
GATA B
- I
1 I
in O
differentiating O
erythroid O
cells O
. O

Analyses O
with O
cultured O
cells O
and O
cell O
- O
free O
systems O
have O
provided O
strong O
evidence O
that O
GATA B
- I
1 I
is O
involved O
in O
control O
of O
globin B
gene I
expression O
during O
erythroid O
differentiation O
. O

The O
response O
of O
mammalian O
cells O
to O
stress O
is O
controlled O
by O
transcriptional B
regulatory I
proteins I
such O
as O
nuclear B
factor I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
to O
induce O
a O
wide O
variety O
of O
early B
response I
genes I
. O

In O
comparison O
to O
other O
activators O
of O
NF B
- I
kappa I
B I
such O
as O
phorbol O
myristate O
acetate O
or O
tumor B
necrosis I
factor I
, O
we O
did O
not O
detect O
changes O
in O
the O
tyrosine O
phosphorylation O
status O
of O
I B
kappa I
B I
alpha I
following O
treatment O
with O
either O
of O
these O
agents O
. O

Furthermore O
, O
the O
NFKB2 B
precursor O
is O
physically O
associated O
with O
c B
- I
Rel I
and O
with O
Tax B
in O
HTLV O
- O
I O
infected O
cells O
. O

This O
phenomenon O
is O
correlated O
with O
inhibition O
of O
GATA1 B
induction O
in O
the O
early O
stages O
of O
erythropoietic O
differentiation O
. O

We O
have O
previously O
shown O
that O
a O
human O
B O
lymphoma O
cell O
line O
, O
B104 O
, O
expressed O
surface O
IgM O
( O
sIgM B
) O
and O
surface O
IgD O
( O
sIgD B
) O
, O
and O
that O
crosslinking O
of O
sIgM B
and O
sIgD B
by O
anti O
- O
IgM O
antibody O
( O
Ab O
) O
and O
anti O
- O
IgD O
Ab O
, O
respectively O
, O
induced O
Ca2 O
+ O
influx O
to O
almost O
the O
same O
degree O
, O
whereas O
only O
sIgM B
- O
crosslinking O
caused O
B104 O
cell O
death O
. O

Phorbol O
myristate O
acetate O
induced O
Egr B
- I
1 I
mRNA I
expression O
but O
forskolin O
and O
dibutyryl O
cyclic O
AMP O
did O
not O
. O

Because O
erythrocytes O
are O
anucleated O
, O
these O
results O
are O
discussed O
as O
evidence O
for O
biochemical O
changes O
by O
TCDD O
without O
requiring O
the O
activation O
of O
gene B
products I
. O

Irrespective O
of O
the O
human O
cell O
partner O
used O
for O
fusion O
, O
a O
certain O
number O
of O
hybrids O
lost O
CD5 B
surface O
expression O
over O
a O
period O
of O
time O
in O
culture O
. O

Electrophoretic O
mobility O
shift O
assays O
indicate O
that O
MS B
- I
2beta I
and O
MS B
- I
2gamma I
interact O
with O
nuclear B
factors I
that O
are O
induced O
during O
U937 O
differentiation O
. O

These O
factors O
are O
detected O
at O
the O
time O
the O
CD11b B
promoter I
is O
activated O
. O

The O
presence O
of O
multiple O
potential O
binding O
sites O
for O
MS B
- I
2 I
in O
the O
promoter O
regions O
of O
a O
wide O
range O
of O
genes O
expressed O
in O
mature O
myeloid O
cells O
suggests O
this O
factor O
plays O
a O
general O
role O
in O
myeloid O
differentiation O
. O

Acetylsalicylic O
acid O
and O
sodium O
salicylate O
inhibit O
LPS O
- O
induced O
NF O
- O
kappa O
B O
/ O
c O
- O
Rel O
nuclear O
translocation O
, O
and O
synthesis O
of O
tissue B
factor I
( O
TF B
) O
and O
tumor O
necrosis O
factor O
alfa O
( O
TNF B
- I
alpha I
) O
in O
human O
monocytes O
. O

Interferon O
augments O
PML B
and O
PML B
/ I
RAR I
alpha I
expression O
in O
normal O
myeloid O
and O
acute O
promyelocytic O
cells O
and O
cooperates O
with O
all O
- O
trans O
retinoic O
acid O
to O
induce O
maturation O
of O
a O
retinoid O
- O
resistant O
promyelocytic O
cell O
line O
. O

PML B
is O
expressed O
in O
diverse O
tissues O
and O
cell O
lines O
and O
localized O
in O
the O
nucleus O
with O
a O
typical O
speckled O
pattern O
. O

Neutral B
sphingomyelinase I
( O
SMase B
) O
can O
be O
activated O
by O
extracellular O
signals O
to O
produce O
ceramide O
, O
which O
may O
affect O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
activities O
. O

Ara O
- O
C O
activated O
JNKs B
only O
after O
prolonged O
incubation O
( O
90 O
- O
120 O
minutes O
) O
. O

The O
transmembrane O
domains O
are O
well O
conserved O
, O
but O
there O
is O
striking O
sequence O
divergence O
of O
the O
carboxy O
- O
terminal O
cytoplasmic O
domain O
essential O
for O
B O
- O
cell O
immortalization O
and O
interaction O
with O
the O
tumor B
necrosis I
factor I
receptor I
signaling O
pathway O
. O

Distinct O
patterns O
of O
chromosome B
1 I
abnormalities O
were O
found O
among O
the O
histologic O
types O
of O
breast O
carcinoma O
. O

We O
have O
observed O
that O
the O
R24 O
mAb O
stimulates O
GD3 O
+ O
T O
cell O
proliferation O
, O
cytotoxicity O
, O
and O
surface O
marker O
expression O
of O
IL B
- I
2R I
alpha I
- I
chain I
, O
IL B
- I
2R I
beta I
- I
chain I
, O
HLA B
- I
DR I
, O
CD11a B
, O
and O
CD11c B
. O

R24 B
- O
stimulated O
increases O
in O
proliferation O
, O
cytotoxicity O
, O
and O
cell O
surface O
protein O
expression O
could O
be O
blocked O
by O
cyclosporin O
and O
staurosporin O
, O
indicating O
that O
cyclophilin O
/ O
calcineurin O
and O
protein B
kinase I
C I
may O
be O
involved O
in O
the O
R24 B
signaling O
pathway O
. O

Additionally O
, O
herbimycin O
A O
, O
a O
tyrosine B
kinase I
inhibitor O
, O
blocked O
the O
R24 B
- O
stimulated O
increase O
in O
proliferation O
but O
not O
cytotoxicity O
at O
concentrations O
consistent O
with O
specificity O
for O
tyrosine B
kinases I
. O

Using O
fluorescence O
in O
situ O
hybridization O
( O
FISH O
) O
, O
we O
show O
here O
that O
the O
genes B
encoding O
the O
TATA B
- I
box I
binding I
protein I
( O
TBP B
) O
, O
TFIIB O
, O
TFIIE O
alpha O
, O
TFIIE O
beta O
, O
RAP30 O
, O
RAP74 O
and O
the O
62 O
kDa O
subunit O
, O
of O
TFIIH B
are O
located O
at O
the O
human O
chromosomal O
bands O
6q26 O
- O
27 O
, O
1p21 O
- O
22 O
, O
3q21 O
- O
24 O
, O
8p12 O
, O
13q14 O
, O
19p13 O
. O
3 O
and O
11p14 O
- O
15 O
. O
1 O
, O
respectively O
. O

Although O
no O
proof O
yet O
exists O
of O
a O
role O
for O
these O
lesions O
in O
DLCL O
pathogenesis O
, O
the O
feature O
of O
the O
BCL B
- I
6 I
gene I
product I
, O
its O
specific O
pattern O
of O
expression O
in O
B O
cells O
, O
and O
the O
clustering O
of O
lesions O
disrupting O
its O
regulatory O
domain O
strongly O
suggest O
that O
deregulation O
of O
BCL B
- I
6 I
expression O
may O
contribute O
to O
DLCL O
development O
. O

To O
further O
elucidate O
the O
role O
of O
this O
variant O
octamer B
motif I
in O
the O
regulation O
of O
germline B
transcription O
from O
the O
unrearranged O
kappa B
locus I
, O
we O
have O
quantitated O
the O
relative O
binding O
affinity O
of O
Oct B
- I
1 I
and O
Oct B
- I
2 I
for O
the O
variant O
octamer B
motif I
and O
determined O
the O
functional O
role O
of O
this O
octamer B
motif I
in O
transcriptional O
activation O
. O

In O
the O
present O
study O
, O
we O
showed O
that O
CD14 O
+ O
adherent O
human O
monocytes O
can O
differentiate O
into O
CD1 O
+ O
relB O
+ O
dendritic O
cells O
( O
DC O
) O
by O
the O
combination O
of O
GM B
- I
CSF I
plus O
interleukin B
- I
4 I
( O
IL B
- I
4 I
) O
and O
that O
they O
differentiate O
into O
tartrate O
- O
resistant O
acid O
phosphatase O
( O
TRAP O
) O
- O
positive O
osteoclast O
- O
like O
multinucleated O
giant O
cells O
( O
MGC O
) O
by O
the O
combination O
of O
M B
- I
CSF I
plus O
IL B
- I
4 I
. O

The O
mechanism O
of O
inhibition O
is O
related O
to O
the O
surface O
expression O
of O
several O
cell O
adhesion B
molecules I
. O

Flow O
cytometry O
analyses O
on O
cultured O
cells O
that O
were O
treated O
with O
tepoxalin O
or O
antisense O
oligonucleotides O
to O
the O
P65 O
/ O
p50 O
subunit O
of O
NF B
- I
kappa I
B I
, O
and O
then O
stimulated O
with O
PMA O
, O
revealed O
a O
reduced O
expression O
of O
CD11b B
/ I
CD18 I
on O
monocytic O
HL60 O
cells O
, O
and O
endothelial O
adhesion O
molecule O
- O
1 O
( O
CD62E B
) O
and O
vascular O
adhesion O
molecule O
- O
1 O
( O
CD106 B
) O
on O
human O
umbilical O
vein O
endothelial O
cells O
. O

Tepoxalin O
also O
inhibited O
the O
secretion O
of O
a O
NF O
- O
kappa O
B O
regulated O
chemokine O
, O
IL B
- I
8 I
, O
a O
known O
inducer O
of O
CD11b B
/ I
CD18 I
expression O
. O

Thus O
the O
suppression O
of O
CD11b B
/ I
CD18 I
expression O
by O
tepoxalin O
may O
involve O
IL B
- I
8 I
. O

The O
monoclonal B
antibody I
( O
mAb B
) O
J393 O
induces O
apoptosis O
in O
Jurkat O
T O
- O
cells O
. O

NH2 B
- O
terminal O
amino O
acid O
sequence O
analysis O
identified O
the O
140 O
- O
kDa O
surface O
antigen O
for O
mAb B
J393 I
as O
CD43 O
/ O
leukosialin O
, O
the O
major O
sialoglycoprotein O
of O
leukocytes O
. O

While O
Jurkat O
cells O
co O
- O
expressed O
two O
discrete O
cell O
- O
surface O
isoforms O
of O
CD43 B
, O
recognized O
by O
mAb B
J393 I
and O
mAb O
G10 O
- O
2 O
, O
respectively O
, O
only O
J393 B
/ I
CD43 I
signaled O
apoptosis O
. O

Tyrosine B
kinase I
inhibition O
by O
herbimycin O
A O
diminished O
J393 B
/ I
CD43 I
- O
mediated O
apoptosis O
, O
whereas O
inhibition O
of O
phosphotyrosine O
phosphatase O
activity O
by O
bis O
( O
maltolato O
) O
oxovanadium O
- O
IV O
enhanced O
cell O
death O
. O

Consequently O
, O
the O
present O
study O
was O
addressed O
to O
understand O
this O
phenomenon O
and O
revealed O
the O
existence O
of O
a O
unique O
47 O
kDa O
protein O
factor O
having O
affinity O
for O
this O
SRE B
sequence I
in O
lymphocytes O
from O
normal O
subjects O
as O
well O
as O
its O
absence O
in O
lymphocytes O
from O
untreated O
CML O
patients O
. O

To O
understand O
the O
mechanism O
by O
which O
PRL B
regulates O
the O
biphasic O
expression O
of O
IRF B
- I
1 I
, O
we O
cloned O
the O
rat O
IRF O
- O
1 O
gene O
and O
functionally O
characterized O
the O
IRF B
- I
1 I
promoter I
. O

Hence O
, O
the O
PRL B
- O
induced O
biphasic O
expression O
of O
the O
IRF B
- I
1 I
gene I
appears O
to O
be O
controlled O
by O
separate O
PRL O
- O
responsive O
elements O
: O
elements O
in O
the O
first O
0 O
. O
2 O
kb O
of O
the O
IRF O
- O
1 O
promoter O
region O
act O
during O
early O
activation O
, O
and O
elements O
between O
0 O
. O
2 O
and O
1 O
. O
7 O
kb O
act O
in O
concert O
with O
the O
proximal O
0 O
. O
2 O
- O
kb O
region O
during O
S O
phase O
progression O
. O

The O
SCL B
protein I
displays O
cell O
- O
specific O
heterogeneity O
in O
size O
. O

The O
restricted O
pattern O
of O
SCL B
protein I
synthesis O
is O
consistent O
with O
the O
restricted O
expression O
of O
SCL B
mRNA I
documented O
previously O
. O

Pervanadate O
activated O
NF O
- O
kappa O
B O
, O
as O
shown O
by O
an O
increase O
in O
DNA O
- O
binding O
activity O
of O
this O
transcription B
factor I
. O

Signals O
transduced O
via O
the O
TCR B
activate O
the O
transcription B
factor I
nuclear B
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
, O
which O
, O
in O
turn O
, O
is O
critical O
to O
the O
transcriptional O
induction O
of O
many O
genes O
important O
for O
the O
proliferation O
and O
expression O
of O
a O
differentiated O
phenotype O
. O

Here O
we O
identify O
intracellular O
signaling O
components O
involved O
in O
activation O
of O
NF B
- I
kappaB I
following O
TCR B
stimulation O
. O

T O
- O
cell O
- O
directed O
TAL B
- I
1 I
expression O
induces O
T O
- O
cell O
malignancies O
in O
transgenic O
mice O
. O

The O
survival O
rate O
of O
tal B
- I
1 I
transgenic O
animals O
was O
much O
lower O
as O
compared O
with O
control O
mice O
. O

To O
further O
unravel O
the O
tal B
- I
1 I
oncogenic O
potential O
, O
a O
strain O
of O
tal B
- I
1 I
transgenic O
mice O
was O
crossbred O
with O
p53 O
- O
/ O
- O
mice O
; O
the O
survival O
rate O
in O
these O
animals O
was O
reduced O
by O
more O
than O
one O
- O
half O
when O
compared O
with O
that O
of O
tal B
- I
1 I
mice O
, O
and O
histopathological O
analysis O
revealed O
exclusively O
T O
- O
cell O
lymphomas O
. O

TSC2 B
is O
a O
gene O
on O
chromosome B
16p13 I
. I
3 I
associated O
with O
the O
autosomal O
dominant O
neurocutaneous O
disorder O
, O
tuberous O
sclerosis O
complex O
( O
TSC O
) O
. O

Fas B
- O
mediated O
apoptosis O
plays O
an O
important O
role O
in O
regulating O
the O
immune O
response O
in O
peripheral O
T O
cells O
. O

In O
contrast O
, O
interleukin O
- O
1beta O
- O
converting O
enzyme O
family O
protease O
inhibitors O
Ac O
- O
DEVD O
- O
CHO O
and O
CrmA O
blocked O
Fas B
- O
mediated O
apoptosis O
. O

These O
results O
suggest O
that O
peripheral O
T O
cells O
use O
distinct O
apoptosis O
signaling O
pathways O
with O
differential O
sensitivity O
to O
Bcl B
- I
2 I
and O
interleukin O
- O
1beta O
- O
converting O
enzyme O
family O
protease O
inhibitors O
. O

However O
, O
in O
contrast O
to O
human O
lymphocytes O
, O
IFN B
- I
gamma I
production O
was O
inhibited O
and O
IFN B
- I
gamma I
mRNA I
levels O
were O
unaffected O
at O
24 O
h O
and O
only O
slightly O
upregulated O
at O
48 O
and O
72 O
h O
of O
culture O
in O
murine O
splenocytes O
incubated O
with O
cipro O
( O
20 O
micrograms O
/ O
ml O
) O
. O

Cipro O
did O
not O
affect O
the O
nuclear B
transcription I
factors I
AP B
- I
1 I
or O
NFIL O
- O
2A O
. O

Furthermore O
, O
the O
physical O
interaction O
of O
Tax B
with O
p100 B
leads O
to O
the O
inhibition O
of O
Tax B
- O
induced O
activation O
of O
the O
HTLV O
- O
I O
and O
human O
immunodeficiency O
virus O
type O
1 O
long O
terminal O
repeats O
, O
reflecting O
p100 B
- O
mediated O
cytoplasmic O
sequestration O
of O
the O
normally O
nuclearly O
expressed O
Tax B
protein I
. O

In O
vertebrates O
, O
five O
distinct O
DNA B
binding I
subunits I
are O
currently O
known O
which O
might O
extensively O
heterodimerize O
, O
thereby O
forming O
complexes O
with O
distinct O
transcriptional O
activity O
, O
DNA O
sequence O
specificity O
, O
and O
cell O
type O
- O
and O
cell O
stage O
- O
specific O
distribution O
. O

Other O
I B
kappa I
B I
proteins I
are O
rather O
involved O
in O
terminating O
NF B
- I
kappa I
B I
' O
s O
activity O
in O
the O
nucleus O
. O

The O
intracellular O
events O
that O
lead O
to O
the O
inactivation O
of O
I B
kappa I
B I
, O
i O
. O
e O
. O
the O
activation O
of O
NF B
- I
kappa I
B I
, O
are O
complex O
. O

In O
previous O
studies O
, O
it O
was O
shown O
that O
the O
fusion O
region O
of O
the O
pml O
/ O
RAR O
- O
alpha O
protein O
, O
expressed O
by O
acute O
promyelocytic O
leukemia O
( O
APL O
) O
cells O
, O
can O
be O
specifically O
recognized O
in O
vitro O
by O
donor O
( O
D O
. O
E O
. O
) O
CD4 O
T O
cells O
in O
a O
HLA B
class I
II I
DR11 O
- O
restricted O
fashion O
. O

Interferon B
- I
gamma I
( O
IFN B
- I
gamma I
) O
is O
produced O
by O
natural O
killer O
cells O
and O
certain O
subsets O
of O
T O
cells O
, O
but O
the O
basis O
for O
its O
selective O
expression O
is O
unknown O
. O

The O
proximal O
element O
is O
a O
composite O
site O
that O
binds O
members O
of O
the O
CREB B
/ I
ATF I
, O
AP B
- I
1 I
, O
and O
octamer O
families O
of O
transcription B
factors I
. O

S107 O
plasmacytoma O
cells O
, O
which O
express O
CD40 B
but O
are O
defective O
for O
the O
nuclear O
appearance O
of O
p50 O
/ O
p65 O
- O
NF O
- O
kappaB O
, O
do O
not O
express O
RelB B
after O
CD40 B
stimulation O
. O

The O
predicted O
amino O
acid O
sequence O
of O
the O
amino O
- O
terminal O
portion O
of O
Sp140 B
was O
similar O
to O
Sp100 B
, O
a O
previously O
identified O
NB O
protein O
. O

B O
lymphocyte O
stimulation O
via O
both O
CD40 B
and O
surface O
Ig O
( O
sIg O
) O
receptors O
substantially O
induced O
fra B
- I
1 I
expression O
, O
and O
for O
both O
receptors O
, O
induction O
was O
protein B
kinase I
C I
( O
PKC B
) O
dependent O
. O

Induction O
of O
fra B
- I
1 I
following O
engagement O
of O
CD40 B
did O
not O
require O
protein O
synthesis O
, O
suggesting O
that O
the O
PKC B
- O
dependent O
linkage O
between O
CD40 B
and O
fra B
- I
1 I
is O
direct O
. O

The O
other O
two O
SR O
patients O
had O
an O
abnormally O
low O
GR B
number O
with O
normal O
binding O
affinity O
that O
was O
not O
limited O
to O
T O
cells O
. O

This O
may O
be O
due O
to O
the O
low O
prevalence O
of O
overexpressed O
ER B
and O
the O
small O
number O
of O
controls O
. O

Inhibition O
of O
RANTES B
expression O
did O
not O
appear O
to O
be O
secondary O
to O
IL B
- I
2 I
inhibition O
and O
required O
binding O
to O
the O
intracellular O
glucocorticoid B
receptor I
. O

Association O
of O
TRAF1 B
, O
TRAF2 B
, O
and O
TRAF3 B
with O
an O
Epstein O
- O
Barr O
virus O
LMP1 O
domain O
important O
for O
B O
- O
lymphocyte O
transformation O
: O
role O
in O
NF B
- I
kappaB I
activation O
. O

The O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
transforming O
protein O
LMP1 O
appears O
to O
be O
a O
constitutively O
activated O
tumor O
necrosis O
factor O
receptor O
( O
TNFR B
) O
on O
the O
basis O
of O
an O
intrinsic O
ability O
to O
aggregate O
in O
the O
plasma O
membrane O
and O
an O
association O
of O
its O
cytoplasmic O
carboxyl O
terminus O
( O
CT O
) O
with O
TNFR B
- I
associated I
factors I
( O
TRAFs B
) O
. O

TRAF1 B
, O
TRAF2 B
, O
and O
TRAF3 B
bind O
to O
a O
single O
site O
in O
the O
LMP1 O
CT O
corresponding O
to O
amino O
acids O
( O
aa O
) O
199 O
to O
214 O
, O
within O
a O
domain O
which O
is O
important O
for O
B O
- O
lymphocyte O
growth O
transformation O
( O
aa O
187 O
to O
231 O
) O
. O

NF B
- I
kappaB I
activation O
by O
LMP1 B
( O
1 O
- O
231 O
) O
is O
likely O
to O
be O
mediated O
by O
TRAF1 B
/ B
TRAF2 I
heteroaggregates O
since O
TRAF1 B
is O
unique O
among O
the O
TRAFs B
in O
coactivating O
NF B
- I
kappaB I
with O
LMP1 B
( O
1 O
- O
231 O
) O
, O
a O
TRAF2 B
dominant O
- O
negative O
mutant O
can O
block O
LMP1 B
( O
1 O
- O
231 O
) O
- O
mediated O
NF B
- I
kappaB I
activation O
as O
well O
as O
TRAF1 B
coactivation O
, O
and O
30 O
% O
of O
TRAF2 B
is O
associated O
with O
TRAF1 B
in O

The O
gene O
encoding O
the O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
- O
specific O
dUTPase O
was O
amplified O
from O
virus B
DNA I
by O
PCR O
. O

Two O
pp56 O
( O
lck O
) O
mutants O
lacking O
either O
the O
entire O
catalytic B
domain I
or O
the O
entire O
NH2 B
regulatory B
domain I
were O
generated O
, O
and O
their O
abilities O
to O
trigger O
transactivation O
of O
the O
TCR O
- O
regulated O
nuclear O
factor O
of O
activated O
T O
cells O
( O
NF O
- O
AT O
) O
region O
of O
the O
IL B
- I
2 I
promoter I
were O
compared O
. O

The O
results O
showed O
that O
the O
average O
number O
of O
GCR B
in O
asthmatics O
was O
significantly O
lower O
than O
that O
in O
healthy O
subjects O
( O
P O
< O
0 O
. O
01 O
) O
, O
and O
there O
was O
a O
linear O
correlation O
between O
the O
number O
of O
GCR B
and O
the O
course O
of O
asthma O
. O

These O
findings O
suggest O
that O
there O
is O
no O
primary O
and O
general O
impairment O
of O
glucocorticoid O
metabolism O
in O
the O
asthmatics O
, O
but O
the O
number O
of O
GCR B
in O
the O
asthmatics O
is O
lower O
than O
that O
in O
healthy O
controls O
. O

The O
macrophage B
colony I
- I
stimulating I
factor I
( I
M I
- I
CSF I
) I
receptor I
is O
expressed O
in O
a O
tissue O
- O
specific O
fashion O
from O
two O
distinct O
promoters B
in O
monocytes O
/ O
macrophages O
and O
the O
placenta O
. O

The O
number O
of O
GCR B
may O
be O
improved O
by O
inhalation O
of O
oxygen O
. O

Signaling O
via O
IL B
- I
2 I
and O
IL B
- I
4 I
in O
JAK3 O
- O
deficient O
severe O
combined O
immunodeficiency O
lymphocytes O
: O
JAK3 B
- O
dependent O
and O
independent O
pathways O
. O

However O
, O
IL B
- I
4 I
- O
induced O
effects O
were O
clearly O
improved O
following O
JAK3 B
expression O
. O

Interleukin B
2 I
( O
IL B
- I
2 I
) O
stimulates O
IL B
- I
2R I
alpha I
. O

Tumor B
necrosis I
factor I
receptor I
- I
1 I
( O
TNFR B
- I
1 I
) O
and O
CD95 B
( O
also O
called O
Fas B
or O
APO B
- I
1 I
) O
are O
cytokine B
receptors I
that O
engage O
the O
apoptosis O
pathway O
through O
a O
region O
of O
intracellular O
homology O
, O
designated O
the O
` O
` O
death B
domain I
. O
' O
' O
Another O
death O
domain O
- O
containing O
member O
of O
the O
TNFR O
family O
, O
death O
receptor O
3 O
( O
DR3 B
) O
, O
was O
identified O
and O
was O
shown O
to O
induce O
both O
apoptosis O
and O
activation O
of O
nuclear B
factor I
kappaB I
. O

Differential O
nuclear O
localization O
of O
p50 B
, O
p52 B
, O
and O
RelB B
proteins O
in O
human O
accessory O
cells O
of O
the O
immune O
response O
in O
situ O
. O

The O
different O
patterns O
of O
p50 B
, O
p52 B
and O
RelB B
protein O
nuclear O
localization O
may O
provide O
insight O
into O
their O
different O
roles O
during O
the O
immune O
response O
in O
vivo O
. O

Although O
mutation O
of O
either O
Y113 O
and O
Y128 O
has O
a O
minimal O
effect O
on O
SLP B
- I
76 I
function O
, O
mutation O
of O
both O
residues O
decreases O
significantly O
the O
ability O
of O
SLP B
- I
76 I
to O
promote O
T O
cell O
activation O
. O

The O
IRF B
- I
2 I
promoter B
region I
contains O
a O
CpG O
island O
, O
with O
several O
GC O
boxes O
, O
a O
putative O
NF B
- I
kappa I
B I
- I
binding I
site I
, O
and O
a O
CAAT B
box I
, O
but O
no O
TATA B
box I
. O

When O
the O
promoter B
region I
was O
linked O
with O
a O
heterologous O
reporter O
gene O
, O
we O
found O
that O
the O
promoter B
region I
is O
inducible O
by O
both O
interferons B
( O
interferon O
- O
alpha O
and O
- O
gamma O
) O
and O
interferon B
regulatory I
factor I
1 I
. O

Interferon B
alpha I
selectively O
affects O
expression O
of O
the O
human B
myeloid I
cell I
nuclear I
differentiation I
antigen I
in O
late O
stage O
cells O
in O
the O
monocytic O
but O
not O
the O
granulocytic O
lineage O
. O

Although O
, O
the O
level O
of O
MNDA B
mRNA I
in O
primary O
monocytes O
is O
very O
low O
it O
was O
up O
- O
regulated O
at O
6 O
h O
following O
the O
addition O
of O
interferon B
alpha I
. O

This O
reduced O
level O
of O
mRNA B
could O
then O
be O
elevated O
with O
subsequent O
interferon B
alpha I
treatment O
. O

We O
identified O
a O
protein O
, O
p37 O
, O
which O
specifically O
bound O
to O
DRE B
1 I
. O

Binding O
of O
the O
cDNA O
fusion O
protein O
, O
similarly O
to O
the O
results O
obtained O
with O
purified O
Jurkat O
protein O
, O
was O
decreased O
by O
introduction O
of O
site O
- O
specific O
mutations O
in O
the O
DRE B
1 I
regulatory I
sequence I
. O

These O
results O
describe O
for O
the O
first O
time O
the O
rapid O
modulation O
of O
the O
NT3R B
in O
response O
to O
the O
combined O
influence O
of O
cold O
exposure O
and O
reduced O
circulating O
T4 O
and O
TSH O
. O

HIV B
- I
1 I
LTR I
activity O
in O
human O
CD40 O
- O
activated O
B O
lymphocytes O
is O
dependent O
on O
NF B
- I
kappaB I
. O

In O
these O
cells O
, O
nuclear B
factors I
involved O
in O
activation O
of O
the O
HIV B
- I
1 I
LTR I
, O
which O
contains O
the O
transcriptional O
control O
elements O
of O
the O
virus O
, O
are O
unknown O
. O

In O
preincubated O
cells O
, O
the O
cycloheximide O
response O
is O
decreased O
, O
especially O
in O
the O
case O
of O
FOSB B
. O

Cell O
specific O
expression O
of O
human O
Bruton O
' O
s O
agammaglobulinemia O
tyrosine O
kinase O
gene O
( O
Btk B
) O
is O
regulated O
by O
Sp1 B
- I
and O
Spi O
- O
1 O
/ O
PU O
. O
1 O
- O
family O
members O
. O

In O
vitro O
footprinting O
analysis O
within O
this O
part O
of O
the O
promoter B
revealed O
two O
Sp1 B
binding I
sites I
as O
well O
as O
a O
PU B
- I
box I
. O

In O
addition O
Spi B
- I
B I
as O
well O
as O
PU B
. I
1 I
were O
able O
to O
transactivate O
Btk B
expression O
. O

CD14 B
- O
mediated O
signal O
pathway O
of O
Porphyromonas O
gingivalis O
lipopolysaccharide O
in O
human O
gingival O
fibroblasts O
. O

In O
this O
study O
, O
we O
observed O
unexpectedly O
by O
immunohistochemical O
, O
Western O
blotting O
( O
immunoblotting O
) O
, O
and O
Northern O
( O
RNA O
) O
blotting O
assays O
that O
CD14 B
is O
expressed O
at O
high O
density O
in O
human O
gingival O
fibroblasts O
. O

The O
inhibitor O
also O
dramatically O
inhibited O
monocyte O
chemotactic O
activity O
of O
and O
MCP B
- I
1 I
production O
by O
the O
cells O
. O

Thus O
, O
the O
tyrosine B
kinase I
activated O
by O
G B
- I
CSF I
appears O
to O
directly O
transduce O
a O
signal O
to O
a O
protein O
which O
functions O
as O
a O
transcriptional O
regulator O
. O

As O
showed O
on O
tissue O
sections O
, O
we O
detected O
the O
p50 B
in O
both O
cytoplasm O
and O
nucleus O
of O
FDC O
. O

In O
addition O
, O
analysis O
of O
EBV O
protein O
expression O
by O
IH O
revealed O
a O
heterogeneous O
pattern O
of O
EBV B
gene I
expression O
at O
the O
single O
- O
cell O
level O
consisting O
of O
both O
LMP1 O
+ O
and O
LMP1 O
- O
tumour O
cells O
, O
suggesting O
a O
mixture O
of O
latency O
I O
and O
II O
. O

Moreover O
, O
ZK161422 O
, O
but O
not O
ZK157202 O
, O
showed O
preference O
for O
gene O
activation O
from O
a O
promoter B
carrying O
a O
VD O
response O
element O
with O
a O
palindromic O
arrangement O
of O
two O
hexameric O
receptor O
binding O
sites O
spaced O
by O
9 O
nucleotides O
( O
IP9 O
) O
rather O
than O
for O
activation O
from O
a O
response B
element I
formed O
by O
a O
direct O
repeat O
spaced O
by O
3 O
nucleotides O
( O
DR3 O
) O
. O

The O
process O
of O
activation O
involves O
calcium O
mobilization O
, O
activation O
of O
protein B
kinase I
C I
( O
PKC B
) O
, O
and O
phosphorylation O
of O
tyrosine B
kinases I
. O

The O
involvement O
of O
p21 B
( I
ras I
) I
in O
the O
regulation O
of O
calcium O
- O
dependent O
signals O
has O
been O
suggested O
through O
analysis O
of O
its O
role O
in O
the O
activation O
of O
NF B
- I
AT I
. O

The O
expression O
of O
activated O
p21 B
( I
ras I
) I
negatively O
regulated O
the O
induction O
of O
IE B
genes I
by O
calcium O
ionophore O
. O

A O
later O
result O
of O
inhibition O
of O
this O
activation O
pathway O
by O
p21 B
( I
ras I
) I
was O
down O
- O
regulation O
of O
the O
activity O
of O
the O
transcription B
factor I
AP B
- I
1 I
and O
subsequent O
coordinate O
reductions O
in O
IL B
- I
2 I
gene I
expression O
and O
protein O
production O
. O

Calcineurin B
acts O
in O
synergy O
with O
PMA O
to O
inactivate O
I O
kappa O
B O
/ O
MAD3 O
, O
an O
inhibitor O
of O
NF B
- I
kappa I
B I
. O

Calcineurin B
stimulates O
the O
NF B
- I
kappa I
B I
element I
by O
enhancing O
inactivation O
of O
I O
kappa O
B O
/ O
MAD3 O
, O
an O
inhibitor O
of O
NF B
- I
kappa I
B I
, O
thereby O
increasing O
the O
amount O
of O
nuclear O
NF B
- I
kappa I
B I
DNA O
binding O
activity O
. O

Inhibition O
of O
membrane O
IL B
- I
2R I
alpha I
and O
IL B
- I
2R I
beta I
expression O
by O
10 O
( O
- O
6 O
) O
M O
DM O
was O
partially O
reversible O
by O
recombinant O
human O
IL O
- O
2 O
( O
rhIL O
- O
2 O
) O
. O

The O
mechanism O
of O
action O
of O
DM O
on O
IL B
- I
2R I
alpha I
transcription O
was O
examined O
by O
determining O
the O
mRNA O
levels O
of O
the O
p50 O
subunit O
of O
nuclear O
factor O
kappa O
B O
( O
NF B
- I
kappa I
B I
) O
, O
a O
transcription B
factor I
that O
stimulates O
IL B
- I
2R I
alpha I
gene O
expression O
. O

The O
protein B
- I
tyrosine I
kinase I
ZAP B
- I
70 I
is O
implicated O
, O
together O
with O
the O
Src O
kinase O
p56 B
( I
lck I
) I
, O
in O
controlling O
the O
early O
steps O
of O
the O
T O
- O
cell O
antigen O
receptor O
( O
TCR B
) O
signaling O
cascade O
. O

To O
help O
elucidate O
further O
the O
mechanism O
by O
which O
ZAP B
- I
70 I
regulates O
these O
initial O
events O
, O
we O
used O
a O
dominant O
- O
negative O
mutant O
approach O
. O

ZAP B
- I
70 I
will O
then O
be O
able O
to O
effectively O
control O
phosphorylation O
of O
its O
substrates O
and O
lead O
to O
gene O
activation O
. O

Peripheral O
blood O
mononuclear O
cell O
GCR B
binding O
affinities O
for O
dexamethasone O
and O
budesonide O
were O
also O
determined O
for O
both O
patient O
groups O
by O
using O
a O
radioligand O
binding O
assay O
and O
Scatchard O
analysis O
. O

The O
GCR B
binding O
affinity O
for O
budesonide O
was O
significantly O
higher O
in O
both O
groups O
( O
i O
. O
e O
. O
, O
lower O
dissociation O
constant O
) O
than O
that O
obtained O
for O
dexamethasone O
. O

Characterization O
of O
the O
murine O
cyclin O
- O
dependent O
kinase O
inhibitor O
gene O
p27Kip1 B
. O

Primer O
extension O
and O
nuclease O
S1 O
protection O
analysis O
revealed O
two O
major O
transcription B
initiation I
sites I
. O

Furthermore O
, O
overexpression O
and O
constitutive O
nuclear O
localization O
of O
NF B
- I
AT I
, O
but O
not O
Jun O
, O
Fos O
, O
NF O
- O
kappaB O
, O
Oct O
or O
Ets O
family O
members O
, O
renders O
the O
interleukin B
- I
2 I
enhancer I
in O
Jurkat O
T O
lymphocytes O
resistant O
to O
FK506 O
and O
cyclosporin O
A O
. O

These O
findings O
thus O
reveal O
the O
presence O
of O
a O
second O
inducible O
autoregulated O
inhibitory O
pathway O
that O
helps O
ensure O
the O
rapid O
but O
transient O
action O
of O
nuclear B
NF I
- I
kappa I
B I
. O

First O
, O
anti O
- O
CD45 O
antibodies O
did O
not O
affect O
basal O
but O
decreased O
activated O
levels O
of O
expression O
from O
the O
HIV B
- I
1 I
LTR I
. O

The O
expression O
of O
GM B
- I
CSF I
and O
IL B
- I
2 I
is O
inhibited O
by O
immunosuppressive O
drugs O
such O
as O
cyclosporin O
A O
( O
CsA O
) O
and O
FK506 O
. O

The O
constitutively O
active O
type O
of O
the O
CN O
A O
subunit O
, O
which O
lacks O
the O
auto O
- O
inhibitory O
and O
calmodulin O
- O
binding O
domains O
, O
acts O
in O
synergy O
with O
PMA O
to O
activate O
transcription O
from O
the O
GM B
- I
CSF I
promoter I
. O

TCDD O
mediates O
atrophy O
induction O
through O
its O
specific O
receptor O
( O
the O
AhR B
) O
and O
not O
through O
effects O
on O
the O
estrogen O
receptor O
. O

It O
predicts O
for O
two O
open B
reading I
frames I
( O
ORFs B
) O
. O

To O
investigate O
the O
mechanisms O
of O
transcriptional O
activation O
of O
interleukin B
- I
1beta I
( O
IL B
- I
1beta I
) O
in O
non O
- O
monocytic O
cells O
, O
we O
constructed O
a O
series O
of O
reporter O
plasmids O
with O
the O
bacterial O
chloramphenicol O
acetyltransferase O
gene O
linked O
to O
various O
parts O
of O
the O
human B
IL I
- I
1beta I
promoter I
and O
performed O
transient O
transfection O
experiments O
. O

Egr B
- I
1 I
expression O
correlates O
with O
the O
cellular O
phenotype O
and O
the O
specific O
pattern O
of O
viral O
latency O
established O
within O
the O
individual O
cell O
lines O
. O

In O
all O
cells O
tested O
, O
IL B
- I
10 I
activated O
Stat1 B
and O
Stat3 B
and O
induced O
the O
formation O
of O
three O
distinct O
DNA B
binding I
complexes I
that O
contained O
different O
combinations O
of O
these O
two O
transcription B
factors I
. O

Using O
a O
structure O
- O
function O
mutagenesis O
approach O
, O
two O
tyrosine O
residues O
( O
Tyr427 O
and O
Tyr477 O
) O
in O
the O
intracellular B
domain I
of O
the O
murine O
IL B
- I
10 I
receptor O
were O
found O
to O
be O
redundantly O
required O
for O
receptor O
function O
and O
for O
activation O
of O
Stat3 B
but O
not O
for O
Stat1 B
or O
Stat5 B
. O

This O
study O
thus O
supports O
the O
concept O
that O
utilization O
of O
distinct O
STAT B
proteins I
by O
different O
cytokine B
receptors I
is O
dependent O
on O
the O
expression O
of O
particular O
ligand O
- O
activatable O
, O
tyrosine O
- O
containing O
STAT O
docking O
sites O
in O
receptor O
intracellular O
domains O
. O

Silencing O
of O
human O
fetal O
globin B
expression O
is O
impaired O
in O
the O
absence O
of O
the O
adult O
beta O
- O
globin O
gene O
activator O
protein O
EKLF B
. O

Globin B
genes I
are O
subject O
to O
tissue O
- O
specific O
and O
developmental O
stage O
- O
specific O
regulation O
. O

E3 B
, O
a O
hematopoietic O
- O
specific O
transcript O
directly O
regulated O
by O
the O
retinoic B
acid I
receptor I
alpha I
. O

E3 B
, O
one O
of O
nine O
sequences O
identified O
, O
was O
upregulated O
in O
an O
immediate O
- O
early O
manner O
, O
with O
transcript O
levels O
peaking O
after O
60 O
minutes O
exposure O
to O
RA O
. O

E3 B
transcripts I
were O
RA O
- O
inducible O
in O
HL60 O
cells O
, O
but O
not O
in O
an O
RA O
- O
resistant O
subclone O
, O
HL60R O
, O
that O
harbors O
a O
mutated O
RAR B
alpha I
gene I
. O

These O
results O
indicate O
that O
E3 B
is O
a O
hematopoietic O
- O
specific O
gene O
that O
is O
an O
immediate O
target O
for O
the O
activated O
RAR B
alpha I
during O
myelopoiesis O
. O

The O
molecular O
mechanism O
underlying O
IL B
- I
2 I
transcriptional O
blockade O
in O
anergic O
T O
cell O
clones O
is O
not O
fully O
understood O
. O

To O
examine O
whether O
an O
active O
negative O
regulatory O
process O
occurs O
, O
we O
created O
a O
reporter B
construct I
containing O
as O
an O
enhancer B
four O
copies O
of O
the O
NF B
- I
AT I
site I
and O
one O
copy O
of O
the O
octamer B
site I
( O
4X O
NF O
- O
AT O
- O
Oct O
) O
. O

The O
simplest O
model O
to O
explain O
these O
results O
is O
that O
anergy O
is O
mediated O
by O
a O
complex O
of O
multiple O
transcription B
factors I
that O
exert O
a O
cis O
- O
acting O
dominant O
negative O
regulatory O
effect O
on O
the O
trans O
- O
activation O
of O
the O
IL B
- I
2 I
gene I
. O

In O
contrast O
, O
expression O
of O
the O
activation O
- O
dependent O
cell O
surface O
markers O
CD25 B
and O
CD69 B
was O
within O
normal O
limits O
. O

Whereas O
AP B
- I
1 I
, O
NF O
- O
kappa O
B O
, O
Oct B
, O
CREB B
and O
SP1 B
displayed O
normal O
binding O
activities O
in O
nuclear O
extracts O
, O
the O
binding O
of O
NF B
- I
AT I
to O
its O
IL B
- I
2 I
promoter O
response O
element O
was O
barely O
detectable O
both O
before O
and O
after O
T O
cell O
stimulation O
. O

Our O
results O
strongly O
suggest O
that O
this O
NF B
- I
AT I
/ O
DNA O
binding O
defect O
is O
responsible O
for O
the O
multiple O
cytokine B
deficiency O
and O
the O
SCID O
phenotype O
observed O
in O
the O
two O
infant O
brothers O
. O

During O
Epstein O
- O
Barr O
virus O
latent O
infection O
of O
B O
lymphocytes O
in O
vitro O
, O
six O
viral O
nuclear O
antigens O
( O
EBNAs B
) O
are O
expressed O
from O
one O
of O
two O
promoters B
, O
Cp B
or O
Wp B
, O
whose O
activities O
are O
mutually O
exclusive O
. O

Deletion O
of O
the O
EBNA2 B
- I
dependent I
enhancer I
located O
upstream O
of O
Cp B
resulted O
in O
a O
ca O
. O
two O
- O
to O
fivefold O
reduction O
in O
Cp B
activity O
in O
the O
LCLs O
assayed O
. O

Deletion O
of O
the O
glucocorticoid O
response O
elements O
located O
at O
ca O
. O
bp O
- O
850 O
upstream O
of O
Cp B
did O
not O
result O
in O
a O
significant O
loss O
in O
activity O
. O

The O
identification O
of O
oriP B
and O
the O
EBNA2 B
- I
dependent I
enhancer I
as O
the O
major O
positive O
cis B
elements I
involved O
in O
regulating O
Cp B
activity O
in O
LCL O
suggests O
that O
EBNA B
gene I
transcription O
is O
largely O
autoregulated O
by O
EBNA O
1 O
and O
EBNA B
2 I
. O

Expression O
of O
interleukin B
1beta I
and O
other O
cytokines B
, O
such O
as O
interleukin B
6 I
and O
tumor B
necrosis I
factor I
alpha I
, O
has O
been O
shown O
to O
be O
dependent O
on O
the O
activation O
of O
the O
transcription B
factor I
, O
NFkappaB B
. O

HIV O
- O
1 O
infection O
resulted O
in O
constitutive O
, O
low O
- O
level O
expression O
of O
type O
1 O
interferon O
( O
IFN B
) O
at O
the O
mRNA O
level O
. O

We O
suggest O
that O
HIV O
- O
1 O
infection O
of O
myeloid O
cells O
induces O
IFN B
production O
and O
PKR B
activity O
, O
which O
in O
turn O
contribute O
to O
enhanced O
IkappaBalpha B
phosphorylation O
and O
subsequent O
degradation O
. O

Nuclear O
translocation O
of O
NF B
- I
kappaB I
subunits I
may O
ultimately O
increase O
the O
intracellular O
pool O
of O
NF O
- O
kappaB O
/ O
IkappaBalpha O
by O
an O
autoregulatory O
mechanism O
. O

The O
transcription O
and O
transformation O
activity O
of O
c B
- I
Jun I
is O
governed O
by O
a O
27 O
- O
amino O
acid O
regulatory O
motif O
, O
labeled O
the O
delta O
- O
domain O
, O
which O
is O
deleted O
in O
v O
- O
Jun O
. O

Here O
, O
we O
report O
that O
differentiated O
B O
cells O
contain O
a O
novel O
substoichiometric O
TAF O
of O
105 O
kDa O
not O
found O
associated O
with O
TFIID B
isolated O
from O
other O
cell O
types O
. O

All O
cells O
tested O
express O
TAFII105 O
mRNA O
, O
but O
only O
B O
cells O
contain O
significant O
levels O
of O
protein O
associated O
with O
TFIID B
. O

The O
association O
of O
20q B
deletions I
with O
myeloid O
` O
` O
stem O
cell O
' O
' O
disorders O
suggests O
that O
the O
deletions O
mark O
the O
site O
of O
one O
or O
more O
genes O
, O
loss O
or O
inactivation O
of O
which O
plays O
a O
role O
in O
the O
regulation O
of O
normal O
hematopoietic O
progenitors O
. O

In O
contrast O
to O
MM O
cells O
, O
normal O
splenic O
B O
cells O
express O
dephosphorylated B
pRB I
. O

Although O
CD40 B
ligand I
( O
CD40L B
) O
triggers O
a O
shift O
from O
dephosphorylated O
to O
phosphorylated O
pRB B
and O
proliferation O
of O
B O
cells O
, O
the O
addition O
of O
exogenous O
IL B
- I
6 I
to O
CD40L B
- O
treated O
B O
cells O
does O
not O
alter O
either O
pRB B
or O
proliferation O
, O
as O
observed O
in O
MM O
cells O
. O

Soluble B
factors I
secreted O
by O
activated O
T O
- O
lymphocytes O
modulate O
the O
transcription O
of O
the O
immunosuppressive O
cytokine O
TGF B
- I
beta I
2 I
in O
glial O
cells O
. O

These O
data O
along O
with O
previous O
observations O
demonstrating O
the O
potent O
immunosuppressive O
activity O
of O
TGF B
- I
beta I
2 I
, O
support O
a O
model O
for O
a O
feedback O
mechanism O
between O
the O
activated O
T O
- O
lymphocytes O
and O
astrocytes O
via O
TGF B
- I
beta I
2 I
to O
regulate O
the O
immune O
response O
. O

We O
have O
examined O
the O
requirements O
of O
the O
individual O
E B
- I
boxes I
in O
MLV O
transcriptional O
regulation O
. O

In O
lymphoid O
cell O
lines O
only O
, O
the O
E O
( O
gre O
) O
- O
binding O
protein O
complexes O
included O
ALF1 B
or O
HEB B
and O
E2A O
basic O
helix O
- O
loop O
- O
helix O
proteins O
. O

ALF1 B
transactivated O
transcription O
of O
Akv O
MLV O
through O
the O
two O
E B
( I
gre I
) I
motifs I
equally O
, O
whereas O
E2A B
protein I
required O
the O
promoter O
- O
proximal O
E B
( I
gre I
) I
motif O
. O

Moreover O
, O
ectopic O
Id1 O
repressed O
E B
( I
gre I
) I
- O
directed O
but O
not O
EA B
/ I
S I
- O
directed O
MLV O
transcription O
in O
lymphoid O
cell O
lines O
. O

In O
conclusion O
, O
E B
( I
gre I
) I
motifs O
and O
interacting O
basic B
helix I
- I
loop I
- I
helix I
proteins I
are O
important O
determinants O
for O
MLV O
transcriptional O
activity O
in O
lymphocytic O
cell O
lines O
. O

We O
cloned O
human O
nur77 O
beta O
cDNA O
, O
called O
TINUR B
. O

Although O
NGFI B
- I
B I
/ I
nur77 I
is O
essential O
for O
TCR O
- O
mediated O
apoptosis O
in O
T O
- O
cell O
hybridomas O
, O
the O
reports O
on O
nur77 O
knock O
- O
out O
mice O
and O
nur77 O
dominant O
negative O
transgenic O
mice O
suggest O
that O
there O
is O
a O
functional O
redundancy O
among O
NGFI B
- I
B I
/ I
nur77 I
family I
. O

Correlations O
were O
found O
between O
plasma O
IFN O
alpha O
and O
receptor O
Kd O
on O
monocytes O
of O
AIDS O
- O
GR O
( O
r O
= O
0 O
. O
77 O
) O
and O
between O
IFN B
alpha I
and O
plasma O
cortisol O
in O
the O
same O
group O
( O
r O
= O
0 O
. O
74 O
) O
. O

By O
contrast O
, O
glucocorticoids O
failed O
to O
inhibit O
IFNalpha B
production O
from O
AIDS O
- O
GR O
monocytes O
( O
approximately O
20 O
% O
inhibition O
) O
. O

This O
activation O
differed O
substantially O
from O
that O
mediated O
by O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
PMA O
) O
and O
Ca2 O
+ O
ionophore O
or O
produced O
by O
costimulation O
with O
antibodies B
against O
the O
T B
cell I
receptor I
- I
CD3 I
complex I
and O
to O
CD28 B
. O

Induction O
of O
bcl B
- I
2 I
expression O
by O
phosphorylated O
CREB O
proteins O
during O
B O
- O
cell O
activation O
and O
rescue O
from O
apoptosis O
. O

These O
stimuli O
result O
in O
phosphorylation O
of O
CREB B
at O
serine O
133 O
. O

It O
is O
possible O
that O
the O
CRE B
site I
is O
responsible O
for O
induction O
of O
bcl B
- I
2 I
expression O
in O
other O
cell O
types O
, O
particularly O
those O
in O
which O
protein B
kinase I
C I
is O
involved O
. O

MNDA B
( O
myeloid O
cell O
nuclear O
differentiation O
antigen O
) O
is O
an O
interferon O
alpha O
regulated O
nuclear O
protein O
expressed O
only O
in O
cells O
of O
the O
human O
myelomonocytic O
lineage O
. O

In O
addition O
, O
DNA O
methylation O
was O
revealed O
as O
one O
of O
the O
possible O
factors O
in O
establishing O
MNDA B
expression O
. O

Characterization O
of O
a O
new O
isoform O
of O
the O
NFAT B
( O
nuclear B
factor I
of I
activated I
T I
cells I
) O
gene O
family O
member O
NFATc B
[ O
published O
erratum O
appears O
in O
J O
Biol O
Chem O
1996 O
Dec O
27 O
; O
271 O
( O
52 O
) O
: O
33705 O
] O

The O
amino B
acid I
sequence I
of O
NFATc B
. I
beta I
differs O
from O
that O
of O
NFATc B
. O

Transient O
expression O
of O
NFATc B
. I
beta I
was O
capable O
of O
activating O
an O
interleukin O
- O
2 O
NFAT O
- O
driven O
reporter O
gene O
in O
stimulated O
Jurkat O
cells O
in O
a O
CsA O
- O
sensitive O
manner O
. O

However O
, O
NFATc B
. I
beta I
neither O
bound O
to O
the O
kappa3 O
element O
( O
an O
NFAT B
- I
binding I
site I
) O
in O
the O
tumor B
necrosis I
factor I
- I
alpha I
promoter I
nor O
activated O
the O
tumor B
necrosis I
factor I
- I
alpha I
promoter I
in O
cotransfection O
assays O
. O

Both O
are O
located O
in O
the O
particulate O
fraction O
following O
platelet O
activation O
and O
are O
also O
able O
to O
bind O
to O
a O
GST O
- O
construct O
containing O
the O
SH2 O
and O
SH3 O
domains O
of O
phospholipase B
C I
gamma I
1 I
. O

Constitutive O
expression O
of O
IFN O
- O
alpha5 O
and O
IFN B
- I
beta I
was O
detected O
in O
different O
lymphoid O
cells O
including O
peripheral O
blood O
mononuclear O
cells O
from O
normal O
individuals O
following O
amplification O
of O
IFN O
mRNA O
by O
reverse B
transcriptase I
- O
polymerase O
chain O
reaction O
and O
direct O
sequencing O
of O
the O
amplified O
product O
. O

These O
results O
suggest O
that O
IFN O
- O
alpha5 O
and O
IFN B
- I
beta I
are O
produced O
at O
low O
levels O
in O
normal O
tissues O
and O
play O
an O
important O
role O
in O
the O
regulation O
of O
cell O
function O
and O
in O
the O
maintenance O
of O
homeostasis O
. O

Thus O
, O
IL B
- I
2 I
- O
induced O
IL B
- I
2R I
alpha I
promoter I
activity O
requires O
a O
complex O
upstream O
element O
, O
which O
appears O
to O
contain O
binding B
sites I
for O
both O
positive O
and O
negative O
regulatory O
factors O
. O

Lymphocytes O
from O
CML O
patients O
lack O
a O
47 B
kDa I
factor I
having O
affinity O
for O
a O
genomic O
sterol O
regulatory O
sequence O
. O

The O
proximal O
sequence O
element O
( O
PSE O
) O
- O
binding O
transcription O
factor O
( O
PTF B
) O
, O
which O
binds O
the O
PSE O
of O
both O
RNA O
polymerase O
II O
- O
and O
RNA O
polymerase O
III O
- O
transcribed O
mammalian O
small O
nuclear O
RNA O
( O
snRNA O
) O
genes O
, O
is O
essential O
for O
their O
transcription O
. O

Here O
we O
describe O
the O
isolation O
and O
expression O
of O
a O
cDNA B
encoding O
PTF B
beta I
, O
as O
well O
as O
functional O
studies O
using O
anti O
- O
PTF O
beta O
antibodies O
. O

Tyloxapol O
inhibits O
NF B
- I
kappa I
B I
and O
cytokine B
release O
, O
scavenges O
HOCI O
, O
and O
reduces O
viscosity O
of O
cystic O
fibrosis O
sputum O
. O

Tyloxapol O
inhibits O
activation O
of O
the O
transcription B
factor I
nuclear I
factor I
- I
kappa I
B I
( O
NK B
- I
kappa I
B I
) O
, O
reduces O
resting O
secretion O
of O
the O
cytokine B
interleukin B
- I
8 I
( O
IL B
- I
8 I
) O
in O
cultured O
human O
monocytes O
, O
and O
inhibits O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O
release O
of O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
, O
IL B
- I
1 I
beta I
, O
IL B
- I
6 I
, O
IL B
- I
8 I
, O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
, O
and O
the O

In O
this O
study O
, O
we O
examined O
the O
molecular O
mechanism O
by O
which O
agents O
that O
elevate O
intracellular O
cAMP O
inhibit O
the O
expression O
of O
the O
tumor B
necrosis I
factor I
alpha I
( O
TNFalpha B
) O
, O
tissue B
factor I
, O
endothelial B
leukocyte I
adhesion I
molecule I
- I
1 I
, O
and O
vascular O
cell O
adhesion O
molecule O
- O
1 O
genes O
. O

We O
propose O
that O
direct O
interaction O
between O
the O
glucocorticoid B
receptor I
and O
nuclear O
factor O
- O
kappa O
B O
factors O
is O
at O
least O
a O
partial O
explanation O
for O
the O
effects O
of O
this O
hormone O
in O
inflammatory O
diseases O
. O

Abnormalities O
in O
the O
p16 B
, I
p15 I
and I
CDK4 I
genes I
that O
regulate O
transition O
through O
the O
G1 O
phase O
of O
the O
cell O
cycle O
have O
been O
implicated O
in O
the O
malignant O
progression O
of O
astrocytomas O
. O

The O
primary O
and O
recurrent O
tumors O
in O
Group O
A O
did O
not O
show O
structural O
alterations O
in O
the O
p16 O
, O
p15 O
or O
CDK4 O
genes O
, O
whereas O
homozygous O
codeletion O
of O
p16 B
and O
p15 B
was O
observed O
in O
both O
primary O
and O
recurrent O
tumors O
in O
Group O
B O
. O

The O
primary O
tumors O
in O
Group O
C O
had O
a O
normal O
profile O
of O
p16 B
, O
p15 B
and O
CDK4 B
at O
presentation O
. O

Approximately O
40 O
% O
of O
diffuse O
large O
cell O
lymphoma O
are O
associated O
with O
chromosomal O
translocations O
that O
deregulate O
the O
expression O
of O
the O
BCL6 B
gene I
by O
juxtaposing O
heterologous B
promoters I
to O
the O
BCL O
- O
6 O
coding O
domain O
. O

In O
transient O
transfectin O
experiments O
, O
BCL6 B
can O
repress O
transcription O
from O
promoters B
linked O
to O
its O
DNA O
target O
sequence O
and O
this O
activity O
is O
dependent O
upon O
specific O
DNA O
- O
binding O
and O
the O
presence O
of O
an O
intact O
N B
- I
terminal I
half I
of O
the O
protein O
. O

As O
the O
NF B
- I
kappa I
B I
transcription I
factor I
has O
a O
central O
role O
in O
the O
control O
of O
transcription O
of O
several O
genes B
involved O
in O
immune O
and O
inflammatory O
responses O
, O
the O
authors O
have O
analysed O
the O
activation O
of O
NF B
- I
kappa I
B I
in O
human O
umbilical O
cord O
T O
lymphocytes O
. O

The O
key O
role O
of O
erythropoietin B
( O
Epo B
) O
for O
colony O
formation O
by O
early O
erythroid O
progenitors O
( O
burst O
- O
forming O
units O
- O
erythroid O
[ O
BFU O
- O
E O
] O
) O
has O
been O
confirmed O
. O

We O
previously O
suggested O
that O
the O
measurement O
of O
corticosteroid B
receptors I
in O
lymphocytes O
is O
an O
index O
of O
an O
analogous O
pattern O
in O
brain O
. O

Analysis O
of O
the O
ligand B
- I
binding I
domain I
of O
human O
retinoic O
acid O
receptor O
alpha O
by O
site O
- O
directed O
mutagenesis O
. O

Three O
subtypes O
of O
retinoic B
acid I
receptors I
( O
RAR B
) O
, O
termed O
RAR B
alpha I
, O
RAR B
beta I
, O
and O
RAR B
gamma I
, O
have O
been O
described O
. O

RARs B
specifically O
bind O
all O
- O
trans O
- O
retinoic O
acid O
( O
RA O
) O
, O
9 O
- O
cis O
- O
RA O
, O
and O
retinoid O
analogs O
. O

In O
spite O
of O
this O
similar O
downstream O
signalling O
, O
IL4 B
and O
IL13 B
used O
a O
different O
set O
of O
Janus B
kinases I
: O
IL13 B
is O
unable O
to O
activate O
JAK1 B
and O
JAK3 B
. O

Our O
findings O
support O
the O
recently O
determined O
calcineurin B
X O
- O
ray O
crystal O
structure O
, O
provide O
evidence O
that O
calcineurin B
is O
the O
only O
CsA O
- O
sensitive O
component O
limiting O
signaling O
from O
the O
T B
cell I
receptor I
to O
the O
nucleus O
, O
and O
suggest O
a O
means O
to O
render O
cells O
and O
tissues O
resistant O
to O
the O
toxic O
side O
effects O
of O
CsA O
and O
FK506 O
. O

A O
3 O
' O
- O
- O
> O
5 O
' O
XPB O
helicase O
defect O
in O
repair O
/ O
transcription O
factor O
TFIIH B
of O
xeroderma O
pigmentosum O
group O
B O
affects O
both O
DNA O
repair O
and O
transcription O
. O

Although O
identical O
in O
composition O
and O
stoichiometry O
to O
TFIIHwt B
, O
TFIIHmut B
shows O
a O
reduced O
3 O
' O
- O
- O
> O
5 O
' O
XPB B
helicase O
activity O
. O

The O
XPB B
mutation O
causes O
a O
severe O
NER O
defect O
. O

PU B
. I
1 I
is O
completely O
absent O
from O
peripheral O
T O
cells O
and O
most O
T O
cell O
lines O
based O
on O
sensitive O
RT O
- O
PCR O
assays O
. O

In O
contrast O
, O
Spi B
- I
B I
is O
expressed O
exclusively O
in O
lymphoid O
cells O
and O
can O
be O
detected O
in O
early O
fetal O
thymus O
and O
spleen O
. O

In O
situ O
hybridization O
and O
Northern O
blot O
analysis O
suggest O
that O
Spi B
- I
B I
gene O
expression O
increases O
during O
B O
cell O
maturation O
and O
decreases O
during O
T O
cell O
maturation O
. O

Taken O
together O
, O
these O
data O
suggest O
that O
differences O
in O
patterns O
of O
expression O
between O
Spi B
- I
B I
and O
PU B
. I
1 I
distinguish O
the O
function O
of O
each O
protein O
during O
development O
of O
the O
immune O
system O
. O

DNase B
I I
hypersensitive I
site I
( O
DHS O
) O
mapping O
revealed O
that O
the O
perforin O
locus O
contained O
six O
DHS O
within O
7 O
. O
0 O
kb O
of O
the O
5 B
' I
upstream I
sequence I
( O
- O
7 O
. O
0 O
kb O
) O
and O
two O
DHS O
in O
intron O
2 O
. O

Chloramphenicol B
acetyltransferase I
( O
CAT B
) O
activities O
directed O
by O
5 O
' O
upstream O
promoter O
were O
detected O
preferentially O
in O
perforin O
- O
expressing O
cell O
lines O
. O

When O
single O
- O
point O
mutation O
was O
introduced O
to O
each O
GC B
box I
, O
EBS B
, O
and O
GT B
box I
in O
PFP9a20 B
, O
at O
least O
3 O
- O
fold O
less O
CAT B
activity O
was O
observed O
in O
CTLL O
- O
R8 O
cells O
. O

The O
results O
suggest O
that O
a O
combination O
of O
the O
three O
proximal O
cis B
- I
acting I
elements I
may O
constitute O
a O
minimal O
region O
responsible O
for O
CTL O
- O
specific O
expression O
of O
perforin B
. O

Thus O
Oct B
- I
2 I
plays O
an O
important O
role O
in O
the O
regulation O
of O
cellular O
gene O
expression O
in O
both O
B O
cells O
and O
neuronal O
cells O
as O
well O
as O
in O
the O
control O
of O
viral O
latency O
. O

Instead O
, O
ATF B
- I
2 I
and O
Jun B
proteins I
bind O
to O
the O
composite O
kappa O
3 O
/ O
CRE O
site O
and O
NFATp B
binds O
to O
a O
newly O
identified O
second O
NFAT B
site I
centered O
at O
- O
76 O
nucleotides O
relative O
to O
the O
TNF O
- O
alpha O
transcription O
start O
site O
. O

Consistent O
with O
these O
results O
, O
quantitative O
DNase B
footprinting O
of O
the O
TNF B
- I
alpha I
promoter I
using O
increasing O
amounts O
of O
recombinant O
NFATp B
demonstrated O
that O
the O
- O
76 O
site O
binds O
to O
NFATp B
with O
a O
higher O
affinity O
than O
the O
kappa O
3 O
site O
. O

Thus O
, O
through O
the O
differential O
use O
of O
the O
same O
promoter B
element I
, O
the O
composite O
kappa O
3 O
/ O
CRE O
site O
, O
the O
TNF B
- I
alpha I
gene I
is O
regulated O
in O
a O
cell O
- O
type O
- O
specific O
manner O
in O
response O
to O
the O
same O
extracellular O
signal O
. O

To O
address O
possible O
mechanisms O
that O
could O
explain O
this O
selective O
activity O
of O
c B
- I
ErbB I
, O
we O
analyzed O
the O
ability O
of O
these O
receptors O
to O
activate O
the O
different O
members O
of O
the O
Stat O
transcription O
factor O
family O
. O

Ligand O
activation O
of O
c B
- I
ErbB I
induced O
the O
tyrosine O
phosphorylation O
, O
DNA O
- O
binding O
, O
and O
reporter B
gene I
transcription O
of O
Stat B
5b I
in O
erythroblasts O
. O

In O
contrast O
, O
ligand O
activation O
of O
c B
- I
Kit I
was O
unable O
to O
induce O
any O
of O
these O
effects O
in O
the O
same O
cells O
. O

Sequence O
- O
specific O
DNA O
binding O
of O
the O
B B
- I
cell I
- I
specific I
coactivator I
OCA B
- I
B I
. O

Precise O
alignment O
of O
sites O
required O
for O
mu B
enhancer I
activation O
in O
B O
cells O
. O

The O
lymphocyte O
- O
specific O
immunoglobulin O
mu O
heavy O
- O
chain O
gene O
intronic O
enhancer O
is O
regulated O
by O
multiple O
nuclear B
factors I
. O

The O
previously O
defined O
minimal O
enhancer O
containing O
the O
muA O
, O
muE3 O
, O
and O
muB O
sites O
is O
transactivated O
by O
a O
combination O
of O
the O
ETS O
- O
domain O
proteins O
PU B
. I
1 I
and O
Ets B
- I
1 I
in O
nonlymphoid O
cells O
. O

The O
core O
GGAAs O
of O
the O
muA O
and O
muB O
sites O
are O
separated O
by O
30 O
nucleotides O
, O
suggesting O
that O
ETS B
proteins I
bind O
to O
these O
sites O
from O
these O
same O
side O
of O
the O
DNA O
helix O
. O

In O
allergic O
bronchial O
asthma O
, O
inflammation O
seems O
to O
be O
orchestrated O
predominantly O
by O
a O
subset O
of O
T O
lymphocytes O
, O
with O
a O
phenotype O
similar O
to O
the O
Th2 O
subset O
able O
to O
produce O
IL B
- I
4 I
and O
IL B
- I
5 I
. O

Nuclear O
factor O
of O
activated O
T O
cells O
- O
family O
proteins O
( O
NFAT1 O
/ O
NFATp O
, O
NFATc B
, O
NFAT3 O
, O
and O
NFAT4 O
/ O
NFATx O
/ O
NFATc3 O
) O
play O
a O
key O
role O
in O
the O
transcription O
of O
cytokine B
genes I
and O
other O
genes O
during O
the O
immune O
response O
. O

Our O
results O
emphasize O
the O
multiple O
levels O
at O
which O
NFAT O
- O
dependent O
transactivation O
is O
regulated O
, O
and O
predict O
significant O
differences O
in O
the O
architecture O
of O
cooperative O
transcription B
complexes I
containing O
different O
NFAT B
- I
family I
proteins I
. O

A O
major O
obstacle O
in O
understanding O
the O
signaling O
events O
that O
follow O
CD28 B
receptor O
ligation O
arises O
from O
the O
fact O
that O
CD28 B
acts O
as O
a O
costimulus O
to O
TCR B
engagement O
, O
making O
it O
difficult O
to O
assess O
the O
relative O
contribution O
of O
CD28 B
signals O
as O
distinct O
from O
those O
of O
the O
TCR B
. O

This O
revealed O
that O
NF B
- I
kappaB I
generation O
was O
sensitive O
to O
chloroquine O
, O
an O
inhibitor O
of O
acidic B
sphingomyelinase I
, O
but O
not O
to O
the O
phosphatidylinositol B
3 I
- I
kinase I
inhibitor O
, O
wortmannin O
. O

To O
investigate O
the O
presence O
of O
various O
isoforms O
of O
the O
estrogen B
receptor I
( O
ER B
) O
in O
SLE O
we O
isolated O
RNA O
from O
mononuclear O
cells O
of O
lupus O
patients O
and O
normal O
controls O
. O

Sialoadhesin B
expression O
was O
functional O
as O
shown O
by O
cell O
adhesion O
assays O
with O
human O
RBCs O
. O

In O
contrast O
to O
freshly O
isolated O
T O
cells O
, O
in O
vitro O
- O
cultured O
T O
cells O
did O
not O
require O
costimulation O
for O
cytokine B
secretion O
in O
response O
to O
anti B
- I
CD3 I
alone O
. O

The O
induction O
of O
T O
cell O
proliferation O
requires O
signals O
from O
the O
TCR B
and O
a O
co O
- O
receptor O
molecule O
, O
such O
as O
CD28 B
, O
that O
activate O
parallel O
and O
partially O
cross O
- O
reactive O
signaling O
pathways O
. O

Our O
results O
suggest O
that O
PKA B
inhibits O
T O
cell O
activation O
by O
interfering O
with O
multiple O
events O
along O
the O
two O
signaling O
pathways O
operating O
downstream O
of O
the O
TCR B
and O
the O
CD28 O
co O
- O
receptor O
molecules O
. O

This O
pattern O
of O
STAT B
activation O
was O
seen O
in O
all O
BCP O
- O
ALL O
cases O
that O
respond O
to O
IL B
- I
7 I
in O
proliferation O
assays O
. O

To O
determine O
the O
contribution O
of O
the O
cytoplasmic B
domain I
of O
the O
IL O
- O
7 O
receptor O
alpha O
chain O
( O
IL B
- I
7R I
alpha I
) O
to O
activation O
of O
STAT B
proteins I
, O
transfectants O
of O
the O
murine O
pro O
- O
B O
cell O
line O
BAF3 O
were O
made O
that O
express O
chimeric O
receptors O
consisting O
of O
the O
extracellular B
domain I
of O
human O
granulocyte O
colony O
- O
stimulating O
factor O
receptor O
( O
G O
- O
CSF O
- O
R O
) O
and O
the O
transmembrane O
and O
intracellular O
domains O
of O
human O
IL O
- O
7R O
alpha O
. O

The O
percentage O
of O
cells O
expressing O
CD40 B
in O
T O
and O
B O
cell O
co O
- O
cultures O
increased O
from O
4 O
. O
2 O
% O
to O
13 O
. O
8 O
% O
after O
oligo O
stimulation O
in O
patients O
, O
while O
it O
increased O
form O
4 O
. O
7 O
% O
to O
48 O
. O
6 O
% O
in O
healthy O
controls O
. O

We O
demonstrate O
that O
CaMKIV B
/ I
Gr I
reconstitutes O
the O
capacity O
of O
the O
cytosolic O
component O
of O
NFAT B
to O
direct O
transcription O
from O
NFAT O
sites O
in O
non O
- O
T O
cells O
. O

This O
was O
identified O
as O
the O
mRNA B
encoding O
the O
transcription B
factor I
egr B
- I
1 I
, O
which O
is O
expressed O
with O
fast O
kinetics O
in O
T O
and O
NK O
cells O
upon O
IL B
- I
2 I
, O
but O
not O
IL B
- I
12 I
, O
stimulation O
. O

Increasing O
the O
levels O
of O
BCL B
- I
2 I
retarded O
the O
G0 O
- O
- O
> O
S O
transition O
, O
sustained O
the O
levels O
of O
cyclin O
- O
dependent O
kinase O
inhibitor O
p27Kip1 O
, O
and O
repressed O
postactivation O
death O
. O

However O
, O
the O
transcription O
and O
synthesis O
of O
interleukin B
2 I
and O
other O
delayed O
early O
cytokines B
were O
markedly O
attenuated O
by O
BCL B
- I
2 I
. O

On O
the O
basis O
of O
several O
independent O
assays O
, O
we O
now O
report O
a O
physical O
and O
functional O
interaction O
between O
Tax B
and O
the O
transcription B
factor I
, O
TFIIA B
. O

Finally O
, O
TFIIA B
facilitates O
Tax B
transactivation O
in O
vitro O
and O
in O
vivo O
. O

Inhibition O
of O
transcription B
factor I
Stat1 B
activity O
in O
mononuclear O
cell O
cultures O
and O
T O
cells O
by O
the O
cyclic O
AMP O
signaling O
pathway O
. O

Suppression O
of O
c B
- I
jun I
by O
antisense O
oligonucleotides O
inhibits O
cell O
adhesion O
but O
not O
respiratory O
burst O
during O
phorbol O
ester O
- O
induced O
differentiation O
of O
U937 O
human O
monoblastic O
cells O
. O

GM B
- I
CSF I
gene I
activation O
in O
T O
cells O
is O
known O
to O
involve O
the O
transcription B
factors I
nuclear B
factor I
- I
kappa I
B I
, O
AP B
- I
1 I
, O
NFAT B
, O
and O
Sp1 O
. O

A O
2 O
- O
bp O
mutation O
within O
the O
CBF B
site O
resulted O
in O
a O
2 O
- O
3 O
- O
fold O
decrease O
in O
the O
activities O
of O
both O
a O
69 O
- O
bp O
proximal O
promoter O
fragment O
and O
a O
627 O
- O
bp O
full O
- O
length O
promoter O
fragment O
. O

The O
AML1 O
and O
CBF O
beta O
genes O
that O
encode O
CBF B
each O
have O
the O
ability O
to O
influence O
cell O
growth O
and O
differentiation O
and O
have O
been O
implicated O
as O
proto B
- I
oncogenes I
in O
acute O
myeloid O
leukemia O
. O

The O
GM O
- O
CSF O
locus O
may O
represent O
one O
of O
several O
target O
genes B
that O
are O
dysregulated O
in O
acute O
myeloid O
leukemia O
. O

The O
preferential O
induction O
of O
c B
- I
jun I
by O
H2O2 O
did O
not O
represent O
redox O
stabilization O
of O
mRNA B
transcripts I
, O
and O
oxidative O
signals O
closely O
resembled O
PHA O
/ O
PMA O
stimulation O
by O
effectively O
transactivating O
the O
full O
length O
c B
- I
jun I
promoter O
via O
the O
proximal O
jun1 O
tumor O
promoter O
- O
responsive O
element O
( O
TRE O
) O
- O
like O
promoter O
element O
. O

Furthermore O
, O
sublethal O
levels O
of O
H2O2 O
actively O
suppressed O
the O
transcriptional O
activation O
of O
NF B
- I
AT I
and O
IL O
- O
2 O
reporters O
as O
well O
as O
the O
expression O
of O
IL B
- I
2 I
mRNA I
in O
cells O
stimulated O
with O
PHA O
/ O
PMA O
. O

These O
results O
suggest O
that O
oxidative O
signals O
can O
positively O
and O
negatively O
regulate O
T O
cell O
transcriptional O
events O
and O
that O
changes O
in O
cellular O
redox O
can O
uncouple O
AP B
- I
1 I
regulation O
of O
c B
- I
jun I
from O
transcriptional O
up O
- O
regulation O
of O
IL B
- I
2 I
via O
NF B
- I
AT I
. O

Many O
of O
Pb O
' O
s O
effects O
on O
the O
immune O
system O
could O
be O
explained O
through O
activation O
of O
the O
transcription B
factor I
, O
NF B
- I
kappa I
B I
. O

Tyrosine B
kinase I
and O
cAMP B
- I
dependent I
protein I
kinase I
activities O
in O
CD40 O
- O
activated O
human O
B O
lymphocytes O
. O

In O
vitro O
, O
human O
B O
lymphocytes O
undergo O
long O
- O
term O
proliferation O
when O
activated O
through O
CD40 B
, O
a O
protein O
expressed O
on O
their O
cell O
surface O
. O

Rather O
, O
tyrosine O
phosphorylation O
was O
shown O
to O
be O
directly O
involved O
in O
mediating O
CD40 B
- O
dependent O
signals O
. O

To O
examine O
the O
potential O
effects O
of O
stress O
on O
TH1 O
/ O
TH2 O
balance O
, O
we O
studied O
the O
ability O
of O
three O
prototype O
stress O
hormones O
- O
dexamethasone O
( O
a O
synthetic O
glucocorticoid O
) O
and O
the O
catecholamines O
norepinephrine O
and O
epinephrine O
- O
to O
alter O
the O
production O
of O
IL B
- I
12 I
( O
p70 B
) O
and O
IL B
- I
10 I
induced O
by O
bacterial O
lipopolysaccharide O
( O
LPS O
) O
in O
human O
whole O
blood O
. O

The O
effects O
of O
either O
catecholamine O
on O
IL B
- I
12 I
or O
IL B
- I
10 I
secretion O
were O
blocked O
completely O
by O
propranolol O
, O
a O
beta O
- O
adrenoreceptor O
antagonist O
, O
indicating O
that O
they O
were O
mediated O
by O
the O
beta O
- O
adrenergic O
receptor O
. O

Acylation O
of O
OspA B
and O
the O
synthetic O
peptides O
was O
requisite O
for O
cell O
activation O
. O

Finally O
, O
the O
biological O
relevance O
of O
the O
observation O
that O
T B
. I
pallidum I
lipoproteins I
- O
lipopeptides O
induce O
both O
NF B
- I
kappa I
B I
and O
cytokine B
production O
in O
monocytes O
was O
supported O
by O
the O
ability O
of O
the O
synthetic O
analogs O
to O
promote O
human O
immunodeficiency O
virus O
replication O
in O
chronically O
infected O
U1 O
monocytoid O
cells O
; O
these O
observations O
also O
suggest O
a O
potential O
mechanism O
whereby O
a O
syphilitic O
chancre O
can O
serve O
as O
a O
cofactor O
for O
human O
immunodeficiency O
virus O
transmission O
. O

The O
present O
study O
describes O
the O
cloning O
of O
a O
lymphoid O
- O
restricted O
gene O
, O
LYSP100 B
, O
that O
is O
homologous O
to O
another O
protein O
that O
localizes O
to O
PML O
NBs O
, O
SP100 B
. O

We O
term O
the O
LYSP100 B
structures O
` O
` O
LANDs O
, O
' O
' O
for O
LYSP100 B
- O
associated O
nuclear O
domains O
. O

To O
better O
understand O
the O
contribution O
of O
the O
GR O
N O
- O
terminal O
transactivation O
domain O
in O
mediating O
murine O
thymocyte O
apoptosis O
, O
we O
stably O
transfected O
GR B
, O
GR O
variants O
, O
and O
the O
androgen B
receptor I
( O
AR B
) O
into O
receptor O
- O
negative O
S49 O
murine O
thymoma O
cells O
. O

One O
p21ras B
effector O
pathway O
involves O
the O
MAP B
kinase I
ERK B
- I
2 I
, O
and O
we O
have O
examined O
its O
role O
in O
NFAT B
regulation O
. O

Gel O
mobility O
shift O
and O
immunoprecipitation O
analyses O
revealed O
that O
in O
addition O
to O
activating O
STAT3 B
( O
signal B
transducer I
and I
activator I
of I
transcription I
- I
3 I
) O
and O
STAT5 B
, O
IL B
- I
2 I
induced O
tyrosine O
and O
serine O
phosphorylation O
of O
STAT1 B
alpha I
, O
which O
formed O
IFN O
- O
gamma O
- O
activated O
sequence O
- O
binding O
complexes O
by O
itself O
and O
with O
STAT3 B
. O

Although O
IL B
- I
2 I
and O
IFN B
- I
alpha I
activated O
STAT1 B
alpha I
and O
STAT5 B
, O
IL B
- I
2 I
predominantly O
activated O
STAT5 B
, O
while O
IFN B
- I
alpha I
predominantly O
activated O
STAT1 B
alpha I
. O

STAT1 B
alpha I
activation O
by O
IL B
- I
12 I
correlated O
with O
increased O
phosphorylation O
of O
serine O
, O
but O
not O
tyrosine O
. O

Direct O
evidence O
that O
N O
- O
acetylcysteine O
( O
NAC O
) O
enhances O
the O
immune O
response O
of O
peripheral O
blood O
T O
cells O
at O
the O
level O
of O
NF B
( I
kappa I
) I
B I
is O
presented O
. O

In O
addition O
, O
NAC O
blocks O
the O
suppression O
of O
T O
cell O
mitogenesis O
and O
cytokine B
production O
by O
protease O
inhibitors O
such O
as O
N O
- O
tosylphenylalanine O
chloromethyl O
ketone O
( O
TPCK O
) O
. O

Our O
data O
support O
the O
notion O
that O
NF B
( I
kappa I
) I
B I
and O
I O
( O
kappa O
) O
B O
proteases O
play O
obligate O
roles O
in O
T O
cell O
activation O
and O
mitogenesis O
, O
roles O
that O
are O
enhanced O
significantly O
by O
NAC O
. O

Recently O
it O
has O
become O
clear O
that O
these O
cytokines B
activate O
a O
number O
of O
important O
intracellular B
signaling I
molecules I
, O
including O
the O
Janus B
kinases I
JAK1 B
and O
JAK3 B
and O
members O
of O
the O
transcription O
factor O
family O
of O
signal O
transducers O
and O
activators B
of I
transcription I
( O
STATs B
) O
. O

In O
this O
review O
we O
examine O
the O
structure O
and O
function O
of O
cytokine B
receptors I
and O
the O
signaling O
pathways O
involved O
in O
their O
regulation O
of O
gene O
expression O
. O

Therefore O
, O
we O
analyzed O
the O
expression O
, O
DNA O
binding O
, O
and O
transcriptional O
activity O
of O
the O
endogenous O
RA O
and O
VitD3 O
receptors O
[ O
retinoic B
acid I
receptors I
( O
RARs B
) O
, O
retinoid B
X I
receptors I
( O
RXRs B
) O
, O
and O
VitD3 O
receptor O
( O
VDR B
) O
] O
in O
the O
U O
- O
937 O
cell O
line O
, O
in O
which O
RA O
and O
VitD3 O
induce O
distinct O
monocytic O
differentiation O
pathways O
. O

Also O
, O
VitD3 O
inhibited O
the O
expression O
of O
CD23 B
and O
CD49f O
, O
characteristic O
markers O
of O
retinoid O
- O
induced O
U O
- O
937 O
cell O
differentiation O
. O

Freshly O
isolated O
monocytes O
expressed O
94 B
- I
kD I
STAT5A I
, O
92 O
- O
kD O
STAT5B B
, O
and O
an O
80 O
- O
kD O
STAT5A O
molecule O
. O

STAT5A O
- O
STAT5A O
homodimers O
and O
STAT5A O
- O
STAT5B O
heterodimers O
formed O
in O
response O
to O
GM B
- I
CSF I
. O

Translocation O
( O
3 O
; O
14 O
) O
( O
q27 O
; O
q11 O
) O
: O
a O
new O
variant O
translocation O
in O
a O
patient O
with O
non O
- O
Hodgkin O
' O
s O
lymphoma O
of O
B O
- O
cell O
type O
with O
BCL6 B
rearrangement O
. O

Southern O
blot O
analysis O
showed O
rearrangement O
of O
BCL6 B
, O
JH O
, O
and O
TCR B
beta I
but O
not O
of O
TCR O
delta O
. O

Basal O
total O
white O
blood O
cell O
and O
granulocyte O
counts O
did O
not O
appreciably O
differ O
between O
PML B
/ I
RARalpha I
transgenic O
and O
control O
mice O
. O

As O
expected O
, O
nearly O
all O
control O
mice O
( O
94 O
. O
4 O
% O
) O
survived O
irradiation O
, O
yet O
this O
irradiation O
was O
lethal O
to O
45 O
. O
8 O
% O
of O
PML B
/ I
RARalpha I
transgenic O
mice O
. O

B O
- O
cell O
immortalization O
by O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
is O
dependent O
on O
permanent O
control O
of O
the O
cellular O
processes O
which O
normally O
regulate O
cell O
division O
and O
apoptosis O
, O
functions O
possessed O
by O
p53 B
in O
a O
number O
of O
normal O
cell O
types O
. O

Latent B
membrane I
protein I
1 I
and O
, O
to O
a O
lesser O
extent O
, O
EBV O
nuclear O
antigen O
2 O
mediated O
the O
increase O
in O
p53 B
levels O
via O
activation O
of O
the O
NF B
- I
kappaB I
transcription B
factor I
. O

Tissue O
- O
specific O
expression O
of O
interleukin B
- I
3 I
( O
IL B
- I
3 I
) O
is O
mediated O
via O
cis B
- I
acting I
elements I
located O
within O
315 O
base O
pairs O
of O
the O
transcription O
start O
. O

In O
the O
current O
studies O
, O
IL B
- I
2 I
production O
by O
T O
cells O
from O
elderly O
( O
mean O
78 O
years O
) O
and O
young O
( O
mean O
37 O
years O
) O
humans O
was O
measured O
in O
cultures O
stimulated O
with O
PHA B
, O
PHA B
plus O
PMA O
, O
crosslinked O
anti O
- O
CD3 O
mAB O
OKT3 O
plus O
PMA O
, O
or O
PMA O
plus O
ionomycin O
. O

By O
contrast O
, O
T O
cells O
from O
elderly O
subjects O
with O
normal O
levels O
of O
IL B
- I
2 I
production O
exhibited O
normal O
activation O
of O
AP B
- I
1 I
and O
NF B
- I
AT I
. O

IL B
- I
13 I
caused O
rapid O
phosphorylation O
of O
the O
three O
out O
of O
four O
members O
of O
the O
known O
Janus O
family O
of O
kinases O
( O
JAKs B
) O
. O

IL B
- I
4 I
also O
stimulated O
all O
three O
kinases B
and O
substrates O
, O
but O
unlike O
in O
immune O
cells O
, O
IL B
- I
4 I
did O
not O
involve O
JAK3 B
activation O
for O
its O
signaling O
in O
colon O
cancer O
cell O
lines O
. O

Furthermore O
, O
JAK2 B
associated O
with O
the O
IL B
- I
4R I
p140 I
before O
and O
after O
stimulation O
with O
IL B
- I
13 I
. O

Differential O
regulation O
of O
IL B
- I
6 I
gene I
transcription O
and O
expression O
by O
IL B
- I
4 I
and O
IL B
- I
10 I
in O
human O
monocytic O
cell O
lines O
. O

To O
investigate O
the O
molecular O
mechanism O
of O
the O
inhibitory O
effect O
on O
transcriptional O
or O
post O
- O
transcriptional O
regulation O
of O
IL B
- I
6 I
gene I
expression O
by O
IL B
- I
4 I
and O
IL B
- I
10 I
, O
we O
studied O
IL B
- I
6 I
production O
, O
expression O
level O
of O
IL B
- I
6 I
mRNA I
, O
IL B
- I
6 I
promoter O
activity O
, O
transcriptional O
activity O
of O
NF B
- I
kappaB I
and O
NF B
- I
IL I
- I
6 I
, O
and O
IL B
- I
6 I
mRNA I
stability O
in O
human O
monocytic O
cell O
lines O
, O
THP O
- O
1 O
and O
U937 O
, O
stimulated O
by O
PMA O
and O
LPS O
in O
the O
absence O
or O
the O
presence O
of O
IL B
- I
4 I
or O
IL B
- I
10 I
. O

In O
chloramphenicol B
acetyltransferase I
assays O
, O
utilizing O
the O
transient O
transfection O
of O
a O
chloramphenicol O
acetyltransferase O
reporter O
plasmid O
containing O
the O
IL O
- O
6 O
gene O
promoter O
, O
IL B
- I
4 I
, O
but O
not O
IL B
- I
10 I
, O
suppressed O
the O
transcriptional O
activity O
of O
the O
IL O
- O
6 O
gene O
promoter O
stimulated O
by O
PMA O
and O
LPS O
. O

On O
the O
other O
hand O
, O
IL B
- I
10 I
enhanced O
the O
degradation O
of O
IL B
- I
6 I
mRNA I
in O
a O
mRNA O
stability O
assay O
. O

These O
results O
suggest O
that O
IL B
- I
4 I
may O
inhibit O
the O
transcription O
of O
the O
IL B
- I
6 I
gene I
by O
affecting O
NF B
- I
kappaB I
binding O
activity O
, O
while O
IL B
- I
10 I
may O
inhibit O
the O
IL B
- I
6 I
mRNA I
levels O
post O
- O
transcriptionally O
, O
without O
suppressing O
promoter O
activity O
. O

IL B
- I
2 I
production O
by O
CsA O
- O
treated O
cells O
is O
therefore O
dramatically O
reduced O
. O

Electrophoretic O
mobility O
shift O
assay O
showed O
the O
induction O
of O
a O
CsA O
- O
resistant O
NFAT O
complex O
in O
the O
nuclear O
extracts O
of O
peripheral O
blood O
T O
cells O
stimulated O
with O
PMA O
plus O
alphaCD28 B
. O

We O
compared O
the O
effects O
of O
the O
deactivating O
cytokine O
interleukin B
10 I
( O
IL B
- I
10 I
) O
on O
human O
peripheral O
blood O
mononuclear O
cell O
( O
PBMC O
) O
responses O
to O
lipopolysaccharide O
( O
LPS O
) O
, O
Cryptococcus O
neoformans O
, O
and O
Candida O
albicans O
. O

Characterization O
and O
purification O
of O
a O
protein B
kinase I
C I
substrate I
in O
human O
B O
cells O
. O

To O
determine O
whether O
the O
IL B
- I
10R I
has O
signaling O
functions O
similar O
to O
IL B
- I
6R I
in O
cells O
normally O
expressing O
these O
receptors O
, O
leukocytes O
of O
the O
B O
- O
, O
T O
- O
, O
and O
NK O
- O
cell O
lineages O
were O
treated O
with O
either O
cytokine O
. O

The O
IL B
- I
10R I
, O
together O
with O
reporter O
gene O
constructs O
containing O
different O
IL O
- O
6 O
- O
responsive O
gene O
elements O
, O
reconstituted O
in O
hepatoma O
cells O
an O
induction O
of O
transcription O
by O
IL B
- I
10 I
that O
was O
comparable O
to O
that O
by O
IL B
- I
6 I
. O

These O
receptor O
functions O
required O
the O
presence O
of O
the O
box O
3 O
motifs O
, O
as O
shown O
by O
the O
analysis O
of O
the O
mouse O
IL B
- I
10R I
constructs O
containing O
progressively O
truncated O
cytoplasmic O
domains O
. O

These O
results O
suggest O
that O
both O
common O
mechanisms O
, O
such O
as O
the O
one O
mediated O
by O
the O
CIITA B
trans I
- I
activator I
, O
and O
distinct O
tissue O
- O
specific O
constraints O
contribute O
to O
the O
transcriptional O
control O
of O
constitutive O
and O
IFN B
- I
gamma I
- O
induced O
MHC B
class I
II I
gene I
expression O
. O

There O
are O
four O
putative O
NF B
- I
kappa I
B I
binding I
sites I
( O
kappa O
B O
- O
1 O
, O
kappa O
B O
- O
2 O
, O
kappa O
B O
- O
3 O
, O
kappa O
B O
- O
4 O
) O
in O
human B
TNF I
- I
alpha I
promoter I
. O

In O
this O
study O
we O
have O
analysed O
the O
structural O
requirements O
for O
transcriptional O
activation O
by O
BSAP B
. O

We O
have O
demonstrated O
that O
the O
level O
of O
CRE O
binding O
protein O
( O
CREB B
) O
was O
the O
same O
in O
all O
cell O
lines O
and O
that O
the O
putative O
AR O
- O
CRE O
forms O
specific O
and O
compatible O
protein O
interactions O
with O
CREB B
. O

In O
these O
cells O
, O
CD36 B
is O
involved O
in O
phagocytosis O
of O
apoptotic O
cells O
, O
and O
foam O
cell O
formation O
by O
uptake O
of O
oxidized O
low O
density O
lipoprotein O
. O

Biochemical O
analysis O
of O
the O
region O
- O
158 O
/ O
- O
90 O
revealed O
a O
binding O
site O
for O
transcription B
factors I
of O
the O
polyomavirus B
enhancer I
- I
binding I
protein I
2 I
/ I
core I
- I
binding I
factor I
( I
PEBP2 I
/ I
CBF I
) I
family I
at O
position O
- O
103 O
. O

Appearance O
of O
the O
STAT1 B
factor O
is O
significantly O
reduced O
in O
the O
presence O
of O
cyclosporin O
A O
, O
and O
blocked O
by O
cycloheximide O
, O
indicating O
that O
its O
activation O
is O
dependent O
upon O
a O
protein O
( O
s O
) O
synthesized O
in O
response O
to O
initial O
signaling O
events O
. O

Neutralizing O
antiserum O
against O
IFN B
- I
gamma I
, O
but O
not O
other O
cytokines B
tested O
, O
blocked O
activation O
of O
the O
factor O
almost O
completely O
, O
and O
IFN B
- I
gamma I
was O
found O
in O
the O
culture O
supernatants O
of O
stimulated O
cells O
at O
levels O
at O
which O
recombinant O
IFN B
- I
gamma I
could O
activate O
the O
factor O
in O
naive O
cells O
. O

Therefore O
, O
a O
STAT1 B
transcription B
factor I
is O
activated O
by O
IFN B
- I
gamma I
synthesized O
and O
released O
upon O
stimulation O
of O
T O
lymphocyte O
populations O
. O

While O
Jurkat O
cells O
both O
secrete O
and O
respond O
to O
IFN B
- I
gamma I
in O
an O
autocrine O
loop O
, O
it O
seems O
likely O
that O
the O
responding O
cells O
may O
differ O
from O
those O
synthesizing O
this O
cytokine B
in O
the O
mononuclear O
cell O
cultures O
in O
the O
light O
of O
the O
recent O
report O
that O
Th1 O
cells O
lack O
the O
IFN B
- I
gamma I
receptor O
chain O
necessary O
for O
activation O
of O
STAT1 B
( O
Pernis O
, O
A O
. O
, O
Gupta O
, O
S O
. O
, O
Gollob O
, O
K O
. O
J O
. O
, O
Garfein O
, O
E O
. O
, O
Coffman O
, O
R O
. O
L O
. O
, O
Schindler O
, O
C O
. O
, O
and O
Rothman O

Based O
on O
the O
presence O
of O
T O
cell O
receptor O
- O
beta O
( O
TcR O
- O
beta O
) O
gene O
rearrangements O
in O
L428 O
and O
HDLM O
- O
1 O
cells O
, O
the O
expression O
of O
CD2 B
in O
HDLM O
- O
1 O
cells O
, O
and O
the O
presence O
of O
immunoglobulin O
heavy O
- O
chain O
( O
IgH O
) O
gene O
rearrangement O
in O
KM O
- O
H2 O
cells O
, O
some O
researchers O
have O
concluded O
that O
these O
long O
- O
term O
cell O
lines O
derived O
from O
patients O
with O
Hodgkin O
' O
s O
disease O
are O
lymphoid O
in O
nature O
. O

Expression O
of O
the O
MAP O
kinase O
- O
specific O
phosphatase O
, O
MKP B
- I
1 I
, O
which O
blocks O
ERK B
activation O
, O
inhibited O
IL B
- I
2 I
promoter I
and O
NF B
- I
AT I
- O
driven O
transcription O
stimulated O
by O
a O
calcium O
ionophore O
and O
PMA O
, O
and O
in O
addition O
, O
MKP B
- I
1 I
neutralized O
the O
transcriptional O
enhancement O
caused O
by O
active O
Raf O
- O
1 O
and O
MEK1 O
expression O
. O

Although O
GM B
- I
CSF I
does O
not O
appear O
to O
be O
essential O
for O
normal O
hemopoiesis O
, O
overexpression O
of O
GM O
- O
CSF O
has O
been O
implicated O
in O
the O
pathogenesis O
of O
some O
diseases O
such O
as O
myeloid O
leukemia O
and O
chronic O
inflammation O
. O

We O
investigated O
oligonucleotide O
- O
directed O
triple O
helix O
formation O
across O
this O
regulatory O
sequence O
as O
a O
potential O
tool O
to O
inhibit O
GM B
- I
CSF I
gene O
transcription O
. O

Finally O
, O
GM3 O
greatly O
reduced O
the O
concentration O
of O
endogenous O
GM B
- I
CSF I
mRNA I
induced O
by O
different O
stimuli O
in O
Jurkat O
T O
cells O
but O
did O
not O
affect O
interleukin O
3 O
mRNA O
levels O
in O
the O
same O
cells O
. O

We O
conclude O
that O
the O
kappaB B
element I
in O
the O
GM B
- I
CSF I
promoter I
plays O
a O
central O
role O
in O
the O
transcriptional O
activation O
of O
the O
endogenous O
GM B
- I
CSF I
gene I
. O

Colinear O
triplex O
formation O
acts O
as O
a O
selective O
transcriptional O
repressor O
of O
the O
GM B
- I
CSF I
gene I
and O
may O
have O
potential O
therapeutic O
application O
in O
cases O
of O
undesirable O
overexpression O
of O
this O
protein O
. O

Modulation O
of O
endogenous O
IL B
- I
1 I
beta I
and O
IL B
- I
1 I
receptor I
antagonist O
results O
in O
opposing O
effects O
on O
HIV O
expression O
in O
chronically O
infected O
monocytic O
cells O
. O

Costimulation O
of O
U1 O
cells O
with O
LPS O
plus O
GM B
- I
CSF I
resulted O
in O
the O
accumulation O
of O
steady O
- O
state O
levels O
of O
HIV B
RNA I
; O
however O
, O
only O
a O
weak O
induction O
of O
HIV B
long I
terminal I
repeat I
- O
driven O
transcription O
, O
which O
was O
not O
associated O
with O
the O
activation O
of O
the O
cellular B
transcription I
factor I
nuclear B
factor I
- I
kappa I
B I
, O
was O
noted O
. O

IL B
- I
12 I
is O
a O
novel O
heterodimeric B
cytokine I
important O
for O
the O
regulation O
and O
differentiation O
of O
lymphocytes O
and O
NK O
cells O
. O

Using O
these O
T O
cells O
as O
a O
model O
of O
IL B
- I
12 I
signal O
transduction O
, O
we O
confirmed O
that O
these O
events O
involve O
members O
of O
the O
Janus O
kinase O
family O
of O
nonreceptor O
tyrosine O
kinases O
JAK2 B
, O
TYK2 B
, O
and O
signal B
transducer I
and I
activator I
of I
transcription I
4 I
. O

These O
mechanisms O
include O
the O
assembly O
of O
higher O
order O
nucleoprotein O
complexes O
and O
other O
protein O
- O
protein O
interactions O
that O
enhance O
the O
functional O
specificity O
of O
transcriptional B
regulators I
in O
lymphocytes O
. O

Thus O
it O
appears O
that O
there O
may O
often O
be O
malfunction O
of O
the O
normal O
glucocorticoid O
response O
in O
HIV O
- O
infected O
cells O
probably O
due O
to O
altered O
interactions O
between O
the O
glucocorticoid B
receptor I
and O
its O
hormone O
. O

Nuclei O
of O
unstimulated O
PBL O
from O
different O
donors O
expressed O
p62c B
- I
fos I
and O
p39c B
- I
jun I
, O
but O
AP B
- I
1 I
was O
not O
detected O
in O
the O
majority O
of O
samples O
. O

Following O
PHA B
stimulation O
of O
PBL O
, O
the O
increase O
in O
AP B
- I
1 I
activity O
was O
delayed O
with O
respect O
to O
the O
augmentation O
of O
p39c B
- I
jun I
expression O
. O

However O
, O
no O
cytoplasmic O
p62c O
- O
fos O
was O
detected O
in O
unstimulated O
PBL O
, O
although O
in O
some O
cases O
cytoplasmic O
p39c O
- O
jun O
was O
detected O
, O
suggesting O
that O
subcellular O
compartmentalization O
of O
these O
proteins B
may O
occur O
under O
certain O
circumstances O
. O

However O
, O
the O
inducible O
degradation O
of O
p105 B
is O
not O
coupled O
with O
the O
generation O
of O
p50 B
. O

Together O
, O
these O
studies O
demonstrate O
that O
the O
processing O
and O
inducible O
degradation O
of O
p105 B
are O
differentially O
regulated O
. O

However O
, O
synthesis O
of O
the O
26 O
- O
kDa O
membrane O
form O
of O
TNF B
was O
effectively O
blocked O
by O
CNI O
- O
1493 O
. O

r B
- I
hTBP I
- I
1 I
and O
rhu B
TNFR I
: I
Fc I
also O
decreased O
p24 B
antigen I
synthesized O
by O
U1 O
cells O
in O
response O
to O
other O
stimuli O
, O
including O
phytohemagglutinin O
( O
PHA O
) O
- O
induced O
supernatant O
, O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
, O
interleukin B
- I
6 I
, O
and O
TNF B
. O

Addition O
of O
r B
- I
hTBP I
- I
1 I
to O
U1 O
cells O
during O
the O
last O
4 O
h O
of O
a O
24 O
h O
incubation O
with O
PMA O
still O
inhibited O
p24 B
antigen I
production O
by O
15 O
% O
. O

r B
- I
hTBP I
- I
1 I
also O
partially O
reversed O
inhibition O
of O
U1 O
cellular O
proliferation O
caused O
by O
PMA O
. O

Transcriptional O
activation O
of O
RNA O
polymerase O
III O
- O
dependent O
genes O
by O
the O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
tax I
protein I
. O

The O
viral O
protein O
Tax O
was O
likely O
responsible O
for O
this O
higher O
level O
of O
class B
II I
gene I
transcription O
, O
as O
purified O
Tax O
was O
found O
to O
stimulate O
both O
genes O
when O
added O
to O
the O
uninfected O
cell O
extract O
or O
in O
reconstituted O
systems O
. O

Efficient O
gene O
activation O
requires O
the O
heterodimerization O
of O
VDR B
with O
Retinoid B
X I
Receptors I
( O
RXR B
) O
. O

We O
have O
generated O
rabbit O
antisera O
against O
this O
putative O
p13MTCP1 O
protein O
and O
screened O
for O
expression O
of O
p13MTCP1 B
normal O
lymphoid O
tissues O
and O
33 O
cases O
of O
immature O
and O
mature O
lymphoid O
T O
- O
cell O
proliferations O
using O
a O
sensitive O
Western O
blot O
assay O
. O

A O
variety O
of O
cytokines B
and O
growth B
factors I
act O
through O
an O
induction O
of O
gene O
expression O
mediated O
by O
a O
family O
of O
latent O
transcription O
factors O
called O
STAT O
( O
signal O
transducers O
and O
activators O
of O
transcription O
) O
proteins O
. O

Electrophoretic O
mobility O
shift O
assays O
( O
EMSAs O
) O
demonstrated O
that O
unstimulated O
monocytes O
predominantly O
expressed O
p50 B
NF B
- I
kappa I
B I
. O

However O
, O
the O
combined O
stimulation O
did O
not O
result O
in O
enhanced O
p50 B
and O
p65 B
protein I
expression O
. O

The O
effects O
of O
IFN B
- I
gamma I
on O
the O
transcription B
factors I
were O
specific O
, O
since O
no O
change O
was O
observed O
in O
the O
expression O
of O
NF B
- I
IL I
- I
6 I
or O
I B
kappa I
B I
alpha I
, O
the O
inhibitor O
of O
NF B
- I
kappa I
B I
. O

We O
conclude O
that O
the O
effects O
of O
IFN B
- I
gamma I
on O
the O
expression O
of O
the O
transcription B
factors I
AP B
- I
1 I
and O
NF B
- I
kappa I
B I
may O
be O
important O
for O
the O
modulatory O
effects O
of O
IFN B
- I
gamma I
on O
the O
cytokine B
expression O
in O
activated O
human O
monocytes O
. O

The O
expression O
of O
MIP B
- I
1 I
alpha I
is O
induced O
during O
cellular O
activation O
of O
CD4 O
+ O
T O
- O
cells O
and O
monocytes O
. O

We O
have O
previously O
identified O
a O
new O
transcription O
factor O
family O
( O
the O
MNP O
family O
) O
whose O
expression O
is O
crucial O
for O
the O
induction O
of O
MIP B
- I
1 I
alpha I
transcription O
during O
cellular O
activation O
and O
in O
transformed O
B O
cells O
. O

In O
this O
report O
we O
show O
induction O
of O
MNP B
- I
1 I
in O
Jurkat O
T O
- O
cells O
expressing O
HIV B
- I
1 I
tat I
. O

Differentiation O
of O
T O
- O
helper O
lymphocytes O
: O
selective O
regulation O
by O
members O
of O
the O
STAT B
family I
of O
transcription B
factors I
. O

Specific O
docking B
sites I
within O
individual O
cytokine B
receptors I
have O
been O
identified O
for O
almost O
all O
Stat B
proteins I
. O

The O
direct O
coupling O
between O
cytokine B
receptor I
and O
transcription B
factor I
helps O
to O
explain O
how O
different O
cytokines B
elicit O
distinct O
patterns O
of O
gene O
expression O
. O

Here O
we O
identify O
the O
gene O
encoding O
the O
lymphocyte O
homing O
and O
migration O
protein O
CD44 B
as O
a O
target O
of O
EGR1 B
regulation O
in O
B O
cells O
. O

The O
EGR1 O
binding O
motif O
was O
shown O
to O
be O
necessary O
for O
stimulus O
- O
induced O
expression O
of O
a O
CD44 B
promoter O
- O
chloramphenicol O
acetyltransferase O
reporter O
construct O
in O
nontransformed O
B O
lymphocytes O
and O
was O
required O
for O
transactivation O
by O
an O
EGR1 O
expression O
vector O
in O
a O
B O
- O
cell O
line O
. O

These O
studies O
identify O
EGR1 B
as O
an O
intermediary O
linking O
BCR B
- O
derived O
signals O
to O
the O
induction O
of O
CD44 B
. O

In O
Jurkat O
cells O
that O
are O
not O
sensitive O
to O
H2O2 O
- O
induced O
NF B
- I
kappaB I
activation O
, O
H2O2 O
potentiated O
NF B
- I
kappaB I
activation O
in O
the O
presence O
of O
sustained O
high O
[ O
Ca2 O
+ O
] O
i O
following O
thapsigargin O
treatment O
. O

A O
mutant O
Tax B
protein I
deficient O
in O
transactivation O
of O
genes O
by O
the O
nuclear B
factor I
( I
NF I
) I
- I
kappaB I
pathway O
was O
unable O
to O
induce O
transcriptional O
activity O
of O
IL O
- O
1alpha O
promoter O
- O
CAT O
constructs O
, O
but O
was O
rescued O
by O
exogenous O
provision O
of O
p65 O
/ O
p50 O
NF B
- I
kappaB I
. O

Although O
a O
13 O
- O
kilobase O
- O
pair O
( O
kb O
) O
human O
c O
- O
fes O
transgene O
exhibits O
high O
levels O
of O
expression O
in O
mice O
, O
the O
sequences O
that O
confer O
myeloid O
- O
cell O
- O
specific O
expression O
of O
the O
human B
c I
- I
fes I
gene I
have O
not O
been O
defined O
. O

Electrophoretic O
mobility O
shift O
analyses O
demonstrated O
that O
the O
151 O
- O
bp O
region O
contains O
nuclear B
protein I
binding I
sites I
for O
Sp1 B
, O
PU B
. I
1 I
, O
and O
/ O
or O
Elf B
- I
1 I
, O
and O
a O
novel B
factor I
. O

IL B
- I
10 I
markedly O
reduces O
nuclear O
factor O
( B
NF I
) I
- I
kappa I
B I
/ I
Rel I
nuclear O
activity O
induced O
in O
PBMC O
by O
stimulation O
with O
the O
anti B
- I
CD3 I
mAb I
OKT3 B
. O

As O
judged O
by O
supershifting O
the O
DNA B
- I
protein I
complexes I
with O
Abs B
recognizing O
specific O
components O
of O
the O
NF O
- O
kappa O
B O
/ O
Rel O
protein O
family O
, O
the O
p50 B
/ I
p65 I
( O
Rel B
A I
) O
heterodimeric O
form O
of O
NF B
- I
kappa I
B I
is O
primarily O
affected O
. O

The O
maximal O
effect O
is O
observed O
at O
the O
IL B
- I
10 I
concentration O
of O
20 O
U O
/ O
ml O
. O

Our O
results O
demonstrate O
that O
IL B
- I
10 I
can O
inhibit O
the O
induction O
of O
NF B
- I
kappa I
B I
/ I
Rel I
nuclear O
activity O
in O
CD3 O
- O
stimulated O
T O
lymphocytes O
. O

In O
a O
panel O
of O
32 O
B O
- O
cell O
lines O
, O
A B
- I
myb I
was O
very O
strongly O
expressed O
in O
most O
Burkitt O
' O
s O
lymphoma O
( O
BL O
) O
cell O
lines O
, O
but O
weak O
or O
negative O
in O
2 O
pre O
- O
B O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
, O
4 O
non O
- O
Hodgkin O
' O
s O
lymphoma O
( O
NHL O
) O
, O
6 O
Epstein O
- O
Barr O
virus O
- O
immortalized O
lymphoblastoid O
cell O
lines O
, O
and O
6 O
myeloma O
lines O
. O

C O
- O
myb O
and O
B B
- I
myb I
were O
expressed O
in O
all O
neoplastic O
groups O
, O
except O
in O
CLL O
cells O
. O

Thus O
, O
A B
- I
myb I
expression O
, O
unlike O
that O
of O
c B
- I
myb I
and O
B B
- I
myb I
, O
is O
restricted O
to O
a O
subset O
of O
B O
- O
cell O
neoplasias O
( O
in O
particular O
BL O
and O
slg O
+ O
B O
- O
ALL O
) O
representative O
of O
a O
specific O
stage O
of O
B O
- O
cell O
differentiation O
. O

It O
remains O
open O
whether O
the O
growth O
retarding O
property O
of O
the O
EBNA2 O
- O
oestrogen O
receptor O
fusion O
protein O
in O
B O
cell O
lymphoma O
lines O
is O
due O
to O
unphysiologically O
high O
expression O
of O
the O
chimeric B
protein I
or O
to O
interference O
with O
a O
cellular O
programme O
driving O
proliferation O
in O
these O
cell O
lines O
. O

These O
results O
indicate O
that O
, O
as O
already O
reported O
for O
the O
IL2Rbeta O
promoter O
, O
GA B
- I
binding I
protein I
is O
an O
essential O
component O
of O
gammac O
basal O
promoter O
activity O
. O

Expression O
of O
ATF B
- I
2 I
in O
S O
. O
cerevisiae O
did O
not O
activate O
TRE B
- I
1 I
in O
the O
presence O
of O
Tax B
. O

This O
shows O
that O
in O
a O
eukaryotic O
nucleus O
, O
Tax B
specifically O
interacts O
with O
the O
basic O
domain O
- O
leucine O
zipper O
region O
of O
ATF B
- I
1 I
, O
CREB B
, O
and O
CREM B
. O

Trapoxin O
is O
a O
microbially O
derived O
cyclotetrapeptide O
that O
inhibits O
histone B
deacetylation O
in O
vivo O
and O
causes O
mammalian O
cells O
to O
arrest O
in O
the O
cell O
cycle O
. O

Phorbol O
ester O
treatment O
of O
monocytes O
inhibited O
IFN O
alpha O
- O
stimulated O
tyrosine O
phosphorylation O
of O
the O
transcription B
factors I
Stat1alpha B
, O
Stat2 B
, O
and O
Stat3 B
and O
of O
the O
tyrosine B
kinase I
Tyk2 B
but O
had O
no O
effect O
on O
IFN B
- I
gamma I
activation O
of O
Stat1alpha B
. O

Pretreatment O
of O
cells O
with O
vanadate O
prevented O
the O
effects O
of O
PMA O
with O
regard O
to O
PMA O
- O
induced O
Tyk2 B
dephosphorylation O
. O

Interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
promoter I
- B
reporter I
gene I
behavior O
closely O
parallels O
the O
endogenous B
gene I
in O
response O
to O
T B
cell I
receptor I
and O
costimulatory O
signals O
. O

The O
RAR B
- I
RXR I
as O
well O
as O
the O
RXR B
- I
RXR I
pathway O
is O
involved O
in O
signaling O
growth O
inhibition O
of O
human O
CD34 O
+ O
erythroid O
progenitor O
cells O
. O

Previous O
studies O
have O
shown O
that O
retinoic O
acid O
( O
RA O
) O
, O
similar O
to O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
, O
can O
act O
as O
a O
bifunctional O
regulator O
of O
the O
growth O
of O
bone O
marrow O
progenitors O
, O
in O
that O
it O
can O
stimulate O
granulocyte O
- O
macrophage O
colony O
- O
stimulating O
factor O
( O
GM O
- O
CSF O
) O
- O
or O
interleukin O
- O
3 O
( O
IL O
- O
3 O
) O
- O
induced O
GM O
colony O
formation O
, O
but O
potently O
inhibit O
G B
- I
CSF I
- O
induced O
growth O
. O

At O
this O
concentration O
, O
Ro O
13 O
- O
7410 O
potently O
inhibited O
G B
- I
CSF I
- O
stimulated O
myeloid O
as O
well O
as O
SCF B
+ O
Epo B
- O
induced O
erythroid O
colony O
growth O
. O

At O
the O
same O
concentration O
, O
Ro O
25 O
- O
6603 O
and O
Ro O
25 O
- O
7386 O
had O
little O
or O
no O
effect O
on O
G B
- I
CSF I
- O
induced O
colony O
formation O
, O
whereas O
they O
inhibited O
75 O
% O
and O
53 O
% O
, O
respectively O
, O
of O
SCF B
+ O
Epo B
- O
stimulated O
BFU O
- O
E O
colony O
growth O
. O

Thus O
, O
the O
RAR B
- I
RXR I
response O
pathway O
can O
signal O
growth O
inhibition O
of O
normal O
bone O
marrow O
myeloid O
and O
erythroid O
progenitor O
cells O
. O

After O
treatment O
of O
APL O
cells O
with O
AM580 O
either O
alone O
or O
in O
combination O
with O
granulocyte B
colony I
- I
stimulating I
factor I
( O
G B
- I
CSF I
) O
, O
the O
compound O
induces O
granulocytic O
maturation O
, O
as O
assessed O
by O
determination O
of O
the O
levels O
of O
leukocyte O
alkaline O
phosphatase O
, O
CD11b O
, O
CD33 O
, O
and O
G O
- O
CSF O
receptor O
mRNA O
, O
at O
concentrations O
that O
are O
10 O
- O
to O
100 O
- O
fold O
lower O
than O
those O
of O
ATRA O
necessary O
to O
produce O
similar O
effects O
. O

By O
contrast O
, O
AM580 O
is O
not O
effective O
as O
ATRA O
in O
modulating O
the O
expression O
of O
these O
differentiation B
markers I
in O
the O
HL O
- O
60 O
cell O
line O
and O
in O
freshly O
isolated O
granulocytes O
obtained O
from O
the O
peripheral O
blood O
of O
chronic O
myelogenous O
leukemia O
patients O
during O
the O
stable O
phase O
of O
the O
disease O
. O

These O
results O
show O
that O
AM580 O
is O
more O
powerful O
than O
ATRA O
in O
modulating O
the O
expression O
of O
differentiation O
antigens O
only O
in O
cells O
in O
which O
PML B
- I
RAR I
is O
present O
. O

Binding O
experiments O
, O
using O
COS O
- O
7 O
cells O
transiently O
transfected O
with O
PML B
- I
RAR I
and O
the O
normal O
RAR B
alpha I
, O
show O
that O
AM580 O
has O
a O
lower O
affinity O
than O
ATRA O
for O
both O
receptors O
. O

In O
addition O
, O
vitamin O
D O
- O
resistant O
cell O
nuclear O
extract O
contained O
a O
protein O
( O
s O
) O
which O
was O
bound O
specifically O
to O
the O
VDRE B
and O
was O
capable O
of O
completely O
inhibiting O
VDR O
- O
RXR O
- O
VDRE O
complex O
formation O
; O
these O
effects O
were O
not O
demonstrated O
with O
nuclear O
extract O
from O
the O
wild O
type O
cell O
line O
or O
with O
the O
post O
- O
nuclear O
extract O
of O
the O
vitamin O
D O
- O
resistant O
cell O
line O
. O

We O
conclude O
that O
a O
VDRE O
- O
binding O
protein O
( O
s O
) O
, O
distinct O
from O
IDBP B
and O
present O
in O
nuclear O
extract O
of O
cells O
from O
a O
prototypical O
vitamin O
D O
- O
resistant O
NWP O
, O
is O
capable O
of O
inhibiting O
normal O
VDR B
- I
RXR I
heterodimer O
binding O
to O
the O
VDRE B
. O

Finally O
, O
the O
activation O
- O
induced O
changes O
in O
one O
set O
of O
phosphoproteins B
were O
dramatically O
inhibited O
by O
cyclosporin O
A O
. O

Like O
IkappaBalpha B
, O
Tax B
- O
mediated O
breakdown O
of O
IkappaBbeta B
in O
transfected O
T O
lymphocytes O
is O
blocked O
either O
by O
cell O
- O
permeable O
proteasome O
inhibitors O
or O
by O
mutation O
Of O
IkappaBbeta B
at O
two O
serine O
residues O
present O
within O
its O
N B
- I
terminal I
region I
. O

Although O
a O
role O
of O
p16 B
in O
this O
regulation O
has O
been O
presumed O
, O
there O
is O
no O
proof O
so O
far O
that O
loss O
of O
this O
tumor B
suppressor I
gene I
really O
affects O
E2F B
- O
mediated O
regulations O
. O

Nuclear B
factors I
from O
unstimulated O
, O
but O
not O
from O
activated O
cells O
, O
bound O
a O
site O
, O
META B
( I
D I
- I
) I
, O
adjacent O
to O
META B
( I
D I
+ I
) I
. O

We O
have O
isolated O
a O
novel O
cDNA O
clone O
encoding O
interferon O
( O
IFN O
) O
consensus O
sequence O
- O
binding O
protein O
in O
adult O
T O
- O
cell O
leukemia O
cell O
line O
or O
activated O
T O
cells O
( O
ICSAT B
) O
; O
this O
protein O
is O
the O
human O
homolog O
of O
the O
recently O
cloned O
Pip O
/ O
LSIRF O
. O

Here O
, O
we O
describe O
the O
effect O
of O
383 O
- O
bp O
( O
delta383 O
) O
and O
99 O
- O
bp O
( O
delta99 O
) O
sequences O
containing O
the O
PYBF O
- O
binding O
site O
on O
transcription O
from O
various O
globin O
and O
non O
- O
globin O
promoters O
, O
using O
a O
transient O
assay O
with O
the O
cat B
reporter I
gene I
in O
murine O
erythroleukemia O
( O
MEL O
) O
cells O
, O
a O
cell O
line O
with O
abundant O
PYBF B
activity O
. O

Translocation O
breakpoints O
in O
three O
patients O
with O
campomelic O
dysplasia O
and O
autosomal O
sex O
reversal O
map O
more O
than O
130 O
kb O
from O
SOX9 B
. O

Campomelic O
dysplasia O
( O
CMPD1 O
) O
and O
autosomal O
XY O
sex O
reversal O
( O
SRA1 O
) O
are O
caused O
by O
mutations O
in O
the O
SRY O
- O
related O
gene O
SOX9 B
on O
17q O
. O

Unexpectedly O
, O
the O
17q O
breakpoints O
in O
four O
CMPD1 O
translocation O
cases O
previously O
analyzed O
by O
us O
and O
others O
map O
50 O
kb O
or O
more O
from O
SOX9 B
. O

DeltaSpi B
- I
B I
product O
was O
not O
able O
to O
bind O
DNA O
and O
was O
recovered O
in O
cytoplasmic O
cellular O
extracts O
. O

Both O
CIITA B
and O
Bob1 B
increase O
the O
expression O
from O
the O
DRA B
promoter I
, O
which O
is O
a O
prototypic O
class O
II O
promoter O
. O

However O
, O
the O
growth O
of O
most O
mutated O
viruses O
was O
suppressed O
in O
primary O
rhesus O
monkey O
alveolar O
macrophages O
( O
SIVmacMER O
approximately O
2xNFkappaB O
approximately O
substNFkappaB B
> O
deltaNFkappaB B
> O
deltaNFkappaB B
deltaSpl234 B
approximately O
deltaNFkappaBdeltaSp B
> O
deltaSpl234 B
approximately O
substSpl2 B
> O
substSp23 B
approximately O
substSp34 B
approximately O
substSpl234 B
> O
or O
= O
SIVmac239 O
) O
. O

Ca2 O
+ O
- O
modulating O
cyclophilin O
ligand O
( O
CAML B
) O
was O
originally O
described O
as O
a O
cyclophilin B
B I
- I
binding I
protein I
whose O
overexpression O
in O
T O
cells O
causes O
a O
rise O
in O
intracellular O
calcium O
, O
thus O
activating O
transcription B
factors I
responsible O
for O
the O
early O
immune O
response O
. O

The O
chromosome O
17 O
breakpoint O
was O
localized O
to O
intron O
2 O
of O
RARA B
by O
Southern O
blotting O
, O
and O
there O
was O
no O
evidence O
at O
the O
molecular O
level O
for O
rearrangement O
at O
PML O
locus O
. O

In O
these O
same O
animals O
, O
E1A B
protein I
was O
detected O
20 O
days O
after O
infection O
in O
two O
and O
47 O
days O
after O
infection O
in O
one O
while O
persistent O
bronchiolitis O
was O
observed O
in O
four O
and O
three O
animals O
20 O
and O
47 O
days O
after O
infection O
, O
respectively O
. O

Cyclic O
AMP O
- B
responsive I
element I
- O
dependent O
activation O
of O
Epstein O
- O
Barr O
virus O
zebra B
promoter I
by O
human O
herpesvirus O
6 O
. O

Mutation O
of O
the O
consensus O
AP O
- O
1 O
/ O
CRE O
site O
within O
ZII B
abolished O
the O
inducibility O
of O
Zp B
by O
HHV O
- O
6 O
, O
whereas O
positioning O
of O
the O
ZII B
domain I
upstream O
of O
the O
beta O
- O
globin O
minimal O
promoter O
conferred O
responsiveness O
following O
HHV O
- O
6 O
infection O
. O

Antibodies O
against O
CRE O
- O
binding O
( O
CREB O
) O
protein O
but O
not O
against O
c B
- I
Fos I
or O
c B
- I
Jun I
were O
able O
to O
supershift O
the O
DNA B
- I
protein I
complex I
, O
identifying O
the O
nature O
of O
the O
transcription B
factor I
which O
binds O
to O
ZII B
as O
a O
member O
of O
the O
CREB O
family O
of O
proteins O
. O

Regulation O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
in O
stably O
transfected O
Jurkat O
cell O
clones O
. O

Glucocorticoids O
induced O
down O
- O
regulation O
of O
glucocorticoid B
receptor I
mRNA O
expression O
in O
asthma O
. O

The O
lymphoid B
- I
specific I
transcription I
factor I
Oct B
- I
2a I
is O
implicated O
in O
B O
cell O
- O
specific O
transcriptional O
activity O
via O
the O
octamer O
motif O
. O

Structure O
/ O
function O
analysis O
of O
various O
Oct O
- O
2a O
effector O
regions O
in O
the O
context O
of O
the O
GAL4 B
DNA I
- I
binding I
domain I
revealed O
that O
Oct B
- I
2a I
contains O
two O
functionally O
different O
activation B
domains I
at O
the O
N O
and O
the O
C O
termini O
. O

In O
this O
study O
we O
present O
a O
deletion O
analysis O
of O
the O
N B
- I
terminal I
region I
of O
Oct B
- I
2a I
to O
determine O
the O
minimal O
repression O
domain O
. O

The O
possibility O
that O
Oct B
- I
2a I
can O
act O
as O
an O
activator O
and O
/ O
or O
a O
repressor O
may O
have O
important O
consequences O
for O
the O
function O
of O
Oct B
- I
2a I
in O
B O
cell O
differentiation O
and O
other O
developmental O
processes O
. O

Although O
there O
have O
been O
a O
number O
of O
reports O
demonstrating O
that O
glucocorticoids O
( O
in O
particular O
dexamethasone O
) O
antagonize O
the O
eosinophil O
life O
- O
prolonging O
effects O
of O
hemopoietins B
, O
direct O
effects O
of O
dexamethasone O
on O
eosinophil O
apoptosis O
have O
not O
been O
documented O
. O

The O
first O
was O
to O
abruptly O
terminate O
tumor O
necrosis O
factor O
- O
induced O
NF B
- I
kappaB I
binding O
to O
the O
enhancer O
sequences O
in O
U1 O
monocytic O
cells O
, O
using O
a O
short O
pulse O
of O
exogenous O
tumor O
necrosis O
factor O
. O

Together O
, O
our O
results O
indicate O
that O
occupancy O
of O
the O
viral B
enhancer I
by O
NF O
- O
kappaB O
( O
p50 O
/ O
p65 O
) O
heterodimers O
is O
required O
for O
ongoing O
transcription O
of O
integrated O
HIV O
provirus O
in O
monocytes O
, O
even O
in O
cells O
chronically O
infected O
and O
permanently O
producing O
functional O
HIV O
Tat O
protein O
. O

In O
an O
attempt O
to O
identify O
changes O
in O
gene O
expression O
that O
accompany O
the O
T O
- O
cell O
stimulation O
defects O
associated O
with O
the O
loss O
of O
Rel B
, O
we O
have O
examined O
the O
expression O
of O
cell B
surface I
activation I
markers I
and O
cytokine O
production O
in O
mitogen O
- O
stimulated O
Rel O
- O
/ O
- O
T O
cells O
. O

Exogenous O
IL B
- I
2 I
, O
which O
restitutes O
the O
proliferative O
response O
of O
the O
anti O
- O
CD3 O
- O
and O
anti O
- O
CD28 O
- O
treated O
Rel O
- O
/ O
- O
T O
cells O
, O
restores O
production O
of O
IL O
- O
5 O
, O
TNF B
- I
alpha I
, O
and O
IFN B
- I
gamma I
, O
but O
not O
IL B
- I
3 I
and O
GM B
- I
CSF I
expression O
to O
approximately O
normal O
levels O
. O

These O
findings O
establish O
that O
Rel B
can O
function O
as O
an O
activator O
or O
repressor O
of O
gene O
expression O
and O
is O
required O
by O
T O
lymphocytes O
for O
production O
of O
IL B
- I
3 I
and O
GM B
- I
CSF I
. O

Nuclear O
appearance O
of O
a O
factor O
that O
binds O
the O
CD28 B
response I
element I
within O
the O
interleukin B
- I
2 I
enhancer I
correlates O
with O
interleukin B
- I
2 I
production O
. O

These O
results O
indicate O
that O
mitogenic O
combinations O
of O
T O
cell O
activation O
signals O
are O
integrated O
at O
the O
level O
of O
NF B
- I
MATp35 I
induction O
. O

Two O
explanations O
for O
hyporesponsiveness O
of O
the O
human O
iNOS O
promoter O
to O
LPS O
+ O
/ O
- O
IFN B
- I
gamma I
were O
found O
: O
( O
1 O
) O
multiple O
inactivating O
nucleotide O
substitutions O
in O
the O
human O
counterpart O
of O
the O
enhancer B
element I
that O
has O
been O
shown O
to O
regulate O
LPS O
/ O
IFN B
- I
gamma I
induced O
expression O
of O
the O
mouse O
iNOS O
gene O
; O
and O
( O
2 O
) O
and O
absence O
of O
one O
or O
more O
nuclear B
factors I
in O
human O
macrophages O
( O
e O
. O
g O
. O
, O
an O
LPS O
- O
inducible O
nuclear O
factor O
- O
kappa O
B O
/ O
Rel O
complex O
) O
, O
that O
is O
( O
are O
) O
required O
for O

Severe O
skewing O
of O
X O
inactivation O
resulting O
in O
inactivity O
of O
the O
intact O
X B
was O
found O
in O
blood O
and O
cultures O
of O
both O
types O
of O
skin O
, O
but O
analysis O
of O
DNA O
prepared O
directly O
from O
hypopigmented O
skin O
showed O
significant O
inactivation O
of O
the O
translocated O
X B
, O
inconsistent O
with O
the O
usual O
mechanism O
of O
phenotypic O
expression O
in O
X O
; O
autosome O
translocations O
. O

While O
partial O
variable O
monosomy O
of O
loci O
on O
chromosome O
17p O
can O
not O
be O
excluded O
as O
contributing O
to O
the O
phenotype O
in O
this O
patient O
, O
it O
is O
argued O
that O
the O
major O
likely O
factor O
is O
partial O
functional O
disomy O
of O
sequences O
on O
Xp O
in O
cell O
lineages O
that O
have O
failed O
to O
inactivate O
the O
intact O
X B
chromosome I
. O

After O
several O
round O
of O
subcloning O
followed O
by O
transfection O
, O
oriP B
was O
mapped O
to O
a O
1 B
. I
955 I
- I
kb I
viral I
segment I
. O

Large O
amounts O
of O
AP B
- I
1 I
and O
NF B
- I
kappa I
B I
and O
significant O
quantities O
of O
NF B
- I
AT I
were O
induced O
in O
SEA O
- O
activated O
CD4 O
+ O
spleen O
T O
cells O
, O
whereas O
Oct O
- O
1 O
and O
Oct O
- O
2 O
DNA O
binding O
activity O
was O
similar O
in O
both O
resting O
and O
activated O
T O
cells O
. O

Fas B
ligation O
induces O
apoptosis O
and O
Jun B
kinase I
activation O
independently O
of O
CD45 B
and O
Lck B
in O
human O
T O
cells O
. O

More O
is O
known O
regarding O
signal O
transduction O
events O
that O
occur O
after O
ligation O
of O
the O
T B
- I
cell I
antigen I
receptor I
( O
TCR B
) O
. O

Although O
prior O
studies O
suggest O
a O
role O
for O
protein B
tyrosine I
kinases I
and O
phosphatases O
in O
Fas B
signaling O
, O
we O
report O
here O
that O
Fas O
ligation O
induces O
apoptosis O
in O
T O
cells O
deficient O
in O
either O
CD45 B
or O
Lck B
. O

These O
data O
indicate O
that O
, O
in O
contrast O
to O
most O
LPS O
effects O
, O
AP B
- I
1 I
, O
but O
not O
nuclear B
factor I
- I
kappaB I
, O
mediates O
LPS O
induction O
of O
collagenase B
transcription O
in O
macrophagelike O
cells O
. O

LPS O
treatment O
of O
RAW O
264 O
. O
7 O
cells O
, O
murine O
bone O
marrow O
- O
derived O
macrophages O
, O
and O
the O
human O
monocyte O
cell O
line O
THP O
- O
1 O
resulted O
in O
rapid O
activation O
of O
the O
p46 O
and O
p54 O
isoforms O
of O
JNK B
. O

These O
results O
suggest O
that O
LPS O
activation O
of O
JNK B
in O
monocyte O
/ O
macrophage O
cells O
is O
a O
CD14 O
- O
and O
protein O
tyrosine O
phosphorylation O
- O
dependent O
event O
that O
may O
mediate O
the O
early O
activation O
of O
AP B
- I
1 I
in O
regulating O
LPS O
- O
triggered O
gene O
induction O
. O

A O
cell O
type O
- O
specific O
enhancer O
in O
the O
human B
B7 I
. I
1 I
gene I
regulated O
by O
NF B
- I
kappaB I
. O

This O
183 O
- O
bp O
region O
was O
both O
cell O
type O
specific O
and O
responsive O
to O
two O
distinct O
stimuli O
, O
lipopolysaccharide O
and O
dibutyryl O
cAMP O
, O
known O
to O
regulate O
B7 B
. I
1 I
expression O
. O

Deletional O
and O
site O
- O
directed O
mutagenesis O
revealed O
the O
presence O
of O
multiple O
functionally O
critical O
cis B
elements I
within O
this O
region O
, O
one O
of O
which O
was O
a O
nuclear O
factor O
( O
NF O
) O
- O
kappaB O
consensus O
sequence O
. O

This O
is O
the O
first O
description O
, O
to O
our O
knowledge O
, O
of O
regulatory B
elements I
that O
control O
expression O
of O
a O
gene O
encoding O
a O
B7 O
costimulatory O
molecule O
. O

Recombinant O
c B
- I
Jun I
and O
c B
- I
Fos I
were O
ubiquitinylated O
by O
the O
ubiquitin O
carrier O
enzymes O
E214K B
, O
E220K B
, O
or O
E232K O
in O
the O
presence O
of O
the O
ubiquitin O
- O
activating O
enzyme O
, O
E1 B
. O

mBob1 B
interacts O
with O
the O
octamer B
transcription I
factors I
Oct B
- I
1 I
and O
Oct B
- I
2 I
and O
stimulates O
transcription O
mediated O
by O
these O
factors O
. O

Moreover O
, O
gp120 B
induces O
tyrosine O
phosphorylation O
of O
signal B
transducer I
and I
activator I
of I
transcription I
( O
STAT O
- O
1 O
alpha O
) O
as O
well O
as O
the O
Janus B
kinase I
( O
JAK2 B
) O
in O
glial O
cells O
. O

Northern O
blot O
analysis O
as O
well O
as O
Ab O
blocking O
and O
cytokine B
secretion O
studies O
indicated O
that O
the O
induction O
of O
either O
endogenous B
TNF I
- I
alpha I
or O
IL B
- I
10 I
was O
not O
involved O
in O
the O
cooperativity O
, O
nor O
was O
an O
up O
- O
regulation O
of O
TNF O
- O
alpha O
receptors O
. O

Interaction O
of O
HTLV B
- I
I I
Tax I
with O
the O
human O
proteasome O
: O
implications O
for O
NF B
- I
kappa I
B I
induction O
. O

We O
identified O
a O
physical O
interaction O
between O
Tax B
and O
the O
HsN3 O
subunit O
of O
the O
human O
proteasome O
. O

This O
raises O
the O
intriguing O
possibility O
that O
physical O
association O
of O
the O
HsN3 O
proteasome O
subunit O
with O
HTLV B
- I
I I
Tax I
coupled O
with O
the O
independent O
interaction O
of O
Tax B
with O
either O
p100 O
or O
p65 O
- O
I B
kappa I
B I
alpha I
targets O
these O
cytoplasmic O
NF O
- O
kappa O
B O
/ O
Rel O
complexes O
to O
the O
proteasome B
for O
processing O
. O

We O
have O
focused O
on O
the O
study O
of O
the O
signal O
transduction O
pathways O
triggered O
by O
CD23 B
in O
human O
monocytes O
and O
the O
promonocytic O
cell O
line O
U937 O
. O

IkappaBalpha B
phosphorylation O
and O
degradation O
was O
analyzed O
by O
Western O
blot O
. O

Paclitaxel O
and O
other O
drugs O
that O
disturb O
microtubule B
dynamics O
kill O
cells O
in O
a O
Fas B
/ B
Fas I
ligand I
( O
FasL B
) O
- O
dependent O
manner O
; O
antibody O
to O
FasL B
inhibits O
paclitaxel O
- O
induced O
apoptosis O
. O

Without O
NFAT B
nuclear O
translocation O
, O
the O
FasL B
gene O
is O
not O
transcribed O
. O

The O
effects O
of O
Bcl B
- I
2 I
can O
be O
overcome O
, O
at O
least O
partially O
, O
through O
phosphorylation O
of O
Bcl B
- I
2 I
. O

Regulatory O
effects O
of O
interleukin B
- I
11 I
during O
acute O
lung O
inflammatory O
injury O
. O

Recently O
, O
we O
and O
others O
have O
shown O
that O
thrombopoietin B
induces O
rapid O
tyrosine O
phosphorylation O
of O
Jak2 B
and O
other O
proteins O
in O
human O
platelets O
and O
BaF3 O
cells O
, O
genetically O
engineered O
to O
express O
c O
- O
Mpl O
, O
a O
receptor O
for O
thrombopoietin B
. O

Thus O
, O
our O
data O
indicate O
that O
Stat3 B
and O
Stat5 B
may O
be O
involved O
in O
signal O
transduction O
after O
ligand O
binding O
to O
c O
- O
Mpl O
and O
that O
this O
event O
may O
have O
a O
role O
in O
megakaryopoiesis O
/ O
thrombopoiesis O
or O
possibly O
a O
mature O
platelet O
function O
such O
as O
aggregation O
. O

One O
such O
example O
is O
the O
excessive O
expression O
of O
` O
` O
normal O
' O
' O
lymphokines O
of O
cytokines B
which O
accompanies O
many O
lymphoproliferative O
diseases O
. O

The O
dysregulated O
expression O
of O
cytokines B
during O
malignancy O
can O
result O
in O
the O
augmentation O
of O
growth O
of O
transformed O
lymphocytes O
, O
as O
well O
as O
an O
alteration O
of O
the O
anti O
- O
tumor O
immune O
response O
. O

IL B
- I
4 I
activates O
gene O
expression O
by O
inducing O
tyrosine O
phosphorylation O
, O
homodimerization O
, O
and O
nuclear O
translocation O
of O
the O
latent O
transcription O
factor O
, O
STAT6 B
( O
signal B
transducer I
and I
activator I
of I
transcription I
- I
6 I
) O
. O

Because O
STAT6 B
activation O
is O
essential O
for O
IL B
- I
4 I
- O
induced O
gene O
expression O
, O
we O
examined O
the O
ability O
of O
type O
I O
and O
type O
II O
IFNs B
to O
regulate O
activation O
of O
STAT6 B
by O
IL B
- I
4 I
in O
primary O
human O
monocytes O
. O

The O
shift O
from O
complex B
I I
to O
complex B
II I
seen O
only O
in O
SCM O
- O
1 O
- O
producer O
T O
cell O
lines O
upon O
activation O
was O
completely O
suppressed O
by O
cyclosporin O
A O
. O

One O
- O
hybrid O
assays O
in O
yeast O
isolated O
NF O
- O
ATp O
as O
an O
E1 O
binding O
protein O
, O
and O
transfection O
of O
NF B
- I
ATp I
into O
T O
and O
B O
cell O
lines O
strongly O
enhanced O
the O
activation O
- O
dependent O
SCM O
- O
1 O
promoter O
activity O
. O

The O
importance O
of O
NF O
- O
kappaB O
sites O
was O
confirmed O
by O
using O
vectors O
containing O
wild O
- O
type O
or O
mutant O
kappaB O
sites O
in O
a O
heterologous B
promoter I
. O

Consistent O
with O
the O
role O
of O
NF B
- I
kappaB I
in O
mediating O
dopamine O
responsiveness O
, O
the O
proteasome O
inhibitor O
MG132 O
abolished O
dopamine O
- O
induced O
transcriptional O
activation O
. O

In O
this O
study O
, O
we O
analyzed O
the O
binding O
activity O
of O
IL O
- O
10 O
- O
and O
IFN O
- O
gamma O
- O
activated O
STAT O
molecules O
to O
two O
kinds O
of O
GAS B
- O
motif O
sequences O
. O

This O
may O
explain O
the O
difference O
between O
IL B
- I
10 I
and O
IFN B
- I
gamma I
in O
biological O
activity O
, O
and O
the O
inhibitory O
effect O
of O
IL B
- I
10 I
on O
IFN B
- I
gamma I
activities O
. O

To O
investigate O
a O
potential O
role O
of O
E2F B
- I
1 I
in O
differentiation O
, O
we O
assayed O
the O
ability O
of O
megakaryocytes O
to O
form O
platelets O
in O
an O
in O
vivo O
transgenic O
model O
. O

Administration O
of O
megakaryocyte O
growth O
and O
development O
factor O
or O
interleukin B
6 I
could O
not O
overcome O
the O
differentiation O
block O
. O

A O
recent O
sib O
- O
pair O
analysis O
revealed O
a O
tight O
linkage O
between O
markers O
on O
5q31 O
. O
1 O
and O
a O
major O
susceptibility O
gene O
controlling O
total O
serum O
IgE B
levels O
. O

Evidence O
for O
lowered O
induction O
of O
nuclear B
factor I
kappa I
B I
in O
activated O
human O
T O
lymphocytes O
during O
aging O
. O

Inhibition O
of O
lipopolysaccharide O
- O
induced O
monocyte O
interleukin O
- O
1 O
receptor O
antagonist O
synthesis O
by O
cortisol O
: O
involvement O
of O
the O
mineralocorticoid B
receptor I
. O

The O
mineralocorticoid O
aldosterone O
exerted O
a O
significant O
decrease O
in O
LPS O
- O
induced O
monocyte O
IL B
- I
1ra I
secretion O
in O
vitro O
, O
which O
was O
blocked O
by O
coincubation O
with O
spironolactone O
. O

Moreover O
, O
we O
provide O
evidence O
that O
, O
in O
addition O
to O
a O
glucocorticoid B
receptor I
- O
mediated O
effect O
, O
the O
mineralocorticoid B
receptor I
is O
involved O
in O
the O
inhibition O
of O
monocyte O
IL B
- I
1ra I
secretion O
by O
cortisol O
. O

Here O
, O
we O
have O
readdressed O
the O
issue O
of O
CD8 O
( O
+ O
) O
T O
cells O
specific O
for O
the O
72 O
- O
kDa O
major O
immediate O
- O
early O
protein O
( O
IE B
- I
1 I
) O
, O
which O
is O
nonstructural O
but O
is O
found O
very O
early O
and O
throughout O
the O
replicative O
cycle O
. O

In O
summary O
, O
our O
results O
suggest O
that O
IE B
- I
1 I
is O
far O
more O
important O
as O
a O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
target O
than O
current O
opinion O
suggests O
. O

E1A B
oncogene I
induction O
of O
cellular O
susceptibility O
to O
killing O
by O
cytolytic O
lymphocytes O
through O
target O
cell O
sensitization O
to O
apoptotic O
injury O
. O

Since O
CLs O
can O
induce O
either O
apoptotic O
or O
necrotic O
cell O
death O
, O
we O
asked O
whether O
E1A B
sensitization O
to O
injury O
- O
induced O
apoptosis O
is O
sufficient O
to O
explain O
E1A B
- O
induced O
cytolytic O
susceptibility O
. O

TCL1 B
oncogene I
expression O
in O
AIDS O
- O
related O
lymphomas O
and O
lymphoid O
tissues O
. O

We O
find O
that O
TCL1 B
is O
expressed O
in O
the O
majority O
of O
AIDS O
IBLP O
tumors O
examined O
. O

They O
also O
indicate O
that O
abundant O
TCL1 B
expression O
in O
quiescent O
mantle O
zone O
B O
cells O
is O
down O
- O
regulated O
in O
activated O
germinal O
center O
follicular O
B O
cells O
in O
parallel O
to O
the O
known O
expression O
pattern O
of O
BCL B
- I
2 I
. O

High O
- O
level O
expression O
in O
nonproliferating O
B O
cells O
suggests O
that O
TCL1 B
may O
function O
in O
protecting O
naive O
preactivated O
B O
cells O
from O
apoptosis O
. O

Here O
, O
we O
report O
a O
model O
of O
CD28 B
costimulation O
using O
PMA O
plus O
the O
natural O
ligand O
CD80 O
that O
resulted O
in O
very O
limited O
stimulation O
of O
IL B
- I
2 I
, O
as O
evidenced O
by O
both O
cytokine B
production O
and O
IL B
- I
2 I
promoter I
stimulation O
. O

We O
have O
determined O
that O
the O
JAK B
/ B
STAT I
pathway O
positively O
regulates O
Qp B
activity O
. O

In O
transient O
- O
transfection O
assays O
, O
a O
Qp O
- O
CAT O
reporter O
was O
activated O
by O
cotransfected O
JAK B
- I
1 I
and O
by O
treatment O
of O
cells O
with O
the O
cytokine B
IL B
- I
6 I
. O

Consistent O
with O
a O
role O
for O
STATs B
in O
Qp B
function O
, O
Qp B
using O
Burkitt O
' O
s O
lymphoma O
Rael O
cells O
and O
cultured O
nasopharyngeal O
carcinoma O
( O
NPC O
) O
cells O
contained O
nuclear O
STAT B
protein I
. O

This O
negative O
regulation O
required O
Zta B
DNA O
- O
binding O
activity O
. O

We O
provide O
evidence O
that O
Zta B
up O
- O
regulation O
of O
p53 B
leads O
to O
p53 B
- O
mediated O
interference O
with O
JAK B
/ B
STAT I
activation O
of O
Qp B
. O

Reactive O
oxygen O
intermediate O
- O
release O
of O
fibre O
- O
exposed O
monocytes O
increases O
inflammatory O
cytokine B
- I
mRNA I
level O
, O
protein B
tyrosine I
kinase I
and O
NF B
- I
kappaB I
activity O
in O
co O
- O
cultured O
bronchial O
epithelial O
cells O
( O
BEAS O
- O
2B O
) O
. O

We O
show O
here O
that O
the O
response O
of O
the O
HIV O
- O
1 O
long O
terminal O
repeat O
( O
LTR B
) O
to O
mitogenic O
or O
Tat B
- O
mediated O
activation O
is O
sensitive O
to O
the O
suppressive O
action O
of O
a O
Herpesvirus O
saimiri O
( O
HVS O
) O
- O
transformed O
CD8 O
+ O
T O
cell O
clone O
from O
an O
HIV O
- O
infected O
individual O
and O
supernatants O
from O
CD8 O
+ O
T O
cells O
of O
HIV O
- O
1 O
- O
infected O
asymptomatic O
subjects O
( O
CD4 B
+ I
> O
350 O
/ O
microliters O
) O
. O

Mutagenesis O
of O
NF O
kappa O
B O
or O
Sp O
- O
1 O
elements O
within O
the O
LTR B
resulted O
in O
no O
change O
in O
the O
ability O
of O
CD8 O
+ O
T O
cell O
supernatants O
to O
inhibit O
Tat O
- O
or O
mitogen O
- O
mediated O
LTR O
transcription O
. O

Taken O
together O
, O
these O
observations O
suggest O
that O
mitogenic O
activation O
, O
mediated O
primarily O
through O
the O
NF B
kappa I
B I
enhancer I
, O
is O
susceptible O
to O
CD8 B
- O
mediated O
inhibition O
, O
however O
, O
inhibition O
of O
Tat B
- O
mediated O
activation O
may O
rely O
upon O
a O
different O
pathway O
that O
is O
NFAT B
- I
1 I
dependent O
. O

Nuclear B
factor I
( I
NF I
) I
- I
kappa I
B I
is O
a O
redox O
sensitive O
cytosolic O
transcription O
factor O
. O

Induction O
of O
endothelial B
adhesion I
molecules I
by O
the O
cytokine B
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
) O
can O
occur O
independently O
of O
protein B
kinase I
C I
and O
activation O
of O
a O
protein B
tyrosine I
kinase I
( O
PTK B
) O
has O
recently O
been O
implicated O
in O
the O
upregulation O
of O
vascular B
cell I
adhesion I
molecule I
1 I
( O
VCAM B
- I
1 I
) O
by O
interleukin B
- I
4 I
( O
IL B
- I
4 I
) O
on O
endothelial O
cells O
. O

In O
this O
study O
, O
we O
demonstrate O
that O
constitutive O
expression O
of O
bcl B
- I
xl I
but O
not O
bcl B
- I
2 I
, O
bcl O
- O
xs O
, O
bak B
, O
bad B
, O
or O
bax B
was O
associated O
with O
apoptosis O
resistance O
after O
IL B
- I
2 I
deprivation O
in O
CTLL O
- O
2 O
cells O
that O
expressed O
Tax B
. O

Transient O
- O
transfection O
assays O
showed O
that O
bcl B
- I
x I
promoter I
was O
transactivated O
by O
wild O
- O
type O
Tax O
. O

We O
find O
that O
recruitment O
of O
EKLF B
to O
5 B
' I
HS2 I
requires O
the O
TATA B
box I
, O
but O
recruitment O
to O
5 B
' I
HS3 I
depends O
on O
the O
CACCC O
and O
TATA O
boxes O
of O
the O
beta B
- I
globin I
promoter I
. O

We O
have O
found O
that O
the O
recruitment O
of O
EKLF B
to O
5 B
' I
HS3 I
depends O
on O
the O
presence O
of O
5 B
' I
HS2 I
in O
cis O
, O
but O
the O
recruitment O
to O
5 B
' I
HS2 I
does O
not O
depend O
on O
5 B
' I
HS3 I
. O

Based O
on O
these O
results O
, O
we O
present O
a O
model O
that O
illustrates O
how O
EKLF B
may O
be O
recruited O
to O
the O
beta B
- I
globin I
locus I
. O

We O
also O
report O
that O
in O
RAW O
264 O
. O
7 O
cells O
, O
an O
E O
( O
2 O
) O
receptor O
- O
positive O
murine O
monocytic O
line O
, O
E O
( O
2 O
) O
downregulates O
cytokine O
- O
induced O
TNF B
gene O
expression O
by O
decreasing O
the O
activity O
of O
the O
Jun O
NH O
( O
2 O
) O
- O
terminal O
kinase O
( O
JNK B
) O
. O

The O
resulting O
diminished O
phosphorylation O
of O
c B
- I
Jun I
and O
JunD B
at O
their O
NH O
( O
2 O
) O
- O
termini O
decreases O
the O
ability O
of O
these O
nuclear O
proteins O
to O
autostimulate O
the O
expression O
of O
the O
c O
- O
Jun O
and O
JunD O
genes O
, O
thus O
leading O
to O
lower O
production O
of O
c B
- I
Jun I
and O
JunD B
. O

Recent O
data O
show O
that O
TCR B
/ I
CD3 I
stimulation O
induces O
activation O
of O
Stat5 B
in O
murine O
T O
cells O
. O

In O
conclusion O
, O
we O
show O
that O
CD3 B
ligation O
by O
mAb B
and O
SE O
triggers O
a O
rapid O
, O
PP1 B
- O
sensitive O
tyrosine O
and O
serine O
phosphorylation O
of O
Stat3 B
in O
human O
CD4 O
+ O
T O
cells O
. O

Clusters O
of O
genes B
expressed O
by O
stromal O
cells O
and O
lymphocytes O
in O
the O
breast O
tumors O
also O
were O
identified O
in O
this O
analysis O
. O

Stimulation O
of O
T O
cells O
with O
calcium O
ionophore O
induced O
a O
shift O
in O
the O
molecular O
weight O
of O
NFATp B
that O
is O
due O
to O
its O
dephosphorylation O
. O

The O
B O
cell O
- O
associated O
surface O
molecule O
CD40 B
plays O
a O
key O
role O
in O
T O
cell O
- O
dependent O
B O
cell O
maturation O
, O
as O
individuals O
with O
defects O
in O
either O
CD40 B
or O
its O
ligand O
are O
impaired O
in O
immunoglobulin B
isotype O
class O
switching O
and O
germinal O
center O
formation O
. O

CD40 B
signaling O
activates O
downstream O
effectors O
, O
including O
the O
tyrosine B
protein I
kinase I
, O
Lyn B
, O
the O
phosphatidylinositol B
- I
3 I
- I
kinase I
( O
PI B
- I
3 I
kinase I
) O
, O
and O
the O
transcription O
factor O
, O
NF B
- I
kappa I
B I
. O

In O
this O
study O
, O
we O
demonstrate O
that O
stress B
- I
activated I
protein I
kinases I
( O
SAPK B
) O
are O
activated O
after O
CD40 B
cross O
- O
linking O
on O
various O
B O
cell O
lines O
or O
human O
tonsillar O
B O
cells O
. O

In O
summary O
, O
CD40 B
signaling O
preferentially O
induces O
SAPK B
but O
not O
MAPK B
. O

Using O
CD45 O
- O
or O
CD3 O
- O
negative O
variants O
of O
the O
Jurkat O
leukemic O
T O
- O
cell O
line O
we O
show O
that O
the O
different O
biochemical O
events O
induced O
by O
pervanadate O
appeared O
to O
be O
dependent O
on O
the O
presence O
at O
the O
cell O
surface O
of O
either O
CD45 B
or O
CD3 B
. O

CD45 B
- O
dependent O
events O
such O
as O
tyrosine B
phosphorylation I
of O
Shc B
, O
activation O
of O
nuclear B
factor I
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
, O
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
, O
transcription B
factors I
, O
and O
stimulation O
of O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
promoter I
and O
of O
CD69 B
and O
CD25 B
surface O
expression O
paralleled O
activation O
of O
the O
tyrosine B
kinases I
lck B
and O
fyn B
. O

Here O
we O
show O
that O
1alpha O
, O
25 O
( O
OH O
) O
2 O
- O
d5 O
- O
previtamin O
D3 O
( O
HF O
) O
, O
JN O
, O
KH1060 O
, O
and O
MC903 O
induce O
expression O
of O
PKC B
alpha I
and O
PKC O
delta O
and O
translocation O
of O
both O
isoforms O
to O
the O
particulate O
fraction O
, O
and O
PKC B
alpha I
to O
the O
nuclear O
fraction O
. O

Retinoic O
acid O
can O
directly O
modulate O
gene O
expression O
via O
binding O
to O
its O
nuclear B
receptors I
, O
which O
can O
, O
in O
turn O
, O
activate O
transcription O
of O
target B
genes I
. O

Tax B
has O
been O
shown O
to O
transactivate O
several O
cellular B
genes I
. O

Induced O
MIP B
- I
1alpha I
expression O
and O
secretion O
in O
PMA O
/ O
PHA O
stimulated O
tax O
transfected O
cells O
correlate O
with O
the O
noninduction O
of O
MNP B
- I
1 I
transcription B
factor I
, O
which O
is O
intimately O
involved O
in O
downmodulating O
the O
MIP O
- O
1alpha O
gene O
. O

The O
other O
major O
subpopulation O
expressing O
the O
CD4 B
receptor I
, O
namely O
, O
the O
double O
- O
positive O
( O
DP O
) O
CD4 O
( O
+ O
) O
CD8 O
( O
+ O
) O
CD3 O
( O
+ O
/ O
- O
) O
thymocytes O
, O
despite O
the O
entry O
of O
the O
virus O
, O
do O
not O
produce O
a O
significant O
level O
of O
virus O
, O
presumably O
because O
they O
are O
unresponsive O
to O
TNF B
and O
IL B
- I
7 I
. O

Activation O
of O
CD40 B
is O
essential O
for O
thymus O
- O
dependent O
humoral O
immune O
responses O
and O
rescuing O
B O
cells O
from O
apoptosis O
. O

MBP B
over O
the O
concentration O
range O
of O
0 O
. O
1 O
to O
10 O
microM O
stimulated O
the O
release O
of O
up O
to O
approximately O
8 O
ng O
/ O
ml O
IL B
- I
8 I
. O

MBP B
also O
induced O
transient O
increases O
in O
mRNA B
for O
macrophage O
inflammatory O
protein O
( O
MIP O
) O
- O
1alpha O
and O
MIP O
- O
1beta O
, O
but O
did O
not O
stimulate O
the O
release O
of O
either O
chemokine B
. O

A O
high O
- O
affinity O
calcineurin B
- O
binding O
peptide O
was O
selected O
from O
combinatorial O
peptide O
libraries O
based O
on O
the O
calcineurin O
docking O
motif O
of O
NFAT B
. O

Substitution O
of O
the O
optimized O
peptide O
sequence O
into O
the O
natural O
calcineurin O
docking O
site O
increased O
the O
calcineurin B
responsiveness O
of O
NFAT B
. O

Compounds O
that O
interfere O
selectively O
with O
the O
calcineurin B
- B
NFAT I
interaction O
without O
affecting O
calcineurin B
phosphatase B
activity O
may O
be O
useful O
as O
therapeutic O
agents O
that O
are O
less O
toxic O
than O
current O
drugs O
. O

9 O
- O
cis O
retinoic O
acid O
induces O
monocyte B
chemoattractant I
protein I
- I
1 I
secretion O
in O
human O
monocytic O
THP O
- O
1 O
cells O
. O

Thus O
, O
both O
copies O
of O
BRCA1 B
were O
retained O
in O
tumor O
. O

Therefore O
, O
we O
investigated O
whether O
IVS1 O
- O
10T O
- O
- O
> O
C O
deleteriously O
affected O
BRCA1 B
splicing O
or O
expression O
, O
and O
thereby O
inactivated O
the O
other O
BRCA1 B
allele I
. O

We O
have O
investigated O
mechanisms O
and O
consequences O
of O
STAT5 B
activation O
through O
the O
human O
IL O
- O
4 O
receptor O
( O
IL B
- I
4R I
) O
. O

By O
functionally O
expressing O
receptor O
mutants O
in O
the O
murine O
pro O
- O
B O
cell O
line O
Ba O
/ O
F3 O
, O
we O
could O
show O
that O
phosphorylated O
tyrosine O
residues O
within O
the O
IL B
- I
4R I
alpha I
chain I
are O
dispensable O
for O
IL B
- I
4 I
- O
induced O
STAT5 B
activity O
. O

An O
inhibitory O
, O
` O
` O
dominant O
- O
negative O
, O
' O
' O
form O
of O
the O
calcineurin O
catalytic O
( O
A O
) O
subunit O
was O
prepared O
, O
which O
lacks O
the O
calmodulin O
- O
binding O
domain O
, O
autoinhibitory B
domain I
and O
most O
of O
its O
catalytic O
core O
but O
possesses O
the O
regulatory O
( O
B O
) O
subunit O
binding O
domain O
. O

Immunoprecipitation O
of O
epitope O
- O
labeled O
BKO O
demonstrated O
for O
the O
formation O
of O
a O
tight O
complex O
with O
endogenous O
B O
subunit O
in O
Jurkat O
cells O
, O
consistent O
with O
an O
inhibitory O
mechanism O
that O
involves O
the O
sequestration O
of O
the O
B B
subunit I
. O

RNA B
was O
extracted O
by O
phenol O
/ O
chloroform O
and O
c B
- I
fos I
expression O
was O
analyzed O
by O
PCR O
assisted O
mRNA O
assay O
. O

A O
significant O
2 O
- O
4 O
fold O
increase O
of O
c B
- I
fos I
expression O
was O
observed O
within O
30 O
min O
of O
stimulation O
with O
IL B
- I
10 I
( O
p O
< O
0 O
. O
01 O
) O
. O

Since O
this O
is O
the O
first O
report O
on O
IL B
- I
10 I
induced O
signal O
transduction O
, O
these O
data O
may O
help O
to O
identify O
the O
intracellular O
mechanisms O
by O
which O
IL B
- I
10 I
stimulates O
human O
B O
- O
cells O
. O

MNDA B
was O
not O
detected O
in O
normal O
tissue O
histiocytes O
but O
was O
found O
in O
activated O
macrophages O
and O
foreign O
body O
giant O
cells O
associated O
with O
inflammation O
. O

Flow O
cytometric O
cell O
sorting O
of O
normal O
bone O
marrow O
established O
that O
MNDA B
is O
initially O
expressed O
in O
myeloid O
blast O
cells O
. O

Peroxisome B
proliferator I
- I
activated I
receptors I
( O
PPARs B
) O
, O
members O
of O
the O
nuclear B
receptor I
superfamily I
of O
transcription B
factors I
, O
are O
activated O
by O
fatty O
acid O
metabolites O
, O
peroxisome O
proliferators O
, O
and O
thiazolidinediones O
and O
are O
now O
recognized O
as O
important O
mediators O
in O
the O
inflammatory O
response O
. O

Expression O
of O
wild O
- O
type O
SHP1 O
had O
a O
very O
small O
effect O
on O
the O
TCR O
- O
induced O
tyrosine O
phosphorylation O
of O
ZAP B
- I
70 I
and O
Syk B
, O
even O
when O
SHP1 B
was O
overexpressed O
20 O
- O
100 O
- O
fold O
over O
endogenous O
SHP1 O
. O

However O
, O
the O
two O
SH2 B
domains I
of O
SHP1 B
did O
not O
facilitate O
its O
recognition O
of O
ZAP B
- I
70 I
and O
Syk B
as O
substrates O
in O
intact O
cells O
. O

Eosinophil B
granule I
major I
basic I
protein I
( O
MBP B
) O
is O
expressed O
exclusively O
in O
eosinophils O
and O
basophils O
in O
hematopoietic O
cells O
. O

In O
the O
cell O
line O
HT93A O
, O
which O
is O
capable O
of O
differentiating O
towards O
both O
the O
eosinophil O
and O
neutrophil O
lineages O
in O
response O
to O
retinoic O
acid O
( O
RA O
) O
, O
C O
/ O
EBPalpha O
mRNA O
expression O
decreased O
significantly O
concomitant O
with O
eosinophilic O
and O
neutrophilic O
differentiation O
, O
whereas O
C B
/ I
EBPbeta I
expression O
was O
markedly O
increased O
. O

Furthermore O
, O
we O
have O
demonstrated O
that O
both O
C B
/ I
EBPbeta I
and O
GATA B
- I
1 I
can O
bind O
simultaneously O
to O
the O
C O
/ O
EBP O
- O
and O
GATA B
- I
binding I
sites I
in O
the O
MBP B
promoter I
. O

Role O
of O
the O
camp O
response O
element O
site O
in O
mediating O
repression O
by O
the O
upstream B
regulatory I
region I
. O

DNase B
I I
footprinting O
identified O
several O
protected O
areas O
including O
Sp1 O
, O
Sp1 O
/ O
AP O
- O
2 O
, O
and O
cAMP O
response O
element O
( O
CRE O
) O
binding O
sites O
within O
the O
201 O
- O
bp O
core O
promoter O
region O
and O
Sp1 O
, O
NRE O
- O
2a O
, O
TCF O
- O
1 O
/ O
LEF O
- O
1 O
, O
and O
Sp1 O
/ O
NF O
- O
AT O
binding O
sites O
in O
the O
upstream B
regulatory I
region I
. O

Electrophoretic O
mobility O
shift O
assay O
analysis O
of O
proteins O
binding O
to O
the O
CRE B
site I
identified O
both O
ATF B
- I
1 I
and O
ATF B
- I
2 I
in O
Jurkat O
cells O
. O

In O
summary O
, O
we O
have O
identified O
a O
tissue O
- O
specific O
regulatory O
region O
5 O
' O
of O
the O
ecto O
- O
5 O
' O
- O
NT O
core O
promoter O
that O
requires O
the O
presence O
of O
a O
functional O
CRE B
site I
within O
the O
basal B
promoter I
for O
its O
suppressive O
activity O
. O

Extracellular O
signal O
- O
regulated O
protein O
kinase O
( O
ERK O
) O
- O
dependent O
and O
ERK O
- O
independent O
pathways O
target O
STAT3 B
on O
serine O
- O
727 O
in O
human O
neutrophils O
stimulated O
by O
chemotactic B
factors I
and O
cytokines B
. O

( O
2 O
- O
Amino O
- O
3 O
' O
- O
methoxyphenyl O
) O
oxanaphthalen O
- O
4 O
- O
one O
( O
PD O
98059 O
) O
, O
an O
inhibitor O
of O
extracellular O
signal O
- O
regulated O
protein O
kinase O
( O
ERK B
) O
activation O
, O
blocked O
the O
serine O
phosphorylation O
of O
STAT3 B
induced O
by O
chemotactic B
factors I
or O
PMA O
. O

These O
foci O
, O
which O
were O
preferentially O
found O
adjacent O
to O
nucleoli O
or O
at O
the O
nuclear O
periphery O
, O
did O
not O
represent O
sites O
of O
active O
transcription O
or O
binding O
of O
GATA B
- I
1 I
to O
consensus O
sites O
in O
the O
beta O
- O
globin O
loci O
. O

After O
exercise O
following O
placebo O
administration O
we O
observed O
increases O
in O
concentrations O
of O
blood O
substrates O
, O
plasma O
adrenocorticotropin O
( O
ACTH O
) O
, O
growth O
hormone O
and O
cortisol O
and O
in O
the O
number O
of O
glucocorticoid B
receptors I
in O
lymphocytes O
without O
changes O
in O
the O
dissociation O
constant O
. O

Putative O
steroid O
binding O
domain O
of O
the O
human B
mineralocorticoid I
receptor I
, O
expressed O
in O
E O
. O
coli O
in O
the O
presence O
of O
heat B
shock I
proteins I
shows O
typical O
native O
receptor O
characteristics O
. O

Renal O
cell O
carcinoma O
- O
derived O
gangliosides O
suppress O
nuclear B
factor I
- I
kappaB I
activation O
in O
T O
cells O
. O

In O
this O
study O
, O
we O
investigate O
the O
role O
of O
TNFalpha B
- O
inducible O
reactive O
oxygen O
species O
( O
ROS O
) O
in O
IL B
- I
8 I
expression O
by O
` O
` O
monocyte O
- O
like O
' O
' O
U937 O
histiocytic O
lymphoma O
cells O
. O

These O
data O
indicate O
that O
TNFalpha B
induces O
a O
delayed O
ROS O
- O
dependent O
signalling O
pathway O
that O
is O
required O
for O
NF B
- I
kappaB I
transcriptional O
activation O
and O
is O
separable O
from O
that O
required O
for O
its O
nuclear O
translocation O
. O

Estrogen B
receptors I
influence O
non O
- O
genomic O
events O
, O
which O
are O
rapid O
in O
onset O
and O
genomic O
events O
, O
which O
are O
longer O
acting O
responses O
. O

Protein B
kinase I
C I
and O
calcineurin B
synergize O
to O
activate O
IkappaB B
kinase I
and O
NF B
- I
kappaB I
in O
T O
lymphocytes O
. O

We O
also O
demonstrate O
that O
the O
IKK B
complex I
, O
but O
not O
p90 B
( I
rsk I
) I
, O
is O
responsible O
for O
the O
in O
vivo O
phosphorylation O
of O
IkappaBalpha B
mediated O
by O
the O
co O
- O
activation O
of O
PKC B
and O
calcineurin B
. O

The O
p53 B
paradox O
in O
the O
pathogenesis O
of O
tumor O
progression O
. O

Additional O
upstream O
gene O
segments O
dramatically O
affected O
B29 B
minimal B
promoter I
activity O
. O

These O
findings O
indicate O
that O
B29 B
gene I
expression O
is O
controlled O
by O
the O
complex O
interplay O
of O
positive O
and O
negative B
regulatory I
elements I
. O

A O
novel O
immunosuppressive O
factor O
in O
bovine O
colostrum O
blocks O
activation O
of O
the O
interleukin O
2 O
gene O
enhancer O
at O
the O
NFAT B
site I
. O

A O
factor O
in O
bovine O
colostrum O
( O
colostrum O
inhibitory O
factor O
, O
CIF B
) O
inhibits O
interleukin B
2 I
( O
IL2 B
) O
production O
in O
activated O
T O
helper O
cells O
by O
blocking O
the O
accumulation O
of O
IL2 O
mRNA O
. O

To O
determine O
whether O
CIF B
blocks O
at O
the O
level O
of O
IL2 B
transcription O
, O
we O
introduced O
reporter O
plasmids O
into O
the O
human O
T O
leukemia O
cell O
line O
Jurkat O
by O
transient O
transfection O
. O

The O
NFAT O
- O
controlled O
luciferase O
gene O
system O
distinguishes O
CIF B
from O
other O
T O
cell O
inhibitory O
activities O
present O
in O
colostrum O
, O
in O
particular O
, O
TGF B
beta I
1 I
and O
TGF B
beta I
2 I
and O
the O
glucocorticoids O
. O

The O
NFAT B
- O
luc O
assay O
is O
a O
useful O
technique O
for O
the O
rapid O
, O
sensitive O
measurement O
of O
CIF B
or O
other O
immunosuppressants O
with O
a O
similar O
mode O
of O
action O
. O

To O
propel O
itself O
in O
infected O
cells O
, O
the O
pathogen O
Shigella O
flexneri O
subverts O
the O
Cdc42 B
- O
controlled O
machinery O
responsible O
for O
actin B
assembly O
during O
filopodia O
formation O
. O

Using O
a O
combination O
of O
bacterial O
motility O
assays O
in O
platelet O
extracts O
with O
Escherichia O
coli O
expressing O
the O
Shigella O
IcsA O
protein O
and O
in O
vitro O
analysis O
of O
reconstituted O
systems O
from O
purified O
proteins O
, O
we O
show O
here O
that O
the O
bacterial O
protein O
IcsA O
binds O
N B
- I
WASP I
and O
activates O
it O
in O
a O
Cdc42 B
- O
like O
fashion O
. O

c B
- I
Maf I
induces O
monocytic O
differentiation O
and O
apoptosis O
in O
bipotent O
myeloid O
progenitors O
. O

We O
have O
shown O
that O
the O
c B
- I
Maf I
and O
c O
- O
Myb O
transcription O
factors O
physically O
interact O
in O
myeloid O
cells O
to O
form O
inhibitory O
complexes O
that O
hinder O
transactivation O
of O
c O
- O
Myb O
target O
genes O
through O
direct O
binding O
to O
Myb O
consensus O
sites O
. O

Analysis O
of O
targets O
that O
could O
mediate O
these O
phenotypic O
changes O
indicated O
that O
c B
- I
Maf I
likely O
plays O
a O
key O
role O
in O
myeloid O
cell O
development O
through O
dual O
mechanisms O
; O
inhibition O
of O
a O
select O
set O
of O
c B
- I
Myb I
regulated O
targets O
, O
such O
as O
Bcl B
- I
2 I
and O
CD13 O
/ O
APN O
, O
coupled O
with O
the O
activation O
of O
as O
yet O
undefined O
differentiation O
- O
promoting O
genes O
. O

We O
have O
examined O
the O
effect O
of O
Rb B
expression O
on O
the O
activation O
of O
the O
promoter O
for O
HLA B
- I
DRA I
, O
the O
prototype O
class O
II O
gene O
. O

These O
findings O
suggest O
that O
BCL B
- I
6 I
may O
play O
a O
role O
in O
regulating O
differentiation O
of O
normal O
germinal O
center O
B O
cells O
and O
that O
its O
deregulated O
expression O
caused O
by O
rearrangements O
may O
contribute O
to O
lymphomagenesis O
. O

Activation O
of O
NF B
- I
kappa I
B I
is O
induced O
by O
prooxidants O
and O
several O
stimuli O
eliciting O
oxidative O
stress O
, O
such O
as O
cytokines B
, O
lipopolysaccharide O
, O
UV O
irradiation O
and O
other O
mediators O
. O

To O
better O
understand O
the O
assembly O
mechanism O
for O
the O
progesterone B
receptor I
( O
PR B
) O
, O
we O
have O
developed O
cell O
- O
free O
systems O
for O
studying O
interactions O
of O
PR B
, O
hsp90 B
, O
and O
other O
associated O
proteins O
. O

These O
interactions O
require O
ATP O
/ O
Mg2 O
+ O
and O
when O
ATP O
is O
limiting O
the O
PR B
complex O
is O
altered O
to O
one O
containing O
the O
proteins O
p60 B
and O
p48 B
, O
but O
lacking O
immunophilins B
and O
p23 B
. O

One O
contains O
hsp90 B
bound O
to O
hsp70 B
and O
p60 B
and O
this O
complex O
forms O
spontaneously O
in O
the O
absence O
of O
ATP O
. O

This O
explains O
, O
in O
part O
, O
the O
known O
effects O
of O
ATP O
and O
molybdate O
on O
assembly O
of O
PR B
complexes I
. O

Since O
NF O
- O
kappaB O
/ O
IkappaB B
system O
regulates O
the O
transcription O
of O
proinflammatory B
genes I
, O
including O
those O
responsible O
for O
ROS O
generation O
, O
we O
tested O
the O
hypothesis O
that O
hydrocortisone O
may O
stimulate O
IkappaB B
production O
thus O
inhibiting O
NF B
- I
kappaB I
translocation O
from O
the O
cytosol O
into O
the O
nucleus O
in O
MNC O
, O
in O
vivo O
. O

The O
total O
protein O
content O
of O
NF B
- I
kappaB I
subunit I
( O
P65 B
) O
in O
MNC O
lysates O
also O
showed O
a O
decrease O
following O
hydrocortisone O
injection O
. O

Our O
data O
demonstrate O
that O
hydrocortisone O
induces O
IkappaB B
and O
suppresses O
NF B
- I
kappaB I
expression O
in O
MNC O
in O
parallel O
. O

Proinflammatory B
cytokines I
such O
as O
IL B
- I
1beta I
and O
TNF B
- I
alpha I
were O
down O
- O
regulated O
by O
GC O
treatment O
. O

Continuous O
treatment O
of O
monocytes O
with O
IL B
- I
1beta I
, O
but O
not O
with O
TNF B
- I
alpha I
, O
could O
almost O
completely O
prevent O
GC O
- O
induced O
cell O
death O
. O

The O
addition O
of O
mifepristone O
or O
caspase O
- O
3 O
inhibitor O
could O
partially O
abrogate O
GC O
- O
induced O
apoptosis O
as O
well O
as O
GC O
- O
induced O
inhibition O
of O
IL B
- I
1beta I
. O

The O
inflammatory O
mediators O
lipopolysaccharide O
( O
LPS O
) O
and O
tumor B
necrosis I
factor I
( O
TNF B
) O
are O
potent O
activators O
of O
NF B
- I
kappaB I
. O

Kinase O
assays O
showed O
that O
TNF B
elicited O
a O
rapid O
but O
short O
- O
lived O
induction O
of O
IKK B
activity O
with O
a O
3 O
- O
fold O
greater O
effect O
on O
IKK B
- I
alpha I
than O
on O
IKK B
- I
beta I
, O
peaking O
at O
5 O
min O
. O

Furthermore O
, O
our O
studies O
showed O
association O
of O
the O
IKK O
- O
alpha O
/ O
beta O
heterodimer O
with O
NIK B
, O
IkappaB B
- I
alpha I
and O
- O
epsilon O
in O
unstimulated O
cells O
. O

The O
aim O
of O
this O
study O
was O
to O
examine O
the O
ability O
of O
tumor B
necrosis I
factor I
alpha I
( O
TNFalpha B
, O
a O
proinflammatory B
cytokine I
) O
and O
interleukin B
( I
IL I
) I
- I
10 I
( O
an O
anti O
- O
inflammatory O
cytokine O
) O
to O
differentially O
regulate O
the O
sensitivity O
of O
human O
monocytes O
/ O
macrophages O
to O
glucocorticoids O
. O

Finally O
, O
we O
investigated O
whether O
the O
modulation O
of O
corticosensitivity O
in O
TNFalpha O
- O
and O
IL O
- O
10 O
- O
pretreated O
U937 O
cells O
was O
related O
to O
a O
change O
of O
the O
glucocorticoid B
receptor I
concentration O
and O
affinity O
. O

TNFalpha B
decreased O
( O
P O
< O
0 O
. O
001 O
) O
, O
while O
IL B
- I
10 I
increased O
( O
P O
< O
0 O
. O
001 O
) O
, O
the O
concentration O
of O
dexamethasone O
binding O
sites O
in O
these O
cells O
, O
with O
no O
discernible O
effect O
on O
their O
binding O
affinity O
. O

We O
conclude O
that O
glucocorticoids O
differentially O
modulate O
TNFalpha B
and O
IL B
- I
10 I
secretion O
by O
human O
monocytes O
in O
a O
LPS O
dose O
- O
dependent O
fashion O
and O
that O
the O
sensitivity O
of O
these O
cells O
to O
glucocorticoids O
is O
altered O
by O
TNFalpha B
or O
IL B
- I
10 I
pretreatment O
; O
TNFalpha B
blocks O
their O
effects O
, O
whereas O
IL B
- I
10 I
acts O
synergistically O
with O
glucocorticoids O
. O

Because O
NF B
- I
kappa I
B I
contributes O
to O
the O
transcription O
of O
numerous O
inflammatory B
genes I
and O
has O
been O
shown O
to O
be O
a O
molecular O
target O
of O
antiinflammatory O
drugs O
, O
we O
sought O
to O
characterize O
the O
functional O
role O
of O
the O
NF O
- O
kappa O
B O
protein O
complex O
in O
lupus O
T O
cells O
. O

Also O
, O
NF B
- I
kappa I
B I
activity O
remained O
absent O
in O
follow O
- O
up O
studies O
. O

As O
p65 B
complexes I
are O
transcriptionally O
active O
in O
comparison O
to O
the O
p50 O
homodimer O
, O
this O
novel O
finding O
may O
provide O
insight O
on O
the O
origin O
of O
abnormal O
cytokine O
or O
other O
gene O
transcription O
in O
SLE O
patients O
. O

Here O
, O
we O
investigate O
further O
the O
events O
triggered O
by O
TLR2 B
in O
response O
to O
LPS O
. O

Intracellular O
deletion O
variants O
of O
TLR2 B
lacking O
C O
- O
terminal O
13 O
or O
141 O
aa O
fail O
to O
recruit O
IRAK B
, O
which O
is O
consistent O
with O
the O
inability O
of O
these O
mutants O
to O
transmit O
LPS O
cellular O
signaling O
. O

Here O
we O
provide O
novel O
evidence O
that O
AG O
- O
490 O
potently O
inhibits O
the O
autokinase O
activity O
of O
JAK3 B
and O
tyrosine O
phosphorylation O
and O
DNA O
binding O
of O
signal O
transducer O
and O
activator O
of O
transcription O
5a O
and O
5b O
( O
STAT5a O
/ O
b O
) O
. O

AG O
- O
490 O
also O
inhibited O
IL B
- I
2 I
- O
mediated O
proliferative O
growth O
in O
human O
T O
cells O
with O
an O
IC50 O
) O
= O
25 O
microM O
that O
was O
partially O
recoverable O
. O

Taken O
together O
, O
these O
findings O
suggest O
that O
AG O
- O
490 O
inhibits O
the O
JAK3 B
- O
mediated O
Type O
II O
signaling O
pathway O
but O
not O
the O
T O
cell O
receptor O
- O
derived O
Type O
I O
pathway O
and O
possesses O
therapeutic O
potential O
for O
T O
cell O
- O
derived O
pathologies O
such O
as O
graft O
- O
versus O
- O
host O
disease O
, O
allergy O
, O
and O
autoimmune O
disorders O
. O

Two O
- O
color O
immunohistochemistry O
demonstrated O
that O
both O
macrophages O
and O
fibroblast O
- O
like O
synoviocytes O
were O
positive O
for O
nuclear O
C B
/ I
EBP I
beta I
. O

PU B
. I
1 I
is O
a O
hematopoietic O
- O
specific O
Ets O
family O
transcription O
factor O
that O
is O
required O
for O
development O
of O
some O
lymphoid O
and O
myeloid O
lineages O
. O

We O
find O
that O
PU B
. I
1 I
interacts O
directly O
with O
GATA B
- I
1 I
, O
a O
zinc B
finger I
transcription I
factor I
required O
for O
erythroid O
differentiation O
. O

Both O
the O
DNA O
binding O
and O
transactivation B
domains I
of O
PU B
. I
1 I
are O
required O
for O
repression O
and O
both O
domains O
are O
also O
needed O
to O
block O
terminal O
differentiation O
in O
MEL O
cells O
. O

To O
better O
clarify O
the O
molecular O
basis O
of O
IL B
- I
12 I
action O
, O
we O
set O
out O
to O
characterize O
genes O
up O
- O
regulated O
by O
IL B
- I
12 I
, O
first O
by O
contrasting O
IL B
- I
12 I
- O
and O
IFN O
- O
alpha O
- O
inducible O
genes O
. O

We O
identified O
several O
genes O
up O
- O
regulated O
by O
IL B
- I
12 I
, O
namely O
, O
MIP B
- I
1alpha I
, O
MIP O
- O
1beta O
, O
IL B
- I
1RA I
, O
and O
IFN O
regulatory O
factor O
- O
1 O
( O
IRF O
- O
1 O
) O
. O

Therefore O
, O
IRF B
- I
1 I
may O
be O
an O
important O
contributor O
to O
IL B
- I
12 I
signaling O
, O
and O
we O
speculate O
that O
the O
defective O
IL B
- I
12 I
responses O
seen O
in O
IRF B
- O
1 O
- O
/ O
- O
mice O
might O
be O
attributable O
, O
in O
part O
, O
to O
the O
absence O
of O
this O
transcription B
factor I
. O

To O
determine O
whether O
it O
is O
possible O
to O
artificially O
enhance O
the O
opening O
of O
the O
chromatin O
structure O
of O
a O
minimal O
beta O
- O
globin O
promoter O
, O
we O
placed O
a O
101bp O
, O
erythroid O
- O
specific O
DNase O
1 O
hypersensitive O
site O
- O
forming O
element O
( O
HSFE B
) O
immediately O
upstream O
of O
the O
beta O
- O
globin O
promoter O
and O
gene O
. O

This O
remodeling O
of O
promoter O
chromatin O
structure O
resulted O
in O
3 O
- O
fold O
increases O
in O
beta B
- I
globin I
gene I
transcription O
and O
induction O
, O
and O
inhibited O
long O
- O
term O
beta B
- I
globin I
gene I
silencing O
. O

Regulation O
of O
low O
shear O
flow O
- O
induced O
HAEC O
VCAM B
- I
1 I
expression O
and O
monocyte O
adhesion O
. O

Here O
we O
investigate O
the O
hypothesis O
that O
low O
shear O
- O
induced O
activation O
of O
NF B
- I
kappaB I
is O
responsible O
for O
enhanced O
expression O
of O
vascular B
cell I
adhesion I
molecule I
( O
VCAM B
- I
1 I
) O
resulting O
in O
augmented O
endothelial O
cell O
- O
monocyte O
( O
EC O
- O
Mn O
) O
adhesion O
and O
that O
this O
activation O
is O
dependent O
on O
intracellular O
oxidant O
activity O
. O

These O
data O
suggest O
that O
NF B
- I
kappaB I
plays O
a O
key O
role O
in O
low O
shear O
- O
induced O
VCAM B
- I
1 I
expression O
and O
that O
pathways O
mediating O
low O
shear O
- O
and O
cytokine O
- O
induced O
EC O
- O
Mn O
adhesion O
may O
be O
differentially O
regulated O
. O

Nuclear O
factor O
- O
90 O
of O
activated O
T O
- O
cells O
: O
A O
double B
- I
stranded I
RNA I
- O
binding O
protein O
and O
substrate O
for O
the O
double B
- I
stranded I
RNA I
- I
dependent I
protein I
kinase I
, O
PKR B
. O

Using O
in O
vitro O
translated O
polypeptides O
, O
we O
have O
demonstrated O
that O
NF90 B
specifically O
binds O
to O
double B
- I
stranded I
RNA I
. O

C5a O
- O
induced O
reporter B
gene I
expression O
was O
abolished O
by O
introducing O
mutations O
into O
the O
kappaB B
sites I
and O
by O
coexpression O
of O
a O
dominant O
negative O
IkappaBalpha O
construct O
resistant O
to O
agonist O
- O
induced O
phosphorylation O
. O

Pertussis O
toxin O
, O
which O
ADP O
- O
ribosylates O
the O
Gi O
proteins O
known O
to O
couple O
to O
the O
C5a O
receptor O
, O
produced O
minimal O
inhibition O
of O
C5a O
- O
induced O
IL B
- I
8 I
expression O
and O
had O
little O
effect O
on O
C5a O
- O
induced O
calcium O
mobilization O
in O
RAW264 O
. O
7 O
cells O
. O

CD40 B
/ B
CD40 I
ligand O
interactions O
play O
a O
key O
role O
in O
the O
immune O
responses O
of O
B O
lymphocytes O
, O
monocytes O
, O
and O
dendritic O
cells O
. O

However O
, O
the O
components O
of O
the O
NF B
- I
kappaB I
complexes I
were O
different O
in O
monocytes O
and O
B O
cells O
, O
because O
p50 B
is O
part O
of O
the O
NF B
- I
kappaB I
complex I
induced O
by O
CD40 B
triggering O
in O
both O
monocytes O
and O
B O
cells O
, O
whereas O
p65 B
was O
only O
induced O
in O
B O
cells O
. O
In O
contrast O
, O
although O
the O
Janus O
kinase O
3 O
tyrosine O
kinase O
was O
associated O
with O
CD40 B
molecules O
in O
both O
monocytes O
and O
resting O
B O
cells O
, O
Janus B
kinase I
3 I
phosphorylation O
induction O
was O
observed O
only O
in O
CD40 O
- O
activated O
monocytes O
, O
with O
subsequent O
induction O
of O
STAT5a B
DNA O
binding O
activity O
in O
the O
nucleus O
. O

Interestingly O
, O
when O
we O
fused O
HT O
- O
2 O
cells O
expressing O
the O
EPOR B
with O
Ba O
/ O
F3 O
cells O
in O
a O
complementation O
assay O
, O
the O
resulting O
hybridomas O
proliferated O
and O
potently O
activated O
STAT B
- I
5 I
and O
MAPK B
in O
response O
to O
EPO B
. O

Moreover O
, O
Ba O
/ O
F3 O
cells O
apparently O
express O
this O
factor O
( O
s O
) O
and O
somatic O
fusions O
can O
, O
therefore O
, O
confer O
EPO B
- O
responsiveness O
to O
HT O
- O
2 O
cells O
that O
lack O
this O
factor O
. O

When O
a O
drug O
appears O
to O
be O
less O
effective O
than O
preclinical O
models O
suggest O
, O
can O
failures O
in O
effectiveness O
from O
delivery O
or O
dosing O
be O
differentiated O
? O
The O
disappointing O
results O
of O
clinical O
trials O
with O
IL B
- I
10 I
- O
- O
so O
at O
odds O
with O
the O
prediction O
of O
benefit O
from O
animal O
models O
- O
- O
bring O
into O
question O
the O
validity O
of O
those O
models O
as O
well O
as O
the O
soundness O
of O
design O
of O
the O
clinical O
trials O
on O
which O
efficacy O
of O
IL B
- I
10 I
is O
judged O
. O

Potent O
and O
stable O
attenuation O
of O
live O
- O
HIV O
- O
1 O
by O
gain O
of O
a O
proteolysis O
- O
resistant O
inhibitor O
of O
NF B
- I
kappaB I
( O
IkappaB B
- I
alphaS32 I
/ I
36A I
) O
and O
the O
implications O
for O
vaccine O
development O
. O

Multiple O
NF B
- I
ATc I
isoforms I
with O
individual O
transcriptional O
properties O
are O
synthesized O
in O
T O
lymphocytes O
. O

The O
transcription B
factor I
NF B
- I
ATc I
that O
controls O
gene O
expression O
in O
T O
lymphocytes O
and O
embryonic O
cardiac O
cells O
is O
expressed O
in O
three O
prominent O
isoforms O
. O

Various O
stimuli O
of O
T O
cells O
that O
induce O
the O
activity O
of O
TAD B
- I
A I
also O
enhance O
the O
activity O
of O
TAD B
- I
B I
, O
but O
, O
unlike O
TAD B
- I
A I
, O
TAD B
- I
B I
remains O
unphosphorylated O
by O
protein O
from O
12 O
- O
O O
- O
tetradecanoyl O
12 O
- O
phorbol O
13 O
- O
acetate O
- O
stimulated O
T O
cells O
. O

Selection O
and O
long O
- O
term O
persistence O
of O
reactive O
CTL O
clones O
during O
an O
EBV O
chronic O
response O
are O
determined O
by O
avidity O
, O
CD8 B
variable O
contribution O
compensating O
for O
differences O
in O
TCR B
affinities O
. O

We O
found O
a O
wide O
range O
of O
TCR B
affinities O
among O
the O
different O
clonotypes O
that O
segregated O
with O
Vbeta O
usage O
. O

Packaging O
of O
viral O
particles O
, O
integration O
into O
the O
target O
genome O
, O
and O
stability O
of O
the O
integrated O
provirus O
are O
not O
affected O
by O
the O
LTR B
modification O
. O

Regulation O
of O
Fas B
ligand I
expression O
and O
cell O
death O
by O
apoptosis O
- O
linked O
gene O
4 O
. O

These O
results O
indicate O
that O
ALG O
- O
4 O
is O
necessary O
and O
sufficient O
for O
FasL B
expression O
. O

We O
now O
find O
that O
LMP1 B
signaling O
through O
TRADD B
differs O
from O
TNFR1 B
signaling O
through O
TRADD B
. O

Inhibition O
of O
NF B
- I
kappa I
B I
resulted O
in O
the O
externalization O
of O
phosphatidylserine O
, O
induction O
of O
DNA O
breaks O
, O
and O
morphological O
changes O
consistent O
with O
apoptosis O
. O

Among O
upstream O
signaling O
molecules O
of O
ERK B
, O
Shc B
was O
constitutively O
associated O
with O
Grb2 O
and O
was O
not O
tyrosine O
- O
phosphorylated O
by O
GM B
- I
CSF I
and O
FMLP O
, O
and O
Sos1 B
and O
c B
- I
Raf I
- I
1 I
were O
not O
phosphorylated O
by O
GM B
- I
CSF I
, O
IL O
- O
3 O
, O
TNF O
, O
and O
FMLP O
in O
monocytes O
, O
whereas O
all O
these O
signaling O
molecules O
were O
affected O
and O
/ O
or O
utilized O
by O
GM B
- I
CSF I
in O
MO7e O
cells O
. O

In O
contrast O
to O
neutrophils O
, O
p38 B
was O
constitutively O
phosphorylated O
and O
agonist O
- O
dependent O
phosphorylation O
and O
activation O
was O
not O
detected O
in O
human O
monocytes O
. O

Functional O
analysis O
indicates O
that O
the O
BRs B
are O
involved O
in O
control O
of O
hIL B
- I
5 I
promoter I
activity O
. O

PNU156804 O
action O
is O
restricted O
to O
some O
signaling O
pathways O
; O
it O
does O
not O
affect O
NF B
- I
kappa I
B I
activation O
by O
PMA O
in O
T O
cells O
but O
blocks O
that O
induced O
by O
CD40 B
cross O
- O
linking O
in O
B O
lymphocytes O
. O

The O
expression O
of O
STAT1 B
and O
STAT5 B
in O
a O
human O
T O
- O
cell O
line O
was O
induced O
by O
Tax B
. O

Transcriptional O
control O
of O
the O
IL B
- I
5 I
gene O
by O
human O
helper O
T O
cells O
: O
IL B
- I
5 I
synthesis O
is O
regulated O
independently O
from O
IL B
- I
2 I
or O
IL B
- I
4 I
synthesis O
. O

METHODS O
: O
Allergen O
- O
specific O
T O
- O
cell O
clones O
and O
T O
- O
cell O
hybridomas O
were O
established O
from O
the O
peripheral O
blood O
lymphocytes O
of O
patients O
with O
asthma O
, O
and O
the O
transcriptional O
regulation O
of O
the O
IL B
- I
5 I
gene I
was O
investigated O
with O
transient O
transfection O
and O
electrophoretic O
mobility O
shift O
analysis O
. O

RESULTS O
: O
A O
human O
IL B
- I
5 I
promoter I
/ I
enhancer I
- I
luciferase I
gene I
construct I
, O
pIL O
- O
5 O
( O
- O
511 O
) O
Luc O
, O
was O
transcribed O
on O
activation O
of O
IL O
- O
5 O
- O
producing O
T O
- O
cell O
clones O
, O
but O
not O
IL O
- O
5 O
- O
nonproducing O
clones O
. O

CONCLUSION O
: O
IL B
- I
5 I
synthesis O
by O
human O
helper O
T O
cells O
is O
regulated O
at O
the O
transcriptional O
level O
. O

We O
used O
an O
adenoviral O
technique O
of O
blocking O
NF B
- I
kappaB I
through O
overexpression O
of O
the O
inhibitory B
subunit I
IkappaBalpha B
, O
which O
has O
the O
advantage O
that O
it O
can O
be O
used O
in O
the O
diseased O
tissue O
itself O
, O
with O
> O
90 O
% O
of O
the O
synovial O
macrophages O
, O
fibroblasts O
, O
and O
T O
cells O
infected O
. O

Of O
even O
more O
interest O
, O
IkappaBalpha B
overexpression O
inhibited O
the O
production O
of O
matrix O
metalloproteinases O
1 O
and O
3 O
while O
not O
affecting O
their O
tissue O
inhibitor O
. O

Clonality O
analysis O
utilizing O
X B
- I
chromosome I
inactivation O
has O
been O
used O
in O
the O
study O
of O
various O
diseases O
, O
including O
hematological O
malignancies O
. O

A O
high O
expression O
of O
WT1 B
has O
been O
detected O
in O
a O
range O
of O
acute O
leukemias O
, O
and O
WT1 B
is O
downregulated O
during O
induced O
differentiation O
of O
some O
leukemic O
cell O
lines O
. O

K562 O
cells O
express O
endogenous O
WT1 B
, O
which O
is O
downregulated O
as O
a O
response O
to O
induced O
differentiation O
along O
the O
erythroid O
and O
megakaryocytic O
pathways O
. O

However O
, O
activation O
of O
STAT6 B
, O
CD23 B
expression O
, O
and O
IgE B
synthesis O
induced O
by O
IL B
- I
4 I
were O
not O
affected O
in O
p47phox O
- O
deficient O
patients O
, O
which O
raises O
the O
possibility O
that O
p47phox O
may O
be O
important O
in O
other O
signaling O
activities O
as O
well O
in O
B O
cells O
. O

METHODS O
: O
Protein O
production O
in O
supernatants O
was O
assessed O
by O
ELISA O
, O
and O
mRNA B
expression O
was O
evaluated O
by O
semiquantitative O
RT O
- O
PCR O
. O

On O
the O
contrary O
, O
the O
release O
of O
MCP B
- I
1 I
was O
significantly O
inhibited O
, O
also O
in O
a O
dose O
- O
dependent O
manner O
. O

Messenger B
RNA I
production O
coding O
for O
IL B
- I
8 I
, O
RANTES B
, O
and O
MCP B
- I
1 I
showed O
parallel O
variations O
to O
the O
production O
of O
the O
correspondent O
proteins O
. O

Furthermore O
, O
SLP B
- I
76 I
and O
Vav B
have O
a O
synergistic O
effect O
on O
interleukin O
( O
IL O
) O
- O
2 O
promoter O
activity O
in O
T O
cells O
. O

Surprisingly O
, O
we O
find O
also O
that O
the O
interaction O
between O
SLP B
- I
76 I
and O
Vav B
is O
not O
required O
for O
their O
cooperation O
in O
augmenting O
IL B
- I
2 I
promoter I
activity O
, O
as O
the O
two O
molecules O
appear O
to O
function O
in O
different O
signaling O
pathways O
upstream O
of O
IL B
- I
2 I
gene I
expression O
. O

In O
contrast O
, O
overexpression O
of O
Vav B
leads O
to O
enhanced O
nuclear B
factor I
of I
activated I
T I
cells I
activity O
without O
affecting O
AP B
- I
1 I
. O

Additionally O
, O
overexpression O
of O
Vav B
, O
but O
not O
SLP B
- I
76 I
, O
augments O
CD28 O
- O
induced O
IL B
- I
2 I
promoter I
activity O
. O

Here O
, O
we O
show O
that O
Jagged1 B
is O
a O
Rel O
/ O
NF O
- O
kappaB O
- O
responsive O
gene O
. O

Our O
results O
demonstrated O
that O
: O
( O
i O
) O
PGN O
induced O
phosphorylation O
of O
the O
transcription B
factors I
ATF B
- I
1 I
and O
CREB B
; O
( O
ii O
) O
ATF B
- I
1 I
and O
CREB B
bound O
DNA O
as O
a O
dimer O
and O
induced O
transcriptional O
activation O
of O
a O
CRE O
reporter O
plasmid O
, O
which O
was O
inhibited O
by O
dominant O
negative O
CREB B
and O
ATF B
- I
1 I
; O
( O
iii O
) O
PGN O
induced O
phosphorylation O
of O
c B
- I
Jun I
, O
protein O
synthesis O
of O
JunB B
and O
c B
- I
Fos I
, O
and O
transcriptional O
activation O
of O
the O
AP O
- O
1 O
reporter O
plasmid O
, O
which O
was O

inhibited O
by O
dominant O
negative O
c B
- I
Fos I
; O
and O
( O
iv O
) O
PGN O
- O
induced O
activation O
of O
CREB B
/ I
ATF I
and O
AP B
- I
1 I
was O
mediated O
through O
CD14 B
. O

In O
contrast O
to O
these O
findings O
, O
mucosal O
hGR B
levels O
were O
significantly O
decreased O
in O
both O
steroid O
- O
treated O
( O
18 O
. O
0 O
+ O
/ O
- O
15 O
. O
5 O
) O
and O
not O
steroid O
- O
treated O
( O
37 O
. O
8 O
+ O
/ O
- O
30 O
. O
5 O
) O
patients O
compared O
with O
control O
subjects O
( O
125 O
. O
6 O
+ O
/ O
- O
97 O
. O
1 O
; O
P O
= O
0 O
. O
00009 O
and O
P O
= O
0 O
. O
0008 O
respectively O
) O
. O

In O
this O
study O
, O
we O
created O
transgenic O
mice O
overexpressing O
ICSAT B
in O
lymphocytes O
. O

Our O
findings O
offer O
important O
insights O
into O
parasite O
survival O
strategies O
and O
demonstrate O
that O
parasite O
- O
induced O
constitutive O
NF B
- I
kappaB I
activation O
is O
an O
essential O
step O
in O
maintaining O
the O
transformed O
phenotype O
of O
the O
infected O
cells O
. O

A O
polymorphism O
that O
affects O
OCT B
- I
1 I
binding O
to O
the O
TNF O
promoter O
region O
is O
associated O
with O
severe O
malaria O
[ O
see O
comments O
] O

The O
results O
show O
that O
the O
CYP1A1 B
mRNA I
level O
induced O
by O
UV O
in O
the O
presence O
of O
tryptophan O
was O
higher O
than O
that O
induced O
by O
UV O
alone O
in O
both O
HaCaT O
cells O
and O
lymphocytes O
after O
3 O
h O
of O
incubation O
post O
- O
UV O
irradiation O
. O

This O
shows O
that O
the O
induction O
of O
gene O
expression O
by O
FICZ O
and O
UV O
is O
Ah B
receptor I
dependent O
. O

Thus O
, O
the O
photoproducts O
of O
tryptophan O
are O
suggested O
to O
be O
mediators O
of O
light O
via O
binding O
to O
the O
Ah B
receptor I
and O
as O
such O
also O
could O
have O
a O
role O
in O
light O
- O
regulated O
biological O
rhythms O
. O

Repression O
by O
Ikaros B
and O
Aiolos B
is O
mediated O
through O
histone B
deacetylase I
complexes I
. O

To O
better O
understand O
signals O
controlling O
proliferation O
and O
viability O
, O
erythroid O
cells O
that O
resist O
apoptosis O
in O
the O
absence O
of O
EPO B
were O
subcloned O
and O
characterized O
( O
HCD57 O
- O
SREI O
cells O
) O
. O

Enforced O
expression O
of O
Id3 B
, O
which O
has O
the O
capacity O
to O
inhibit O
many O
basic B
helix I
- I
loop I
- I
helix I
( I
bHLH I
) I
transcription I
factors I
, O
in O
human O
CD34 O
( O
+ O
) O
hematopoietic O
progenitor O
cells O
that O
have O
not O
undergone O
T O
cell O
receptor O
( O
TCR O
) O
gene O
rearrangements O
inhibits O
development O
of O
the O
transduced O
cells O
into O
TCRalpha O
beta O
and O
gamma O
delta O
cells O
in O
a O
fetal O
thymic O
organ O
culture O
( O
FTOC O
) O
. O

HIV O
- O
1 O
reactivation O
in O
resting O
peripheral O
blood O
mononuclear O
cells O
of O
infected O
adults O
upon O
in O
vitro O
CD4 B
cross O
- O
linking O
by O
ligands O
of O
the O
CDR2 O
- O
loop O
in O
extracellular O
domain O
1 O
. O

Additionally O
, O
virus O
reactivation O
in O
resting O
PBMCs O
infected O
in O
vitro O
with O
HIV O
- O
1 O
was O
found O
to O
be O
specifically O
induced O
by O
ligands O
of O
the O
CDR2 O
- O
loop O
in O
domain O
1 O
( O
D1 O
) O
of O
CD4 B
( O
virus O
envelope O
and O
anti O
- O
CD4 O
monoclonal O
antibodies O
) O
. O

In O
contrast O
, O
virus O
reactivation O
was O
not O
observed O
following O
CD4 B
oligomerization O
by O
antibodies B
that O
bind O
other O
epitopes O
in O
D1 O
, O
including O
the O
D1 O
/ O
CDR3 O
- O
loop O
. O

Our O
results O
indicate O
that O
the O
signaling O
events O
initiated O
in O
PBMCs O
by O
oligomerization O
of O
CD4 B
at O
the O
D1 O
/ O
CDR2 O
- O
loop O
can O
trigger O
HIV O
- O
1 O
upregulation O
in O
infected O
individuals O
. O

Signaling O
through O
the O
lymphotoxin O
- O
beta O
receptor O
stimulates O
HIV O
- O
1 O
replication O
alone O
and O
in O
cooperation O
with O
soluble O
or O
membrane B
- I
bound I
TNF I
- I
alpha I
. O

Given O
the O
critical O
role O
that O
LT B
- I
alpha1beta2 I
plays O
in O
lymphoid O
architecture O
, O
we O
speculate O
that O
LT B
- I
alpha1beta2 I
may O
be O
involved O
in O
HIV O
- O
associated O
abnormalities O
of O
the O
lymphoid O
organs O
. O

The O
secretion O
levels O
of O
interleukin B
- I
6 I
( O
IL B
- I
6 I
) O
and O
von O
Willebrand O
factor O
( O
vWF O
) O
were O
determined O
, O
to O
serve O
as O
markers O
for O
EC O
activation O
. O

In O
addition O
, O
nuclear O
extracts O
of O
the O
mAECA O
- O
treated O
EC O
were O
analyzed O
for O
the O
induction O
of O
translocation O
of O
nuclear B
factor I
kappaB I
( O
NF B
- I
kappaB I
) O
, O
using O
a O
specific O
NF B
- I
kappaB I
oligoprobe O
in O
an O
electrophoretic O
mobility O
shift O
assay O
. O

The O
mAECA B
, O
but O
not O
normal O
human O
IgG O
, O
had O
anti O
- O
human O
aortic O
EC O
activity O
. O

Four O
of O
the O
6 O
mAECA B
activated O
EC O
, O
manifested O
by O
increased O
IL B
- I
6 I
and O
vWF O
secretion O
. O

Both O
PPARalpha B
activators O
decreased O
cytokine O
- O
induced O
VCAM B
- I
1 I
mRNA O
expression O
without O
altering O
its O
mRNA O
half O
- O
life O
. O

Such O
findings O
also O
have O
implications O
regarding O
the O
clinical O
use O
of O
lipid O
- O
lowering O
agents O
, O
like O
fibric O
acids O
, O
which O
can O
activate O
PPARalpha B
. O

CBP B
/ I
p300 I
integrates O
Raf B
/ O
Rac B
- O
signaling O
pathways O
in O
the O
transcriptional O
induction O
of O
NF B
- I
ATc I
during O
T O
cell O
activation O
. O

Inhibition O
of O
NF B
- I
kappaB I
has O
been O
achieved O
by O
pharmacological O
and O
genetic O
approaches O
; O
however O
, O
monocyte O
interactions O
with O
activated O
endothelium O
in O
shear O
flow O
following O
gene O
transfer O
of O
the O
NF B
- I
kappaB I
inhibitor O
IkappaB B
- I
alpha I
have O
not O
been O
studied O
. O

This O
was O
associated O
with O
a O
reduction O
in O
endothelial O
MCP B
- I
1 I
secretion O
and O
GRO B
- I
alpha I
immobilization O
. O

Adhesion O
assays O
under O
physiological O
shear O
flow O
conditions O
showed O
that O
firm O
arrest O
, O
spreading O
, O
and O
transmigration O
of O
monocytes O
on O
TNF B
- I
alpha I
- O
activated O
endothelium O
was O
markedly O
inhibited O
by O
IkappaB B
- I
alpha I
overexpression O
. O

In O
contrast O
, O
rolling O
of O
monocytes O
was O
increased O
by O
IkappaB B
- I
alpha I
transfer O
and O
was O
partly O
mediated O
by O
P B
- I
selectin I
; O
however O
, O
it O
appeared O
to O
be O
unaffected O
by O
the O
inhibition O
of O
E B
- I
selectin I
induction O
. O

The O
effect O
of O
oestrogens O
on O
oestrogen O
- O
receptive O
organs O
and O
cells O
is O
mediated O
via O
intracellular B
receptors I
( O
ERalpha O
and O
ERbeta B
) O
. O

USF B
/ I
c I
- I
Myc I
enhances O
, O
while O
Yin B
- I
Yang I
1 I
suppresses O
, O
the O
promoter O
activity O
of O
CXCR4 B
, O
a O
coreceptor O
for O
HIV O
- O
1 O
entry O
. O

We O
have O
identified O
an O
E B
box I
around O
- O
260 O
and O
a O
YY1 B
binding I
site I
around O
- O
300 O
relative O
to O
the O
transcription B
start I
site I
. O

RCC O
- O
S O
did O
not O
alter O
the O
cytoplasmic O
levels O
of O
RelA B
and O
NF O
- O
kappaB1 O
but O
did O
suppress O
their O
nuclear O
localization O
and O
inhibited O
the O
activation O
of O
RelA O
/ O
NF O
- O
kappaB1 O
binding O
complexes O
. O

These O
results O
show O
that O
RCC O
- O
S O
can O
induce O
in O
normal O
T O
cells O
the O
same O
phenotype O
of O
impaired O
NF B
- I
kappaB I
activation O
that O
is O
detected O
in O
T O
cells O
of O
RCC O
patient O
. O

We O
investigated O
the O
involvement O
of O
signal B
transducers I
and I
activators I
of I
transcription I
( I
STAT I
) I
factors I
in O
this O
phenomenon O
and O
reported O
the O
specific O
, O
time O
- O
dependent O
, O
activation O
of O
STAT1 B
protein O
starting O
at O
day O
0 O
/ O
1 O
of O
cultivation O
and O
maximally O
expressed O
at O
day O
5 O
. O

STAT1 B
activity O
was O
evident O
on O
the O
STAT O
binding O
sequences O
( O
SBE O
) O
present O
in O
the O
promoters B
of O
genes O
which O
are O
up O
- O
regulated O
during O
monocyte O
to O
macrophage O
maturation O
such O
as O
FcgammaRI B
and O
ICAM B
- I
1 I
, O
and O
in O
the O
promoter O
of O
the O
transcription O
factor O
IFN O
regulatory O
factor O
- O
1 O
. O

Compared O
with O
monocytes O
adherent O
on O
plastic O
surfaces O
, O
freshly O
isolated O
cells O
allowed O
to O
adhere O
either O
to O
fibronectin O
- O
or O
laminin O
- O
coated O
flasks O
exhibited O
an O
increased O
STAT1 B
binding O
activity O
both O
in O
control O
and O
in O
IFN O
- O
gamma O
- O
treated O
cells O
. O

Thereafter O
, O
PML B
is O
downmodulated O
in O
late O
granulocytic O
maturation O
, O
whereas O
it O
is O
sustainably O
expressed O
through O
the O
erythroid O
pathway O
. O

Furthermore O
, O
PML B
and O
pRb B
105 I
were O
co O
- O
immunoprecipitated O
in O
cellular O
lysates O
derived O
from O
erythroid O
precursors O
indicating O
that O
this O
functional O
interaction O
may O
have O
a O
biochemical O
basis O
. O

These O
data O
suggest O
that O
the O
physiological O
relationship O
between O
binding O
and O
function O
of O
the O
glucocorticoid B
receptor I
is O
disturbed O
in O
MS O
. O

Treatment O
of O
cells O
with O
PD98059 O
, O
a O
specific O
inhibitor O
of O
mitogen B
- I
activated I
protein I
kinase I
kinase I
( O
MEK B
) O
, O
inhibited O
TPA O
- O
induced O
ERK2 B
activity O
. O

RESULTS O
: O
The O
number O
of O
glucocorticoid B
receptors I
on O
mononuclear O
leukocytes O
( O
MNL O
) O
was O
comparable O
in O
patients O
with O
anorexia O
nervosa O
, O
patients O
with O
active O
Cushing O
' O
s O
disease O
, O
and O
normal O
subjects O
( O
binding O
capacity O
3 O
. O
3 O
+ O
/ O
- O
0 O
. O
23 O
vs O
. O
3 O
. O
7 O
+ O
/ O
- O
0 O
. O
30 O
and O
3 O
. O
5 O
+ O
/ O
- O
0 O
. O
20 O
fmol O
/ O
10 O
( O
6 O
) O
cells O
) O
. O

Different O
sequence O
requirements O
for O
expression O
in O
erythroid O
and O
megakaryocytic O
cells O
within O
a O
regulatory B
element I
upstream O
of O
the O
GATA B
- I
1 I
gene I
. O

We O
have O
localized O
a O
317 O
base O
pair O
cis O
- O
acting O
regulatory O
element O
, O
HS B
I I
, O
associated O
with O
a O
hematopoietic O
- O
specific O
DNase O
I O
hypersensitive O
site O
, O
which O
lies O
approx O
. O

This O
core O
contains O
a O
GATA B
site I
separated O
by O
10 O
base O
pairs O
from O
an O
E B
- I
box I
motif I
. O

In O
addition O
, O
sodium O
salicylate O
and O
additional O
NSAIDs O
used O
at O
concentrations O
that O
activate O
HSF1 B
also O
inhibited O
the O
expression O
of O
other O
monocytic O
genes O
( O
TNF B
- I
alpha I
, O
IL B
- I
1beta I
, O
IL B
- I
6 I
, O
IL B
- I
8 I
, O
IL B
- I
10 I
, O
ICAM B
- I
1 I
) O
activated O
by O
exposure O
to O
a O
pro O
- O
inflammatory O
stimulus O
( O
lipopolysaccharide O
, O
LPS O
) O
. O

FGF B
- I
1 I
is O
abundantly O
expressed O
in O
the O
synovium O
in O
rheumatoid O
arthritis O
and O
in O
rejecting O
allografts O
, O
sites O
of O
chronic O
immune O
- O
mediated O
inflammation O
. O

In O
this O
paper O
, O
we O
show O
that O
HCMV O
down O
regulates O
gamma O
interferon O
( O
IFN B
- I
gamma I
) O
- O
induced O
HLA B
- I
DR I
expression O
in O
U373 O
MG O
astrocytoma O
cells O
due O
to O
a O
defect O
downstream O
of O
STAT1 B
phosphorylation O
and O
nuclear O
translocation O
. O

Inhibition O
of O
NF B
- I
kappaB I
transcriptional O
activity O
and O
promotion O
of O
IkappaBalpha B
degradation O
. O

DZA O
inhibits O
the O
transcriptional O
activity O
of O
NF B
- I
kappaB I
through O
the O
hindrance O
of O
p65 B
( O
Rel B
- I
A I
) O
phosphorylation O
without O
reduction O
of O
its O
nuclear O
translocation O
and O
DNA O
binding O
activity O
. O

The O
inhibitory O
effect O
of O
DZA O
on O
NF B
- I
kappaB I
transcriptional O
activity O
is O
potentiated O
by O
the O
addition O
of O
homocysteine O
. O

Decidual O
gammadelta O
T O
cells O
, O
which O
significantly O
increase O
in O
number O
during O
pregnancy O
, O
might O
play O
a O
role O
in O
recognition O
of O
fetal B
antigens I
and O
also O
in O
determining O
the O
quality O
of O
the O
response O
to O
these O
antigens B
. O

Here O
, O
we O
investigate O
the O
role O
of O
Rho B
in O
regulating O
the O
distribution O
of O
the O
monocyte B
- I
binding I
receptors I
E B
- I
selectin I
, O
ICAM B
- I
1 I
, O
and O
VCAM B
- I
1 I
in O
human O
endothelial O
cells O
. O

C3 O
transferase O
and O
cytochalasin O
D O
did O
not O
alter O
the O
expression O
levels O
of O
monocyte B
- I
binding I
receptors I
on O
endothelial O
cells O
, O
but O
did O
inhibit O
clustering O
of O
E B
- I
selectin I
, O
ICAM B
- I
1 I
, O
and O
VCAM B
- I
1 I
on O
the O
cell O
surface O
induced O
by O
monocyte O
adhesion O
or O
cross O
- O
linking O
antibodies O
. O

Similarly O
, O
N19RhoA B
inhibited O
receptor O
clustering O
. O

CD28 B
costimulation O
augments O
IL B
- I
2 I
secretion O
of O
activated O
lamina O
propria O
T O
cells O
by O
increasing O
mRNA O
stability O
without O
enhancing O
IL B
- I
2 I
gene O
transactivation O
. O

Previous O
studies O
have O
characterized O
the O
CD28 B
augmentation O
of O
TCR B
- O
mediated O
signaling O
in O
peripheral O
blood O
T O
cells O
through O
transcriptional O
activation O
of O
an O
IL B
- I
2 I
promoter O
CD28 B
response I
element I
( O
CD28RE B
) O
, O
along O
with O
enhanced O
mRNA O
stability O
. O

LPMC O
exhibited O
increased O
IL B
- I
2 I
production O
in O
response O
to O
CD28 B
costimulation O
, O
compared O
with O
cells O
activated O
through O
CD2 B
alone O
. O

In O
conclusion O
, O
production O
of O
a O
Th1 O
cytokine O
, O
IFN B
- I
gamma I
, O
by O
HBsAg B
- O
reactive O
cells O
was O
associated O
with O
hepatocyte O
damage O
in O
chronic O
hepatitis O
B O
, O
while O
no O
counteracting O
effect O
of O
Th2 B
cytokines I
produced O
by O
those O
cells O
was O
observed O
. O

Caspase B
- I
3 I
activation O
, O
usually O
resulting O
from O
delta O
psi O
( O
m O
) O
collapse O
, O
was O
not O
always O
associated O
with O
As2O3 O
- O
induced O
apoptosis O
. O

As2O3 O
induced O
PML O
( O
promyelocytic O
leukemia O
) O
protein O
degradation O
but O
did O
not O
modulate O
expression O
of O
cell O
cycle O
- O
related O
proteins O
, O
including O
c B
- I
myc I
, O
retinoblastoma B
protein I
, O
cyclin O
- O
dependent O
kinase O
4 O
, O
cyclin O
D1 O
, O
and O
p53 B
, O
or O
expression O
of O
differentiation O
- O
related O
antigens O
. O

A20 O
can O
be O
regulated O
by O
the O
NF B
- I
kappaB I
transcription B
factor I
, O
which O
is O
known O
to O
be O
activated O
by O
the O
EBV O
LMP O
- O
1 O
protein O
. O

CTLA B
- I
4 I
ligation O
inhibited O
CD3 O
/ O
CD28 B
- O
induced O
IL B
- I
2 I
mRNA I
accumulation O
by O
inhibiting O
IL B
- I
2 I
transcription O
, O
which O
appears O
to O
be O
mediated O
in O
part O
through O
decreasing O
NF B
- I
AT I
accumulation O
in O
the O
nuclei O
. O

Further O
, O
CTLA B
- I
4 I
engagement O
inhibited O
progression O
through O
the O
cell O
cycle O
by O
inhibiting O
the O
production O
of O
cyclin B
D3 I
, O
cyclin O
- O
dependent O
kinase O
( O
cdk O
) O
4 O
, O
and O
cdk6 O
when O
the O
T O
cells O
were O
stimulated O
with O
anti O
- O
CD3 O
/ O
CD28 O
and O
with O
anti B
- I
CD3 I
alone O
. O

Dexamethasone O
( O
Dex O
) O
, O
a O
synthetic O
glucocorticoid O
hormone O
, O
cooperated O
with O
Epo B
and O
stem B
cell I
factor I
to O
induce O
erythroid O
progenitors O
to O
undergo O
15 O
to O
22 O
cell O
divisions O
, O
corresponding O
to O
a O
10 O
( O
5 O
) O
- O
to O
10 O
( O
6 O
) O
- O
fold O
amplification O
of O
erythroid O
cells O
. O

We O
conclude O
that O
NF B
- I
kappaB I
is O
a O
context O
- O
dependent O
apoptosis O
regulator O
. O

SOCS B
- I
3 I
protein O
was O
detectable O
as O
early O
as O
30 O
min O
following O
IL B
- I
2 I
stimulation O
, O
while O
CIS B
was O
seen O
only O
at O
low O
levels O
after O
2 O
h O
. O

Tyrosine O
phosphorylation O
of O
SOCS B
- I
3 I
was O
observed O
upon O
coexpression O
with O
Jak1 B
and O
Jak2 B
but O
only O
weakly O
with O
Jak3 B
. O

Finally O
, O
proliferation O
induced O
by O
both O
IL B
- I
2 I
- O
and O
IL B
- I
3 I
was O
significantly O
inhibited O
in O
the O
presence O
of O
SOCS B
- I
3 I
. O

There O
was O
, O
however O
, O
a O
significant O
difference O
in O
the O
amounts O
of O
the O
nuclear B
protein I
, O
REF B
- I
1 I
( O
which O
regulates O
AP B
- I
1 I
DNA O
binding O
by O
altering O
the O
redox O
status O
of O
FOS B
and O
JUN B
proteins I
) O
, O
in O
alveolar O
macrophages O
compared O
with O
monocytes O
. O

Finally O
, O
addition O
of O
REF B
- I
1 I
from O
activated O
monocytes O
to O
alveolar O
macrophage O
nuclear O
proteins O
resulted O
in O
a O
marked O
increase O
in O
AP B
- I
1 I
DNA O
binding O
. O

The O
costimulatory O
molecule O
CD28 B
has O
a O
restricted O
tissue O
distribution O
and O
is O
expressed O
on O
T O
cells O
and O
some O
plasmacytoma O
cells O
. O

In O
vivo O
, O
CD8 O
+ O
T O
cells O
and O
, O
less O
frequently O
, O
CD4 O
+ O
T O
cells O
may O
completely O
lose O
CD28 B
surface O
expression O
during O
chronic O
infections O
and O
with O
aging O
. O

A O
role O
for O
RanBP1 B
in O
the O
release O
of O
CRM1 B
from O
the O
nuclear B
pore I
complex I
in O
a O
terminal O
step O
of O
nuclear O
export O
. O

It O
also O
stimulates O
nuclear O
export O
in O
cells O
that O
have O
not O
been O
preincubated O
with O
RanQ69L B
. O

In O
a O
model O
where O
foreign O
cells O
( O
rat O
fibroblasts O
) O
were O
cocultured O
with O
human O
IL O
- O
2 O
activated O
NK O
cells O
, O
we O
observed O
that O
NK O
cells O
were O
capable O
of O
efficiently O
killing O
their O
targets O
only O
if O
the O
cells O
overexpressed O
the O
oncogene O
c B
- I
Myc I
or O
E1A B
. O

These O
results O
provided O
evidence O
that O
c B
- I
Myc I
and O
E1A B
activated O
the O
NK O
cell O
induced O
cytolysis O
at O
a O
post O
- O
triggering O
stage O
of O
NK O
cell O
- O
target O
cell O
interaction O
. O

In O
the O
culture O
system O
reported O
here O
, O
( O
1 O
) O
the O
growth B
factor I
( O
GF O
) O
stimulus O
induces O
cord O
blood O
( O
CB O
) O
progenitor O
cells O
to O
proliferate O
and O
differentiate O
/ O
mature O
exclusively O
along O
the O
erythroid O
lineage O
; O
( O
2 O
) O
this O
erythropoietic O
wave O
is O
characterized O
by O
less O
than O
4 O
% O
apoptotic O
cells O
; O
( O
3 O
) O
asymmetric O
divisions O
are O
virtually O
absent O
, O
ie O
, O
nonresponsive O
hematopoietic O
progenitors O
with O
no O
erythropoietic O
potential O
are O
forced O
into O
apoptosis O
; O
( O
4 O
) O
the O
system O
is O
cell O
division O
controlled O
( O
cdc O

Single O
- O
cell O
reverse B
transcriptase I
- O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
analysis O
was O
applied O
to O
this O
culture O
system O
to O
investigate O
gene O
expression O
of O
diverse O
receptors B
, O
markers O
of O
differentiation O
, O
and O
transcription B
factors I
( O
EKLF B
, O
GATA B
- I
1 I
, O
GATA B
- I
2 I
, O
p45 B
NF I
- I
E2 I
, O
PU B
. I
1 I
, O
and O
SCL B
/ I
Tal1 I
) O
at O
discrete O
stages O
of O
erythropoietic O
development O
. O

However O
, O
stimulation O
with O
IL B
- I
2 I
resulted O
in O
Jak3 B
and O
STAT5 B
phosphorylation O
in O
both O
leukemic O
ATLL O
cells O
and O
IL O
- O
2 O
- O
dependent O
lines O
. O

A O
skewed O
XCI O
pattern O
with O
greater O
than O
75 O
% O
amplification O
of O
1 O
allele B
( O
allele B
ratio O
> O
3 O
: O
1 O
) O
was O
found O
in O
22 O
( O
9 O
. O
1 O
% O
) O
of O
242 O
control O
subjects O
. O

Here O
we O
report O
that O
in O
erythroid O
cells O
, O
GATA B
- I
1 I
strongly O
induces O
the O
expression O
of O
the O
anti O
- O
apoptotic O
protein O
bcl B
- I
xL I
, O
but O
not O
the O
related O
proteins O
bcl B
- I
2 I
and O
mcl O
- O
1 O
. O

In O
T O
lymphocytes O
, O
the O
hematopoietic O
cytokine O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
uses O
phosphatidylinositol B
3 I
- I
kinase I
( O
PI B
3 I
- I
kinase I
) O
- O
induced O
signaling O
pathways O
to O
regulate O
E2F B
transcriptional O
activity O
, O
a O
critical O
cell O
cycle O
checkpoint O
. O

PI B
3 I
- I
kinase I
also O
regulates O
the O
activity O
of O
p70 B
( I
s6k I
) I
, O
the O
40S O
ribosomal O
protein O
S6 O
kinase O
, O
a O
response O
that O
is O
abrogated O
by O
the O
macrolide O
rapamycin O
. O

Moreover O
, O
the O
effects O
of O
rapamycin O
on O
, O
and O
the O
role O
of O
p70 B
( I
s6k I
) I
in O
, O
IL B
- I
2 I
and O
PI B
3 I
- I
kinase I
activation O
of O
E2Fs O
have O
not O
been O
characterized O
. O

Our O
present O
results O
show O
that O
IL B
- I
2 I
- O
and O
PI B
3 I
- I
kinase I
- O
induced O
pathways O
for O
the O
regulation O
of O
E2F B
transcriptional O
activity O
include O
both O
rapamycin O
- O
resistant O
and O
rapamycin O
- O
sensitive O
components O
. O

Thus O
, O
the O
rapamycin O
- O
controlled O
processes O
involved O
in O
E2F B
regulation O
appear O
to O
be O
mediated O
by O
p70 B
( I
s6k I
) I
. O

These O
include O
the O
Ikaros B
, O
LKLF O
, O
and O
GATA3 O
zinc O
- O
finger O
proteins O
; O
the O
Ets B
, O
CREB B
/ I
ATF I
, O
and O
NF O
- O
kappa O
B O
/ O
Rel O
/ O
NFAT O
transcription O
factors O
; O
the O
Stat B
proteins I
; O
and O
HMG O
box O
transcription O
factors O
such O
as O
LEF1 B
, O
TCF1 O
, O
and O
Sox4 O
. O

Paradoxical O
priming O
effects O
of O
IL B
- I
10 I
on O
cytokine B
production O
. O

Interestingly O
, O
an O
enhanced O
frequency O
of O
CD16 B
and O
CD68 O
( O
+ O
) O
cells O
among O
the O
CD14 O
( O
+ O
) O
cells O
was O
observed O
in O
the O
presence O
of O
IL B
- I
10 I
, O
independently O
of O
the O
pre O
- O
culture O
conditions O
of O
the O
PBMC O
. O

Transcription B
factors I
Sp1 B
and O
AP B
- I
2 I
mediate O
induction O
of O
acid B
sphingomyelinase I
during O
monocytic O
differentiation O
. O

A O
PMA B
responsive I
element I
was O
localized O
to O
a O
region O
between O
- O
319 O
and O
- O
219 O
bp O
upstream O
of O
the O
initiation O
codon O
and O
co O
- O
transfections O
with O
transcription O
factor O
expression O
plasmids O
for O
AP B
- I
2 I
and O
Sp1 B
resulted O
in O
augmented O
ASM O
promoter O
activity O
, O
which O
was O
abolished O
when O
the O
binding B
sites I
for O
these O
two O
factors O
were O
deleted O
. O

NF B
- I
kappaB I
DNA O
binding O
was O
evaluated O
by O
electrophoretic O
mobility O
shift O
assay O
. O

Direct O
activation O
of O
PKC B
with O
PMA O
induced O
both O
NF B
- I
kappaB I
activation O
and O
TNF B
- I
alpha I
production O
by O
human O
monocytes O
. O

Furthermore O
, O
our O
results O
provide O
evidence O
that O
PTK B
plays O
a O
role O
in O
LPS O
- O
induced O
NF B
- I
kappaB I
activation O
and O
TNF B
- I
alpha I
release O
in O
human O
monocytes O
and O
thus O
could O
be O
a O
potential O
therapeutic O
target O
in O
inflammatory O
states O
. O

The O
effects O
of O
GDSP O
on O
pancreatic O
weight O
, O
serum O
amylase O
and O
lipase O
, O
morphologic O
changes O
in O
the O
pancreas O
, O
neutrophil O
infiltration O
, O
and O
nuclear O
factor O
KB O
( O
NF B
- I
KB I
) O
activation O
were O
measured O
in O
rats O
infused O
with O
supramaximal O
dose O
of O
cerulein O
( O
5 O
( O
g O
/ O
kg O
/ O
h O
) O
for O
6 O
h O
. O

The O
nature O
of O
the O
nuclear B
factor I
( O
s O
) O
that O
control O
TNF B
- I
alpha I
gene O
transcription O
in O
humans O
remains O
obscure O
, O
although O
NF B
- I
kappaB I
has O
been O
suggested O
. O

Our O
previous O
studies O
pertaining O
to O
macrophage O
response O
to O
LPS O
identified O
a O
novel O
DNA B
- I
binding I
domain I
located O
from O
- O
550 O
to O
- O
487 O
in O
the O
human B
TNF I
- I
alpha I
promoter I
that O
contains O
transcriptional O
activity O
, O
but O
lacks O
any O
known O
NF B
- I
kappaB I
- B
binding I
sites I
. O

Inhibition O
of O
LITAF O
mRNA O
expression O
in O
THP O
- O
1 O
cells O
resulted O
in O
a O
reduction O
of O
TNF B
- I
alpha I
transcripts O
. O

Characterization O
of O
expression O
of O
the O
gene O
for O
human O
pterin O
carbinolamine O
dehydratase O
/ O
dimerization O
cofactor O
of O
HNF1 B
. O

In O
the O
nucleus O
, O
it O
functions O
as O
a O
dimerization O
cofactor O
of O
HNF1 B
and O
increases O
the O
transcriptional O
activity O
of O
HNF1 B
. O

Transfection O
of O
Jurkat O
cells O
with O
the O
NF B
- I
kappaB I
subunits I
p50 B
and O
p65 B
confers O
resistance O
against O
Fas O
- O
mediated O
apoptosis O
. O

Capacitance O
would O
simply O
involve O
expression O
of O
IL O
- O
12R O
beta O
1 O
and O
beta O
2 O
subunits O
, O
regulated O
by O
TCR O
, O
IL B
- I
4 I
and O
IFNs B
. O

The O
activation O
of O
STAT3 B
was O
not O
found O
in O
human O
eosinophils O
, O
monocytes O
, O
and O
HL O
- O
60 O
cells O
, O
although O
the O
STAT3 O
protein O
was O
expressed O
in O
these O
cells O
. O

The O
transcription B
factor I
NF B
- I
ATc I
is O
synthesized O
in O
three O
prominent O
isoforms B
. O

Together O
, O
these O
results O
demonstrate O
that O
ER B
and O
PR B
can O
be O
activated O
by O
endogenous O
or O
exogenous O
ligands O
to O
induce O
a O
genetic O
response O
that O
impairs O
TNF B
- I
alpha I
- O
induced O
apoptosis O
in O
U937 O
cells O
. O

Inhibition O
of O
T O
cell O
signaling O
by O
mitogen O
- O
activated O
protein O
kinase O
- O
targeted O
hematopoietic O
tyrosine O
phosphatase O
( O
HePTP B
) O
. O

Activation O
of O
T O
lymphocytes O
to O
produce O
cytokines B
is O
regulated O
by O
the O
counterbalance O
of O
protein B
- I
tyrosine I
kinases I
and O
protein O
- O
tyrosine O
phosphatases O
, O
many O
of O
which O
have O
a O
high O
degree O
of O
substrate O
specificity O
because O
of O
physical O
association O
with O
their O
targets O
. O

In O
contrast O
, O
HePTP B
had O
no O
effects O
on O
N O
- O
terminal O
c O
- O
Jun O
kinase O
or O
on O
events O
upstream O
of O
the O
MAP O
kinases O
. O

However O
, O
p38 B
MAPK I
is O
activated O
strongly O
and O
synergistically O
by O
either O
CD3 B
/ I
CD28 I
coligation O
or O
PMA O
/ O
Ca2 O
+ O
ionophore O
stimulation O
, O
which O
mimics O
TCR B
- O
CD3 B
/ I
CD28 I
- O
mediated O
signaling O
. O

We O
have O
compared O
the O
effects O
of O
Epo B
and O
the O
chemical O
inducers O
, O
delta O
- O
aminolaevulinic O
acid O
( O
delta O
- O
ALA O
) O
and O
haemin O
on O
the O
differentiation O
capacity O
of O
UT O
- O
7 O
cells O
. O

Epo B
alone O
promoted O
relatively O
early O
events O
in O
erythroid O
maturation O
, O
without O
significant O
changes O
in O
haemoglobin O
production O
or O
morphology O
. O

Epo B
caused O
an O
increase O
in O
the O
proportion O
of O
cells O
expressing O
cell O
surface O
glycophorin O
A O
( O
GPA B
) O
and O
up O
- O
regulated O
beta O
- O
and O
gamma O
- O
globin O
by O
several O
fold O
. O

These O
data O
suggest O
that O
, O
in O
this O
inflammatory O
model O
, O
initial O
activation O
of O
NF B
- I
kappaB I
occurs O
in O
alveolar O
macrophages O
and O
the O
ensuing O
production O
of O
TNF B
- I
alpha I
may O
propagate O
NF B
- I
kappaB I
activation O
to O
other O
cell O
types O
in O
the O
lung O
. O

Interferon B
- I
beta I
mediates O
stromal O
cell O
rescue O
of O
T O
cells O
from O
apoptosis O
. O

Interferon O
- O
alpha O
and O
- O
beta O
promote O
the O
reversion O
of O
blast O
Tcells O
to O
a O
resting O
G0 O
/ O
G1 O
configuration O
with O
all O
the O
characteristic O
features O
of O
stromal O
cell O
rescue O
; O
such O
as O
high O
Bcl B
- I
XL I
expression O
and O
low O
Bcl B
- I
2 I
. O

We O
also O
show O
that O
DFX O
treatment O
limits O
the O
in O
vivo O
activation O
of O
NF B
- I
kappaB I
, O
a O
transcription B
factor I
involved O
in O
both O
TNF B
- I
alpha I
gene O
transcription O
and O
TNF B
- I
alpha I
signalling O
( O
P O
< O
0 O
. O
005 O
) O
. O

These O
data O
indicated O
that O
two O
NF B
- I
kappaB I
- I
binding I
sites I
, O
which O
are O
located O
between O
- O
3134 O
and O
- O
3059 O
, O
are O
critical O
for O
the O
activation O
of O
proIL O
- O
1beta O
gene O
transcription O
. O

N O
- O
acetyl O
- O
L O
- O
cysteine O
inhibits O
primary O
human O
T O
cell O
responses O
at O
the O
dendritic O
cell O
level O
: O
association O
with O
NF B
- I
kappaB I
inhibition O
. O

Gel O
supershift O
assays O
demonstrated O
that O
thrombin B
induced O
binding O
of O
NF O
- O
kappa O
Bp65 O
( O
Rel B
A I
) O
to O
downstream O
NF B
- I
kappa I
B I
site I
of O
the O
ICAM B
- I
1 I
promoter I
. O

Thrombin B
receptor O
activation O
peptide O
, O
a O
14 O
- O
amino O
- O
acid O
peptide O
representing O
the O
new O
NH2 O
terminus O
of O
proteolytically O
activated O
receptor O
- O
1 O
, O
mimicked O
thrombin B
' O
s O
action O
in O
inducing O
ICAM B
- I
1 I
expression O
. O

These O
data O
indicate O
that O
thrombin B
activates O
endothelial O
ICAM B
- I
1 I
expression O
and O
polymorphonuclear O
leukocyte O
adhesion O
by O
NF O
- O
kappa O
Bp65 O
binding O
to O
the O
downstream O
NF B
- I
kappa I
B I
site I
of O
ICAM B
- I
1 I
promoter I
after O
proteolytically O
activated O
receptor O
- O
1 O
activation O
. O

Here O
we O
demonstrate O
that O
both O
Smad6 B
and O
Smad7 B
are O
human O
bone O
morphogenetic O
protein O
- O
2 O
( O
hBMP B
- I
2 I
) O
- O
inducible O
antagonists O
of O
hBMP B
- I
2 I
- O
induced O
growth O
arrest O
and O
apoptosis O
in O
mouse O
B O
cell O
hybridoma O
HS O
- O
72 O
cells O
. O

RA O
previously O
was O
found O
to O
inhibit O
granulocyte B
colony I
- I
stimulating I
factor I
- O
- O
and O
not O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
- O
- O
stimulated O
proliferation O
of O
CD34 O
+ O
cells O
. O

Interestingly O
, O
CyA O
and O
indomethacin O
did O
not O
suppress O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
- O
induced O
adhesion O
molecule O
expression O
on O
HUVECs O
, O
whereas O
aspirin O
had O
an O
inhibitory O
effect O
. O

CONCLUSION O
: O
Our O
results O
show O
that O
the O
tested O
agents O
( O
except O
indomethacin O
) O
are O
inhibitors O
of O
the O
T O
cell O
- O
mediated O
immune O
response O
, O
as O
expected O
, O
that O
aspirin O
is O
an O
effective O
suppressor O
of O
adhesion B
molecule I
expression O
, O
and O
that O
all O
three O
agents O
can O
induce O
Hsp60 B
in O
HUVECs O
. O

However O
, O
we O
detected O
a O
significant O
reduction O
of O
the O
GR B
mRNA I
levels O
in O
the O
endobronchial O
biopsy O
specimens O
after O
FP O
treatment O
( O
36 O
. O
6 O
+ O
/ O
- O
23 O
. O
1 O
and O
25 O
. O
0 O
+ O
/ O
- O
10 O
. O
9 O
amol O
GR B
mRNA I
/ O
microg O
RNA O
, O
respectively O
; O
P O
< O
. O
01 O
) O
. O

In O
the O
peripheral O
blood O
lymphocytes O
an O
even O
more O
striking O
downregulation O
of O
the O
GR O
by O
its O
cognate O
ligand O
was O
documented O
( O
30 O
. O
3 O
+ O
/ O
- O
26 O
. O
5 O
and O
8 O
. O
8 O
+ O
/ O
- O
5 O
amol O
GR B
mRNA I
/ O
microg O
RNA O
, O
respectively O
; O
P O
< O
. O
001 O
) O
, O
possibly O
reflecting O
differences O
in O
glucocorticoid O
sensitivity O
between O
tissues O
. O

The O
action O
of O
glucocorticosteroids O
is O
mediated O
through O
glucocorticoid B
receptors I
present O
in O
the O
cellular O
cytoplasm O
. O

50 O
% O
HCS O
downregulates O
the O
alpha B
- I
chain I
and O
slightly O
upregulates O
the O
beta B
- I
chain I
. O

Inhibition O
of O
IL B
- I
4 I
- O
inducible O
gene O
expression O
in O
human O
monocytes O
by O
type B
I I
and I
type I
II I
interferons I
. O

However O
, O
the O
mechanism O
by O
which O
IFNs B
mediate O
this O
inhibition O
has O
not O
been O
defined O
. O

Because O
STAT6 B
activation O
plays O
an O
essential O
role O
in O
IL B
- I
4 I
/ O
IL B
- I
13 I
- O
induced O
gene O
expression O
, O
the O
ability O
of O
IFN B
- I
beta I
and O
IFN B
- I
gamma I
to O
inhibit O
STAT6 B
activity O
provides O
an O
explanation O
for O
how O
IFNs B
can O
suppress O
IL B
- I
4 I
/ O
IL B
- I
13 I
- O
inducible O
gene O
expression O
. O

HLA O
class O
I O
Ags O
have O
been O
implicated O
to O
play O
a O
major O
role O
in O
this O
process O
, O
since O
signaling O
via O
HLA B
class I
I I
molecules I
can O
induce O
the O
proliferation O
of O
aortic O
endothelial O
as O
well O
as O
smooth O
muscle O
cells O
. O

A O
cdk2 O
inhibitor O
, O
Olomoucine O
, O
as O
well O
as O
a O
dominant O
- O
negative O
cdk2 O
construct O
prevented O
HLA B
class I
I I
- O
mediated O
inactivation O
of O
Rb B
; O
in O
contrast O
, O
dominant O
- O
negative O
cdk4 O
and O
cdk6 O
constructs O
had O
no O
effect O
. O

PG490 O
inhibits O
interleukin B
( I
IL I
) I
- I
2 I
expression O
by O
normal O
human O
peripheral O
blood O
lymphocytes O
stimulated O
with O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
PMA O
) O
and O
antibody O
to O
CD3 B
( O
IC50 O
of O
10 O
ng O
/ O
ml O
) O
, O
and O
with O
PMA O
and O
ionomycin O
( O
Iono O
, O
IC50 O
of O
40 O
ng O
/ O
ml O
) O
. O

In O
Jurkat O
T O
- O
cells O
, O
PG490 O
inhibits O
PMA O
/ O
Iono O
- O
stimulated O
IL B
- I
2 I
transcription O
. O

PG490 O
can O
completely O
inhibit O
transcriptional O
activation O
at O
the O
purine O
- O
box O
/ O
ARRE O
/ O
NF O
- O
AT O
and O
NF O
- O
kappaB O
target O
DNA O
sequences O
triggered O
by O
all O
stimuli O
examined O
( O
PMA O
, O
PMA O
/ O
Iono O
, O
tumor B
necrosis I
factor I
- I
alpha I
) O
. O

PG490 O
also O
inhibits O
PMA O
- O
stimulated O
activation O
of O
a O
chimeric B
transcription I
factor I
in O
which O
the O
C O
- O
terminal O
TA1 O
transactivation O
domain O
of O
NF O
- O
kappaB O
p65 O
is O
fused O
to O
the O
DNA B
binding I
domain I
of O
GAL4 B
. O

Unexpected O
and O
coordinated O
expression O
of O
Spi B
- I
1 I
, O
Fli B
- I
1 I
, O
and O
megakaryocytic B
genes I
in O
four O
Epo O
- O
dependent O
cell O
lines O
established O
from O
transgenic O
mice O
displaying O
erythroid O
- O
specific O
expression O
of O
a O
thermosensitive B
SV40 I
T I
antigen I
. O

Most O
erythroleukemic O
cell O
lines O
established O
in O
vitro O
coexpress O
erythrocytic O
and O
megakaryocytic O
markers O
that O
often O
are O
associated O
with O
expression O
of O
Spi B
- I
1 I
and O
/ O
or O
Fli O
- O
1 O
transcription O
factors O
known O
as O
transactivators O
of O
megakaryocyte O
- O
specific O
promoters O
. O

However O
, O
like O
normal O
Ter O
119 O
erythroid O
cells O
, O
these O
Ter O
119 O
positive O
cells O
from O
transgenic O
mice O
still O
expressed O
high O
levels O
of O
beta B
- I
globin I
and O
very O
low O
or O
undetectable O
glycoprotein B
IIb I
and O
platelet O
factor O
4 O
megakaryocytic O
transcripts O
. O

Taken O
together O
, O
these O
data O
indicate O
that O
the O
unexpected O
expression O
of O
megakaryocytic B
genes I
is O
a O
specific O
property O
of O
immortalized O
cells O
that O
can O
not O
be O
explained O
only O
by O
enhanced O
expression O
of O
Spi O
- O
1 O
and O
/ O
or O
Fli O
- O
1 O
genes O
. O

Fludarabine O
- O
induced O
immunosuppression O
is O
associated O
with O
inhibition O
of O
STAT1 B
signaling O
. O

STAT1 B
, O
which O
is O
activated O
in O
response O
to O
many O
lymphocyte O
- O
activating O
cytokines O
including O
the O
interferons B
, O
is O
essential O
for O
cell O
- O
mediated O
immunity O
, O
as O
the O
absence O
of O
this O
protein O
is O
associated O
with O
prominent O
defects O
in O
the O
ability O
to O
control O
viral O
infections O
. O

Here O
we O
show O
that O
fludarabine O
, O
but O
not O
the O
immunosuppressant O
cyclosporine O
A O
, O
inhibits O
the O
cytokine B
- O
induced O
activation O
of O
STAT1 B
and O
STAT1 B
- O
dependent O
gene O
transcription O
in O
normal O
resting O
or O
activated O
lymphocytes O
. O

Fludarabine O
caused O
a O
specific O
depletion O
of O
STAT1 O
protein O
( O
and O
mRNA O
) O
but O
not O
of O
other O
STATs B
. O

This O
loss O
of O
STAT1 B
was O
also O
seen O
in O
cells O
from O
patients O
treated O
with O
fludarabine O
in O
vivo O
. O

Thus O
, O
STAT1 B
may O
be O
a O
useful O
target O
in O
the O
development O
of O
new O
immunosuppressive O
and O
antineoplastic O
agents O
. O

Furthermore O
, O
it O
demonstrates O
that O
aging O
does O
not O
influence O
the O
sensitivity O
of O
this O
phosphatase B
. O

Spi B
- I
C I
, O
a O
novel O
Ets B
protein I
that O
is O
temporally O
regulated O
during O
B O
lymphocyte O
development O
. O

Spi B
- I
C I
interacted O
with O
DNA O
similarly O
to O
PU B
. I
1 I
as O
judged O
by O
methylation O
interference O
, O
band O
- O
shift O
and O
site O
selection O
analysis O
, O
and O
activated O
transcription O
of O
a O
kappaY O
element O
reporter O
gene O
upon O
co O
- O
transfection O
of O
HeLa O
cells O
. O

The O
viral B
protein I
Tax B
induces O
the O
activation O
and O
nuclear O
translocalization O
of O
transcription B
factor I
NF B
- I
kappaB I
, O
which O
is O
proposed O
to O
play O
a O
crucial O
role O
in O
the O
transformation O
of O
T O
cells O
by O
HTLV O
- O
I O
. O

However O
, O
the O
HTLV O
- O
I O
genes O
including O
Tax B
are O
not O
expressed O
significantly O
in O
primary O
leukemic O
cells O
from O
ATL O
patients O
. O

We O
found O
that O
leukemic O
cells O
from O
ATL O
patients O
, O
like O
HTLV O
- O
I O
- O
infected O
T O
- O
cell O
lines O
, O
display O
constitutive O
NF B
- I
kappaB I
DNA O
binding O
activity O
and O
increased O
degradation O
of O
IkappaBalpha B
( O
an O
inhibitor O
of O
NF B
- I
kappaB I
) O
. O

One O
T O
- O
cell O
line O
derived O
from O
ATL O
leukemic O
cells O
, O
TL O
- O
Om1 O
, O
displayed O
constitutive O
NF B
- I
kappaB I
activity O
, O
as O
well O
as O
enhanced O
degradation O
of O
IkappaBalpha B
, O
despite O
the O
lack O
of O
detectable O
Tax B
expression O
. O

Interestingly O
, O
the O
NF B
- I
kappaB I
in O
TL O
- O
Om1 O
consists O
of O
p50 B
/ I
p50 I
and O
p50 B
/ I
p65 I
like O
that O
in O
fresh O
primary O
leukemic O
cells O
. O

The O
most O
characterized O
pathway O
is O
via O
JAK B
- B
STAT I
signaling O
. O

Therefore O
, O
this O
study O
was O
designed O
to O
analyze O
the O
role O
of O
Lck B
in O
IFN B
- I
alpha I
signaling O
by O
using O
the O
Jurkat O
, O
JCam O
( O
an O
Lck O
- O
defective O
cell O
line O
derived O
from O
Jurkat O
) O
, O
and O
JCam O
/ O
Lck O
( O
JCam O
cells O
with O
Lck B
restored O
) O
. O

Finally O
, O
the O
results O
demonstrate O
that O
IFN B
- I
alpha I
exerts O
an O
antiproliferative O
effect O
in O
all O
three O
cell O
lines O
. O

We O
investigated O
the O
MAPk O
kinase O
( O
MKK B
) O
that O
activates O
p38 B
MAPk I
in O
response O
to O
LPS O
, O
the O
p38 B
MAPk I
isoforms I
that O
are O
activated O
as O
part O
of O
this O
pathway O
, O
and O
the O
functional O
responses O
affected O
by O
p38 B
MAPk I
activation O
. O

Although O
MKK3 B
, O
MKK4 O
, O
and O
MKK6 O
all O
activated O
p38 B
MAPk I
in O
experimental O
models O
, O
only O
MKK3 B
was O
found O
to O
activate O
recombinant O
p38 B
MAPk I
in O
LPS O
- O
treated O
neutrophils O
. O

The O
I B
gamma I
3 I
ECS B
lies O
upstream O
of O
the O
major O
I O
gamma O
3 O
transcription O
initiation O
site O
and O
displays O
more O
than O
90 O
% O
identity O
with O
the O
corresponding O
human O
I O
gamma O
1 O
, O
I O
gamma O
2 O
, O
and O
I O
gamma O
4 O
regions O
. O

In O
these O
transfected O
CL O
- O
01 O
cells O
, O
CD40 O
: O
CD40L B
engagement O
and O
exposure O
to O
IL B
- I
4 I
synergistically O
induced O
gamma O
3 O
ECS O
- O
dependent O
luciferase B
reporter I
gene I
activation O
. O

Electrophoretic O
mobility O
shift O
assays O
showed O
that O
p50 O
/ O
p65 O
/ O
c O
- O
Rel O
and O
STAT B
- I
6 I
are O
effectively O
induced O
by O
CD40L B
and O
IL B
- I
4 I
, O
respectively O
, O
and O
bind O
to O
specific O
DNA O
motifs O
within O
the O
ECS B
. O

CIITA B
- O
induced O
occupation O
of O
MHC B
class I
II I
promoters I
is O
independent O
of O
the O
cooperative O
stabilization O
of O
the O
promoter O
- O
bound O
multi O
- O
protein O
complexes O
. O

Activation O
of O
MHC B
class I
II I
promoters I
requires O
binding O
of O
at O
least O
three O
distinct O
multi O
- O
protein O
complexes O
( O
RFX B
, O
X2BP O
and O
NF B
- I
Y I
) O
. O

We O
show O
, O
however O
, O
that O
the O
presence O
of O
CIITA B
does O
not O
affect O
the O
stability O
of O
the O
higher O
- O
order O
protein O
complex O
formed O
on O
DNA O
by O
RFX B
, O
X2BP O
and O
NF B
- I
Y I
. O

Finally O
, O
we O
conclude O
that O
this O
effect O
of O
CIITA B
is O
cell O
- O
type O
specific O
, O
since O
expression O
of O
CIITA B
is O
not O
required O
for O
normal O
occupation O
of O
MHC B
class I
II I
promoters I
in O
B O
lymphocytes O
. O

SH2 O
domain O
- O
containing O
protein O
76 O
( O
SLP B
- I
76 I
) O
interacts O
with O
the O
guanine B
nucleotide I
exchange I
factor I
Vav B
to O
activate O
the O
nuclear O
factor O
of O
activated O
cells O
( O
NF B
- I
AT I
) O
, O
and O
its O
expression O
is O
required O
for O
normal O
T O
cell O
development O
. O

In O
contrast O
, O
another O
inducible O
gene O
expression O
of O
monocyte B
chemotactic I
protein I
- I
1 I
( O
a O
CC O
chemokine O
) O
and O
the O
activation O
of O
the O
transcriptional B
factor I
( O
FcRFgamma O
) O
bound O
to O
the O
gamma B
response I
region I
were O
similarly O
or O
less O
abundantly O
induced O
by O
IFNgamma B
treatment O
in O
PMA O
- O
or O
RA O
- O
differentiated O
U937 O
cells O
, O
indicating O
that O
increased O
IP B
- I
10 I
mRNA I
induction O
was O
not O
due O
to O
the O
augmented O
ability O
of O
the O
cells O
to O
respond O
to O
the O
presence O
of O
IFNgamma B
. O

Role O
of O
cellular O
tumor O
necrosis O
factor O
receptor O
- O
associated O
factors O
in O
NF B
- I
kappaB I
activation O
and O
lymphocyte O
transformation O
by O
herpesvirus O
Saimiri O
STP O
. O

In O
addition O
, O
a O
somewhat O
divergent O
region O
of O
STP B
- I
C488 I
is O
critical O
for O
TRAF B
association O
. O

In O
contrast O
, O
caspase O
1 O
( O
ICE O
) O
did O
not O
cleave O
SP1 B
in O
vitro O
. O

Comparison O
of O
tumor O
specimen O
from O
MM O
precursor O
lesions O
, O
primary O
tumors O
, O
and O
metastases O
revealed O
that O
CD40 B
surface O
expression O
is O
down O
- O
regulated O
during O
tumor O
progression O
. O

CD40 B
expression O
was O
confirmed O
in O
7 O
human O
MM O
cell O
lines O
established O
from O
immunogenic O
primary O
tumors O
or O
metastases O
, O
whereas O
11 O
cell O
lines O
established O
from O
advanced O
stages O
were O
CD40 B
negative O
. O

Furthermore O
, O
CD40 B
ligation O
of O
a O
HLA O
- O
A2 O
+ O
, O
MelanA O
/ O
MART1 O
+ O
MM O
cell O
line O
enhanced O
its O
susceptibility O
to O
specific O
lysis O
by O
a O
HLA O
- O
A2 O
- O
restricted O
, O
MelanA O
/ O
MART O
- O
1 O
- O
specific O
CTL O
clone O
. O

MDS1 B
/ I
EVI1 I
is O
inappropriately O
activated O
in O
myeloid O
leukemias O
following O
chromosomal O
rearrangements O
involving O
band O
3q26 O
. O

This O
fusion O
protein O
contains O
the O
DNA B
- I
binding I
domain I
of O
the O
transcription B
factor I
AML1 B
fused O
in O
- O
frame O
to O
the O
entire O
MDS1 B
/ I
EVI1 I
with O
the O
exclusion O
of O
its O
first O
12 O
amino O
acids O
. O

By O
using O
the O
yeast O
two O
- O
hybrid O
system O
, O
we O
also O
show O
that O
EVI1 B
( O
contained O
in O
its O
entirety O
in O
MDS1 B
/ I
EVI1 I
and O
AML1 B
/ I
MDS1 I
/ I
EVI1 I
) O
physically O
interacts O
with O
SMAD3 O
, O
which O
is O
an O
intracellular O
mediator O
of O
TGF B
- I
beta1 I
signaling O
. O

The O
levels O
of O
cAMP B
- I
dependent I
protein I
kinase I
and O
Rap1 B
were O
assessed O
by O
Western O
blot O
analysis O
, O
immunostaining O
, O
and O
computer O
- O
assisted O
imaging O
. O

Tcf B
- I
1 I
- O
mediated O
transcription O
in O
T O
lymphocytes O
: O
differential O
role O
for O
glycogen O
synthase O
kinase O
- O
3 O
in O
fibroblasts O
and O
T O
cells O
. O

Recently O
, O
members O
of O
the O
Lef O
/ O
Tcf O
transcription O
factor O
family O
have O
been O
identified O
as O
protein O
partners O
of O
beta B
- I
catenin I
, O
explaining O
how O
beta B
- I
catenin I
alters O
gene O
expression O
. O

In O
contrast O
, O
in O
C57MG O
fibroblast O
cells O
, O
lithium O
inactivates O
GSK B
- I
3beta I
and O
induces O
Tcf O
- O
controlled O
transcription O
. O

Overexpression O
of O
SIT B
in O
Jurkat O
cells O
downmodulates O
T O
cell O
receptor O
- O
and O
phytohemagglutinin O
- O
mediated O
activation O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NF B
- I
AT I
) O
by O
interfering O
with O
signaling O
processes O
that O
are O
probably O
located O
upstream O
of O
activation O
of O
phospholipase B
C I
. O

However O
, O
binding O
of O
SHP2 B
to O
SIT B
is O
not O
required O
for O
inhibition O
of O
NF B
- I
AT I
induction O
, O
suggesting O
that O
SIT B
not O
only O
regulates O
NF B
- I
AT I
activity O
but O
also O
controls O
NF B
- I
AT I
unrelated O
pathways O
of O
T O
cell O
activation O
involving O
SHP2 B
. O

We O
investigated O
the O
function O
of O
conditionally O
expressed O
EBNA2 B
in O
the O
context O
of O
the O
IFN B
response O
in O
Burkitt O
' O
s O
lymphoma O
cell O
lines O
. O

Expression O
of O
EBNA2 B
led O
to O
the O
transcriptional O
activation O
of O
both O
endogenous O
or O
transfected O
IFN O
- O
stimulated O
genes O
( O
ISGs B
) O
, O
genes O
which O
contain O
within O
their O
promoters B
either O
the O
interferon B
- I
stimulated I
response I
element I
( O
ISRE B
) O
or O
the O
gamma O
interferon O
activation O
site O
( O
GAS B
) O
. O

Interestingly O
, O
the O
combination O
of O
1 O
, O
25 O
( O
OH O
) O
2D3 O
and O
RA O
markedly O
enhanced O
the O
levels O
of O
p27 B
( I
KIP1 I
) I
transcript O
and O
protein O
as O
compared O
with O
levels O
induced O
by O
1 O
, O
25 O
( O
OH O
) O
2D3 O
alone O
. O

Previous O
studies O
have O
implicated O
a O
role O
for O
intracellular O
thiols O
in O
the O
activation O
of O
nuclear B
factor I
- I
kappaB I
and O
transcriptional O
regulation O
of O
endothelial B
cell I
adhesion I
molecules I
. O

This O
study O
demonstrates O
that O
changes O
in O
endothelial O
cell O
GSSG O
/ O
GSH O
cause O
transcription O
- O
independent O
and O
transcription O
- O
dependent O
surface O
expression O
of O
different O
endothelial B
cell I
adhesion I
molecules I
, O
which O
leads O
to O
a O
2 O
- O
phase O
neutrophil O
- O
endothelial O
adhesion O
response O
. O

Angiotensin O
II O
activates O
the O
proinflammatory O
transcription O
factor O
nuclear B
factor I
- I
kappaB I
in O
human O
monocytes O
. O

ANG B
II I
, O
like O
TNFalpha B
, O
caused O
rapid O
activation O
of O
NF B
- I
kappaB I
in O
human O
mononuclear O
cells O
isolated O
from O
peripheral O
blood O
by O
Ficoll O
density O
gradient O
. O

Increased O
mRNA B
and O
surface O
expression O
of O
E B
- I
selectin I
, O
ICAM B
- I
1 I
, O
and O
VCAM B
- I
1 I
were O
noted O
within O
hours O
. O

Transient O
pseudo O
- O
hypoaldosteronism O
following O
resection O
of O
the O
ileum O
: O
normal O
level O
of O
lymphocytic B
aldosterone I
receptors I
outside O
the O
acute O
phase O
. O

In O
contrast O
, O
treatment O
of O
HL O
- O
60 O
cells O
with O
retinoic O
acid O
or O
DMSO O
, O
which O
results O
in O
a O
granulocytic O
differentiation O
of O
these O
cells O
, O
decreases O
4E B
- I
BP1 I
amount O
without O
affecting O
its O
phosphorylation O
and O
strongly O
increases O
4E B
- I
BP2 I
amount O
. O

Markedly O
impaired O
binding O
was O
observed O
, O
consistent O
with O
both O
the O
use O
of O
different O
anchor O
residues O
and O
with O
changes O
in O
levels O
of O
DQ O
cis O
- O
dimer B
availability O
for O
peptide O
binding O
interactions O
. O

Consequently O
, O
cytosolic O
activation O
, O
nuclear O
translocation O
and O
DNA O
- O
binding O
of O
nuclear B
factor I
- I
kappaB I
were O
decreased O
. O

In O
typical O
AITL O
, O
some O
neoplastic O
cells O
were O
positive O
for O
Bcl B
- I
6 I
, O
showing O
variable O
degrees O
of O
staining O
. O

( O
2 O
) O
Intrafollicular O
CD3 O
+ O
T O
cells O
, O
many O
of O
which O
were O
also O
positive O
for O
Bcl B
- I
6 I
, O
were O
markedly O
depleted O
in O
AITL O
/ O
GC O
, O
with O
increased O
interfollicular O
Bcl O
- O
6 O
+ O
/ O
CD3 O
+ O
cells O
, O
suggesting O
an O
outward O
migration O
of O
intrafollicular O
T O
cells O
in O
this O
condition O
. O

( O
5 O
) O
Some O
neoplastic O
cells O
in O
AITL O
stained O
for O
Bcl B
- I
6 I
, O
suggesting O
up O
- O
regulation O
of O
Bcl B
- I
6 I
expression O
in O
this O
tumor O
. O

Because O
these O
induced O
gene O
products O
have O
NF O
- O
kappaB O
sites O
in O
their O
promoter B
regions I
, O
we O
next O
examined O
whether O
there O
was O
an O
up O
- O
regulation O
of O
nuclear O
NF B
- I
kappaB I
levels O
. O

Previous O
characterization O
of O
the O
GPIX B
promoter I
identified O
a O
functional O
Ets O
site O
that O
, O
when O
disrupted O
, O
reduced O
promoter O
activity O
. O

These O
results O
suggest O
that O
Fli B
- I
1 I
is O
likely O
to O
regulate O
lineage O
- O
specific O
genes O
during O
megakaryocytopoiesis O
. O

However O
, O
I B
( I
kappa I
) I
B I
( I
alpha I
) I
has O
also O
been O
detected O
in O
the O
nucleus O
of O
cell O
lines O
and O
when O
overexpressed O
by O
transient O
transfection O
. O

Immunoprecipitation O
experiments O
failed O
to O
demonstrate O
an O
association O
between O
nuclear O
I B
( I
kappa I
) I
B I
( I
alpha I
) I
and O
NF B
- I
kappaB I
proteins O
. O

SERCA B
activity O
was O
measured O
as O
the O
thapsigargin O
sensitive O
, O
Ca2 O
+ O
dependent O
and O
ouabain O
resistant O
, O
ATP O
hydrolyses O
in O
platelet O
membranes O
. O

Additionally O
, O
CoCl2 O
caused O
a O
two O
- O
to O
threefold O
increase O
in O
the O
rate O
of O
transendothelial O
migration O
of O
monocyte O
- O
like O
HL O
- O
60 O
cells O
and O
a O
twentyfold O
increase O
in O
phosphorylation O
of O
platelet O
endothelial O
cell O
adhesion O
molecules O
( O
PECAM B
- I
1 I
) O
. O

Activation O
of O
NF B
- I
kappaB I
is O
thought O
to O
be O
required O
for O
cytokine O
release O
from O
LPS O
- O
responsive O
cells O
, O
a O
critical O
step O
for O
endotoxic O
effects O
. O

LPS O
- O
induced O
NF B
- I
kappaB I
activation O
was O
not O
inhibited O
by O
a O
dominant O
negative O
mutant O
of O
TRAF2 B
that O
is O
involved O
in O
TNF B
signaling O
. O

Tyrosine O
phosphorylation O
of O
IFN B
- I
gammaR I
, O
Jak1 B
, O
Jak2 B
, O
and O
Stat1alpha B
was O
examined O
by O
immunoblotting O
. O

In O
addition O
, O
IFN B
- I
gamma I
enhanced O
the O
DNA O
- O
binding O
activity O
of O
Stat1alpha B
. O

Moreover O
, O
several O
transgenic O
mice O
developed O
acute O
leukemia O
, O
classified O
as O
T O
- O
ALL O
based O
on O
the O
surface O
marker O
analysis O
and O
DNA O
rearrangements O
, O
suggesting O
that O
an O
additional O
event O
is O
required O
for O
malignant O
transformation O
of O
lymphoid O
cells O
expressing O
E2A B
- I
HLF I
. O

Our O
findings O
provide O
insight O
into O
the O
biological O
function O
of O
E2A B
- I
HLF I
in O
lymphoid O
development O
and O
also O
its O
role O
in O
leukemogenesis O
. O

This O
RXR B
agonist O
activity O
is O
blocked O
by O
RAR B
- O
specific O
antagonists O
, O
suggesting O
extensive O
cross O
- O
talk O
between O
the O
partners O
of O
the O
RXR O
- O
RARalpha403 O
heterodimer O
. O

We O
found O
IL B
- I
2Ralpha I
expression O
to O
be O
increased O
in O
BAL O
cells O
from O
involved O
sites O
of O
active O
pulmonary O
tuberculosis O
. O

Expression O
of O
the O
alpha B
- I
chain I
of O
IL B
- I
2Ralpha I
on O
peripheral O
blood O
monocytes O
( O
PBM O
) O
was O
induced O
by O
M O
. O
tuberculosis O
by O
flow O
cytometry O
evaluation O
. O

Furthermore O
, O
the O
two O
VDR B
3 I
' I
- I
UTR I
haplotypes O
conferred O
an O
identical O
half O
- O
life O
on O
a O
heterologous O
beta O
- O
globin O
reporter O
gene O
, O
in O
an O
in O
vitro O
assay O
. O

The O
IL B
- I
2 I
growth O
hormone O
is O
the O
major O
growth O
factor O
of O
activated O
T O
lymphocytes O
during O
a O
developing O
immune O
response O
. O

In O
several O
cell O
types O
, O
activation O
of O
NF B
- I
kappa I
B I
and O
/ O
or O
activating B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
has O
been O
demonstrated O
to O
be O
extremely O
important O
in O
blocking O
apoptosis O
. O

Similarly O
, O
IL B
- I
2 I
neither O
activates O
JNK B
nor O
increases O
AP B
- I
1 I
binding O
activity O
to O
a O
consensus O
o O
- O
tetradecanoylphorbol O
13 O
- O
acetate O
( O
TPA O
) O
response O
element O
. O

The O
phosphorylation O
appears O
to O
be O
related O
to O
the O
signaling O
events O
that O
are O
activated O
by O
TRAF2 B
under O
these O
circumstances O
, O
since O
two O
nonfunctional O
mutants O
were O
found O
to O
be O
phosphorylated O
significantly O
less O
than O
the O
wild O
- O
type O
protein O
. O

We O
conclude O
from O
these O
studies O
that O
the O
phosphorylation O
of O
TRAF2 B
is O
likely O
to O
play O
an O
important O
role O
in O
regulating O
signaling O
by O
virtue O
of O
its O
ability O
to O
influence O
the O
CD40 B
- B
TRAF2 I
interaction O
. O

Unlike O
the O
proposed O
role O
of O
Cbl B
as O
a O
negative O
regulator O
, O
our O
results O
suggest O
that O
the O
Cbl B
homologue O
Cbl B
- I
b I
has O
a O
positive O
role O
in O
T O
- O
cell O
signaling O
, O
most O
likely O
via O
a O
direct O
interaction O
with O
the O
upstream B
kinase I
Zap B
- I
70 I
. O

Grf40 B
, O
A O
novel O
Grb2 B
family I
member I
, O
is O
involved O
in O
T O
cell O
signaling O
through O
interaction O
with O
SLP B
- I
76 I
and O
LAT B
. O

As O
a O
result O
of O
its O
transforming O
abilities O
, O
activated B
Ras I
is O
expressed O
in O
a O
great O
number O
of O
cancers O
. O

This O
review O
will O
discuss O
the O
mechanisms O
by O
which O
Ras B
expressing O
tumors O
are O
able O
to O
evade O
destruction O
by O
the O
immune O
system O
and O
enhance O
their O
growth O
and O
metastatic O
potential O
. O

Though O
the O
levels O
of O
DP1 O
and O
- O
2 O
increase O
when O
cells O
progress O
from O
G0 O
to O
S O
, O
the O
proportion O
of O
DP1 B
to O
DP2 B
remains O
relatively O
constant O
during O
the O
cell O
cycle O
. O

We O
also O
observed O
an O
increase O
in O
electrophoretic O
mobility O
of O
the O
predominant O
E2F O
components O
, O
DP1 B
and O
E2F4 B
, O
as O
B O
- O
lymphocytes O
progressed O
from O
G0 O
into O
early O
G1 O
. O

The O
therapeutic O
potential O
of O
drugs O
that O
block O
the O
induction O
of O
cyclooxygenase B
- I
2 I
has O
been O
emphasized O
. O

When O
two O
4 O
- O
trifluoromethyl O
salicylate O
derivatives O
[ O
2 O
- O
acetoxy O
- O
4 O
- O
trifluoromethyl O
- O
benzoic O
acid O
( O
triflusal O
) O
and O
its O
deacetylated O
metabolite O
2 O
- O
hydroxy O
- O
4 O
- O
trifluoromethylbenzo O
acid O
( O
HTB O
) O
] O
were O
compared O
with O
aspirin O
and O
sodium O
salicylate O
as O
cyclooxygenase B
- I
2 I
( O
COX O
- O
2 O
) O
inhibitors O
, O
we O
observed O
that O
in O
bacterial O
lipopolysaccharide O
- O
activated O
human O
blood O
, O

The O
CD34 O
+ O
myelomonocytic O
cell O
line O
KG1 O
differentiates O
into O
dendritic O
- O
like O
cells O
in O
response O
to O
granulocyte B
- I
macrophage I
CSF I
plus O
TNF B
- I
alpha I
, O
or O
PMA O
( O
with O
or O
without O
the O
calcium O
ionophore O
ionomycin O
, O
or O
TNF B
- I
alpha I
) O
, O
with O
different O
stimuli O
mediating O
different O
aspects O
of O
the O
process O
. O

In O
this O
study O
, O
we O
examined O
whether O
gp41 B
- O
induced O
IL B
- I
10 I
up O
- O
regulation O
is O
mediated O
by O
the O
previously O
described O
synergistic O
activation O
of O
cAMP O
and O
NF B
- I
kappaB I
pathways O
. O

The O
transcription B
factors I
PU B
. I
1 I
and O
C B
/ I
EBPalpha I
are O
responsible O
for O
normal O
myeloid O
differentiation O
from O
stem O
cells O
to O
monocytes O
or O
granulocytes O
. O

However O
, O
the O
phenotypic O
analysis O
of O
NF B
- I
AT I
- O
deficient O
mice O
supports O
the O
idea O
that O
there O
are O
tissue O
- O
and O
gene O
- O
specific O
functions O
as O
well O
. O

Thus O
CTL O
clones O
that O
recognized O
the O
viral O
, O
self O
, O
and O
bacterial O
peptides O
expressed O
a O
highly O
restricted O
alphabeta O
TCR B
phenotype O
. O

RFLAT B
- I
1 I
: O
a O
new O
zinc B
finger I
transcription I
factor I
that O
activates O
RANTES B
gene I
expression O
in O
T O
lymphocytes O
. O

Furthermore O
, O
these O
oxidative O
stresses O
inhibited O
activity O
of O
calcineurin O
, O
a O
serine O
/ O
threonine O
phosphatase O
that O
regulates O
NFAT B
activation O
. O

Several O
intracellular O
signaling O
proteins O
, O
such O
as O
CBL B
and O
VAV B
, O
were O
phosphorylated O
on O
tyrosine O
in O
response O
to O
CD80 B
, O
CD86 B
, O
and O
anti B
- I
CD28 I
mAb I
. O

In O
addition O
, O
the O
association O
of O
phosphoinositide B
3 I
- I
kinase I
with O
CD28 B
and O
enhanced O
tyrosine O
phosphorylation O
of O
phospholipase O
Cgamma O
were O
seen O
after O
anti O
- O
CD28 O
mAb O
and O
CHO O
- O
CD80 O
stimulation O
but O
to O
a O
much O
lesser O
extent O
after O
CHO B
- I
CD86 I
stimulation O
. O

However O
, O
CD80 B
and O
CD86 B
also O
induce O
distinct O
signal O
transduction O
pathways O
including O
the O
tyrosine O
phosphorylation O
of O
CD28 B
and O
phospholipase B
Cgamma1 I
and O
the O
SH2 B
- O
dependent O
association O
of O
phosphoinositide B
3 I
- I
kinase I
with O
CD28 B
. O

Binding O
of O
HMG B
- I
I I
( I
Y I
) I
elicits O
structural O
changes O
in O
a O
silencer O
of O
the O
human B
beta I
- I
globin I
gene I
. O

If O
there O
is O
a O
reciprocal O
elevation O
of O
gamma B
- I
globin I
expression O
upon O
repression O
, O
this O
approach O
could O
be O
useful O
in O
additional O
hemoglobinopathies O
. O

We O
demonstrate O
that O
binding O
of O
HMG B
- I
I I
( I
Y I
) I
to O
this O
oligonucleotide O
causes O
bending O
/ O
flexure O
of O
the O
DNA O
. O

The O
master O
switch O
for O
the O
expression O
of O
these O
genes O
is O
the O
class B
II I
transactivator I
( O
CIITA B
) O
. O

In O
contrast O
, O
overexpression O
of O
CREB B
inhibited O
GAL4 B
- O
p65 O
( O
286 O
- O
551 O
) O
- O
mediated O
transcription O
. O

Glucocorticoid B
receptors I
in O
cord O
blood O
lymphocytes O
of O
healthy O
neonates O
and O
of O
preterms O
suffering O
from O
respiratory O
distress O
syndrome O
. O

We O
measured O
the O
number O
of O
glucocorticoid B
receptors I
( O
GR B
) O
in O
cord O
blood O
lymphocytes O
and O
the O
binding O
affinity O
( O
Kd O
) O
in O
15 O
term O
and O
in O
20 O
preterm O
babies O
. O

The O
number O
of O
GR B
and O
the O
Kd O
were O
similar O
in O
the O
term O
and O
preterm O
( O
with O
and O
without O
NRDS O
) O
babies O
. O

In O
order O
to O
elucidate O
the O
role O
of O
NF B
- I
ATp I
, O
one O
of O
the O
most O
prominent O
members O
of O
family O
of O
NF O
- O
AT O
transcription O
factors O
in O
peripheral O
T O
lymphocytes O
, O
in O
T O
cell O
activation O
and O
differentiation O
we O
created O
NF B
- I
ATp I
- O
deficient O
mice O
by O
gene O
targeting O
. O

Apart O
from O
clear O
- O
cut O
defects O
in O
the O
synthesis O
of O
mRNAs B
for O
Th2 O
- O
type O
lymphokines O
, O
such O
as O
IL B
- I
4 I
, O
IL B
- I
5 I
, O
IL B
- I
10 I
and O
IL B
- I
13 I
, O
in O
primary O
and O
secondary O
stimulations O
of O
spleen O
cells O
in O
vitro O
, O
of O
a O
distinct O
impaired O
deletion O
of O
V O
beta O
11 O
+ O
/ O
CD4 O
+ O
T O
lymphocytes O
from O
these O
mice O
was O
detected O
after O
superantigen O
injection O
. O

Moreover O
, O
NF B
- I
ATp I
- O
/ O
- O
mice O
older O
than O
6 O
weeks O
show O
an O
2 O
- O
5 O
fold O
increase O
in O
number O
of O
lymphocytes O
. O

Our O
data O
constitute O
a O
starting O
point O
for O
studies O
to O
elucidate O
the O
molecular O
mechanism O
by O
which O
TGF B
- I
beta I
regulates O
IgA B
production O
. O

Using O
synovial O
cells O
from O
rheumatoid O
arthritis O
( O
RA O
) O
patients O
, O
we O
demonstrated O
that O
CD44 O
cross O
- O
linking O
and O
binding O
to O
hyaluronan O
augmented O
VCAM B
- I
1 I
expression O
and O
subsequently O
VCAM B
- I
1 I
- O
mediated O
cell O
adhesion O
. O

In O
neutrophils O
, O
TNF B
- I
alpha I
caused O
a O
gliotoxin O
- O
inhibitable O
activation O
of O
an O
inducible O
form O
of O
NF B
- I
kappaB I
, O
a O
response O
that O
may O
underlie O
the O
ability O
of O
TNF B
- I
alpha I
to O
delay O
apoptosis O
at O
later O
times O
( O
12 O
- O
24 O
h O
) O
and O
limit O
its O
early O
killing O
effect O
. O

We O
previously O
identified O
a O
Fas O
ligand O
regulatory O
element O
( O
FLRE B
) O
in O
the O
Fas O
ligand O
( O
fasL O
) O
promoter O
that O
binds O
Egr O
family O
proteins O
and O
demonstrated O
that O
Egr B
- I
3 I
( O
PILOT B
) O
but O
not O
Egr B
- I
1 I
( O
NGFI O
- O
A O
, O
Krox O
- O
24 O
, O
Tis O
- O
8 O
, O
and O
Zif O
- O
268 O
) O
induces O
transcription O
of O
fasL B
. O

The O
aberrant O
CD4 O
( O
- O
) O
CD8 O
( O
- O
) O
T O
cells O
from O
lpr O
/ O
lpr O
and O
gld O
/ O
gld O
mice O
, O
which O
have O
mutations O
in O
the O
genes O
encoding O
Fas B
and O
FasL B
, O
respectively O
, O
have O
an O
activated O
phenotype O
and O
constitutively O
express O
high O
levels O
of O
fasL B
mRNA I
, O
prompting O
us O
to O
ask O
what O
role O
if O
any O
the O
FLRE B
and O
Egr O
family O
proteins O
have O
in O
this O
aberrant O
expression O
of O
fasL B
. O

Although O
overexpressed O
Egr B
- I
1 I
was O
ineffective O
, O
overexpressed O
Egr B
- I
2 I
was O
as O
potent O
as O
Egr B
- I
3 I
in O
inducing O
fasL O
promoter O
- O
dependent O
reporter O
constructs O
in O
T O
cell O
hybridomas O
and O
HeLa O
cells O
, O
and O
both O
up O
- O
regulated O
endogenous O
fasL B
mRNA I
in O
HeLa O
cells O
. O

The O
activity O
of O
the O
CCAAT O
- O
box O
binding O
factor O
NF O
- O
Y O
is O
modulated O
through O
the O
regulated O
expression O
of O
its O
A B
subunit I
during O
monocyte O
to O
macrophage O
differentiation O
: O
regulation O
of O
tissue O
- O
specific O
genes O
through O
a O
ubiquitous O
transcription B
factor I
. O

Recent O
studies O
have O
suggested O
that O
Y319 O
also O
positively O
regulate O
ZAP B
- I
70 I
function O
. O

Deletion O
of O
interdomain B
B I
did O
not O
affect O
the O
ability O
of O
ZAP B
- I
70 I
to O
bind O
to O
the O
receptor O
. O

Differential O
induction O
of O
DNA O
- O
binding O
activities O
following O
CD19 B
cross O
- O
linking O
in O
human O
B O
lineage O
cells O
. O

The O
B O
cell O
- O
specific O
cell O
surface O
molecule O
CD19 B
is O
expressed O
at O
all O
stages O
of O
B O
cell O
development O
, O
including O
normal O
plasma O
cells O
, O
and O
mediates O
signal O
transduction O
via O
interaction O
with O
cytoplasmic O
effector O
proteins O
. O

Oxidants O
, O
transcription B
factors I
, O
and O
intestinal O
inflammation O
. O

The O
regulatory B
regions I
of O
several O
genes O
specifically O
expressed O
in O
B O
cells O
contain O
functional O
binding O
sites O
for O
Oct2 B
. O

These O
target B
genes I
show O
quite O
distinct O
expression O
patterns O
demonstrating O
that O
transcription B
factors I
in O
addition O
to O
Oct2 B
are O
involved O
in O
their O
regulation O
. O

The O
protein O
has O
no O
known O
DNA B
- I
binding I
domain I
but O
does O
contain O
three O
ankyrin O
repeats O
that O
are O
likely O
to O
be O
important O
in O
protein O
- O
protein O
interactions O
. O

Binding O
of O
c B
- I
Rel I
to O
STAT5 O
target O
sequences O
in O
HTLV O
- O
I O
- O
transformed O
T O
cells O
. O

Fas B
( O
CD95 B
) O
and O
Fas B
ligand I
( O
CD95L B
) O
are O
an O
interacting O
receptor O
- O
ligand O
pair O
required O
for O
immune O
homeostasis O
. O

Although O
resting O
Jurkat O
cells O
express O
Fas B
, O
Fas O
mRNA O
was O
induced O
approximately O
10 O
- O
fold O
in O
2 O
h O
upon O
P O
/ O
I O
stimulation O
. O

The O
functional O
contribution O
of O
the O
kappaB O
- O
Sp1 O
composite O
site O
in O
P O
/ O
I O
- O
inducible O
fas O
promoter O
activation O
was O
verified O
by O
using O
kappaB O
- O
Sp1 B
concatamers O
( O
- O
295 O
to O
- O
286 O
) O
in O
a O
thymidine O
kinase O
promoter O
- O
driven O
reporter O
construct O
and O
native O
promoter O
constructs O
in O
Jurkat O
cells O
overexpressing O
IkappaB B
- I
alpha I
. O

The O
induction O
of O
clonal O
anergy O
in O
a O
T O
cell O
inhibits O
IL B
- I
2 I
secretion O
because O
of O
the O
development O
of O
a O
proximal O
signal O
transduction O
defect O
. O

Members O
of O
the O
cyclic O
adenosine O
monophosphate O
( O
cAMP O
) O
response O
element O
binding O
( O
CREB O
) O
/ O
activating O
transcription O
factor O
1 O
( O
ATF O
- O
1 O
) O
family O
of O
transcription B
factors I
bind O
three O
21 B
- I
bp I
repeats I
( O
Tax B
- I
responsive I
element I
- I
1 I
, O
or O
TRE B
- I
1 I
) O
within O
the O
viral B
promoter I
and O
are O
important O
for O
basal O
and O
Tax O
- O
mediated O
transcription O
. O

However O
, O
while O
HUVECs O
contained O
endothelial O
NOS O
protein O
, O
no O
inducible O
NOS B
was O
detected O
in O
either O
tolerant O
or O
nontolerant O
cells O
. O

The O
inhibition O
of O
IL B
- I
2 I
production O
was O
observed O
in O
the O
CD3 B
( O
+ O
) O
T O
- O
lymphocyte O
cytoplasm O
as O
early O
as O
4 O
h O
after O
activation O
by O
PMA O
+ O
ionomycin O
. O

Delta O
- O
opioid O
receptors O
expressed O
by O
Jurkat O
T O
cells O
enhance O
IL B
- I
2 I
secretion O
by O
increasing O
AP B
- I
1 I
complexes I
and O
activity O
of O
the O
NF O
- O
AT O
/ O
AP O
- O
1 O
- O
binding O
promoter O
element O
. O

Reporter O
gene O
constructs O
were O
used O
to O
map O
this O
effect O
of O
deltorphin O
to O
the O
AP O
- O
1 O
- O
and O
NF O
- O
AT O
/ O
AP O
- O
1 O
- O
binding O
sites O
of O
the O
IL B
- I
2 I
promoter I
. O

These O
cells O
, O
stimulated O
by O
an O
agonistic O
monoclonal O
antibody O
against O
CD40 B
or O
by O
transfection O
with O
a O
CD40L O
expression O
vector O
, O
secreted O
p40 B
and O
showed O
enhanced O
p40 O
mRNA O
expression O
. O

We O
have O
mapped O
the O
DNase O
- O
I O
- O
hypersensitive O
( O
HS O
) O
regions O
of O
the O
human B
GATA I
- I
3 I
gene I
in O
T O
- O
cells O
and O
non O
- O
T O
- O
cells O
and O
studied O
their O
transcriptional O
activities O
. O

HS O
I O
- O
III O
, O
located O
5 O
' O
from O
the O
transcriptional B
initiation I
site I
, O
were O
found O
in O
hematopoietic O
and O
non O
- O
hematopoietic O
cells O
, O
whereas O
HS O
IV O
- O
VII O
, O
located O
3 O
' O
from O
the O
transcriptional B
start I
site I
, O
were O
exclusively O
observed O
in O
T O
- O
cells O
. O

Among O
these O
hypersensitive O
sites O
, O
two O
transcriptional O
control O
elements O
were O
found O
, O
one O
in O
the O
first B
intron I
of O
the O
GATA O
- O
3 O
gene O
and O
the O
other O
between O
8 O
. O
3 O
and O
5 O
. O
9 O
kilobases O
5 O
' O
from O
the O
GATA O
- O
3 O
transcriptional O
initiation O
site O
. O

The O
3 O
' O
- O
CAGGTG O
E O
- O
box O
could O
bind O
USF O
proteins O
, O
the O
ubiquitous O
repressor O
ZEB B
, O
or O
the O
basic B
helix I
- I
loop I
- I
helix I
proteins I
E2A B
and O
HEB B
, O
and O
we O
showed O
that O
a O
competition O
between O
ZEB B
and O
E2A O
/ O
HEB O
proteins O
is O
involved O
in O
the O
silencer O
activity O
. O

Reactive O
oxygen O
intermediate O
- O
dependent O
NF B
- I
kappaB I
activation O
by O
interleukin B
- I
1beta I
requires O
5 B
- I
lipoxygenase I
or O
NADPH O
oxidase O
activity O
. O

However O
, O
the O
sources O
for O
ROIs O
in O
various O
cell O
types O
are O
yet O
to O
be O
determined O
and O
might O
include O
5 B
- I
lipoxygenase I
( O
5 B
- I
LOX I
) O
and O
NADPH O
oxidase O
. O

Stimulation O
of O
lymphoid O
cells O
with O
interleukin B
- I
1beta I
( O
IL B
- I
1beta I
) O
led O
to O
ROI O
production O
and O
NF B
- I
kappaB I
activation O
, O
which O
could O
both O
be O
blocked O
by O
antioxidants O
or O
FLAP B
inhibitors O
, O
confirming O
that O
5 B
- I
LOX I
was O
the O
source O
of O
ROIs O
and O
was O
required O
for O
NF B
- I
kappaB I
activation O
in O
these O
cells O
. O

Cutting O
edge O
: O
dominant O
effect O
of O
Ile50Val O
variant O
of O
the O
human O
IL O
- O
4 O
receptor O
alpha O
- O
chain O
in O
IgE B
synthesis O
. O

Constitutive O
expression O
of O
human O
colony O
- O
stimulating O
factor O
- O
1 O
receptor O
( O
CSF B
- I
1R I
) O
confers O
long O
- O
lasting O
CSF B
- I
1 I
- O
dependent O
proliferation O
to O
mouse O
myeloid O
cell O
lines O
. O

In O
agar O
cultures O
, O
47 O
. O
10 O
cells O
form O
7 O
- O
and O
14 O
- O
day O
colonies O
in O
response O
to O
a O
cocktail O
of O
granulocyte B
/ I
macrophage I
colony I
- I
stimulating I
factor I
( O
2 O
. O
5 O
ng O
/ O
mL O
) O
, O
interleukin B
- I
3 I
( O
1 O
ng O
/ O
mL O
) O
, O
and O
mouse O
CSF B
- I
1 I
( O
10 O
ng O
/ O
mL O
) O
. O

Regulation O
of O
IL B
- I
4 I
expression O
by O
the O
transcription B
factor I
JunB B
during O
T O
helper O
cell O
differentiation O
. O

Here O
we O
show O
that O
JunB B
, O
but O
not O
the O
other O
Jun O
family O
members O
, O
was O
selectively O
induced O
in O
Th2 O
cells O
and O
not O
in O
Th1 O
cells O
during O
differentiation O
. O

The O
finding O
of O
Tax B
mutants O
segregating O
these O
two O
pathways O
suggested O
that O
the O
NF B
- I
kappaB I
pathway O
was O
essential O
for O
IL B
- I
2 I
- O
independent O
growth O
of O
CTLL O
- O
2 O
cells O
while O
the O
CRE B
pathway O
was O
unnecessary O
. O

Our O
results O
show O
that O
Tax B
has O
at O
least O
two O
distinct O
activities O
on O
T O
cells O
, O
and O
suggest O
that O
Tax B
plays O
a O
crucial O
role O
in O
IL B
- I
2 I
- O
independent O
T O
- O
cell O
transformation O
induced O
by O
HTLV O
- O
1 O
, O
in O
addition O
to O
its O
well O
- O
known O
IL B
- I
2 I
- O
dependent O
cell O
transformation O
. O

The O
present O
study O
was O
designed O
to O
analyze O
the O
roles O
of O
the O
two O
GR B
isoforms I
on O
glucocorticoid O
- O
mediated O
transrepression O
of O
the O
IL B
- I
2 I
gene I
. O

Furthermore O
, O
GRbeta B
did O
not O
antagonize O
the O
repressive O
effects O
of O
GRalpha B
on O
IL B
- I
2 I
promoter I
activity O
. O

Surprisingly O
, O
overexpression O
of O
GRbeta B
in O
Jurkat O
cells O
did O
not O
cause O
significant O
inhibition O
of O
GRalpha B
- O
induced O
transactivation O
of O
a O
GRE O
- O
dependent O
luciferase O
reporter O
gene O
either O
. O

Extinction O
of O
immunoglobulin B
gene I
expression O
in O
B O
cells O
upon O
fusion O
with O
HeLa O
cells O
is O
preceded O
by O
rapid O
nuclear O
depletion O
of O
essential O
transcription O
factors O
and O
is O
accompanied O
by O
widespread O
inactivation O
of O
genes O
expressed O
in O
a O
B O
cell O
- O
specific O
manner O
. O

Evidence O
for O
suppressed O
activity O
of O
the O
transcription B
factor I
NFAT1 B
at O
its O
proximal O
binding O
element O
P0 B
in O
the O
IL B
- I
4 I
promoter I
associated O
with O
enhanced O
IL B
- I
4 I
gene I
transcription O
in O
T O
cells O
of O
atopic O
patients O
. O

In O
a O
series O
of O
electrophoretic O
mobility O
shift O
assays O
with O
protein O
extracts O
of O
highly O
polarized O
Th2 O
clones O
from O
atopics O
and O
Th1 O
clones O
from O
controls O
we O
compared O
DNA O
- O
binding O
activities O
at O
the O
two O
NFAT B
- I
binding I
elements I
P0 B
and O
P1 B
of O
the O
crucial O
proximal O
human O
IL B
- I
4 I
promoter I
. O

At O
the O
most O
proximal O
P0 B
site O
, O
NFAT O
- O
containing O
complexes O
devoid O
of O
NFAT2 B
were O
readily O
inducible O
in O
the O
Th1 O
clones O
, O
but O
hardly O
or O
not O
in O
the O
Th2 O
clones O
. O

These O
findings O
suggest O
that O
high O
- O
level O
IL B
- I
4 I
production O
in O
atopic O
Th2 O
cells O
is O
associated O
with O
selective O
reduction O
of O
suppressive O
NFAT1 B
activity O
at O
the O
IL O
- O
4 O
P0 O
element O
and O
that O
some O
patients O
with O
this O
multifactorial O
disease O
may O
have O
a O
putative O
systemic O
disorder O
at O
this O
level O
. O

A O
role O
for O
changes O
in O
immunophilins B
, O
causing O
glucocorticoid O
resistance O
in O
neotropical O
primates O
, O
is O
supported O
by O
the O
following O
: O
the O
changes O
in O
FKBP51 B
and O
FKBP52 B
were O
observed O
in O
cells O
from O
other O
neotropical O
primates O
with O
glucocorticoid O
resistance O
; O
the O
elevated O
level O
of O
FKBP51 B
was O
reflected O
in O
an O
abundance O
of O
FKBP51 B
in O
heat O
shock O
protein O
90 O
complexes O
in O
SML O
; O
when O
cytosols O
of O
SML O
and O
L929 O
cells O
were O
mixed O
, O
the O
decrease O
in O
GR O
binding O
was O
associated O
with O
incorporation O
of O
FKBP51 B
into O

GR O
heterocomplexes O
; O
the O
effect O
of O
SML O
cytosol O
on O
GR O
binding O
was O
reproduced O
with O
cytosol O
from O
COS O
cells O
expressing O
squirrel O
monkey O
FKBP51 B
; O
and O
both O
the O
effect O
of O
SML O
cytosol O
on O
GR O
binding O
and O
the O
incorporation O
of O
FKBP51 B
into O
GR O
heterocomplexes O
were O
blocked O
by O
FK506 O
. O

The O
prevalent O
complex O
is O
the O
heterodimer B
p50 I
- I
p65 I
. O

NF B
- I
kappaB I
activity O
is O
tightly O
correlated O
with O
the O
transcriptional O
activity O
of O
a O
long B
terminal I
repeat I
( O
LTR B
) O
of O
HIV O
- O
1 O
transfected O
in O
thymocytes O
. O

These O
findings O
indicate O
that O
imbalanced O
expression O
of O
the O
GR B
isoforms I
may O
be O
a O
mechanism O
of O
GC O
resistance O
, O
and O
may O
have O
implications O
for O
tumorigenesis O
by O
enhancing O
cell O
survival O
. O

Serial O
sectioning O
of O
6 O
micrometer O
was O
performed O
using O
a O
cryostat O
, O
and O
samples O
were O
immunohistochemicall O
stained O
using O
the O
streptoavidin O
- B
biotin I
peroxidase I
method O
and O
a O
monoclonal O
antibody O
against O
c O
- O
fos O
. O

In O
patients O
whose O
infiltration O
of O
c B
- I
fos I
- I
positive I
lymphocytes I
into O
tumor O
tissues O
were O
moderate O
or O
remarkable O
at O
4 O
Gy O
of O
radiotherapy O
, O
the O
tumors O
responded O
significantly O
well O
to O
radiation O
therapy O
( O
P O
< O
0 O
. O
025 O
, O
chi2 O
test O
) O
, O
and O
the O
patients O
took O
a O
significantly O
favorable O
clinical O
course O
( O
P O
< O
0 O
. O
05 O
, O
chi2 O
test O
) O
. O

The O
allele O
- O
specific O
expression O
profiles O
of O
other O
imprinted O
genes O
, O
IGF2 O
and O
H19 O
, O
on O
human B
chromosome I
11 I
were O
constant O
and O
consistent O
with O
those O
in O
other O
tissues O
. O

Our O
unexpected O
observations O
of O
paternal O
or O
biallelic O
expression O
of O
WT1 B
in O
fibroblasts O
and O
lymphocytes O
, O
together O
with O
the O
previous O
findings O
of O
maternal O
or O
biallelic O
expression O
in O
placentae O
and O
brains O
, O
suggest O
that O
the O
allele O
- O
specific O
regulatory O
system O
of O
WT1 B
is O
unique O
and O
may O
be O
controlled O
by O
a O
putative O
tissue O
- O
and O
individual O
- O
specific O
modifier O
. O

Six O
of O
20 O
patients O
with O
SS O
and O
10 O
/ O
19 O
controls O
proliferated O
to O
La O
( O
rSSB B
) O
. O

Tumor B
necrosis I
factor I
( I
TNF I
) I
- I
alpha I
- O
induced O
HIV O
- O
1 O
replication O
in O
OM10 O
. O
1 O
or O
Ach2 O
cells O
was O
significantly O
inhibited O
by O
non O
- O
cytotoxic O
doses O
of O
AuTG O
( O
> O
10 O
microM O
in O
OM10 O
. O
1 O
cells O
and O
> O
25 O
F O
. O
M O
in O
Ach2 O
cells O
) O
, O
while O
25 O
microM O
of O
the O
counter O
- O
anion O
thioglucose O
( O
TG B
) O
or O
gold O
compound O
containing O
divalent O
gold O
ion O
, O
HAuCl3 O
, O
had O
no O
effect O
. O

Specific O
staining O
as O
well O
as O
electron O
microscopic O
examinations O
revealed O
the O
accumulation O
of O
metal O
gold O
in O
the O
cells O
, O
supporting O
our O
previous O
hypothesis O
that O
gold O
ions O
could O
block O
NF B
- I
kappaB I
- O
DNA O
binding O
by O
a O
redox O
mechanism O
. O

This O
pro B
- I
IL I
- I
16 I
is O
subsequently O
processed O
to O
the O
mature O
cytokine O
of O
13 O
kDa O
. O

The O
5 O
' O
sequences O
up O
to O
nucleotide O
- O
120 O
of O
the O
human O
and O
murine O
IL B
- I
16 I
genes O
share O
> O
84 O
% O
sequence O
homology O
and O
harbor O
promoter O
elements O
for O
constitutive O
and O
inducible O
transcription O
in O
T O
cells O
. O

Indeed O
, O
the O
availability O
of O
selective O
and O
orally O
active O
proteasome O
inhibitors O
should O
prove O
useful O
in O
delineating O
the O
roles O
of O
the O
proteasome O
and O
NF B
- I
kappa I
B I
in O
other O
pathophysiological O
conditions O
such O
as O
cancer O
and O
heart O
disease O
. O

A O
Taq O
I O
polymorphism O
was O
identified O
which O
enabled O
chicken O
IL2 B
to O
be O
mapped O
to O
chromosome O
4 O
, O
linked O
to O
ANX5 O
, O
with O
synteny O
with O
mouse O
chromosome O
3 O
and O
human B
chromosome I
4 I
. O

There O
is O
increasing O
evidence O
that O
IFN B
- I
alpha I
has O
an O
important O
role O
in O
T O
- O
cell O
biology O
. O

The O
induction O
of O
these O
genes O
is O
associated O
with O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
- O
induced O
T O
- O
cell O
proliferation O
. O

Taken O
together O
, O
our O
results O
suggest O
that O
IFN B
- I
alpha I
, O
IL B
- I
2 I
, O
IL B
- I
12 I
, O
and O
IL B
- I
15 I
have O
overlapping O
activities O
on O
human O
T O
cells O
. O

The O
Megakaryocyte O
/ O
Platelet O
- O
specific O
enhancer O
of O
the O
alpha2beta1 O
integrin O
gene O
: O
two O
tandem O
AP1 O
sites O
and O
the O
mitogen B
- I
activated I
protein I
kinase I
signaling O
cascade O
. O

Transcriptional O
regulation O
of O
the O
alpha2 B
integrin I
gene I
in O
cells O
undergoing O
megakaryocytic O
differentiation O
requires O
a O
core B
promoter I
between O
bp O
- O
30 O
and O
- O
92 O
, O
a O
silencer B
between O
bp O
- O
92 O
and O
- O
351 O
, O
and O
megakaryocytic O
enhancers O
in O
the O
distal B
5 I
' I
flank I
. O

Therefore O
, O
our O
data O
not O
only O
reveal O
that O
Nmi B
can O
potentiate O
STAT B
- O
dependent O
transcription O
, O
but O
also O
suggest O
that O
it O
can O
augment O
coactivator O
protein O
recruitment O
to O
at O
least O
some O
members O
of O
a O
group O
of O
sequence B
- I
specific I
transcription I
factors I
. O

In O
contrast O
, O
activation O
in O
THP B
- I
1 I
cells I
occurred O
in O
the O
absence O
of O
vanadate O
and O
was O
unaffected O
by O
catalase B
. O

These O
findings O
suggest O
the O
presence O
in O
vaginal O
fluid O
of O
agent O
( O
s O
) O
derived O
from O
indigenous O
bacteria O
that O
can O
activate O
the O
HIV B
- I
1 I
LTR I
, O
cytokine B
production O
, O
and O
NF B
- I
kappaB I
in O
cells O
of O
macrophage O
lineage O
, O
with O
possible O
influence O
on O
vaginal O
physiology O
and O
host O
defense O
. O

Activated O
primed O
CD4 O
T O
cells O
contain O
more O
NFAT1 B
and O
support O
greater O
NFAT B
- O
directed O
transcription O
than O
unprimed O
CD4 O
T O
cells O
, O
while O
activator B
protein I
1 I
binding O
and O
activator B
protein I
1 I
- O
mediated O
transcription O
by O
both O
cell O
types O
is O
similar O
. O

These O
agents O
also O
significantly O
decreased O
TNF B
- O
and O
LPS O
- O
stimulated O
increases O
in O
HUVEC O
surface O
VCAM O
- O
1 O
. O

TNF B
stimulated O
expression O
of O
both O
intercellular B
adhesion I
molecule I
- I
1 I
and O
E B
- I
selectin I
in O
HUVECs O
, O
but O
in O
HUAECs O
, O
only O
intercellular B
adhesion I
molecule I
- I
1 I
was O
increased O
. O

AR B
can O
be O
visualized O
with O
the O
anti B
- I
AR I
antibodies I
in O
the O
cytoplasm O
of O
permeabilized O
T O
cells O
by O
using O
CLSM O
, O
though O
AR B
are O
not O
detectable O
in O
cytosol O
fractions O
when O
using O
the O
charcoal O
binding O
assay O
with O
3H O
- O
R1881 O
as O
ligand O
. O

By O
contrast O
, O
the O
cell B
surface I
receptors I
for O
testosterone O
are O
in O
a O
functionally O
active O
state O
, O
enabling O
T O
cells O
a O
nongenomic O
response O
to O
testosterone O
. O

Limited O
proteolysis O
for O
assaying O
ligand O
binding O
affinities O
of O
nuclear B
receptors I
. O

B O
lymphocytes O
from O
patients O
with O
chronic O
lymphocytic O
leukemia O
contain O
signal O
transducer O
and O
activator O
of O
transcription O
( O
STAT O
) O
1 O
and O
STAT3 B
constitutively O
phosphorylated O
on O
serine O
residues O
. O

In O
summary O
, O
the O
constitutive O
serine O
phosphorylation O
of O
STAT1 B
and O
STAT3 B
is O
present O
in O
all O
CLL O
samples O
tested O
to O
date O
, O
although O
the O
physiologic O
significance O
of O
this O
modification O
remains O
to O
be O
determined O
. O

Highly O
purified O
monocytes O
were O
incubated O
with O
IL B
- I
10 I
for O
60 O
to O
90 O
minutes O
before O
the O
addition O
of O
IFNgamma B
or O
IFNalpha B
. O

IL B
- I
10 I
preincubation O
resulted O
in O
the O
inhibition O
of O
gene O
expression O
for O
several O
IFN O
- O
induced O
genes O
, O
such O
as O
IP B
- I
10 I
, O
ISG54 O
, O
and O
intercellular B
adhesion I
molecule I
- I
1 I
. O

IL B
- I
10 I
treatment O
prevented O
the O
downregulation O
of O
p27 B
( I
Kip1 I
) O
, O
an O
inhibitory B
protein I
that O
controls O
progression O
out O
of O
the O
G0 O
phase O
of O
the O
cell O
cycle O
. O

Associated O
with O
the O
inhibition O
of O
the O
cell O
cycle O
, O
IL B
- I
10 I
suppressed O
SEB B
induction O
of O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
. O

Although O
this O
reversal O
by O
IL B
- I
2 I
was O
pronounced O
, O
it O
was O
not O
complete O
, O
suggesting O
that O
IL B
- I
10 I
may O
have O
some O
effects O
not O
directly O
related O
to O
the O
suppression O
of O
IL B
- I
2 I
production O
. O

IL B
- I
4 I
and O
IL B
- I
13 I
induced O
dose O
- O
and O
time O
- O
dependent O
increases O
in O
IL O
- O
1RI O
and O
IL O
- O
1RII O
mRNA O
levels O
. O

IFN B
- I
gamma I
decreased O
basal O
expression O
as O
well O
as O
the O
induction O
of O
these O
genes O
by O
IL B
- I
4 I
and O
IL B
- I
13 I
. O

Inhibition O
of O
IL B
- I
1RI I
and O
IL O
- O
1RII O
mRNA O
levels O
by O
IFN B
- I
gamma I
was O
transcriptionally O
mediated O
, O
and O
correlated O
directly O
with O
decreased O
production O
of O
soluble O
IL B
- I
1RII I
. O

In O
both O
cell O
types O
, O
the O
cytokine B
that O
inhibits O
the O
induction O
of O
IkappaBalpha B
by O
DEX O
, O
also O
rescues O
these O
cells O
from O
DEX O
- O
induced O
apoptosis O
, O
although O
the O
rescue O
cytokine O
is O
different O
in O
Th1 O
and O
Th2 O
cells O
. O

Infection O
of O
human O
monocytes O
with O
influenza O
A O
virus O
induces O
a O
broad O
range O
of O
proinflammatory B
cytokines I
and O
mononuclear O
cell O
attracting O
chemokines B
before O
the O
infected O
cells O
undergo O
apoptosis O
. O

In O
conclusion O
, O
the O
long O
- O
term O
regulation O
of O
transcription B
factor I
gene O
expression O
in O
non O
- O
proliferating O
cells O
seems O
to O
be O
of O
minor O
importance O
after O
influenza O
infection O
since O
in O
apoptosisprone O
cells O
an O
immediate O
availability O
of O
transcription O
factor O
proteins O
is O
required O
. O

Patients O
with O
diabetic O
nephropathy O
showed O
higher O
NF B
- I
kappaB I
binding O
activity O
in O
Electrophoretic O
Mobility O
Shift O
Assays O
and O
stronger O
immunohistological O
staining O
for O
activated O
NF O
- O
kappaBp65 O
than O
patients O
without O
renal O
complications O
. O

We O
incubated O
sodium O
oleate O
with O
human O
umbilical O
vein O
endothelial O
cells O
for O
0 O
to O
72 O
hours O
, O
followed O
by O
coincubation O
of O
oleate O
with O
human O
recombinant O
tumor O
necrosis O
factor O
, O
interleukin O
( O
IL O
) O
- O
1alpha O
, O
IL B
- I
1beta I
, O
IL B
- I
4 I
, O
Escherichia O
coli O
lipopolysaccharide O
( O
LPS O
) O
, O
or O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
for O
a O
further O
6 O
to O
24 O
hours O
. O

The O
endothelial O
expression O
of O
vascular B
cell I
adhesion I
molecule I
- I
1 I
( O
VCAM B
- I
1 I
) O
, O
E B
- I
selectin I
, O
and O
intercellular B
adhesion I
molecule I
- I
1 I
was O
monitored O
by O
cell O
surface O
enzyme O
immunoassays O
or O
flow O
cytometry O
, O
and O
steady O
- O
state O
levels O
of O
VCAM B
- I
1 I
mRNA I
were O
assessed O
by O
Northern O
blot O
analysis O
. O

The O
importance O
of O
BCL2 B
and O
Stat3 B
on O
IL B
- I
6 I
- O
induced O
macrophage O
- O
differentiation O
and O
apoptosis O
was O
studied O
with O
1A9 O
- O
M O
cells O
expressing O
human O
BCL2 O
or O
a O
dominant O
- O
negative O
form O
of O
Stat3 B
, O
respectively O
. O

IL B
- I
6 I
- O
induced O
apoptosis O
, O
but O
not O
macrophage O
- O
differentiation O
, O
was O
blocked O
by O
continuously O
expressed O
BCL2 B
. O

Interleukin B
- I
8 I
( O
IL B
- I
8 I
) O
is O
a O
chemokine B
that O
belongs O
to O
the O
alpha O
- O
chemokine O
or O
CXC O
subfamily O
and O
is O
produced O
by O
a O
wide O
variety O
of O
human O
cells O
, O
including O
monocytes O
and O
polymorphonuclear O
cells O
( O
PMN O
) O
. O

IL B
- I
8 I
is O
secreted O
in O
response O
to O
inflammatory O
stimuli O
, O
notably O
bacterial O
products O
such O
as O
lipopolysaccharide O
( O
LPS O
) O
, O
but O
little O
is O
known O
about O
the O
mechanisms O
by O
which O
these O
agents O
mediate O
IL B
- I
8 I
induction O
. O

In O
this O
report O
, O
we O
show O
that O
Mycoplasma O
fermentans O
lipid O
- O
associated O
membrane O
proteins O
( O
LAMPf B
) O
induce O
the O
production O
of O
high O
levels O
of O
IL B
- I
8 I
by O
THP O
- O
1 O
( O
human O
monocyte O
) O
cells O
and O
PMN O
at O
the O
same O
extent O
as O
LPS O
. O

In O
this O
study O
we O
investigated O
the O
effects O
of O
C3a B
and O
C3a B
( I
desArg I
) I
on O
gene O
expression O
and O
protein O
secretion O
of O
IL B
- I
6 I
in O
human O
PBMCs O
, O
either O
alone O
or O
in O
combination O
with O
LPS O
or O
IL B
- I
1beta I
. O

Furthermore O
, O
we O
investigated O
the O
effects O
of O
C3a B
and O
C3a B
( I
desArg I
) I
on O
induction O
of O
NF B
- I
kappaB I
and O
activating B
protein I
- I
1 I
binding O
. O

These O
results O
demonstrate O
the O
capacity O
of O
intact O
C3a B
and O
its O
circulating O
des O
- O
Arg O
form O
to O
exert O
immunmodulatory O
effects O
in O
vitro O
. O

Therefore O
we O
investigated O
the O
properties O
and O
function O
of O
the O
glucocorticoid B
receptors I
( O
GR B
) O
in O
FMS O
patients O
and O
compared O
the O
results O
with O
those O
of O
healthy O
persons O
and O
patients O
with O
chronic O
low O
back O
pain O
( O
LBP O
a O
localized O
pain O
condition O
) O
. O

The O
suggested O
roles O
of O
the O
downstream O
3 O
' O
regions O
acting O
as O
a O
Locus B
Control I
Region I
( O
LCR B
) O
, O
have O
allowed O
comparisons O
to O
be O
made O
between O
the O
regulation O
of O
the O
IgH B
locus I
with O
other O
model O
systems O
whose O
gene O
expression O
is O
governed O
by O
LCR B
activity O
. O

MATERIALS O
AND O
METHODS O
: O
Peptides O
derived O
from O
oncogenic B
proteins I
were O
screened O
for O
the O
presence O
of O
HLA O
binding O
motifs O
; O
actual O
binding O
were O
evaluated O
by O
HLA O
stabilization O
experiments O
using O
transfectants O
and O
specific O
anti O
- O
HLA O
antibodies O
. O

RESULTS O
: O
We O
identified O
peptides O
derived O
from O
EWS O
/ O
FLI O
- O
1 O
fusion O
protein O
and O
from O
mutated O
K O
- O
RAS O
protein O
( O
encompassing O
respectively O
the O
fusion B
point I
and O
the O
mutation O
at O
position O
12 O
) O
that O
showed O
binding O
motif O
for O
HLA B
- I
Cw I
* I
0702 I
and O
HLA B
- I
A3 I
respectively O
. O

OCA B
- I
B I
is O
a O
functional O
analog O
of O
VP16 B
but O
targets O
a O
separate O
surface O
of O
the O
Oct B
- I
1 I
POU I
domain I
[ O
published O
erratum O
appears O
in O
Mol O
Cell O
Biol O
1998 O
Apr O
; O
18 O
( O
4 O
) O
: O
2430 O
] O

Here O
, O
we O
show O
that O
OCA B
- I
B I
alters O
the O
activity O
of O
Oct B
- I
1 I
in O
two O
ways O
. O

These O
results O
emphasize O
the O
structural O
versatility O
of O
the O
Oct B
- I
1 I
POU I
domain I
in O
its O
interaction O
with O
coregulators O
. O

Phosphatidylinositol B
3 I
- I
kinase I
couples O
the O
interleukin B
- I
2 I
receptor I
to O
the O
cell B
cycle I
regulator I
E2F B
. O

We O
eliminate O
both O
Stat5 B
and O
Raf B
/ B
MEK I
pathways O
from O
E2F B
regulation O
. O

TRADD B
was O
the O
only O
protein O
that O
interacted O
with O
wild O
- O
type O
TES2 O
and O
not O
with O
isoleucine O
- O
mutated O
TES2 O
. O

In O
transfection O
assays O
, O
TRADD B
and O
TES2 B
synergistically O
mediated O
high O
- O
level O
NF B
- I
kappaB I
activation O
. O

Although O
experimental O
evidence O
is O
lacking O
, O
lytic O
viral O
DNA O
replication O
is O
believed O
to O
remove O
modifications O
or O
binding B
factors I
from O
the O
genome O
which O
serve O
to O
repress O
late O
gene O
expression O
during O
latency O
or O
the O
early O
lytic O
cycle O
. O

This O
induction O
of O
C B
/ I
EBP I
epsilon I
mRNA I
expression O
is O
transcriptionally O
mediated O
and O
occurs O
in O
the O
absence O
of O
synthesis O
of O
additional O
protein B
factors I
. O

Core O
- O
specific O
mAb O
inhibited O
mCD14 B
- O
mediated O
uptake O
of O
homologous O
and O
heterologous O
LPS O
, O
while O
producing O
less O
concurrent O
enhancement O
of O
non O
- O
mCD14 B
- O
mediated O
LPS O
uptake O
. O

Transfection O
of O
EL O
- O
4 O
cells O
with O
the O
IL O
- O
4 O
promoter O
- O
reporter O
constructs O
carrying O
mutated O
P O
- O
like O
elements O
showed O
that O
four O
P B
- I
like I
elements I
, O
CLE0 B
, O
P B
, O
P2 B
and O
P4 B
, O
but O
not O
P3 B
, O
were O
required O
for O
optimal O
activation O
of O
the O
IL B
- I
4 I
promoter I
. O

From O
these O
observations O
we O
conclude O
that O
free O
thiols O
in O
the O
IL O
- O
1RI O
complex O
are O
essential O
for O
the O
activation O
of O
the O
IL B
- I
1RI I
- I
associated I
protein I
kinase I
and O
that O
this O
process O
is O
mandatory O
for O
IL B
- I
1 I
signaling O
leading O
to O
NF B
- I
kappa I
B I
activation O
. O

Strikingly O
, O
Western O
blotting O
and O
immunocytochemical O
experiments O
indicated O
that O
PDTC O
promoted O
a O
transient O
and O
rapid O
shuttling O
of O
NFATp B
and O
NFATc B
, O
leading O
to O
their O
accelerated O
export O
from O
the O
nucleus O
of O
activated O
T O
cells O
. O

Its O
normal O
cellular O
equivalent O
c B
- I
myb I
, O
has O
been O
shown O
to O
promote O
the O
proliferation O
and O
block O
the O
differentiation O
of O
haematopoietic O
cells O
in O
several O
experimental O
models O
and O
is O
required O
for O
fetal O
haematopoiesis O
. O

Both O
have O
been O
shown O
to O
be O
transcription B
factors I
. O

These O
studies O
indicate O
that O
A B
- I
myb I
plays O
a O
role O
during O
a O
narrow O
window O
of O
normal O
B O
cell O
differentiation O
. O

Expression O
of O
bcl B
- I
6 I
protein I
in O
normal O
skin O
and O
epidermal O
neoplasms O
. O

We O
recently O
identified O
the O
winged B
- I
helix I
transcription I
factor I
Trident B
and O
described O
its O
expression O
pattern O
in O
synchronized O
fibroblasts O
. O

The O
estrogen B
receptor I
( O
ER B
) O
repressed O
erythroid O
differentiation O
and O
erythroid B
- I
specific I
gene I
expression O
. O

Recently O
, O
cyclin O
E O
- O
Cdk2 O
- O
and O
cyclin O
A O
- O
Cdk2 O
- O
dependent O
phosphorylation O
of O
a O
single O
conserved O
serine O
residue O
( O
Ser5 O
) O
in O
Id2 B
has O
been O
shown O
to O
occur O
during O
late O
G1 O
- O
to O
- O
S O
phase O
transition O
of O
the O
cell O
cycle O
, O
and O
this O
neutralizes O
the O
function O
of O
Id2 B
in O
abrogating O
E B
- I
box I
- I
dependent I
bHLH I
homo O
- O
or O
heterodimer O
complex O
formation O
in O
vitro O
( O
E O
. O
Hara O
, O
M O
. O
Hall O
, O
and O
G O
. O
Peters O
, O
EMBO O
J O
. O
16 O
: O
332 O
- O

In O
the O
mouse O
embryo O
, O
mNFATc B
transcript I
was O
strongly O
expressed O
in O
thymus O
, O
lung O
and O
submandibular O
gland O
and O
weakly O
in O
skeletal O
muscle O
and O
heart O
suggesting O
that O
mNFATc B
may O
have O
a O
role O
both O
in O
embryogenesis O
and O
in O
mature O
T O
cells O
. O

These O
data O
indicate O
that O
the O
TRE O
- O
like O
cAMP O
- O
responsive O
DSE O
sites O
within O
the O
5 O
' O
- O
untranslated O
leader O
can O
mediate O
the O
transcriptional O
cooperativity O
between O
TNFalpha B
and O
the O
cAMP O
/ B
PKA I
pathway O
. O

Furthermore O
, O
we O
show O
that O
patients O
with O
GC O
- O
insensitive O
asthma O
have O
cytokine O
- O
induced O
abnormalities O
in O
the O
DNA O
binding O
capability O
of O
the O
GCR B
. O

Mutation O
of O
the O
CBF1 B
/ I
RBP I
- I
Jkappa I
binding I
site I
in O
EBNA3C B
abrogated O
repression O
, O
strongly O
suggesting O
that O
CBF1 B
/ I
RBP I
- I
Jkappa I
is O
necessary O
for O
targeting O
the O
viral O
protein O
to O
Cp B
. O

PURPOSE O
: O
To O
clarify O
the O
relationship O
between O
the O
glucocorticoid B
receptor I
and O
the O
effectiveness O
of O
glucocorticoid O
therapy O
in O
patients O
with O
ulcerative O
colitis O
, O
we O
investigated O
the O
number O
and O
apparent O
dissociation O
constant O
of O
glucocorticoid B
receptor I
in O
peripheral O
blood O
mononuclear O
leukocytes O
of O
patients O
with O
ulcerative O
colitis O
. O

The O
apparent O
dissociation O
constant O
of O
the O
glucocorticoid B
receptors I
from O
the O
nonresponders O
, O
responders O
, O
and O
healthy O
controls O
were O
7 O
. O
03 O
( O
range O
, O
5 O
. O
66 O
- O
10 O
) O
, O
4 O
. O
27 O
( O
range O
, O
4 O
- O
5 O
. O
13 O
) O
, O
and O
6 O
. O
18 O
( O
range O
, O
5 O
. O
86 O
- O
6 O
. O
74 O
) O
nM O
, O
respectively O
. O

Nonresponders O
had O
a O
significant O
increase O
both O
in O
the O
number O
of O
binding B
sites I
and O
in O
the O
apparent O
dissociation O
constant O
compared O
with O
responders O
( O
P O
= O
0 O
. O
045 O
; O
P O
= O
0 O
. O
029 O
) O
. O

Cooperation O
of O
binding B
sites I
for O
STAT6 B
and O
NF B
kappa I
B I
/ I
rel I
in O
the O
IL B
- I
4 I
- O
induced O
up O
- O
regulation O
of O
the O
human O
IgE O
germline O
promoter O
. O

In O
contrast O
, O
lipopolysaccharide O
stimulation O
primarily O
induced O
the O
p65 B
/ I
p50 I
heterodimer I
that O
has O
been O
shown O
to O
result O
in O
gene O
activation O
. O

Cyclosporin O
A O
inhibits O
early O
mRNA O
expression O
of O
G0 O
/ O
G1 O
switch O
gene O
2 O
( O
G0S2 B
) O
in O
cultured O
human O
blood O
mononuclear O
cells O
. O

In O
cells O
that O
have O
been O
preincubated O
to O
lower O
mRNA O
levels O
, O
there O
is O
a O
transient O
increase O
in O
G0S2 B
mRNA I
, O
peaking O
between O
1 O
- O
2 O
h O
, O
in O
response O
to O
Concanavalin O
- O
A O
( O
ConA O
) O
, O
or O
to O
the O
combination O
of O
phorbol O
ester O
( O
TPA O
) O
, O
and O
the O
calcium O
ionophore O
, O
ionomycin O
. O

YY1 B
, O
a O
widely O
distributed O
human B
transcription I
factor I
, O
is O
known O
to O
inhibit O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
transcription O
and O
virus O
production O
. O

LSF B
( O
also O
known O
as O
LBP O
- O
1 O
, O
UBP O
, O
and O
CP O
- O
2 O
) O
has O
been O
shown O
to O
repress O
LTR O
transcription O
in O
vitro O
, O
but O
transient O
expression O
of O
LSF B
has O
no O
effect O
on O
LTR B
activity O
in O
vivo O
. O

Relative O
affinities O
of O
transcriptional B
regulatory I
elements I
for O
their O
respective O
factor O
have O
been O
essentially O
studied O
by O
bandshift O
analysis O
. O

This O
result O
, O
confirmed O
by O
competitions O
with O
each O
GATA B
site I
, O
demonstrated O
the O
higher O
relative O
affinity O
( O
at O
least O
sevenfold O
) O
of O
site O
3 O
. O

Stable O
transfection O
of O
U937 O
cells O
with O
sense O
or O
antisense O
RXR O
- O
alpha O
cDNA O
suggests O
a O
role O
for O
RXR B
- I
alpha I
in O
the O
control O
of O
monoblastic O
differentiation O
induced O
by O
retinoic O
acid O
and O
vitamin O
D O
. O

The O
role O
of O
the O
viral O
trans O
- O
activator O
Tax O
protein O
in O
the O
induction O
of O
VCAM B
- I
1 I
was O
first O
indicated O
by O
the O
detection O
of O
this O
adhesion B
molecule I
on O
Jurkat O
T O
- O
cell O
clones O
stably O
expressing O
the O
tax O
gene O
. O

The O
effect O
of O
Tax B
on O
VCAM B
- I
1 I
gene O
transcription O
was O
next O
confirmed O
in O
JPX O
- O
9 O
cells O
, O
a O
subclone O
of O
Jurkat O
cells O
, O
carrying O
the O
tax O
sequences O
under O
the O
control O
of O
an O
inducible B
promoter I
. O

Furthermore O
, O
deletion O
and O
mutation O
analyses O
of O
the O
VCAM B
- I
1 I
promoter I
performed O
with O
chloramphenicol O
acetyltransferase O
constructs O
revealed O
that O
Tax B
was O
trans O
activating O
the O
VCAM B
- I
1 I
promoter I
via O
two O
NF O
- O
kappaB O
sites O
present O
at O
bp O
- O
72 O
and O
- O
57 O
in O
the O
VCAM O
- O
1 O
gene O
promoter O
, O
with O
both O
of O
them O
being O
required O
for O
the O
Tax B
- O
induced O
expression O
of O
this O
adhesion B
molecule I
. O

We O
have O
investigated O
the O
effects O
of O
Vpr B
on O
host O
cell O
activation O
and O
confirm O
that O
it O
influences O
cellular O
proliferation O
. O

In O
the O
absence O
of O
TCR B
- O
mediated O
activation O
, O
Vpr B
induces O
apoptosis O
whereas O
in O
its O
presence O
, O
Vpr B
interrupts O
the O
expected O
induction O
of O
apoptosis O
. O

Our O
finding O
that O
Vpr B
can O
regulate O
NF B
- I
kappa I
B I
supports O
the O
hypothesis O
that O
some O
aspects O
of O
viral O
pathogenesis O
are O
the O
consequence O
of O
cell O
dysregulation O
by O
Vpr B
. O

In O
fact O
, O
by O
employing O
a O
novel O
haptenized O
lysis O
synthetic O
substrate O
which O
allows O
the O
isolation O
of O
glutaminyl O
- O
tTG O
substrates O
in O
vivo O
, O
we O
identified O
pRB B
as O
a O
potential O
tTG O
substrate O
in O
U937 O
cells O
undergoing O
apoptosis O
. O

Interleukin B
2 I
( O
IL B
- I
2 I
) O
induces O
tyrosine O
phosphorylation O
of O
STATs O
3 O
and O
5 O
( O
signal O
transducer O
and O
activator O
of O
transcription O
) O
. O

IL B
- I
2 I
and O
T B
cell I
antigen I
receptor I
complex I
induction O
of O
STAT3alpha B
serine O
727 O
phosphorylation O
is O
dependent O
on O
the O
activity O
of O
the O
MEK B
/ B
ERK I
pathway O
. O

These O
results O
thus O
show O
that O
STAT3 B
proteins I
are O
targets O
for O
multiple O
kinase O
pathways O
in O
T O
cells O
and O
can O
integrate O
signals O
from O
both O
cytokine B
receptors I
and O
antigen O
receptors O
. O

In O
addition O
, O
both O
RelA B
and O
c B
- I
Rel I
, O
but O
not O
NF B
- I
kappa I
B1 I
, O
were O
shown O
to O
transactivate O
an O
ICAM O
- O
1 O
kappa O
B O
- O
reporter O
construct O
. O

Competent O
transcription O
initiation O
by O
RNA B
polymerase I
II I
in O
cell O
- O
free O
extracts O
from O
xeroderma O
pigmentosum O
groups O
B O
and O
D O
in O
an O
optimized O
RNA O
transcription O
assay O
. O

Patients O
with O
renin B
values O
less O
than O
0 O
. O
13 O
ng O
angiotensin O
I O
/ O
L O
per O
second O
were O
markedly O
less O
sensitive O
to O
cortisol O
than O
those O
with O
higher O
values O
. O

The O
composite O
PU O
. O
1 O
and O
Pip O
site O
likely O
accounts O
for O
both O
lineage O
and O
stage O
- O
specific O
expression O
of O
CD20 B
whereas O
the O
CD20 O
E O
box O
binding O
proteins O
enhance O
overall O
promoter O
activity O
and O
may O
link O
the O
promoter O
to O
a O
distant O
enhancer O
. O

The O
generality O
of O
this O
finding O
was O
confirmed O
by O
the O
induction O
of O
Bcl B
- I
xL I
in O
human O
myeloid O
U O
- O
937 O
cells O
, O
human O
peripheral O
blood O
monocytes O
exposed O
to O
phorbol O
ester O
, O
and O
mouse O
thioglycollate O
- O
activated O
and O
resident O
peritoneal O
macrophages O
. O

Furthermore O
, O
the O
degree O
of O
CN B
inhibition O
was O
reflected O
by O
a O
similar O
degree O
of O
reduction O
in O
lymphocyte O
proliferation O
and O
IFN B
- I
gamma I
production O
in O
the O
allogeneic O
mixed O
lymphocyte O
cultures O
. O

Thus O
, O
the O
reduction O
of O
CN B
activity O
observed O
in O
CsA O
- O
treated O
patients O
is O
accompanied O
by O
a O
similar O
degree O
of O
reduction O
in O
lymphocyte B
gene I
activation O
, O
and O
accounts O
for O
the O
immunosuppression O
observed O
. O

Control O
of O
NF B
- I
kappa I
B I
activity O
by O
the O
I O
kappa O
B O
beta O
inhibitor O
. O

The O
transcription B
factor I
NF B
- I
kappa I
B I
is O
maintained O
in O
an O
inactive O
cytoplasmic O
state O
by O
I O
kappa O
B O
inhibitors O
. O

G28 B
- I
5 I
sFv I
was O
a O
more O
potent O
agonist O
than O
G28 B
- I
5 I
IgG I
and O
was O
able O
to O
stimulate O
CD40 B
responses O
by O
B O
cells O
and O
monocytes O
. O

Increased O
CRH B
promoter O
activity O
following O
phorbol O
ester O
treatment O
was O
inhibited O
by O
a O
dominant O
negative O
NF O
- O
IL6 O
mutant O
, O
showing O
that O
the O
effects O
of O
phorbol O
ester O
were O
principally O
mediated O
by O
C B
/ I
EBP I
. O

We O
screened O
TSG101 B
for O
somatic O
mutations O
in O
DNA O
and O
RNA O
samples O
isolated O
from O
a O
variety O
of O
common O
human O
malignancies O
, O
EBV O
- O
immortalised O
B O
- O
cells O
, O
and O
normal O
lung O
parenchyma O
. O

Intragenic O
TSG101 B
deletions O
in O
RNA B
transcripts I
were O
frequently O
found O
in O
all O
types O
of O
samples O
. O

A O
similar O
spectrum O
of O
transcript O
deletions O
has O
previously O
been O
described O
in O
the O
putative O
tumour O
suppressor O
gene O
FHIT B
. O

Interleukin B
- I
7 I
upregulates O
the O
interleukin B
- I
2 I
- I
gene I
expression O
in O
activated O
human O
T O
lymphocytes O
at O
the O
transcriptional O
level O
by O
enhancing O
the O
DNA O
binding O
activities O
of O
both O
nuclear O
factor O
of O
activated O
T O
cells O
and O
activator B
protein I
- I
1 I
. O

Production O
of O
IL B
- I
2 I
requires O
the O
formation O
of O
transcription B
factors I
involved O
in O
the O
IL B
- I
2 I
- I
gene I
regulation O
. O

The O
visualization O
of O
heavy O
and O
light O
chain O
genes O
in O
B O
- O
lymphoid O
cells O
showed O
that O
the O
three O
Ig B
genes I
are O
differentially O
and O
nonrandomly O
distributed O
in O
different O
nuclear O
subvolumes O
: O
the O
kappa O
genes O
were O
found O
to O
be O
preferentially O
confined O
to O
an O
outer O
nuclear O
volume O
, O
whereas O
the O
gamma O
and O
lambda O
genes O
consistently O
occupied O
more O
central O
positions O
within O
the O
nucleus O
, O
the O
lambda O
genes O
being O
more O
interior O
when O
compared O
with O
the O
gamma O
genes O
. O

We O
have O
therefore O
investigated O
the O
transcriptional O
activity O
of O
A B
- I
MYB I
and O
its O
regulation O
in O
several O
human O
lymphoid O
cell O
lines O
using O
co O
- O
transfection O
assays O
and O
show O
that O
A B
- I
MYB I
is O
transcriptionally O
active O
in O
all O
the O
B O
cell O
lines O
studied O
, O
but O
not O
in O
T O
cells O
. O

Transcription O
factor O
Egr B
- I
1 I
activity O
down O
- O
regulates O
Fas O
and O
CD23 O
expression O
in O
B O
cells O
. O

Transcription B
factor I
NF B
- I
kappa I
B I
must O
be O
released O
from O
cytoplasmic O
inhibitory O
molecules O
( O
I O
kappa O
Bs O
) O
in O
order O
to O
move O
to O
the O
nucleus O
and O
to O
activate O
its O
target B
genes I
. O

TCR B
beta I
analysis O
showed O
that O
while O
there O
was O
loop O
length O
restriction O
in O
the O
putative O
peptide O
contact O
site O
of O
all O
responding O
beta O
chains O
, O
diverse O
and O
unique O
( O
non O
- O
recurrent O
) O
TCR O
beta O
clonotypes O
were O
selected O
in O
individuals O
during O
primary O
infection O
and O
continued O
to O
emerge O
after O
long O
- O
term O
virus O
exposure O
. O

CD40 B
ligation O
leads O
to O
B O
cell O
activation O
events O
such O
as O
proliferation O
, O
Ig O
secretion O
, O
isotype O
switching O
, O
and O
up O
- O
regulation O
of O
cell B
surface I
molecules I
, O
as O
well O
as O
the O
generation O
of O
memory O
B O
cells O
. O

Many O
of O
these O
events O
are O
dependent O
upon O
the O
ability O
of O
CD40 B
to O
activate O
the O
transcription O
factor O
NF B
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
. O

To O
define O
the O
CD40 B
signaling O
components O
upstream O
of O
NF B
- I
kappa I
B I
activation O
and O
the O
functional O
consequences O
downstream O
of O
NF B
- I
kappa I
B I
activation O
, O
we O
examined O
mouse O
B O
cell O
transfectants O
expressing O
wild O
- O
type O
or O
mutant O
human O
CD40 O
. O

A O
threonine O
residue O
at O
position O
234 O
, O
previously O
shown O
to O
be O
important O
for O
CD40 B
association O
with O
TNF O
receptor O
- O
associated O
factor O
2 O
( O
TRAF2 B
) O
, O
TRAF3 B
, O
and O
TRAF5 B
, O
was O
not O
required O
for O
NF B
- I
kappa I
B I
activation O
. O

NF B
- I
kappa I
B I
activation O
was O
independent O
of O
the O
transmembrane B
domain I
of O
CD40 B
, O
suggesting O
that O
it O
is O
independent O
of O
p23 B
, O
a O
molecule O
that O
associates O
with O
CD40 B
in O
a O
region O
other O
than O
the O
cytoplasmic B
domain I
. O

NF B
- I
kappa I
B I
activation O
correlated O
with O
the O
ability O
of O
CD40 B
to O
induce O
Ab O
secretion O
and O
the O
up O
- O
regulation O
of O
ICAM B
- I
1 I
and O
LFA B
- I
1 I
. O

The O
M B
- I
CSF I
receptor I
was O
first O
detectable O
in O
the O
myeloid O
- O
committed O
CD34 O
+ O
Thy O
- O
l O
- O
CD45RA O
+ O
subset O
. O

Addition O
of O
GM B
- I
CSF I
to O
this O
basic O
cocktail O
consistently O
increased O
the O
clonogenic O
capacity O
of O
single O
CD34 O
+ O
Thy O
- O
1 O
+ O
cells O
, O
and O
this O
effect O
was O
further O
enhanced O
( O
up O
to O
72 O
. O
3 O
+ O
/ O
- O
4 O
. O
3 O
% O
on O
day O
7 O
) O
by O
the O
inclusion O
of O
TNF B
- I
alpha I
. O

Induction O
of O
endothelial O
cell O
surface O
adhesion O
molecules O
by O
tumor B
necrosis I
factor I
is O
blocked O
by O
protein O
tyrosine O
phosphatase O
inhibitors O
: O
role O
of O
the O
nuclear B
transcription I
factor I
NF I
- I
kappa I
B I
. O

The O
induction O
of O
ICAM B
- I
1 I
, O
VCAM B
- I
1 I
, O
and O
ELAM B
- I
1 I
by O
TNF B
in O
MVEC O
occurred O
within O
6 O
h O
and O
was O
also O
completely O
down O
- O
regulated O
by O
PAO O
in O
a O
dose O
- O
dependent O
manner O
. O

In O
contrast O
, O
I B
kappa I
B I
- I
alpha I
levels O
in O
PBMC O
and O
monocytes O
from O
healthy O
subjects O
or O
from O
patients O
with O
nontuberculous O
pulmonary O
conditions O
were O
intact O
. O

Further O
, O
M O
. O
tuberculosis O
and O
its O
tuberculin O
, O
purified O
protein O
derivative O
, O
induced O
the O
degradation O
of O
I B
kappa I
B I
- I
alpha I
and O
the O
expression O
of O
I B
kappa I
B I
- I
alpha I
mRNA I
, O
and O
purified O
protein O
derivative O
induced O
the O
activation O
of O
NF B
- I
kappa I
B I
in O
monocytes O
. O

Spi B
- I
1 I
/ I
PU I
. I
1 I
is O
a O
myeloid O
- O
and O
B O
- O
cell O
specific O
transcription O
factor O
which O
is O
also O
involved O
in O
Friend O
virus O
- O
induced O
murine O
erythroleukemia O
. O

These O
results O
show O
that O
Spi O
- O
1 O
/ O
PU B
. I
1 I
requires O
signals O
emanating O
from O
specific O
cytokine O
and O
growth O
factor O
receptors O
to O
affect O
the O
survival O
, O
proliferation O
and O
differentiation O
control O
of O
primary O
erythroblasts O
. O

They O
also O
suggest O
that O
the O
function O
of O
Spi B
- I
1 I
/ I
PU I
. I
1 I
in O
the O
late O
phase O
of O
Friend O
leukemia O
requires O
specific O
signaling O
from O
the O
gp55 O
- O
modified O
EpoR O
generated O
during O
the O
early O
phase O
of O
the O
disease O
. O

Inhibition O
of O
TF B
induction O
in O
the O
presence O
of O
high O
CsA O
blood O
concentrations O
was O
also O
observed O
when O
stimulation O
of O
cells O
was O
performed O
with O
interferon B
- I
gamma I
or O
interleukin B
- I
1beta I
. O

As O
shown O
by O
reverse O
transcription O
- O
polymerase O
chain O
reaction O
and O
electrophoretic O
mobility O
shift O
assay O
, O
respectively O
, O
treatment O
with O
CsA O
leads O
to O
decreased O
TF B
mRNA I
expression O
and O
reduced O
activation O
of O
the O
NF B
- I
kappaB I
transcription I
factor I
, O
which O
is O
known O
to O
contribute O
to O
the O
induction O
of O
the O
TF O
promotor O
in O
human O
monocytes O
. O

Inhibition O
of O
monocyte O
TF B
induction O
by O
CsA O
may O
contribute O
to O
its O
successful O
use O
in O
cardiac O
transplant O
medicine O
and O
might O
be O
useful O
in O
managing O
further O
settings O
of O
vascular O
pathology O
also O
known O
to O
involve O
TF B
expression O
and O
NF B
- I
kappaB I
activation O
. O

Both O
cytokines B
induced O
assembly O
of O
STAT5A B
and O
STAT5B B
containing O
complexes O
capable O
of O
binding O
to O
the O
interferon B
- I
gamma I
activation I
sequence I
( O
GAS B
) O
, O
and O
these O
complexes O
rapidly O
translocated O
( O
within O
1 O
min O
) O
into O
the O
nucleus O
of O
IL O
- O
2 O
- O
or O
IL O
- O
7 O
- O
treated O
cells O
. O

IL B
- I
2 I
and O
IL B
- I
7 I
were O
equivalent O
in O
their O
ability O
to O
induce O
tyrosine O
phosphorylation O
of O
STAT5A B
and O
STAT5B B
and O
to O
facilitate O
binding O
of O
these O
STATs B
to O
an O
immobilized O
GAS O
element O
. O

These O
data O
suggest O
that O
IL B
- I
2 I
and O
IL B
- I
7 I
induce O
assembly O
of O
STAT O
heterodimers O
in O
a O
similar O
manner O
and O
that O
subsequent O
cellular O
responses O
may O
be O
driven O
by O
induction O
of O
similar O
sets O
of O
genes B
. O

The O
POU O
transcription O
factors O
Oct B
- I
1 I
and O
Oct B
- I
2 I
regulate O
the O
activity O
of O
octamer O
- O
dependent O
promoters O
, O
including O
those O
that O
direct O
transcription O
from O
rearranged O
immunoglobulin B
genes I
. O

The O
class B
II I
trans I
- I
activator I
( O
CIITA B
) O
is O
a O
bi O
- O
or O
multi O
- O
functional O
domain O
protein O
which O
plays O
a O
critical O
role O
in O
the O
expression O
of O
MHC B
class I
II I
genes I
. O

Transient O
transfection O
of O
a O
B O
lymphoma O
line O
resulted O
in O
up O
to O
89 O
% O
reduction O
of O
constitutive O
MHC B
class I
II I
expression O
within O
5 O
days O
and O
suppression O
of O
HLA B
- I
DRA I
mRNA I
synthesis O
. O

We O
show O
here O
that O
helenalin O
, O
and O
, O
to O
a O
much O
lesser O
degree O
, O
11alpha O
, O
13 O
- O
dihydrohelenalin O
and O
chamissonolid O
, O
inhibit O
activation O
of O
transcription B
factor I
NF B
- I
kappaB I
. O

Rather O
, O
helenalin O
modifies O
the O
NF O
- O
kappaB O
/ O
IkappaB O
complex O
, O
preventing O
the O
release O
of O
IkappaB B
. O

The O
tax B
protein I
of O
human O
T O
- O
cell O
leukemia O
virus O
type O
1 O
mediates O
the O
transactivation O
of O
the O
c O
- O
sis O
/ O
platelet O
- O
derived O
growth O
factor O
- O
B O
promoter O
through O
interactions O
with O
the O
zinc O
finger O
transcription O
factors O
Sp1 B
and O
NGFI B
- I
A I
/ I
Egr I
- I
1 I
. O

In O
the O
present O
work O
, O
we O
have O
investigated O
the O
mechanism O
( O
s O
) O
whereby O
Tax B
transactivates O
the O
c O
- O
sis O
/ O
PDGF O
- O
B O
proto O
- O
oncogene O
. O

Interestingly O
, O
co O
- O
immunoprecipitation O
analysis O
also O
revealed O
that O
Tax B
mutant O
IEXC29S B
is O
unable O
to O
interact O
with O
NGFI B
- I
A I
/ I
Egr I
- I
1 I
, O
whereas O
Tax B
mutant O
IEXL320G B
is O
able O
to O
interact O
with O
NGFI B
- I
A I
/ I
Egr I
- I
1 I
. O

Immunohistochemical O
staining O
demonstrated O
RelB B
within O
the O
differentiated O
lymph O
node O
interdigitating O
DC O
and O
follicular O
DC O
, O
but O
not O
undifferentiated O
DC O
in O
normal O
skin O
. O

NF B
- I
AT I
activation O
induced O
by O
a O
CAML B
- O
interacting O
member O
of O
the O
tumor B
necrosis I
factor I
receptor I
superfamily I
. O

The O
CAML O
( O
calcium O
- O
modulator O
and O
cyclophilin O
ligand O
) O
protein O
is O
a O
coinducer O
of O
NF B
- I
AT I
activation O
when O
overexpressed O
in O
Jurkat O
T O
cells O
. O

In O
most O
cells O
, O
Rel B
/ I
NF I
- I
kappa I
B I
transcription B
factors I
appear O
to O
mediate O
survival O
signals O
that O
protect O
cells O
from O
apoptosis O
; O
however O
, O
under O
some O
circumstances O
, O
activation O
of O
these O
factors O
may O
also O
promote O
apoptosis O
. O

These O
results O
suggest O
that O
coordination O
of O
NF B
- I
kappaB I
and O
STAT6 B
may O
be O
required O
for O
induction O
of O
germline B
Cepsilon O
transcription O
by O
IL B
- I
4 I
, O
and O
that O
CD40 B
- O
mediated O
NF B
- I
kappaB I
activation O
may O
be O
important O
in O
regulating O
both O
enhancement O
of O
germline B
Cepsilon O
transcription O
and O
class O
switching O
to O
IgE B
. O

Proteins O
of O
the O
ATF O
/ O
CREB B
class O
of O
transcription B
factors I
stimulate O
gene O
expression O
of O
several O
cell O
growth O
- O
related O
genes O
through O
protein O
kinase O
A O
- O
related O
cAMP O
response O
elements O
. O

One O
ATF O
/ O
CRE O
motif O
is O
located O
in O
the O
distal B
promoter I
at O
the O
nuclear O
matrix O
- O
associated O
Site O
IV O
, O
and O
the O
second O
motif O
is O
present O
in O
the O
proximal B
promoter I
at O
Site O
I O
. O

Site O
- O
directed O
mutational O
studies O
demonstrate O
that O
Site O
I O
and O
Site O
IV O
together O
support O
ATF1 O
- O
and O
CREB O
- O
induced O
trans O
- O
activation O
of O
the O
H4 B
promoter I
. O

Indeed O
, O
addition O
of O
inhibitors O
of O
NF B
- I
kappa I
B I
activation O
pyrrolidine O
dithiocarbamate O
( O
PDTC O
) O
, O
to O
the O
lymphocytes O
of O
the O
chemically O
- O
exposed O
group O
was O
capable O
of O
inhibiting O
programmed O
cell O
death O
by O
40 O
% O
. O

This O
reversal O
of O
apoptosis O
almost O
to O
the O
control O
level O
by O
inhibitor O
of O
NF B
- I
kappa I
B I
activation O
may O
indicate O
involvement O
of O
this O
signaling B
molecule I
in O
MTBE O
and O
benzene O
induction O
of O
programmed O
cell O
death O
. O

Using O
a O
radiolabeled O
chemical O
probe O
, O
we O
here O
purified O
a O
target O
of O
SR O
31747A O
and O
called O
it O
SR O
31747A O
- O
binding O
protein O
( O
SR B
- I
BP I
) O
. O

Northern O
blot O
analysis O
of O
SR B
- I
BP I
gene O
expression O
revealed O
a O
single O
transcript O
of O
2 O
kilobases O
which O
was O
widely O
expressed O
among O
organs O
, O
with O
the O
highest O
abundance O
in O
liver O
and O
the O
lowest O
abundance O
in O
brain O
. O

Here O
we O
report O
the O
induction O
of O
the O
synthesis O
and O
of O
the O
hydrolytic O
activity O
of O
phospholipase B
C I
gamma I
1 I
( O
PLC O
gamma O
1 O
) O
in O
human O
T O
lymphocytes O
by O
IFN B
- I
beta I
. O

The O
increased O
level O
of O
PLC O
gamma O
1 O
becomes O
evident O
after O
90 O
min O
of O
IFN B
- I
beta I
treatment O
and O
is O
still O
detectable O
after O
24 O
h O
. O

Neither O
the O
PLC O
gamma O
1 O
overexpression O
induced O
by O
IFN B
nor O
the O
increased O
hydrolytic O
activity O
of O
the O
enzyme B
appear O
to O
be O
affected O
by O
pretreatment O
of O
the O
cells O
with O
the O
protein O
tyrosine B
kinase I
inhibitor O
genistein O
, O
which O
is O
known O
to O
prevent O
the O
association O
of O
ISGF3 B
components O
. O

These O
results O
suggest O
that O
in O
human O
T O
lymphocytes O
IFN B
- I
beta I
can O
activate O
other O
transcription B
factor I
( O
s O
) O
distinct O
from O
ISGF3 B
to O
regulate O
PLC O
gamma O
1 O
expression O
. O

Moreover O
, O
anti B
- I
TNF I
- I
alpha I
inhibited O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
- O
driven O
transcription O
of O
a O
reporter B
gene I
in O
primary O
T O
cells O
in O
response O
to O
activation O
, O
either O
in O
the O
presence O
or O
the O
absence O
of O
HIV B
- I
1 I
Tat I
. O

Our O
results O
support O
an O
important O
role O
for O
autocrine O
TNF B
- I
alpha I
secretion O
in O
controlling O
HIV O
replication O
in O
primary O
T O
cells O
because O
of O
its O
ability O
to O
maintain O
NF B
- I
kappa I
B I
elevated O
in O
the O
nucleus O
of O
T O
cells O
. O

Intercellular B
adhesion I
molecule I
1 I
( O
ICAM B
- I
1 I
) O
is O
an O
important O
molecule O
in O
promotion O
of O
polymorphonuclear O
neutrophil O
transendothelial O
migration O
during O
inflammation O
. O

These O
results O
indicate O
that O
JAK2 B
/ B
STAT5 I
activation O
is O
a O
common O
JAK B
/ B
STAT I
pathway O
for O
hIL B
- I
5 I
- O
mediated O
signal O
in O
these O
cells O
. O

Nuclear O
factor O
- O
kappa O
B O
( O
NF O
- O
kappa O
B O
) O
/ O
Rel O
transcription O
factors O
may O
be O
involved O
in O
atherosclerosis O
, O
as O
is O
suggested O
by O
the O
presence O
of O
activated O
NF B
- I
kappa I
B I
in O
human O
atherosclerotic O
lesions O
. O

This O
activation O
of O
NF B
- I
kappa I
B I
was O
inhibited O
by O
the O
antioxidant O
and O
H2O2 O
scavenger O
pyrrolidine O
dithiocarbamate O
and O
the O
proteasome B
inhibitor O
PSI O
. O

The O
oxLDL B
- O
induced O
NF B
- I
kappa I
B I
activation O
was O
accompanied O
by O
an O
initial O
depletion O
of O
I B
kappa I
B I
- I
alpha I
followed O
by O
a O
slight O
transient O
increase O
in O
the O
level O
of O
this O
inhibitor O
protein O
. O

These O
observations O
provide O
additional O
evidence O
that O
oxLDL B
is O
a O
potent O
modulator O
of O
gene O
expression O
and O
suggest O
that O
( O
dys O
) O
regulation O
of O
NF B
- I
kappa I
B I
/ I
Rel I
is O
likely O
to O
play O
an O
important O
role O
in O
atherogenesis O
. O

PURPOSE O
: O
To O
demonstrate O
that O
leukocyte O
adhesion O
to O
cultured O
corneal O
endothelial O
cells O
is O
mediated O
by O
the O
CD18 O
antigen O
, O
and O
to O
determine O
whether O
dexamethasone O
directly O
suppresses O
adhesion O
by O
inhibiting O
activation O
of O
nuclear B
factor I
kappa I
B I
( O
NFkappaB B
) O
. O

RESULTS O
: O
Neutrophil O
adhesion O
to O
cultured O
corneal O
endothelial O
cells O
increased O
significantly O
on O
exposure O
to O
TNFalpha B
( O
451 O
. O
4 O
+ O
/ O
- O
45 O
. O
4 O
cells O
/ O
mm2 O
, O
n O
= O
16 O
) O
compared O
to O
control O
( O
156 O
. O
7 O
+ O
/ O
- O
27 O
. O
3 O
cells O
/ O
mm2 O
, O
n O
= O
16 O
, O
P O
< O
0 O
. O
01 O
) O
. O

The O
transcriptional O
start O
sites O
were O
identified O
by O
an O
RNase B
protection O
assay O
. O

Since O
GH B
stimulates O
the O
development O
and O
function O
of O
granulocytes O
, O
we O
investigated O
the O
expression O
of O
GH B
in O
granulocyte O
subsets O
. O

In O
addition O
, O
BHRF1 B
protected O
these O
cells O
from O
monocyte O
- O
mediated O
killing O
but O
failed O
to O
protect O
them O
from O
killing O
mediated O
by O
lymphokine O
- O
activated O
killer O
cells O
. O

Genomic O
organization O
, O
sequence O
, O
and O
transcriptional O
regulation O
of O
the O
human B
eotaxin I
gene I
. O

The O
pp52 B
promoter I
contains O
an O
initiator O
specifying O
the O
unique O
5 O
' O
terminus O
of O
pp52 O
mRNA O
, O
tandem O
pairs O
of O
Ets O
and O
SP1 O
motifs O
, O
and O
a O
lone O
C O
/ O
EBP O
motif O
. O

BACKGROUND O
: O
Recent O
studies O
have O
raised O
the O
hypothesis O
that O
glucocorticoids O
could O
diminish O
the O
ability O
of O
endothelial O
cells O
to O
direct O
leukocyte O
traffic O
into O
inflamed O
tissues O
by O
inhibiting O
expression O
of O
the O
adhesion B
molecules I
endothelial B
- I
leukocyte I
adhesion I
molecule I
- I
1 I
and O
intercellular B
adhesion I
molecule I
- I
1 I
. O

The O
immediate O
- O
early O
gene O
product O
Egr B
- I
1 I
regulates O
the O
human O
interleukin O
- O
2 O
receptor O
beta O
- O
chain O
promoter O
through O
noncanonical O
Egr O
and O
Sp1 O
binding O
sites O
. O

In O
Jurkat O
cells O
, O
both O
sites O
were O
required O
for O
maximal O
IL B
- I
2Rbeta I
promoter O
activity O
, O
and O
in O
HeLaS3 O
cells O
, O
transfection O
of O
Egr B
- I
1 I
could O
drive O
activity O
of O
a O
reporter O
construct O
containing O
both O
sites O
. O

Acquisition O
of O
heat O
shock O
factor O
2 O
( O
HSF2 O
) O
DNA O
binding O
activity O
is O
accompanied O
by O
induced O
transcription O
of O
heat B
shock I
genes I
in O
hemin O
- O
treated O
K562 O
cells O
undergoing O
erythroid O
differentiation O
. O

These O
defects O
are O
paralleled O
by O
an O
impaired O
ability O
to O
produce O
Th1 B
cytokines I
( O
IL B
- I
2 I
and O
IFN B
- I
gamma I
) O
. O

Like O
the O
class B
II I
genes I
, O
the O
HLA O
- O
DM O
genes O
contain O
upstream O
regulatory O
sequences O
similar O
to O
the O
S O
- O
X O
- O
Y O
regulatory O
region O
as O
well O
as O
additional O
putative O
regulatory O
sites O
. O

The O
class O
II O
- O
specific O
transcription O
factors O
RFX B
and O
CIITA B
are O
also O
required O
for O
expression O
, O
as O
cell O
lines O
deficient O
in O
these O
factors O
failed O
to O
allow O
transcription O
from O
the O
DM B
promoters I
. O

In O
addition O
, O
in O
vivo O
footprint O
analysis O
showed O
the O
putative O
X B
and I
Y I
boxes I
to O
be O
occupied O
by O
transcription B
factors I
in O
wild O
- O
type O
B O
cells O
, O
but O
not O
in O
RFX O
- O
deficient O
B O
cells O
. O

Critical O
cytoplasmic B
domains I
of O
human O
interleukin O
- O
9 O
receptor O
alpha O
chain O
in O
interleukin B
- O
9 O
- O
mediated O
cell O
proliferation O
and O
signal O
transduction O
. O

In O
a O
previous O
study O
, O
we O
demonstrated O
that O
bufalin O
, O
which O
is O
an O
active O
principle O
of O
Chinese O
medicine O
, O
chan O
' O
su O
, O
caused O
apoptosis O
in O
human O
leukemia O
U937 O
cells O
by O
anomalous O
activation O
of O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
via O
the O
signaling O
pathway O
of O
Ras B
, O
Raf B
- I
1 I
, O
and O
MAPK B
kinase I
- I
1 I
. O

Here O
, O
we O
report O
the O
effect O
of O
overexpression O
of O
bcl B
- I
2 I
in O
U937 O
cells O
on O
the O
signaling O
pathway O
of O
apoptosis O
that O
is O
induced O
by O
bufalin O
. O

We O
report O
the O
identification O
and O
characterization O
of O
simple O
tandem O
repeat O
DNA O
polymorphisms O
in O
the O
genes O
encoding O
HNF O
- O
3alpha O
, O
- O
3beta O
, O
- O
3gamma O
, O
- O
4gamma O
, O
and O
- O
6 O
and O
the O
mapping O
of O
HNF O
- O
6 O
to O
chromosome B
bands I
15q21 O
. O
1 O
- O
21 O
. O
2 O
by O
fluorescence O
in O
situ O
hybridization O
. O

Anti B
- I
E I
. I
chaffeensis I
antibody I
complexed O
with O
E O
. O
chaffeensis O
significantly O
enhanced O
mRNA O
expression O
of O
IL B
- I
1beta I
in O
THP O
- O
1 O
cells O
. O

Decreased O
transcriptional O
activation O
by O
N O
- O
terminal O
deletions O
of O
CIITA B
is O
correlated O
directly O
with O
their O
reduced O
binding O
to O
TAFII32 B
. O

Ligand O
binding O
and O
activation O
of O
the O
IL B
- I
10 I
receptor I
expressed O
on O
B O
- O
CLL O
cells O
results O
in O
the O
phosphorylation O
of O
signal O
transducer O
and O
activator O
of O
transcription O
1 O
( O
STAT1 B
) O
and O
STAT3 B
proteins O
. O

When O
18C7 B
was O
incubated O
with O
MR B
before O
aldosterone O
or O
progesterone O
, O
the O
antibody O
inhibited O
75 O
- O
80 O
% O
of O
the O
binding O
. O

Molecular O
cloning O
of O
SLAP B
- I
130 I
, O
an O
SLP O
- O
76 O
- O
associated O
substrate O
of O
the O
T O
cell O
antigen O
receptor O
- O
stimulated O
protein O
tyrosine O
kinases O
. O

These O
data O
suggest O
that O
SLP B
- I
76 I
recruits O
a O
negative O
regulator O
, O
SLAP B
- I
130 I
, O
as O
well O
as O
positive O
regulators O
of O
signal O
transduction O
in O
T O
cells O
. O

From O
analyses O
of O
mice O
deficient O
in O
transcription B
factor I
genes I
and O
from O
the O
characterizations O
of O
chromosome O
breakpoints O
in O
human O
leukemias O
, O
it O
has O
become O
evident O
that O
transcription B
factors I
are O
important O
regulators O
of O
hematopoiesis O
. O

In O
THP O
- O
1 O
cells O
transfected O
with O
HIV O
plasmid O
constructs O
, O
both O
organisms O
induced O
transcription O
from O
the O
HIV B
long I
terminal I
repeat I
that O
was O
dependent O
on O
intact O
NF O
- O
kappaB O
binding O
sequences O
. O

In O
this O
report O
we O
present O
the O
characterisation O
of O
NF B
- I
kappaB I
subunits I
engaged O
in O
complexes O
binding O
to O
the O
HIV O
- O
1 O
NF O
- O
kappaB O
site O
in O
human O
8e51 O
T O
- O
cells O
, O
that O
harbour O
a O
defective O
HIV O
- O
1 O
. O

With O
the O
use O
of O
specific B
antibodies I
we O
have O
determined O
the O
composition O
of O
each O
complex O
using O
electrophoretic O
mobility O
shift O
assays O
. O

c B
- I
Myb I
and O
Ets B
proteins I
synergize O
to O
overcome O
transcriptional O
repression O
by O
ZEB B
. O

IL B
- I
4 I
- O
dependent O
activation O
of O
Stat6 B
was O
also O
observed O
in O
HC11 O
mammary O
epithelial O
cells O
. O

In O
these O
cells O
, O
Stat6 B
activation O
led O
to O
the O
induction O
of O
the O
beta O
- O
casein O
gene O
promoter O
. O

In O
pre O
- O
B O
cells O
( O
Ba O
/ O
F3 O
) O
, O
the O
transactivation O
domain O
of O
Stat6 B
was O
IL B
- I
4 I
regulated O
, O
independently O
from O
its O
DNA O
binding O
function O
. O

Activation O
of O
helper O
T O
cells O
results O
in O
coordinate O
expression O
of O
a O
number O
of O
cytokines B
involved O
in O
differentiation O
, O
proliferation O
and O
activation O
of O
the O
haematopoietic O
system O
. O

Granulocyte B
- I
macrophage I
colony I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
is O
one O
such O
cytokine B
, O
whose O
increased O
expression O
results O
mostly O
from O
increases O
in O
transcription O
. O

ETS1 B
is O
a O
transcription B
factor I
of O
the O
ETS B
family I
that O
is O
expressed O
in O
T O
cells O
. O

We O
have O
previously O
shown O
that O
ETS1 B
can O
transactivate O
GM B
- I
CSF I
in O
Jurkat O
T O
cells O
, O
but O
only O
after O
the O
cells O
have O
been O
stimulated O
by O
treatment O
with O
PMA O
and O
ionomycin O
, O
agents O
that O
mimic O
T O
cell O
activation O
. O

CD40 B
is O
an O
important O
signaling O
and O
activation O
Ag O
found O
on O
certain O
bone O
marrow O
- O
derived O
cells O
. O

Recently O
, O
CD40 B
also O
has O
been O
shown O
to O
be O
expressed O
by O
mesenchymal O
cells O
, O
including O
human O
fibroblasts O
. O

Little O
is O
known O
about O
the O
role O
of O
CD40 B
in O
fibroblasts O
. O

The O
current O
study O
investigates O
the O
hypothesis O
that O
CD40 B
expressed O
on O
lung O
fibroblasts O
is O
an O
activation O
structure O
and O
mechanism O
for O
interaction O
with O
hemopoietic O
cells O
. O

Signaling O
through O
CD40 B
with O
soluble O
CD40 B
ligand O
stimulated O
fibroblast O
activation O
, O
as O
evidenced O
by O
mobilization O
of O
nuclear O
factor O
- O
kappaB O
and O
by O
induction O
of O
the O
proinflammatory O
and O
chemoattractant O
cytokines B
IL B
- I
6 I
and O
IL B
- I
8 I
. O

In O
contrast O
, O
it O
was O
found O
to O
be O
TNF B
- I
alpha I
independent O
in O
the O
early O
time O
point O
. O

In O
fact O
, O
mAb B
L243 I
but O
not O
the O
staphylococcal B
superantigens I
, O
staphylococcal O
exotoxin O
toxic O
shock O
syndrome O
toxin O
- O
I O
or O
staphylococcal B
enterotoxin I
B I
, O
regulate O
the O
NF B
- I
kappa I
B I
binding O
activity O
. O

Fusion O
proteins O
involving O
the O
retinoic O
acid O
receptor O
alpha O
( O
RAR B
alpha I
) O
and O
the O
PML B
or O
PLZF O
nuclear O
protein O
are O
the O
genetic O
markers O
of O
acute O
promyelocytic O
leukemias O
( O
APLs O
) O
. O

Cytomegalovirus O
( O
CMV O
) O
infection O
induced O
interleukin B
- I
8 I
( O
IL B
- I
8 I
) O
gene O
transcription O
in O
a O
human O
monocytic O
cell O
line O
, O
THP O
- O
1 O
cells O
, O
leading O
to O
IL B
- I
8 I
secretion O
. O

Moreover O
, O
electrophoretic O
mobility O
shift O
assays O
demonstrated O
that O
CMV O
induced O
the O
formation O
of O
NF B
- I
kappaB I
and O
AP B
- I
1 I
complexes I
. O

Interleukin B
- I
12 I
( O
IL B
- I
12 I
) O
is O
a O
cytokine B
that O
exhibits O
pleiotropic O
effects O
on O
lymphocytes O
and O
natural O
killer O
cells O
and O
has O
been O
shown O
to O
have O
promise O
for O
the O
immunotherapy O
of O
cancer O
. O

Plasma O
sialyltransferase B
levels O
in O
psychiatric O
disorders O
as O
a O
possible O
indicator O
of O
HPA O
axis O
function O
. O

While O
there O
was O
a O
significant O
increase O
in O
plasma O
cortisol O
levels O
in O
the O
depressed O
group O
, O
there O
were O
no O
changes O
in O
the O
lymphocyte O
GR B
binding O
parameters O
( O
K O
( O
m O
) O
and O
Bmax O
) O
. O

Using O
a O
previously O
described O
mutant O
of O
the O
Jurkat O
T O
cell O
line O
, O
we O
show O
that O
proximal O
signaling O
events O
dependent O
on O
the O
presence O
of O
the O
CD45 O
tyrosine O
phosphatase O
are O
required O
for O
TCR B
- O
stimulated O
CD95 B
ligand I
expression O
. O

Together O
, O
these O
studies O
begin O
a O
dissection O
of O
the O
biochemical O
events O
that O
lead O
to O
expression O
of O
CD95 B
ligand I
, O
a O
required O
step O
for O
TCR B
- O
induced O
apoptosis O
. O

Large O
germline O
deletions O
of O
TSC2 B
occur O
in O
< O
5 O
% O
of O
cases O
, O
and O
a O
number O
of O
small O
intragenic O
mutations O
have O
been O
described O
. O

TCP O
succinate O
( O
200 O
microM O
, O
24 O
h O
) O
reduced O
TNF O
- O
induced O
VCAM O
- O
1 O
and O
E B
- I
selectin I
expression O
from O
a O
specific O
mean O
fluorescence O
intensity O
of O
151 O
+ O
/ O
- O
28 O
to O
12 O
+ O
/ O
- O
4 O
channels O
and O
from O
225 O
+ O
/ O
- O
38 O
to O
79 O
+ O
/ O
- O
21 O
channels O
, O
respectively O
. O

The O
Eed B
- O
mediated O
transcriptional O
effects O
are O
likely O
to O
reflect O
the O
interaction O
of O
Eed B
with O
multiple O
molecular O
partners O
, O
including O
K B
protein I
. O

When O
macrophages O
were O
pretreated O
with O
low O
doses O
of O
IFN B
- I
gamma I
and O
then O
stimulated O
with O
IFN B
- I
alpha I
, O
clearly O
enhanced O
formation O
of O
specific O
transcription B
factor I
complexes O
was O
detected O
. O

Activation O
and O
regulation O
of O
NF B
- I
kappa I
B I
are O
tightly O
controlled O
by O
a O
group O
of O
inhibitory B
proteins I
( O
I B
kappa I
B I
) O
that O
sequester O
NF B
- I
kappa I
B I
in O
the O
cytoplasm O
of O
immune O
/ O
inflammatory O
effector O
cells O
. O

Liberated O
NF B
- I
kappa I
B I
migrates O
to O
the O
nucleus O
, O
where O
it O
binds O
to O
specific O
promoter O
sites O
and O
activates O
gene O
transcription O
. O

Constitutive O
expression O
of O
E2a B
- I
Pbx1 I
did O
not O
induce O
apoptosis O
or O
continued O
cycling O
of O
Rat O
- O
1 O
fibroblasts O
in O
low O
serum O
conditions O
. O

The O
human O
C O
/ O
EBPepsilon O
gene O
is O
transcribed O
by O
two O
alternative O
promoters B
, O
Palpha O
and O
Pbeta O
. O

A O
combination O
of O
differential O
splicing O
and O
alternative O
use O
of O
promoters B
generates O
four O
mRNA O
isoforms O
, O
of O
2 O
. O
6 O
kb O
and O
1 O
. O
3 O
- O
1 O
. O
5 O
kb O
in O
size O
. O

C B
/ I
EBPepsilon I
mRNA I
was O
greatly O
induced O
during O
in O
vitro O
granulocytic O
differentiation O
of O
human O
primary O
CD34 O
( O
+ O
) O
cells O
. O

We O
now O
report O
that O
PO B
- I
B I
DNA O
- O
binding O
in O
HL O
- O
60 O
cells O
is O
similarly O
induced O
during O
differentiation O
to O
the O
granulocytic O
lineage O
( O
with O
either O
retinoic O
acid O
or O
dimethylsulfoxide O
) O
. O

Recent O
studies O
have O
revealed O
that O
interactions O
between O
transcription B
factors I
play O
an O
important O
role O
in O
regulation O
of O
gene O
expression O
in O
eukaryotic O
cells O
. O

Oct B
- I
2 I
expressed O
in O
this O
tester O
strain O
represses O
the O
expression O
of O
the O
reporter O
gene O
and O
changes O
the O
phenotype O
of O
the O
cell O
from O
Lac O
+ O
to O
Lac O
- O
. O

One O
of O
them O
, O
hT86 O
, O
encoding O
a O
putative O
zinc O
finger O
protein O
was O
found O
to O
derepress O
beta B
- I
galactosidase I
activity O
in O
the O
Oct B
- I
2 I
- O
harboring O
tester O
strain O
at O
the O
transcriptional O
level O
. O

Thus O
, O
Tap B
is O
likely O
to O
be O
an O
important O
cellular O
mediator O
of O
Tip B
function O
in O
T O
cell O
transformation O
by O
herpesvirus O
saimiri O
. O

Triggering O
of O
the O
T B
- I
cell I
receptor I
- I
CD3 I
complex I
activates O
two O
major O
signal O
cascades O
in O
T O
lymphocytes O
, O
( O
i O
) O
Ca2 O
+ O
- O
dependent O
signal O
cascades O
and O
( O
ii O
) O
protein B
kinase I
cascades O
. O

Both O
signal O
cascades O
contribute O
to O
the O
induction O
of O
the O
interleukin B
2 I
( I
IL I
- I
2 I
) I
gene I
during O
T O
- O
cell O
activation O
. O

Functional O
analysis O
of O
monocytic O
THP O
- O
1 O
cells O
transfected O
with O
plasmids B
containing O
various O
lengths O
of O
TNF B
- I
alpha I
promoter I
localized O
enhancer B
elements I
in O
a O
region O
( O
- O
182 O
to O
- O
37 O
base O
pairs O
( O
bp O
) O
) O
that O
were O
required O
for O
optimal O
transcription O
of O
the O
TNF B
- I
alpha I
gene I
in O
response O
to O
LPS O
. O

In O
unstimulated O
THP O
- O
1 O
, O
CRE O
- O
binding O
protein O
and O
, O
to O
a O
lesser O
extent O
, O
c O
- O
Jun O
complexes O
were O
found O
to O
bind O
to O
the O
CRE B
site I
. O

The O
CRE O
and O
kappaB3 O
sites O
in O
region B
II I
together O
conferred O
strong O
LPS O
responsiveness O
to O
a O
heterologous B
promoter I
, O
whereas O
individually O
they O
failed O
to O
provide O
transcriptional O
activation O
. O

Furthermore O
, O
increasing O
the O
spacing O
between O
the O
CRE O
and O
the O
kappaB3 O
sites O
completely O
abolished O
LPS O
induction O
, O
suggesting O
a O
cooperative O
interaction O
between O
c O
- O
Jun O
complexes O
and O
p50 B
/ I
p65 I
. O

IFN B
- I
alpha I
/ I
beta I
specifically O
induced O
tyrosine O
phosphorylation O
and O
translocation O
into O
nucleus O
of O
signal O
transducers O
and O
activators O
of O
transcription O
( O
STAT O
) O
2 O
protein O
in O
the O
T O
cell O
clones O
. O

IL B
- I
10 I
inhibition O
of O
IFN B
- I
gamma I
- O
induced O
ICAM B
- I
1 I
expression O
was O
apparent O
as O
early O
as O
3 O
hours O
and O
was O
blocked O
by O
an O
anti O
- O
IL O
- O
10 O
antibody O
but O
not O
by O
an O
isotype O
- O
matched O
control O
antibody O
. O

The O
other O
, O
CIITA B
, O
encodes O
a O
large O
protein O
with O
a O
defined O
acidic O
transcriptional O
activation O
domain O
; O
this O
protein O
does O
not O
interact O
with O
DNA O
. O

However O
, O
these O
plasmids B
produced O
transcriptional O
activity O
in O
HeLa O
cells O
only O
in O
conjunction O
with O
interferon B
gamma I
stimulation O
, O
a O
condition O
in O
which O
expression O
of O
both O
CIITA B
and O
class O
II O
major O
histocompatibility O
complex O
surface O
proteins O
are O
induced O
. O

Thus O
, O
RFX5 B
can O
activate O
transcription O
only O
in O
cooperation O
with O
CIITA B
. O

Phosphatidylinositol B
3 I
- I
kinase I
( O
PI3 B
- I
K I
) O
has O
been O
implicated O
in O
the O
regulation O
of O
cell O
proliferation O
in O
many O
cell O
types O
. O

Acute O
promyelocytic O
leukemia O
( O
APL O
) O
is O
associated O
with O
reciprocal O
chromosomal O
translocations O
involving O
the O
retinoic O
acid O
receptor O
alpha O
( O
RARalpha O
) O
locus O
on O
chromosome B
17 I
. O

The O
resulting O
fusion O
genes O
encode O
the O
two O
structurally O
unique O
PML B
/ I
RARalpha I
and O
RARalpha O
/ O
PML O
fusion O
proteins O
as O
well O
as O
aberrant O
PML O
gene O
products O
, O
the O
respective O
pathogenetic O
roles O
of O
which O
have O
not O
been O
elucidated O
. O

Interferon O
- O
gamma O
( O
IFN B
- I
gamma I
) O
is O
a O
key O
cytokine O
of O
T O
lymphocytes O
with O
major O
regulatory O
functions O
in O
the O
immune O
system O
. O

This O
novel O
target O
site O
, O
denoted O
the O
C B
- I
site I
, O
was O
shown O
by O
several O
criteria O
, O
including O
cell O
distribution O
studies O
, O
stimulation O
experiments O
, O
supershift O
assays O
, O
and O
cross O
- O
competition O
electrophoretic O
mobility O
shift O
assays O
to O
bind O
the O
transcription B
factor I
AP I
- I
1 I
. O

Mutation O
of O
the O
C B
- I
site I
that O
prevented O
AP B
- I
1 I
binding O
to O
this O
site O
was O
sufficient O
strikingly O
to O
reduce O
inducible O
promoter O
activity O
in O
primary O
CD45R0 O
T O
cells O
. O

The O
involvement O
of O
the O
CCK B
( I
B I
) I
receptor I
in O
such O
a O
stimulation O
was O
demonstrated O
by O
the O
inhibiting O
effect O
of O
the O
selective O
CCK B
( I
B I
) I
receptor I
antagonist O
PD O
- O
135 O
, O
158 O
. O

To O
better O
understand O
the O
AP B
- I
1 I
- O
dependent O
luciferase B
expression O
in O
Jurkat O
T O
cells O
, O
we O
tested O
two O
specific O
inhibitors O
of O
serine O
/ O
threonine O
phosphatases O
- O
1 O
and O
- O
2A O
: O
okadaic O
acid O
and O
calyculin O
A O
. O

In O
Jurkat O
T O
cells O
activated O
by O
phorbol O
- O
12 O
- O
myristate O
- O
13 O
- O
acetate O
and O
phytohemagglutinin B
, O
CCK O
- O
8 O
induced O
IL O
- O
2 O
expression O
. O

Our O
results O
indicate O
that O
CCK O
- O
8 O
exerts O
a O
trophic O
effect O
in O
Jurkat O
T O
cells O
through O
stimulation O
of O
CCK B
( I
B I
) I
receptors I
by O
modulation O
of O
expression O
of O
AP O
- O
1 O
- O
regulated O
genes O
. O

Binding B
sites I
at O
the O
core O
region O
show O
little O
conservation O
with O
consensus O
sites O
. O

While O
the O
activation O
of O
JAK2 B
, O
Shc B
, O
Erk B
, O
and O
STAT5 B
proteins I
correlated O
with O
hGM B
- I
CSF I
- O
mediated O
cell O
growth O
, O
cellular O
differentiation O
occurred O
in O
the O
absence O
of O
activation O
of O
these O
signal O
transduction O
pathways O
. O

Molecular O
cloning O
and O
characterization O
of O
a O
cDNA B
, O
CHEMR1 B
, O
encoding O
a O
chemokine B
receptor I
with O
a O
homology O
to O
the O
human O
C O
- O
C O
chemokine O
receptor O
, O
CCR O
- O
4 O
. O

Chemokines B
refer O
to O
a O
rapidly O
expanding O
family O
of O
small O
cytokines B
whose O
primary O
function O
is O
recruitment O
of O
leukocytes O
to O
inflammatory O
sites O
. O

This O
suggests O
that O
CHEMR1 B
may O
be O
a O
receptor O
for O
unidentified O
C O
- O
C O
chemokine O
or O
a O
low O
- O
affinity O
receptor O
for O
MIP B
- I
1alpha I
. O

Its O
N B
- I
terminal I
region I
is O
capable O
of O
activating O
transcription O
from O
a O
reporter O
gene O
when O
fused O
to O
a O
DNA B
binding I
domain I
. O

To O
understand O
the O
mechanisms O
underlined O
in O
this O
regulation O
in O
normal O
human O
cells O
, O
we O
have O
analysed O
in O
vivo O
protein O
- O
DNA O
interactions O
at O
the O
Cyclin B
A I
locus O
in O
primary O
T O
lymphocytes O
. O

The O
third O
site O
was O
occupied O
in O
quiescent O
cells O
or O
in O
cells O
stimulated O
by O
anti B
CD2 I
or O
anti B
CD28 I
alone O
. O

Human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
Tat I
, O
an O
early O
regulatory B
protein I
that O
is O
critical O
for O
viral O
gene O
expression O
and O
replication O
, O
transactivates O
the O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
via O
its O
binding O
to O
the O
transactivation O
response O
element O
( O
TAR B
) O
and O
, O
along O
with O
other O
cellular O
factors O
, O
increases O
viral O
transcription O
initiation O
and O
elongation O
. O

In O
this O
study O
, O
a O
combined O
pharmacologic O
and O
genetic O
strategy O
using O
two O
PKC B
( O
NF B
- I
kappa I
B I
) O
inhibitors O
, O
pentoxifylline O
( O
PTX O
) O
and O
Go O
- O
6976 O
, O
and O
a O
stably O
expressed O
anti O
- O
Tat O
single O
- O
chain O
intracellular O
antibody O
( O
sFv O
intrabody O
) O
was O
employed O
to O
obtain O
cooperative O
inhibition O
of O
both O
HIV O
- O
1 O
LTR B
- O
driven O
gene O
expression O
and O
HIV O
- O
1 O
replication O
. O

Treatment O
of O
cells O
with O
PTX O
and O
Go O
- O
6976 O
resulted O
in O
cooperative O
inhibition O
of O
both O
HIV B
- I
1 I
LTR I
- O
driven O
gene O
expression O
and O
HIV O
- O
1 O
replication O
. O

The O
combined O
treatment O
resulted O
in O
more O
durable O
inhibition O
of O
HIV O
- O
1 O
replication O
than O
was O
seen O
with O
the O
NF B
- I
kappa I
B I
inhibitors O
alone O
or O
the O
anti O
- O
Tat O
sFv O
intrabodies O
alone O
. O

CD28 B
is O
an O
important O
costimulatory O
molecule O
in O
the O
activation O
of O
human O
T O
cells O
. O

Also O
in O
the O
current O
study O
, O
binding O
activity O
to O
the O
CD28RE O
/ O
AP O
- O
1 O
sequence O
of O
the O
IL B
- I
2 I
promoter I
is O
evaluated O
. O

These O
data O
indicate O
that O
functional O
complexes O
encompassing O
both O
the O
CD28RE B
and O
the O
AP B
- I
1 I
- I
binding I
sites I
influence O
IL B
- I
2 I
promoter I
activity O
in O
CD28 B
- O
costimulated O
T O
cells O
. O

Upon O
activation O
of O
Jurkat O
T O
cells O
and O
primary O
murine O
thymocytes O
with O
phorbol O
esters O
and O
ionomycin O
, O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
expression O
and O
transactivation O
function O
were O
induced O
. O

In O
fact O
, O
the O
offspring O
of O
alcoholics O
have O
higher O
levels O
of O
G B
( I
S I
) I
alpha I
expression O
in O
certain O
tissues O
compared O
with O
the O
offspring O
of O
nonalcoholics O
. O

The O
aim O
of O
this O
research O
was O
to O
test O
the O
hypothesis O
that O
a O
causal O
relationship O
exists O
between O
the O
level O
of O
expression O
of O
G B
( I
S I
) I
alpha I
and O
induction O
of O
the O
adenylyl B
cyclase I
( O
AC O
) O
cascade O
. O

The O
methodology O
employed O
transient O
transfection O
of O
HEK O
293 O
cells O
with O
a O
cDNA O
for O
the O
52 O
- O
kDa O
form O
of O
G B
( I
S I
) I
alpha I
under O
regulation O
by O
inducible O
metallothionein O
promoters O
. O

VSMCs O
derived O
from O
human O
coronary O
atherosclerotic O
plaques O
that O
apoptose O
even O
in O
serum O
also O
generated O
thrombin B
( O
AUC O
of O
260 O
+ O
/ O
- O
2 O
nmol O
x O
min O
/ O
L O
; O
PT O
of O
128 O
+ O
/ O
- O
4 O
nmol O
/ O
L O
) O
. O

Patients O
with O
one O
type O
of O
major O
histocompatibility O
complex O
class O
II O
combined O
immunodeficiency O
have O
mutations O
in O
a O
gene O
termed O
class B
II I
transactivator I
( O
CIITA B
) O
, O
which O
coordinately O
controls O
the O
transcription O
of O
the O
three O
major O
human O
class O
II O
genes O
, O
HLA O
- O
DR O
, O
- O
DQ O
, O
and O
- O
DP O
. O

We O
report O
here O
that O
ectopic O
expression O
of O
CIITA O
cDNAs O
derived O
by O
reverse O
transcriptase O
polymerase O
chain O
reaction O
from O
clone O
13 O
do O
not O
restore O
expression O
of O
HLA B
- I
DQ I
in O
another O
CIITA O
- O
deficient O
cell O
line O
, O
RJ2 O
. O
2 O
. O
5 O
. O

In O
contrast O
, O
somatic O
cell O
fusion O
between O
clone O
13 O
and O
RJ2 O
. O
2 O
. O
5 O
restored O
expression O
of O
the O
HLA B
- I
DQ I
haplotype O
encoded O
by O
the O
RJ2 O
. O
2 O
. O
5 O
DQB O
gene O
. O

The O
cytokines B
interleukin B
( I
IL I
) I
- I
4 I
and O
IL B
- I
13 I
play O
a O
critical O
role O
in O
inducing O
Cepsilon B
germline I
transcripts I
and O
IgE B
isotype I
switching O
in O
human O
B O
cells O
. O

We O
show O
that O
ligand O
- O
induced O
homodimerization O
of O
chimeric O
surface O
receptors O
consisting O
of O
the O
extracellular O
and O
transmembrane O
domains O
of O
the O
erythropoietin B
receptor I
and O
of O
the O
intracellular B
domain I
of O
IL B
- I
4Ralpha I
induces O
Janus O
kinase O
1 O
( O
Jak1 B
) O
activation O
, O
STAT6 B
activation O
, O
and O
Cepsilon B
germline I
transcripts I
in O
human O
B O
cell O
line O
BJAB O
. O

Analysis O
of O
these O
PBLs O
revealed O
that O
activation O
of O
the O
NF B
- I
kappaB I
pathway O
is O
sufficient O
to O
promote O
the O
growth O
response O
to O
IL B
- I
2 I
. O

To O
understand O
the O
molecular O
mechanisms O
controlling O
CD19 B
gene O
expression O
, O
we O
isolated O
and O
functionally O
characterized O
the O
CD19 B
promoter I
using O
in O
vivo O
footprinting O
, O
gel O
shift O
assays O
, O
and O
transfection O
studies O
. O

EBF B
and O
E47 B
collaborate O
to O
induce O
expression O
of O
the O
endogenous B
immunoglobulin I
surrogate I
light I
chain I
genes I
. O

Taken O
together O
, O
these O
data O
suggest O
that O
EBF B
and O
E47 B
synergize O
to O
activate O
expression O
of O
a O
subset O
of O
genes O
that O
define O
an O
early O
stage O
of O
the O
B O
cell O
lineage O
. O

Treatment O
of O
cells O
expressing O
the O
chimeric B
receptor I
kit B
/ I
IL I
- I
4R I
alpha I
with O
SCF B
induces O
activation O
of O
the O
IL O
- O
4R O
alpha O
- O
associated O
kinase O
JAK B
- I
1 I
and O
the O
transcription B
factor I
STAT6 B
. O

Dose O
- O
dependence O
studies O
using O
histamine O
and O
dimaprit O
showed O
that O
the O
EC50 O
values O
for O
cAMP O
production O
and O
c B
- I
fos I
increase O
were O
similar O
, O
suggesting O
that O
cAMP O
might O
be O
involved O
in O
c B
- I
fos I
induction O
via O
H2 B
receptors I
. O

After O
4 O
hours O
, O
IL B
- I
1 I
beta I
and O
IL B
- I
8 I
concentration O
of O
the O
cell O
- O
free O
supernatant O
had O
increased O
by O
268 O
+ O
/ O
- O
36 O
% O
and O
210 O
+ O
/ O
- O
7 O
% O
, O
respectively O
, O
and O
cellular O
MCP B
- I
1 I
content O
had O
increased O
by O
170 O
+ O
/ O
- O
8 O
% O
. O

Clonal O
analysis O
revealed O
individual O
responses O
to O
the O
two O
immediate O
early O
proteins O
BZLF1 B
and O
BRLF1 B
, O
and O
to O
three O
( O
BMLF1 B
, O
BMRF1 B
, O
and O
BALF2 O
) O
of O
the O
six O
early O
proteins O
tested O
. O

Triggering O
of O
HLA B
class I
II I
antigens I
by O
the O
anti O
- O
HLA O
- O
DR O
monoclonal O
antibody O
( O
mAb O
) O
L243 O
significantly O
( O
P O
< O
0 O
. O
05 O
) O
and O
differentially O
enhanced O
the O
release O
of O
tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
by O
the O
non O
- O
Hodgkin O
' O
s O
lymphoma O
cells O
Ri O
- O
I O
, O
Ci O
- O
I O
, O
and O
Sc O
- O
I O
, O
which O
are O
at O
a O
distinct O
stage O
of O
B O
- O
cell O
differentiation O
, O
and O
by O
the O
more O
mature O
Burkitt O
lymphoma O
cell O
Raji O
; O
in O
contrast O
, O
it O
did O
not O
induce O
TNF O
- O

Altogether O
, O
our O
data O
demonstrate O
that O
: O
( O
a O
) O
the O
ability O
of O
B O
cells O
to O
release O
TNF O
- O
alpha O
after O
triggering O
of O
HLA B
- I
DR I
antigens I
depends O
on O
their O
stage O
of O
differentiation O
; O
( O
b O
) O
levels O
of O
released O
TNF B
- I
alpha I
seem O
to O
correlate O
with O
the O
stage O
of O
B O
- O
cell O
maturation O
but O
do O
not O
correlate O
with O
the O
amounts O
of O
cell O
surface O
HLA O
- O
DR O
antigens O
; O
( O
c O
) O
secreted O
TNF B
- I
alpha I
regulates O
the O
levels O
of O
expression O
of O
NF B
- I
kappa I
B I
and O
AP B
- I
1 I
by O
an O
autocrine O
loop O
; O
and O
( O
d O
) O
intracellular O
signals O
mediating O

TNF B
- I
alpha I
release O
by O
B O
cells O
are O
distinct O
from O
those O
regulating O
homotypic O
aggregation O
and O
proliferation O
. O

To O
identify O
genes O
that O
are O
expressed O
in O
T O
cells O
after O
stimulation O
, O
mRNA O
from O
T O
lymphocytes O
that O
had O
been O
activated O
by O
the O
simultaneous O
stimulation O
of O
the O
CD3 B
and O
CD28 B
trigger O
molecules O
was O
transcribed O
for O
a O
differential O
mRNA O
display O
analysis O
into O
cDNA O
and O
was O
compared O
with O
cDNA O
from O
CD28 B
- O
or O
CD3 B
- O
activated O
or O
resting O
lymphocytes O
. O

The O
predictive O
protein O
- O
coding O
region O
of O
RP1 B
had O
a O
significant O
homology O
to O
members O
of O
the O
recently O
found O
adenomatous O
polyposis O
coli O
( O
APC O
) O
protein O
- O
binding O
EB1 O
gene O
family O
, O
which O
codes O
for O
yet O
unknown O
protein O
( O
s O
) O
. O

Bacterially O
expressed O
RP1 O
protein O
revealed O
specific O
binding O
to O
wild B
- I
type I
but O
not O
to O
mutated O
APC O
protein O
. O

Cyclosporin O
A O
interferes O
with O
the O
inducible O
degradation O
of O
NF B
- I
kappa I
B I
inhibitors O
, O
but O
not O
with O
the O
processing O
of O
p105 O
/ O
NF B
- I
kappa I
B1 I
in O
T O
cells O
. O

We O
show O
for O
human O
Jurkat O
T O
leukemia O
cells O
, O
as O
well O
as O
human O
and O
mouse O
primary O
T O
lymphocytes O
, O
that O
this O
inhibitory O
effect O
is O
accompanied O
by O
an O
impaired O
nuclear O
translocation O
of O
the O
Rel B
proteins I
c B
- I
Rel I
, O
RelA B
/ I
p65 I
and O
NF O
- O
kappa O
B1 O
/ O
p50 O
, O
whereas O
the O
nuclear O
appearance O
of O
RelB B
remains O
unaffected O
. O

Accordingly O
, O
immunoblot O
experiments O
showed O
that O
amongst O
NF B
- I
kappa I
B I
/ B
Rel I
proteins I
, O
RelA B
and O
p50 B
are O
mobilized O
to O
the O
nucleus O
following O
microglial O
cell O
stimulation O
with O
A O
beta O
( O
25 O
- O
35 O
) O
plus O
IFN B
gamma I
. O

Higher O
concentrations O
of O
A O
beta O
( O
25 O
- O
35 O
) O
were O
effective O
by O
themselves O
in O
inducing O
NF B
- I
kappa I
B I
activation O
, O
both O
in O
the O
N9 O
microglial O
cell O
line O
and O
in O
rat O
primary O
microglia O
, O
as O
well O
as O
in O
human O
monocytes O
. O

For O
purposes O
of O
comparison O
, O
microglia O
were O
also O
stimulated O
with O
bacterial O
LPS O
, O
a O
known O
NF B
- I
kappa I
B I
inducer O
. O

As O
expected O
, O
LPS O
strongly O
induced O
the O
formation O
of O
two O
NF B
- I
kappa I
B I
DNA O
- O
binding O
activities O
, O
one O
of O
which O
was O
identified O
as O
RelA O
/ O
p50 O
. O

Collectively O
, O
these O
findings O
indicate O
that O
NF B
- I
kappa I
B I
activation O
might O
constitute O
one O
of O
the O
mechanisms O
underlying O
the O
inducible O
expression O
of O
kappa O
B O
- O
dependent O
genes O
in O
microglia O
stimulated O
by O
A O
beta O
peptides O
and O
IFN B
gamma I
, O
or O
by O
LPS O
. O

We O
have O
generated O
transgenic O
mice O
that O
express O
a O
catalytically B
inactive I
form I
of O
Ca2 B
+ I
/ I
calmodulin I
- I
dependent I
protein I
kinase I
IV I
( O
CaMKIV B
) O
specifically O
in O
thymic O
T O
cells O
. O

We O
isolated O
a O
new O
mouse B
gene I
that O
is O
highly O
expressed O
in O
thymocytes O
, O
testis O
, O
and O
brain O
. O

Rabbit O
antiserum O
raised O
against O
a O
COOH O
- O
terminal O
polypeptide O
of O
the O
SRG3 B
recognized O
a O
protein O
with O
an O
apparent O
molecular O
mass O
of O
155 O
kD O
. O

Transcriptional O
induction O
of O
collagenase B
- I
1 I
in O
differentiated O
monocyte O
- O
like O
( O
U937 O
) O
cells O
is O
regulated O
by O
AP B
- I
1 I
and O
an O
upstream O
C O
/ O
EBP O
- O
beta O
site O
. O

In O
particular O
, O
Western O
, O
supershift O
, O
and O
promoter O
deletion O
analyses O
suggested O
a O
role O
for O
CCAAT O
/ O
enhancer O
- O
binding O
protein O
- O
beta O
( O
C O
/ O
EBP O
- O
beta O
) O
binding O
site O
between O
- O
2010 O
and O
- O
1954 O
in O
regulating O
transcription O
of O
collagenase B
- I
1 I
in O
monocytic O
cells O
. O

It O
has O
been O
recently O
claimed O
that O
polymorphism O
for O
the O
vitamin B
D I
receptor I
( O
VDR B
) O
influences O
several O
aspects O
of O
calcium O
and O
bone O
metabolism O
. O

To O
evaluate O
the O
physiologic O
plausibility O
of O
these O
claims O
, O
we O
compared O
the O
abundance O
of O
the O
VDR B
mRNA I
in O
peripheral O
blood O
mononuclear O
cells O
( O
PBMCs O
) O
between O
different O
VDR O
genotypes O
using O
a O
quantitative O
reverse O
transcribed O
polymerase O
chain O
reaction O
- O
based O
method O
. O

The O
concentration O
of O
the O
VDR B
mRNA I
, O
corrected O
for O
the O
number O
of O
monocytes O
, O
was O
similar O
among O
the O
three O
genotype O
groups O
, O
as O
were O
the O
other O
variables O
examined O
: O
serum O
calcitriol O
, O
serum O
osteocalcin O
, O
and O
vertebral O
and O
hip O
bone O
density O
. O

Unexpectedly O
, O
a O
second O
, O
stronger O
RBP B
- I
Jkappa I
- I
binding I
site I
, O
which O
lies O
within O
the O
intracellular B
domain I
close O
to O
the O
transmembrane O
region O
and O
significantly O
augments O
association O
with O
RBP B
- I
Jkappa I
, O
was O
not O
needed O
for O
oncogenesis O
or O
for O
transcriptional O
activation O
. O

In O
support O
of O
this O
interpretation O
, O
mutation O
of O
putative O
nuclear B
localization I
sequences I
decreased O
nuclear O
localization O
and O
increased O
transcriptional O
activation O
by O
membrane B
- I
bound I
DeltaE I
. O

These O
studies O
have O
indicated O
that O
the O
individual O
repeats O
are O
not O
identical O
with O
respect O
to O
the O
cellular B
factors I
with O
which O
they O
interact O
. O

EMS O
analyses O
utilizing O
a O
series O
of O
mutated O
pp O
repeat O
elements O
demonstrate O
that O
the O
nucleotide O
sequence O
requirements O
for O
U1 B
( O
U1A B
/ I
U1B I
) O
and O
U2 B
formation O
are O
separable O
from O
those O
required O
for O
C1 B
- I
C3 I
formation O
. O

EMS O
supershift O
analyses O
have O
demonstrated O
that O
Sp1 B
is O
involved O
in O
U1A O
formation O
while O
Sp3 B
is O
involved O
in O
U1B O
and O
U2 O
formation O
. O

Signal B
transducer I
and I
activator I
of I
transcription I
- I
3 I
( O
STAT3 B
) O
is O
constitutively O
activated O
in O
normal O
, O
self O
- O
renewing O
B O
- O
1 O
cells O
but O
only O
inducibly O
expressed O
in O
conventional O
B O
lymphocytes O
[ O
see O
comments O
] O

Cytokine B
and O
growth O
factor O
receptor O
engagement O
leads O
to O
the O
rapid O
phosphorylation O
and O
activation O
of O
latent O
, O
cytosolic O
signal O
transducers O
and O
activators O
of O
transcription O
( O
STAT O
) O
proteins O
, O
which O
then O
translocate O
to O
the O
nucleus O
where O
they O
regulate O
transcriptional O
events O
from O
specific O
promoter O
sequences O
. O

Induction O
of O
STAT3 B
is O
inhibited O
by O
both O
the O
serine O
/ O
threonine O
protein O
kinase O
inhibitor O
H O
- O
7 O
and O
the O
immunosuppressive O
drug O
rapamycin O
and O
requires O
de O
novo O
protein O
synthesis O
, O
demonstrating O
novel O
coupling O
between O
sIg B
and O
STAT B
proteins I
that O
differs O
from O
the O
classical O
paradigm O
for O
STAT B
induction O
by O
cytokine B
receptors I
. O

This O
effect O
was O
specifically O
due O
to O
Tat B
, O
since O
Jurkat O
and O
U937 O
cells O
cotransfected O
either O
with O
tat B
cDNA I
in O
antisense O
orientation O
( O
tat O
/ O
AS O
) O
, O
tat B
carrying O
a O
mutation O
in O
the O
aminoacid O
cys22 O
- O
gly22 O
( O
tat O
22 O
/ O
S O
) O
or O
with O
the O
backbone O
vector O
alone O
( O
pRPneo O
- O
SL3 O
) O
did O
not O
show O
any O
significant O
difference O
in O
c B
- I
fos I
promoter I
activity O
as O
compared O
to O
cells O
transfected O
with O
FC3 O
plasmid O
alone O
. O

c B
- I
Fos I
protein O
was O
shown O
essential O
for O
an O
optimal O
transactivation O
of O
the O
HIV O
- O
1 O
long B
terminal I
repeat I
( O
LTR B
) O
by O
Tat B
: O
incubation O
of O
Jurkat O
cells O
with O
antisense O
, O
but O
not O
sense O
, O
c O
- O
fos O
oligonucleotides O
significantly O
reduced O
either O
the O
Tat B
- O
enhanced O
expression O
of O
an O
LTR O
- O
CAT O
reporter O
construct O
or O
the O
levels O
of O
gag O
p24 O
in O
the O
culture O
supernatants O
of O
Jurkat O
cells O
and O
PBMC O
acutely O
infected O
with O
HIV O
- O
1 O
. O

Regulation O
of O
the O
tissue B
factor I
gene I
in O
human O
monocytic O
cells O
. O

Role O
of O
AP B
- I
1 I
, O
NF B
- I
kappa I
B I
/ I
Rel I
, O
and O
Sp1 B
proteins O
in O
uninduced O
and O
lipopolysaccharide O
- O
induced O
expression O
. O

The O
human O
TF O
promoter O
contains O
binding O
sites O
for O
the O
transcription O
factors O
AP B
- I
1 I
, O
c O
- O
Rel O
/ O
p65 O
, O
Egr B
- I
1 I
, O
and O
Sp1 B
. O

The O
two O
AP B
- I
1 I
sites I
bound O
c B
- I
Fos I
/ I
c I
- I
Jun I
heterodimers I
in O
both O
unstimulated O
and O
LPS O
- O
stimulated O
cells O
. O

Inhibitory O
effect O
of O
growth O
hormone O
on O
TNF B
- I
alpha I
secretion O
and O
nuclear B
factor I
- I
kappaB I
translocation O
in O
lipopolysaccharide O
- O
stimulated O
human O
monocytes O
. O

The O
present O
study O
demonstrates O
that O
human O
THP O
- O
1 O
promonocytic O
cells O
, O
engineered O
by O
gene O
transfer O
to O
constitutively O
produce O
human O
growth O
hormone O
( O
hGH O
) O
, O
secreted O
depressed O
amounts O
of O
TNF B
- I
alpha I
in O
response O
to O
challenge O
by O
LPS O
. O

Previously O
, O
we O
showed O
that O
fibroblast O
conditioned O
medium O
( O
FCM O
) O
is O
able O
to O
inhibit O
both O
TNF B
mRNA I
accumulation O
and O
protein O
release O
in O
peripheral O
blood O
- O
derived O
human O
monocytes O
( O
PBM O
) O
stimulated O
with O
lipopolysaccharide O
( O
LPS O
) O
. O

Furthermore O
, O
we O
show O
that O
exogenous O
PGE2 O
mimics O
the O
NF B
- I
kappaB I
inhibitory O
effect O
of O
FCM O
. O

Immunoblot O
and O
flow O
cytometry O
analysis O
revealed O
a O
limited O
proteolysis O
of O
the O
carboxyl B
terminus I
of O
the O
alphaIIb B
subunit I
heavy I
chain I
( O
alphaIIbH B
) O
, O
as O
judged O
by O
the O
disappearance O
of O
the O
epitope O
for O
the O
monoclonal O
antibody O
PMI O
- O
1 O
. O

Treatment O
by O
NE B
of O
ATP O
- O
depleted O
platelets O
or O
Chinese O
hamster O
ovary O
cells O
expressing O
human O
recombinant O
alphaIIbbeta3 O
clearly O
established O
that O
activation O
of O
the O
integrin B
was O
independent O
of O
signal O
transduction O
events O
and O
was O
concomitant O
with O
the O
proteolysis O
of O
alphaIIbH B
. O

The O
suppression O
of O
productive O
LAI O
replication O
in O
naive O
T O
cells O
is O
not O
due O
to O
differential O
expression O
of O
viral O
coreceptors O
, O
nor O
is O
it O
due O
to O
inhibition O
of O
activation O
of O
the O
important O
HIV O
transcription B
factors I
, O
nuclear B
factor I
- I
kappaB I
and O
activator B
protein I
- I
1 I
. O

Redox O
regulation O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
pathway O
during O
lymphocyte O
activation O
. O

In O
earlier O
studies O
, O
we O
have O
identified O
the O
transcription B
factors I
NF B
- I
kappa I
B I
and O
AP B
- I
1 I
as O
molecular O
targets O
for O
oxidative O
signalling O
processes O
during O
cell O
cycle O
entry O
, O
and O
have O
shown O
that O
oxidative O
signalling O
is O
involved O
in O
the O
regulation O
of O
early O
changes O
in O
gene O
expression O
during O
the O
G0 O
to O
G1 O
phase O
transition O
. O

Using O
the O
yeast O
two O
- O
hybrid O
system O
to O
screen O
for O
proteins O
which O
interact O
with O
Tax1 B
, O
we O
isolated O
the O
B B
subunit I
of O
the O
CCAAT B
binding I
protein I
NF B
- I
Y I
from O
a O
HeLa O
cDNA O
library O
. O

The O
interaction O
of O
Tax1 B
with O
NF B
- I
YB I
was O
specific O
in O
that O
NF B
- I
YB I
did O
not O
interact O
with O
a O
variety O
of O
other O
transcription B
factors I
, O
including O
human O
immunodeficiency O
virus O
Tat O
, O
human O
papillomavirus O
E6 O
, O
and O
Bicoid O
, O
or O
with O
the O
M7 O
( O
amino O
acids O
29CP O
- O
AS O
) O
Tax1 O
mutant O
. O

However O
, O
NF B
- I
YB I
did O
interact O
with O
the O
C O
- O
terminal O
Tax1 O
mutants O
M22 B
( O
130TL O
- O
AS O
) O
and O
M47 B
( O
319LL O
- O
RS O
) O
. O

Through O
activation O
of O
this O
and O
other O
NF B
- I
Y I
driven O
promoters B
, O
the O
Tax1 B
- B
NF I
- I
Y I
interaction O
may O
play O
a O
critical O
role O
in O
causing O
cellular O
transformation O
and O
HTLV O
- O
1 O
pathogenesis O
. O

In O
murine O
Ba O
/ O
F3 O
cells O
transfected O
with O
the O
human O
G O
- O
CSFR O
and O
NFS O
- O
60 O
cells O
constitutively O
expressing O
the O
murine O
G O
- O
CSFR O
, O
G B
- I
CSF I
induced O
tyrosine O
phosphorylation O
and O
activation O
of O
Jak1 B
, O
Jak2 B
, O
and O
Tyk2 B
. O

Using O
a O
mitogenically O
incompetent O
human O
G O
- O
CSFR O
mutant O
in O
which O
Pro639 O
and O
Pro641 O
were O
substituted O
by O
alanine O
, O
the O
box O
1 O
PDP O
motif O
was O
found O
to O
be O
required O
for O
activation O
of O
Jak B
kinases I
, O
tyrosine O
phosphorylation O
of O
the O
G B
- I
CSFR I
, O
and O
recruitment O
of O
Stat B
proteins I
. O

Activation O
of O
the O
Jak B
- B
Stat I
pathway O
correlates O
with O
proliferative O
signaling O
by O
the O
G B
- I
CSFR I
and O
requires O
the O
membrane O
- O
proximal O
box O
1 O
PXP O
motif O
, O
which O
is O
conserved O
in O
members O
of O
the O
cytokine O
receptor O
superfamily O
. O

Impaired O
induction O
of O
c O
- O
fos O
/ O
c O
- O
jun O
genes O
and O
of O
transcriptional B
regulatory I
proteins I
binding O
distinct O
c O
- O
fos O
/ O
c O
- O
jun O
promoter O
elements O
in O
activated O
human O
T O
cells O
during O
aging O
. O

In O
addition O
, O
RNase B
protection O
assays O
revealed O
that O
anti O
- O
CD3 O
/ O
PMA O
- O
stimulated O
T O
cells O
from O
a O
substantial O
proportion O
of O
elderly O
subjects O
exhibited O
decreased O
levels O
of O
c O
- O
fos O
and O
/ O
or O
c O
- O
jun O
mRNA O
compared O
to O
T O
cells O
from O
young O
subjects O
. O

CONCLUSION O
: O
These O
studies O
suggest O
that O
RA O
can O
augment O
IL B
- I
2 I
mRNA I
production O
by O
T O
cells O
with O
a O
possible O
paracrine O
effect O
on O
IL B
- I
2R I
- I
alpha I
expression O
. O

Interleukin B
- I
6 I
levels O
are O
increased O
in O
lung O
transplant O
patients O
clinically O
diagnosed O
with O
CMV O
pneumonitis O
. O

In O
contrast O
, O
the O
RelA B
( I
p65 I
) I
subunit I
was O
barely O
detectable O
in O
monocytes O
, O
but O
its O
level O
increased O
markedly O
in O
MDMs O
. O

In O
MDMs O
, O
an O
upregulation O
of O
I B
kappa I
B I
alpha I
synthesis O
as O
well O
as O
the O
appearance O
of O
a O
novel O
M O
( O
r O
) O
40 O
, O
000 O
form O
of O
I B
kappa I
B I
alpha I
were O
also O
observed O
. O

However O
, O
the O
intensity O
of O
p65 B
labeling O
was O
much O
higher O
in O
several O
thymocytes O
from O
the O
medulla O
. O

These O
observations O
suggest O
that O
p65 O
and O
c O
- O
Rel O
complexes O
play O
distinct O
roles O
in O
gene O
expression O
and O
that O
both O
forms O
of O
NF B
- I
kappa I
B I
play O
critical O
roles O
during O
late O
stages O
of O
the O
intrathymic O
maturation O
of O
T O
cells O
. O

The O
function O
of O
LEF B
- I
1 I
is O
dependent O
, O
in O
part O
, O
on O
the O
HMG B
domain I
that O
induces O
a O
sharp O
bend O
in O
the O
DNA O
helix O
, O
and O
on O
an O
activation B
domain I
that O
stimulates O
transcription O
only O
in O
a O
specific O
context O
of O
other O
enhancer B
- I
binding I
proteins I
. O

Overexpression O
of O
ALY B
stimulates O
the O
activity O
of O
the O
TCR B
alpha I
enhancer I
complex I
reconstituted O
in O
transfected O
nonlymphoid O
HeLa O
cells O
, O
whereas O
down O
- O
regulation O
of O
ALY B
by O
anti O
- O
sense O
oligonucleotides O
virtually O
eliminates O
TCR B
alpha I
enhancer I
activity O
in O
T O
cells O
. O

AML1 B
may O
play O
a O
role O
in O
growth O
and O
differentiation O
of O
cells O
along O
erythroid O
and O
/ O
or O
megakaryocytic O
lineages O
, O
because O
a O
significant O
level O
of O
the O
AML1 B
gene O
is O
expressed O
in O
these O
cells O
. O

We O
overexpressed O
AML1a B
( O
without O
the O
transcription O
- O
activating O
domain O
) O
and O
AML1b B
( O
with O
the O
domain O
) O
proteins O
in O
K562 O
leukemia O
cells O
, O
which O
can O
be O
induced O
to O
differentiate O
into O
hemoglobin O
- O
producing O
cells O
and O
megakaryocytes O
. O

We O
have O
cloned O
and O
sequenced O
a O
portion O
of O
the O
ER B
upstream B
regulatory I
region I
from O
the O
ER O
- O
positive O
MCF O
- O
7 O
and O
the O
ER O
- O
negative O
MDA O
- O
MB O
- O
231 O
breast O
cancer O
cell O
lines O
to O
determine O
if O
sequence O
alterations O
in O
this O
region O
account O
for O
the O
ER B
- O
negative O
phenotype O
of O
some O
tumors O
. O

The O
influence O
of O
the O
anti O
- O
allergy O
agent O
azelastine O
hydrochloride O
( O
Azeptin O
) O
on O
NF B
- I
kappa I
B I
activation O
associated O
with O
the O
generation O
of O
cytokines B
and O
nitric O
oxide O
( O
NO O
) O
was O
investigated O
in O
various O
kinds O
of O
human O
and O
mouse O
cells O
. O

In O
parallel O
with O
the O
decreased O
cytokine B
generation O
, O
each O
cytokine B
mRNA I
was O
less O
expressed O
in O
the O
presence O
of O
10 O
( O
- O
5 O
) O
M O
Azeptin O
. O

In O
addition O
, O
both O
inducible O
nitric B
oxide I
synthase I
- O
mRNA O
level O
and O
NO O
generation O
in O
mouse O
peritoneal O
macrophages O
were O
suppressed O
by O
10 O
( O
- O
5 O
) O
M O
Azeptin O
. O

Using O
anti O
- O
C O
/ O
EBPbeta O
( O
NF B
- I
IL6 I
) O
, O
anti O
- O
C O
/ O
EBPdelta O
( O
NF B
- I
IL6beta I
) O
, O
anti O
- O
NF O
- O
ATc O
, O
anti B
- I
NF I
- I
ATp I
, O
anti B
- I
Fos I
, O
and O
anti O
- O
Jun O
Abs O
we O
demonstrate O
that O
the O
previously O
identified O
PRE O
- O
I O
binding O
factor O
POS B
- I
1 I
is O
composed O
of O
different O
transcription B
factors I
in O
different O
Th O
cell O
subsets O
. O

Different O
cytokines B
activate O
transcription O
at O
the O
appropriate O
germline B
promoter I
. O

A O
molecular O
basis O
for O
induction O
of O
antibodies B
to O
DNA O
and O
eukaryotic B
transcription I
factors I
. O

Secondly O
, O
we O
investigated O
whether O
polyomavirus O
reactivation O
occurs O
in O
SLE O
patients O
, O
and O
whether O
antibodies B
to O
T B
- I
antigen I
, O
DNA O
, O
and O
to O
TBP B
and O
CREB B
are O
linked O
to O
such O
events O
. O

The O
results O
described O
here O
indicate O
that O
cognate O
interaction O
of O
B O
cells O
recognizing O
DNA O
or O
DNA O
- O
associated O
proteins O
and O
T O
cells O
recognizing O
T B
antigen I
had O
taken O
place O
as O
a O
consequence O
of O
complex O
formation O
between O
T O
ag O
and O
DNA O
in O
vivo O
in O
the O
context O
of O
polyomavirus O
reactivations O
. O

Thus O
, O
gammac B
is O
not O
necessary O
to O
trigger O
IL B
- I
4 I
- O
mediated O
responses O
in O
B O
cells O
, O
but O
its O
presence O
is O
important O
for O
optimal O
IL B
- I
4 I
- O
signaling O
. O

Cell O
- O
to O
- O
cell O
contact O
activates O
the O
long B
terminal I
repeat I
of O
human O
immunodeficiency O
virus O
1 O
through O
its O
kappaB O
motif O
. O

Cell O
- O
to O
- O
cell O
contact O
between O
peripheral O
blood O
lymphocytes O
and O
transfected O
human O
colonic O
carcinoma O
cell O
line O
HT29 O
activates O
transcription O
of O
the O
long B
terminal I
repeats I
( O
LTR B
) O
of O
human O
immunodeficiency O
virus O
. O

HIV B
- I
1 I
LTR I
transcription O
is O
controlled O
by O
a O
complex O
array O
of O
virus O
- O
encoded O
and O
cellular O
proteins O
. O

Identification O
of O
nucleotide B
sequences I
that O
regulate O
transcription O
of O
the O
MCF13 O
murine O
leukemia O
virus O
long B
terminal I
repeat I
in O
activated O
T O
cells O
. O

Differentiation O
of O
U O
- O
937 O
promonocytic O
cells O
by O
etoposide O
and O
ICRF O
- O
193 O
, O
two O
antitumour O
DNA B
topoisomerase I
II I
inhibitors O
with O
different O
mechanisms O
of O
action O
. O

By O
contrast O
, O
the O
binding O
activity O
of O
the O
NF B
- I
kappa I
( I
B I
) I
and O
EGR B
- I
1 I
transcription B
factors I
was O
little O
affected O
. O

GATA B
- I
1 I
DNA O
binding O
activity O
is O
down O
- O
regulated O
in O
late O
S O
phase O
in O
erythroid O
cells O
. O

These O
results O
may O
also O
relate O
to O
recent O
data O
implicating O
GATA B
- I
1 I
function O
in O
apoptosis O
and O
cell O
cycle O
progression O

Activated O
neutrophils O
have O
the O
ability O
to O
upregulate O
the O
expression O
of O
many O
genes O
, O
in O
particular O
those O
encoding O
cytokines B
and O
chemokines B
, O
and O
to O
subsequently O
release O
the O
corresponding O
proteins O
. O

Following O
neutrophil O
stimulation O
with O
proinflammatory O
agonists O
( O
such O
as O
lipopolysaccharide O
[ O
LPS O
] O
, O
tumor B
necrosis I
factor I
- I
alpha I
[ O
TNF B
- I
alpha I
] O
, O
and O
fMet O
- O
Leu O
- O
Phe O
) O
that O
induce O
the O
production O
of O
cytokines B
and O
chemokines B
in O
these O
cells O
, O
NF B
- I
kappaB I
/ I
Rel I
proteins I
translocated O
to O
nuclear O
fractions O
, O
resulting O
in O
a O
transient O
induction O
of O
NF B
- I
kappaB I
DNA O
binding O
activity O
, O
as O
determined O
in O
gel O
mobility O
shift O
assays O
. O

The O
onset O
of O
both O
processes O
was O
found O
to O
be O
closely O
paralleled O
by O
, O
and O
dependent O
on O
, O
IkappaB B
- I
alpha I
degradation O
. O

Two O
distinct O
pathways O
of O
interleukin B
- I
5 I
synthesis O
in O
allergen O
- O
specific O
human O
T O
- O
cell O
clones O
are O
suppressed O
by O
glucocorticoids O
. O

GC O
efficiently O
suppressed O
IL B
- I
5 I
synthesis O
of O
T O
- O
cell O
clones O
activated O
via O
either O
T B
- I
cell I
receptor I
( O
TCR B
) O
or O
IL B
- I
2 I
receptor I
( O
IL B
- I
2R I
) O
. O

Stimulation O
of O
CD2 B
or O
TCR B
/ I
CD3 I
induced O
activation O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NFAT B
) O
, O
the O
binding B
site I
of O
which O
is O
included O
in O
the O
IL B
- I
2 I
gene I
promoter I
. O

Nuclear O
transcription O
factor O
kB O
( O
NF B
- I
kappa I
B I
) O
is O
a O
ubiquitous B
transcription I
factor I
and O
pleiotropic O
regulator O
of O
numerous O
genes O
involved O
in O
the O
immune O
and O
inflammatory O
responses O
. O

This O
transcription B
factor I
is O
activated O
via O
the O
selective O
phosphorylation O
, O
ubiquination O
and O
degradation O
of O
its O
inhibitor O
protein O
I O
- O
kB O
thereby O
allowing O
translocation O
of O
NF B
- I
kappa I
B I
into O
the O
nucleus O
where O
it O
upregulates O
the O
transcription O
of O
a O
variety O
of O
adhesion B
molecules I
( O
e O
. O
g O
. O
ICAM B
- I
1 I
, O
VCAM B
- I
1 I
) O
, O
cytokines B
( O
TNF B
, O
IL B
- I
1 I
, O
IL B
- I
6 I
) O
and O
enzymes B
( O
iNOS B
) O
. O

Based O
upon O
work O
from O
our O
laboratory O
, O
we O
propose O
that O
inhibition O
of O
NF B
- I
kappa I
B I
activation O
produces O
significant O
anti O
inflammatory O
activity O
which O
may O
be O
mediated O
by O
the O
inhibition O
of O
transcription O
of O
certain O
pro O
- O
inflammatory O
mediators O
and O
adhesion B
molecules I
. O

Generation O
of O
cytotoxic O
T O
lymphocytes O
against O
immunorecessive B
epitopes I
after O
multiple O
immunizations O
with O
adenovirus O
vectors O
is O
dependent O
on O
haplotype O
. O

Understanding O
the O
cis O
- O
and O
transacting O
factors O
that O
regulate O
the O
tissue O
- O
specific O
expression O
of O
PECAM B
- I
1 I
should O
increase O
our O
understanding O
of O
the O
mechanisms O
by O
which O
vascular O
- O
specific O
gene O
expression O
is O
achieved O
. O

However O
, O
little O
is O
known O
about O
negative O
regulation O
of O
IL B
- I
1beta I
expression O
at O
the O
transcriptional O
level O
, O
which O
may O
play O
an O
important O
role O
in O
anti O
- O
inflammatory O
and O
immunosuppressive O
effects O
. O

Interaction O
of O
transcription B
factors I
RFX1 B
and O
MIBP1 B
with O
the O
gamma O
motif O
of O
the O
negative B
regulatory I
element I
of O
the O
hepatitis O
B O
virus O
core O
promoter O
. O

The O
negative B
regulatory I
element I
( O
NRE B
) O
of O
the O
hepatitis O
B O
virus O
( O
HBV O
) O
core O
promoter O
contains O
three O
subregions O
which O
act O
synergistically O
to O
suppress O
core O
promoter O
activity O
. O

In O
addition O
, O
RFX1 B
can O
bind O
simultaneously O
, O
most O
likely O
as O
a O
heterodimer B
, O
with O
the O
transcription B
factor I
MIBP1 B
to O
NRE B
gamma I
. O

LR1 B
also O
binds O
Ig B
heavy I
chain I
switch O
region O
sequences O
and O
may O
function O
in O
class O
switch O
recombination O
. O

Both O
of O
these O
parameters O
, O
however O
, O
did O
not O
change O
significantly O
after O
mitogen B
stimulation O
. O

There O
was O
a O
significant O
negative O
correlation O
between O
IC50S O
of O
prednisolone O
and O
increase O
- O
ratios O
( O
post O
/ O
pre O
ratio O
) O
of O
Bmax O
after O
mitogen B
stimulation O
( O
p O
< O
0 O
. O
05 O
) O
. O

The O
Bmax O
and O
Kd O
were O
not O
significantly O
changed O
after O
mitogen B
stimulation O
in O
both O
subgroups O
of O
CRF O
. O

The O
ZEBRA B
protein I
from O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
activates O
a O
switch O
from O
the O
latent O
to O
the O
lytic O
expression O
program O
of O
the O
virus O
. O

The O
additional O
function O
that O
is O
required O
for O
initiation O
of O
the O
lytic O
viral O
life O
cycle O
is O
likely O
to O
require O
phosphorylation O
of O
serine O
186 O
of O
the O
ZEBRA B
protein I
, O
which O
may O
influence O
either O
DNA O
recognition O
or O
transcriptional O
activation O
of O
lytic O
viral O
promoters O
in O
a O
chromatinized O
viral O
episome O
. O

Immune O
hyperactivation O
of O
HIV O
- O
1 O
- O
infected O
T O
cells O
mediated O
by O
Tat B
and O
the O
CD28 B
pathway O
. O

CONCLUSIONS O
: O
The O
reduction O
of O
symptoms O
due O
to O
topical O
fluticasone O
propionate O
in O
patients O
with O
rhinitis O
and O
allergy O
to O
house O
dust O
mite O
is O
not O
correlated O
with O
the O
characteristics O
of O
the O
glucocorticoid B
receptor I
. O

We O
demonstrated O
that O
constitutive O
expression O
of O
NF B
- I
kappaB I
in O
primary O
human O
monocytes O
changed O
significantly O
with O
differentiation O
in O
vitro O
to O
monocyte O
- O
derived O
macrophages O
( O
MDMs O
) O
and O
differentiation O
in O
vivo O
to O
alveolar O
macrophages O
( O
AMs O
) O
. O

NF B
- I
kappa I
B I
- O
independent O
suppression O
of O
HIV O
expression O
by O
ascorbic O
acid O
. O

Pretreatment O
of O
ACH O
- O
2 O
T O
cells O
by O
NAC O
followed O
by O
stimulation O
with O
PMA O
, O
TNF B
- I
alpha I
, O
or O
hydrogen O
peroxide O
( O
H2O2 O
) O
resulted O
in O
strong O
suppression O
of O
NF B
- I
kappa I
B I
activation O
. O

These O
results O
suggest O
that O
the O
molecular O
mechanism O
of O
HIV O
inhibition O
by O
ascorbate O
is O
not O
mediated O
via O
NF B
- I
kappa I
B I
inhibition O
, O
unlike O
that O
seen O
with O
other O
antioxidants O
. O

A O
T B
cell I
- I
specific I
enhancer I
in O
the O
interleukin O
- O
3 O
locus O
is O
activated O
cooperatively O
by O
Oct O
and O
NFAT O
elements O
within O
a O
DNase B
I I
- I
hypersensitive I
site I
. O

Interleukin B
- I
3 I
( O
IL B
- I
3 I
) O
is O
a O
cytokine B
that O
is O
expressed O
primarily O
in O
activated O
T O
cells O
. O

We O
suggest O
that O
the O
T O
cell O
- O
specific O
expression O
of O
the O
IL B
- I
3 I
gene I
is O
partly O
controlled O
through O
the O
enhancer O
by O
cooperation O
between O
Oct O
and O
NFAT O
family O
proteins O
. O

The O
adenovirus O
E1B O
19K O
gene O
plays O
an O
essential O
role O
in O
transformation O
of O
primary O
rodent O
cells O
in O
cooperation O
with O
E1A B
and O
in O
the O
inhibition O
of O
apoptosis O
during O
lytic O
infection O
. O

Activation O
of O
Ras O
and O
mitogen B
- I
activated I
protein I
kinase I
pathway O
by O
terminal B
complement I
complexes I
is O
G B
protein I
dependent O
. O

Mutants O
of O
type O
5 O
adenovirus O
( O
Ad5 O
) O
with O
reiterated O
DNA O
sequences O
in O
the O
E1a B
region I
appeared O
in O
a O
human O
T O
- O
lymphocyte O
cell O
line O
, O
Molt O
- O
4 O
, O
persistently O
infected O
with O
H5sub304 O
, O
a O
deletion O
/ O
substitution O
mutant O
that O
has O
a O
wild O
- O
type O
phenotype O
in O
viral O
replication O
. O

There O
was O
not O
any O
DNA O
homology O
between O
the O
breakpoints O
in O
the O
second O
exon B
and O
the O
inserting O
sequences O
( O
starting O
at O
nt O
532 O
, O
710 O
, O
or O
792 O
) O
. O

Residues O
432 O
, O
435 O
, O
437 O
, O
438 O
, O
and O
440 O
( O
position O
P1 O
, O
P4 O
, O
P6 O
, O
P7 O
, O
and O
P9 O
) O
contributed O
to O
DQ2 B
binding O
, O
whereas O
residues O
431 O
, O
433 O
, O
434 O
, O
and O
436 O
( O
positions O
P O
1 O
, O
P2 O
, O
P3 O
, O
and O
P5 O
) O
contributed O
to O
TCR B
contact O
. O

The O
hypothesis O
that O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NF B
- I
AT I
) O
may O
influence O
HIV O
- O
1 O
replication O
is O
therefore O
compelling O
given O
the O
tight O
correlation O
of O
HIV O
- O
1 O
transcriptional O
induction O
to O
T O
cell O
activation O
. O

These O
results O
link O
regulatory B
factors I
critical O
to O
T O
cell O
commitment O
directly O
to O
HIV O
- O
1 O
replication O
. O

eTh2 O
cells O
are O
the O
major O
source O
of O
IL B
- I
4 I
, O
while O
gamma B
interferon I
is O
produced O
by O
eTh1 O
cells O
. O

However O
, O
although O
NFAT B
DNA O
binding O
is O
similarly O
induced O
in O
both O
eTh1 O
and O
eTh2 O
cells O
upon O
antigen O
stimulation O
, O
only O
the O
NFAT B
complexes I
present O
in O
eTh2 O
cells O
are O
able O
to O
mediate O
high O
- O
level O
transcription O
, O
and O
relatively O
little O
NFAT B
transcriptional O
activity O
was O
induced O
in O
eTh1 O
cells O
. O

V3 B
loop I
of O
human O
immunodeficiency O
virus O
type O
1 O
suppresses O
interleukin B
2 I
- O
induced O
T O
cell O
growth O
[ O
published O
erratum O
appears O
in O
AIDS O
Res O
Hum O
Retroviruses O
1997 O
May O
1 O
; O
13 O
( O
7 O
) O
: O
633 O
] O

V3 B
- I
BH10 I
neither O
blocked O
radiolabeled O
IL B
- I
2 I
binding O
to O
IL B
- I
2 I
receptors I
nor O
affected O
tyrosyl O
phosphorylation O
of O
several O
cellular B
proteins I
( O
p120 B
, O
p98 B
, O
p96 O
, O
p54 O
, O
and O
p38 B
) O
, O
which O
is O
immediately O
induced O
by O
IL B
- I
2 I
stimulation O
. O

However O
, O
V3 B
- I
BH10 I
enhanced O
IL B
- I
2 I
- B
induced I
mRNA I
expression O
of O
c B
- I
fos I
but O
not O
c B
- I
myc I
or O
junB B
. O

CONCLUSIONS O
: O
Our O
results O
establish O
that O
PI B
3 I
- I
kinase I
can O
both O
positively O
and O
negatively O
regulate O
T O
- O
cell O
function O
, O
and O
uncover O
a O
previously O
unrecognized O
function O
for O
PI B
3 I
- I
kinase I
in O
T O
cells O
as O
a O
selective O
negative O
regulator O
of O
TCR B
- O
signalling O
events O
and O
therefore O
as O
a O
determinant O
of O
T O
- O
cell O
homeostasis O
. O

Pax B
- I
5a I
was O
detectable O
in O
pro O
- O
, O
pre O
- O
, O
and O
mature O
B O
- O
cell O
lines O
, O
but O
not O
in O
two O
plasmacytomas O
; O
Pax B
- I
5b I
was O
shown O
to O
be O
present O
at O
low O
levels O
in O
mature O
B O
- O
cell O
lines O
and O
, O
unexpectedly O
, O
in O
one O
plasma O
cell O
line O
, O
but O
not O
in O
pro O
- O
B O
- O
cell O
or O
T O
- O
cell O
lines O
. O

The O
two O
related O
protein B
- I
tyrosine I
kinases I
Syk B
and O
Zap B
are O
rapidly O
phosphorylated O
on O
tyrosine O
residues O
and O
enzymatically O
activated O
upon O
crosslinking O
of O
the O
T B
cell I
antigen I
receptor I
. O

One O
means O
of O
understanding O
the O
role O
of O
p38 B
in O
these O
responses O
is O
to O
identify O
proteins O
with O
functions O
regulated O
by O
p38 B
- O
catalysed O
phosphorylation O
. O

The O
predominant O
E2F O
complex O
in O
human O
primary O
haemopoietic O
cells O
and O
in O
AML O
blasts O
contains O
E2F B
- I
4 I
, O
DP B
- I
1 I
and O
p130 B
. O

Associated O
with O
its O
inhibitor O
, O
I B
kappaB I
, O
NF B
- I
kappaB I
resides O
as O
an O
inactive O
form O
in O
the O
cytoplasm O
. O

The O
transduction O
pathways O
that O
lead O
to O
I B
kappaB I
inactivation O
remain O
poorly O
understood O
. O

In O
this O
study O
, O
we O
have O
characterized O
a O
cellular O
mutant O
, O
the O
70 O
/ O
Z3 O
- O
derived O
1 O
. O
3E2 O
murine O
pre O
- O
B O
cell O
line O
, O
that O
does O
not O
activate O
NF B
- I
kappaB I
in O
response O
to O
several O
stimuli O
. O

Our O
results O
demonstrate O
that O
1 O
. O
3E2 O
is O
a O
cellular O
transduction O
mutant O
exhibiting O
a O
defect O
in O
a O
step O
that O
is O
required O
by O
several O
different O
stimuli O
to O
activate O
NF B
- I
kappaB I
. O

In O
order O
to O
evaluate O
the O
conditions O
for O
optimal O
expression O
and O
immunogenicity O
of O
varicella O
- O
zoster O
virus O
( O
VZV O
) O
proteins O
in O
a O
herpes O
simplex O
virus O
- O
1 O
( O
HSV O
- O
1 O
) O
vector O
, O
we O
selected O
the O
VZV O
glycoprotein O
E O
( O
gE O
) O
, O
encoded O
by O
ORF O
68 O
and O
the O
VZV O
product O
of O
ORF O
62 O
, O
an O
immediate O
- O
early O
major O
tegument O
protein O
( O
IE62 B
) O
. O

Immunoblot O
analysis O
and O
immunoperoxidase O
staining O
of O
infected O
cell O
monolayers O
demonstrated O
vector O
expression O
of O
VZV B
proteins I
. O

When O
tested O
in O
cytotoxicity O
assays O
using O
T O
- O
lymphocytes O
from O
VZV O
immune O
human O
donors O
, O
the O
range O
of O
precursor O
frequencies O
for O
T O
- O
lymphocytes O
that O
recognized O
VZV B
gE I
or O
VZV B
IE62 I
was O
similar O
whether O
these O
proteins O
were O
expressed O
by O
HSV O
- O
1 O
or O
a O
vaccinia O
vector O
. O

In O
this O
report O
, O
we O
demonstrate O
that O
the O
active O
form O
of O
NF B
- I
AT1 I
is O
also O
present O
in O
the O
nuclei O
of O
HTLV O
- O
I O
- O
transformed O
T O
cells O
that O
express O
the O
Tax B
protein I
. O

Interestingly O
, O
the O
constitutive O
activation O
of O
NF B
- I
AT1 I
in O
these O
T O
cells O
is O
associated O
with O
its O
dephosphorylation O
. O

Expression O
of O
NFAT B
- I
family I
proteins I
in O
normal O
human O
T O
cells O
. O

Higher O
- O
molecular O
- O
weight O
species O
of O
NFATc B
( O
of O
110 O
and O
140 O
kDa O
) O
were O
also O
detected O
. O

In O
contrast O
to O
ionomycin O
treatment O
, O
exposure O
of O
cells O
to O
phorbol O
myristate O
acetate O
( O
PMA O
) O
plus O
anti B
- I
CD28 I
did O
not O
induce O
NFATc B
, O
indicating O
that O
under O
these O
conditions O
, O
interleukin B
- I
2 I
synthesis O
by O
these O
cells O
is O
apparently O
independent O
of O
NFATc B
. O

Cotransfection O
experiments O
revealed O
that O
both O
hGATA B
- I
4 I
and O
PMA O
/ O
A23187 O
stimulation O
are O
necessary O
for O
the O
IL B
- I
5 I
promoter I
activation O
. O

The O
requirement O
of O
another O
regulatory B
element I
called O
CLE0 B
, O
which O
lies O
downstream O
of O
the O
- B
70 I
GATA I
site I
, O
was O
also O
demonstrated O
. O

The O
electrophoretic O
mobility O
shift O
assay O
with O
extracts O
of O
COS O
cells O
expressing O
GATA B
- I
binding I
proteins I
showed O
that O
GATA B
- I
4 I
has O
the O
highest O
binding O
affinity O
to O
the O
- B
70 I
GATA I
site I
among O
the O
three O
GATA B
- I
binding I
proteins I
. O

These O
results O
demonstrate O
the O
selective O
role O
of O
GATA B
- I
4 I
in O
the O
transcriptional O
regulation O
of O
the O
IL B
- I
5 I
gene I
in O
a O
circumstance O
where O
multiple O
members O
of O
the O
GATA B
- I
binding I
proteins I
are O
expressed O
. O

We O
found O
that O
NFATx1 B
DNA O
binding O
activity O
and O
interaction O
with O
AP O
- O
1 O
polypeptides O
were O
dependent O
on O
its O
central O
Rel O
similarity O
region O
and O
that O
transcriptional O
activation O
was O
reduced O
by O
deletions O
of O
either O
its O
N B
- I
terminal I
domain I
or O
its O
C B
- I
terminal I
domain I
, O
suggesting O
the O
presence O
of O
intrinsic O
transcriptional O
activation O
motifs O
in O
both O
regions O
. O

NO O
is O
produced O
from O
at O
least O
three O
different O
NO O
synthase O
( O
NOS O
) O
isoforms O
: O
neuronal O
NOS O
( O
nNOS B
) O
, O
endothelial O
NOS O
, O
and O
immunologic O
NOS O
( O
iNOS B
) O
. O

Pyrrolidine O
dithiocarbamate O
( O
PDTC O
) O
is O
an O
inhibitor O
of O
NF B
kappaB I
in O
most O
cells O
; O
however O
, O
we O
show O
that O
PDTC O
is O
also O
a O
potent O
scavenger O
of O
NO O
through O
formation O
of O
mononitrosyl O
iron O
complexes O
with O
PDTC O
. O

Contrary O
to O
the O
results O
in O
Jurkat O
cells O
, O
PDTC O
did O
not O
inhibit O
tumor B
necrosis I
factor I
- I
alpha I
- O
induced O
NF B
kappaB I
activation O
in O
astrocytes O
; O
instead O
PDTC O
itself O
induces O
NF B
kappaB I
activation O
in O
astrocytes O
, O
and O
this O
may O
be O
related O
to O
scavenging O
of O
endogenously O
produced O
NO O
by O
the O
PDTC O
iron O
complex O
. O

In O
astrocytes O
PDTC O
also O
dramatically O
induces O
the O
NF O
kappaB O
- O
dependent O
enzyme O
, O
iNOS B
, O
supporting O
the O
physiologic O
relevance O
of O
endogenous O
NO O
regulation O
of O
NF B
kappaB I
. O

Involvement O
of O
Stat3 B
in O
interleukin B
- I
6 I
- O
induced O
IgM B
production O
in O
a O
human O
B O
- O
cell O
line O
. O

EGF O
treatment O
induced O
IgM B
production O
in O
cells O
transfected O
with O
an O
intact O
gp130 O
cytoplasmic O
tail O
, O
but O
not O
in O
untransfected O
cells O
or O
cells O
transfected O
with O
a O
cytoplasmic B
tail I
lacking O
all O
four O
signal O
transducers O
and O
activators O
of O
transcription O
( O
Stat O
) O
binding O
sites O
. O

Moreover O
, O
EGF O
treatment O
induced O
Stat3 B
phosphorylation O
in O
cells O
transfected O
with O
the O
intact O
chimeric O
EGF O
- O
gp130 O
receptor O
along O
with O
induction O
of O
DNA O
- O
mobility O
shift O
of O
a O
classical O
interferon O
- O
gamma O
- O
activated O
site O
. O

This O
cis B
element I
binds O
a O
protein O
complex O
referred O
to O
as O
HRF B
( O
heme O
- O
responsive O
factor O
) O
, O
which O
is O
greatly O
enhanced O
both O
in O
heme O
- O
treated O
FLCs O
and O
during O
monocyte O
- O
to O
- O
macrophage O
differentiation O
. O

One O
of O
the O
latter O
elements O
, O
the O
IgH B
3 I
' I
enhancer I
, O
is O
of O
particular O
interest O
: O
( O
1 O
) O
it O
is O
B O
cell O
- O
specific O
and O
active O
only O
in O
late O
B O
cell O
development O
; O
( O
2 O
) O
in O
rodent O
plasmacytomas O
and O
in O
some O
human O
Burkitt O
' O
s O
lymphomas O
it O
is O
part O
of O
a O
locus B
control I
region I
( O
LCR B
) O
that O
is O
involved O
in O
deregulation O
of O
the O
c B
- I
myc I
oncogene I
as O
a O
result O
of O
translocation O
into O
the O
IgH B
locus I
; O
and O
( O
3 O
) O
it O
has O
been O
implicated O
in O
the O
mechanisms O
that O
control O
Ig O
gene O
class O
switch O
recombination O

Reactive O
oxygen O
species O
( O
ROS O
) O
such O
as O
hydrogen O
peroxide O
serve O
as O
second O
messengers O
in O
the O
induction O
of O
the O
transcription B
factor I
NF B
- I
kappaB I
, O
and O
hence O
in O
the O
activation O
and O
replication O
of O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
in O
human O
cells O
. O

NF B
- I
kappaB I
activation O
was O
very O
effective O
when O
cells O
were O
subjected O
to O
hyperthermia O
before O
being O
treated O
with O
HOCl O
. O

Collectively O
, O
these O
results O
suggest O
that O
HOCl O
should O
be O
considered O
as O
an O
oxidative O
species O
capable O
of O
inducing O
NF B
- I
kappaB I
in O
a O
T O
- O
lymphocytic O
cell O
line O
through O
a O
transduction O
mechanism O
involving O
ROS O
, O
and O
having O
a O
long O
- O
distance O
effect O
through O
subsequent O
TNF B
- I
alpha I
release O
. O

Rap1 B
is O
a O
small O
, O
Ras O
- O
like O
GTPase O
whose O
function O
and O
regulation O
are O
still O
largely O
unknown O
. O

Stimulation O
of O
blood O
platelets O
with O
alpha B
- I
thrombin I
or O
other O
platelet O
activators O
caused O
a O
rapid O
and O
strong O
induction O
of O
Rap1 B
that O
associated O
with O
RBD B
in O
vitro O
. O

From O
our O
results O
, O
we O
conclude O
that O
Rap1 B
activation O
in O
platelets O
is O
an O
important O
common O
event O
in O
early O
agonist O
- O
induced O
signalling O
, O
and O
that O
this O
activation O
is O
mediated O
by O
an O
increased O
intracellular O
Ca2 O
+ O
concentration O

The O
transcriptional B
regulatory I
elements I
of O
many O
inducible B
T I
- I
cell I
genes I
contain O
adjacent O
or O
overlapping B
binding I
sites I
for O
the O
Ets O
and O
NF O
- O
kappaB O
/ O
NFAT O
families O
of O
transcription B
factors I
. O

From O
AML1 B
gene I
, O
two O
representative O
forms O
of O
proteins O
, O
AML1a B
and O
AML1b B
, O
are O
produced O
by O
an O
alternative O
splicing O
. O

These O
data O
strongly O
suggest O
that O
a O
transcriptionally O
active O
form O
of O
AML1 B
is O
essential O
for O
the O
myeloid O
cell O
differentiation O
. O

When O
introduced O
into O
interleukin B
3 I
( O
IL B
- I
3 I
) O
- O
dependent O
mouse O
pro O
- O
B O
lymphocytes O
, O
E2A B
- I
HLF I
prevents O
apoptosis O
induced O
by O
growth B
factor I
deprivation O
, O
suggesting O
that O
IL B
- I
3 I
mediates O
cell O
survival O
through O
activation O
of O
a O
transcription B
factor I
whose O
activity O
can O
be O
constitutively O
replaced O
by O
the O
chimeric B
oncoprotein I
. O

The O
expression O
and O
binding O
activity O
of O
the O
Nfil3 O
protein O
( O
also O
called O
E4bp4 O
) O
, O
but O
not O
of O
Hlf B
, O
Dbp O
, O
or O
Tef O
, O
was O
found O
to O
be O
regulated O
by O
IL B
- I
3 I
in O
mouse O
pro O
- O
B O
cell O
lines O
( O
Baf O
- O
3 O
and O
FL5 O
. O
12 O
) O
. O

Common O
and O
distinct O
intracellular O
signaling O
pathways O
in O
human O
neutrophils O
utilized O
by O
platelet B
activating I
factor I
and O
FMLP B
. O

Stimulation O
of O
human O
neutrophils O
with O
chemoattractants B
FMLP B
or O
platelet B
activating I
factor I
( O
PAF B
) O
results O
in O
different O
but O
overlapping O
functional O
responses O
. O

Stimulation O
with O
either O
PAF B
or O
FMLP B
resulted O
in O
equivalent O
phosphorylation O
and O
activation O
of O
the O
mitogen O
- O
activated O
protein O
kinase O
( O
MAPk O
) O
homologue O
38 O
- O
kD O
murine O
MAP O
kinase O
homologous O
to O
HOG O
- O
1 O
( O
p38 O
) O
MAPk O
. O

A O
specific O
p38 B
MAPk I
inhibitor O
( O
SK O
& O
F O
86002 O
) O
blocked O
superoxide O
anion O
production O
in O
response O
to O
FMLP B
and O
reduced O
adhesion O
and O
chemotaxis O
in O
response O
to O
PAF B
or O
FMLP B
. O

Chicken O
NF O
- O
M O
transcription O
factor O
, O
in O
cooperation O
with O
either O
c B
- I
Myb I
or O
v B
- I
Myb I
, O
is O
active O
in O
the O
combinatorial O
activation O
of O
myeloid B
- I
cell I
- I
specific I
genes I
in O
heterologous O
cell O
types O
, O
such O
as O
embryonic O
fibroblasts O
. O

In O
the O
present O
report O
, O
we O
show O
that O
A6H B
costimulated O
cell O
proliferation O
and O
cytokine B
production O
in O
purified O
CD4 O
+ O
T O
cells O
. O

Co O
- O
ligation O
of O
the O
A6H B
antigen O
and O
the O
CD3 O
complex O
induced O
expression O
of O
the O
transcription B
factor I
AP B
- I
1 I
in O
CD4 O
+ O
T O
cells O
, O
whereas O
no O
increase O
in O
NF B
- I
kappa I
B I
and O
octamer O
- O
binding O
( O
Oct O
) O
proteins O
was O
seen O
compared O
to O
T O
cells O
stimulated O
with O
anti B
- I
CD3 I
alone O
. O

Molecular O
differences O
of O
the O
A6H O
molecule O
or O
distinct O
regulation O
of O
the O
A6H B
transduced O
AP B
- I
1 I
activation O
pathway O
may O
exist O
in O
CD4 O
+ O
and O
CD8 O
+ O
T O
cell O
subpopulations O
. O

The O
DNA B
- I
binding I
domain I
( O
amino O
acids O
421 O
- O
486 O
) O
is O
completely O
conserved O
among O
human O
, O
squirrel O
monkey O
, O
owl O
monkey O
, O
and O
cotton O
- O
top O
tamarin O
receptors O
. O

Expressions O
of O
human O
and O
squirrel O
monkey O
glucocorticoid B
receptors I
and O
a O
squirrel O
monkey O
receptor O
in O
which O
Phe774 O
was O
mutated O
to O
Leu O
( O
F774L O
) O
were O
similar O
. O

The O
gamma O
( O
c O
) O
subunit O
can O
be O
employed O
in O
receptor O
complexes O
for O
IL O
- O
2 O
, O
- O
4 O
, O
- O
7 O
, O
- O
9 O
, O
and O
- O
15 O
, O
and O
the O
multiple O
signaling O
defects O
that O
would O
result O
from O
a O
defective O
gamma B
( I
c I
) I
chain I
in O
these O
receptors O
are O
proposed O
to O
cause O
the O
severe O
phenotype O
of O
X O
- O
SCID O
patients O
. O

These O
observations O
suggest O
the O
functional O
importance O
of O
gamma B
( I
c I
) I
in O
the O
IL B
- I
7R I
complex I
. O

In O
this O
study O
we O
determined O
the O
effects O
of O
SAC O
on O
NF B
- I
kappa I
B I
activation O
in O
human O
T O
lymphocytes O
( O
Jurkat O
cells O
) O
induced O
by O
tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
and O
H2O2 O
. O

Elf B
- I
2 I
, O
a O
rhombotin O
- O
2 O
binding O
ets O
transcription O
factor O
: O
discovery O
and O
potential O
role O
in O
T O
cell O
leukemia O
. O

By O
screening O
a O
T O
cell O
cDNA B
library I
, O
we O
identified O
a O
novel O
ets O
transcription O
factor O
that O
binds O
RBTN B
- I
2 I
. O

The O
expression O
patterns O
suggest O
that O
RBTN B
- I
2 I
normally O
interacts O
equally O
with O
elf B
- I
2a I
and O
elf B
- I
2b I
. O

In O
contrast O
, O
when O
RBTN B
- I
2 I
is O
inappropriately O
expressed O
in O
T O
cells O
, O
RBTN B
- I
2 I
would O
interact O
predominantly O
with O
elf B
- I
2b I
; O
this O
interaction O
may O
lead O
to O
T O
cell O
proliferation O
. O

When O
immunoglobulin O
( O
Ig O
) O
- O
secreting O
plasmacytomas O
are O
fused O
to O
a O
T O
- O
cell O
lymphoma O
, O
Ig B
gene I
expression O
ceases O
in O
greater O
than O
95 O
% O
of O
the O
resulting O
hybrids O
. O

Nuclear B
factor I
of I
activated I
T I
cells I
and O
AP B
- I
1 I
are O
insufficient O
for O
IL B
- I
2 I
promoter I
activation O
: O
requirement O
for O
CD28 B
up O
- O
regulation O
of O
RE B
/ I
AP I
. O

Disturbance O
of O
both O
the O
immune O
surveillance O
as O
well O
as O
viral B
gene I
regulation O
may O
result O
in O
EBV O
- O
associated O
disease O
. O

3BP2 B
was O
selectively O
expressed O
in O
hematopoietic O
/ O
lymphoid O
tissues O
and O
bound O
via O
its O
SH2 O
domain O
activated O
Syk O
- O
family O
kinases O
in O
mammalian O
cells O
, O
including O
in O
antigen O
receptor O
- O
stimulated O
T O
cells O
. O

Furthermore O
, O
recombinant O
TIMP B
- I
1 I
, O
but O
not O
TIMP O
- O
2 O
or O
a O
synthetic O
metalloproteinase O
inhibitor O
( O
BB O
- O
94 O
) O
, O
confers O
resistance O
to O
apoptosis O
induced O
by O
both O
CD95 O
- O
dependent O
and O
- O
independent O
( O
cold O
shock O
, O
serum O
deprivation O
, O
and O
gamma O
- O
radiation O
) O
pathways O
in O
TIMP O
- O
1 O
- O
negative O
BL O
lines O
. O

To O
investigate O
in O
vivo O
regulatory O
mechanisms O
that O
control O
the O
population O
of O
type O
2 O
T O
cells O
and O
disease O
susceptibility O
, O
we O
have O
created O
lines O
of O
transgenic O
mice O
in O
which O
expression O
of O
a O
chimeric O
cytokine O
receptor O
( O
the O
mouse O
interleukin O
2 O
receptor O
beta O
chain O
[ O
IL O
- O
2Rbeta O
] O
extracellular O
domain O
fused O
to O
the O
cytoplasmic B
tail I
of O
IL B
- I
4Ralpha I
) O
is O
targeted O
to O
the O
T O
lymphoid O
lineage O
using O
the O
proximal O
lck O
promoter O
. O

We O
have O
recently O
cloned O
the O
carboxylesterase O
upstream O
sequence O
and O
showed O
its O
basal B
promoter I
activity O
in O
CHO O
cells O
. O

The O
role O
of O
the O
Ikaros B
gene I
in O
lymphocyte O
development O
and O
homeostasis O
. O

In O
the O
adult O
, O
however O
, O
lymphoid O
lineages O
rely O
on O
Ikaros B
at O
distinct O
phases O
of O
their O
development O
. O

Furthermore O
, O
Ikaros O
- O
null O
thymocytes O
hyperproliferate O
in O
response O
to O
T B
cell I
receptor I
( O
TCR B
) O
signaling O
; O
within O
days O
after O
their O
appearance O
in O
the O
thymus O
, O
clonally O
expanding O
populations O
are O
detected O
. O

Deregulated O
TCR B
- O
mediated O
responses O
and O
the O
fast O
kinetics O
of O
tumor O
development O
in O
these O
mutant O
thymocytes O
implicate O
Ikaros O
as O
a O
central O
tumor O
suppressor O
gene O
for O
the O
T O
cell O
lineage O
. O

The O
role O
of O
Aiolos B
, O
a O
lymphoid O
- O
restricted O
and O
structurally O
related O
gene O
, O
in O
lymphoid O
differentiation O
is O
discussed O
. O

STAT1 B
pathway O
is O
involved O
in O
activation O
of O
caprine O
arthritis O
- O
encephalitis O
virus O
long O
terminal O
repeat O
in O
monocytes O
. O

Substitution O
mutations O
in O
this O
consensus B
sequence I
eliminate O
binding O
of O
the O
inducible B
factor I
. O

1 B
, I
25 I
- I
Dihydroxyvitamin I
D3 I
receptors I
in O
peripheral O
blood O
mononuclear O
cells O
from O
patients O
with O
renal O
insufficiency O
. O

No O
correlation O
was O
seen O
between O
VDR B
and O
serum O
calcitriol O
or O
PTH O
levels O
, O
when O
considering O
both O
groups O
of O
patients O
together O
or O
separately O
. O

Conversely O
, O
a O
significant O
negative O
correlation O
was O
found O
between O
VDR B
and O
serum O
creatinine O
values O
when O
A O
- O
CRF O
and O
M O
- O
CRF O
were O
considered O
altogether O
( O
r O
= O
- O
0 O
. O
63 O
; O
p O
< O
0 O
. O
01 O
) O
. O

In O
particular O
, O
TRAF6 B
interacted O
with O
membrane O
- O
proximal O
determinants O
distinct O
from O
those O
binding O
TRAFs O
1 O
, O
2 O
, O
3 O
, O
and O
5 O
. O

The O
molecular O
mechanisms O
by O
which O
IL B
- I
4 I
induces O
expression O
of O
the O
IL B
- I
4 I
gene I
are O
not O
known O
, O
although O
the O
IL O
- O
4 O
- O
activated O
transcription O
factor O
signal O
transducer O
and O
activator O
of O
transcription O
6 O
( O
Stat6 B
) O
is O
required O
for O
this O
effect O
. O

CONCLUSIONS O
: O
Intestinal O
epithelial O
cells O
initiate O
an O
inflammatory O
response O
with O
resulting O
neutrophil O
- O
mediated O
tissue O
damage O
in O
response O
to O
E O
. O
histolytica O
infection O
; O
this O
inflammatory O
cascade O
can O
be O
blocked O
by O
inhibiting O
the O
transcription O
of O
genes O
regulated O
by O
nuclear B
factor I
kappaB I
. O

The O
triptolide O
- O
induced O
apoptosis O
is O
accompanied O
by O
increase O
of O
DEVD O
- O
cleavable O
caspases B
activity O
and O
degradation O
of O
caspase O
substrate O
poly O
( O
ADP O
- O
ribose O
) O
polymerase O
( O
PARP B
) O
. O

A O
specific O
inhibitor O
of O
caspases B
, O
zVAD O
- O
FMK O
, O
prevents O
triptolide O
- O
induced O
PARP B
degradation O
and O
DNA O
fragmentation O
but O
not O
growth O
arrest O
. O

A O
novel O
transcription B
factor I
regulates O
expression O
of O
the O
vacuolar O
H O
+ O
- O
ATPase O
B2 O
subunit O
through O
AP O
- O
2 O
sites O
during O
monocytic O
differentiation O
. O

In O
mobility O
shift O
assays O
, O
a O
nuclear B
factor I
from O
THP O
- O
1 O
and O
U O
- O
937 O
cells O
was O
identified O
that O
binds O
to O
several O
AP O
- O
2 O
response O
elements O
within O
the O
B2 B
promoter I
, O
but O
does O
not O
react O
with O
AP O
- O
2 O
antibodies O
, O
and O
has O
a O
DNA B
sequence I
binding O
affinity O
profile O
that O
differs O
from O
AP B
- I
2 I
. O

It O
has O
been O
shown O
that O
eosinophil O
stimulation O
by O
these O
cytokines B
is O
associated O
with O
increases O
in O
tyrosine O
phosphorylation O
of O
several O
cellular O
substrates O
. O

Time O
- O
course O
experiments O
showed O
that O
nuclear O
levels O
of O
GATA B
- I
1 I
and O
p45 B
NF I
- I
E2 I
proteins O
increased O
during O
BA O
treatment O
. O

The O
upstream O
regions O
UAS3 B
( O
- O
1168 O
to O
- O
440 O
) O
and O
UAS2 B
( O
- O
352 O
to O
- O
264 O
) O
both O
functioned O
in O
a O
cell O
lineage O
- O
independent O
manner O
and O
were O
together O
responsible O
for O
the O
bulk O
of O
Wp O
activity O
in O
non O
- O
B O
cells O
; O
mutational O
analysis O
indicated O
the O
importance O
of O
a O
YY1 B
binding I
site I
in O
UAS2 B
in O
that O
context O
. O

By O
contrast O
, O
UAS1 B
( O
- O
140 O
to O
- O
87 O
) O
was O
B O
cell O
specific O
and O
was O
the O
key O
determinant O
of O
the O
promoter O
' O
s O
increased O
activity O
in O
B O
cell O
lines O
. O

Pharmacologic O
blockade O
of O
endogenous B
NFAT I
activity O
by O
FK506 O
or O
CsA O
inhibited O
synthesis O
of O
reverse O
transcription O
and O
also O
potently O
blocked O
HIV O
- O
1 O
replication O
. O

The O
first O
step O
in O
the O
nuclear O
import O
process O
is O
recognition O
of O
a O
nuclear B
localization I
sequence I
( O
NLS B
) O
within O
the O
karyophilic O
protein O
by O
a O
cytoplasmic B
receptor I
such O
as O
the O
importin O
( O
karyopherin O
) O
- O
alpha O
subunit O
. O

NLS B
peptide O
- O
mediated O
disruption O
of O
the O
nuclear O
import O
of O
these O
transcription B
factors I
results O
in O
inhibition O
of O
I O
kappa O
B O
alpha O
and O
IL O
- O
2 O
gene O
expression O
, O
processes O
dependent O
on O
NF B
- I
kappa I
B I
or O
the O
combination O
of O
NF B
- I
kappa I
B I
, O
AP B
- I
1 I
, O
and O
NFAT B
. O

Further O
, O
we O
show O
that O
inhibitory O
NLS B
peptide O
interacts O
in O
vitro O
with O
a O
cytoplasmic O
NLS O
receptor O
complex O
comprised O
of O
the O
Rch1 O
/ O
importin O
( O
karyopherin O
) O
- O
beta O
heterodimer O
expressed O
in O
Jurkat O
T O
cells O
. O

Forty O
- O
eight O
hours O
after O
transfection O
, O
EC O
were O
stimulated O
with O
NK O
cells O
or O
NK O
cell O
membrane O
extracts O
for O
7 O
hr O
and O
activation O
was O
measured O
by O
a O
luciferase B
assay O
. O

CONCLUSIONS O
: O
Human O
NK O
cell O
membrane O
- O
bound O
LT O
signals O
across O
species O
via O
TNFRI B
, O
leading O
to O
NF B
- I
kappaB I
nuclear O
translocation O
and O
transcription O
of O
E B
- I
selectin I
and O
IL B
- I
8 I
, O
which O
results O
in O
EC O
activation O
. O

Ras B
- O
dependent O
, O
Ca2 O
+ O
- O
stimulated O
activation O
of O
nuclear B
factor I
of I
activated I
T I
cells I
by O
a O
constitutively O
active O
Cbl B
mutant I
in O
T O
cells O
. O

Blood O
monocytes O
spontaneously O
activate O
endothelial O
cells O
in O
culture O
, O
leading O
to O
adhesion O
of O
monocytic O
cells O
onto O
the O
endothelial O
surface O
and O
overproduction O
of O
endothelial O
proteins O
such O
as O
von B
Willebrand I
factor I
( O
vWf B
) O
and O
plasminogen O
activator O
inhibitor O
type O
1 O
( O
PAI B
- I
1 I
) O
. O

Under O
these O
conditions O
HUVEC B
adhesion I
molecules I
, O
E B
- I
selectin I
, O
VCAM B
- I
1 I
and O
ICAM B
- I
1 I
, O
were O
increased O
at O
3 O
h O
with O
only O
ICAM B
- I
1 I
remaining O
overexpressed O
at O
24 O
h O
. O

Quantitative O
reverse B
transcriptase I
- O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
showed O
an O
increase O
in O
steady O
- O
state O
TNF B
- I
alpha I
mRNA I
after O
3 O
to O
4 O
hours O
of O
cross O
- O
linking O
. O

CD2 B
cross O
- O
linking O
concurrently O
increased O
phosphorylation O
of O
CREB B
detected O
by O
immunoblot O
assay O
eightfold O
. O

These O
data O
indicate O
specific O
modulation O
of O
the O
CREB O
/ O
ATF O
- O
1 O
family O
of O
transcription B
factors I
by O
the O
CD2 B
signalling O
pathway O
and O
suggest O
CD2 B
receptor O
modulation O
of O
CRE B
- O
mediated O
transcription O
following O
ligand O
engagement O
( O
e O
. O
g O
. O
cell O
- O
to O
- O
cell O
contact O
) O
. O

In O
the O
present O
report O
we O
show O
that O
in O
various O
transiently O
or O
stably O
transfected O
cell O
lines O
, O
X O
- O
ray O
irradiation O
up O
- O
regulates O
HIV B
- I
1 I
LTR I
transcription O
through O
the O
kappaB B
regulatory I
elements I
. O

In O
addition O
, O
X O
- O
ray O
activation O
of O
HIV B
- I
1 I
LTR I
in O
transiently O
or O
stably O
transfected O
cell O
lines O
is O
inhibited O
by O
a O
potent O
antioxidant O
drug O
, O
pyrrolidine O
dithiocarbamate O
and O
by O
another O
drug O
, O
known O
for O
its O
role O
in O
the O
trapping O
of O
growth B
factors I
, O
suramin O
. O

Restoration O
of O
the O
CCAAT B
box I
at O
- O
70 O
bp O
, O
or O
insertion O
of O
an O
EKLF B
binding I
site I
at O
- O
85 O
bp O
or O
- O
95 O
bp O
in O
the O
promoter B
significantly O
increased O
delta O
globin O
gene O
expression O
in O
hAEC O
. O

Constitutive O
association O
of O
JAK1 B
and O
STAT5 B
in O
pro O
- O
B O
cells O
is O
dissolved O
by O
interleukin B
- I
4 I
- O
induced O
tyrosine O
phosphorylation O
of O
both O
proteins O
. O

Nuclear B
factor I
- I
kappaB I
was O
found O
to O
be O
activated O
in O
ventilated O
macrophages O
. O

Based O
on O
the O
high O
specificity O
of O
this O
compound O
for O
PKC B
, O
we O
conclude O
that O
PKC B
is O
necessary O
for O
FN B
- O
induced O
IL B
- I
1beta I
protein O
production O
. O

A O
novel O
member O
of O
the O
tumor O
necrosis O
factor O
( O
TNF O
) O
receptor O
family O
, O
designated O
TRAMP B
, O
has O
been O
identified O
. O

Overexpression O
of O
TRAMP B
leads O
to O
two O
major O
responses O
, O
NF B
- I
kappaB I
activation O
and O
apoptosis O
. O

Using O
a O
nuclear O
run O
- O
on O
assay O
, O
IL B
- I
4 I
stimulation O
was O
shown O
to O
enhance O
transcription O
by O
two O
- O
to O
threefold O
. O

Conversely O
, O
IL B
- I
4 I
and O
IL B
- I
13 I
markedly O
and O
significantly O
inhibited O
HIV O
replication O
at O
the O
transcriptional O
level O
in O
monocyte O
- O
derived O
macrophages O
, O
and O
this O
occurred O
whether O
these O
cytokines B
were O
added O
before O
or O
after O
HIV O
infection O
. O

Interleukin B
- I
10 I
( O
IL B
- I
10 I
) O
protects O
animals O
from O
lethal O
endotoxemia O
. O

Evidence O
suggests O
that O
IL B
- I
10 I
may O
inhibit O
activation O
of O
the O
transcription B
factor I
nuclear B
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
through O
an O
unknown O
mechanism O
. O

We O
hypothesized O
that O
IL B
- I
10 I
prevents O
human O
monocyte O
NF B
- I
kappaB I
activation O
and O
resultant O
TNF B
- I
alpha I
production O
by O
stabilization O
of O
IkappaB B
- I
alpha I
. O

Cells O
were O
stimulated O
with O
endotoxin B
( O
LPS O
, O
100 O
ng O
/ O
mL O
) O
with O
and O
without O
human O
IL B
- I
10 I
( O
10 O
ng O
/ O
mL O
) O
. O

IL B
- I
10 I
attenuated O
LPS O
- O
stimulated O
TNF B
- I
alpha I
production O
( O
297 O
+ O
/ O
- O
54 O
; O
p O
< O
. O
001 O
versus O
LPS O
alone O
) O
. O

IL B
- I
10 I
appears O
to O
prevent O
activation O
of O
NF B
- I
kappaB I
by O
preserving O
IkappaB B
- I
alpha I
protein O
levels O
, O
leading O
to O
a O
reduction O
in O
TNF B
- I
alpha I
release O
. O

Down O
- O
regulation O
of O
human O
granzyme B
B I
expression O
by O
glucocorticoids O
. O

These O
results O
indicate O
that O
dexamethasone O
is O
able O
to O
abrogate O
the O
transcriptional O
activity O
of O
the O
human O
granzyme O
B O
gene O
promoter O
by O
inhibiting O
the O
binding O
of O
nuclear B
factors I
at O
the O
AP O
- O
1 O
and O
Ikaros O
sites O
. O

Therefore O
in O
this O
study O
, O
we O
have O
examined O
the O
role O
of O
glucocorticoid O
receptor O
/ O
s O
( O
GR B
) O
characteristics O
in O
the O
developing O
of O
these O
abnormalities O
in O
patients O
with O
PCOS O
. O

Immuno O
- O
histochemical O
analysis O
confirmed O
the O
presence O
of O
NGAL B
within O
breast O
carcinoma O
cells O
but O
detected O
only O
low O
levels O
of O
this O
protein O
in O
normal O
ductal O
epithelium O
. O

In O
contrast O
, O
a O
significant O
correlation O
between O
NGAL B
expression O
in O
breast O
cancer O
was O
found O
with O
several O
other O
markers O
of O
poor O
prognosis O
, O
including O
estrogen O
and O
progesterone B
receptor I
- O
negative O
status O
and O
high O
proliferation O
( O
S O
- O
phase O
fraction O
) O
. O

BASH B
, O
a O
novel O
signaling O
molecule O
preferentially O
expressed O
in O
B O
cells O
of O
the O
bursa O
of O
Fabricius O
. O

The O
gene O
encodes O
an O
85 B
- I
kDa I
protein I
, O
designated O
BASH B
( O
B O
cell O
adaptor O
containing O
SH2 O
domain O
) O
, O
that O
contains O
N O
- O
terminal O
acidic O
domains O
with O
SH2 O
domain O
- O
binding O
phosphotyrosine O
- O
based O
motifs O
, O
a O
proline O
- O
rich O
domain O
, O
and O
a O
C B
- I
terminal I
SH2 I
domain I
. O

These O
studies O
revealed O
that O
the O
major B
protein I
in O
extracts O
of O
PMN O
activated O
by O
G B
- I
CSF I
to O
bind O
the O
high O
- O
affinity O
serum O
- O
inducible O
element O
( O
hSIE B
) O
is O
a O
72 O
- O
kDa O
protein O
that O
cross O
- O
reacts O
with O
Stat3 O
monoclonal O
antibody O
, O
which O
we O
have O
designated O
Stat3gamma B
. O

In O
order O
to O
investigate O
the O
factors O
that O
influence O
the O
induction O
of O
ICAM B
- I
1 I
molecules O
, O
Northern O
blot O
analysis O
to O
measure O
the O
expression O
level O
of O
ICAM O
- O
1 O
mRNAs O
and O
Southern O
blot O
hybridization O
to O
analyze O
the O
integration O
of O
human O
T O
- O
cell O
- O
leukemia O
virus O
type O
1 O
( O
HTLV O
- O
1 O
) O
provirus O
were O
done O
. O

Since O
the O
AES O
proteins O
are O
part O
of O
a O
set O
of O
transcriptional O
repressors O
encoded O
by O
the O
Enhancer O
of O
split O
[ O
E O
( O
spl O
) O
] O
genes O
, O
and O
since O
these O
repressors O
are O
activated O
to O
suppress O
cell O
differentiation O
in O
response O
to O
Notch B
receptors I
signalling O
, O
the O
AES O
peptides O
may O
represent O
a O
novel O
class O
of O
self B
- I
antigens I
that O
deserve O
further O
consideration O
as O
tumor O
Ag O
in O
epithelial O
cancers O
. O

Our O
data O
show O
that O
IFNs B
and O
IL B
- I
1 I
upregulate O
PML O
transcript O
and O
protein O
expression O
in O
a O
time O
and O
dose O
- O
dependent O
manner O
. O

Glucocorticoid B
receptors I
( O
GR B
) O
and O
3 O
- O
O O
- O
methyl O
- O
D O
glucose O
( O
3 O
- O
O O
- O
MG O
) O
transport O
were O
determined O
in O
mononuclear O
leukocytes O
( O
MNL O
) O
from O
11 O
abdominal O
obese O
subjects O
, O
10 O
pituitary O
- O
dependent O
Cushing O
' O
s O
syndrome O
( O
Cushing O
' O
s O
disease O
) O
and O
10 O
healthy O
controls O
. O

Interleukin B
- I
10 I
( O
IL B
- I
10 I
) O
and O
transforming B
growth I
factor I
beta I
( O
TGF B
- I
beta I
) O
are O
inhibitory O
for O
B O
and O
T O
cells O
, O
IgE B
production O
, O
and O
mast O
cell O
proliferation O
, O
and O
they O
induce O
apoptosis O
in O
eosinophils O
. O

The O
IL B
- I
10 I
gene O
polymorphism O
was O
a O
C O
- O
to O
- O
A O
exchange O
571 O
base O
pairs O
upstream O
from O
the O
translation B
start I
site I
and O
was O
present O
between O
consensus O
binding O
sequences O
for O
Sp1 B
and O
elevated O
total O
serum O
. O

However O
, O
it O
was O
only O
the O
IL B
- I
2 I
promoter I
whose O
activation O
by O
Tpl B
- I
2 I
was O
fully O
blocked O
by O
the O
dominant O
negative O
mutant O
MEK1S218 O
/ O
222A O
and O
the O
MEK1 O
/ O
MEK2 O
inhibitor O
PD098059 O
. O

Since O
the O
protein O
has O
a O
homeodomain B
and O
can O
activate O
transcription O
, O
it O
probably O
exerts O
at O
least O
some O
of O
its O
effects O
in O
vivo O
by O
regulation O
of O
target B
genes I
. O

We O
investigated O
the O
function O
of O
the O
evolutionary O
conserved O
X2 B
box I
in O
the O
promoter B
of O
the O
HLA B
- I
DRA I
gene I
from O
the O
human O
major O
histocompatibility O
complex O
( O
MHC B
) O
in O
resting O
and O
activated O
B O
cells O
. O

Thymocytes O
control O
the O
CD4 B
gene I
differently O
from O
mature O
T O
lymphocytes O
. O

The O
action O
of O
adenoviral O
E1A O
oncoprotein O
on O
host O
immune O
- O
response O
genes O
has O
been O
attributed O
to O
interaction O
with O
p300 O
/ O
CBP O
- O
type O
transcriptional O
coactivators O
in O
competition O
with O
endogenous O
transcription O
factors O
such O
as O
signal B
transducer I
and I
activator I
of I
transcription I
( I
STAT I
) I
proteins I
. O

Effect O
of O
environmental O
estrogens O
on O
IL B
- I
1beta I
promoter I
activity O
in O
a O
macrophage O
cell O
line O
. O

17beta O
- O
estradiol O
( O
E2 O
) O
markedly O
enhanced O
lipopolysaccharide O
- O
( O
LPS O
) O
induced O
IL B
- I
1beta I
promoter I
- O
driven O
CAT B
activity O
in O
a O
dose O
- O
dependent O
manner O
. O

Unlike O
the O
mycoestrogens O
, O
none O
of O
the O
compounds O
, O
with O
the O
exception O
of O
genistein O
, O
synergized O
with O
LPS O
to O
enhance O
IL B
- I
1beta I
promoter I
activity O
. O

In O
order O
to O
elucidate O
possible O
mechanisms O
underlying O
endothelial O
cell O
activation O
by O
xenogeneic O
serum O
, O
we O
focussed O
on O
transcription B
factor I
NF I
- I
kappa I
B I
, O
a O
central O
regulator O
for O
the O
induction O
of O
different O
genes O
, O
including O
adhesive O
molecules O
and O
chemoattractants B
. O

Anaphylatoxins B
C5a B
and O
C3a B
induce O
nuclear B
factor I
kappaB I
activation O
in O
human O
peripheral O
blood O
monocytes O
. O

These O
results O
imply O
a O
potential O
role O
of O
the O
anaphylatoxins B
C5a B
and O
C3a B
in O
regulating O
leukocytes O
gene O
expression O
through O
G O
protein O
- O
coupled O
transcription O
factor O
activation O
. O

Plasma O
TPO B
levels O
are O
regulated O
by O
the O
platelet O
and O
megakaryocyte O
mass O
through O
Mpl O
receptor O
binding O
, O
internalization O
and O
degradation O
. O

The O
Mpl O
receptor O
is O
a O
member O
of O
the O
hematopoietin B
receptor I
superfamily I
lacking O
intrinsic O
kinase O
activity O
. O

Promoter O
analysis O
revealed O
that O
a O
GATA B
site I
in O
a O
cryptic O
promoter O
in O
the O
second B
intron I
was O
essential O
and O
sufficient O
for O
the O
TAL1 O
- O
and O
LMO O
- O
dependent O
transcriptional O
activation O
, O
and O
GATA3 B
binds O
to O
this O
site O
. O

Several O
neuroendocrine O
- O
immune O
interactions O
could O
be O
responsible O
for O
reduced O
GR B
levels O
with O
age O
and O
sport O
activity O
in O
man O
. O

In O
non O
- O
rheumatoid O
arthritis O
, O
binding O
of O
NF B
- I
kappa I
B I
in O
synovial O
T O
cells O
was O
exclusively O
mediated O
by O
p50 B
/ I
p50 I
homodimers I
. O

X B
chromosome I
inactivation O
patterns O
in O
normal O
females O
. O

Since O
one O
of O
the O
two O
X B
chromosomes I
is O
randomly O
inactivated O
at O
an O
early O
stage O
of O
female O
embryonic O
development O
, O
X O
- O
linked O
markers O
have O
been O
used O
to O
study O
the O
origin O
and O
development O
of O
various O
neoplastic O
disorders O
in O
affected O
heterozygous O
women O
; O
clonality O
assays O
have O
provided O
a O
useful O
tool O
to O
the O
understanding O
of O
the O
mechanisms O
underlying O
the O
development O
of O
neoplasia O
. O

The O
rapid O
expansion O
of O
the O
number O
of O
women O
now O
suitable O
for O
X O
inactivation O
analysis O
has O
however O
given O
rise O
to O
new O
controversies O
, O
one O
of O
the O
more O
troublesome O
being O
the O
possibility O
of O
a O
modification O
of O
the O
pattern O
of O
X B
- I
chromosome I
inactivation O
pattern O
in O
blood O
cells O
of O
elderly O
women O
. O

We O
show O
here O
that O
IFN B
- I
alpha I
/ I
beta I
act O
directly O
on O
human O
T O
cells O
to O
drive O
Th1 O
development O
, O
bypassing O
the O
need O
for O
IL B
- I
12 I
- O
induced O
signaling O
, O
whereas O
IFN B
- I
alpha I
can O
not O
substitute O
IL B
- I
12 I
for O
mouse O
Th1 O
development O
. O

Unlike O
IL B
- I
12 I
, O
which O
acts O
only O
on O
Th1 O
cells O
, O
IFN B
- I
alpha I
/ I
beta I
can O
activate O
Stat4 B
not O
only O
in O
human O
Th1 O
, O
but O
also O
in O
Th2 O
cells O
. O

Inhibition O
of O
Th1 O
development O
mediated O
by O
GATA B
- I
3 I
through O
an O
IL O
- O
4 O
- O
independent O
mechanism O
. O

These O
motifs O
are O
regulatory B
sequences I
within O
the O
so O
- O
called O
AU O
- O
rich O
elements O
( O
AREs O
) O
often O
found O
in O
3 O
' O
untranslated O
regions O
of O
genes O
such O
as O
cytokines B
, O
proto B
- I
oncogenes I
, O
and O
transcription B
factors I
. O

Transcription O
factor O
NF B
- I
kappaB I
regulation O
of O
renal O
fibrosis O
during O
ureteral O
obstruction O
. O

The O
nuclear O
factor O
- O
kappa O
B O
( O
NF O
- O
kappaB O
) O
family O
of O
transcription B
factors I
regulates O
genes O
involved O
in O
inflammation O
, O
cell O
proliferation O
, O
and O
cell O
differentiation O
. O

At O
the O
same O
time O
there O
was O
no O
change O
in O
the O
level O
of O
expression O
of O
the O
cell O
surface O
antigenes O
CD33 B
, O
CD34 B
, O
CD45 B
, O
CD71 B
and O
glycophorin O
A O
. O

The O
class B
II I
transactivator I
( O
CIITA B
) O
is O
essential O
for O
the O
expression O
of O
major B
histocompatibility I
complex I
( I
MHC I
) I
class I
II I
antigens I
. O

In O
contrast O
, O
luciferase B
expression O
was O
not O
stimulated O
after O
IFN B
- I
gamma I
treatment O
when O
the O
construct O
was O
transfected O
in O
macrophage O
or O
in O
epithelial O
cell O
lines O
. O

These O
studies O
investigate O
the O
relationship O
between O
leukocyte O
populations O
, O
steroid B
hormone I
receptor I
expression O
, O
proliferative O
activity O
, O
bcl B
- I
2 I
expression O
and O
apoptosis O
in O
eutopic O
and O
ectopic O
endometrium O
from O
women O
with O
endometriosis O
or O
adenomyosis O
at O
different O
phases O
of O
the O
menstrual O
cycle O
. O

Here O
, O
we O
demonstrate O
through O
the O
use O
of O
intracellular O
staining O
that O
interleukin B
- I
1beta I
( O
IL B
- I
1beta I
) O
is O
expressed O
in O
LCLs O
and O
investigate O
the O
influence O
of O
the O
individual O
latent B
proteins I
on O
the O
expression O
of O
IL B
- I
1beta I
. O

Electrophoretic O
mobility O
shift O
assays O
( O
EMSAs O
) O
demonstrated O
that O
the O
- O
300 O
region O
of O
the O
IL B
- I
1beta I
promoter O
, O
which O
contains O
a O
nuclear O
factor O
- O
kappaB O
( O
NF O
- O
kappaB O
) O
binding O
site O
, O
contained O
a O
functional O
RBP O
binding O
site O
. O

CD27 B
/ O
CD70 O
interaction O
augments O
IgE B
secretion O
by O
promoting O
the O
differentiation O
of O
memory O
B O
cells O
into O
plasma O
cells O
. O

The O
induction O
of O
IgE B
switching O
in O
B O
cells O
requires O
several O
signals O
given O
by O
cytokines B
and O
cell O
contact O
- O
delivered O
signals O
. O

Here O
, O
we O
investigated O
the O
role O
of O
CD27 B
/ O
CD70 O
interaction O
in O
B O
cell O
IgE B
synthesis O
. O

CD27 O
/ O
CD70 O
interaction O
enhanced O
B O
cell O
proliferation O
in O
the O
presence O
of O
IL B
- I
4 I
or O
IL B
- I
4 I
plus O
anti B
- I
CD40 I
. O

Recent O
studies O
, O
however O
, O
demonstrate O
that O
the O
transcribed O
5 O
' O
- O
untranslated O
leader O
region O
( O
5 B
' I
- I
UTR I
) O
also O
contains O
important O
transcriptional O
elements O
. O

These O
regulatory B
elements I
situated O
downstream O
of O
transcription O
interact O
with O
constitutive O
and O
inducible O
transcription B
factors I
, O
mediate O
transmission O
of O
cellular O
activation O
signals O
, O
and O
are O
important O
for O
efficient O
HIV O
- O
1 O
transcription O
and O
replication O
. O

Regulation O
of O
PAK O
activation O
and O
the O
T O
cell O
cytoskeleton O
by O
the O
linker O
protein O
SLP B
- I
76 I
. O

In O
turn O
, O
assembly O
of O
this O
complex O
mediates O
the O
enzymatic O
activation O
of O
the O
p21 O
- O
activated O
protein O
kinase O
1 O
and O
facilitates O
actin B
polymerization O
. O

LOX B
- I
1 I
is O
an O
endothelial O
receptor O
for O
oxidized O
low O
- O
density O
lipoprotein O
that O
plays O
essential O
roles O
in O
atherogenesis O
. O

In O
the O
present O
study O
, O
we O
cloned O
and O
characterized O
the O
human B
LOX I
- I
1 I
gene I
( O
HGMW O
- O
approved O
symbol O
OLR1 O
) O
. O

In O
contrast O
, O
the O
expression O
pattern O
of O
LOX B
- I
1 I
is O
different O
from O
that O
of O
the O
natural B
killer I
cell I
receptors I
; O
LOX B
- I
1 I
is O
expressed O
in O
vascular O
- O
rich O
organs O
, O
but O
not O
in O
lymphocytes O
. O

These O
results O
demonstrate O
that O
the O
human B
LOX I
- I
1 I
gene I
is O
a O
new O
member O
of O
the O
natural B
killer I
gene I
complex I
with O
a O
unique O
expression O
profile O
. O

In O
this O
report O
, O
we O
describe O
the O
transcriptional O
regulation O
of O
the O
beta B
- I
casein I
gene I
by O
cytokines B
in O
T O
cells O
. O

Coincidentally O
, O
a O
deletion O
of O
this O
region O
enhanced O
the O
IL B
- I
2 I
- O
induced O
expression O
of O
beta B
- I
casein I
. O

In O
addition O
, O
Ras B
( I
G12V I
) I
complemented O
signaling O
by O
an O
erythropoietin O
receptor O
mutant O
defective O
in O
Ras B
activation O
and O
augmented O
the O
activation O
of O
the O
beta B
- I
casein I
promoter I
by O
the O
mutant O
erythropoietin O
receptor O
signaling O
, O
suggesting O
a O
possible O
role O
of O
Ras B
in O
Stat5 B
- O
mediated O
gene O
expression O
. O

GATA B
- I
3 I
represses O
gp91phox B
gene I
expression O
in O
eosinophil O
- O
committed O
HL O
- O
60 O
- O
C15 O
cells O
. O

Ligation O
of O
CD3 B
also O
induces O
the O
tyrosine O
phosphorylation O
of O
HS1 B
, O
a O
75 O
- O
kDa O
hematopoietic O
cell O
- O
specific O
intracellular O
signaling O
protein O
of O
unknown O
function O
. O

Costimulation O
through O
CD28 B
and O
/ O
or O
CD2 B
did O
not O
modulate O
the O
CD3 B
- O
dependent O
phosphorylation O
of O
HS1 B
. O

In O
addition O
, O
Northern O
blot O
analysis O
of O
cord O
and O
adult O
samples O
revealed O
similar O
maximal O
increases O
in O
c B
- I
fos I
( O
99 O
+ O
/ O
- O
15 O
and O
126 O
+ O
/ O
- O
11 O
% O
, O
p O
= O
0 O
. O
0126 O
) O
and O
c O
- O
jun O
( O
123 O
+ O
/ O
- O
9 O
and O
185 O
+ O
/ O
- O
38 O
% O
, O
p O
= O
0 O
. O
0291 O
) O
mRNA O
expression O
, O
respectively O
, O
as O
early O
as O
15 O
min O
post O
- O
alphaCD3 B
stimulation O
. O

Receptors O
for O
the O
Fc O
portion O
of O
immunoglobulin O
molecules O
( O
FcR B
) O
present O
on O
leukocyte O
cell O
membranes O
mediate O
a O
large O
number O
of O
cellular O
responses O
that O
are O
very O
important O
in O
host O
defense O
, O
including O
phagocytosis O
, O
cell O
cytotoxicity O
, O
production O
and O
secretion O
of O
inflammatory B
mediators I
, O
and O
modulation O
of O
the O
immune O
response O
. O

Cross O
- O
linking O
of O
FcR B
, O
on O
the O
THP O
- O
1 O
monocytic O
cell O
line O
, O
by O
immune B
complexes I
resulted O
in O
both O
activation O
of O
the O
transcription B
factor I
NF B
- I
kappaB I
and O
interleukin B
1 I
production O
. O

BCL B
- I
6 I
mutations O
in O
normal O
germinal O
center O
B O
cells O
: O
evidence O
of O
somatic O
hypermutation O
acting O
outside O
Ig B
loci I
. O

Thirty O
percent O
of O
GC O
B O
cells O
, O
but O
not O
naive O
B O
cells O
, O
displayed O
mutations O
in O
the O
742 O
bp O
region O
analyzed O
within O
the O
first O
intron O
of O
BCL B
- I
6 I
( O
overall O
frequency O
: O
5 O
x O
10 O
( O
- O
4 O
) O
/ O
bp O
) O
. O

The O
ability O
of O
E2A B
- I
HLF I
to O
prolong O
the O
survival O
of O
interleukin O
- O
3 O
( O
IL O
- O
3 O
) O
- O
dependent O
murine O
pro O
- O
B O
cells O
after O
IL B
- I
3 I
withdrawal O
suggests O
that O
it O
disrupts O
signaling O
pathways O
normally O
responsible O
for O
cell O
suicide O
, O
allowing O
the O
cells O
to O
accumulate O
as O
transformed O
lymphoblasts O
. O

Neither O
the O
E12 B
nor O
the O
E47 B
product O
of O
the O
E2A B
gene I
nor O
the O
wild O
- O
type O
HLF O
protein O
was O
able O
to O
protect O
the O
cells O
from O
apoptosis O
induced O
by O
IL B
- I
3 I
deprivation O
. O

Surprisingly O
, O
different O
combinations O
of O
disabling O
mutations O
within O
the O
HLF O
bZIP O
domain O
had O
little O
effect O
on O
the O
antiapoptotic O
property O
of O
the O
chimeric B
protein I
, O
so O
long O
as O
the O
amino O
- O
terminal O
portion O
of O
E2A B
remained O
intact O
. O

These O
results O
suggest O
that O
1 O
) O
lipid O
A O
myristoyl O
fatty O
acid O
, O
although O
it O
is O
important O
for O
the O
induction O
of O
inflammatory B
cytokine I
production O
by O
human O
monocytes O
, O
is O
not O
necessary O
for O
the O
induction O
of O
Mn B
SOD I
, O
2 O
) O
endotoxin B
- O
mediated O
induction O
of O
Mn B
SOD I
and O
inflammatory O
cytokines B
are O
regulated O
, O
at O
least O
in O
part O
, O
through O
different O
signal O
transduction O
pathways O
, O
and O
3 O
) O
failure O
of O
the O
mutant B
endotoxin I
to O
induce O
tumor B
necrosis I
factor I
- I
alpha I
production O
is O
, O
at O
least O
in O
part O
, O
due O
to O
its O
inability O
to O
activate O
mitogen B
- I
activated I
protein I
kinase I
. O

Characterization O
of O
cytokine B
differential O
induction O
of O
STAT B
complexes I
in O
primary O
human O
T O
and O
NK O
cells O
. O

Finally O
, O
we O
observed O
that O
activated O
STAT5a B
and O
STAT5b B
proteins O
form O
distinct O
Fc O
gamma O
RI O
GAS O
binding O
patterns O
in O
T O
and O
NK O
cells O
, O
suggesting O
that O
they O
might O
have O
different O
roles O
in O
gene O
regulation O
. O

A O
regulatory B
element I
in O
the O
CD95 O
( O
APO O
- O
1 O
/ O
Fas O
) O
ligand O
promoter O
is O
essential O
for O
responsiveness O
to O
TCR B
- O
mediated O
activation O
. O

The O
DNA O
sequence O
at O
- B
120 I
also O
contains O
two O
DNA O
motifs O
homologous O
to O
the O
binding O
site O
for O
NF B
- I
AT I
. O

NF B
- I
AT I
does O
not O
directly O
bind O
to O
this O
element O
. O

Progesterone O
acts O
distally O
to O
the O
initial O
steps O
of O
T B
cell I
receptor I
( O
TCR B
) O
- O
mediated O
signal O
transduction O
, O
since O
it O
blocks O
sustained O
Ca2 O
+ O
signals O
after O
thapsigargin O
stimulation O
, O
as O
well O
as O
oscillatory O
Ca2 O
+ O
signals O
, O
but O
not O
the O
Ca2 O
+ O
transient O
after O
TCR B
stimulation O
. O

Progesterone O
effectively O
blocked O
a O
broad O
spectrum O
of O
K B
+ I
channels I
, O
reducing O
both O
Kv1 O
. O
3 O
and O
charybdotoxin O
- O
resistant O
components O
of O
KV B
current O
and O
KCa B
current O
in O
T O
cells O
, O
as O
well O
as O
blocking O
several O
cloned O
KV O
channels O
expressed O
in O
cell O
lines O
. O

The O
chemokine B
receptor I
, O
BLR1 B
, O
is O
a O
major O
regulator O
of O
the O
microenvironmental O
homing O
of O
B O
cells O
in O
lymphoid O
organs O
. O

Activation O
of O
the O
CD4 B
promoter I
occurs O
in O
the O
presence O
of O
the O
viral O
DNA O
polymerase O
inhibitor O
phosphonoformic O
acid O
, O
which O
limits O
expression O
to O
the O
immediate O
- O
early O
and O
early O
classes O
of O
viral O
genes O
. O

Both O
Tax B
- O
mediated O
apoptosis O
and O
oxidative O
stress O
can O
be O
potently O
suppressed O
by O
antioxidants O
, O
as O
is O
seen O
with O
the O
administration O
of O
recombinant O
thioredoxin O
( O
adult O
T O
cell O
leukemia O
- O
derived O
factor O
) O
or O
pyrrolidine O
dithiocarbamate O
. O

Nor O
was O
fragmentation O
observed O
after O
treatment O
with O
RU38486 O
, O
indicating O
that O
repression O
of O
AP B
- I
1 I
activity O
is O
not O
involved O
. O

Dexamethasone O
treatment O
completely O
blocked O
12 O
- O
O O
- O
tetradecanoylphorbol O
13 O
- O
acetate O
induction O
of O
nuclear B
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
activity O
and O
elicited O
an O
increase O
in O
the O
amount O
of O
immunoreactive O
IkappaB O
alpha O
in O
sensitive O
6TG1 O
. O
1 O
cells O
but O
not O
in O
resistant O
ICR27TK O
. O
3 O
cells O
. O

It O
was O
proposed O
that O
the O
mechanism O
of O
antiviral O
action O
of O
S9a O
was O
on O
the O
host O
cell O
, O
by O
blocking O
TNF B
- I
alpha I
transcription O
via O
a O
Tat B
- O
induced O
tar O
- O
independent O
loop O
, O
which O
decreases O
downstream O
NF B
- I
kappaB I
activation O
of O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
. O

Intestinal O
epithelial O
cells O
can O
express O
HLA B
class I
II I
antigens I
and O
may O
function O
as O
antigen O
- O
presenting O
cells O
to O
CD4 O
( O
+ O
) O
T O
cells O
within O
the O
intestinal O
mucosa O
. O

We O
determined O
whether O
Hsp70 B
induction O
by O
TS O
was O
mediated O
by O
the O
activation O
of O
the O
HS O
transcription O
factor O
, O
HSF B
. O

Thus O
, O
we O
also O
determined O
the O
effects O
of O
TS O
on O
NFkappaB B
. O

TS O
activated O
HSF B
, O
which O
was O
associated O
with O
Hsp70 B
overexpression O
and O
inhibition O
of O
NFkappaB B
binding O
activity O
and O
TNFalpha B
release O
. O

[ O
Molecular O
mechanism O
of O
cytokine B
gene I
expression O
in O
Th1 O
and O
Th2 O
] O

Among O
them O
, O
both O
the O
activation O
of O
PKC O
/ O
Ras O
- O
and O
CaM O
/ O
CN O
- O
mediated O
pathways O
play O
a O
central O
role O
in O
the O
signal O
transduction O
of O
cytokine B
gene I
expression O
. O

Activation O
of O
T O
cells O
results O
in O
the O
rapid O
calcineurin B
- O
dependent O
translocation O
of O
NFAT B
transcription B
factors I
from O
the O
cytoplasm O
to O
the O
nucleus O
. O

Unexpectedly O
, O
we O
found O
that O
conventional O
procedures O
employed O
to O
prepare O
cellular O
extracts O
cause O
the O
release O
of O
proteolytic O
activities O
that O
are O
normally O
stored O
in O
intracellular O
granules O
, O
resulting O
in O
the O
degradation O
of O
various O
NF B
- I
kappaB I
/ I
Rel I
and O
STAT B
proteins I
. O

In O
addition O
, O
the O
procedure O
described O
herein O
could O
prove O
useful O
in O
other O
cell O
types O
that O
express O
high O
levels O
of O
endogenous B
proteases I
. O

The O
capacity O
of O
neonatal O
T O
cells O
to O
secrete O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
has O
been O
reported O
to O
be O
variable O
. O

PDBu O
+ O
iono O
induced O
equally O
high O
IL B
- I
2 I
levels O
in O
both O
groups O
and O
, O
when O
stimulated O
with O
plate O
- O
bound O
anti B
- I
CD3 I
monoclonal I
antibody I
( O
mAb B
) O
, O
the O
IL B
- I
2 I
secretion O
by O
neonatal O
cells O
was O
undetectable O
and O
adult O
cells O
produced O
low O
amounts O
of O
IL B
- I
2 I
( O
mean O
331 O
+ O
/ O
- O
86 O
pg O
/ O
ml O
) O
. O

As O
NF B
- I
kappa I
B I
is O
a O
critical O
transcription B
factor I
in O
the O
control O
of O
IL B
- I
2 I
expression O
, O
we O
next O
analysed O
its O
nuclear O
translocation O
in O
neonatal O
and O
adult O
T O
cells O
using O
the O
electrophoretic O
mobility O
shift O
assay O
and O
, O
because O
induction O
of O
reactive O
oxygen O
intermediates O
( O
ROI O
) O
is O
required O
for O
the O
activation O
of O
NF B
- I
kappa I
B I
, O
we O
also O
analysed O
levels O
of O
intracellular O
ROI O
in O
these O
cells O
using O
the O
ROI O
- O
reactive O
fluorochrome O
DCFH O
- O
DA O
and O
flow O
cytometry O
. O

Our O
results O
suggest O
that O
reduced O
IL B
- I
2 I
production O
by O
neonatal O
T O
cells O
is O
specific O
for O
anti B
- I
CD3 I
and O
anti B
- I
CD3 I
+ O
anti B
- I
CD28 I
- O
mediated O
stimulation O
and O
that O
these O
activators O
can O
not O
effectively O
activate O
the O
ROI O
- B
NF I
- I
kappa I
B I
signalling O
pathway O
in O
neonatal O
T O
cells O
. O

CL O
- O
01 O
cells O
are O
IgM B
+ O
IgD B
+ O
CD30 B
+ O
and O
switch O
to O
IgG B
, O
IgA B
, O
and O
IgE B
when O
exposed O
to O
CD40L B
and O
IL B
- I
4 I
. O

Switching O
is O
hampered O
by O
CD30 B
coengagement O
, O
possibly O
through O
interference O
with O
the O
CD40 B
- O
mediated O
NF B
- I
kappaB I
- O
dependent O
transcriptional O
activation O
of O
downstream O
C O
( O
H O
) O
genes O
. O

Are O
there O
effects O
of O
CyA O
and O
FK O
506 O
all O
attributable O
to O
CN O
inhibition O
, O
and O
how O
much O
of O
them O
are O
mediated O
through O
the O
NFATC O
family O
of O
transcription B
factors I
? O

Signal B
transducer I
and I
activator I
of I
transcription I
3 I
( O
Stat3 B
) O
has O
recently O
been O
shown O
to O
exist O
in O
two O
alternatively O
spliced O
isoforms O
, O
a O
short O
form O
, O
Stat3beta B
, O
and O
a O
longer O
form O
, O
Stat3alpha B
, O
displaying O
differences O
in O
transcriptional O
activity O
. O

It O
is O
unknown O
which O
Stat3 O
isoform O
( O
s O
) O
is O
activated O
in O
response O
to O
interleukin B
( I
IL I
) I
- I
2 I
and O
IL B
- I
15 I
. O

Relationship O
between O
IkappaBalpha B
constitutive O
expression O
, O
TNFalpha B
synthesis O
, O
and O
apoptosis O
in O
EBV O
- O
infected O
lymphoblastoid O
cells O
. O

In O
order O
to O
understand O
the O
role O
of O
NF B
- I
kappaB I
in O
EBV O
transformation O
we O
have O
established O
stably O
transfected O
IkappaBalpha B
into O
lymphoblastoid O
cells O
. O

Our O
results O
suggest O
that O
the O
TNFalpha O
gene O
could O
be O
one O
of O
the O
targets O
of O
NF B
- I
kappaB I
in O
EBV O
infected O
cells O
and O
that O
NF O
- O
kappaB O
protects O
EBV O
- O
infected O
cells O
from O
apoptosis O
induced O
by O
TNFalpha B
, O
which O
may O
favour O
the O
proliferative O
effect O
of O
this O
cytokine B
. O

Two O
chronically O
HIV O
- O
1 O
- O
infected O
cell O
lines O
, O
U1 O
( O
monocytic O
) O
and O
ACH O
- O
2 O
( O
T O
lymphocytic O
) O
, O
were O
stimulated O
with O
TNF B
- I
alpha I
or O
PMA O
and O
cultured O
in O
the O
presence O
of O
various O
concentrations O
of O
the O
compound O
. O

This O
study O
shows O
that O
expression O
of O
LMP1 B
activates O
transcription O
from O
p50 O
/ O
p65 O
- O
and O
c O
- O
Rel O
- O
responsive O
promoters O
, O
and O
that O
this O
activity O
can O
be O
completely O
inhibited O
by O
expression O
of O
a O
dominant O
inhibitory O
IkappaB O
mutant O
. O

Furthermore O
, O
LMP1 B
- O
induced O
cell O
size O
increase O
of O
primary O
B O
cells O
was O
unaffected O
by O
IkappaB B
expression O
. O

The O
eosinophilic O
characteristics O
of O
YJ O
cells O
were O
confirmed O
by O
histochemical O
staining O
with O
Fast O
- O
Green O
/ O
Neutral O
- O
Red O
and O
by O
the O
expression O
of O
mRNAs B
for O
eosinophil O
- O
associated O
granule O
proteins O
, O
eosinophil B
cationic I
protein I
( O
ECP B
) O
, O
eosinophil O
- O
derived O
neurotoxin O
( O
EDN B
) O
, O
eosinophil B
peroxidase I
( O
EPO B
) O
, O
and O
major O
basic O
protein O
( O
MBP B
) O
, O
and O
for O
the O
Charcot O
- O
Leyden O
crystal O
( O
CLC O
) O
protein O
. O

The O
expression O
of O
genes O
for O
transcription B
factors I
involved O
in O
myeloid O
differentiation O
was O
evaluated O
by O
Northern O
blot O
analysis O
. O

To O
examine O
the O
hypothesis O
that O
interleukin B
- I
6 I
( O
IL B
- I
6 I
) O
contributes O
to O
PMN O
infiltration O
and O
lung O
damage O
in O
HS O
, O
we O
examined O
the O
lungs O
of O
rats O
subjected O
to O
unresuscitated O
and O
resuscitated O
HS O
for O
the O
production O
of O
IL B
- I
6 I
and O
activation O
of O
Stat3 B
. O

Electrophoretic O
mobility O
shift O
assay O
of O
protein O
extracts O
from O
shock O
lungs O
exhibited O
an O
increase O
in O
Stat3 B
activation O
with O
kinetics O
similar O
to O
IL B
- I
6 I
mRNA I
. O

The O
MHC B
class I
II I
transactivator I
( O
CIITA B
) O
requires O
conserved O
leucine B
charged I
domains I
for O
interactions O
with O
the O
conserved O
W O
box O
promoter O
element O
. O

The O
ability O
of O
mutants O
to O
activate O
a O
reporter O
gene O
under O
the O
control O
of O
MHC B
class I
II I
conserved O
W O
- O
X O
- O
Y O
or O
X O
- O
Y O
regulatory O
elements O
was O
determined O
. O

Two O
mutants O
displayed O
differential O
activity O
between O
the O
two O
promoters B
, O
activating O
transcription O
with O
the O
W O
- O
X O
- O
Y O
but O
not O
the O
X O
- O
Y O
elements O
. O

All O
mutants O
were O
tested O
for O
their O
ability O
to O
interfere O
with O
wild O
- O
type O
CIITA B
activity O
. O

The O
characterization O
of O
CIITA O
mutants O
that O
are O
able O
to O
discriminate O
between O
promoters O
with O
or O
without O
the O
W O
box O
strongly O
suggests O
that O
CIITA B
requires O
such O
interactions O
for O
function O
. O

Recently O
, O
it O
was O
suggested O
that O
activation O
of O
the O
alpha O
isoform O
of O
PPAR B
by O
the O
potent O
proinflammatory O
mediator O
leukotriene O
B4 O
( O
LTB4 O
) O
enhanced O
degradation O
of O
this O
eicosanoid O
, O
offersuggesting O
a O
new O
aspect O
of O
down O
- O
regulation O
of O
inflammation O
. O

Thus O
, O
this O
study O
provides O
no O
evidence O
indicating O
a O
regulatory O
function O
of O
PPARalpha B
in O
LTB4 O
induced O
adhesive O
interactions O
between O
endothelial O
cells O
and O
neutrophils O

We O
determined O
whether O
the O
interaction O
of O
SS O
RBC O
with O
cultured O
endothelial O
cells O
induced O
cellular O
oxidant O
stress O
that O
would O
culminate O
in O
expression O
of O
cell B
adhesion I
molecules I
( O
CAMs B
) O
involved O
in O
the O
adhesion O
and O
diapedesis O
of O
monocytes O
and O
the O
adherence O
of O
SS O
reticulocytes O
. O

Changes O
in O
these O
signaling O
molecules O
during O
cytokine B
treatment O
were O
also O
investigated O
. O

Correlations O
of O
TCRzeta B
or O
p56 B
( I
lck I
) I
levels O
with O
response O
or O
disease O
variables O
, O
except O
for O
lower O
TCRzeta B
levels O
( O
P O
< O
0 O
. O
001 O
) O
in O
the O
presence O
of O
bone O
metastases O
, O
were O
not O
found O
. O

In O
the O
majority O
of O
patients O
with O
advanced O
RCC O
, O
peripheral O
blood O
T O
cells O
express O
TCRzeta B
and O
p56 B
( I
lck I
) I
, O
and O
in O
a O
subset O
, O
reduced O
levels O
of O
these O
TCRzeta O
associated O
molecules O
are O
seen O
that O
may O
increase O
during O
cytokine B
- O
based O
therapy O
. O

Identification O
of O
transcription B
factors I
expressed O
during O
ATRA O
- O
induced O
neutrophil O
differentiation O
of O
HL60 O
cells O
. O

Interleukin O
- O
4 O
and O
- O
13 O
induce O
upregulation O
of O
the O
murine O
macrophage O
12 O
/ O
15 O
- O
lipoxygenase O
activity O
: O
evidence O
for O
the O
involvement O
of O
transcription B
factor I
STAT6 B
. O

The O
cytokine B
- O
dependent O
upregulation O
of O
the O
murine O
macrophage O
12 O
- O
lipoxygenase O
and O
its O
induction O
during O
experimental O
anemia O
suggests O
its O
close O
relatedness O
with O
the O
human O
reticulocyte O
- O
type O
15 O
- O
lipoxygenase O
despite O
their O
differences O
in O
the O
positional O
specificity O
of O
arachidonic O
acid O
oxygenation O
. O

Interferon O
- O
gamma O
- O
induced O
factor O
binding O
to O
the O
interleukin O
- O
4 O
- O
responsive O
element O
of O
CD23b B
promoter I
in O
human O
tonsillar O
mononuclear O
cells O
: O
role O
in O
transient O
up O
- O
regulation O
of O
the O
interleukin O
- O
4 O
- O
induced O
CD23b O
mRNA O
. O

Activation O
of O
E2F B
- O
mediated O
transcription O
by O
human O
T O
- O
cell O
leukemia O
virus O
type O
I O
Tax O
protein O
in O
a O
p16 O
( O
INK4A O
) O
- O
negative O
T O
- O
cell O
line O
. O

Consequently O
, O
Tax B
can O
activate O
the O
signaling O
pathway O
that O
lead O
to O
the O
release O
of O
E2F B
that O
in O
turn O
induces O
expression O
of O
factors O
required O
for O
cell O
cycle O
progression O
. O

In O
addition O
, O
Tax B
also O
stimulates O
the O
transcription O
of O
the O
E2F O
- O
1 O
gene O
itself O
. O

These O
studies O
indicate O
that O
iNO O
attenuates O
iNOS B
expression O
in O
macrophages O
and O
inhibits O
monocyte O
adhesion O
to O
endothelial O
cells O
, O
and O
suggest O
that O
endogenously O
derived O
iNO O
may O
be O
an O
important O
autoregulatory O
inhibitor O
of O
vascular O
inflammation O

These O
results O
corroborate O
previous O
findings O
that O
the O
presence O
of O
ER B
variants O
is O
not O
a O
characteristic O
of O
breast O
cancer O
. O

p21ras B
initiates O
Rac B
- I
1 I
but O
not O
phosphatidyl O
inositol O
3 O
kinase O
/ O
PKB O
, O
mediated O
signaling O
pathways O
in O
T O
lymphocytes O
. O

We O
also O
examined O
the O
possibility O
that O
Akt B
/ I
PKB I
is O
regulated O
by O
Ras O
signaling O
pathways O
in O
T O
lymphocytes O
. O

Moreover O
, O
neither O
TCR B
or O
Ras B
activation O
of O
AP B
- I
1 I
is O
dependent O
on O
PtdIns B
3 I
- I
kinase I
. O

The O
present O
data O
thus O
highlight O
that O
PtdIns B
3 I
- I
kinase I
and O
Akt B
/ I
PKB I
are O
not O
universal O
Ras O
effector O
molecules O
. O

LNCaP O
cells O
treated O
with O
prostaglandin O
E2 O
showed O
neither O
a O
reduction O
in O
proliferation O
nor O
a O
down O
- O
regulation O
of O
AR B
and O
PSA B
levels O
. O

In O
addition O
, O
recombinant O
IL B
- I
1beta I
was O
able O
to O
replace O
MCM O
for O
the O
inhibition O
of O
proliferation O
and O
down O
- O
regulation O
of O
AR B
and O
PSA B
proteins O
. O

LNCaP O
cells O
were O
shown O
to O
express O
the O
IL B
- I
1beta I
receptor O
type O
1 O
, O
which O
transduces O
IL B
- I
1beta I
signal O
. O

Differential O
responsiveness O
of O
the O
IL O
- O
5 O
and O
IL O
- O
4 O
genes O
to O
transcription B
factor I
GATA I
- I
3 I
. O

Here O
, O
we O
show O
that O
ectopic O
expression O
of O
GATA B
- I
3 I
is O
sufficient O
to O
drive O
IL B
- I
5 I
but O
not O
IL B
- I
4 I
gene O
expression O
. O

Mutations O
of O
sites O
that O
suppress O
NF B
- I
AT I
binding O
impair O
the O
induction O
and O
strong O
NF B
- I
ATp I
- O
mediated O
transactivation O
of O
the O
CD25 B
promoter I
in O
T O
cells O
. O

Antibodies B
to O
Duffy O
antigens O
are O
responsible O
for O
some O
cases O
of O
transfusion O
incompatibility O
and O
newborn O
hemolytic O
disease O
. O

The O
Duffy O
protein O
is O
a O
receptor O
for O
the O
Plasmodium O
vivax O
erythrocyte O
- O
binding O
protein O
and O
is O
also O
a O
receptor O
for O
various O
chemokines B
( O
thus O
renamed O
Duffy O
Antigen O
Receptor O
for O
Chemokines O
[ O
DARC B
] O
) O
. O

The O
271C O
- O
- O
> O
T O
substitution O
represents O
a O
considerable O
change O
in O
chemical O
nature O
( O
Arg91 O
- O
- O
> O
Cys O
) O
, O
one O
which O
may O
affect O
the O
antigenic O
determinants O
of O
DARC B
, O
and O
thus O
be O
of O
clinical O
significance O
. O

The O
functions O
of O
NFAT B
proteins I
are O
directly O
controlled O
by O
the O
calcium B
- I
and I
calmodulin I
- I
dependent I
phosphatase I
calcineurin B
. O

Expression O
of O
the O
IL B
- I
2 I
gene I
requires O
activation O
of O
T O
cells O
through O
stimulation O
of O
the O
TCR B
and O
costimulation O
through O
accessory O
receptors O
. O

In O
this O
study O
, O
we O
analyzed O
whether O
activities O
of O
these O
phosphatases O
are O
necessary O
for O
the O
expression O
of O
the O
IL B
- I
2 I
gene I
. O

In O
both O
activated O
peripheral O
blood O
T O
lymphocytes O
and O
activated O
tumorigenic O
T O
cell O
lines O
, O
IL B
- I
2 I
gene O
expression O
was O
blocked O
at O
the O
transcriptional O
level O
by O
okadaic O
acid O
. O

The O
transcription B
factors I
active O
at O
the O
IL B
- I
2 I
promoter I
were O
differentially O
influenced O
: O
upon O
down O
- O
modulation O
of O
okadaic O
acid O
- O
sensitive O
phosphatases O
, O
transactivation O
by O
octamer O
, O
NF B
- I
kappa I
B I
, O
and O
NF O
of O
activated O
T O
cells O
proteins O
was O
abrogated O
, O
while O
transactivation O
by O
AP O
- O
1 O
proteins O
was O
even O
enhanced O
. O

The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
effects O
of O
bis O
[ O
4 O
- O
[ O
2 O
, O
4 O
- O
dioxo O
- O
5 O
- O
thiazolidinyl O
) O
methyl O
] O
phenyl O
] O
methane O
( O
YM O
- O
268 O
) O
, O
a O
thiazolidinedione O
derivative O
, O
on O
glucose O
uptake O
, O
adipocyte O
differentiation O
through O
peroxisome O
proliferator O
- O
activated O
receptor O
gamma O
( O
PPARgamma B
) O
, O
and O
phosphatidylinositol B
3 I
- I
kinase I
( O
PI B
3 I
- I
kinase I
) O
activity O
in O
cultured O
cells O
. O

The O
nuclear B
receptor I
PPARgamma B
- O
bigger O
than O
fat O
. O

PPARgamma B
has O
also O
been O
implicated O
recently O
in O
the O
biology O
of O
monocytes O
and O
in O
cell O
- O
cycle O
regulation O
and O
cancer O
. O

Although O
common O
members O
of O
the O
apoptotic O
cascade O
are O
shared O
between O
different O
cell O
types O
, O
it O
appears O
that O
cell B
- I
specific I
factors I
can O
influence O
the O
response O
to O
a O
given O
apoptotic O
stimuli O
. O

These O
results O
establish O
an O
independent O
role O
for O
enhanced O
p75TNF B
- I
R I
production O
in O
the O
pathogenesis O
of O
inflammatory O
disease O
and O
implicate O
the O
direct O
involvement O
of O
this O
receptor O
in O
a O
wide O
range O
of O
human O
inflammatory O
pathologies O
. O

We O
have O
determined O
how O
the O
phosphorylation O
of O
the O
retinoblastoma O
family O
( O
pRb B
, O
p107 B
, O
and O
p130 B
) O
is O
governed O
in O
individual O
cell O
cycle O
phases O
of O
Daudi O
B O
- O
cells O
during O
cell O
cycle O
exit O
triggered O
by O
alpha B
- I
interferon I
( O
alpha B
- I
IFN I
) O
. O

alpha B
- I
IFN I
causes O
dephosphorylation O
of O
pRb B
and O
loss O
of O
p130 O
phosphorylated O
Form O
3 O
. O

However O
, O
the O
change O
in O
p130 B
phosphorylation O
in O
response O
to O
alpha B
- I
IFN I
occurs O
before O
dephosphorylation O
of O
pRb B
is O
complete O
because O
loss O
of O
p130 O
Form O
3 O
occurs O
throughout O
the O
cell O
cycle O
prior O
to O
complete O
arrest O
in O
G1 O
, O
whereas O
pRb B
is O
dephosphorylated O
only O
in O
G1 O
. O

p130 B
, O
predominantly O
in O
Form O
1 O
, O
and O
hypophosphorylated O
pRb O
bind O
an O
E2F O
DNA O
binding O
site O
; O
p130 B
complexes O
E2F B
- I
4 I
, O
whereas O
pRb B
binds O
both O
E2F O
- O
4 O
and O
E2F B
- I
1 I
. O

The O
phosphorylated O
forms O
of O
E2F B
- I
4 I
that O
bind O
to O
the O
E2F O
DNA O
site O
are O
different O
from O
hyperphosphorylated O
E2F B
- I
4 I
, O
which O
predominates O
in O
primary O
hemopoietic O
cells O
in O
G0 O
. O

In O
contrast O
, O
v B
- I
myb I
reduces O
MRP14 B
promoter I
activity O
. O

Northern O
blot O
analysis O
of O
L132 O
cells O
transfected O
with O
the O
C B
/ I
EBP I
alpha I
expression O
vector O
demonstrate O
that O
C B
/ I
EBP I
alpha I
is O
sufficient O
to O
enhance O
MRP14 B
expression O
in O
the O
context O
of O
the O
whole O
genome O
. O

This O
observation O
prompted O
us O
to O
postulate O
that O
signal O
2 O
( O
costimulatory O
signal O
) O
alone O
without O
signal O
1 O
( O
TCR B
signal O
) O
can O
activate O
T O
cells O
. O

This O
pathway O
resulted O
in O
the O
induction O
of O
the O
transcription B
factors I
NF B
- I
kappa I
B I
, O
NF B
- I
AT I
, O
and O
proteins O
binding O
to O
the O
CD28 B
response O
element O
of O
the O
IL B
- I
2 I
promoter I
. O

In O
contrast O
to O
the O
differential O
signaling O
of O
BW B
828 I
and O
9 O
. O
3 O
in O
resting O
T O
cells O
, O
the O
two O
mAbs O
exhibited O
a O
similar O
pattern O
of O
early O
signaling O
events O
in O
activated O
T O
cells O
and O
Jurkat O
cells O
( O
p56 B
( I
lck I
) I
activation O
, O
association O
of O
phosphatidylinositol B
3 I
- I
kinase I
with O
CD28 B
) O
, O
indicating O
that O
the O
signaling O
capacity O
of O
CD28 B
changes O
with O
activation O
. O

IL B
- I
12 I
is O
a O
75 O
- O
kDa O
heterodimeric O
cytokine O
composed O
of O
two O
covalently O
linked O
p35 O
and O
p40 O
chains O
. O

Metabolic O
labeling O
combined O
with O
pulse O
- O
chase O
experiments O
and O
biochemical O
analysis O
showed O
that O
the O
majority O
of O
class B
II I
molecules I
in O
infected O
cells O
became O
resistant O
to O
endoglycosidase O
H O
, O
consistent O
with O
normal O
Golgi O
processing O
. O

However O
, O
results O
of O
intracellular O
staining O
and O
dual O
color O
confocal O
microscopy O
revealed O
a O
significant O
defect O
in O
transport O
of O
newly O
synthesized O
class B
II I
molecules I
through O
the O
endocytic O
compartment O
. O

Thus O
, O
compared O
with O
findings O
in O
control O
cells O
, O
class B
II I
molecules I
in O
infected O
cells O
colocalized O
to O
a O
minimal O
extent O
with O
a O
lysosomal O
- O
associated O
membrane O
protein O
- O
1 O
+ O
endosomal O
compartment O
. O

Analyzed O
DNA B
sequences I
included O
delta O
and O
beta O
5 O
' O
flanking O
regions O
extending O
from O
approximately O
- O
500 O
to O
+ O
50bp O
( O
promoter B
regions I
) O
, O
truncated O
delta O
and O
beta O
5 O
' O
flanking O
regions O
extending O
from O
approximately O
- O
250 O
to O
+ O
50 O
bp O
, O
and O
chimeric O
promoter O
constructions O
, O
which O
consisted O
of O
a O
distal O
delta O
or O
beta O
fragment O
fused O
to O
a O
proximal O
beta O
or O
delta O
sequence O
. O

In O
CAT O
reporter O
constructions O
no O
appreciable O
level O
of O
CAT B
activity O
was O
supported O
by O
the O
beta B
globin I
promoter I
, O
and O
only O
low O
level O
activity O
by O
the O
delta B
promoter I
. O

Fusion O
of O
the O
upstream B
portion I
of O
the O
delta B
promoter I
to O
the O
truncated O
beta B
globin I
promoter I
yielded O
a O
modest O
increase O
in O
promoter O
strength O
relative O
to O
the O
truncated O
beta O
gene O
promoter O
, O
indicating O
the O
presence O
of O
a O
positive O
transcriptional O
element O
( O
s O
) O
in O
the O
upstream O
delta O
globin O
regulatory O
region O
. O

The O
induction O
of O
IgE B
by O
IL B
- I
4 I
and O
IL B
- I
13 I
occurs O
through O
the O
activation O
of O
the O
intracellular O
signal O
- O
transducing O
protein O
Stat6 O
, O
whereas O
the O
inhibition O
of O
IgE B
class O
switching O
by O
interferon O
- O
y O
( O
IFN B
- I
gamma I
) O
occurs O
through O
the O
activation O
of O
Statl O
. O

NFAT B
regulates O
transcription O
of O
a O
number O
of O
cytokine O
and O
other O
immunoregulatory O
genes O
. O

We O
also O
report O
three O
additional O
isoforms O
of O
NFATx B
, O
designated O
NFATx2 B
, O
NFATx3 O
, O
and O
NFATx4 O
. O

5 B
' I
HS3 I
contains O
six O
G O
- O
rich O
motifs O
that O
are O
essential O
for O
its O
activity O
. O

We O
show O
that O
the O
function O
of O
such O
closely O
related O
proteins O
can O
be O
distinguished O
in O
vivo O
by O
matching O
point O
mutations O
in O
5 B
' I
HS3 I
with O
amino O
acid O
changes O
in O
the O
zinc B
fingers I
of O
Sp1 B
and O
EKLF B
. O

The O
transition O
of O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
from O
latency O
into O
the O
lytic O
cycle O
is O
associated O
with O
the O
expression O
of O
two O
immediate O
- O
early O
viral O
genes O
, O
BZLF1 B
and O
BRLF1 B
. O

In O
HH514 O
- O
16 O
cells O
, O
transfection O
of O
Rta B
leads O
to O
synthesis O
of O
ZEBRA B
, O
viral O
DNA O
replication O
, O
and O
late O
gene O
expression O
. O

Expression O
of O
either O
BZLF1 B
or O
BRLF1 B
triggers O
expression O
of O
the O
other O
immediate O
- O
early O
factor O
, O
and O
together O
these O
activators O
act O
individually O
or O
in O
synergy O
on O
downstream O
targets O
to O
activate O
the O
viral O
lytic O
cycle O
. O

We O
first O
demonstrate O
, O
in O
human O
and O
mouse O
intraspecies O
hybrids O
, O
the O
coordinate O
suppression O
of O
MHC B
class I
II I
, O
Ii B
( O
invariant O
chain O
) O
and O
HLA O
- O
DM O
gene O
transcription O
, O
and O
the O
release O
of O
the O
silencing O
by O
the O
addition O
of O
interferon B
gamma I
. O

These O
data O
indicate O
that O
the O
IFN B
- I
gamma I
- O
independent O
component O
of O
the O
target O
cell O
HLA B
- I
DR I
expression O
induced O
by O
lymphocyte O
adhesion O
uses O
a O
signaling O
pathway O
that O
is O
distinct O
from O
the O
IFN B
- I
gamma I
- O
dependent O
mechanism O
and O
also O
suggest O
that O
CIITA B
is O
not O
required O
. O

In O
this O
report O
expression O
profiles O
and O
activation O
of O
PKC B
were O
analyzed O
in O
human O
Raji O
B O
lymphoblastoid O
cells O
. O

Transient O
transfection O
analysis O
with O
target O
plasmids O
containing O
either O
DRA B
promoter I
( O
wild O
- O
type O
or O
mutated O
) O
or O
TPA O
response O
elements O
demonstrated O
that O
pretreatment O
with O
the O
selective O
PKC B
inhibitor O
GF O
109203X O
repressed O
TPA O
- O
mediated O
activation O
. O

Together O
, O
these O
results O
show O
that O
activated O
HLA B
- I
DRA I
expression O
in O
response O
to O
TPA O
treatment O
is O
strictly O
dependent O
on O
PKC B
activation O
acting O
on O
the O
X2 B
box I
of O
the O
DRA B
promoter I
and O
that O
selective O
inhibition O
of O
PKC B
enzymatic O
activity O
does O
not O
influence O
subcellular O
localization O
of O
expressed O
PKC B
isoenzymes I
. O

These O
synthetic O
ligands O
specifically O
inhibit O
DNA O
- O
binding O
of O
each O
transcription B
factor I
and O
HIV O
type O
1 O
transcription O
in O
cell O
- O
free O
assays O
. O

In O
situ O
hybridisation O
revealed O
musculin B
expression O
in O
embryos O
was O
largely O
restricted O
to O
the O
embryonic O
skeletal O
muscle O
lineage O
. O

JNK B
enzymatic O
activity O
was O
blocked O
in O
anergized O
T O
cells O
. O

Previously O
, O
we O
demonstrated O
that O
granulocyte O
colony O
- O
stimulating O
factor O
( O
G O
- O
CSF O
) O
receptor O
mRNA O
was O
undetectable O
and O
granulocyte O
maturation O
blocked O
in O
CCAAT B
enhancer I
binding I
protein I
alpha I
( O
C B
/ I
EBPalpha I
) O
- O
deficient O
mice O
. O

Although O
bacterial O
lipopolysaccharides O
( O
LPS O
) O
and O
several O
other O
microbial O
agonists O
can O
bind O
to O
mCD14 B
( O
membrane B
CD14 I
) O
, O
a O
cell O
- O
surface O
receptor O
found O
principally O
on O
monocytes O
and O
neutrophils O
, O
host O
- O
derived O
mCD14 B
ligands O
are O
poorly O
defined O
. O

We O
report O
here O
that O
phosphatidylinositol O
( O
PtdIns O
) O
, O
phosphatidylinositol O
- O
4 O
- O
phosphate O
, O
and O
other O
phosphatidylinositid O
can O
bind O
to O
mCD14 B
. O

Despite O
progress O
in O
understanding O
the O
death O
signals O
transduced O
from O
Fas B
, O
very O
little O
is O
known O
with O
regard O
to O
the O
mechanisms O
by O
which O
Fas B
expression O
is O
regulated O
. O

PKC B
- O
dependent O
Fas B
expression O
was O
also O
observed O
in O
several O
murine O
and O
human O
tumor O
cell O
lines O
. O

Since O
the O
inhibition O
of O
Ca2 O
+ O
redistribution O
by O
an O
inhibitor O
of O
intracellular O
Ca2 O
+ O
mobilization O
, O
8 O
- O
( O
diethylamino O
) O
- O
octyl O
- O
3 O
, O
4 O
, O
5 O
- O
trimethoxybenzoate O
hydrochloride O
, O
inhibited O
TCR O
- O
induced O
FasL O
but O
not O
Fas B
, O
the O
expression O
of O
Fas B
appears O
to O
be O
independent O
of O
Ca2 O
+ O
mobilization O
. O

Anti B
- I
CD40 I
+ O
IL B
- I
4 I
- O
mediated O
proliferation O
of O
PBMC O
and O
B O
cells O
was O
inhibited O
by O
RA O
in O
a O
dose O
- O
dependent O
manner O
, O
with O
maximal O
inhibition O
of O
62 O
% O
+ O
/ O
- O
5 O
% O
in O
PBMC O
and O
55 O
% O
+ O
/ O
- O
4 O
. O
4 O
% O
in O
B O
cells O
by O
all O
- O
trans O
RA O
, O
and O
58 O
% O
+ O
/ O
- O
6 O
. O
7 O
% O
and O
51 O
% O
+ O
/ O
- O
4 O
. O
7 O
% O
, O
respectively O
by O
13 O
- O
cis O
RA O
. O

IgE B
synthesis O
was O
even O
more O
markedly O
inhibited O
by O
RA O
starting O
at O
concentrations O
of O
> O
10 O
( O
- O
14 O
) O
mol O
/ O
L O
for O
B O
cells O
and O
> O
10 O
( O
- O
10 O
) O
mol O
/ O
L O
for O
PBMC O
. O

Low O
concentrations O
of O
RA O
inhibiting O
IgE B
synthesis O
( O
10 O
( O
- O
10 O
) O
mol O
/ O
L O
) O
affected O
neither O
B O
- O
cell O
proliferation O
nor O
the O
production O
of O
IgA B
, O
IgG B
, O
and O
IgM B
. O

To O
differentiate O
whether O
the O
RA O
effect O
was O
mediated O
by O
RA O
receptors O
alpha O
, O
beta O
, O
and O
gamma O
, O
the O
expression O
of O
the O
retinoic B
acid I
receptors I
( O
RAR B
) O
was O
examined O
by O
reverse B
transcriptase I
- O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
. O

Taken O
together O
, O
this O
study O
shows O
that O
RA O
inhibits O
IgE B
production O
of O
anti O
- O
CD40 O
+ O
IL O
- O
4 O
- O
stimulated O
B O
cells O
in O
vitro O
. O

In O
contrast O
, O
a O
mutant O
of O
Tax B
termed O
M22 B
, O
which O
does O
not O
induce O
NF B
- I
kappaB I
, O
fails O
to O
activate O
either O
IKKalpha B
or O
IKKbeta B
. O

The O
pathological O
alteration O
of O
this O
cytokine O
pathway O
leading O
to O
NF B
- I
kappaB I
activation O
by O
Tax B
may O
play O
a O
central O
role O
in O
HTLV O
- O
1 O
- O
mediated O
transformation O
of O
human O
T O
cells O
, O
clinically O
manifested O
as O
the O
adult O
T O
- O
cell O
leukemia O

Recently O
, O
we O
have O
reported O
that O
the O
tumor B
necrosis I
factor I
and O
interleukin B
1 I
signaling O
pathways O
activate O
two O
kinases O
, O
IKK1 B
and O
IKK2 B
. O

Here O
, O
we O
report O
that O
LPS O
induces O
IKK B
activity O
in O
human O
monocytes O
and O
THP O
- O
1 O
monocytic O
cells O
. O

In O
contrast O
, O
a O
dominant O
negative O
mutant O
of O
IKK2 B
inhibited O
LPS O
induction O
of O
kappaB B
- O
dependent O
transcription O
in O
a O
dose O
- O
dependent O
manner O
. O

IL B
- I
7 I
did O
not O
maintain O
v B
- I
Abl I
- O
mediated O
differentiation O
arrest O
of O
the O
pre O
- O
B O
cells O
, O
as O
activation O
of O
NF B
- I
kappaB I
and O
RAG B
gene I
transcription O
was O
unaffected O
by O
IL B
- I
7 I
. O

Functional O
analysis O
of O
the O
promoter O
by O
transient O
transfection O
assays O
indicated O
that O
synergistic O
action O
between O
an O
SP B
- I
1 I
- I
like I
element I
at O
- O
21 O
/ O
- O
12 O
, O
a O
GATA B
site I
at O
- O
59 O
/ O
- O
54 O
, O
and O
a O
novel O
regulatory O
element O
, O
CPRE O
( O
- O
GGACTACAG O
- O
) O
at O
- O
49 O
/ O
- O
41 O
, O
is O
essential O
for O
the O
promoter O
activity O
in O
murine O
erythroleukemia O
( O
MEL O
) O
cells O
. O

Administration O
of O
the O
cytokine O
interleukin O
- O
2 O
( O
IL B
- I
2 I
) O
can O
result O
in O
therapeutic O
benefits O
for O
individuals O
with O
renal O
cell O
carcinoma O
and O
melanoma O
. O

Here O
we O
report O
an O
analysis O
of O
the O
transcription O
factor O
families O
AP O
- O
1 O
, O
Sp1 O
, O
NF B
- I
kappaB I
, O
and O
signal B
transducers I
and I
activators I
of I
transcription I
( O
STAT B
) O
in O
cancer O
patients O
' O
lymphocytes O
before O
and O
after O
IL B
- I
2 I
immunotherapy O
, O
as O
assessed O
by O
a O
gel O
- O
shift O
assay O
. O

The O
role O
of O
platelets O
for O
monocyte B
chemotactic I
protein I
- I
1 I
( O
MCP B
- I
1 I
) O
secretion O
and O
surface O
expression O
of O
intercellular O
adhesion O
molecule O
- O
1 O
( O
ICAM B
- I
1 I
) O
on O
endothelial O
cells O
has O
been O
assessed O
. O

Nuclear B
receptors I
are O
important O
regulators O
of O
erythroid O
cell O
development O
. O

Here O
we O
investigated O
the O
impact O
of O
retinoid B
X I
receptor I
( O
RXR B
) O
, O
retinoic B
acid I
receptor I
( O
RAR B
) O
, O
and O
of O
the O
c O
- O
erbA O
/ O
thyroid O
hormone O
( O
T3 O
) O
receptor O
( O
c B
- I
erbA I
/ I
TR I
) O
on O
growth O
and O
differentiation O
of O
erythroid O
cells O
using O
an O
in O
vitro O
culture O
system O
of O
stem O
cell O
factor O
- O
dependent O
erythroid O
progenitors O
. O

RXR B
, O
RAR B
, O
and O
c B
- I
erbA I
/ I
TR I
- O
specific O
ligands O
were O
found O
to O
induce O
erythroid B
- I
specific I
gene I
expression O
and O
to O
accelerate O
erythroid O
differentiation O
in O
culture O
, O
with O
T3 O
being O
most O
effective O
. O

Thus O
, O
c B
- I
erbA I
/ I
TR I
appears O
to O
act O
as O
a O
binary O
switch O
affecting O
erythroid O
cell O
fate O
: O
unliganded O
c B
- I
erbA I
/ I
TR I
supports O
growth O
while O
ligand O
- O
activated O
c B
- I
erbA I
/ I
TR I
induces O
differentiation O
. O

In O
marked O
contrast O
, O
expression O
of O
the O
dominant O
interfering O
deltaDNA O
- O
binding O
domain O
RXR B
, O
containing O
a O
deletion O
of O
the O
entire B
DNA I
- I
binding I
domain I
, O
was O
incompatible O
with O
erythroid O
cell O
growth O
in O
vitro O
, O
suggesting O
a O
pivotal O
role O
of O
RXR B
for O
erythroid O
cell O
development O
. O

T O
lymphocytes O
from O
6 O
of O
the O
14 O
patients O
also O
exhibited O
an O
increased O
expression O
of O
the O
dual O
specificity O
phosphatase O
, O
map O
kinase O
phosphatase O
- O
1 O
( O
MKP B
- I
1 I
) O
. O

We O
studied O
the O
number O
of O
glucocorticoid B
receptors I
and O
dissociation O
constant O
in O
isolated O
human O
lymphocytes O
as O
well O
as O
blood O
concentrations O
of O
hormones O
produced O
by O
the O
hypothalamic O
- O
hypophyseal O
- O
adrenocortical O
system O
in O
three O
experimental O
series O
: O
at O
normal O
( O
17 O
subjects O
) O
, O
decreased O
( O
10 O
subjects O
, O
a O
360 O
- O
d O
head O
- O
down O
bed O
rest O
) O
and O
increased O
( O
8 O
subjects O
, O
physical O
exercise O
on O
bicycle O
ergometer O
) O
levels O
of O
motor O
activity O
. O

The O
small O
GTP O
- O
binding O
protein O
Rho O
potentiates O
AP B
- I
1 I
transcription O
in O
T O
cells O
. O

The O
effect O
of O
Rho B
on O
AP B
- I
1 I
is O
independent O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
pathway O
, O
as O
a O
dominant O
- O
negative O
MEK O
and O
a O
MEK B
inhibitor O
( O
PD98059 O
) O
did O
not O
affect O
Rho B
- O
induced O
AP B
- I
1 I
activity O
. O

Using O
mRNA O
differential O
display O
we O
demonstrated O
abnormally O
high O
expression O
of O
the O
signal B
transducer I
and I
activator I
of I
transcription I
( O
STAT1alpha B
) O
in O
monocytes O
from O
the O
proband O
II O
- O
2 O
. O

The O
activation O
of O
NF B
- I
kappaB I
has O
been O
recognized O
to O
regulate O
a O
number O
of O
genes O
necessary O
for O
normal O
T O
cell O
responses O
including O
IL B
- I
2 I
, O
IL B
- I
6 I
, O
IL B
- I
8 I
, O
and O
several O
T O
cell O
surface O
receptors O
. O

Uncoupling O
of O
nonreceptor O
tyrosine B
kinases I
from O
PLC O
- O
gamma1 O
in O
an O
SLP O
- O
76 O
- O
deficient O
T O
cell O
. O

SLP B
- I
76 I
was O
not O
required O
for O
TCR B
- O
induced O
tyrosine O
phosphorylation O
of O
most O
proteins O
, O
but O
was O
required O
for O
optimal O
tyrosine O
phosphorylation O
and O
activation O
of O
phospholipase O
C O
- O
gamma1 O
( O
PLC O
- O
gamma1 O
) O
, O
as O
well O
as O
Ras B
pathway O
activation O
. O

Thus O
, O
coupling O
of O
TCR O
- O
regulated O
PTKs O
to O
downstream O
signaling O
pathways O
requires O
SLP B
- I
76 I
. O

In O
addition O
, O
we O
have O
shown O
that O
Stat1alpha B
, O
but O
not O
Stat3 B
, O
is O
involved O
in O
EPO B
- O
induced O
cellular O
proliferation O
. O

Dominant O
negative O
forms O
of O
Stat1alpha B
or O
Stat3 B
promoted O
the O
EPO B
- O
induced O
erythroid O
differentiation O
of O
UT O
- O
7 O
/ O
GM O
cells O
, O
even O
in O
the O
presence O
of O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
, O
although O
this O
cytokine O
never O
induced O
erythroid O
differentiation O
of O
the O
parent O
UT O
- O
7 O
/ O
GM O
cells O
with O
or O
without O
EPO B
. O

Taken O
together O
, O
our O
data O
suggest O
that O
Stat1alpha B
and O
Stat3 B
act O
as O
negative O
regulators O
in O
EPO B
- O
induced O
erythroid O
differentiation O
. O

Data O
obtained O
by O
electrophoretic O
mobility O
shift O
assay O
suggested O
that O
the O
activated O
Stat O
- O
3 O
protein O
associates O
with O
the O
human O
serum O
- O
inducible O
element O
( O
hSIE O
) O
DNA O
- O
probe O
derived O
from O
the O
interferon O
- O
gamma O
activated O
site O
( O
GAS B
) O
in O
the O
c B
- I
fos I
promoter I
, O
a O
common O
DNA O
sequence O
for O
Stat B
protein I
binding O
. O

In O
conclusion O
, O
our O
data O
suggest O
the O
involvement O
of O
the O
Jak B
/ I
Stat I
signal O
pathway O
in O
MHC B
- I
I I
- O
induced O
signal O
transduction O
in O
T O
cells O
. O

We O
further O
demonstrate O
that O
0 O
. O
1 O
- O
0 O
. O
5 O
microM O
DMDTC O
inhibits O
intracellular O
IL B
- I
2 I
production O
and O
decreases O
surface O
expression O
of O
CD25 B
( O
the O
alpha B
subunit I
of O
the O
IL B
- I
2 I
receptor I
) O
in O
T O
cells O
stimulated O
with O
phorbol O
ester O
. O

To O
determine O
whether O
the O
acquisition O
of O
antitumor O
function O
during O
ex O
vivo O
activation O
is O
associated O
with O
modifications O
in O
signal O
transduction O
capacity O
, O
the O
protein O
tyrosine B
kinases I
p56lck B
and O
p59fyn B
and O
proteins O
of O
the O
NF B
- I
kappaB I
family I
were O
analyzed O
in O
tumor O
- O
draining O
LN O
T O
cells O
. O

In O
contrast O
, O
the O
cytoplasmic O
levels O
of O
c B
- I
Rel I
and O
Rel B
A I
were O
normal O
in O
freshly O
isolated O
tumor O
- O
draining O
LN O
, O
as O
was O
nuclear O
kappaB B
DNA O
- O
binding O
activity O
induced O
by O
anti B
- I
CD3 I
mAb I
or O
phorbol O
myristate O
acetate O
. O

BACKGROUND O
: O
The O
class B
II I
transactivator I
( O
CIITA B
) O
is O
a O
bi O
- O
or O
multifunctional O
domain O
protein O
that O
acts O
as O
a O
transcriptional B
activator I
and O
plays O
a O
critical O
role O
in O
the O
expression O
of O
MHC B
class I
II I
genes I
. O

Transient O
transfectants O
of O
the O
porcine O
B O
- O
cell O
line O
L23 O
with O
the O
mutated O
CIITA B
constructs I
were O
tested O
for O
the O
suppression O
of O
constitutive O
SLA O
- O
DR O
and O
SLA O
- O
DQ O
expression O
. O

Macrophages O
in O
human O
atheroma O
contain O
PPARgamma B
: O
differentiation O
- O
dependent O
peroxisomal O
proliferator O
- O
activated O
receptor O
gamma O
( O
PPARgamma B
) O
expression O
and O
reduction O
of O
MMP B
- I
9 I
activity O
through O
PPARgamma B
activation O
in O
mononuclear O
phagocytes O
in O
vitro O
. O

Mononuclear O
phagocytes O
play O
an O
important O
role O
in O
atherosclerosis O
and O
its O
sequela O
plaque O
rupture O
in O
part O
by O
their O
secretion O
of O
matrix O
metalloproteinases O
( O
MMPs O
) O
, O
including O
MMP B
- I
9 I
. O

The O
role O
of O
PPARgamma B
in O
human O
atherosclerosis O
is O
unexplored O
. O

In O
addition O
, O
PPARgamma B
mRNA I
expression O
in O
U937 O
cells O
increased O
during O
phorbol O
12 O
- O
myristate O
13 O
acetate O
- O
induced O
differentiation O
. O

We O
examined O
signaling O
by O
erythropoietin B
in O
highly O
purified O
human O
colony O
forming O
unit O
- O
erythroid O
cells O
, O
generated O
in O
vitro O
from O
CD34 O
( O
+ O
) O
cells O
. O

We O
found O
that O
erythropoietin B
induces O
tyrosine O
phosphorylation O
of O
Jak2 B
, O
STAT5A B
, O
and O
STAT5B B
. O

Tyrosine O
phosphorylation O
of O
Jak2 B
reaches O
a O
peak O
around O
10 O
minutes O
after O
stimulation O
and O
is O
maximum O
at O
5 O
U O
/ O
mL O
of O
erythropoietin B
. O

Effects O
of O
oxidative O
stress O
on O
stimulation O
- O
dependent O
signal O
transduction O
, O
leading O
to O
IL B
- I
2 I
expression O
, O
were O
studied O
. O

Eosinophils O
infiltrating O
hamster O
cutaneous O
wounds O
were O
found O
to O
express O
TGFs B
sequentially O
. O

IL B
- I
3 I
, O
IL B
- I
4 I
, O
and O
IL B
- I
5 I
independently O
up O
- O
regulated O
TGF B
- I
beta1 I
mRNA I
and O
product O
expression O
by O
eosinophils O
in O
all O
donors O
. O

The O
observation O
that O
IL B
- I
4 I
can O
differentially O
regulate O
the O
expression O
of O
TGF B
- I
alpha I
and O
TGF B
- I
beta1 I
suggests O
that O
IL B
- I
4 I
may O
serve O
as O
a O
physiologic O
molecular O
switch O
of O
TGF B
expression O
by O
the O
infiltrating O
eosinophils O
in O
wound O
healing O
and O
carcinogenesis O
. O

A O
recent O
study O
showed O
a O
MLL O
/ O
AF10 O
fusion O
in O
all O
cases O
of O
AML O
with O
t B
( I
10 I
; I
11 I
) I
and O
various O
breakpoints O
on O
chromosome O
11 O
ranging O
from O
q13 O
to O
q23 O
. O

We O
recently O
cloned O
CALM B
( O
Clathrin O
Assembly O
Lymphoid O
Myeloid O
leukemia O
gene O
) O
, O
the O
fusion O
partner O
of O
AF10 B
at O
11q14 O
in O
the O
monocytic O
cell O
line O
U937 O
. O

In O
particular O
, O
one O
class O
of O
helix B
- I
loop I
- I
helix I
proteins I
, O
termed O
E B
- I
proteins I
, O
have O
been O
implicated O
in O
the O
regulation O
of O
gene O
expression O
during O
B O
- O
cell O
development O
. O

Dominant B
negative I
mutants I
of O
NIK B
, O
IKKalpha B
, O
or O
IKKbeta B
substantially O
inhibited O
NF B
- I
kappaB I
activation O
by O
LMP1 B
or O
by O
each O
of O
its O
effector B
sites I
. O

MyD88 B
, O
originally O
isolated O
as O
a O
myeloid O
differentiation O
primary O
response O
gene O
, O
is O
shown O
to O
act O
as O
an O
adaptor O
in O
interleukin B
- I
1 I
( O
IL B
- I
1 I
) O
signaling O
by O
interacting O
with O
both O
the O
IL B
- I
1 I
receptor I
complex I
and O
IL B
- I
1 I
receptor I
- I
associated I
kinase I
( O
IRAK B
) O
. O

Furthermore O
, O
IL B
- I
18 I
- O
induced O
activation O
of O
NF B
- I
kappaB I
and O
c B
- I
Jun I
N I
- I
terminal I
kinase I
( O
JNK B
) O
is O
blocked O
in O
MyD88 O
- O
/ O
- O
Th1 O
- O
developing O
cells O
. O

Taken O
together O
, O
these O
results O
demonstrate O
that O
MyD88 B
is O
a O
critical O
component O
in O
the O
signaling O
cascade O
that O
is O
mediated O
by O
IL B
- I
1 I
receptor I
as O
well O
as O
IL O
- O
18 O
receptor O
. O

In O
addition O
, O
transcriptional O
activity O
of O
IL B
- I
2 I
and O
metallothionein O
enhancer O
and O
promoter O
regions O
and O
transcription B
factors I
AP B
- I
1 I
, O
NF B
- I
kappaB I
, O
and O
NF B
- I
AT I
were O
analyzed O
by O
chloramphenicol B
acetyltransferase I
( O
CAT B
) O
and O
electrophoretic O
mobility O
shift O
assays O
, O
respectively O
. O

Simple O
activation O
of O
RXRs B
is O
not O
sufficient O
to O
induce O
apoptosis O
of O
the O
cells O
. O

Thrombopoietin B
supports O
in O
vitro O
erythroid O
differentiation O
via O
its O
specific O
receptor O
c O
- O
Mpl O
in O
a O
human O
leukemia O
cell O
line O
. O

More O
than O
50 O
% O
of O
TPO O
- O
treated O
UT O
- O
7 O
/ O
GMT O
cells O
positively O
stained O
for O
Hb B
. O

Because O
the O
GATA B
- I
1 I
gene I
is O
located O
on O
the O
X B
chromosome I
, O
which O
is O
randomly O
inactivated O
in O
every O
cell O
, O
heterozygous O
females O
can O
bear O
either O
an O
active O
wild O
- O
type O
or O
mutant O
( O
referred O
to O
as O
GATA B
- I
1 I
. I
05 I
) O
GATA B
- I
1 I
allele O
, O
consequently O
leading O
to O
variable O
anemic O
severity O
. O

The O
GATA B
- I
1 I
heterozygous O
mutant O
mouse O
shows O
a O
phenotype O
that O
is O
analogous O
to O
human O
myelodysplastic O
syndrome O
and O
thus O
may O
serve O
as O
a O
useful O
model O
for O
this O
disorder O
. O

Differential O
regulation O
of O
the O
Janus B
kinase I
- B
STAT I
pathway O
and O
biologic O
function O
of O
IL B
- I
13 I
in O
primary O
human O
NK O
and O
T O
cells O
: O
a O
comparative O
study O
with O
IL B
- I
4 I
. O

We O
observed O
that O
Abs O
directed O
against O
unique O
domains O
of O
STAT6 B
have O
differential O
effects O
on O
complexes O
in O
T O
cells O
but O
not O
in O
NK O
cells O
, O
suggesting O
different O
STAT6 O
isoforms O
. O

These O
findings O
show O
that O
IL B
- I
13 I
and O
IL B
- I
4 I
have O
the O
ability O
to O
regulate O
NK O
and O
T O
cell O
activation O
and O
that O
IL B
- I
13 I
is O
a O
potent O
regulator O
of O
STAT6 B
and O
JAK3 B
in O
these O
cell O
types O
. O

NFkappaB B
activity O
is O
independent O
from O
FADD B
, O
caspases B
, O
and O
apoptosis O
induction O
. O

To O
study O
the O
influence O
of O
NFkappaB B
activity O
on O
apoptosis O
mediated O
by O
TRAIL B
, O
CD95 O
, O
TNFalpha B
, O
or O
doxorubicin O
, O
NFkappaB B
activation O
was O
inhibited O
using O
the O
proteasome B
inhibitor O
N O
- O
acetyl O
- O
L O
- O
leucinyl O
- O
L O
- O
leucinyl O
- O
L O
- O
norleucinal O
or O
transient O
overexpression O
of O
mutant B
IkappaBalpha I
. O

Loss O
- O
and O
gain O
- O
of O
- O
function O
mutations O
reveal O
an O
important O
role O
of O
BSAP B
( O
Pax B
- I
5 I
) O
at O
the O
start O
and O
end O
of O
B O
cell O
differentiation O
. O

However O
, O
its O
interactions O
with O
these O
histone B
acetyltransferases I
are O
not O
equivalent O
, O
as O
CBP B
and O
p300 B
, O
but O
not O
P B
/ I
CAF I
, O
utilize O
EKLF B
as O
a O
substrate O
for O
in O
vitro O
acetylation O
within O
its O
trans O
- O
activation B
region I
. O

We O
conclude O
that O
contact O
with O
fibrinogen O
- O
derived O
proteins O
may O
contribute O
to O
mononuclear O
phagocyte O
activation O
by O
signaling O
through O
CD11b B
/ I
CD18 I
, O
resulting O
in O
selective O
activation O
of O
transcriptional B
regulatory I
factors I
, O
including O
NF B
- I
kappa I
B I
. O

Variant O
receptor O
transcripts O
lacking O
exon B
5 I
or O
exon B
7 I
, O
which O
encodes O
the O
hormone O
binding O
domain O
, O
were O
identified O
in O
the O
majority O
of O
the O
cells O
. O

A O
nondegradable O
mutant O
of O
I B
kappa I
B I
blocked O
both O
FasL B
expression O
and O
apoptosis O
induced O
by O
DNA O
damage O
but O
not O
Fas B
ligation O
. O

These O
stimuli O
also O
induced O
the O
stress O
- O
activated O
kinase O
pathway O
( O
SAPK B
/ B
JNK I
) O
, O
which O
was O
required O
for O
the O
maximal O
induction O
of O
apoptosis O
. O

The O
implication O
of O
protein O
tyrosine O
kinase O
( O
s O
) O
, O
protein B
kinase I
A I
and O
/ O
or O
protein B
kinase I
C I
was O
highlighted O
by O
the O
abrogation O
of O
the O
ManLAM O
- O
mediated O
activation O
of O
HIV O
- O
1 O
LTR O
- O
driven O
gene O
expression O
using O
herbimycin O
A O
and O
H7 O
. O

These O
findings O
suggest O
that O
LTR B
sequence I
changes O
can O
significantly O
affect O
basal O
LTR B
function O
and O
transcription B
factor I
recruitment O
, O
which O
may O
, O
in O
turn O
, O
alter O
the O
course O
of O
viral O
replication O
in O
cells O
of O
CNS O
and O
immune O
system O
origin O
. O

These O
insights O
in O
the O
molecular O
events O
that O
are O
involved O
in O
TCF O
/ O
LEF O
function O
in O
these O
organisms O
may O
eventually O
lead O
to O
the O
understanding O
of O
the O
function O
of O
these O
HMG B
box I
proteins I
in O
lymphoid O
development O

Elf B
- I
1 I
binds O
exclusively O
to O
the O
underphosphorylated O
form O
of O
Rb B
and O
fails O
to O
bind O
to O
Rb O
mutants O
derived O
from O
patients O
with O
retinoblastoma O
. O

In O
this O
study O
we O
analyzed O
the O
T O
cell O
receptor O
( O
TcR O
) O
delta O
transcripts O
expressed O
by O
CD3 O
- O
CD16 O
+ O
cells O
and O
we O
investigated O
whether O
these O
cells O
expressed O
the O
hGATA B
- I
3 I
T I
cell I
transcription I
factor I
and O
the O
recombination O
- O
activating O
gene O
( O
RAG O
) O
- O
1 O
. O

Sequence O
analysis O
of O
nine O
different O
2 O
. O
3 O
- O
kb O
cDNA O
clones O
obtained O
from O
NK O
- O
derived O
polyA O
+ O
RNA O
confirmed O
that O
they O
corresponded O
to O
an O
unrearranged O
TcR B
delta I
gene I
. O

All O
NK O
clones O
and O
cell O
lines O
studied O
were O
found O
to O
express O
hGATA O
- O
3 O
- O
specific O
mRNA O
, O
suggesting O
that O
hGATA B
- I
3 I
may O
be O
involved O
in O
the O
regulation O
of O
the O
unrearranged O
TcR B
delta I
gene I
expression O
in O
NK O
cells O
. O

To O
correlate O
changes O
in O
nuclear O
factor O
binding O
in O
vitro O
with O
transcriptional O
activity O
in O
vivo O
and O
define O
the O
structural O
requirements O
for O
IL B
- I
2 I
promoter I
repression O
, O
we O
used O
transient O
DNA O
transfections O
. O

Jurkat O
cells O
were O
transfected O
with O
plasmids B
containing O
either O
the O
intact O
IL B
- I
2 I
promoter I
or O
its O
AP O
- O
1 O
, O
NF O
- O
AT O
, O
and O
NF O
- O
kB O
motifs O
. O

Other O
bacterial O
toxins O
, O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
) O
, O
interleukin B
- I
1 I
( O
IL B
- I
1 I
) O
, O
T B
cell I
mitogens I
, O
UV O
light O
, O
gamma O
rays O
and O
oxidative O
stress O
were O
reported O
to O
induce O
NF B
- I
kappa I
B I
. O

Antisera O
to O
Fos B
inhibits O
NF B
- I
AT I
DNA O
binding O
as O
does O
an O
oligonucleotide O
containing O
a O
binding O
site O
for O
AP1 O
. O

Despite O
a O
wide O
range O
, O
the O
mean O
GR B
count O
and O
affinity O
in O
MNC O
from O
septic O
patients O
did O
not O
differ O
from O
those O
in O
normal O
controls O
, O
suggesting O
that O
glucocorticoids O
could O
still O
be O
effective O
in O
the O
hemodynamic O
compensatory O
phase O
of O
sepsis O
. O

Activation O
of O
the O
HIV O
- O
1 O
provirus O
correlated O
with O
the O
activation O
of O
binding O
of O
55 O
- O
and O
85 O
- O
kDa O
proteins O
to O
the O
kappa B
B I
enhancer I
and O
binding O
of O
the O
50 O
- O
kDa O
HLP O
- O
1 O
protein O
to O
the O
LBP O
- O
1 O
sequences O
of O
the O
HIV B
- I
1 I
long I
terminal I
repeat I
. O

Surprisingly O
, O
the O
NF B
- I
kappa I
B I
and O
HLP O
- O
1 O
binding O
activities O
were O
substantially O
inhibited O
in O
acyclovir O
- O
treated O
cells O
. O

Transcriptional O
activation O
of O
the O
macrophage O
colony O
- O
stimulating O
factor O
gene O
by O
IL B
- I
2 I
is O
associated O
with O
secretion O
of O
bioactive O
macrophage O
colony O
- O
stimulating O
factor O
protein O
by O
monocytes O
and O
involves O
activation O
of O
the O
transcription B
factor I
NF B
- I
kappa I
B I
. O

Transcriptional O
activation O
of O
the O
M B
- I
CSF I
gene I
by O
IL B
- I
2 I
is O
preceded O
by O
enhanced O
binding O
activity O
of O
the O
transcription B
factor I
NF B
- I
kappa I
B I
to O
its O
recognition O
sequence O
in O
the O
5 O
' O
regulatory O
enhancer O
region O
of O
the O
M B
- I
CSF I
gene I
. O

We O
localized O
the O
LAM O
- O
, O
lipopolysaccharide O
( O
LPS O
) O
- O
, O
and O
TNF B
- I
alpha I
- B
inducible I
promoter I
activity O
to O
a O
- O
131 O
/ O
+ O
15 O
( O
positions O
- O
131 O
to O
+ O
15 O
) O
DNA O
fragment O
of O
the O
IL B
- I
1 I
beta I
gene I
by O
deletion O
analysis O
and O
chloramphenicol B
acetyltransferase I
assay O
. O

Site O
- O
directed O
mutagenesis O
demonstrated O
that O
the O
two O
NF O
- O
IL O
- O
6 O
motifs O
could O
be O
independently O
activated O
by O
LAM O
, O
LPS O
, O
or O
TNF B
- I
alpha I
and O
that O
they O
acted O
in O
an O
orientation O
- O
independent O
manner O
. O

Additionally O
, O
Nef O
expressing O
cells O
were O
transiently O
transfected O
with O
a O
plasmid O
in O
which O
HIV O
- O
1 O
AP O
- O
1 O
DNA O
recognition O
sequences O
were O
cloned O
downstream O
of O
the O
chloramphenicol B
acetyltransferase I
( O
CAT B
) O
gene O
. O

A O
serum B
response I
element I
and O
a O
binding O
site O
for O
NF O
- O
Y O
mediate O
the O
serum O
response O
of O
the O
human O
thrombospondin O
1 O
gene O
. O

Two O
transcriptional O
elements O
in O
the O
TSP B
1 I
promoter O
, O
a O
distal O
element O
at O
- O
1280 O
and O
a O
proximal O
element O
at O
- O
65 O
, O
were O
required O
for O
the O
response O
of O
the O
human O
TSP O
1 O
gene O
to O
serum O
. O

The O
human O
T O
- O
cell O
leukemia O
virus O
type O
I O
( O
HTLV O
- O
I O
) O
and O
HTLV O
- O
II O
Tax O
proteins O
are O
potent O
transactivators B
of O
viral O
and O
cellular O
gene O
expression O
. O

A O
carboxy O
terminal O
Tax O
deletion O
mutant O
was O
deficient O
in O
transactivation O
of O
both O
the O
PTHrP O
and O
IL2R O
alpha O
promoters O
but O
not O
the O
HTLV O
- O
I O
long O
terminal O
repeat O
( O
LTR B
) O
. O

Here O
we O
have O
investigated O
the O
transcriptional O
regulation O
of O
the O
gamma B
chain I
gene O
by O
analyzing O
the O
2 O
. O
5 O
- O
kilobase O
sequence O
upstream O
of O
the O
transcription O
start O
site O
. O

This O
sequence O
contains O
a O
promoter B
specific O
to O
cells O
of O
hematopoietic O
lineage O
. O

However O
, O
the O
tissue O
specificity O
of O
this O
promoter B
is O
only O
partial O
because O
it O
is O
active O
in O
all O
of O
the O
hematopoietic O
cells O
tested O
here O
, O
regardless O
of O
whether O
they O
constitutively O
express O
Fc O
epsilon O
RI O
- O
gamma B
chain I
transcripts O
. O

ACH O
- O
2 O
can O
be O
converted O
to O
productive O
infection O
by O
stimulation O
of O
the O
cells O
with O
12 O
- O
O O
- O
tetradecanoylphorbol O
- O
13 O
- O
acetate O
( O
TPA O
) O
, O
mitogen O
or O
cytokines B
( O
TNF B
- I
alpha I
) O
, O
or O
infection O
with O
HSV O
. O

Oxidoreductive O
regulation O
of O
nuclear B
factor I
kappa I
B I
. O

The O
promoter O
activity O
from O
HIV B
long I
terminal I
repeat I
was O
greatly O
augmented O
by O
co O
- O
transfecting O
the O
Trx O
- O
expressing O
plasmid O
, O
whose O
effect O
was O
dependent O
on O
the O
NF B
kappa I
B I
- O
binding O
sites O
. O

We O
have O
demonstrated O
earlier O
that O
the O
crosslinkage O
of O
the O
CD3 B
/ I
TCR I
complex I
with O
the O
CD2 B
antigen I
results O
in O
the O
proliferation O
of O
normal O
human O
T O
cells O
. O

This O
was O
accompanied O
by O
downregulation O
of O
two O
transcription B
factors I
normally O
expressed O
in O
erythroid O
, O
mast O
and O
megakaryocyte O
lineages O
. O

Northern O
analysis O
demonstrated O
coordinate O
downregulation O
of O
alpha B
globin I
and O
gamma B
globin I
in O
addition O
to O
the O
two O
lineage O
- O
restricted O
transcription B
factors I
, O
SCL B
and O
GATA B
- I
1 I
. O

Surface O
marker O
analysis O
showed O
that O
HMBA O
- O
induced O
cells O
expressed O
reduced O
levels O
of O
glycophorin O
A O
, O
CD5 B
, O
CD7 B
and O
CD11b B
. O

Activation O
of O
primary O
human O
T O
- O
lymphocytes O
through O
CD2 O
plus O
CD28 O
adhesion O
molecules O
induces O
long O
- O
term O
nuclear O
expression O
of O
NF B
- I
kappa I
B I
. O

Long O
- O
lasting O
IL B
- I
2 I
receptivity O
is O
associated O
with O
high O
- O
level O
expression O
of O
the O
inducible O
IL O
- O
2 O
receptor O
alpha O
chain O
( O
IL O
- O
2R O
alpha O
) O
gene O
that O
is O
regulated O
at O
both O
transcriptional O
and O
posttranscriptional O
levels O
. O

In O
addition O
, O
an O
inhibitor O
of O
PKC B
blocked O
both O
activated O
ras B
and O
phorbol O
ester O
stimulation O
, O
suggesting O
a O
role O
for O
ras B
upstream O
of O
PKC B
. O

We O
show O
that O
the O
ability O
to O
detect O
NF B
- I
ATp I
in O
a O
gel O
shift O
assay O
, O
which O
is O
essential O
for O
purification O
and O
biochemical O
studies O
of O
this O
protein O
, O
is O
strikingly O
dependent O
on O
the O
precise O
sequence O
of O
the O
NF B
- I
AT I
oligonucleotide O
used O
as O
the O
labeled O
probe O
. O

One O
of O
these O
activities O
was O
found O
to O
be O
a O
novel O
, O
less O
abundant O
, O
Rb O
- O
E2F B
complex O
. O

The O
most O
prominent O
E2F B
activity O
in O
resting O
T O
cells O
( O
termed O
complex O
X O
) O
was O
abundant O
in O
both O
G0 O
and O
G1 O
but O
disappeared O
as O
cells O
entered O
S O
phase O
, O
suggesting O
a O
possible O
role O
in O
negatively O
regulating O
E2F B
function O
. O

Since O
TPA O
activates O
protein B
kinase I
C I
( O
PKC B
) O
, O
we O
examined O
translocation O
of O
PKC B
from O
the O
cytosol O
to O
the O
membrane O
fraction O
. O

To O
determine O
whether O
the O
defect O
in O
the O
patient O
' O
s O
T O
lymphocytes O
involved O
a O
trans B
- I
acting I
factor I
common O
to O
the O
affected O
lymphokine B
genes I
, O
we O
examined O
the O
ability O
of O
nuclear B
factors I
from O
the O
patient O
' O
s O
T O
lymphocytes O
to O
bind O
response O
elements O
present O
in O
the O
regulatory B
region I
of O
IL2 B
. O

In O
contrast O
, O
the O
binding O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NF B
- I
AT I
) O
to O
its O
response O
element O
in O
the O
IL2 O
enhancer O
and O
to O
an O
NF O
- O
AT O
- O
like O
response O
element O
present O
in O
the O
IL4 O
enhancer O
was O
abnormal O
. O

Instead O
, O
they O
form O
tight O
complexes O
with O
two O
different O
classes O
of O
abundant O
cytosolic O
receptors O
called O
immunophilins B
upon O
entering O
the O
cell O
, O
and O
consequently O
inhibit O
their O
peptidyl O
prolyl O
cis O
- O
trans O
isomerase O
activities O
. O

p105 B
and O
p98 B
precursor O
proteins O
play O
an O
active O
role O
in O
NF B
- I
kappa I
B I
- O
mediated O
signal O
transduction O
. O

Association O
with O
the O
precursors O
is O
sufficient O
for O
cytoplasmic O
retention O
of O
either O
p65 B
or O
c B
- I
Rel I
, O
both O
of O
which O
are O
otherwise O
nuclear O
. O

The O
eukaryotic O
transcription B
factor I
nuclear B
factor I
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
participates O
in O
many O
parts O
of O
the O
genetic O
program O
mediating O
T O
lymphocyte O
activation O
and O
growth O
. O

Transfection O
studies O
indicate O
that O
the O
I O
kappa O
B O
alpha O
gene O
is O
specifically O
induced O
by O
the O
65 O
- O
kilodalton O
transactivating O
subunit O
of O
NF B
- I
kappa I
B I
. O

Together O
, O
these O
results O
show O
that O
NF B
- I
kappa I
B I
controls O
the O
expression O
of O
I B
kappa I
B I
alpha O
by O
means O
of O
an O
inducible O
autoregulatory O
pathway O
. O

A O
cell O
- O
type O
- O
independent O
lipopolysaccharide O
( O
LPS O
) O
- O
responsive O
enhancer O
element O
located O
between O
- O
3757 O
and O
- O
2729 O
bp O
upstream O
from O
the O
transcription B
start I
site I
( O
cap B
site I
) O
consisted O
of O
at O
least O
six O
discrete O
subregions O
which O
were O
essential O
to O
the O
maximal O
induction O
by O
LPS O
in O
transfected O
monocytes O
. O

Expression O
of O
PILOT B
, O
a O
putative O
transcription B
factor I
, O
requires O
two O
signals O
and O
is O
cyclosporin O
A O
sensitive O
in O
T O
cells O
. O

Few O
known O
genes B
( O
IL B
- I
2 I
, O
members O
of O
the O
IL O
- O
8 O
family O
, O
interferon B
- I
gamma I
) O
are O
induced O
in O
T O
cells O
only O
through O
the O
combined O
effect O
of O
phorbol O
myristic O
acetate O
( O
PMA O
) O
and O
a O
Ca O
( O
2 O
+ O
) O
- O
ionophore O
, O
and O
expression O
of O
only O
these O
genes B
can O
be O
fully O
suppressed O
by O
Cyclosporin O
A O
( O
CyA O
) O
. O

The O
PILOT B
protein O
has O
a O
calculated O
M O
( O
r O
) O
of O
42 O
. O
6 O
kDa O
and O
contains O
three O
zinc B
fingers I
of O
the O
C2H2 O
- O
type O
at O
the O
carboxyl B
- I
terminus I
which O
are O
highly O
homologous O
to O
the O
zinc O
finger O
regions O
of O
the O
transcription B
factors I
EGR1 B
, O
EGR2 B
, O
and O
pAT O
133 O
. O

In O
contrast O
to O
T O
cells O
, O
in O
fibroblasts O
PILOT B
gene O
expression O
requires O
only O
one O
signal O
( O
PMA O
) O
and O
is O
not O
affected O
by O
CyA O
. O

NF B
- I
kappa I
B I
is O
a O
pleiotropic O
regulator O
of O
a O
variety O
of O
genes O
implicated O
in O
the O
cellular O
response O
to O
injury O
. O

However O
, O
the O
p65 B
antisense O
phosphorothioate O
oligodeoxynucleotide O
had O
no O
significant O
effect O
on O
the O
production O
of O
reactive O
oxygen O
intermediates O
or O
on O
phagocytosis O
by O
these O
cells O
. O

These O
findings O
indicate O
that O
antisense O
oligomers O
to O
p65 B
can O
be O
used O
to O
define O
the O
role O
of O
NF B
- I
kappa I
B I
in O
the O
activation O
pathways O
of O
neutrophils O
. O

Overexpression O
of O
p65 B
increases O
endogenous O
I B
kappa I
B I
protein O
in O
both O
carcinoma O
and O
lymphoid O
cells O
by O
two O
mechanisms O
: O
protein O
stabilization O
and O
increased O
transcription O
of O
I B
kappa I
B I
mRNA I
. O

When O
the O
wild B
- I
type I
hGR I
and O
hGR B
- I
Ile I
729 I
were O
expressed O
in O
COS O
- O
1 O
cells O
and O
assayed O
for O
[ O
3H O
] O
- O
Dexamethasone O
binding O
, O
the O
dissociation O
constants O
were O
0 O
. O
799 O
+ O
/ O
- O
0 O
. O
068 O
and O
1 O
. O
54 O
+ O
/ O
- O
0 O
. O
06 O
nM O
( O
mean O
+ O
/ O
- O
SEM O
) O
( O
P O
< O
0 O
. O
01 O
) O
, O
respectively O
. O

Transcriptional O
regulation O
of O
interleukin B
3 I
( O
IL3 B
) O
in O
primary O
human O
T O
lymphocytes O
. O

Dimerization O
of O
NF O
- O
KB2 O
with O
RelA B
( I
p65 I
) I
regulates O
DNA O
binding O
, O
transcriptional O
activation O
, O
and O
inhibition O
by O
an O
I B
kappa I
B I
- I
alpha I
( O
MAD B
- I
3 I
) O
. O

We O
have O
previously O
found O
that O
NFKB2 O
( O
p49 O
/ O
p52 O
) O
acts O
in O
concert O
with O
RelA B
( I
p65 I
) I
to O
stimulate O
the O
HIV B
enhancer I
in O
Jurkat O
T O
- O
leukemia O
cells O
. O

Transcriptional O
activation O
of O
the O
HIV O
enhancer O
was O
also O
subject O
to O
regulation O
by O
recently O
cloned O
I B
kappa I
B I
- I
alpha I
( O
MAD B
- I
3 I
) O
. O

The O
c O
- O
rel O
protooncogene O
product O
represses O
NF B
- I
kappa I
B I
p65 B
- O
mediated O
transcriptional O
activation O
of O
the O
long O
terminal O
repeat O
of O
type O
1 O
human O
immunodeficiency O
virus O
. O

This O
intracellular O
signaling O
complex O
potently O
stimulates O
kappa O
B O
- O
directed O
transcription O
from O
either O
the O
HIV B
- I
1 I
LTR I
or O
the O
IL B
- I
2R I
alpha I
promoter I
via O
the O
strong O
transactivation O
domain O
present O
in O
p65 B
. O

We O
now O
demonstrate O
that O
nuclear O
expression O
of O
human O
c B
- I
Rel I
, O
which O
is O
induced O
by O
either O
phorbol O
ester O
or O
tumor B
necrosis I
factor I
alpha I
with O
delayed O
kinetics O
relative O
to O
p65 B
, O
markedly O
represses O
p65 B
- O
mediated O
activation O
of O
these O
transcription O
units O
. O

The O
ras O
- O
transformed O
lymphocytes O
displayed O
a O
fully O
functional O
IL B
- I
2r I
, O
as O
assessed O
by O
c B
- I
fos I
induction O
following O
treatment O
with O
IL B
- I
2 I
; O
nevertheless O
, O
they O
were O
not O
growth O
stimulated O
by O
this O
lymphokine B
. O

Somewhat O
unexpectedly O
, O
the O
constitutive O
p21ras B
activity O
did O
not O
cause O
an O
increased O
DNA O
binding O
of O
transcription B
factors I
PEA1 O
( O
AP1 B
) O
, O
PEA3 O
, O
Oct B
- I
2 I
or O
NF O
- O
kB O

Competition O
with O
an O
AP O
- O
1 O
motif O
or O
with O
anti O
- O
Jun O
and O
anti O
- O
Fos O
antibodies O
abolished O
binding O
to O
the O
NFAT B
motif I
in O
both O
T O
and O
B O
cells O
, O
indicating O
that O
Jun O
and O
Fos O
are O
critical O
for O
NFAT B
complex I
formation O
in O
both O
cell O
types O
. O

However O
, O
when O
combined O
with O
unstimulated O
B O
or O
T O
cell O
extracts O
, O
full O
- O
length O
, O
but O
not O
truncated O
, O
Jun O
/ O
Fos O
heterodimers O
were O
able O
to O
form O
an O
NFAT B
complex I
, O
indicating O
the O
presence O
of O
a O
constitutively O
expressed O
nuclear O
factor O
( O
s O
) O
in O
B O
and O
T O
cells O
necessary O
for O
the O
formation O
of O
the O
NFAT B
complex I
in O
both O
cell O
types O
. O

Differential O
autoregulation O
of O
glucocorticoid B
receptor I
expression O
in O
human O
T O
- O
and O
B O
- O
cell O
lines O
. O

In O
contrast O
to O
the O
decrease O
in O
GR B
mRNA I
seen O
in O
IM O
- O
9 O
cells O
after O
treatment O
with O
1 O
microM O
dexamethasone O
for O
16 O
- O
18 O
h O
, O
treatment O
of O
6TG1 O
. O
1 O
cells O
resulted O
in O
an O
8 O
- O
fold O
increase O
in O
GR B
mRNA I
, O
as O
determined O
by O
Northern O
blot O
and O
RNase B
protection O
analysis O
, O
with O
a O
corresponding O
3 O
- O
to O
4 O
- O
fold O
increase O
in O
GR O
protein O
. O

Induction O
of O
CD8 B
antigen I
and O
suppressor O
activity O
by O
glucocorticoids O
in O
a O
CEM O
human O
leukemic O
cell O
clone O
. O

It O
has O
been O
thought O
that O
the O
virally O
induced O
inhibition O
of O
IFN B
- O
MCP O
is O
secondary O
to O
the O
shutdown O
of O
cellular O
macromolecular O
synthesis O
that O
accompanies O
cytopathic O
virus O
infections O
. O

IFN B
- O
MCP O
was O
not O
inhibited O
by O
infection O
with O
dl343 O
, O
despite O
the O
production O
of O
large O
amounts O
of O
both O
early O
( O
E1B B
, O
p55 B
) O
and O
late O
( O
hexon O
) O
Ad O
proteins O
. O

E1A B
' O
s O
inhibition O
of O
IFN B
- O
MCP O
has O
the O
net O
effect O
of O
promoting O
the O
selective O
NK O
cell O
- O
mediated O
clearance O
of O
Ad O
- O
infected O
or O
Ad O
- O
transformed O
human O
cells O
. O

Nuclear B
factor I
of I
activated I
T I
cells I
( O
NF B
- I
AT I
) O
is O
a O
transcriptional B
activator I
involved O
in O
the O
induction O
of O
IL B
- I
2 I
gene O
expression O
. O

We O
find O
that O
a O
short O
enhancer O
element O
containing O
the O
NF B
- I
kappa I
B I
binding I
site I
from O
the O
interleukin B
- I
2 I
receptor I
alpha I
- I
chain I
gene I
( O
IL B
- I
2R I
alpha I
) O
is O
preferentially O
activated O
in O
T O
cells O
. O

Serum B
response I
factor I
( O
SRF B
) O
binds O
to O
a O
site O
adjacent O
to O
the O
NF B
- I
kappa I
B I
site I
in O
the O
IL B
- I
2R I
enhancer I
, O
and O
both O
sites O
together O
have O
strong O
transcriptional O
activity O
specifically O
in O
T O
cells O
. O

Mutual O
regulation O
of O
the O
transcriptional B
activator I
NF B
- I
kappa I
B I
and O
its O
inhibitor O
, O
I B
kappa I
B I
- I
alpha I
. O

In O
previous O
transfection O
analyses O
using O
the O
chloramphenicol B
acetyltransferase I
reporter B
gene I
system O
, O
we O
determined O
that O
linker O
substitution O
( O
LS O
) O
mutations O
between O
- B
201 I
and I
- I
130 I
( O
relative O
to O
the O
transcription O
start O
site O
) O
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
long B
terminal I
repeat I
( O
LTR B
) O
caused O
moderate O
decreases O
in O
LTR B
transcriptional O
activity O
in O
a O
T O
- O
cell O
line O
( O
S O
. O
L O
. O
Zeichner O
, O
J O
. O
Y O
. O
H O
. O
Kim O
, O
and O
J O
. O
C O
. O
Alwine O
, O
J O
. O
Virol O
. O
65 O
: O
2436 O
- O
2444 O
, O
1991 O
) O
. O

If O
GATA O
- O
1 O
- O
red O
cells O
were O
available O
, O
the O
analyses O
would O
involve O
the O
actual O
transcription O
of O
or O
chromatin O
structure O
surrounding O
the O
globin B
genes I
. O

G0S24 B
is O
a O
member O
of O
a O
set O
of O
genes O
( O
putative B
G0 I
/ I
G1 I
switch I
regulatory I
genes I
) O
that O
are O
expressed O
transiently O
within O
1 O
- O
2 O
hr O
of O
the O
addition O
of O
lectin B
or O
cycloheximide O
to O
human O
blood O
mononuclear O
cells O
. O

Groups O
1 O
and O
2 O
have O
a O
serine O
- O
rich O
region O
and O
an O
` O
` O
arginine O
element O
` O
` O
( O
RRLPIF O
) O
at O
the O
carboxyl B
terminus I
. O

Comparison O
of O
group O
1 O
human O
and O
mouse O
genomic O
sequences O
shows O
high O
conservation O
in O
the O
5 B
' I
flank I
and O
exons B
. O

One O
enigmatic O
aspect O
of O
GATA B
factor I
expression O
is O
that O
several O
GATA O
proteins O
, O
which O
ostensibly O
share O
the O
same O
DNA B
- I
binding I
site I
specificity O
, O
are O
coexpressed O
in O
erythroid O
cells O
. O

Thus O
, O
the O
GATA B
- I
2 I
transcription I
factor I
appears O
to O
play O
a O
role O
in O
regulating O
the O
self O
- O
renewal O
capacity O
of O
early O
erythroid O
progenitor O
cells O
. O

PBL O
constitutively O
express O
c B
- I
jun I
transcripts I
, O
and O
the O
level O
of O
c B
- I
jun I
mRNA I
is O
not O
altered O
by O
PHA B
activation O
in O
the O
absence O
or O
presence O
of O
EC O
. O

In O
contrast O
, O
c B
- I
fos I
mRNA I
is O
absent O
from O
resting O
T O
cells O
and O
is O
induced O
on O
PHA B
activation O
. O

Site O
- O
directed O
mutagenesis O
demonstrated O
that O
this O
HS B
- I
40 I
enhancer O
- O
zeta B
2 I
globin I
promoter I
interaction O
is O
mediated O
by O
the O
two O
GATA O
- O
1 O
factor O
binding O
motifs O
located O
at O
- O
230 O
and O
- O
104 O
, O
respectively O
. O

Site O
- O
directed O
mutagenesis O
further O
demonstrated O
that O
the O
enhancer B
function O
of O
one O
of O
the O
two O
NF O
- O
E2 O
/ O
AP1 O
motifs O
of O
HS B
- I
40 I
is O
mediated O
through O
its O
binding O
to O
NF B
- I
E2 I
but O
not O
AP1 O
transcription O
factor O
. O

Within O
this O
region O
, O
we O
define O
a O
minimal B
promoter I
( O
- O
62 O
to O
+ O
54 O
) O
that O
displays O
erythroid O
- O
specific O
activity O
and O
contains O
two O
DNA O
binding O
sites O
. O

Mutations O
and O
deletions O
of O
both O
sites O
indicate O
that O
only O
the O
association O
of O
CCACC O
/ O
Sp1 O
and O
GATA B
binding I
sites I
can O
drive O
efficient O
and O
tissue O
- O
specific O
expression O
of O
this O
R B
- I
PK I
minimal B
promoter I
. O

The O
X B
box I
region I
is O
critical O
for O
directing O
the O
expression O
of O
class B
II I
major I
histocompatibility I
complex I
genes I
in O
B O
lymphocytes O
. O

To O
further O
evaluate O
the O
role O
of O
X O
box O
DNA O
- O
binding O
proteins O
in O
class B
II I
gene I
expression O
, O
the O
role O
of O
the O
X B
box I
region I
was O
examined O
in O
both O
class O
II O
- O
positive O
and O
- O
negative O
lymphoid O
cells O
. O

To O
determine O
whether O
these O
different O
X1 O
box O
activities O
represented O
distinct O
DNA B
binding I
proteins I
or O
multimeric O
forms O
of O
the O
same O
factor O
( O
s O
) O
, O
protease B
treatment O
of O
the O
crude O
nuclear O
extracts O
followed O
by O
DNA O
- O
binding O
assays O
were O
carried O
out O
and O
demonstrated O
that O
B O
cell O
extracts O
contain O
at O
least O
two O
X1 O
- O
specific O
factors O
. O

A O
similar O
comparison O
with O
protease O
- O
treated O
extracts O
prepared O
from O
Jurkat O
cells O
demonstrated O
the O
presence O
of O
the O
band O
1pk O
activity O
despite O
an O
absence O
of O
the O
native O
RFX B
activity O
. O

Human O
immunodeficiency O
viruses O
containing O
heterologous B
enhancer I
/ I
promoters I
are O
replication O
competent O
and O
exhibit O
different O
lymphocyte O
tropisms O
. O

To O
test O
this O
hypothesis O
, O
a O
more O
sensitive O
and O
specific O
polymerase O
chain O
reaction O
( O
PCR O
) O
assay O
was O
developed O
to O
detect O
adenovirus B
DNA I
. O

OBJECTIVE O
: O
To O
examine O
the O
inter O
- O
relationship O
between O
HIV O
- O
1 O
infection O
and O
the O
cell O
surface O
receptors O
for O
tumor B
necrosis I
factor I
( I
TNF I
) I
- I
alpha I
, O
an O
immunoregulatory O
cytokine O
that O
can O
enhance O
HIV O
- O
1 O
replication O
. O

HIV O
- O
1 O
activation O
and O
expression O
was O
quantitated O
by O
reverse B
transcriptase I
assay O
. O

RESULTS O
: O
In O
the O
OM O
- O
10 O
. O
1 O
promyelocytic O
model O
of O
chronic O
infection O
, O
TNF O
- O
alpha O
- O
induced O
HIV O
- O
1 O
expression O
also O
resulted O
in O
a O
substantial O
increase O
in O
75 O
kd O
TNF O
receptor O
( O
TR75 B
) O
expression O
although O
55 O
kD O
TNF O
receptor O
( O
TR55 B
) O
levels O
were O
not O
dramatically O
altered O
. O

Enhanced O
TR75 B
expression O
on O
OM O
- O
10 O
. O
1 O
cells O
followed O
the O
same O
TNF B
- I
alpha I
- O
dose O
dependency O
as O
that O
observed O
for O
HIV O
- O
1 O
production O
. O

Although O
TR55 B
expression O
was O
unaltered O
during O
TNF B
- I
alpha I
- O
induced O
HIV O
activation O
, O
this O
receptor O
was O
still O
involved O
in O
the O
viral O
activation O
process O
. O

A O
reporter B
gene I
under O
the O
control O
of O
a O
T O
- O
cell O
antigen O
receptor O
element O
was O
activated O
in O
Jurkat O
cells O
by O
antigen O
receptor O
triggering O
or O
by O
a O
combination O
of O
phorbol O
myristate O
acetate O
, O
which O
activates O
protein B
kinase I
C I
, O
and O
a O
calcium O
ionophore O
. O

Both O
these O
signals O
were O
necessary O
for O
expression O
of O
the O
reporter B
gene I
. O

When O
co O
- O
transfected O
with O
a O
construct O
capable O
of O
overexpressing O
the O
tyrosine B
kinase I
p59fyn B
, O
the O
reporter B
gene I
was O
activated O
by O
PMA B
alone O
. O

Dependence O
for O
the O
proliferative O
response O
to O
erythropoietin B
on O
an O
established O
erythroid O
differentiation O
program O
in O
a O
human O
hematopoietic O
cell O
line O
, O
UT O
- O
7 O
. O

UT B
- I
7 I
Epo I
and O
UT O
- O
7 O
expressed O
similar O
levels O
of O
GATA B
- I
1 I
mRNA I
and O
binding O
activity O
. O

By O
Northern O
analysis O
, O
UT O
- O
7 O
cells O
expressed O
detectable O
levels O
of O
beta O
- O
and O
gamma O
- O
globin O
but O
not O
alpha B
- I
globin I
. O

Globin O
chains O
( O
alpha B
, O
beta B
and O
gamma B
) O
were O
clearly O
detectable O
by O
affinity O
chromatography O
in O
UT B
- I
7 I
Epo I
but O
not O
in O
UT O
- O
7 O
cells O
. O

Recent O
isolation O
of O
the O
CD11b B
promoter I
shows O
that O
92 O
base O
pairs O
( O
bp O
) O
of O
5 B
' I
- I
flanking I
DNA I
are O
sufficient O
to O
direct O
myeloid O
- O
specific O
expression O
of O
a O
reporter B
gene I
. O

Target O
antigens O
defined O
by O
autoantibodies B
in O
IDDM O
include O
insulin O
, O
a O
putative O
glycolipid O
that O
reacts O
with O
islet O
cell O
antibodies O
, O
and O
a O
64 O
, O
000 O
- O
M O
( O
r O
) O
protein O
recently O
identified O
as O
glutamic B
acid I
decarboxylase I
. O

Okadaic O
acid O
increased O
the O
synthesis O
of O
the O
interleukin B
- I
1 I
beta I
precursor O
and O
mature O
forms O
and O
their O
secretion O
. O

Expression O
of O
tal B
- I
1 I
and O
GATA B
- I
binding I
proteins I
during O
human O
hematopoiesis O
. O

Because O
the O
GATA B
- I
1 I
gene I
is O
known O
to O
transactivate O
several O
genes O
specific O
for O
the O
erythroid O
, O
megakaryocytic O
, O
and O
mastocytic O
/ O
basophilic O
lineages O
, O
we O
studied O
GATA B
- I
1 I
expression O
in O
these O
purified O
hematopoietic O
cells O
. O

Costimulation O
of O
cAMP O
and O
protein B
kinase I
C I
pathways O
inhibits O
the O
CD3 B
- O
dependent O
T O
cell O
activation O
and O
leads O
to O
a O
persistent O
expression O
of O
the O
AP B
- I
1 I
transcription I
factor I
. O

Analysis O
of O
intracellular O
Ca2 O
+ O
mobilization O
suggested O
that O
the O
CD3 B
/ O
TcR B
- O
dependent O
signal O
transduction O
was O
impaired O
in O
PMA O
/ O
Bt2cAMP O
- O
treated O
cells O
. O

The O
observation O
that O
a O
mutated O
LT O
- O
kappa O
B O
construct O
( O
M1 O
- O
CAT O
) O
was O
inactive O
in O
C81 O
- O
66 O
- O
45 O
, O
confirmed O
the O
importance O
of O
NF B
- I
kappa I
B I
in O
LT B
gene O
expression O
. O

In O
JM O
T O
cells O
, O
tax B
induced O
LT B
- I
293 I
activity O
by O
two O
- O
to O
four O
- O
fold O
, O
though O
there O
was O
no O
induction O
of O
M1 O
- O
CAT O
. O

We O
combined O
two O
techniques O
to O
identify O
the O
productive O
replicative O
form O
of O
Epstein B
- I
Barr I
viral I
DNA I
in O
the O
lytic O
cycle O
- O
induced O
cells O
. O

This O
paper O
describes O
how O
the O
expression O
of O
the O
monocyte O
- O
macrophage O
Ag O
, O
CD14 B
, O
and O
the O
low O
affinity O
Fc O
receptor O
for O
IgE B
, O
CD23 B
, O
were O
inversely O
regulated O
during O
VitD3 O
- O
and O
RA O
- O
induced O
monocytic O
differentiation O
of O
human O
U O
- O
937 O
monoblasts O
. O

Cell O
- O
specific O
bifunctional O
role O
of O
Jun O
oncogene O
family O
members O
on O
glucocorticoid B
receptor I
- O
dependent O
transcription O
. O

Here O
we O
report O
that O
this O
interference O
is O
cell O
specific O
, O
as O
TPA O
augmented O
dexamethasone O
- O
induced O
transcriptional O
activation O
of O
the O
MMTV B
LTR I
in O
several O
T O
cell O
lines O
but O
was O
inhibitory O
in O
NIH O
- O
3T3 O
fibroblasts O
. O

Increased O
c B
- I
jun I
, O
jun B
- I
B I
, O
and O
jun B
- I
D I
expression O
above O
basal O
levels O
and O
increased O
transcriptional O
activity O
of O
AP O
- O
1 O
/ O
TPA O
responsive O
elements O
fused O
to O
chloramphenicol O
acetyl O
- O
transferase O
vectors O
were O
observed O
in O
T O
cells O
treated O
with O
TPA O
alone O
or O
in O
combination O
with O
dexamethasone O
. O

Studies O
with O
5 O
' O
deletion O
CD20 O
promoter O
- O
CAT O
constructs O
have O
previously O
revealed O
two O
regions O
of O
the O
promoter B
between O
bases O
- O
186 O
and O
- O
280 O
and O
between O
bases O
- O
280 O
and O
- O
454 O
which O
contained O
positive O
regulatory O
elements O
. O

Cross O
competition O
experiments O
with O
an O
octamer O
sequence O
from O
the O
Ig O
heavy O
chain O
promoter O
, O
the O
BAT B
box I
, O
and O
a O
TA O
- O
rich O
sequence O
present O
in O
the O
CD21 B
promoter I
revealed O
that O
all O
three O
sequences O
bound O
the O
same O
nuclear B
proteins I
suggesting O
that O
the O
BAT B
box I
binding I
proteins I
were O
Oct B
- I
1 I
and O
Oct B
- I
2 I
. O

Despite O
this O
lower O
affinity O
, O
a O
trimer O
of O
the O
BAT O
box O
sequence O
was O
as O
efficiently O
transactivated O
by O
an O
Oct O
- O
2 O
expression O
vector O
as O
was O
a O
trimer O
of O
the O
octamer B
sequence I
in O
HeLa O
cells O
. O

Control O
peptides O
corresponding O
to O
the O
normal O
pml B
and O
RAR O
alpha O
proteins O
were O
not O
recognized O
. O

One O
cDNA B
clone I
of O
a O
primary O
response O
gene O
, O
expressed O
upon O
macrophage O
differentiation O
, O
encoded O
for O
Egr B
- I
1 I
, O
a O
zinc B
finger I
transcription I
factor I
. O

These O
observations O
indicate O
that O
expression O
of O
Egr B
- I
1 I
is O
essential O
for O
and O
restricts O
differentiation O
of O
myeloblasts O
along O
the O
macrophage O
lineage O
. O

Electrophoretic O
mobility O
shift O
assays O
revealed O
three O
specific O
protein B
- I
DNA I
complexes I
formed O
with O
sequences O
of O
the O
EBNA2 O
responsive O
element O
. O

Thus O
, O
these O
experiments O
demonstrate O
that O
EBNA2 B
interacts O
with O
an O
EBNA2 B
responsive I
cis I
- I
element I
of O
the O
TP1 O
promoter O

Agents O
which O
increased O
cAMP O
levels O
, O
including O
cholera O
toxin O
, O
pertussis O
toxin O
, O
dibutyryl O
cAMP O
, O
and O
isoproterenol O
mimicked O
the O
actions O
of O
MM B
- I
LDL I
. O

One O
member O
of O
this O
multigene O
family O
, O
GATA B
- I
3 I
, O
is O
most O
abundantly O
expressed O
in O
T O
lymphocytes O
, O
a O
cellular O
target O
for O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
infection O
and O
replication O
. O

Cotransfection O
of O
an O
hGATA O
- O
3 O
expression O
plasmid O
with O
a O
reporter B
plasmid I
whose O
transcription O
is O
directed O
by O
the O
HIV B
- I
1 I
LTR I
resulted O
in O
6 O
- O
to O
10 O
- O
fold O
stimulation O
of O
LTR B
- O
mediated O
transcription O
, O
whereas O
site O
specific O
mutation O
of O
these O
GATA B
sites I
resulted O
in O
virtual O
abrogation O
of O
the O
activation O
by O
hGATA B
- I
3 I
. O

Conversely O
, O
several O
cytokines B
modulate O
the O
levels O
of O
HIV O
expression O
in O
infected O
cells O
of O
both O
T O
lymphocytic O
and O
mononuclear O
phagocytic O
lineage O
. O

Cloning O
and O
functional O
characterization O
of O
early B
B I
- I
cell I
factor I
, O
a O
regulator O
of O
lymphocyte O
- O
specific O
gene O
expression O
. O

Early B
B I
- I
cell I
factor I
( O
EBF B
) O
was O
identified O
previously O
as O
a O
tissue O
- O
specific O
and O
differentiation O
stage O
- O
specific O
DNA B
- I
binding I
protein I
that O
participates O
in O
the O
regulation O
of O
the O
pre O
- O
B O
and O
B O
lymphocyte O
- O
specific O
mb O
- O
1 O
gene O
. O

Partial O
amino O
acid O
sequences O
obtained O
from O
purified O
EBF B
were O
used O
to O
isolate O
cDNA B
clones I
, O
which O
by O
multiple O
criteria O
encode O
EBF B
. O

DNA O
- O
binding O
assays O
with O
cotranslated O
wild O
- O
type O
and O
truncated O
forms O
of O
EBF B
indicated O
that O
the O
protein O
interacts O
with O
its O
site O
as O
a O
homodimer B
. O

Deletions O
delineated O
a O
carboxy O
- O
terminal O
dimerization O
region O
containing O
two O
repeats O
of O
15 O
amino O
acids O
that O
show O
similarity O
with O
the O
dimerization O
domains O
of O
basic B
- I
helix I
- I
loop I
- I
helix I
proteins I
. O

A O
73 B
kDa I
protein I
was O
identified O
by O
this O
analysis O
: O
this O
protein O
is O
highly O
enriched O
in O
cell O
lines O
of O
B O
lymphoid O
origin O
as O
compared O
to O
pancreatic O
beta O
- O
cells O
and O
fibroblast O
cells O
. O

The O
detection O
of O
this O
protein O
selectively O
in O
extracts O
of O
lymphoid O
cells O
correlates O
with O
the O
presence O
of O
the O
E B
box I
- O
binding O
activity O
LEF1 B
/ I
BCF1 I
in O
these O
cells O
; O
this O
binding O
activity O
was O
previously O
shown O
to O
be O
efficiently O
recognized O
by O
antiserum O
directed O
against O
E2A O
gene O
products O
. O

Furthermore O
, O
we O
evaluated O
the O
mineralocorticoid B
receptor I
( O
MR B
) O
count O
in O
mononuclear O
leukocytes O
in O
the O
2 O
groups O
. O

Induction O
by O
hemin O
increases O
, O
while O
induction O
with O
12 O
- O
O O
- O
tetradecanoylphorbol O
- O
13 O
- O
acetate O
( O
TPA O
) O
represses O
, O
erythroid B
- I
specific I
gene I
expression O
in O
the O
human O
cell O
line O
K562 O
. O

The O
divergent O
effects O
of O
hemin O
and O
TPA O
on O
gene O
expression O
in O
K562 O
cells O
are O
mediated O
, O
in O
part O
, O
by O
their O
contrasting O
effects O
on O
the O
transcription B
factor I
NF B
- I
E2 I
. O

We O
studied O
the O
effect O
of O
interleukin B
- I
4 I
( O
IL B
- I
4 I
) O
on O
the O
lipopolysaccharide O
( O
LPS O
) O
induction O
of O
two O
immediate O
early O
genes O
c B
- I
fos I
and O
c B
- I
jun I
. O

The O
inhibition O
of O
c B
- I
fos I
and O
c O
- O
jun O
expression O
by O
IL B
- I
4 I
in O
LPS O
- O
treated O
cells O
was O
shown O
to O
be O
due O
to O
a O
lower O
transcription O
rate O
of O
the O
c O
- O
fos O
and O
c O
- O
jun O
genes O
. O

These O
involve O
activation O
of O
the O
sodium B
/ I
proton I
exchanger I
of O
the O
cell O
membrane O
at O
very O
low O
, O
physiological O
concentrations O
of O
aldosterone O
with O
an O
acute O
onset O
within O
1 O
- O
2 O
min O
. O

Human O
immunodeficiency O
virus O
type O
1 O
Nef O
protein O
inhibits O
NF B
- I
kappa I
B I
induction O
in O
human O
T O
cells O
. O

These O
results O
indicate O
that O
defective O
recruitment O
of O
NF B
- I
kappa I
B I
may O
underlie O
Nef B
' O
s O
negative O
transcriptional O
effects O
on O
the O
HIV O
- O
1 O
and O
interleukin O
2 O
promoters O
. O

Because O
previous O
work O
has O
demonstrated O
that O
T O
cells O
from O
elderly O
individuals O
may O
display O
normal O
proliferative O
responses O
when O
activated O
via O
the O
anti B
- I
CD2 I
pathway O
, O
c O
- O
jun O
and O
jun O
B O
mRNA O
expression O
was O
also O
studied O
in O
anti O
- O
CD2 O
- O
activated O
purified O
T O
cells O
. O

This O
high O
- O
affinity O
site O
has O
been O
conserved O
in O
the O
promoters B
of O
both O
human O
and O
mouse O
CD19 O
genes O
and O
was O
furthermore O
shown O
to O
confer O
B O
- O
cell O
specificity O
to O
a O
beta O
- O
globin O
reporter O
gene O
in O
transient O
transfection O
experiments O
. O

In O
addition O
, O
BSAP B
was O
found O
to O
be O
the O
only O
abundant O
DNA O
- O
binding O
activity O
of O
B O
- O
cell O
nuclear O
extracts O
that O
interacts O
with O
the O
CD19 B
promoter I
. O

Small O
apolar O
substitutions O
( O
11 O
alpha O
- O
methyl O
, O
11 O
alpha O
- O
fluoromethyl O
) O
did O
not O
markedly O
decrease O
the O
affinity O
for O
the O
vitamin B
D I
receptor I
, O
but O
larger O
( O
11 O
alpha O
- O
chloromethyl O
or O
11 O
alpha O
- O
or O
11 O
beta O
- O
phenyl O
) O
or O
more O
polar O
substitutions O
( O
11 O
alpha O
- O
hydroxymethyl O
, O
11 O
alpha O
- O
( O
2 O
- O
hydroxyethyl O
] O
decreased O
the O
affinity O
to O
less O
than O
5 O
% O
of O
that O
of O
1 O
alpha O
, O
25 O
- O
OH O
) O
2D3 O
. O

The O
helix O
- O
loop O
- O
helix O
( O
HLH O
) O
proteins O
are O
a O
family O
of O
transcription B
factors I
that O
include O
proteins O
critical O
to O
differentiation O
and O
development O
in O
species O
ranging O
from O
plants O
to O
mammals O
. O

Glucocorticoid B
receptor I
in O
patients O
with O
lupus O
nephritis O
: O
relationship O
between O
receptor O
levels O
in O
mononuclear O
leukocytes O
and O
effect O
of O
glucocorticoid O
therapy O
. O

We O
investigated O
the O
clinical O
significance O
of O
glucocorticoid B
receptor I
determination O
in O
20 O
patients O
with O
systemic O
lupus O
erythematosus O
( O
SLE O
) O
who O
afterwards O
developed O
nephrotic O
syndrome O
. O

Improvement O
in O
urinary O
protein O
excretion O
and O
in O
disease O
activity O
, O
which O
was O
scored O
according O
to O
the O
SLE O
Disease O
Activity O
Index O
system O
of O
the O
University O
of O
Toronto O
, O
closely O
related O
to O
the O
glucocorticoid B
receptor I
concentrations O
in O
MNL O
isolated O
from O
the O
corresponding O
patients O
. O

Possible O
relationship O
between O
the O
changes O
in O
IL B
- I
1 I
and O
GR B
in O
aged O
long O
- O
distance O
runner O
and O
its O
physiological O
significance O
are O
discussed O
. O

MR B
were O
reduced O
before O
delivery O
( O
96 O
+ O
/ O
- O
27 O
receptors O
/ O
cell O
) O
, O
and O
SPD O
increased O
( O
64 O
+ O
/ O
- O
8 O
mV O
) O
, O
with O
both O
parameters O
normalizing O
after O
delivery O
( O
MR B
, O
242 O
+ O
/ O
- O
79 O
; O
SPD O
, O
14 O
. O
0 O
+ O
/ O
- O
4 O
mV O
) O
. O

Kinetics O
of O
nuclear O
translocation O
and O
turnover O
of O
the O
vitamin B
D I
receptor I
in O
human O
HL60 O
leukemia O
cells O
and O
peripheral O
blood O
lymphocytes O
- O
- O
coincident O
rise O
of O
DNA O
- O
relaxing O
activity O
in O
nuclear O
extracts O
. O

Pulse O
exposure O
of O
HL60 O
to O
radiolabeled O
hormone O
for O
3 O
h O
followed O
by O
culture O
in O
medium O
without O
serum O
and O
calcitriol O
lead O
to O
nuclear O
retention O
of O
approximately O
1600 O
radiolabeled O
VDR O
by O
8 O
h O
and O
approximately O
1000 O
VDR B
by O
24 O
h O
. O

Enhanced O
activity O
of O
topoisomerases O
in O
nuclear O
extracts O
upon O
translocation O
of O
VDR B
might O
reflect O
interaction O
of O
both O
within O
the O
nuclear O
compartment O
, O
thus O
initiating O
DNA O
- O
unwinding O
, O
a O
prerequisite O
of O
transcription O
initiation O
. O

Regulation O
of O
replicative O
functions O
in O
the O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
genome O
is O
mediated O
through O
activation O
of O
a O
virally O
encoded O
transcription O
factor O
, O
Z B
( O
BZLF1 B
) O
. O

The O
long B
terminal I
repeat I
( I
LTR I
) I
region I
of O
HIV O
proviral O
DNA O
contains O
binding O
sites O
for O
nuclear B
factor I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
, O
and O
this O
transcriptional B
activator I
appears O
to O
regulate O
HIV O
activation O
. O

REV B
LTRs I
work O
efficiently O
in O
human O
lymphoid O
cells O
, O
and O
are O
viable O
alternatives O
to O
promoters B
commonly O
used O
for O
expression O
of O
cloned O
genes O
. O

Thus O
, O
Elf B
- I
1 I
is O
a O
novel O
transcription O
factor O
that O
appears O
to O
be O
required O
for O
the O
T O
- O
cell O
- O
receptor O
- O
mediated O
trans O
activation O
of O
HIV O
- O
2 O
gene O
expression O
. O

Okadaic O
acid O
is O
a O
potent O
inducer O
of O
AP B
- I
1 I
, O
NF B
- I
kappa I
B I
, O
and O
tumor B
necrosis I
factor I
- I
alpha I
in O
human O
B O
lymphocytes O
. O

Treatment O
of O
human O
B O
lymphocytes O
with O
an O
optimal O
concentration O
of O
okadaic O
acid O
, O
an O
inhibitor O
of O
phosphatases B
1 I
and I
2A I
, O
resulted O
in O
the O
induction O
of O
the O
transcription B
factor I
, O
AP B
- I
1 I
and O
a O
marked O
increase O
in O
NF B
- I
kappa I
B I
levels O
. O

Although O
okadaic O
acid O
provides O
a O
potent O
inductive O
signal O
for O
AP B
- I
1 I
and O
NF B
- I
kappa I
B I
it O
did O
not O
induce O
either O
B O
cell O
proliferation O
or O
immunoglobulin B
secretion O
. O

c B
- I
myc I
mRNA I
expression O
in O
minor O
salivary O
glands O
of O
patients O
with O
Sjogren O
' O
s O
syndrome O
. O

These O
data O
show O
that O
aged O
subjects O
have O
reductions O
of O
corticosteroid B
receptors I
that O
are O
not O
associated O
with O
increase O
of O
related O
steroids O
and O
that O
this O
situation O
probably O
represents O
a O
concomitant O
of O
the O
normal O
aging O
process O
. O

IL B
- I
4 I
secreted O
by O
activated O
T O
cells O
is O
a O
pleiotropic B
cytokine I
affecting O
growth O
and O
differentiation O
of O
diverse O
cell O
types O
such O
as O
T O
cells O
, O
B O
cells O
, O
and O
mast O
cells O
. O

A O
novel O
T O
cell O
- O
specific O
negative O
regulatory O
element O
( O
NRE B
) O
composed O
of O
two O
protein O
- O
binding O
sites O
were O
mapped O
in O
the O
5 O
' O
flanking O
region O
of O
the O
IL B
- I
4 I
gene I
: O
- O
311CTCCCTTCT O
- O
303 O
( O
NRE O
- O
I O
) O
and O
- O
288CTTTTTGCTT O
- O
TGC O
- O
300 O
( O
NRE O
- O
II O
) O
. O

A O
T O
cell O
- O
specific O
protein O
Neg O
- O
1 O
and O
a O
ubiquitous B
protein I
Neg O
- O
2 O
binding O
to O
NRE O
- O
I O
and O
NRE O
- O
II O
, O
respectively O
, O
were O
identified O
. O

The O
addition O
of O
antisense O
oligonucleotides O
to O
c B
- I
fos I
significantly O
inhibited O
IL B
6 I
- O
induced O
IgM B
production O
by O
SKW O
6 O
. O
4 O
cells O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
whereas O
control O
oligonucleotides O
had O
no O
inhibitory O
effect O
. O

We O
used O
phenolic O
, O
lipid O
- O
soluble O
, O
chain O
- O
breaking O
antioxidants O
( O
butylated O
hydroxyanisole O
( O
BHA O
) O
, O
nordihydroquairetic O
acid O
, O
or O
alpha O
- O
tocopherol O
( O
vitamin O
E O
) O
to O
show O
that O
peroxyl O
radical O
scavenging O
in O
unstimulated O
and O
PMA O
- O
or O
TNF O
- O
stimulated O
cells O
blocks O
the O
functions O
depending O
on O
NF B
- I
kappa I
B I
activation O
. O

Rather O
, O
TNF B
and O
PMA B
can O
exert O
their O
effect O
only O
if O
cells O
are O
in O
an O
appropriate O
redox O
status O
, O
because O
prior O
modification O
toward O
reduction O
with O
BHA O
treatment O
prevents O
this O
activation O
. O

Selection O
of O
optimal O
kappa O
B O
/ O
Rel O
DNA O
- O
binding O
motifs O
: O
interaction O
of O
both O
subunits O
of O
NF B
- I
kappa I
B I
with O
DNA O
is O
required O
for O
transcriptional O
activation O
. O

Analysis O
of O
the O
p50 B
and O
p65 B
subunits I
of O
the O
NF B
- I
kappa I
B I
transcription I
factor I
complex I
has O
revealed O
that O
both O
proteins O
can O
interact O
with O
related O
DNA O
sequences O
through O
either O
homo O
- O
or O
heterodimer O
formation O
. O

Using O
purified O
recombinant O
p50 B
, O
p65 B
, O
and O
c B
- I
Rel I
proteins I
, O
optimal O
DNA O
- O
binding O
motifs O
were O
selected O
from O
a O
pool O
of O
random O
oligonucleotides O
. O

These O
findings O
demonstrate O
that O
interaction O
of O
both O
subunits O
of O
the O
heterodimeric B
NF I
- I
kappa I
B I
complex I
with O
DNA O
is O
required O
for O
DNA O
binding O
and O
transcriptional O
activation O
and O
suggest O
that O
transcriptional O
activation O
mediated O
by O
the O
individual O
rel O
- O
related O
proteins O
will O
differ O
dramatically O
, O
depending O
on O
the O
specific O
kappa O
B O
motifs O
present O
. O

These O
observations O
indicate O
that O
during O
chronic O
HIV O
infection O
of O
U937 O
cells O
, O
continuous O
NF B
- I
kappa I
B I
( O
p50 B
/ I
p65 I
) O
translocation O
results O
in O
p105 O
promoter O
upregulation O
with O
subsequent O
cytosolic O
NF B
- I
kappa I
B I
accumulation O
, O
ready O
for O
further O
translocation O
. O

Similarly O
, O
IL B
- I
2 I
activates O
NF B
- I
kappa I
B I
in O
the O
human O
monocytic O
cell O
line O
U O
937 O
, O
but O
not O
in O
resting O
human O
T O
- O
cells O
. O

Blockade O
of O
the O
DNA B
- I
binding I
complexes I
with O
an O
anti O
- O
Fos O
mAb O
demonstrated O
a O
direct O
participation O
of O
c B
- I
Fos I
in O
the O
AP B
- I
1 I
complexes I
induced O
by O
anti B
- I
AIM I
mAb I
. O

These O
data O
provide O
the O
evidence O
that O
activation O
of O
human O
peripheral O
blood O
T O
cells O
through O
the O
AIM O
activation O
pathway O
regulate O
the O
activity O
of O
AP B
- I
1 I
. O

Gangliosides O
suppress O
tumor B
necrosis I
factor I
production O
in O
human O
monocytes O
. O

Although O
under O
standard O
culture O
conditions O
, O
bovine O
brain O
gangliosides O
( O
100 O
micrograms O
/ O
ml O
) O
suppressed O
LPS O
- O
stimulated O
TNF B
production O
5 O
- O
fold O
in O
PBMC O
and O
10 O
- O
fold O
in O
Mono O
Mac O
6 O
cells O
, O
suppression O
was O
more O
efficient O
under O
serum O
- O
free O
conditions O
. O

Taken O
together O
, O
our O
data O
demonstrate O
that O
TNF B
gene O
expression O
in O
monocytes O
induced O
by O
different O
types O
of O
stimuli O
can O
be O
blocked O
by O
gangliosides O
at O
an O
early O
step O
of O
signal O
transduction O
. O

Because O
of O
the O
efficient O
binding O
of O
TG B
by O
surrogate B
receptors I
on O
non O
- O
T O
cells O
, O
we O
assessed O
the O
ability O
of O
such O
cells O
to O
present O
TG B
to O
T O
cells O
. O

Proliferation O
in O
response O
to O
TG B
was O
observed O
in O
T O
cells O
from O
only O
1 O
of O
5 O
Hashimoto O
patients O
. O

A O
PMA B
responsive I
element I
was O
localized O
to O
a O
region O
between O
- O
95 O
and O
- O
36 O
bp O
relative O
to O
the O
transcription B
start I
site I
. O

Expression O
of O
M10 B
did O
not O
affect O
induction O
of O
HIV O
transcription O
mediated O
by O
the O
kappa O
B O
regulatory O
element O
or O
Tat B
. O

The O
inhibition O
of O
HIV O
infection O
in O
cells O
stably O
expressing O
a O
transdominant B
Rev I
protein I
, O
in O
the O
absence O
of O
any O
deleterious O
effect O
on O
T O
cell O
function O
, O
suggests O
that O
such O
a O
strategy O
could O
provide O
a O
therapeutic O
effect O
in O
the O
T O
lymphocytes O
of O
acquired O
immunodeficiency O
syndrome O
patients O
. O

The O
present O
work O
has O
examined O
the O
effects O
of O
okadaic O
acid O
, O
an O
inhibitor O
of O
type O
1 O
and O
2A O
protein O
phosphatases O
, O
on O
the O
regulation O
of O
c B
- I
jun I
expression O
during O
monocytic O
differentiation O
of O
U O
- O
937 O
leukemia O
cells O
. O

Mitogen O
stimulation O
of O
T O
- O
cells O
increases O
c B
- I
Fos I
and O
c B
- I
Jun I
protein O
levels O
, O
AP O
- O
1 O
binding O
and O
AP O
- O
1 O
transcriptional O
activity O
. O

Both O
c B
- I
Fos I
and O
c B
- I
Jun I
protein O
levels O
were O
increased O
after O
Con O
A O
and O
PHA O
stimulation O
. O

The O
kinetics O
of O
expression O
of O
the O
two O
genes O
were O
also O
slightly O
different O
, O
with O
c B
- I
fos I
mRNA I
reaching O
a O
peak O
at O
15 O
min O
after O
stimulation O
and O
c B
- I
jun I
at O
30 O
min O
. O

Nuclear O
transcription O
studies O
in O
vitro O
showed O
that O
LTB4 O
increased O
the O
transcription O
of O
the O
c B
- I
fos I
gene I
7 O
- O
fold O
and O
the O
c B
- I
jun I
gene I
1 O
. O
4 O
- O
fold O
. O

Modulation O
of O
normal O
erythroid O
differentiation O
by O
the O
endogenous O
thyroid O
hormone O
and O
retinoic B
acid I
receptors I
: O
a O
possible O
target O
for O
v B
- I
erbA I
oncogene I
action O
. O

Two O
types O
of O
helper O
T O
cell O
( O
Th O
) O
clones O
( O
Th1 O
and O
Th2 O
) O
are O
defined O
on O
the O
basis O
of O
different O
patterns O
of O
cytokine B
( O
lymphokine B
) O
secretion O
. O

Yet O
phorbol O
ester O
alone O
or O
calcium O
ionophore O
alone O
produce O
several O
lymphokines B
. O

GM2 B
defines O
a O
binding B
site I
for O
protein O
( O
s O
) O
whose O
binding O
is O
inducible O
by O
PMA O
. O

Mutations O
in O
the O
Pit B
- I
1 I
gene I
in O
children O
with O
combined O
pituitary O
hormone O
deficiency O
. O

Pit B
- I
1 I
is O
a O
pituitary O
- O
specific O
transcription O
factor O
that O
binds O
to O
and O
transactivates O
promoters B
of O
growth O
hormone O
and O
prolactin O
genes O
. O

Activation O
of O
protein B
kinase I
C I
and O
elevation O
of O
cAMP O
interact O
synergistically O
to O
raise O
c B
- I
Fos I
and O
AP B
- I
1 I
activity O
in O
Jurkat O
cells O
. O

We O
have O
earlier O
found O
that O
in O
Jurkat O
cells O
activation O
of O
protein B
kinase I
C I
( O
PKC B
) O
enhances O
the O
cyclic O
adenosine O
monophosphate O
( O
cAMP O
) O
accumulation O
induced O
by O
adenosine O
receptor O
stimulation O
or O
activation O
of O
Gs O
. O

In O
vivo O
footprint O
analysis O
of O
the O
HLA O
- O
DRA O
gene O
promoter O
: O
cell O
- O
specific O
interaction O
at O
the O
octamer B
site I
and O
up O
- O
regulation O
of O
X O
box O
binding O
by O
interferon B
gamma I
. O

Therefore O
, O
we O
describe O
a O
microtitre O
assay O
system O
for O
glucocorticoid B
receptors I
which O
is O
a O
whole O
- O
cell O
competitive O
binding O
radioassay O
using O
[ O
3H O
] O
- O
dexamethasone O
as O
radioligand O
. O

Thus O
enabled O
to O
perform O
the O
test O
on O
multiple O
blood O
samples O
in O
parallel O
, O
we O
investigated O
cardiac O
infarction O
patients O
over O
a O
12 O
- O
day O
period O
to O
test O
if O
glucocorticoid B
receptor I
binding O
is O
altered O
in O
this O
' O
stressful O
' O
disease O
. O

On O
the O
first O
day O
of O
the O
disease O
, O
glucocorticoid B
receptor I
capacity O
was O
significantly O
decreased O
without O
alteration O
of O
the O
receptor O
- O
ligand O
affinity O
, O
whereas O
on O
days O
4 O
and O
12 O
the O
number O
of O
receptor O
sites O
was O
normal O
again O
. O

CsA O
was O
found O
not O
to O
inhibit O
lck B
gene O
expression O
, O
nor O
the O
activity O
of O
the O
lck O
gene O
product O
. O

The O
IL B
- I
2 I
promoter I
contains O
binding B
sites I
for O
nuclear B
factors I
including O
NFAT B
- I
1 I
, O
Oct B
, O
NF B
- I
kappa I
B I
, O
and O
AP B
- I
1 I
, O
which O
are O
all O
potentially O
sensitive O
to O
activation O
of O
PKC B
. O

Our O
results O
indicate O
that O
the O
AP B
- I
1 I
site I
at O
- B
150 I
bp I
represents O
a O
major O
, O
if O
not O
the O
only O
, O
site O
of O
PKC B
responsiveness O
in O
the O
IL B
- I
2 I
promoter I
. O

Mice O
treated O
with O
antisense O
to O
NF B
- I
kappa I
B I
ODNs O
showed O
rapid O
regression O
of O
transplanted O
fibrosarcomas O
. O

Leukotriene O
B4 O
transcriptionally O
activates O
interleukin B
- I
6 I
expression O
involving O
NK O
- O
chi O
B O
and O
NF B
- I
IL6 I
. O

It O
is O
, O
however O
, O
still O
unclear O
whether O
LTB4 O
acts O
in O
this O
regard O
directly O
or O
indirectly O
by O
stimulating O
the O
release O
of O
chemotactic O
and O
inflammatory B
cytokines I
. O

We O
furthermore O
demonstrate O
that O
this O
process O
involves O
activation O
of O
the O
transcription B
factor I
NF B
- I
chi I
B I
and O
, O
to O
a O
lesser O
extent O
, O
of O
NF B
- I
IL6 I
, O
while O
the O
activity O
of O
the O
transcription B
factor I
AP B
- I
1 I
, O
shown O
to O
otherwise O
confer O
IL B
- I
6 I
inducibility O
, O
appeared O
to O
be O
unaffected O
by O
LTB4 O
. O

The O
signaling O
events O
mediating O
this O
effect O
appeared O
to O
involve O
the O
release O
of O
H2O2 O
, O
since O
LTB4 O
failed O
to O
induce O
NF B
- I
chi I
B I
or O
NF B
- I
IL6 I
in O
the O
presence O
of O
the O
scavenger O
of O
H2O2 O
, O
N O
- O
acetyl O
- O
L O
- O
cysteine O
. O

The O
insertion O
was O
not O
required O
for O
Fc B
gamma I
RII I
to O
modulate O
surface B
immunoglobulin I
- O
triggered O
B O
- O
cell O
activation O
. O

Here O
, O
Stuart O
Schreiber O
and O
Gerald O
Crabtree O
review O
recent O
findings O
that O
indicate O
CsA O
and O
FK506 O
operate O
as O
prodrugs O
: O
they O
bind O
endogenous O
intracellular O
receptors O
, O
the O
immunophilins B
, O
and O
the O
resulting O
complex O
targets O
the O
protein B
phosphatase I
, I
calcineurin B
, O
to O
exert O
the O
immunosuppressive O
effect O
. O

Mutations O
affecting O
the O
5 O
' O
guanine O
residues O
of O
the O
kappa B
B I
site I
were O
unable O
to O
compete O
for O
these O
NF O
- O
kappa O
B O
- O
related O
proteins O
. O

First O
is O
an O
expansion O
phase O
prior O
to O
TCR B
rearrangement O
, O
which O
appears O
to O
be O
correlated O
with O
programming O
of O
at O
least O
some O
response O
genes O
for O
inducibility O
. O

It O
seems O
that O
the O
rearrangement O
of O
the O
TCR O
gamma O
loci O
in O
the O
gamma O
delta O
lineage O
may O
not O
always O
take O
place O
at O
a O
developmental O
stage O
strictly O
equivalent O
to O
the O
rearrangement O
of O
TCR B
beta I
in O
the O
alpha O
beta O
lineage O
, O
and O
it O
is O
not O
clear O
just O
how O
early O
the O
two O
lineages O
diverge O
. O

In O
contrast O
, O
NF B
- I
kappa I
B I
p50 I
alone O
fails O
to O
stimulate O
kappa O
B O
- O
directed O
transcription O
, O
and O
based O
on O
prior O
in O
vitro O
studies O
, O
is O
not O
directly O
regulated O
by O
I B
kappa I
B I
. O

Together O
, O
these O
findings O
suggest O
that O
the O
nuclear O
localization O
signal O
and O
transactivation B
domain I
of O
NF B
- I
kappa I
B I
p65 I
constitute O
a O
bipartite O
system O
that O
is O
critically O
involved O
in O
the O
inhibitory O
function O
of O
I B
kappa I
B I
/ I
MAD I
- I
3 I
. O

This O
interaction O
is O
functional O
as O
it O
leads O
to O
retargeting O
of O
NF B
- I
kappa I
B I
p50 I
from O
the O
nucleus O
to O
the O
cytoplasm O
. O

However O
, O
no O
loss O
of O
DNA O
binding O
activity O
is O
observed O
, O
presumably O
reflecting O
the O
unique O
C B
- I
terminal I
domain I
that O
is O
distinct O
from O
that O
present O
in O
NF B
- I
kappa I
B I
p65 I
. O

We O
have O
biochemically O
and O
functionally O
characterized O
a O
new O
transcription B
factor I
, O
NP O
- O
TCII O
, O
which O
is O
present O
in O
nuclei O
from O
unstimulated O
T O
and O
B O
lymphocytes O
but O
is O
not O
found O
in O
nonhematopoietic O
cells O
. O

Chloramphenicol B
acetyl I
transferase I
( O
CAT B
) O
assays O
using O
the O
HIV O
- O
1 O
( O
- O
139 O
) O
long O
terminal O
repeat O
- O
CAT O
construct O
showed O
no O
PMA O
induction O
of O
CAT B
activity O
in O
these O
subclones O
( O
unlike O
the O
parental O
line O
and O
other O
subclones O
) O
. O

Although O
NF B
- I
AT I
has O
not O
been O
cloned O
or O
purified O
, O
there O
is O
evidence O
that O
it O
is O
a O
major O
target O
for O
immunosuppression O
by O
cyclosporin O
A O
( O
CsA O
) O
and O
FK506 O
( O
refs O
2 O
- O
7 O
) O
. O

[ O
3H O
] O
Thymidine O
incorporation O
was O
decreased O
dose O
- O
dependently O
by O
dexamethasone O
in O
controls O
and O
patients O
; O
the O
effect O
was O
significantly O
blunted O
( O
P O
less O
than O
0 O
. O
05 O
) O
in O
group O
1 O
patients O
, O
which O
suggests O
that O
activation O
of O
glucocorticoid B
receptor I
is O
impaired O
as O
a O
result O
of O
the O
glucocorticoid B
receptor I
abnormality O
. O

After O
the O
DNA B
fragment I
containing O
the O
CAG B
repeats I
is O
amplified O
by O
the O
polymerase O
chain O
reaction O
, O
a O
primer O
extension O
is O
carried O
out O
; O
the O
extension O
of O
the O
end O
- O
labelled O
reverse O
primer O
adjacent O
to O
3 B
' I
end I
of O
CAG B
repeats I
stops O
at O
the O
first O
T O
after O
CAG B
repeats I
with O
the O
incorporation O
of O
dideoxy O
ATP O
in O
the O
reaction O
mixture O
. O

The O
response O
to O
antigen O
proceeds O
at O
the O
T O
helper O
cell O
level O
through O
two O
independent O
forms O
of O
cellular O
collaboration O
, O
contact O
and O
lymphokine B
. O

It O
is O
evident O
that O
assembly O
of O
the O
surface O
domain O
of O
TF B
with O
VIIa B
to O
form O
the O
binary O
TF B
. I
VIIa I
complex I
induces O
a O
significant O
increase O
in O
the O
Kcat O
of O
the O
catalytic B
domain I
of O
VIIa B
for O
small O
peptidyl O
substrates O
and O
more O
profoundly O
for O
protein O
substrate O
. O

It O
is O
also O
evident O
that O
association O
of O
X B
with O
charged O
phospholipid O
surfaces O
enhances O
the O
proteolytic O
activation O
of O
this O
zymogen O
by O
increasing O
recognition O
and O
susceptibility O
of O
the O
sessile O
peptide O
bond O
deduced O
from O
the O
markedly O
decreased O
Km O
and O
increased O
Kcat O
. O

NF B
kappa I
B I
is O
a O
potent O
mediator O
of O
specific O
gene O
expression O
in O
human O
monocytes O
and O
has O
been O
shown O
to O
play O
a O
role O
in O
transcription O
of O
the O
HIV O
- O
1 O
genome O
in O
promonocytic O
leukemias O
. O

There O
is O
little O
information O
available O
on O
the O
response O
of O
NF B
kappa I
B I
to O
cytokines B
in O
normal O
human O
monocytes O
. O

The O
endothelium O
plays O
a O
critical O
role O
in O
inflammation O
by O
directing O
circulating O
leukocytes O
into O
extravascular O
tissues O
by O
expressing O
adhesive O
molecules O
for O
leukocytes O
[ O
e O
. O
g O
. O
, O
endothelial B
- I
leukocyte I
adhesion I
molecule I
1 I
( O
ELAM B
- I
1 I
) O
and O
intercellular B
adhesion I
molecule I
1 I
( O
ICAM B
- I
1 I
) O
] O
. O

In O
contrast O
, O
sodium O
salicylate O
( O
1 O
mM O
) O
inhibited O
neither O
adhesion O
nor O
expression O
of O
these O
adhesion B
molecules I
. O

These O
studies O
suggest O
that O
antagonism O
by O
dexamethasone O
of O
endotoxin B
- O
induced O
inflammation O
is O
a O
specific O
instance O
of O
the O
general O
biological O
principle O
that O
the O
glucocorticoid B
receptor I
is O
a O
hormone O
- O
dependent O
regulator O
of O
transcription O
. O

Biochemical O
purification O
and O
cDNA O
cloning O
has O
now O
revealed O
that O
BSAP B
belongs O
to O
the O
family O
of O
paired O
domain O
proteins O
. O

BSAP B
is O
encoded O
by O
the O
Pax B
- I
5 I
gene I
and O
has O
been O
highly O
conserved O
between O
human O
and O
mouse O
. O

Later O
, O
the O
expression O
of O
the O
BSAP B
gene I
shifts O
to O
the O
fetal O
liver O
where O
it O
correlates O
with O
the O
onset O
of O
B O
lymphopoiesis O
. O

Specific O
NF B
- I
kappa I
B I
subunits I
act O
in O
concert O
with O
Tat B
to O
stimulate O
human O
immunodeficiency O
virus O
type O
1 O
transcription O
. O

NF B
- I
kappa I
B I
is O
a O
protein B
complex I
which O
functions O
in O
concert O
with O
the O
tat B
- I
I I
gene I
product I
to O
stimulate O
human O
immunodeficiency O
virus O
( O
HIV O
) O
transcription O
. O

We O
have O
found O
that O
the O
p49 O
( O
100 O
) O
DNA O
binding O
subunit O
, O
together O
with O
p65 B
, O
can O
act O
in O
concert O
with O
Tat B
- I
I I
to O
stimulate O
the O
expression O
of O
HIV O
- O
CAT O
plasmid O
. O

Little O
effect O
was O
observed O
with O
50 O
- O
kDa O
forms O
of O
p105 B
NF B
- I
kappa I
B I
or O
rel B
, O
in O
combination O
with O
p65 B
or O
full O
- O
length O
c O
- O
rel O
, O
which O
do O
not O
stimulate O
the O
HIV B
enhancer I
in O
these O
cells O
. O

Stable O
expression O
of O
HB24 B
, O
a O
diverged O
human O
homeobox O
gene O
, O
in O
T O
lymphocytes O
induces O
genes O
involved O
in O
T O
cell O
activation O
and O
growth O
. O

In O
the O
studies O
described O
in O
this O
report O
, O
we O
have O
identified O
two O
potential O
Ets B
binding I
sites I
, O
EBS1 O
and O
EBS2 B
, O
which O
are O
conserved O
in O
both O
the O
human O
and O
murine O
interleukin O
- O
2 O
enhancers O
. O

This O
protein O
is O
distinct O
from O
other O
members O
of O
the O
steroid B
/ I
thyroid I
hormone I
receptor I
family I
including O
the O
COUP O
protein O
which O
has O
a O
closely O
related O
DNA O
binding O
specificity O
. O

A O
Tat B
- I
responsive I
element I
is O
found O
upstream O
within O
the O
viral B
promoter I
that O
in O
glial O
- O
derived O
cell O
lines O
allows O
transactivation O
in O
the O
absence O
of O
TAR B
. O

At O
least O
two O
21 B
bp I
repeats I
were O
required O
for O
high O
levels O
of O
AP B
- I
2 I
activation O
and O
mutagenesis O
of O
the O
AP O
- O
2 O
consensus O
binding O
sequences O
in O
the O
21 B
bp I
repeats I
eliminate O
this O
activation O
. O

Activation O
of O
the O
human B
immunodeficiency I
virus I
type I
1 I
enhancer I
is O
not O
dependent O
on O
NFAT B
- I
1 I
. O

Activation O
by O
the O
T B
- I
cell I
antigen I
receptor I
is O
minimal O
in O
Jurkat O
cells O
and O
is O
mediated O
by O
the O
kappa B
B I
sites I
. O

The O
promoter O
of O
the O
major O
histocompatibility O
class O
II O
gene O
DRA B
contains O
an O
octamer B
element I
( O
ATTTGCAT O
) O
that O
is O
required O
for O
efficient O
DRA B
expression O
in O
B O
cells O
. O

In O
vitro O
transcription O
analysis O
using O
protein O
fractions O
enriched O
for O
the O
octamer O
- O
binding O
protein O
OTF B
- I
2 I
demonstrate O
a O
positive O
functional O
role O
for O
OTF B
- I
2 I
in O
DRA B
gene I
transcription O
. O

Recombinant O
OTF O
- O
2 O
protein O
produced O
by O
in O
vitro O
transcription O
/ O
translation O
could O
also O
enhance O
DRA B
gene I
transcription O
in O
vitro O
. O

However O
, O
the O
increase O
in O
ISGF3 B
activity O
ultimately O
correlates O
with O
the O
accumulation O
of O
ISGF3 B
gamma I
induced O
by O
IFN B
- I
alpha I
or O
IFN B
- I
gamma I
. O

Glucocorticoid B
receptor I
and O
inhibition O
of O
3 O
- O
O O
- O
methyl O
- O
D O
- O
glucose O
uptake O
by O
glucocorticoids O
in O
peripheral O
blood O
leukocytes O
from O
normal O
humans O
: O
correlation O
between O
receptor O
level O
and O
hormone O
effect O
in O
vitro O
. O

It O
was O
found O
that O
lipopolysaccharide O
induced O
strongly O
both O
c B
- I
fos I
and O
c B
- I
jun I
expression O
as O
well O
as O
AP1 B
formation O
. O

Regulation O
of O
interleukin B
- I
1 I
beta I
production O
by O
glucocorticoids O
in O
human O
monocytes O
: O
the O
mechanism O
of O
action O
depends O
on O
the O
activation O
signal O
. O

Nuclear B
transcription I
factors I
that O
bind O
to O
elements O
of O
the O
IL B
- I
2 I
promoter I
. O

In O
addition O
, O
p65 B
gave O
per O
se O
, O
with O
low O
affinity O
, O
a O
protein B
- I
DNA I
complex I
that O
migrated O
more O
slowly O
than O
native O
NF B
- I
GM2 I
complex I
. O

Furthermore O
, O
an O
antiserum O
against O
KBF1 B
( O
identical O
to O
50 O
kDa O
NF O
- O
kappa O
B O
protein O
) O
reacted O
with O
the O
p50 B
of O
NF B
- I
GM2 I
, O
indicating O
that O
the O
NF O
- O
GM2 O
polypeptide O
can O
not O
be O
immunologically O
differentiated O
from O
the O
50 O
kDa O
subunit O
of O
NF B
- I
kappa I
B I
. O

This O
suggests O
that O
the O
activation O
mechanism O
of O
the O
GM B
- I
CSF I
gene I
through O
the O
GM2 O
/ O
GC O
- O
box O
sequence O
is O
different O
from O
that O
of O
genes O
carrying O
the O
kappa B
B I
enhancer I
alone O
. O

Characterization O
of O
an O
immediate B
- I
early I
gene I
induced O
in O
adherent O
monocytes O
that O
encodes O
I B
kappa I
B I
- O
like O
activity O
. O

The O
C B
- I
terminus I
has O
a O
putative O
protein O
kinase O
C O
phosphorylation O
site O
. O

A O
DNA O
probe O
that O
spanned O
a O
domain O
conserved O
among O
the O
proto B
- I
oncogene I
c I
- I
rel I
, O
the O
Drosophila O
morphogen O
dorsal O
, O
and O
the O
p50 B
DNA I
binding I
subunit I
of O
NF B
- I
kappa I
B I
was O
generated O
from O
Jurkat O
T O
cell O
complementary O
DNA O
with O
the O
polymerase O
chain O
reaction O
( O
PCR O
) O
and O
degenerate O
oligonucleotides O
. O

In O
vitro O
transcription O
and O
translation O
of O
the O
complementary B
DNA I
resulted O
in O
the O
synthesis O
of O
a O
protein O
with O
an O
apparent O
molecular O
size O
of O
65 O
kilodaltons O
( O
kD O
) O
. O

This O
protein B
- I
DNA I
complex I
comigrated O
with O
the O
complex O
obtained O
with O
the O
purified O
human O
p65 O
NF O
- O
kappa O
B O
subunit O
and O
binding O
was O
inhibited O
by O
I B
kappa I
B I
- I
alpha I
and O
- O
beta O
proteins O
. O

Regulation O
of O
M B
- I
CSF I
expression O
by O
M B
- I
CSF I
: O
role O
of O
protein B
kinase I
C I
and O
transcription B
factor I
NF I
kappa I
B I
. O

To O
date O
, O
little O
is O
known O
about O
the O
intracellular O
pathway O
of O
M B
- I
CSF I
signal O
transduction O
. O

The O
pAT B
133 I
gene I
is O
immediately O
induced O
, O
with O
FOS B
- O
like O
kinetics O
, O
in O
human O
T O
cells O
and O
in O
fibroblasts O
. O

v B
- I
erbA I
overexpression O
is O
required O
to O
extinguish O
c B
- I
erbA I
function O
in O
erythroid O
cell O
differentiation O
and O
regulation O
of O
the O
erbA O
target O
gene O
CAII B
. O

The O
v B
- I
erbA I
oncoprotein I
represents O
a O
retrovirus O
- O
transduced O
oncogenic O
version O
of O
the O
thyroid O
hormone O
( O
T3 O
/ O
T4 O
) O
receptor O
c O
- O
erbA O
( O
type O
alpha O
) O
. O

This O
erbA O
- O
binding O
site O
confers O
thyroid O
hormone O
responsiveness O
to O
a O
heterologous B
promoter I
in O
transient O
expression O
experiments O
and O
is O
a O
target O
for O
efficient O
down O
- O
regulation O
of O
CAII B
transcription O
by O
the O
v B
- I
erbA I
oncoprotein I
. O

The O
effect O
is O
mediated O
by O
the O
NF B
- I
kappa I
B I
transcription B
factor I
which O
is O
potently O
and O
rapidly O
activated O
by O
an O
H2O2 O
treatment O
of O
cells O
from O
its O
inactive O
cytoplasmic O
form O
. O

ROI O
appear O
to O
serve O
as O
messengers O
mediating O
directly O
or O
indirectly O
the O
release O
of O
the O
inhibitory B
subunit I
I B
kappa I
B I
from O
NF B
- I
kappa I
B I
. O

Inhibition O
of O
transcription B
factors I
belonging O
to O
the O
rel B
/ I
NF I
- I
kappa I
B I
family I
by O
a O
transdominant B
negative I
mutant I
. O

A O
mutant O
of O
KBF1 B
/ I
p50 I
( O
delta B
SP I
) O
, O
unable O
to O
bind O
to O
DNA O
but O
able O
to O
form O
homo O
- O
or O
heterodimers B
, O
has O
been O
constructed O
. O

One O
gene O
of O
interest O
is O
the O
glycoprotein O
IIb O
( O
GPIIb O
) O
gene O
; O
GPIIb O
, O
the O
alpha B
subunit I
of O
the O
platelet O
cytoadhesin O
GPIIb O
- O
IIIa O
, O
is O
produced O
in O
megakaryocytes O
at O
an O
early O
stage O
of O
the O
differentiation O
, O
whereas O
the O
other O
subunit O
of O
this O
complex O
, O
GPIIIa O
, O
is O
expressed O
in O
other O
cells O
. O

No O
relationship O
could O
be O
established O
between O
glucocorticoid B
receptor I
binding O
and O
antidepressant O
medication O
. O

These O
data O
support O
the O
view O
of O
an O
impaired O
ligand O
- O
induced O
plasticity O
of O
glucocorticoid B
receptor I
regulation O
rather O
than O
the O
hypothesis O
of O
decreased O
glucocorticoid B
receptor I
numbers O
during O
depression O
. O

The O
promoters B
and O
enhancers B
of O
cell O
type O
- O
specific O
genes O
are O
often O
conserved O
in O
evolution O
, O
and O
hence O
one O
might O
expect O
that O
a O
given O
enhancer B
has O
evolved O
to O
work O
best O
with O
its O
own O
promoter B
. O

Circadian O
rhythm O
in O
glucocorticoid B
receptor I
( O
GR B
) O
was O
studied O
in O
the O
rat O
liver O
and O
human O
peripheral O
leukocytes O
. O

The O
conversion O
of O
the O
TCEd B
to O
a O
' O
perfect O
' O
NF O
- O
kB O
binding O
site O
leads O
to O
a O
tighter O
binding O
of O
NF B
- I
kB I
to O
TCEd B
DNA I
and O
, O
as O
a O
functional O
consequence O
, O
to O
the O
activity O
of O
the O
' O
converted O
' O
TCEd O
motifs O
in O
HeLa O
cells O
. O

A O
region O
upstream O
to O
the O
first O
exon O
, O
and O
highly O
conserved O
between O
mouse O
and O
man O
, O
acts O
as O
an O
erythroid O
specific O
enhancer O
in O
transient O
assays O
, O
if O
linked O
to O
the O
GATA B
- I
1 I
or O
to O
the O
SV40 O
promoter O
. O

More O
strikingly O
, O
the O
80 B
- I
kDa I
protein I
was O
downregulated O
in O
a O
dose O
- O
dependent O
fashion O
by O
1 O
, O
25 O
( O
OH O
) O
2D3 O
; O
this O
effect O
was O
independent O
of O
the O
mode O
of O
lymphocyte O
activation O
and O
specific O
for O
the O
1 O
, O
25 O
( O
OH O
) O
2D3 O
metabolite O
of O
vitamin O
D3 O
. O

Prolonged O
corticosteroid O
treatment O
resulted O
in O
down O
- O
regulation O
of O
GcR B
, O
while O
the O
mean O
level O
of O
GcR B
in O
Cushing O
' O
s O
disease O
was O
normal O
. O

Furthermore O
, O
GcR B
were O
unaltered O
after O
these O
patients O
received O
ketoconazole O
, O
in O
spite O
of O
a O
marked O
reduction O
in O
morning O
plasma O
cortisol O
and O
urinary O
free O
cortisol O
. O

Previously O
, O
transcription O
of O
the O
c B
- I
fos I
gene I
has O
been O
reported O
to O
be O
transactivated O
by O
the O
viral O
transcription O
factor O
, O
Tax1 B
. O

Glucocorticoid B
receptor I
characteristics O
in O
monocytes O
of O
patients O
with O
corticosteroid O
- O
resistant O
bronchial O
asthma O
. O

Vitamin B
D I
receptor I
expression O
in O
human O
lymphocytes O
. O

However O
, O
combination O
of O
OKT3 B
and O
phorbol O
myristate O
acetate O
produced O
a O
concentration O
of O
binding O
sites O
similar O
to O
the O
PHA O
- O
activated O
cells O
. O

The O
receptor O
from O
OKT3 B
and O
OKT3 B
+ O
phorbol O
myristate O
acetate O
- O
activated O
lymphocytes O
exhibited O
decreased O
binding O
to O
DNA O
- O
cellulose O
compared O
to O
PHA O
- O
activated O
lymphocytes O
. O

In O
lymphocytes O
activated O
either O
by O
PHA B
or O
OKT3 B
( O
but O
not O
in O
resting O
cells O
) O
, O
a O
50 O
- O
kDa O
species O
cross O
- O
reacting O
with O
a O
monoclonal B
antibody I
against O
the O
intestinal O
vitamin O
D O
receptor O
was O
detected O
. O

Finally O
, O
RNA O
from O
activated O
lymphocytes O
was O
amplified O
by O
polymerase O
chain O
reaction O
using O
oligonucleotide O
primers O
flanking O
the O
196 O
base O
pair O
long O
region O
encoding O
the O
DNA B
- I
binding I
domain I
of O
the O
human B
intestinal I
receptor I
. O

These O
findings O
suggest O
that O
expression O
of O
the O
1 B
, I
25 I
- I
( I
OH I
) I
2D3 I
receptor I
in O
lymphocytes O
is O
triggered O
by O
distinct O
and O
contingent O
signals O
, O
and O
that O
the O
protein O
and O
the O
mRNA B
encoding O
it O
are O
identical O
to O
the O
classical B
vitamin I
D I
receptor I
. O

The O
kappa B
B I
sequence I
( O
GGGACTTTCC O
) O
binds O
a O
factor O
, O
NF B
- I
kappa I
B I
, O
that O
is O
constitutively O
found O
in O
its O
functional O
, O
DNA O
binding O
form O
only O
in O
B O
lymphocytes O
. O

However O
, O
in O
either O
EL O
- O
4 O
( O
T O
) O
cells O
or O
S194 O
cells O
, O
both O
lower O
- O
affinity O
sites O
can O
be O
significantly O
induced O
by O
the O
tax B
gene I
product I
of O
human O
T O
- O
cell O
leukemia O
virus O
type O
I O
, O
showing O
that O
NF B
- I
kappa I
B I
activity O
can O
be O
modulated O
even O
in O
a O
B O
- O
cell O
line O
that O
constitutively O
expresses O
this O
factor O
. O

Previously O
, O
a O
nuclear B
factor I
, O
IRF B
- I
1 I
( O
interferon B
regulatory I
factor I
1 I
) O
, O
which O
binds O
to O
type O
I O
IFN O
and O
some O
IFN O
- O
inducible O
gene O
promoters O
, O
was O
identified O
and O
cloned O
. O

A O
dimerization O
cofactor O
of O
HNF B
- I
1 I
alpha I
( O
DCoH B
) O
was O
identified O
that O
displayed O
a O
restricted O
tissue O
distribution O
and O
did O
not O
bind O
to O
DNA O
, O
but O
, O
rather O
, O
selectively O
stabilized O
HNF O
- O
1 O
alpha O
dimers O
. O

The O
nuclear O
extracts O
from O
resting O
and O
induced O
ML O
- O
1 O
cells O
contain O
proteins O
binding O
specifically O
to O
the O
AP O
- O
1 O
, O
AP O
- O
2 O
, O
and O
NF O
kappa O
B O
sequence O
located O
within O
the O
TNF B
promoter I
. O

Transforming B
growth I
factor I
- I
beta I
suppresses O
human O
B O
lymphocyte O
Ig O
production O
by O
inhibiting O
synthesis O
and O
the O
switch O
from O
the O
membrane B
form I
to O
the O
secreted O
form O
of O
Ig B
mRNA I
. O

The O
murine O
and O
human O
factors O
are O
abundantly O
expressed O
in O
a O
variety O
of O
human O
and O
murine O
T O
- O
cell O
lines O
and O
can O
activate O
transcription O
through O
a O
tissue O
- O
specific O
GATA O
- O
binding O
site O
identified O
within O
the O
human B
T I
- I
cell I
receptor I
delta I
gene I
enhancer I
. O

The O
expression O
of O
active O
NF B
- I
kappa I
B I
might O
therefore O
also O
be O
regulated O
by O
the O
extent O
of O
processing O
of O
p105 B
. O

Levels O
of O
RNA O
coding O
for O
the O
receptor B
were O
not O
modulated O
by O
exposure O
to O
high O
levels O
of O
ligand O
. O

We O
have O
found O
that O
purified O
human O
peripheral O
- O
blood O
granulocytes O
express O
constitutively O
significant O
levels O
of O
proto B
- I
oncogenes I
c O
- O
jun O
, O
jun O
B O
and O
jun O
D O
mRNA O
. O

The O
29 B
- I
kDa I
proteins I
phosphorylated O
in O
thrombin O
- O
activated O
human O
platelets O
are O
forms O
of O
the O
estrogen O
receptor O
- O
related O
27 O
- O
kDa O
heat O
shock O
protein O
. O

We O
have O
isolated O
a O
human O
cDNA O
clone O
encoding O
a O
zinc O
finger O
protein O
( O
NF B
- I
E1 I
) O
that O
binds O
to O
the O
negative O
- O
acting O
segment O
of O
the O
kappa B
E3 I
' I
enhancer I
. O

NF B
- I
E1 I
is O
also O
the O
human B
homologue I
of O
the O
mouse O
delta O
protein O
, O
which O
binds O
to O
ribosomal O
protein O
gene O
promoters O
. O

Cotransfection O
studies O
with O
this O
cDNA B
indicate O
that O
it O
can O
repress O
basal B
promoter I
activity O
. O

There O
is O
a O
suitably O
located O
TATA B
box I
, O
but O
potential O
sites O
for O
CCAAT O
- O
box O
binding O
factors O
are O
far O
upstream O
, O
embedded O
in O
a O
42 O
- O
nucleotide O
repeat O
element O
. O

HIV B
- I
TF1 I
had O
a O
molecular O
weight O
of O
39 O
, O
000 O
. O

The O
activity O
of O
dihydropyrimidine B
dehydrogenase I
( O
DPD B
) O
, O
the O
initial O
enzyme B
of O
pyrimidine O
( O
and O
FUra O
) O
catabolism O
, O
in O
peripheral O
blood O
mononuclear O
cells O
was O
measured O
in O
each O
subject O
by O
a O
specific O
radiometric O
assay O
using O
FUra O
as O
the O
substrate O
. O

Monitoring O
DPD B
activity O
may O
be O
important O
in O
the O
management O
of O
patients O
experiencing O
severe O
toxicity O
secondary O
to O
FUra O
chemotherapy O
. O

The O
human O
T O
cell O
- O
specific O
transcription O
factor O
TCF B
- I
1 I
alpha I
plays O
a O
key O
role O
in O
the O
tissue O
- O
specific O
activation O
of O
the O
T B
cell I
receptor I
( O
TCR B
) O
C O
alpha O
enhancer O
and O
binds O
to O
pyrimidine O
- O
rich O
elements O
( O
5 O
' O
- O
PyCTTTG O
- O
3 O
' O
) O
present O
in O
a O
variety O
of O
other O
T O
cell O
- O
specific O
control O
regions O
. O

TCF B
- I
1 I
alpha I
is O
currently O
unique O
among O
the O
newly O
emerging O
family O
of O
DNA O
- O
binding O
regulatory O
proteins O
that O
share O
the O
HMG O
motif O
in O
that O
it O
is O
a O
highly O
tissue O
- O
specific O
RNA O
polymerase O
II O
transcription B
factor I
. O

We O
describe O
the O
isolation O
and O
characterization O
of O
multiple O
cDNAs O
encoding O
mouse O
Oct2 O
from O
a O
mature O
B O
- O
cell O
line O
and O
we O
show O
that O
a O
variety O
of O
isoforms O
of O
this O
transcription B
factor I
is O
generated O
from O
a O
single O
gene O
by O
an O
alternative O
splicing O
mechanism O
. O

Different O
amounts O
of O
the O
various O
isoforms B
are O
present O
within O
the O
same O
B O
- O
cell O
regardless O
of O
the O
developmental O
stage O
of O
B O
- O
cell O
differentiation O
and O
at O
least O
some O
of O
the O
isoforms B
are O
conserved O
between O
mouse O
and O
humans O
. O

In O
cotransfection O
experiments O
we O
show O
that O
all O
the O
isoforms B
are O
able O
to O
activate O
an O
octamer B
containing O
promoter B
element I
in O
fibroblasts O
revealing O
an O
unexpected O
functional O
redundancy O
. O

The O
decrease O
of O
the O
number O
of O
glucocorticoid B
receptors I
in O
patients O
with O
type O
IIa O
hyperlipidemia O
seems O
to O
be O
a O
compensatory O
response O
of O
cells O
culminating O
in O
activation O
of O
endogenous O
cholesterol O
synthesis O
. O

Thus O
, O
both O
NF B
- I
kappa I
B I
- I
binding I
complexes I
are O
needed O
for O
optimal O
viral O
transcription O
. O

Binding O
of O
the O
65 B
- I
kDa I
plus O
50 O
- O
kDa O
heterodimer O
to O
the O
HIV B
- I
1 I
enhancer I
can O
be O
negatively O
regulated O
in O
monocytes O
, O
providing O
one O
mechanism O
restricting O
HIV B
- I
1 I
gene I
expression O
. O

An O
age O
- O
related O
decrease O
in O
the O
number O
of O
GR B
was O
suggested O
between O
subjects O
younger O
than O
20 O
years O
and O
elderly O
subjects O
; O
there O
was O
no O
apparent O
seasonal O
variation O
in O
GR B
. O

Eight O
patients O
with O
dermatomyositis O
/ O
polymyositis O
were O
examined O
to O
determine O
whether O
the O
number O
of O
GR B
in O
MNL O
could O
be O
down O
- O
regulated O
by O
their O
cognate O
ligands O
. O

Formation O
of O
the O
protein B
- I
DNA I
complex I
with O
the O
C26 O
subfragment O
was O
positively O
affected O
by O
p40tax B
. O

Human O
tumor B
necrosis I
factor I
alpha I
gene O
regulation O
in O
phorbol O
ester O
stimulated O
T O
and O
B O
cell O
lines O
. O

Moreover O
, O
kappa O
1 O
- O
kappa O
3 O
can O
each O
be O
deleted O
from O
the O
TNF B
- I
alpha I
promoter I
with O
little O
effect O
on O
the O
gene O
' O
s O
inducibility O
by O
PMA O
. O

We O
have O
generated O
a O
monoclonal B
antibody I
, O
BZ1 B
, O
to O
BZLF1 B
which O
reacts O
in O
immunohistology O
, O
immunoblotting O
, O
and O
immunoprecipitation O
and O
which O
recognizes O
both O
the O
active O
, O
dimeric O
form O
and O
the O
inactive O
, O
monomeric O
form O
of O
the O
protein O
. O

The O
hormone B
receptors I
of O
the O
primary O
tumor O
were O
known O
in O
15 O
( O
ER B
) O
and O
14 O
( O
PR B
) O
patients O
, O
respectively O
. O

NF B
- I
kB I
is O
a O
eukaryotic O
transcription O
regulatory O
factor O
. O

[ O
Regulatory O
effect O
of O
insulin B
on O
glucocorticoid B
receptor I
in O
human O
peripheral O
leukocytes O
] O

After O
3 O
h O
incubation O
the O
specific O
binding O
power O
with O
[ O
3H O
] O
Dex O
was O
decreased O
by O
23 O
. O
3 O
+ O
/ O
- O
10 O
. O
0 O
, O
32 O
. O
2 O
+ O
/ O
- O
13 O
. O
2 O
and O
54 O
. O
3 O
+ O
/ O
- O
9 O
. O
2 O
% O
( O
P O
greater O
than O
0 O
. O
05 O
, O
P O
greater O
than O
0 O
. O
05 O
and O
P O
less O
than O
0 O
. O
01 O
as O
compared O
with O
the O
control O
value O
of O
100 O
in O
the O
absence O
of O
insulin B
) O
respectively O
in O
the O
presence O
of O
20 O
mU O
/ O
L O
( O
physiological O
testing O
concentration O
) O
, O
200 O
mU O
/ O
L O
( O
physiological O
upper O
limit O
) O
and O
2 O
, O
000 O
mU O
/ O
L O
( O
pharmacological O
concentration O
) O
insulin O

Moreover O
, O
M B
- I
CSF I
- O
induced O
expression O
of O
the O
fos O
- O
related O
gene O
, O
fra B
- I
1 I
, O
was O
delayed O
compared O
to O
that O
for O
both O
c B
- I
fos I
and O
fos B
- I
B I
. O

The O
insertion O
of O
multiple O
copies O
of O
the O
binding B
site I
for O
the O
former O
or O
latter O
factor O
into O
a O
heterologous B
promoter I
reduced O
the O
promoter O
activity O
to O
one O
- O
tenth O
or O
one O
- O
third O
, O
respectively O
. O

Other O
cellular O
parameters O
, O
such O
as O
glycosidase O
activities O
, O
cytokine B
release O
, O
and O
filament O
expression O
, O
returned O
to O
levels O
similar O
to O
that O
observed O
in O
uninduced O
cells O
. O

Levels O
of O
c O
- O
fos O
and O
c O
- O
jun O
transcripts O
remained O
elevated O
during O
periods O
of O
PKC B
activation O
and O
also O
returned O
to O
levels O
observed O
in O
control O
cells O
by O
30 O
- O
36 O
days O
, O
when O
the O
cells O
entered O
retrodifferentiation O
. O

DNA O
binding O
by O
all O
four O
of O
these O
Rel O
- O
related O
factors O
is O
blocked O
by O
selective O
chemical O
modification O
of O
lysine O
and O
arginine O
residues O
, O
suggesting O
that O
both O
of O
these O
basic O
amino O
acids O
are O
required O
for O
binding O
to O
the O
kappa B
B I
element I
. O

In O
contrast O
, O
mild O
oxidation O
with O
glucose O
oxidase O
selectively O
inhibits O
p75 B
and O
p85 B
binding O
while O
not O
blocking O
p50 B
and O
p55 B
interactions O
. O

[ O
Changes O
in O
leucocytic O
estrogen B
receptor I
levels O
in O
patients O
with O
climacteric O
syndrome O
and O
therapeutic O
effect O
of O
liuwei O
dihuang O
pills O
] O

The O
numbers O
of O
estrogen B
receptor I
( O
ER B
) O
in O
human O
peripheral O
leucocytes O
in O
22 O
women O
with O
climacteric O
syndrome O
were O
measured O
by O
radioligand O
method O
. O

In O
addition O
, O
cell B
- I
free I
synthesized I
hGR I
was O
capable O
of O
specific O
binding O
to O
glucocorticoid O
response O
element O
( O
GRE O
) O
- O
containing O
DNA O
fragments O
. O

Addition O
of O
KCl O
resulted O
in O
less O
DNA O
binding O
either O
due O
to O
blockage O
of O
DNA O
- O
receptor B
complex I
formation O
or O
disruption O
of O
the O
complexes O
. O

Oligonucleotides O
containing O
the O
consensus O
GRE O
were O
the O
most O
efficient O
competitors O
, O
and O
fragments O
containing O
regulatory B
sequences I
from O
glucocorticoid O
- O
repressible O
genes O
were O
somewhat O
competitive O
, O
whereas O
single O
stranded O
oligonucleotides O
were O
unable O
to O
compete O
for O
mouse B
mammary I
tumor I
virus I
- I
long I
terminal I
repeat I
DNA O
binding O
, O
except O
when O
competitor O
was O
present O
at O
extremely O
high O
concentrations O
. O

Expression O
of O
1 B
, I
25 I
( I
OH I
) I
2D3 I
receptors I
on O
alveolar O
lymphocytes O
from O
patients O
with O
pulmonary O
granulomatous O
diseases O
. O

1 B
, I
25 I
( I
OH I
) I
2D3 I
receptors I
were O
expressed O
to O
a O
greater O
extent O
on O
CD8 O
+ O
T O
- O
lymphocytes O
than O
on O
CD4 O
+ O
T O
- O
lymphocytes O
in O
sarcoidosis O
, O
whereas O
a O
greater O
proportion O
of O
CD4 O
+ O
than O
of O
CD8 O
+ O
T O
- O
lymphocytes O
from O
patients O
with O
tuberculosis O
were O
receptor O
- O
positive O
. O

Role O
for O
the O
Epstein B
- I
Barr I
virus I
nuclear I
antigen I
2 I
in O
viral B
promoter I
switching O
during O
initial O
stages O
of O
infection O
. O

These O
studies O
have O
been O
extended O
to O
show O
that O
( O
i O
) O
a O
mutant O
EBV O
strain O
lacking O
the O
gene O
encoding O
EBNA B
2 I
fails O
to O
switch O
from O
Wp O
to O
Cp B
usage O
in O
primary O
B O
lymphocytes O
, O
although O
the O
virus O
contains O
a O
functional O
Cp B
; O
( O
ii O
) O
a O
region O
from O
- O
429 O
to O
- O
245 O
base O
pairs O
upstream O
of O
Cp B
is O
essential O
for O
Cp B
activity O
in O
B O
lymphocytes O
, O
but O
only O
in O
the O
context O
of O
upstream B
and I
downstream I
sequences I
; O
( O
iii O
) O
this O
region O
contains O
an O
EBNA B
2 I
- I
dependent I
enhancer I
; O
and O
( O
iv O
) O
DNase B
I I
protection O
employing O
nuclear O
extracts O
from O
B O
and O

T O
lymphocytes O
revealed O
a O
B O
- O
cell O
- O
specific O
footprint O
in O
the O
region O
of O
the O
EBNA B
2 I
- I
dependent I
enhancer I
. O

Five O
T O
- O
cell O
clones O
specific O
for O
a O
T O
- O
cell O
epitope O
located O
at O
the O
carboxyterminal O
region O
of O
HBxAg B
were O
established O
and O
found O
to O
belong O
to O
the O
CD2 O
/ O
CD4 O
- O
positive O
, O
CD8 O
- O
negative O
subtype O
. O

[ O
Changes O
in O
leucocytic B
estrogen I
receptor I
levels O
in O
patients O
with O
gynecomastia O
] O

The O
NF O
kappa O
B O
independent O
cis O
- O
acting O
sequences O
in O
HIV B
- I
1 I
LTR I
responsive O
to O
T O
- O
cell O
activation O
. O

The O
rate O
of O
transcription O
initiation O
directed O
by O
the O
long B
terminal I
repeat I
( O
LTR O
) O
of O
HIV O
- O
1 O
increases O
in O
response O
to O
mitogenic O
stimuli O
of O
T O
cells O
. O

The O
rate O
of O
LTR B
- O
directed O
gene O
expression O
increased O
in O
response O
to O
treatment O
with O
either O
a O
phorbol O
ester O
or O
tumor B
necrosis I
factor I
alpha I
if O
either O
the O
NFAT B
- I
1 I
or O
NF B
kappa I
B I
binding I
sites I
were O
deleted O
, O
but O
failed O
to O
respond O
to O
these O
mitogenic O
stimuli O
if O
both O
sequences O
were O
absent O
. O

Activation O
of O
proenkephalin O
transcription O
by O
JunD B
is O
dependent O
upon O
a O
previously O
characterized O
cAMP O
- O
, O
phorbol O
ester O
- O
, O
and O
Ca O
( O
2 O
+ O
) O
- O
inducible O
enhancer O
, O
and O
JunD B
is O
shown O
to O
bind O
the O
enhancer B
as O
a O
homodimer B
. O

Plasma O
cortisol O
concentration O
and O
blood O
leukocyte O
content O
of O
glucocorticoid B
receptors I
( O
GCR B
) O
were O
assayed O
in O
20 O
patients O
with O
deficiency O
syndromes O
, O
10 O
cold O
in O
property O
( O
deficiency O
- O
cold O
) O
, O
the O
other O
10 O
hot O
in O
property O
( O
deficiency O
- O
heat O
) O
, O
and O
also O
in O
10 O
healthy O
individuals O
as O
normal O
control O
for O
the O
purpose O
of O
investigating O
the O
nature O
of O
cold O
and O
heat O
syndromes O
. O

This O
tight O
correlation O
between O
c B
- I
jun I
expression O
, O
the O
generation O
of O
AP B
- I
1 I
activity O
, O
and O
differentiation O
suggests O
a O
critical O
role O
for O
this O
gene O
and O
transcriptional B
complex I
during O
this O
process O
. O

A O
transcription B
factor I
, O
NF B
- I
AT I
, O
which O
is O
essential O
for O
early O
T O
- O
cell O
gene O
activation O
, O
seems O
to O
be O
a O
specific O
target O
of O
cyclosporin O
A O
and O
FK506 O
action O
because O
transcription O
directed O
by O
this O
protein O
is O
blocked O
in O
T O
cells O
treated O
with O
these O
drugs O
, O
with O
little O
or O
no O
effect O
on O
other O
transcription B
factors I
such O
as O
AP B
- I
1 I
and O
NF B
- I
kappa I
B I
. O

Glucocorticoid B
receptors I
in O
lymphocytes O
in O
anorexia O
nervosa O
. O

CONCLUSIONS O
Hypercortisolaemia O
does O
not O
down O
- O
regulate O
the O
lymphocyte O
glucocorticoid B
receptors I
in O
anorexia O
nervosa O
and O
a O
post O
- O
receptor O
defect O
might O
be O
involved O
in O
peripheral O
tissue O
resistance O
to O
the O
effects O
of O
glucocorticoid O
hormones O
in O
undernutrition O
. O

The O
induction O
of O
AP1 B
by O
okadaic O
acid O
suggests O
that O
protein B
phosphatases I
1 I
and I
2A I
( O
PP1 B
and O
PP2A B
) O
may O
be O
involved O
in O
T O
cell O
activation O
as O
important O
negative O
regulators O
of O
the O
transcription B
factor I
AP1 B
. O

CD3 B
- O
epsilon O
gene O
expression O
is O
confined O
to O
the O
T O
cell O
lineage O
. O

TCF B
- I
1 I
belonged O
to O
a O
novel O
family O
of O
genes O
that O
contain O
the O
so O
- O
called O
high O
mobility O
group O
1 O
( O
HMG O
) O
box O
. O

Two O
splice O
alternatives O
were O
identified O
that O
were O
not O
previously O
observed O
in O
human B
TCF I
- I
1 I
. O

Third O
, O
TCF B
- I
1 I
bound O
specifically O
to O
a O
functional O
T O
cell O
- O
specific O
element O
in O
the O
T B
cell I
receptor I
alpha I
( I
TCR I
- I
alpha I
) I
enhancer I
. O

There O
is O
a O
single O
methionine O
codon O
- O
initiated O
open O
reading O
frame O
of O
1 O
, O
458 O
nt O
in O
frame O
with O
a O
homeobox O
and O
a O
CAX O
repeat O
, O
and O
the O
open B
reading I
frame I
is O
predicted O
to O
encode O
a O
protein O
of O
51 O
, O
659 O
daltons O
. O

Characterization O
of O
HB24 B
expression O
in O
lymphoid O
and O
select O
developing O
tissues O
was O
performed O
by O
in O
situ O
hybridization O
. O

Platelet B
- I
activating I
factor I
induces O
phospholipid O
turnover O
, O
calcium O
flux O
, O
arachidonic O
acid O
liberation O
, O
eicosanoid O
generation O
, O
and O
oncogene B
expression O
in O
a O
human O
B O
cell O
line O
. O

Tandem O
copies O
of O
this O
67 O
- O
bp O
MnlI O
- O
AluI O
fragment O
, O
when O
fused O
to O
the O
chloramphenicol B
acetyltransferase I
gene I
driven O
by O
the O
conalbumin O
promoter O
, O
stimulated O
transcription O
in O
B O
cells O
but O
not O
in O
Jurkat O
T O
cells O
or O
HeLa O
cells O
. O

Gel O
mobility O
shift O
assays O
using O
a O
synthetic O
E6 O
motif O
detected O
a O
B B
- I
cell I
- I
specific I
complex I
in O
addition O
to O
a O
ubiquitous O
band O
found O
also O
in O
T O
cells O
and O
HeLa O
cells O
. O

Interestingly O
, O
the O
MnlI B
- I
AluI I
fragment I
could O
suppress O
the O
basal O
- O
level O
activity O
of O
the O
conalbumin O
promoter O
in O
both O
Jurkat O
and O
HeLa O
cells O
. O

The O
involvement O
of O
ion O
channels O
in O
B O
and O
T O
lymphocyte O
activation O
is O
supported O
by O
many O
reports O
of O
changes O
in O
ion O
fluxes O
and O
membrane O
potential O
after O
mitogen B
binding O
. O

However O
, O
blockade O
of O
the O
Ca O
( O
2 O
+ O
) O
- O
activated O
K O
+ O
channel O
is O
not O
associated O
with O
changes O
in O
cell O
- O
cycle O
gene O
activation O
, O
IL B
- I
2 I
production O
, O
IL B
- I
2R I
expression O
or O
B O
and O
T O
cell O
mitogenesis O
. O

From O
information O
available O
in O
the O
literature O
on O
the O
substrate O
specificity O
of O
the O
three O
enzymes B
, O
it O
is O
clear O
that O
a O
cysteine O
is O
not O
accepted O
in O
any O
of O
the O
S2 O
, O
S1 O
, O
S1 O
' O
, O
and O
S2 O
' O
subsites O
of O
cathepsin O
B O
and O
L O
, O
and O
not O
in O
the O
S1 O
and O
S1 O
' O
subsites O
of O
cathepsin O
D O
. O

Starting O
with O
a O
replication O
- O
incompetent O
molecular O
clone O
of O
human O
immunodeficiency O
virus O
type O
1 O
, O
lacking O
all O
the O
NF O
- O
kappa O
B O
and O
Sp1 O
binding O
sites O
present O
in O
the O
native O
long O
terminal O
repeat O
( O
LTR B
) O
, O
proviruses O
containing O
reconstructed O
LTRs O
with O
individual O
or O
combinations O
of O
NF O
- O
kappa O
B O
and O
Sp1 O
elements O
were O
generated O
and O
evaluated O
for O
their O
capacity O
to O
produce O
virus O
progeny O
following O
transfection O
- O
cocultivation O
. O

The O
human O
interferon O
beta O
( O
IFN O
- O
beta O
) O
regulatory O
element O
consists O
of O
multiple O
enhanson O
domains O
which O
are O
targets O
for O
transcription B
factors I
involved O
in O
inducible O
expression O
of O
the O
promoter B
. O

A O
2 O
- O
4 O
- O
fold O
increase O
in O
IFN B
- I
beta I
promoter I
transcription O
was O
observed O
in O
Sendai O
virus O
induced O
extracts O
, O
and O
deletion O
of O
PRDI O
and O
PRDII O
elements O
decreased O
this O
induced O
level O
of O
transcription O
. O

Human O
and O
mouse O
Rhom O
- O
2 O
are O
highly O
conserved O
and O
, O
like O
rhombotin B
, O
encode O
two O
tandem O
cysteine O
- O
rich O
LIM O
domains O
. O

NF B
- I
kappa I
B I
activation O
by O
tumor B
necrosis I
factor I
alpha I
in O
the O
Jurkat O
T O
cell O
line O
is O
independent O
of O
protein B
kinase I
A I
, O
protein B
kinase I
C I
, O
and O
Ca B
( I
2 I
+ I
) I
- I
regulated I
kinases I
. O

Furthermore O
, O
while O
PMA O
activation O
was O
inhibited O
by O
the O
PKC B
inhibitor O
staurosporin O
, O
the O
TNF B
alpha I
effect O
was O
unchanged O
. O

Mutations O
at O
the O
B2 B
site O
abolish O
this O
transcriptional O
activation O
. O

The O
purified O
homodimer B
( O
two O
p50s O
) O
of O
the O
DNA B
- I
binding I
subunit I
of O
NF B
- I
kappa I
B I
binds O
the O
B2 B
site O
of O
proenkephalin O
relatively O
better O
than O
does O
the O
heterotetramer O
( O
two O
p65s O
plus O
two O
p50s O
) O
form O
of O
the O
factor O
. O

However O
, O
as O
NF B
- I
kappa I
B I
is O
ubiquitous O
and O
the O
transcriptional O
activation O
through O
the O
B2 B
site O
is O
T O
cell O
specific O
, O
yet O
another O
T B
- I
cell I
- I
specific I
factor I
which O
synergizes O
with O
NF B
- I
kappa I
B I
should O
be O
considered O
. O

In O
nuclear O
extracts O
from O
monocytes O
or O
macrophages O
, O
induction O
of O
NF B
- I
KB I
occurred O
only O
if O
the O
cells O
were O
previously O
infected O
with O
HIV O
- O
1 O
. O

These O
results O
indicate O
that O
in O
monocytic O
cell O
lineage O
, O
HIV O
- O
1 O
could O
mimic O
some O
differentiation O
/ O
activation O
stimuli O
allowing O
nuclear O
NF B
- I
KB I
expression O
. O

The O
fusion O
cDNA O
results O
from O
an O
interstitial O
deletion O
between O
a O
previously O
unknown O
locus O
, O
SIL O
( O
SCL O
interrupting O
locus O
) O
, O
and O
the O
5 B
' I
untranslated I
region I
of O
SCL B
. O

This O
was O
compared O
with O
the O
TREp B
binding O
of O
reticulocyte O
lysate O
- O
synthesized O
TRs O
. O

Incubation O
of O
each O
of O
the O
TRs B
with O
NE O
from O
COS O
- O
7 O
cells O
, O
which O
do O
not O
possess O
sufficient O
endogenous O
TRs B
to O
mediate O
T3 O
- O
responses O
, O
resulted O
in O
formation O
of O
a O
new O
, O
more O
greatly O
shifted O
complex O
. O

Cell O
- O
specific O
differences O
in O
activation O
of O
NF O
- O
kappa O
B O
regulatory O
elements O
of O
human O
immunodeficiency O
virus O
and O
beta O
interferon O
promoters O
by O
tumor B
necrosis I
factor I
. O

Functional O
analysis O
of O
cis O
- O
linked O
regulatory O
sequences O
in O
the O
HLA B
DRA I
promoter I
by O
transcription O
in O
vitro O
. O

A O
closely O
related O
( O
if O
not O
identical O
) O
protein O
is O
found O
in O
both O
a O
human O
megakaryocytic O
cell O
line O
and O
purified O
human O
megakaryocytes O
; O
it O
binds O
to O
promoter B
regions I
of O
two O
megakaryocytic O
- O
specific O
genes O
. O

Furthermore O
, O
point O
mutations O
that O
abolish O
binding O
of O
NF B
- I
E1 I
result O
in O
a O
70 O
% O
decrease O
in O
the O
transcriptional O
activity O
of O
a O
megakaryocytic O
- O
specific O
promoter O
. O

Transcriptional O
down O
- O
regulation O
of O
c B
- I
myc I
expression O
by O
protein O
synthesis O
- O
dependent O
and O
- O
independent O
pathways O
in O
a O
human O
T O
lymphoblastic O
tumor O
cell O
line O
. O

In O
30 O
of O
these O
cases O
ER B
enzyme O
immunoassay O
( O
ER B
- O
EIA O
) O
was O
also O
performed O
. O

Type B
- I
II I
estrogen I
- I
binding I
sites I
( O
type B
- I
II I
EBS I
) O
have O
been O
demonstrated O
in O
the O
human O
lymphoblastoid O
cell O
line O
IM O
- O
9 O
using O
a O
whole O
- O
cell O
assay O
with O
( O
6 O
, O
7 O
- O
3H O
) O
estradiol O
( O
3H O
- O
E2 O
) O
as O
tracer O
. O

The O
relative O
binding O
affinity O
of O
quercetin O
, O
rutin O
, O
DES O
and O
TAM O
for O
type B
- I
II I
EBS I
correlated O
well O
with O
their O
potency O
as O
cell O
growth O
inhibitors O
. O

Moreover O
, O
hesperidin O
, O
a O
flavonoid O
which O
does O
not O
bind O
to O
type B
- I
II I
EBS I
, O
was O
ineffective O
in O
inhibiting O
cell O
growth O
. O

[ O
Glucocorticoid B
receptors I
in O
peripheral O
blood O
lymphocytes O
of O
patients O
with O
bronchial O
asthma O
] O

Quantitation O
of O
glucocorticoid B
receptors I
( O
GCR B
) O
and O
the O
study O
of O
their O
affinity O
for O
glucocorticosteroids O
( O
GCS O
) O
were O
made O
in O
peripheral O
blood O
lymphocytes O
of O
bronchial O
asthma O
( O
BA O
) O
patients O
in O
consideration O
of O
GCR B
treatment O
and O
serum O
levels O
of O
endogenous O
cortisol O
. O

Two O
glucocorticoid B
binding I
sites I
on O
the O
human B
glucocorticoid I
receptor I
. O

These O
data O
indicate O
that O
CVZ O
is O
recognizing O
two O
glucocorticoid B
binding I
sites I
on O
the O
human O
GR B
or O
a O
protein O
very O
similar O
to O
it O
. O

Retroviral O
mediated O
transfer O
and O
expression O
of O
exogenous O
genes O
in O
primary O
lymphoid O
cells O
: O
assaying O
for O
a O
viral O
transactivator B
activity O
in O
normal O
and O
malignant O
cells O
. O

Incidence O
of O
HLA B
antigens I
was O
determined O
in O
94 O
of O
them O
. O

Several O
mutants O
derived O
from O
transformed O
human O
B O
cell O
lines O
are O
defective O
in O
expressing O
major B
histocompatibility I
complex I
( I
MHC I
) I
class I
II I
genes I
. O

ER B
content O
in O
lymphocytes O
of O
each O
sample O
was O
expressed O
by O
both O
fmol O
/ O
mg O
of O
lymphocyte O
cytosolic O
protein O
and O
fmol O
/ O
micrograms O
of O
lymphocyte O
DNA O
. O

The O
results O
showed O
that O
there O
was O
no O
significant O
difference O
between O
the O
ER B
content O
of O
lymphocytes O
from O
the O
controls O
and O
that O
from O
patients O
with O
SLE O
. O

We O
used O
mouse O
embryonic O
stem O
( O
ES O
) O
cells O
to O
study O
globin B
gene I
expression O
and O
switching O
in O
vitro O
. O

When O
the O
human O
epsilon O
- O
or O
beta O
- O
globin O
genes O
driven O
by O
the O
dominant O
control O
region O
( O
DCR O
) O
are O
introduced O
into O
this O
system O
, O
the O
human O
epsilon O
- O
globin O
gene O
, O
in O
contrast O
to O
the O
beta B
- I
globin I
gene I
, O
is O
not O
deregulated O
by O
the O
presence O
of O
the O
DCR O
and O
is O
expressed O
strictly O
as O
an O
embryonic O
gene O
. O

ZRE B
- I
B I
is O
therefore O
not O
part O
of O
the O
R O
- O
inducible O
enhancer O
. O

However O
, O
one O
palindrome O
, O
either O
alone O
or O
duplicated O
, O
or O
the O
overlapping B
palindromes I
did O
not O
respond O
to O
R O
. O

The O
clinical O
implications O
of O
nuclear O
T3R B
alterations O
of O
circulating O
lymphocytes O
in O
hyperthyroidism O
, O
hypothyroidism O
and O
nonthyroidal O
diseases O
were O
investigated O
. O

Binding O
and O
elution O
properties O
to O
DNA O
- O
cellulose O
, O
however O
, O
differed O
from O
normal O
in O
both O
Ro O
- O
VDR O
and O
A1 O
- O
VDR O
cells O
where O
elution O
from O
DNA O
- O
cellulose O
occurred O
at O
a O
lower O
salt O
concentration O
than O
is O
typical O
of O
the O
1 B
, I
25 I
( I
OH I
) I
2D3 I
receptor I
. O

We O
studied O
the O
effects O
of O
TPA O
on O
the O
regulation O
of O
c B
- I
jun I
gene O
expression O
in O
HL O
- O
60 O
cells O
during O
monocytic O
differentiation O
. O

[ O
Hormonal O
interactions O
and O
glucocorticoid B
receptors I
in O
patients O
with O
the O
nephrotic O
syndrome O
] O

These O
studies O
detected O
two O
novel O
domains O
referred O
to O
as O
L1 B
and O
L2 B
with O
a O
variety O
of O
lymphoid O
but O
not O
HeLa O
extracts O
. O

Characterization O
of O
defensin B
resistance O
phenotypes O
associated O
with O
mutations O
in O
the O
phoP O
virulence O
regulon O
of O
Salmonella O
typhimurium O
. O

The O
defensin B
sensitivities O
of O
Salmonella O
typhimurium O
strains O
with O
mutations O
in O
the O
phoP O
/ O
phoQ O
two O
- O
component O
virulence O
regulon O
were O
tested O
by O
using O
purified O
defensins O
NP B
- I
1 I
and O
NP O
- O
2 O
. O

The O
predicted O
periplasmic O
domain O
of O
the O
PhoQ B
protein I
contained O
a O
markedly O
anionic O
domain O
that O
could O
interact O
with O
cationic B
proteins I
and O
that O
could O
be O
responsible O
for O
resistance O
to O
defensin B
. O

This O
implied O
that O
a O
pag O
( O
phoP O
- O
activated O
gene O
) O
product O
is O
responsible O
for O
defensin B
resistance O
. O

Stimulation O
of O
a O
human O
T O
- O
cell O
clone O
with O
anti B
- I
CD3 I
or O
tumor B
necrosis I
factor I
induces O
NF B
- I
kappa I
B I
translocation O
but O
not O
human O
immunodeficiency O
virus O
1 O
enhancer O
- O
dependent O
transcription O
. O

The O
two O
latter O
signals O
were O
nevertheless O
able O
to O
induce O
NF B
- I
kappa I
B I
translocation O
with O
a O
pattern O
in O
the O
band O
- O
shift O
assay O
indistinguishable O
from O
that O
observed O
using O
phorbol O
ester O
. O

Two O
distinct O
forms O
of O
active O
transcription O
factor O
CREB O
( O
cAMP B
response I
element I
binding I
protein I
) O
. O

The O
two O
proteins O
differ O
by O
a O
14 O
- O
amino O
acid O
serine O
- O
rich O
insertion O
present O
in O
one O
of O
the O
CREB B
isoforms I
. O

Both O
proteins O
impart O
cAMP O
- O
regulated O
transcriptional O
activity O
to O
a O
heterologous B
DNA I
- I
binding I
domain I
, O
showing O
that O
cAMP O
directly O
modulates O
the O
transcriptional O
stimulatory O
activity O
of O
CREB B
. O

Competition O
experiments O
did O
not O
reveal O
any O
high B
- I
affinity I
binding I
site I
for O
BSAP B
in O
known O
regulatory B
regions I
of O
immunoglobulin O
and O
class O
II O
major O
histocompatibility O
( O
MHC O
) O
genes O
, O
suggesting O
that O
BSAP B
is O
a O
regulator O
of O
a O
different O
set O
of O
B O
- O
lymphoid O
- O
specific O
genes O
. O

It O
appears O
that O
the O
B O
cell O
- O
specific O
expression O
of O
Ig B
genes I
is O
mediated O
at O
least O
in O
part O
by O
cell O
type O
- O
specific O
Oct O
factors O
, O
and O
that O
there O
are O
both O
quantitative O
and O
qualitative O
differences O
between O
Oct B
- I
1 I
and O
Oct O
- O
2 O
factors O
. O

We O
find O
that O
the O
factor O
that O
binds O
to O
the O
E3 O
enhancer O
motif O
, O
CATGTGGC O
, O
is O
a O
ubiquitous B
transcription I
factor I
. O

However O
, O
despite O
its O
ability O
to O
activate O
transcription O
of O
a O
transfected B
reporter I
gene I
, O
the O
factor O
is O
apparently O
unable O
to O
bind O
to O
the O
endogenous B
Ig I
heavy I
chain I
enhancer I
in O
non O
- O
lymphoid O
cells O
: O
In O
previous O
experiments O
by O
others O
, O
the O
characteristic O
in O
vivo O
footprint O
of O
this O
factor O
, O
designated O
NF O
- O
muE3 O
, O
was O
detected O
in O
B O
cells O
but O
not O
in O
non O
- O
B O
cells O
. O

A O
study O
was O
made O
of O
adrenocortical O
function O
by O
measuring O
blood O
plasma O
cortisol O
concentration O
and O
amount O
of O
glucocorticoid B
receptors I
in O
lymphocytes O
as O
well O
as O
thyroid O
function O
by O
measuring O
blood O
plasma O
triidothyronine O
and O
thyroxine O
concentration O
in O
58 O
bronchial O
asthma O
children O
aged O
1 O
to O
14 O
years O
. O

TAR B
independent O
activation O
of O
the O
human O
immunodeficiency O
virus O
in O
phorbol O
ester O
stimulated O
T O
lymphocytes O
. O

Multiple O
regulatory O
elements O
in O
the O
human B
immunodeficiency I
virus I
long I
terminal I
repeat I
( O
HIV B
LTR I
) O
are O
required O
for O
activation O
of O
HIV O
gene O
expression O
. O

Results O
in O
all O
cell O
lines O
indicated O
that O
mutations O
of O
the O
SP1 B
, O
TATA B
and O
the O
TAR O
loop O
and O
stem O
secondary O
structure O
resulted O
in O
marked O
decreases O
in O
gene O
expression O
while O
mutations O
of O
the O
enhancer O
motif O
or O
TAR O
primary O
sequence O
resulted O
in O
only O
slight O
decreases O
. O

Induction O
of O
immediate B
early I
response I
genes I
by O
macrophage B
colony I
- I
stimulating I
factor I
in O
normal O
human O
monocytes O
. O

The O
c B
- I
jun I
gene I
expression O
was O
very O
transient O
and O
was O
not O
detectable O
by O
60 O
min O
after O
M B
- I
CSF I
addition O
. O

The O
protein O
synthesis O
inhibitor O
cycloheximide O
did O
not O
block O
the O
induction O
of O
any O
of O
these O
genes O
, O
and O
in O
fact O
, O
super O
- O
induced O
the O
expression O
of O
c B
- I
jun I
and O
hck B
. O

These O
genes O
may O
then O
play O
a O
role O
in O
altering O
the O
physiologic O
status O
of O
the O
cells O
in O
response O
to O
CSF B
. O

Inducible O
nuclear B
factor I
binding O
to O
the O
kappa B
B I
elements I
of O
the O
human B
immunodeficiency I
virus I
enhancer I
in O
T O
cells O
can O
be O
blocked O
by O
cyclosporin O
A O
in O
a O
signal O
- O
dependent O
manner O
. O

We O
have O
purified O
a O
new O
T B
- I
cell I
- I
specific I
factor I
, O
TCF B
- I
1 I
alpha I
, O
that O
is O
implicated O
in O
the O
activation O
of O
genes O
encoding O
a O
major O
component O
of O
the O
human O
T O
- O
cell O
receptor O
( O
TCR B
) O
. O

Curiously O
, O
the O
TCF B
- I
1 I
alpha I
binding O
element O
was O
inactive O
in O
vivo O
when O
removed O
from O
its O
neighboring O
elements O
on O
the O
TCR B
alpha I
enhancer I
and O
positioned O
in O
one O
or O
more O
copies O
upstream O
of O
a O
heterologous B
promoter I
. O

DNA O
- O
protein O
binding O
assays O
with O
nuclear O
extracts O
from O
induced O
cells O
demonstrate O
a O
high O
molecular O
weight O
complex O
on O
the O
enhancer B
. O

Purified O
OTF1 B
from O
HeLa O
cells O
and O
OTF1 B
and O
OTF2 B
from O
B O
cells O
bound O
to O
identical O
sequences O
within O
the O
heavy O
- O
chain O
promoter O
. O

In O
addition O
to O
these O
elements O
, O
we O
identified O
a O
second O
regulatory B
element I
, O
the O
N B
element I
with O
the O
sequence O
5 O
' O
- O
GGAACCTCCCCC O
- O
3 O
' O
. O

NF B
- I
kappa I
B I
as O
inducible O
transcriptional B
activator I
of O
the O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
gene I
. O

The O
same O
agents O
induce O
transcription O
from O
the O
interleukin O
- O
2 O
receptor O
alpha O
- O
chain O
and O
interleukin O
- O
2 O
genes O
, O
depending O
on O
promoter B
elements I
that O
bind O
the O
inducible B
transcription I
factor I
NF B
- I
kappa I
B I
( O
or O
an O
NF B
- I
kappa I
B I
- I
like I
factor I
) O
. O

Two O
kappa O
B O
- O
like O
motifs O
at O
positions O
- O
98 O
to O
- O
108 O
of O
the O
GM B
- I
CSF I
promoter I
were O
also O
recognized O
but O
with O
much O
lower O
affinities O
. O

PMA O
enhanced O
slightly O
the O
stimulatory O
effect O
of O
PHA B
. O

Two O
distinct O
signal O
transmission O
pathways O
in O
T O
lymphocytes O
are O
inhibited O
by O
complexes O
formed O
between O
an O
immunophilin B
and O
either O
FK506 O
or O
rapamycin O
. O

After O
in O
vitro O
adherence O
, O
human O
monocytes O
had O
a O
biphasic O
increase O
in O
PDGF B
( I
B I
) I
mRNA I
with O
peaks O
at O
6 O
h O
and O
13 O
d O
. O

Unexpectedly O
, O
stimulation O
of O
cloned O
stably O
transfected O
Jurkat O
T O
cells O
leads O
to O
a O
bimodal O
pattern O
of O
beta O
- O
gal O
expression O
in O
which O
some O
cells O
express O
no O
beta B
- I
gal I
and O
others O
express O
high O
levels O
. O

Further O
results O
, O
in O
which O
beta B
- I
gal I
activity O
is O
correlated O
with O
NF B
- I
AT I
- O
binding O
activity O
, O
indicate O
that O
the O
concentration O
of O
NF B
- I
AT I
must O
exceed O
a O
critical O
threshold O
before O
transcription O
initiates O
. O

Similar O
constructs O
controlled O
by O
NF B
- I
kappa I
B I
or O
the O
entire O
interleukin B
- I
2 I
enhancer I
show O
bimodal O
expression O
patterns O
during O
induction O
, O
suggesting O
that O
thresholds O
set O
by O
the O
concentration O
of O
transcription B
factors I
may O
be O
a O
common O
property O
of O
inducible B
genes I
. O

In O
lymphoid O
cells O
, O
Z B
or O
R B
alone O
produced O
only O
small O
increases O
in O
EA B
- I
D I
promoter I
activity O
, O
whereas O
both O
transactivators B
together O
produced O
a O
large O
stimulatory O
effect O
. O

In O
lymphoid O
cells O
, O
only O
the O
upstream O
sequences O
are O
required O
for O
transactivation O
by O
the O
Z O
/ O
R O
combination O
, O
and O
the O
AP B
- I
1 I
site I
is O
dispensable O
. O

DNase O
footprinting O
analysis O
corroborated O
the O
functional O
data O
showing O
that O
a O
lymphoid B
- I
specific I
protein I
binds O
to O
the O
microB O
DNA O
motif O
. O

Both O
HIV O
- O
2 O
and O
CMV O
transactivators O
enhance O
HIV O
- O
2 O
gene O
expression O
by O
transcriptional O
activation O
involving O
transcript O
initiation O
as O
well O
as O
elongation O
, O
with O
CMV B
transactivator I
affecting O
elongation O
more O
than O
the O
initiation O
. O

In O
this O
study O
we O
present O
evidence O
for O
reactivity O
of O
pregnancy O
lymphocytes O
, O
but O
not O
nonpregnancy O
lymphocytes O
, O
with O
the O
progesterone B
receptor I
- I
specific I
monoclonal I
antibody I
mPRI O
. O

Interaction O
of O
fibronectin B
with O
VLA O
- O
5 O
receptor O
on O
CD4 O
cells O
induces O
the O
AP B
- I
1 I
transcription I
factor I
. O

Int O
- O
2 O
was O
amplified O
in O
13 O
. O
1 O
% O
and O
c B
- I
myc I
was O
amplified O
in O
10 O
. O
3 O
% O
. O

A O
somewhat O
surprising O
finding O
however O
was O
a O
very O
strong O
association O
between O
oncogene B
amplification O
and O
dense O
lymphocyte O
infiltration O
of O
the O
tumor O
( O
P O
= O
. O
05 O
) O
. O
This O
correlation O
is O
even O
stronger O
when O
only O
high O
levels O
of O
amplification O
are O
considered O
, O
either O
for O
each O
oncogene O
separately O
( O
P O
= O
. O
0048 O
) O
or O
in O
combination O
( O
P O
= O
. O
0007 O
) O
. O

Suppression O
of O
signals O
required O
for O
activation O
of O
transcription B
factor I
NF I
- I
kappa I
B I
in O
cells O
constitutively O
expressing O
the O
HTLV O
- O
I O
Tax O
protein O
. O

Transcription O
factor O
IID O
( O
TFIID B
) O
binds O
to O
the O
TATA O
box O
promoter O
element O
and O
regulates O
the O
expression O
of O
most O
eukaryotic O
genes O
transcribed O
by O
RNA B
polymerase I
II I
. O

Complementary B
DNA I
( O
cDNA B
) O
encoding O
a O
human B
TFIID I
protein I
has O
been O
cloned O
. O

Third O
, O
only O
the O
50 O
kD O
protein O
was O
retained O
on O
a O
biotinylated O
DNA O
- O
streptavidin O
matrix O
when O
the O
DNA O
fragment O
contained O
the O
TRE B
- I
DNA I
. O

Fourth O
, O
extensive O
purification O
by O
several O
cycles O
of O
TRE B
- O
DNA O
affinity O
chromatography O
resulted O
in O
the O
32 O
, O
36 O
to O
42 O
and O
110 O
kD O
proteins O
and O
to O
less O
extent O
the O
50 O
kD O
factor O
. O

The O
cAMP B
- I
response I
element I
CRE B
, O
TGACGTCA O
, O
present O
in O
the O
21 O
base O
- O
pair O
sequence O
, O
appears O
to O
be O
essential O
for O
specific O
protein O
- O
TRE B
- O
DNA O
interactions O
because O
mutation O
of O
the O
two O
G O
' O
s O
destroys O
this O
complex O
. O

Elevated O
glucocorticoid B
receptor I
concentrations O
before O
and O
after O
glucocorticoid O
therapy O
in O
peripheral O
mononuclear O
leukocytes O
of O
patients O
with O
atopic O
dermatitis O
. O

Patients O
with O
AD O
( O
n O
= O
15 O
) O
exhibited O
significantly O
more O
glucocorticoid B
receptors I
( O
GR B
) O
per O
cell O
than O
the O
control O
group O
( O
n O
= O
22 O
) O
, O
while O
the O
GR B
affinity O
did O
not O
differ O
. O

Methylprednisolone O
treatment O
resulted O
in O
a O
significant O
reduction O
of O
the O
GR B
sites O
per O
cell O
in O
the O
steroid O
- O
treated O
control O
group O
( O
n O
= O
10 O
) O
in O
contrast O
to O
the O
patients O
. O

The O
internal O
methionine O
codons O
of O
human O
T O
- O
cell O
leukemia O
virus O
type O
II O
rex O
gene O
are O
not O
required O
for O
p24rex B
production O
or O
virus O
replication O
and O
transformation O
. O

Human O
T O
- O
cell O
leukemia O
virus O
types O
I O
( O
HTLV O
- O
I O
) O
and O
II O
( O
HTLV O
- O
II O
) O
have O
two O
nonstructural O
trans O
- O
acting O
regulatory O
genes O
, O
tax B
and O
rex B
, O
located O
in O
the O
3 B
' I
region I
of O
the O
viral B
genome I
. O

Rex B
acts O
posttranscriptionall O
to O
facilitate O
accumulation O
of O
full O
- O
length O
gag O
/ O
pol O
and O
singly O
spliced O
env O
mRNA O
in O
the O
cytoplasm O
of O
HTLV O
- O
infected O
cells O
. O

By O
using O
an O
infectious O
molecular O
clone O
of O
HTLV O
- O
II O
, O
we O
investigated O
the O
importance O
of O
the O
internal O
ATGs O
of O
the O
rex B
gene I
on O
Rex B
protein O
production O
and O
function O
. O

The O
' B
octamer I
' I
sequence I
, O
ATGCAAAT O
or O
its O
complement O
ATTTGCAT O
, O
is O
a O
key O
element O
for O
the O
transcriptional O
regulation O
of O
immunoglobulin B
genes I
in O
B O
- O
lymphocytes O
as O
well O
as O
a O
number O
of O
housekeeping B
genes I
in O
all O
cell O
types O
. O

In O
lymphocytes O
, O
the O
octamer B
- I
binding I
protein I
Oct B
- I
2A I
and O
variants O
thereof O
are O
thought O
to O
contribute O
to O
the O
B B
- I
cell I
specific I
gene I
expression O
, O
while O
the O
ubiquitous O
protein O
Oct O
- O
1 O
seems O
to O
control O
general O
octamer B
site I
- O
dependent O
transcription O
. O

Therefore O
, O
the O
phosphorylation O
of O
Rex B
is O
required O
for O
the O
viral O
RNA O
partition O
of O
HTLV O
- O
I O
. O

All O
immunoglobulin B
genes I
contain O
a O
conserved O
octanucleotide O
promoter O
element O
, O
ATGCAAAT O
, O
which O
has O
been O
shown O
to O
be O
required O
for O
their O
normal O
B O
- O
cell O
- O
specific O
transcription O
. O

Proteins O
that O
bind O
this O
octamer O
have O
been O
purified O
, O
and O
cDNAs B
encoding O
octamer B
- I
binding I
proteins I
have O
been O
cloned O
. O

Addition O
of O
a O
highly O
enriched O
preparation O
of O
OTF B
- I
1 I
made O
from O
one O
of O
these O
pre O
- O
B O
cells O
or O
from O
HeLa O
cells O
specifically O
stimulated O
in O
vitro O
transcription O
of O
an O
immunoglobulin B
gene I
. O

In O
vitro O
binding O
of O
aldosterone O
to O
mineralocorticoid B
receptors I
on O
human O
mononuclear O
leukocytes O
( O
HML O
) O
and O
its O
effects O
on O
the O
intracellular O
sodium O
and O
potassium O
concentrations O
of O
HML O
have O
already O
been O
described O
. O

The O
number O
of O
mineralocorticoid B
receptors I
/ O
cell O
were O
within O
or O
close O
to O
the O
normal O
range O
( O
n O
= O
9 O
) O
. O

Thus O
, O
EBNA B
- I
2 I
transactivation O
of O
LMP1 B
amplifies O
the O
biological O
impact O
of O
EBNA B
- I
2 I
and O
underscores O
its O
central O
role O
in O
EBV O
- O
induced O
growth O
transformation O
. O

Heat O
shock O
caused O
an O
increase O
in O
c O
- O
fos O
and O
c O
- O
jun O
mRNA O
levels O
and O
a O
decrease O
in O
c B
- I
myc I
mRNA I
levels O
in O
pre O
- O
B O
( O
Hyon O
) O
and O
T O
( O
DND O
- O
41 O
) O
cell O
lines O
as O
well O
as O
in O
freshly O
isolated O
normal O
human O
thymocytes O
. O

Anti O
- O
HBx B
antibody O
titers O
as O
revealed O
by O
peptide O
ELISAs O
were O
highest O
and O
most O
frequent O
in O
patients O
with O
chronic O
hepatitis O
and O
usually O
low O
in O
acutely O
infected O
patients O
and O
asymptomatic O
carriers O
. O

Lt B
- I
4 I
reacted O
with O
all O
HTLV O
- O
I O
- O
bearing O
cell O
lines O
tested O
and O
five O
out O
of O
eight O
simian O
cell O
lines O
bearing O
STLV O
- O
I O
, O
but O
not O
with O
an O
HTLV O
- O
II O
- O
bearing O
cell O
line O
. O

In O
the O
STLV O
- O
I O
- O
bearing O
T O
cell O
lines O
, O
tax1 O
- O
related O
antigen O
molecules O
detected O
by O
Lt B
- I
4 I
were O
heterogeneous O
, O
having O
molecular O
weights O
in O
the O
range O
of O
36 O
- O
41 O
kd O
. O

The O
transcription O
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
is O
under O
the O
control O
of O
cellular B
proteins I
that O
bind O
to O
the O
viral B
long I
terminal I
repeat I
( O
LTR B
) O
. O

The O
corresponding O
region O
in O
the O
second O
AIDS O
retrovirus O
, O
HIV O
- O
2 O
, O
contains O
a O
conserved O
and O
a O
divergent O
NF B
kappa I
B I
binding I
site I
. O

Instead O
of O
NF B
kappa I
B I
, O
the O
activator O
protein O
3 O
binds O
to O
the O
divergent O
site O
in O
HIV O
- O
2 O
. O

Expression O
cloning O
of O
c B
- I
Jun I
. O

Whereas O
c B
- I
Fos I
/ I
c I
- I
Jun I
heterodimers I
do O
not O
exist O
in O
B O
cells O
, O
they O
form O
and O
bind O
to O
the O
X2 B
- I
box I
in O
class O
II O
nonexpressing O
cells O
. O

We O
have O
developed O
a O
system O
to O
monitor O
the O
transcriptional O
activity O
of O
NFAT B
- I
1 I
at O
the O
single O
cell O
level O
in O
whole O
animals O
. O

This O
similarity O
in O
expression O
and O
the O
fact O
that O
NFAT B
- I
1 I
has O
been O
shown O
to O
bind O
functional O
sequences O
in O
HIV B
- I
LTR I
suggest O
a O
role O
for O
NFAT B
- I
1 I
in O
dermal O
activation O
of O
the O
HIV B
- I
LTR I
. O

A O
novel O
T B
- I
cell I
protein I
recognized O
the O
palindromic B
sequence I
within O
site B
B I
and O
also O
bound O
estrogen O
- O
or O
thyroid O
hormone O
- O
response O
elements O
with O
lower O
affinity O
. O

The O
effects O
of O
a O
competitive O
progesterone O
antagonist O
( O
RU486 O
) O
and O
a O
specific O
glucocorticoid B
receptor I
blocker O
( O
RU43044 O
) O
were O
tested O
on O
the O
release O
of O
a O
blocking B
factor I
by O
progesterone O
- O
treated O
pregnancy O
lymphocytes O
. O

It O
has O
previously O
been O
shown O
that O
9S B
, O
untransformed O
progestin O
, O
estrogen O
, O
androgen O
, O
and O
glucocorticoid O
receptor O
complexes O
in O
rabbit O
uterine O
and O
liver O
cytosols O
contain O
a O
59 O
- O
kDa O
protein O
[ O
Tai O
, O
P O
. O
K O
. O
, O
Maeda O
, O
Y O
. O
, O
Nakao O
, O
K O
. O
, O
Wakim O
, O
N O
. O
G O
. O
, O
Duhring O
, O
J O
. O
L O
. O
, O
& O
Faber O
, O
L O
. O
E O
. O
( O
1986 O
) O
Biochemistry O
25 O
, O
5269 O
- O
5275 O
] O
. O

Sequence O
- O
specific O
DNA O
binding O
of O
the O
proto O
- O
oncoprotein O
ets B
- I
1 I
defines O
a O
transcriptional O
activator O
sequence O
within O
the O
long B
terminal I
repeat I
of O
the O
Moloney O
murine O
sarcoma O
virus O
. O

A O
mutant O
LTR O
containing O
four O
base O
pair O
substitutions O
in O
the O
ets B
- I
1 I
binding I
site I
was O
constructed O
and O
was O
shown O
to O
have O
reduced O
binding O
in O
vitro O
. O

We O
propose O
that O
ets B
- I
1 I
functions O
as O
a O
transcriptional O
activator O
of O
mammalian O
type O
- O
C O
retroviruses O
and O
speculate O
that O
ets O
- O
related O
genes O
constitute O
a O
new O
group O
of O
eukaryotic O
DNA O
- O
binding O
proteins O
. O

We O
have O
previously O
reported O
that O
human O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
contain O
type O
II O
estrogen O
binding O
sites O
( O
type B
II I
EBS I
) O
. O

In O
postmenopausal O
women O
the O
mean O
type B
II I
EBS I
levels O
were O
similar O
to O
those O
observed O
in O
the O
follicular O
phase O
of O
the O
cycle O
. O

Tamoxifen O
was O
also O
found O
to O
compete O
with O
17 O
beta O
- O
estradiol O
for O
type B
II I
EBS I
in O
PBMC O
, O
although O
to O
a O
lesser O
extent O
than O
diethylstilbestrol O
. O

The O
effect O
of O
1 O
, O
25 O
- O
dihydroxyvitamin O
D3 O
[ O
1 O
, O
25 O
( O
OH O
) O
2 O
) O
D3 O
] O
, O
a O
steroid O
hormone O
with O
immunomodulating O
properties O
, O
on O
nuclear B
factor I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
proteins O
was O
examined O
in O
in O
vitro O
activated O
normal O
human O
lymphocytes O
by O
Western O
blot O
analysis O
. O

Over O
a O
72 O
- O
hr O
period O
of O
activation O
, O
the O
expression O
of O
the O
50 O
- O
kDa O
NF O
- O
kappa O
B O
, O
p50 B
, O
and O
its O
precursor O
, O
p105 B
, O
was O
increased O
progressively O
. O

Further O
, O
1 O
, O
25 O
( O
OH O
) O
2D3 O
inhibited O
the O
transcriptional O
activity O
of O
NF B
- I
kappa I
B I
in O
Jurkat O
cells O
transiently O
transfected O
with O
a O
construct O
containing O
four O
tandem B
repeats I
of O
the O
NF B
- I
kappa I
B I
binding I
sequence I
of O
the O
immunoglobulin O
kappa O
light O
chain O
gene O
linked O
to O
the O
chloramphenicol B
acetyltransferase I
reporter I
gene I
. O

These O
observations O
demonstrate O
directly O
that O
there O
is O
de O
novo O
synthesis O
of O
NF B
- I
kappa I
B I
during O
human O
lymphocyte O
activation O
and O
suggest O
that O
this O
process O
is O
hormonally O
regulated O
. O

We O
previously O
identified O
the O
DNA O
consensus O
binding O
site O
recognized O
by O
the O
two O
DNA B
binding I
domains I
. O

The O
expression O
vector O
was O
cotransfected O
with O
the O
chloramphenicol B
acetyl I
transferase I
( I
CAT I
) I
reporter I
gene I
regulated O
by O
the O
thymidine B
kinase I
promoter I
containing O
GAL4 O
DNA O
binding O
sites O
into O
NIH O
3T3 O
, O
293 O
, O
K562 O
, O
and O
Jurkat O
cell O
lines O
. O

In O
contrast O
, O
MZF B
- I
1 I
activates O
CAT B
reporter I
gene I
expression O
in O
the O
hematopoietic O
cell O
lines O
K562 O
and O
Jurkat O
. O

The O
MZF B
- I
1 I
binding I
sites I
are O
present O
in O
the O
promoters B
of O
several O
genes B
expressed O
during O
myeloid O
differentiation O
, O
including O
the O
CD34 B
promoter I
. O

The O
role O
of O
BSAP B
( O
Pax B
- I
5 I
) O
in O
B O
- O
cell O
development O
. O

Analysis O
of O
the O
biochemical O
and O
cell O
biological O
properties O
of O
these O
HSFs O
reveals O
that O
HSF3 B
has O
properties O
in O
common O
with O
both O
HSF1 B
and O
HSF2 B
and O
yet O
has O
features O
which O
are O
distinct O
from O
both O
. O

HSF3 B
is O
constitutively O
expressed O
in O
the O
erythroblast O
cell O
line O
HD6 O
, O
the O
lymphoblast O
cell O
line O
MSB O
, O
and O
embryo O
fibroblasts O
, O
and O
yet O
its O
DNA O
- O
binding O
activity O
is O
induced O
only O
upon O
exposure O
of O
HD6 O
cells O
to O
heat O
shock O
. O

Nuclear B
factor I
of I
activated I
T I
cells I
( O
NFAT B
) O
regulates O
transcription O
of O
a O
number O
of O
cytokine B
genes I
, O
and O
NFAT B
DNA O
binding O
activity O
is O
stimulated O
following O
T O
cell O
activation O
. O

Treatment O
of O
immunoprecipitated O
NFATp B
from O
untreated O
HT O
- O
2 O
cells O
with O
calcineurin B
resulted O
in O
the O
dephosphorylation O
of O
NFATp B
, O
demonstrating O
that O
NFATp B
is O
an O
in O
vitro O
substrate O
for O
calcineurin B
. O

Both O
of O
these O
events O
were O
blocked O
by O
preincubation O
of O
the O
cells O
with O
FK506 O
, O
a O
calcineurin B
inhibitor O
, O
consistent O
with O
the O
hypothesis O
that O
NFATp B
is O
a O
calcineurin B
substrate O
in O
cells O
. O

Activation O
and O
expression O
of O
the O
nuclear B
factors I
of O
activated O
T O
cells O
, O
NFATp B
and O
NFATc B
, O
in O
human O
natural O
killer O
cells O
: O
regulation O
upon O
CD16 B
ligand O
binding O
. O

The O
results O
of O
supershift O
assays O
using O
NFATp O
- O
and O
NFATc O
- O
specific O
antibodies O
indicate O
that O
NK O
cell O
activation O
early O
after O
CD16 B
ligand O
binding O
involves O
primarily O
, O
if O
not O
exclusively O
, O
NFATp B
, O
and O
Western O
blot O
analysis O
shows O
that O
this O
has O
the O
same O
electrophoretic O
mobility O
( O
approximately O
120 O
kD O
) O
as O
that O
of O
T O
lymphocytes O
. O

Since O
many O
cytokines B
that O
activate O
Jak B
kinases I
also O
lead O
to O
the O
tyrosine O
phosphorylation O
and O
activation O
of O
members O
of O
the O
Stat B
family I
of O
transcription B
factors I
, O
the O
ability O
of O
IL B
- I
2 I
to O
trigger O
Stat O
phosphorylation O
was O
examined O
. O

Exposure O
of O
activated O
human O
T O
lymphocytes O
or O
of O
a O
natural O
killer O
cell O
line O
( O
NKL O
) O
to O
IL B
- I
2 I
leads O
to O
the O
phosphorylation O
of O
Stat1 B
alpha I
, O
Stat1 O
beta O
, O
and O
Stat3 B
, O
as O
well O
as O
of O
two O
Stat O
- O
related O
proteins O
, O
p94 B
and O
p95 B
. O

These O
Stat B
proteins I
were O
found O
to O
translocate O
to O
the O
nucleus O
and O
to O
bind O
to O
a O
specific O
DNA O
sequence O
. O

Results O
indicated O
that O
( O
i O
) O
constitutive O
c O
- O
fos O
transcript O
levels O
are O
significantly O
higher O
in O
patients O
subsequently O
responding O
to O
IFN B
- I
alpha I
therapy O
( O
p O
< O
0 O
. O
01 O
) O
and O
positively O
correlated O
with O
the O
proportion O
of O
lymphocytes O
( O
r O
= O
0 O
. O
6895 O
, O
p O
< O
0 O
. O
01 O
) O
and O
negatively O
with O
the O
proportion O
of O
immature O
cells O
( O
r O
= O
- O
0 O
. O
568 O
, O
p O
< O
0 O
. O
01 O
) O
contained O
in O
the O
pbmc O
preparations O
tested O
, O
( O
ii O
) O
constitutive O
mRNA O
levels O
of O
the O
hybrid O
bcr O
/ O
abl O
, O
c B
- I
myc I
and O
p53 B
are O

positively O
correlated O
with O
each O
other O
, O
but O
failed O
to O
relate O
to O
disease O
parameters O
, O
and O
( O
iii O
) O
acute O
and O
chronic O
in O
vivo O
exposure O
to O
IFN B
- I
alpha I
is O
accompanied O
by O
upregulation O
of O
c B
- I
fos I
and O
downregulation O
of O
c B
- I
myc I
mRNA I
levels O
in O
responder O
patients O
. O

In O
parallel O
experiments O
, O
IL B
- I
2 I
- O
driven O
proliferation O
was O
inhibited O
significantly O
. O

Yet O
, O
IL B
- I
2 I
- O
driven O
proliferation O
remained O
profoundly O
inhibited O
, O
suggesting O
that O
signaling O
events O
other O
than O
Jak3 B
/ B
Stat I
activation O
had O
also O
been O
changed O
following O
SE B
stimulation O
. O

In O
contrast O
to O
hematopoietic O
cells O
, O
I O
kappa O
B O
alpha O
- O
/ O
- O
embryonic O
fibroblasts O
show O
minimal O
constitutive O
NF O
- O
kappa O
B O
, O
as O
well O
as O
normal O
signal O
- O
dependent O
NF B
- I
kappa I
B I
activation O
that O
is O
concomitant O
with O
I B
kappa I
B I
beta I
degradation O
. O

Moreover O
, O
the O
induction O
of O
both O
Jak O
1 O
and O
3 O
, O
and O
STAT B
5 I
activity O
strongly O
correlated O
with O
the O
growth O
- O
promoting O
effects O
of O
IL B
- I
7 I
, O
suggesting O
that O
this O
signal O
transduction O
mechanism O
may O
play O
a O
key O
role O
in O
IL B
- I
7 I
- O
induced O
proliferation O
. O

Cytokine B
- O
modulating O
activity O
of O
tepoxalin O
, O
a O
new O
potential O
antirheumatic O
. O

Tepoxalin O
also O
inhibits O
the O
activation O
of O
NF B
kappa I
B I
, O
a O
transcription B
factor I
which O
acts O
on O
several O
cytokine B
genes I
. O

Analysis O
of O
the O
expression O
of O
human B
I I
kappa I
B I
alpha I
protein I
in O
stable O
transfectants O
of O
mouse O
70Z O
/ O
3 O
cells O
shows O
that O
, O
as O
for O
the O
endogenous O
murine O
protein O
, O
exogenous O
I B
kappa I
B I
alpha I
is O
degraded O
in O
response O
to O
inducers O
of O
NF B
- I
kappa I
B I
activity O
, O
such O
as O
phorbol O
myristate O
acetate O
or O
lipopolysaccharide O
. O

By O
expressing O
mutant O
forms O
of O
the O
human O
protein O
in O
this O
cell O
line O
, O
we O
have O
been O
able O
to O
delineate O
the O
sequences O
responsible O
for O
both O
the O
ligand O
- O
induced O
phosphorylation O
and O
the O
degradation O
of O
I B
kappa I
B I
alpha I
. O

Interestingly O
, O
microtubule B
disruption O
also O
decreased O
monocyte O
1 O
, O
25 O
( O
OH O
) O
2D3 O
synthesis O
, O
not O
by O
decreasing O
the O
Vmax O
of O
monocyte O
mitochondrial O
1 O
alpha O
- O
hydroxylase O
but O
through O
an O
increase O
in O
the O
Km O
for O
25 O
( O
OH O
) O
2D3 O
. O

Finally O
, O
by O
studying O
a O
further O
series O
of O
patients O
, O
we O
could O
confirm O
that O
the O
decrease O
in O
Rap1 B
protein I
expression O
in O
heart O
failure O
, O
whatever O
its O
extent O
, O
was O
variable O
, O
and O
could O
strictly O
correlate O
the O
expression O
of O
Rap1 B
protein I
with O
the O
stimulatory O
effect O
of O
C B
. I
Sub I
. I
on O
Ca2 O
+ O
transport O
. O

An O
IRF B
- I
1 I
- O
dependent O
pathway O
of O
DNA O
damage O
- O
induced O
apoptosis O
in O
mitogen O
- O
activated O
T O
lymphocytes O
. O

Here O
we O
show O
DNA O
damage O
- O
induced O
apoptosis O
in O
these O
T O
lymphocytes O
is O
dependent O
on O
the O
antioncogenic O
transcription O
factor O
interferon O
regulatory O
factor O
( B
IRF I
) I
- I
1 I
. O

Activation O
through O
the O
Ca2 O
+ O
/ O
calcineurin B
pathway O
is O
essential O
to O
the O
transcription O
of O
many O
cytokine B
genes I
. O

Coexpression O
of O
NF B
- I
kappa I
B I
/ I
Rel I
and O
Sp1 B
transcription B
factors I
in O
human O
immunodeficiency O
virus O
1 O
- O
induced O
, O
dendritic O
cell O
- O
T O
- O
cell O
syncytia O
. O

T O
cells O
lack O
active O
NF B
- I
kappa I
B I
but O
express O
Sp1 B
as O
expected O
. O

Deoxycholate O
treatment O
of O
the O
cytoplasmic O
extract O
prepared O
from O
cells O
stimulated O
by O
TNF B
- I
alpha I
in O
the O
presence O
of O
Cu2 O
+ O
resulted O
in O
the O
release O
of O
NF B
kappa I
B I
from O
I B
kappa I
B I
alpha I
, O
indicating O
that O
Cu2 O
+ O
interferes O
with O
the O
dissociation O
of O
the O
NF O
kappa O
B O
- O
I O
kappa O
B O
complex O
. O

Neither O
phosphorylation O
nor O
degradation O
of O
I B
kappa I
B I
alpha I
was O
observed O
upon O
TNF B
- I
alpha I
stimulation O
in O
the O
presence O
of O
Cu2 O
+ O
. O

Cloning O
a O
cDNA B
from O
human O
NK O
/ O
T O
cells O
which O
codes O
for O
a O
protein O
with O
high O
proline O
content O
. O

The O
present O
study O
verified O
the O
ability O
of O
IL B
- I
2 I
to O
cause O
tyrosine O
phosphorylation O
and O
activation O
of O
JAK1 B
and O
JAK3 B
, O
but O
demonstrated O
that O
IL B
- I
2 I
stimulated O
JAK3 B
to O
a O
significantly O
larger O
extent O
than O
JAK1 B
in O
human O
T O
lymphocytes O
and O
the O
YT O
cell O
line O
. O

Nonetheless O
, O
a O
membrane B
- I
proximal I
region I
of O
human O
IL B
- I
2R I
beta I
( O
Asn240 O
- O
Leu335 O
) O
was O
critical O
for O
JAK3 B
activation O
, O
and O
the O
amount O
of O
JAK3 B
present O
in O
activated O
IL B
- I
2 I
receptor I
complexes I
increased O
with O
time O
, O
suggesting O
that O
stabilization O
of O
JAK3 B
binding O
to O
the O
receptor B
complex I
relies O
on O
both O
IL B
- I
2R I
beta I
and O
IL B
- I
2R I
gamma I
. O

In O
most O
cases O
, O
the O
transcriptional B
factor I
NF B
- I
kappa I
B I
is O
a O
heterodimer B
consisting O
of O
two O
subunits O
, O
p50 B
and O
p65 B
, O
which O
are O
encoded O
by O
two O
distinct O
genes O
of O
the O
Rel B
family I
. O

It O
has O
been O
suggested O
that O
the O
ubiquitin B
- B
proteasome I
system O
is O
involved O
in O
the O
process O
; O
however O
, O
the O
specific O
enzymes B
involved O
and O
the O
mechanism O
of O
limited O
proteolysis O
, O
in O
which O
half O
of O
the O
molecule O
is O
spared O
, O
have O
been O
obscure O
. O

Before O
treatment O
, O
the O
number O
of O
androgen B
receptors I
was O
higher O
in O
the O
luteal O
than O
in O
the O
follicular O
phase O
. O

To O
identify O
osteoblast B
- I
specific I
cis I
- I
acting I
elements I
and O
trans B
- I
acting I
factors I
, O
we O
initiated O
an O
analysis O
of O
the O
promoter B
of O
a O
mouse O
osteocalcin O
gene O
, O
an O
osteoblast B
- I
specific I
gene I
. O

By O
DNA O
cotransfection O
experiments O
, O
we O
also O
demonstrate O
that O
AML B
- I
1B I
can O
increase O
the O
activity O
of O
a O
short O
osteocalcin B
promoter I
through O
its O
binding O
to O
OSE2 O
. O

A O
variety O
of O
other O
cells O
, O
including O
transformed O
erythroid O
precursors O
, O
do O
not O
have O
IBR B
but O
a O
factor O
referred O
to O
as O
IBF B
( O
68 O
to O
70 O
kDa O
) O
that O
recognizes O
the O
same O
IBR B
sites O
. O

IBR B
is O
a O
503 O
- O
amino O
- O
acid O
- O
long O
acidic O
protein O
which O
is O
99 O
. O
0 O
% O
identical O
to O
the O
recently O
reported O
human O
NRF O
- O
1 O
/ O
alpha O
- O
Pal O
factor O
and O
highly O
related O
to O
the O
invertebrate O
transcription B
factors I
P3A2 O
and O
erected O
wing O
gene O
product O
( O
EWG O
) O
. O

We O
present O
evidence O
that O
IBR B
and O
IBF B
are O
most O
likely O
identical O
proteins O
, O
differing O
in O
their O
degree O
of O
glycosylation O
. O

Mutation O
of O
Jak3 B
in O
a O
patient O
with O
SCID O
: O
essential O
role O
of O
Jak3 B
in O
lymphoid O
development O
. O

The O
lack O
of O
Jak3 B
expression O
correlated O
with O
impaired O
B O
cell O
signaling O
, O
as O
demonstrated O
by O
the O
inability O
of O
IL B
- I
4 I
to O
activate O
Stat6 B
in O
the O
EBV O
- O
transformed O
cell O
line O
from O
the O
patient O
. O
These O
observations O
indicate O
that O
the O
functions O
of O
gamma B
c I
are O
dependent O
on O
Jak3 B
and O
that O
Jak3 B
is O
essential O
for O
lymphoid O
development O
and O
signaling O
. O

L B
- I
selectin I
is O
an O
adhesion O
molecule O
of O
the O
selectin O
family O
that O
mediates O
the O
initial O
step O
of O
leukocyte O
adhesion O
to O
vascular O
endothelium O
. O

Upon O
cellular O
activation O
, O
expression O
of O
the O
L B
- I
selectin I
gene I
is O
downregulated O
at O
both O
the O
protein O
and O
mRNA O
levels O
. O

The O
induction O
of O
Tax B
expression O
in O
JPX9 O
cells O
resulted O
in O
about O
a O
twofold O
increase O
in O
the O
mRNA B
expression O
levels O
compared O
with O
the O
basal O
level O
. O

These O
results O
indicated O
that O
ATL O
cells O
constitutively O
overexpress O
the O
L B
- I
selectin I
gene I
that O
can O
be O
transactivated O
by O
HTLV O
- O
1 O
Tax B
. O

There O
was O
no O
difference O
between O
the O
distribution O
of O
the O
VDR B
alleles O
in O
the O
patient O
population O
when O
compared O
with O
the O
normal O
population O
. O

Sequence O
analysis O
of O
the O
5 B
' I
- I
flanking I
region I
of O
the O
CD69 B
gene I
revealed O
the O
presence O
of O
a O
potential O
TATA B
element I
30 O
base O
pairs O
upstream O
of O
the O
major O
transcription B
initiation I
site I
and O
several O
putative O
binding O
sequences O
for O
inducible O
transcription B
factors I
( O
NF B
- I
kappa I
B I
, O
Egr B
- I
1 I
, O
AP B
- I
1 I
) O
, O
which O
might O
mediate O
the O
inducible O
expression O
of O
this O
gene O
. O

The O
exon O
- O
intron O
structure O
of O
the O
5 B
' I
portion I
of O
the O
thromboxane B
receptor I
gene I
was O
determined O
initially O
by O
comparing O
the O
nucleotide O
sequence O
of O
the O
5 O
' O
flanking O
genomic O
clone O
with O
that O
of O
a O
novel O
human O
uterine O
thromboxane O
receptor O
cDNA O
that O
extended O
the O
mRNA B
141 O
bp O
further O
upstream O
than O
the O
previously O
identified O
human O
placental O
cDNA O
. O

Promoter O
function O
of O
the O
5 B
' I
flanking I
region I
of O
the O
thromboxane B
receptor I
gene I
was O
evaluated O
by O
transfection O
of O
thromboxane O
receptor O
gene O
promoter O
/ O
chloramphenicol O
acetyltransferase O
( O
CAT O
) O
chimera O
plasmids O
into O
platelet O
- O
like O
K562 O
cells O
. O

These O
studies O
are O
the O
first O
to O
determine O
the O
structure O
and O
organization O
of O
the O
5 O
' O
end O
of O
the O
thromboxane B
receptor I
gene I
and O
demonstrate O
that O
thromboxane B
receptor I
gene I
expression O
can O
be O
regulated O
by O
activation O
of O
protein B
kinase I
C I
via O
induction O
of O
an O
AP O
- O
2 O
- O
like O
nuclear O
factor O
binding O
to O
upstream O
promoter O
elements O
. O

The O
abundant O
chromosomal O
protein O
HMG B
- I
1 I
belongs O
to O
this O
subgroup O
. O

As O
in O
HMG1B O
, O
the O
overall O
structure O
of O
the O
Sox B
- I
4 I
HMG B
box I
is O
L O
- O
shaped O
and O
is O
maintained O
by O
a O
cluster O
of O
conserved O
, O
mainly O
aromatic O
residues O
. O

Nuclear B
factor I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
is O
stored O
in O
the O
cytoplasm O
as O
an O
inactive O
form O
through O
interaction O
with O
I B
kappa I
B I
. O

We O
have O
recently O
reported O
the O
establishment O
of O
a O
lipopolysaccharide O
( O
LPS O
) O
- O
dependent O
cell O
- O
free O
activation O
system O
of O
NF B
- I
kappa I
B I
in O
association O
with O
the O
induction O
of O
I B
kappa I
B I
alpha I
phosphorylation O
. O

This O
death O
- O
promoting O
activity O
of O
Bik B
can O
be O
suppressed O
by O
coexpression O
of O
Bcl B
- I
2 I
, O
Bcl B
- I
XL I
, O
EBV O
- O
BHRF1 O
and O
E1B O
- O
19 O
kDa O
proteins O
suggesting O
that O
Bik B
may O
be O
a O
common O
target O
for O
both O
cellular O
and O
viral O
anti O
- O
apoptotic O
proteins O
. O

TCF B
- I
1 I
mRNA I
was O
originally O
found O
to O
be O
expressed O
in O
a O
T O
cell O
- O
specific O
fashion O
within O
a O
set O
of O
human O
and O
mouse O
cell O
lines O
. O

Immunohistochemistry O
on O
a O
panel O
of O
human O
tissues O
revealed O
that O
the O
TCF B
- I
1 I
protein I
was O
found O
exclusively O
in O
thymocytes O
and O
in O
CD3 O
+ O
T O
cells O
in O
peripheral O
lymphoid O
tissues O
. O

Signalling O
via O
CD28 B
of O
human O
naive O
neonatal O
T O
lymphocytes O
. O

We O
have O
examined O
the O
role O
of O
CD28 B
in O
modulating O
the O
' O
naive O
' O
neonatal O
T O
cell O
response O
to O
anti B
- I
CD2 I
- O
mediated O
activation O
. O

Costimulation O
with O
anti B
- I
CD28 I
MoAb I
greatly O
enhanced O
the O
proliferative O
response O
of O
neonatal O
T O
cells O
to O
levels O
equivalent O
to O
those O
of O
adult O
T O
cells O
, O
whereas O
adult O
T O
cells O
showed O
only O
slight O
increases O
. O

Although O
IL B
- I
2 I
secretion O
was O
increased O
in O
the O
presence O
of O
anti B
- I
CD28 I
MoAb I
, O
neonatal O
T O
cell O
IL B
- I
2 I
production O
remained O
lower O
than O
in O
adults O
. O

We O
have O
analyzed O
the O
expression O
of O
TCL1 O
mRNA O
and O
protein B
in O
peripheral O
blood O
lymphocytes O
( O
PBLs O
) O
from O
four O
AT O
cases O
and O
from O
healthy O
controls O
. O

We O
found O
that O
the O
TCL1 B
gene I
was O
overexpressed O
in O
the O
PBLs O
of O
an O
AT O
patient O
with O
a O
large O
clonal O
T O
- O
cell O
population O
exhibiting O
the O
t O
( O
14 O
; O
14 O
) O
translocation O
but O
not O
in O
the O
lymphocytes O
of O
the O
other O
cases O
. O

Fluorescence O
in O
situ O
hybridization O
of O
the O
TCL1 O
genomic O
locus O
to O
lymphocyte O
metaphases O
from O
the O
AT O
patient O
with O
the O
T O
- O
cell O
clonal O
expansion O
showed O
that O
the O
breakpoint O
of O
the O
t O
( O
14 O
; O
14 O
) O
translocation O
lies O
within O
the O
TCL1 B
locus I
and O
is O
accompanied O
by O
an O
inverted O
duplication O
of O
the O
distal O
part O
of O
chromosome B
14 I
. O

Deregulation O
of O
TCL1 B
is O
the O
first O
event O
in O
the O
initiation O
of O
malignancy O
in O
these O
types O
of O
leukemias O
and O
represents O
a O
potential O
tool O
for O
clinical O
evaluation O
. O

Inhibition O
of O
endogenous O
C O
/ O
EBP O
proteins O
, O
using O
either O
an O
excess O
of O
C O
/ O
EBP O
binding O
sites O
or O
a O
trans O
- O
dominant O
negative O
inhibitor O
, O
demonstrated O
that O
C B
/ I
EBP I
proteins I
are O
required O
for O
basal O
and O
activated O
levels O
of O
HIV B
- I
1 I
LTR I
transcription O
in O
the O
promonocytic O
cell O
line O
U937 O
. O

Northern O
( O
RNA O
) O
blots O
and O
binding O
assays O
showed O
that O
NF B
- I
IL6 I
is O
the O
only O
known O
C O
/ O
EBP O
family O
member O
which O
is O
increased O
when O
U937 O
cells O
are O
activated O
. O

However O
, O
transcription O
from O
crippled O
HIV O
- O
1 O
LTRs O
lacking O
C B
/ I
EBP I
sites I
can O
still O
be O
induced O
following O
activation O
of O
U937 O
cells O
. O

Since O
expression O
of O
the O
viruses O
is O
in O
large O
part O
regulated O
by O
the O
sequence B
elements I
in O
their O
long B
terminal I
repeats I
( O
LTRs B
) O
, O
this O
study O
was O
directed O
to O
an O
analysis O
of O
the O
regulatory B
elements I
in O
the O
HIV B
- I
2 I
LTR I
. O

The O
HIV B
- I
2 I
LTR I
was O
found O
to O
contain O
two O
enhancers B
. O

A O
comparison O
with O
the O
Stat B
proteins I
induced O
by O
interferon B
- I
gamma I
, O
PRL B
, O
and O
IL B
- I
6 I
in O
T47D O
mammary O
tumor O
cells O
was O
made O
. O

Activation O
of O
a O
second O
protein O
related O
to O
Stat1 B
was O
also O
observed O
. O

Granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
is O
one O
such O
cytokine B
whose O
increased O
expression O
results O
partly O
from O
increases O
in O
transcription O
. O

A O
number O
of O
the O
ETS B
family I
of O
transcription B
factors I
are O
expressed O
in O
T O
cells O
, O
including O
ETS1 B
and O
ELF1 B
. O

Other O
unidentified O
ETS B
- I
like I
factors I
present O
in O
Jurkat O
cells O
are O
also O
capable O
of O
binding O
GM5 B
. O

No O
up O
- O
regulation O
of O
hTR B
beta I
1 I
was O
seen O
in O
hypothyroid O
relative O
to O
euthyroid O
patients O
. O

Using O
varying O
conditions O
, O
three O
distinct O
complexes O
were O
shown O
to O
interact O
specifically O
with O
the O
NIP B
region I
, O
although O
only O
one O
correlates O
with O
repressor O
activity O
. O

DNA O
binding O
specificity O
of O
complex O
3 O
overlaps O
with O
that O
of O
upstream B
stimulatory I
factor I
but O
is O
clearly O
distinct O
. O

Functional O
specificity O
for O
repression O
matches O
the O
DNA O
binding O
specificity O
of O
complex O
3 O
; O
both O
repressor O
activity O
and O
complex O
3 O
binding O
require O
the O
consensus B
sequence I
CTCACNTNC O
. O

The O
hematopoietic B
transcription I
factor I
PU B
. I
1 I
is O
downregulated O
in O
human O
multiple O
myeloma O
cell O
lines O
. O

PU B
. I
1 I
is O
a O
hematopoietic B
transcription I
factor I
belonging O
to O
the O
Ets B
- I
family I
. O

It O
binds O
the O
so O
- O
called O
Pu B
box I
, O
an O
important O
tissue O
- O
specific O
regulatory O
DNA O
element O
present O
in O
a O
number O
of O
genes O
expressed O
in O
these O
cell O
lineages O
. O

We O
have O
analyzed O
the O
expression O
and O
activity O
of O
PU B
. I
1 I
during O
human O
B O
- O
cell O
development O
using O
a O
panel O
of O
B O
- O
cell O
lines O
representing O
different O
stages O
of O
maturation O
, O
from O
early O
precursors O
to O
differentiated O
plasma O
cells O
. O

The O
effects O
of O
CsA O
on O
endothelial O
cells O
were O
also O
detected O
at O
the O
chromatin B
structure O
level O
, O
as O
DNasel O
hypersensitive O
sites O
within O
both O
the O
GM B
- I
CSF I
enhancer O
and O
the O
E B
- I
selectin I
promoter I
were O
suppressed O
by O
CsA O
. O

Protein O
phosphorylation O
has O
an O
important O
role O
in O
the O
regulation O
of O
these O
two O
factors O
: O
( O
1 O
) O
it O
induces O
the O
transactivating O
capacity O
of O
the O
AP B
- I
1 I
protein I
c B
- I
Jun I
; O
and O
( O
2 O
) O
it O
is O
involved O
in O
the O
release O
of O
the O
cytoplasmic B
inhibitor I
, O
I B
kappa I
B I
, O
from O
NF B
- I
kappa I
B I
, O
allowing O
translocation O
of O
the O
latter O
into O
the O
nucleus O
. O

Integration O
of O
the O
signals O
generated O
by O
TCR B
and O
CD28 B
engagement O
occurs O
along O
this O
pathway O
, O
which O
then O
bifurcates O
to O
induce O
I B
kappa I
B I
phosphorylation O
and O
NF B
- I
kappa I
B I
activation O
on O
the O
one O
hand O
, O
and O
JNK B
activation O
and O
c B
- I
Jun I
phosphorylation O
on O
the O
other O
. O

We O
are O
currently O
engaged O
in O
defining O
where O
the O
two O
signals O
integrate O
along O
the O
AP B
- I
1 I
/ O
NF B
- I
kappa I
B I
pathway O
. O

Enhancement O
of O
HIV O
- O
1 O
replication O
is O
related O
in O
part O
to O
increased O
DNA O
- O
binding O
activity O
of O
cellular B
transcription I
factors I
such O
as O
NF B
- I
kappa I
B I
. O

Increased O
intracellular O
stores O
of O
latent O
NF O
- O
kappa O
B O
may O
also O
result O
in O
rapid O
inducibility O
of O
NF B
- I
kappa I
B I
- O
dependent O
cytokine B
gene O
expression O
. O

Elevated O
levels O
of O
several O
inflammatory B
cytokines I
have O
been O
detected O
in O
the O
sera O
of O
HIV O
- O
1 O
- O
infected O
individuals O
. O

We O
measured O
steroid O
mediated O
lysis O
, O
receptor O
number O
and O
induction O
of O
glutamine B
synthetase I
in O
the O
transfected O
cells O
. O

Full O
- O
length O
cDNAs B
and O
genomic O
clones O
were O
isolated O
, O
and O
the O
gene O
structure O
was O
determined O
. O
Comparison O
of O
the O
deduced O
amino O
acids O
shows O
88 O
% O
sequence O
identity O
between O
mouse O
and O
human O
BOB O
. O
1 O
/ O
OBF O
. O
1 O
. O

The O
NH2 O
- O
terminal O
126 O
amino O
acids O
of O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
are O
both O
essential O
and O
sufficient O
for O
interaction O
with O
the O
POU B
domains I
of O
either O
Oct1 B
or O
Oct2 B
. O

As O
this O
phosphorylation O
was O
independent O
of O
protein B
kinase I
C I
activity O
, O
we O
tested O
whether O
a O
calcium B
/ I
calmodulin I
- I
dependent I
protein I
kinase I
( O
CaM O
kinase O
) O
might O
phosphorylate O
the O
Ets O
- O
1 O
protein O
after O
elevation O
of O
intracellular O
free O
calcium O
concentrations O
. O

Furthermore O
, O
we O
identified O
a O
repression O
domain O
at O
the O
N O
- O
terminus O
of O
Oct B
- I
2a I
. O

GP B
Ib I
alpha I
promoter I
activity O
was O
evaluated O
by O
transfection O
of O
human O
erythroleukemia O
cells O
with O
reporter O
plasmids O
coding O
for O
the O
enzyme B
, O
luciferase B
. O

The O
results O
define O
essential O
cis B
- I
acting I
elements I
responsible O
for O
the O
expression O
of O
GP B
Ib I
alpha I
and O
provide O
insights O
into O
molecular O
events O
coinciding O
with O
the O
release O
of O
normal O
platelets O
into O
the O
bloodstream O
. O

CD30 B
is O
a O
recently O
described O
member O
of O
the O
tumor O
necrosis O
factor O
/ O
nerve O
growth O
factor O
receptor O
superfamily O
. O

In O
all O
cell O
lines O
investigated O
, O
the O
NF B
- I
kappa I
B I
complexes I
induced O
following O
CD30 B
engagement O
were O
shown O
to O
contain O
p50 O
NF O
- O
kappa O
B1 O
, O
p65 B
RelA I
, O
and O
possibly O
other O
transcription B
factors I
. O

Estrogen B
and O
progesterone B
receptors I
in O
vernal O
keratoconjunctivitis O
. O

RESULTS O
: O
Both O
the O
epithelium O
and O
subepithelium O
of O
the O
tarsal O
and O
bulbar O
conjunctiva O
of O
patients O
with O
VKC O
, O
but O
not O
those O
of O
four O
nonatopic O
control O
subjects O
, O
showed O
intense O
positive O
staining O
for O
estrogen O
and O
progesterone B
receptors I
. O

The O
expression O
of O
MHC B
class I
II I
genes I
in O
mouse O
T O
cells O
can O
be O
reconstituted O
upon O
transfection O
with O
the O
human O
CIITA O
cDNA O
. O

Because O
HLA B
class I
II I
molecules I
present O
antigen O
to O
T B
cell I
receptors I
( O
TCRs O
) O
, O
we O
have O
searched O
for O
a O
TCR O
gene O
associated O
with O
the O
production O
of O
anti B
- I
Ro I
( I
SSA I
) I
antibodies I
. O

This O
RFLP O
pair O
occurs O
in O
76 O
% O
of O
patients O
with O
Ro B
( I
SSA I
) I
precipitins O
, O
84 O
% O
of O
anti O
- O
Ro B
( I
SSA I
) I
- O
positive O
patients O
lacking O
La B
( I
SSB I
) I
precipitins O
, O
but O
only O
41 O
% O
of O
the O
patients O
lacking O
both O
precipitins O
( O
P O
= O
0 O
. O
0004 O
) O
. O

The O
majority O
of O
patients O
who O
have O
these O
RFLPs B
and O
HLA B
class I
II I
antigens I
previously O
associated O
with O
the O
anti O
- O
Ro B
( I
SSA I
) I
response O
make O
this O
antibody O
, O
suggesting O
that O
interactions O
between O
products O
of O
these O
loci O
occur O
in O
response O
to O
Ro B
( I
SSA I
) I
. O

However O
, O
while O
IL2 B
expression O
requires O
the O
contribution O
of O
Ca O
( O
2 O
+ O
) O
- O
and O
protein B
kinase I
C I
- O
dependent O
signals O
, O
we O
report O
that O
activation O
of O
human O
IL4 O
transcription O
through O
the O
Ca O
( O
2 O
+ O
) O
- O
dependent O
pathway O
is O
diminished O
by O
protein B
kinase I
C I
stimulation O
in O
Jurkat O
T O
cells O
. O

Human B
IL4 I
promoter I
- O
mediated O
transcription O
is O
downregulated O
in O
Jurkat O
cells O
stimulated O
with O
the O
NF O
- O
kappa O
B O
- O
activating O
cytokine O
tumor B
necrosis I
factor I
alpha I
and O
suppressed O
in O
RelA O
- O
overexpressing O
cells O
. O

Many O
cytokines B
activate O
signal O
transducer O
and O
activation O
of O
transcription O
( O
STAT O
) O
transcription O
factors O
, O
which O
, O
in O
turn O
, O
activate O
transcription O
of O
inflammatory O
effector O
genes O
. O

The O
present O
study O
demonstrates O
that O
triggering O
of O
complement B
receptors I
CR1 B
( O
CD35 B
) O
and O
CR3 B
( O
CD11b B
/ I
CD18 I
) O
enhances O
viral O
replication O
in O
HIV O
- O
infected O
human O
monocytic O
cells O
. O

In O
contrast O
, O
in O
cells O
infected O
with O
L O
. O
donovani O
, O
tyrosine O
phosphorylation O
of O
Jak1 B
, O
Jak2 B
, O
and O
Stat1 B
was O
markedly O
impaired O
. O

Unresponsiveness O
to O
gamma B
interferon I
for O
activation O
of O
this O
pathway O
may O
explain O
impaired O
transcriptional O
responses O
in O
leishmania O
- O
infected O
cells O
. O

Implications O
for O
regulation O
of O
immunoglobulin B
heavy I
chain I
expression O
. O

To O
understand O
the O
role O
of O
MARs B
in O
IgH B
enhancer I
regulation O
, O
we O
have O
identified O
a O
novel O
MAR O
- O
binding O
protein O
, O
MAR B
- I
BP1 I
, O
from O
soluble O
nuclear O
matrix O
preparations O
based O
on O
its O
ability O
to O
bind O
to O
the O
MARs B
associated O
with O
the O
IgH B
enhancer I
. O

Purified O
MAR B
- I
BP1 I
migrates O
as O
a O
33 O
- O
kDa O
protein O
, O
and O
it O
can O
be O
found O
in O
nuclear O
matrix O
preparations O
from O
a O
number O
of O
different O
types O
of O
lymphoid O
cell O
lines O
. O

The O
GM B
- I
CSF I
receptor I
alpha I
promoter I
contains O
an O
important O
functional O
site O
between O
positions O
- O
53 O
and O
- O
41 O
as O
identified O
by O
deletion O
analysis O
of O
reporter B
constructs I
. O

C B
/ I
EBP I
alpha I
is O
the O
major O
CCAAT B
/ I
enhancer I
- I
binding I
protein I
( O
C B
/ I
EBP I
) O
form O
binding O
to O
this O
site O
in O
nuclear O
extracts O
of O
U937 O
cells O
. O

Regulation O
of O
c B
- I
jun I
mRNA I
expression O
by O
hydroxyurea O
in O
human O
K562 O
cells O
during O
erythroid O
differentiation O
[ O
published O
erratum O
appears O
in O
Biochim O
Biophys O
Acta O
1995 O
Dec O
27 O
; O
1264 O
( O
3 O
) O
: O
409 O
] O

In O
addition O
, O
HU O
stimulates O
the O
synthesis O
of O
fetal B
hemoglobin I
in O
sickle O
cell O
anemia O
patients O
. O

HU O
induced O
a O
dose O
- O
dependent O
stimulation O
of O
c B
- I
jun I
synthesis O
. O

Because O
NF B
- I
kappa I
B I
activates O
many O
immunoregulatory O
genes O
in O
response O
to O
pro O
- O
inflammatory O
stimuli O
, O
the O
inhibition O
of O
its O
activity O
can O
be O
a O
major O
component O
of O
the O
anti O
- O
inflammatory O
activity O
of O
glucocorticoids O
. O

Transcriptional O
repression O
of O
the O
interleukin B
- I
2 I
gene I
by O
vitamin O
D3 O
: O
direct O
inhibition O
of O
NFATp B
/ I
AP I
- I
1 I
complex I
formation O
by O
a O
nuclear O
hormone O
receptor O
. O

We O
therefore O
examined O
vitamin O
D3 O
- O
mediated O
repression O
of O
activated O
IL B
- I
2 I
expression O
by O
cotransfecting O
Jurkat O
cells O
with O
IL O
- O
2 O
promoter O
/ O
reporter O
constructs O
and O
a O
VDR O
overexpression O
vector O
and O
by O
DNA O
binding O
. O

The O
5 B
' I
flanking I
DNA I
also O
contains O
a O
cluster O
of O
three O
binding B
sites I
for O
the O
GATA B
family I
of O
transcription B
factors I
. O

This O
effect O
is O
thought O
to O
be O
largely O
mediated O
through O
inactivation O
of O
the O
phosphatase O
calcineurin B
, O
which O
in O
turn O
inhibits O
translocation O
of O
an O
NFAT B
component O
to O
the O
nucleus O
. O

These O
data O
point O
to O
a O
new O
mechanism O
for O
CsA O
- O
sensitive O
regulation O
of O
NFATp B
in O
which O
dephosphorylation O
is O
critical O
for O
DNA O
binding O
. O

Cysteamine O
treatment O
inhibited O
both O
expression O
of O
the O
IL B
- I
2 I
mRNA I
and O
secretion O
of O
IL B
- I
2 I
into O
the O
culture O
medium O
. O

The O
Id2 B
mRNA I
was O
abundantly O
expressed O
in O
5 O
/ O
12 O
T O
- O
cell O
and O
3 O
/ O
4 O
B O
- O
cell O
lines O
, O
and O
Id3 B
mRNA I
was O
detected O
in O
4 O
/ O
12 O
T O
- O
cell O
and O
3 O
/ O
4 O
B O
- O
cell O
lines O
. O

In O
addition O
, O
resting O
PBL O
constitutively O
expressed O
prominent O
levels O
of O
Id2 B
mRNA I
, O
but O
not O
Id3 B
mRNA I
. O

Here O
, O
we O
report O
that O
a O
family O
of O
anti O
- O
inflammatory O
agents O
, O
known O
as O
the O
salicylates O
, O
inhibited O
LPS O
induction O
of O
TF O
activity O
and O
TF B
gene I
transcription O
in O
human O
monocytes O
and O
monocytic O
THP O
- O
1 O
cells O
at O
clinically O
relevant O
doses O
. O

Furthermore O
, O
sodium O
salicylate O
blocked O
the O
LPS O
- O
induced O
proteolytic O
degradation O
of O
I B
kappa I
B I
alpha I
, O
which O
prevented O
the O
nuclear O
translocation O
of O
c B
- I
Rel I
/ I
p65 I
heterodimers I
. O

In O
contrast O
, O
two O
other O
nonsteroidal O
anti O
- O
inflammatory O
drugs O
, O
ibuprofen O
and O
indomethacin O
, O
did O
not O
inhibit O
LPS O
induction O
of O
the O
TF B
gene I
. O

Critical O
role O
for O
IL B
- I
6 I
. O

The O
T O
cell O
activation O
is O
initiated O
by O
interaction O
of O
specific O
Ags B
with O
TCR B
, O
followed O
by O
activation O
of O
intracellular O
biochemical O
events O
leading O
to O
activation O
of O
several O
genes O
. O

As O
neutralizing O
anti O
- O
IL O
- O
6 O
Abs O
effectively O
down O
- O
regulated O
the O
early O
induction O
of O
STAT B
proteins I
and O
as O
exogenously O
added O
IL B
- I
6 I
rapidly O
activated O
DNA O
binding O
similar O
to O
TCR B
- O
mediated O
bindings O
, O
it O
can O
be O
concluded O
that O
IL B
- I
6 I
is O
the O
factor O
responsible O
for O
the O
activation O
of O
STAT B
proteins I
in O
a O
primary O
T O
cell O
response O
. O

Our O
data O
suggest O
an O
involvement O
of O
BLR2 B
in O
the O
regulation O
of O
migration O
in O
activated O
lymphocytes O
and O
in O
viral O
pathogenesis O
. O

c B
- I
Myb I
protein I
was O
strongly O
evident O
in O
T O
lymphoblasts O
in O
which O
the O
enhancer B
was O
active O
and O
was O
localized O
within O
discrete O
nuclear O
structures O
. O

Lymphoid B
enhancer I
- I
binding I
factor I
1 I
( O
LEF B
- I
1 I
) O
is O
a O
regulatory O
high O
mobility O
group O
( O
HMG O
) O
protein O
that O
activates O
the O
T B
cell I
receptor I
alpha I
( I
TCR I
alpha I
) I
enhancer I
in O
a O
context O
- O
restricted O
manner O
in O
T O
cells O
. O

We O
conclude O
that O
transcription O
activation O
by O
LEF B
- I
1 I
in O
vitro O
is O
a O
chromatin B
- O
dependent O
process O
that O
requires O
a O
functional O
trans B
- I
activation I
domain I
in O
addition O
to O
the O
HMG B
domain I
. O

HIV O
- O
1 O
envelope O
glycoproteins O
induce O
activation O
of O
activated O
protein B
- I
1 I
in O
CD4 O
+ O
T O
cells O
[ O
published O
erratum O
appears O
in O
J O
Biol O
Chem O
1995 O
Dec O
1 O
; O
270 O
( O
48 O
) O
: O
29038 O
] O

Immunoprecipitation O
of O
the O
gp B
160 I
- O
induced O
nuclear O
extracts O
with O
polyclonal B
antibodies I
to O
Fos B
and O
Jun B
proteins I
indicates O
that O
AP B
- I
1 I
complex I
is O
comprised O
of O
members O
of O
these O
family O
of O
proteins O
. O

This O
stimulation O
can O
also O
be O
abolished O
by O
inhibitors O
of O
protein B
kinase I
C I
, O
but O
it O
is O
unaffected O
by O
calcium O
channel O
blocker O
or O
cyclosporine O
A O
. O

